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A B S T R A C T
Background
Hirsutism occurs in 5% to 10% of women of reproductive age when there is excessive terminal hair growth in androgen-sensitive areas
(male pattern). It is a distressing disorder with a major impact on quality of life. The most common cause is polycystic ovary syndrome.
There are many treatment options, but it is not clear which are most effective.
Objectives
To assess the effects of interventions (except laser and light-based therapies alone) for hirsutism.
Search methods
We searched the Cochrane Skin Group Specialised Register, CENTRAL (2014, Issue 6), MEDLINE (from 1946), EMBASE (from
1974), and five trials registers, and checked reference lists of included studies for additional trials. The last search was in June 2014.
Selection criteria
Randomised controlled trials (RCTs) in hirsute women with polycystic ovary syndrome, idiopathic hirsutism, or idiopathic hyperan-
drogenism.
Data collection and analysis
Two independent authors carried out study selection, data extraction, ’Risk of bias’ assessment, and analyses.
Main results
We included 157 studies (sample size 30 to 80) comprising 10,550 women (mean age 25 years). The majority of studies (123/157)
were ’high’, 30 ’unclear’, and four ’low’ risk of bias. Lack of blinding was the most frequent source of bias. Treatment duration was
six to 12 months. Forty-eight studies provided no usable or retrievable data, i.e. lack of separate data for hirsute women, conference
proceedings, and losses to follow-up above 40%.
Primary outcomes, ’participant-reported improvement of hirsutism’ and ’change in health-related quality of life’, were addressed in few
studies, and adverse events in only half. In most comparisons there was insufficient evidence to determine if the number of reported
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adverse events differed. These included known adverse events: gastrointestinal discomfort, breast tenderness, reduced libido, dry skin
(flutamide and finasteride); irregular bleeding (spironolactone); nausea, diarrhoea, bloating (metformin); hot flushes, decreased libido,
vaginal dryness, headaches (gonadotropin-releasing hormone (GnRH) analogues)).
Clinician’s evaluation of hirsutism and change in androgen levels were addressed in most comparisons, change in body mass index
(BMI) and improvement of other clinical signs of hyperandrogenism in one-third of studies.
The quality of evidence was moderate to very low for most outcomes.
There was low quality evidence for the effect of two oral contraceptive pills (OCPs) (ethinyl estradiol + cyproterone acetate versus ethinyl
estradiol + desogestrel) on change from baseline of Ferriman-Gallwey scores. The mean difference (MD) was -1.84 (95% confidence
interval (CI) -3.86 to 0.18).
There was very low quality evidence that flutamide 250 mg, twice daily, reduced Ferriman-Gallwey scores more effectively than placebo
(MD -7.60, 95%CI -10.53 to -4.67 andMD -7.20, 95%CI -10.15 to -4.25). Participants’ evaluations in one study with 20 participants
confirmed these results (risk ratio (RR) 17.00, 95% CI 1.11 to 259.87).
Spironolactone 100 mg daily was more effective than placebo in reducing Ferriman-Gallwey scores (MD -7.69, 95% CI -10.12 to -
5.26) (low quality evidence). It showed similar effectiveness to flutamide in two studies (MD -1.90, 95% CI -5.01 to 1.21 and MD
0.49, 95% CI -1.99 to 2.97) (very low quality evidence), as well as to finasteride in two studies (MD 1.49, 95% CI -0.58 to 3.56 and
MD 0.40, 95% CI -1.18 to 1.98) (low quality evidence).
Although there was very low quality evidence of a difference in reduction of Ferriman-Gallwey scores for finasteride 5 mg to 7.5 mg
daily versus placebo (MD -5.73, 95% CI -6.87 to -4.58), it was unlikely it was clinically meaningful. These results were reinforced
by participants’ assessments (RR 2.06, 95% CI 0.99 to 4.29 and RR 11.00, 95% CI 0.69 to 175.86). However, finasteride showed
inconsistent results in comparisons with other treatments, and no firm conclusions could be reached.
Metformin demonstrated no benefit over placebo in reduction of Ferriman-Gallwey scores (MD 0.05, 95% CI -1.02 to 1.12), but
the quality of evidence was low. Results regarding the effectiveness of GnRH analogues were inconsistent, varying from minimal to
important improvements.
We were unable to pool data for OCPs with cyproterone acetate 20 mg to 100 mg due to clinical and methodological heterogeneity
between studies. However, addition of cyproterone acetate to OCPs provided greater reductions in Ferriman-Gallwey scores.
Two studies, comparing finasteride 5 mg and spironolactone 100 mg, did not show differences in participant assessments and reduction
of Ferriman-Gallwey scores (low quality evidence). Ferriman-Gallwey scores from three studies comparing flutamide versus metformin
could not be pooled (I² = 62%). One study comparing flutamide 250 mg twice daily with metformin 850 mg twice daily for 12 months,
which reached a higher cumulative dosage than two other studies evaluating this comparison, showed flutamide to be more effective
(MD -6.30, 95% CI -9.83 to -2.77) (very low quality evidence). Data showing reductions in Ferriman-Gallwey scores could not be
pooled for four studies comparing finasteride with flutamide as the results were inconsistent (I² = 67%).
Studies examining effects of hypocaloric diets reported reductions in BMI, but which did not result in reductions in Ferriman-Gallwey
scores. Although certain cosmetic measures are commonly used, we did not identify any relevant RCTs.
Authors’ conclusions
Treatments may need to incorporate pharmacological therapies, cosmetic procedures, and psychological support. For mild hirsutism
there is evidence of limited quality that OCPs are effective. Flutamide 250 mg twice daily and spironolactone 100 mg daily appeared
to be effective and safe, albeit the evidence was low to very low quality. Finasteride 5 mg daily showed inconsistent results in different
comparisons, therefore no firm conclusions can be made. As the side effects of antiandrogens and finasteride are well known, these
should be accounted for in any clinical decision-making. There was low quality evidence that metformin was ineffective for hirsutism
and although GnRH analogues showed inconsistent results in reducing hirsutism they do have significant side effects.
Further research should consist of well-designed, rigorously reported, head-to-head trials examiningOCPs combinedwith antiandrogens
or 5α-reductase inhibitor against OCP monotherapy, as well as the different antiandrogens and 5α-reductase inhibitors against each
other. Outcomes should be based on standardised scales of participants’ assessment of treatment efficacy, with a greater emphasis on
change in quality of life as a result of treatment.
P L A I N L A N G U A G E S U M M A R Y
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Treatments for unwanted male pattern hair growth in women
Background
Up to 5% to 10% of women are hirsute (hair in areas where normally only men have hairs such as moustache, beard area, chest,
belly, back etc). The most common cause is polycystic ovary syndrome. Hirsutism can lead to psychological distress, low self esteem,
decreased self image, depression, feelings of shame and social difficulties.
Review question
Which treatments (except laser and light-based therapies alone) work best for hirsutism?
Study characteristics
We included 157 studies published up to June 2014, which examined 10,550 people. Participants included women with a mean age
of 25 years. There was considerable variation in the quality of how the studies were conducted; more than half were not blinded and
this may have had an impact on the reporting of the outcomes. Most studies were carried out in single centres in Europe and lasted
six to 12 months. A range of treatments were evaluated, mostly in single studies. These included a few topical treatments, lifestyle
modification, oral contraceptive pills (OCPs), medication to inhibit the effect of hormones that are responsible for male traits, and
combination therapies. Participant-assessed improvement and impact on quality of life were evaluated in a minority of the studies,
whilst the majority of the studies measured physician-assessed reduction in hirsutism, as well as androgen levels in the blood. Half of
the studies reported adverse events and around one-third other signs and symptoms, e.g. oily skin and menstrual irregularities that
might be due to an increase of androgen levels in the blood.
Key results
Oral contraceptive pills reduced the amount of hairs, but the reduction was not consistent across the studies, although two OCPs
(ethinyl estradiol 35 µg + cyproterone acetate 2 mg compared to ethinyl estradiol 30 µg + desogestrel 0.15 mg) appeared to be effective
in a way that can be considered important for women with hirsutism.
Of the antiandrogen drugs, flutamide was considered to be more effective than placebo by both the women and the doctors. Spirono-
lactone was also effective, but data were only available for the physicians’ assessments. Finasteride did not show convincing effectiveness
based on the evaluations of the hirsute women and those made by the investigators. The addition of cyproterone acetate (an antian-
drogen) to OCP seemed to enhance the beneficial effect of OCPs on hair reduction.
Insulin sensitisers (antidiabetic drugs) and lifestyle modification did not have any demonstrable benefit in terms of the severity of
hirsutism. Unfortunately, the self assessments by the women, as well as the impact of hirsutism on their quality of life, were outcomes
that were insufficiently addressed in the studies.
The adverse events reported with the different drugs are well known, i.e. pain in the stomach and intestines, breast tenderness, reduced
libido and dry skin with flutamide and finasteride; irregular bleeding with spironolactone; nausea, diarrhoea and abdominal bloating
with metformin; and hot flushes, decreased libido, vaginal dryness, breast tenderness and headaches with the GnRH analogues.
There were no important differences in blood androgen levels between the different treatment groups, OCPs had a positive effect on
acne, and similarly insulin sensitisers improved the menstrual pattern.
We were expecting to find evidence that combined therapies of an OCP with an antiandrogen were more effective than, for example,
OCPs alone, but the lack of studies did not allow us to draw these conclusions.
Overall we concluded that OCPs (especially with antiandrogenic activity), OCPs combined with cyproterone acetate, flutamide and
spironolactone are effective in treating hirsutism. However, additional cosmetic measures (epilating, waxing, bleaching, electrolysis,
laser and photoepilation) are generally required because all treatments need at least six to 12 months to reach the optimum effect. In
addition, because of the distress associated with hirsutism and its impact on quality of life psychological support should be part of the
treatment approach.
Quality of the evidence
The overall quality of the evidence for the different outcomes was on average rated as moderate to very low. Important reasons for this
were that studies were not blinded, or had a small sample size.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ethinyl estradiol 35 µg + cyproterone acetate 2 mg compared to ethinyl estradiol 30 µg + desogestrel 0.15 mg for hirsutism
Patient or population: patients with hirsutism
Intervention: ethinyl estradiol 35 µg + cyproterone acetate 2 mg
Comparison: ethinyl estradiol 30 µg + desogestrel 0.15 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Ethinyl estradiol 30 µg
+ desogestrel 0.15 mg
Ethinyl estradiol 35 µg
+ cyproterone acetate 2
mg
Participant-reported im-
provement of hirsutism -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
Study population RR 0.41
(0.08 to 2.05)
100
(1 study)
⊕⊕⊕©
moderate1
100 per 1000 41 per 1000
(8 to 205)
Low
40 per 100 16 per 1000
(3 to 82)
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Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
The mean clinician’s as-
sessment of improve-
ment of hirsutism ranged
across control groups
from
-1.69 to -9.51
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
intervention groups was
1.84 lower
(3.86 lower to 0.18
higher)
164
(3 studies)
⊕⊕©©
low2,3
Both treatments demon-
strated a clinically im-
portant reduction in Fer-
riman-Gallwey score, but
the MD between the
groups was not statisti-
cally significant
Change in serum andro-
gen levels
See comment See comment Not estimable 184
(4 studies)
⊕⊕⊕⊕
high
There were no clinically
important differences in
serum androgen levels
between the 2 groups
Change in BMI
kg/m²
See comment See comment Not estimable 136
(2 studies)
⊕⊕⊕©
moderate4
MD -0.14 kg/m², 95% CI -
2.44 to 2.16; P value= 0.
90 (Bhattacharya 2012)
and 0.10 kg/m², 95% CI -
2.85 to 3.05; P value =
0.95 (Mastorakos 2006)
Improvement of other
clinical signs of hyper-
androgenism
Acne score - grade 1 to 4
(higher is worse)
The mean improvement
of other clinical signs of
hyperandrogenism in the
control groups was
-1.41
The mean improvement
of other clinical signs of
hyperandrogenism in the
intervention groups was
0.11 lower
(0.61 lower to 0.39
higher)
100
(1 study)
⊕⊕⊕©
moderate5
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; MD: mean difference; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.5
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1Downgraded one level due to serious imprecision (95% confidence interval around the pooled or best estimate of effect includes both
no effect and appreciable harm).
2Downgraded one level due to serious risk of performance and detection bias as in 2 of the 3 studies participants, investigators, and
outcome assessors were not blinded.
3Downgraded one level due to serious imprecision (95% confidence interval around the pooled or best estimate of effect includes both
no effect and appreciable benefit).
4Downgraded one level due to serious imprecision (wide CI for both studies).
5Downgraded one level due to serious imprecision (wide CI).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
We have listed unfamiliar terms in the glossary of terms in Table
1.
Description of the condition
Definition and prevalence
Hirsutism is a condition that occurs when there is an excessive
amount of terminal hair growth in androgen-sensitive areas in
women (male pattern) (Blume-Peytavi 2009; Brodell 2010) (see
Figure 1; Figure 2). It must be differentiated from hypertrichosis,
which is androgen-independent (non-sexual pattern) excessive hair
growth either generalised or localised on the body (Blume-Peytavi
2011; Bode 2012; Castelo-Branco 2010). Hypertrichosis may be
related to ethnic background (Blume-Peytavi 2011), and it can also
be caused by metabolic disorders, such as thyroid dysfunction and
anorexia nervosa (Bode 2012), or medications, e.g. phenytoin, cy-
closporin, andminoxidil (Castelo-Branco 2010;Rosenfield 2005).
Figure 1. Hirsutism on the chin
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Figure 2. Hirsutism on the chest and breasts
Approximately 5% to 10% of women of reproductive age are hir-
sute, as assessed by the Ferriman-Gallwey scoring system (FG)
(Cook 2011; Escobar-Morreale 2012; Somani 2008), but in gen-
eral, a lower percentage of Asian women are affected. This scor-
ing system, which was developed in 1961, scored 11 body sites
(upper lip, chin, chest, upper and lower back, upper and lower
abdomen, upper arm, forearm, thigh, and lower leg) and rated
these sites on a four-point scale (0 = ’no hair’ to 4 = ’frankly virile’)
(Cook 2011; Escobar-Morreale 2012; Rosenfield 2005). The sub-
sequently improved modified FG score (mFG method) excludes
the forearm and lower leg as these areas are less, or not, sensitive
to androgens (Escobar-Morreale 2012; Hatch 1981) (see Figure
3). A score of less than 8 is considered normal, whereas 8 to 15
indicates mild hirsutism, 16 to 25 indicates moderate hirsutism,
and a score above 25 indicates severe hirsutism (Escobar-Morreale
2012; Hatch 1981). The limitations of this scoring system are
well recognised: it is subjective in nature with wide inter-observer
variation; it misses areas such as sideburns and buttocks; and it
does not take into account racial and ethnic variability. Additional
limitations are the difficulties associated with evaluating the de-
gree of hirsutism in women who are using different treatment
methods and also the requirement of a full body examination to
score all areas (Bode 2012; Cook 2011; Somani 2008). However,
it remains the most widely used scoring method and is consid-
ered to be the gold standard in the quantification of hirsutism
(Escobar-Morreale 2012). As there is a substantial racial and eth-
nic variability in terminal hair growth, it has been suggested that
lower cut-off values should be used for Asian women, with higher
cut-off values forMediterranean, Middle Eastern, and East Indian
women (Escobar-Morreale 2012; Somani 2008).
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Figure 3. Modified Ferriman-Gallwey score, each of nine body areas can receive a score from 0 (no hair) to
4 (frankly virile) (van Zuuren EJ, Pijl H. Hirsutism. Ned Tijdschr Geneeskd. 2007 Oct 20;151(42):2313-8
Physiology of hair growth
Fivemillion hair follicles cover the body excluding the palms, soles,
mucosae, and glabrous skin of the genitalia and lips (Brodell 2010;
Escobar-Morreale 2012). Three types of hair can be distinguished:
lanugo hair, which is soft, not pigmented, and sheds sometime
late in gestation or early postpartum (Azziz 2003; Lumachi 2010;
Shah 2009); vellus hairs, which are short, fine, light-coloured, and
barely noticeable but cover most parts of the body; and terminal
hairs, which are thicker, longer, and pigmented, and can be found
on the scalp and in the axillae, the genital region, eye brows, and
eye lashes (Escobar-Morreale 2012; Randall 2008; Shah 2009).
There are three phases of hair growth: anagen, which is the growth
phase; catagen, the involuting or regressing phase; and telogen,
the resting or quiescent phase (Blume-Peytavi 2011b; Escobar-
Morreale 2012; Olsen 1999; Randall 2008).
Androgens stimulate the conversion of vellus into terminal hairs
and prolong the anagen phase (Brodell 2010; Paparodis 2011;
Randall 2008). Other hormones can also affect hair growth (e.g.
growth hormone, thyroid dysfunction), but androgens are con-
sidered to play the most significant role. The most important
circulating androgen is testosterone, which is secreted in equal
amounts from the ovaries (promoted by luteinising hormone (LH)
and insulin) and adrenal glands (promoted by adrenocorticotropic
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hormone (ACTH) but also through peripheral conversion of an-
drogen precursors (Brodell 2010; Escobar-Morreale 2010; Shah
2009)). Free testosterone is the main bioactive portion of plasma
testosterone, but most of the circulating testosterone is bound by
sex hormone-binding globulin (SHBG) (Paparodis 2011), which
has a high affinity for testosterone and can modulate the bioavail-
ability of free testosterone (Escobar-Morreale 2010; Paparodis
2011). The lower the concentration of serum SHBG, the higher
the concentration of free testosterone there will be in the circula-
tion. The more potent dihydrotestosterone is then generated from
testosterone by 5-alpha-reductase (5α-reductase) in the hair fol-
licle and stimulates the dermal papilla to produce terminal hairs
instead of vellus hairs. Androstenedione and dehydroepiandros-
terone (DHEA) areweaker androgens andmay also bemetabolised
in the skin into testosterone and dihydrotestosterone (Azziz 2003).
In view of differences in activity of androgen receptors and 5α-
reductase content, several regions of the skin are more sensitive to
androgens than others (Escobar-Morreale 2012; Randall 2008).
Pathophysiology
Hirsutism is the result of the interaction between circulating an-
drogens and the susceptibility of the hair follicle to androgens
(Escobar-Morreale 2012; Rosenfield 2005). Although the major-
ity, but not all, hirsute women exhibit androgen excess (Azziz
2003; Azziz 2004), it is important to differentiate androgen excess
(endocrine disease) from hirsutism (dermatological signs) (Azziz
2003).Up to70%to80%ofwomenwith androgen excess demon-
strate hirsutism (Azziz 2004).
The most common cause of hirsutism is polycystic ovary syn-
drome (PCOS) (Azziz 2003; Blume-Peytavi 2008; Bode 2012),
which is one of the most frequently encountered endocrinological
disorders in women, with a prevalence of between 5% to 10%
(Ekbäck 2009; Guzel 2012); it accounts for 70% to 80% of the
cases of hirsutism. According to the revised criteria for diagnosing
PCOS, this syndrome is defined if at least two of the following
three criteria are present: oligo-ovulation or anovulation; clinical
or biochemical signs of hyperandrogenism; or polycystic ovaries,
subject to the exclusion of other aetiologies with a similar presenta-
tion (Rotterdam Criteria PCOS 2004). Other possible character-
istics of women with PCOS besides hirsutism are obesity, acne, in-
sulin resistance, infertility (Azziz 2006; Bode 2012; Brodell 2010),
acanthosis nigricans, and female pattern hair loss (Ehrmann 2005;
Rosenfield 2005; van Zuuren 2012).
Women affected with idiopathic hyperandrogenism have elevated
androgen levels, normal menses, normal ovaries at ultrasound, and
no explicable cause for their elevated androgen levels. Idiopathic
hyperandrogenism accounts for 6% to 15% of the causes of hir-
sutism (Bode 2012). Other less common causes of androgen ex-
cess are non-classic congenital adrenal hyperplasia and the rarer
androgen-secreting tumours (Blume-Peytavi 2008; Bode 2012).
Conditions that also lead to androgen excess, but which usu-
ally present with other more prominent symptoms are: Cushing’s
syndrome, acromegaly, thyroid dysfunction, and hyperprolacti-
naemia (Blume-Peytavi 2008; Bode 2012; Rosenfield 2005). Cer-
tain drugs, e.g. anabolic steroids, testosterone, and danazol, can
also lead to hirsutism (Blume-Peytavi 2008; Rosenfield 2005).
Idiopathic hirsutism is defined as hirsutism in the presence of reg-
ular menses and normal circulating androgen levels (Shah 2009).
Increased 5α-reductase activity in the hair follicle or alteration in
androgen receptor function may be the underlying cause (Shah
2009; Somani 2008). However, up to 40% of the women diag-
nosed with idiopathic hirsutism and with a history of regular men-
strual cycles appear to be anovulatory and probably suffer from
PCOS (Azziz 2003). Idiopathic hirsutism accounts for 4% to 7%
of cases (Azziz 2004; Bode 2012), and in line with PCOS, the
diagnosis of idiopathic hirsutism is made by gradually excluding
other possibilities.
Clinical features and symptoms
Some women with hirsutism have no other clinical features than
excessive hair growth, whereas women with hyperandrogenism
may exhibit other clinical features, such as acne, seborrhoea, ir-
regular menses or no menses, obesity, and hair loss. Therefore, a
full clinical and family history is paramount and should include
enquiry about the onset and rate of progression of the hirsutism;
a menstrual and reproductive history; presence of acne; hair loss
or balding; voice change; weight change; and body contour differ-
ences, including the face, enlargement of the clitoris, use of drugs
or medication, and prior treatment for hirsutism (Bode 2012;
Brodell 2010). Hirsutism is often familial because PCOS has a
strong genetic component (Azziz 2003), but idiopathic hirsutism
may also frequently be familial (Bode 2012).
Physical examination should involve assessment of the level and
extent of hirsutism by the Ferriman-Gallwey score and include
measurement of weight, height, body mass index (BMI), exam-
ination for acne, seborrhoea, virilisation, abdominal and pelvic
masses, features found in Cushing’s syndrome (e.g. full moon face
and buffalo hump), galactorrhoea, thyroid enlargement, and hair
loss (Bode 2012; Escobar-Morreale 2012). Laboratory examina-
tion and other investigations, such as ultrasonography, should be
done to ensure the correct diagnosis and to exclude other causes of
hirsutism (See ’Pathophysiology’). Several reviews have extensively
addressed these issues, which are beyond the scope of ourCochrane
review (Azziz 2003; Blume-Peytavi 2009; Escobar-Morreale 2012;
Koulouri 2009; Rosenfield 2005).
Hirsutism caused by PCOS, idiopathic hyperandrogenism, and
idiopathic hirsutism in most cases start around puberty, with slow
progression over the years, and are often associated with a family
history of hyperandrogenism while signs of virilisation are rare
(Escobar-Morreale 2010). A sudden onset and rapid progression
of hirsutism accompanied by virilisation is suggestive of androgen-
secreting tumours (Escobar-Morreale 2012; Rosenfield 2005).
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Hirsutism can lead to psychological distress, low self esteem, de-
creased self image, depression, feelings of shame, body dysmorphic
disorder, and social difficulties, such as social phobia and intro-
version (Barth 1993; Blume-Peytavi 2009; Ekbäck 2009; Lipton
2006). A hair-free body seems to be the social norm of feminin-
ity (Blume-Peytavi 2011; Ekbäck 2009; Tiggeman 1998); thus,
women with body hair are considered less sexually attractive, and
hirsutism may impinge on a woman’s feminine identity (Basow
1998; Housman 2004; Keegan 2003; Tiggeman 1998). Further-
more, hirsutism has been shown to have a negative impact on
health-related quality of life (HRQOL) (Loo 2002; Sonino 1993),
as is the case with the major cause of hirsutism, PCOS, illustrated
by studies using the Polycystic Ovary Syndrome Questionnaire
(PCOSQ) (Coffey 2006; Guyatt 2004). Therefore, the work-up
for evaluating hirsutism should also include an assessment of psy-
chosomatic or even psychiatric problems, in addition to address-
ing if the quality of life of that individual has decreased because of
hirsutism (Blume-Peytavi 2009). Hirsute women may often con-
sider that physicians are less than sympathetic and consequently
experience feelings of rejection; it is important that physicians ac-
knowledge the feelings of the hirsute woman and, notably, the
possible impact on her HRQOL (Blume-Peytavi 2011; Ekbäck
2011; Lipton 2006).
Women with hirsutism may consult general practitioners, gynae-
cologists, endocrinologists, dermatologists, and if required, psy-
chologists or psychiatrists (or both). A multidisciplinary approach
to treatment may be necessary and will depend on the setting and
the experience of the doctor to whom the hirsute woman has been
referred.
Description of the intervention
Treatment should be guided by the degree of severity of hir-
sutism, the woman’s preferences, her reproductive status, the un-
derlying cause, and any potential adverse effects (Bode 2012;
Lumachi 2010). The duration of the hair growth cycle varies
in different parts of the body, ranging from two to 12 months
(scalp hairs have even longer cycles) (Olsen 1999; Paparodis 2011;
Randall 2008); therefore, treatment periods of between six and
12 months are often recommended for optimal effect, but con-
tinuous treatment may also be necessary (Escobar-Morreale 2012;
Rosenfield 2005). Management strategies should focus on reduc-
ing the free androgen level, blocking the peripheral androgen
(Blume-Peytavi 2008; Escobar-Morreale 2012; Paparodis 2011),
and improving cosmetic appearance by the removal of existing hair
(Brodell 2010; Castelo-Branco 2010; Escobar-Morreale 2012).
These should also aim to reduce the risk of related conditions, such
as metabolic disorders, reproductive complaints, and endometrial
cancer (Escobar-Morreale 2010; Lumachi 2010), and be directed
towards improving quality of life (Blume-Peytavi 2011; Brodell
2010). A combination of treatments is often used to achieve opti-
mum results, and these should preferably include a support strat-
egy to help the individual cope emotionally (Blume-Peytavi 2011).
Currently there are no safe pharmacological treatments available
for pregnant or lactating women (Bode 2012).
Available treatment options are listed below:
Lifestyle modification
This might include weight loss and cessation of smoking (
Blume-Peytavi 2011; Bode 2012; Castelo-Branco 2010; Escobar-
Morreale 2012; Koulouri 2008).
Cosmetic measures
These include:
1. shaving, chemical depilatories, bleaching, plucking,
tweezing or threading, and waxing (Bode 2012;
Escobar-Morreale 2012; Lanigan 2001);
2. electrolysis in the form of galvanic electrolysis, thermolysis,
or a combination of both (Blume-Peytavi 2011; Bode 2012;
Escobar-Morreale 2012; Richards 1995); and
3. laser and photo epilation (Escobar-Morreale 2012;
Haedersdal 2011; Lanigan 2001; Sadighha 2009).
The review will not include treatment with laser and photoepila-
tion alone because they are covered in another Cochrane review
(Haedersdal 2006).
Pharmacological treatments
Topical therapy
Eflornithine hydrochloride 13.9% cream applied twice daily
(Blume-Peytavi 2008; Escobar-Morreale 2012; Martin 2008) or
finasteride cream (0.25% or 0.5%) (Iraji 2005; Lucas 2001).
Oral contraceptive pills (OCP)
These might include a combination of an oestrogen (often
ethinyl estradiol) with a varying progestational agent. The
progestins include norethindrone, norgestimate, levonorgestrel,
ethynodiol diacetate, norgestrel, desogestrel, norethisterone, or
norethynodrel. Progestins with an antiandrogenic effect include
drospirenone, chlormadinone, dienogest, and cyproterone ac-
etate (Blume-Peytavi 2011; Escobar-Morreale 2012;Martin 2008;
Paparodis 2011; Shah 2009).
Antiandrogens
These include:
1. spironolactone 50 to 200 mg/day (Bode 2012;
Escobar-Morreale 2012; Martin 2008);
2. cyproterone acetate (CPA) 50 to 100 mg/day (but in the
combined OCP as 2 mg) (Blume-Peytavi 2008; Lumachi 2010;
Martin 2008); and
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3. non-steroidal antiandrogens, such as flutamide 125 to 250
mg twice daily or bicalutamide 25 mg/day (Blume-Peytavi 2008;
Castelo-Branco 2010; Martin 2008).
5α-reductase inhibitor
Finasteride 1 to 5 mg/day (Blume-Peytavi 2008; Brodell 2010;
Paparodis 2011).
Insulin-sensitising agents
The following have mainly been used in women with PCOS:
1. metformin 500 to 1000 mg twice daily (Castelo-Branco
2010; Lumachi 2010; Paparodis 2011); and
2. thiazolidinediones, e.g. rosiglitazone 4 mg to 8 mg daily
and pioglitazone 10 mg to 30 mg (Blume-Peytavi 2008;
Lumachi 2010; Paparodis 2011). The European Medicines
Agency withdrew rosiglitazone in 2010 after concerns about an
increased risk of cardiovascular events. Pioglitazone has been
associated with bladder tumours and has been withdrawn in
some countries.
Gonadotropin-releasing hormone analogues
Leuprolide acetate 7.5 mg monthly intramuscularly combined
with 25 µg to 50 µg transdermal estradiol (Bode 2012; Lumachi
2010).
Glucocorticoids
Prednisone 5 to 10 mg/day (Bode 2012; Escobar-Morreale 2012;
Lumachi 2010).
Miscellaneous treatments options
Other treatments that have been tried for their potential bene-
ficial effect or that appear to have an additional effect on hir-
sutism are spearmint tea (Grant 2010), statins (Banaszewska 2011;
Kaya 2010), ovarian resection (Ashrafinia 2009), acarbose (Ciotta
2001; Penna 2005), inositol (Ciotta 2012; Ciotta 2012B), cimeti-
dine (Lissak 1989) bromocriptine (Murdoch 1987), sibutramine
(Sabuncu 2003), clomiphene (Roth 2012), and electro-acupunc-
ture (Jedel 2011).
How the intervention might work
Lifestyle modification
Women who are obese, especially when they have PCOS, should
be encouraged to lose weight through a combination of exercise
and diet. Weight reduction leads to a lowering of free testosterone,
reduction of androgen production by the ovaries, reduction of
serum insulin, an increase in SHBG, and improvement in fertility (
Blume-Peytavi 2011; Bode 2012; Koulouri 2008). Furthermore, it
leads to improvement in the quality of life of the woman by raising
self esteem and personal well-being. Cessation of smoking should
be encouraged as smoking exacerbates some of the side effects
of pharmacological treatments for hirsutism, e.g. cardiovascular
events in combination with oral contraceptive drugs (Escobar-
Morreale 2012).
Cosmetic measures
1. Shaving, chemical depilatories, bleaching, plucking,
tweezing or threading, and waxing are all rapid hair removal
methods, but they are only temporarily effective. The most
important side effects are irritation or dermatitis. Waxing can
also be painful and lead to folliculitis (Blume-Peytavi 2011; Bode
2012; Escobar-Morreale 2012; Lanigan 2001).
2. Electrolysis (galvanic electrolysis, thermolysis, or a
combination of both (Blume-Peytavi 2011; Bode 2012;
Escobar-Morreale 2012; Richards 1995)), involves the passage of
an electric current through a needle inserted into the follicle to
destroy the hair bulb. Although results are highly dependent on
the skills of the professional providing the treatment, it is
effective, but often rather painful, very slow, and expensive and
might rarely result in scars. Thermolysis is faster, but it is
somewhat less effective and uses a high frequency alternating
current, which produces heat in the hair follicle and leads to
destruction. The combination or blend method combines both
these methods.
3. Laser and photoepilation treatments (Blume-Peytavi 2011;
Escobar-Morreale 2012; Haedersdal 2011; Lanigan 2001) are
among the fastest growing cosmetic procedures in the US and
Europe (Haedersdal 2011), and they are most effective in people
with lighter skin and dark-coloured hairs. These treatments are
widely discussed in another Cochrane review (Haedersdal 2006).
Pharmacological treatments
Topical therapy
Eflornithine hydrochloride irreversibly inhibits ornithine decar-
boxylase and suppresses the mitotic activity in the hair follicle,
thereby reducing the rate of hair growth (Martin 2008; Paparodis
2011). Common side effects are rash and systemic toxicity after
widespread application (Rosenfield 2005). Finasteride is a 5α-re-
ductase inhibitor, more frequently used systemically (see under
5α-reductase inhibitor).
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Oral contraceptive pills (OCP)
Oral contraceptive pills inhibit androgen secretion by the ovaries
and increase SHBG production by the liver, both leading to less
circulating free androgens (Bode 2012; Brodell 2010; Escobar-
Morreale 2012). The most important side effect is an increased
risk of venous thromboembolism. Other side effects are breast
tenderness, headache, and gastrointestinal symptoms.
Antiandrogens
In pregnant women all antiandrogens carry the risk of feminisation
of the male foetus and should therefore always be combined with
effective contraception in women of childbearing age.
1. Spironolactone is an antagonist of both aldosterone and the
androgen receptor (Escobar-Morreale 2012; Lumachi 2010;
Martin 2008; Shah 2009). It should not be used in women with
renal insufficiency or hyperkalaemia. Irregular menstrual
bleeding, headache, hypotension, nausea, and decreased libido
are side effects that are mostly dose-dependent.
2. Cyproterone acetate is a 17-hydroxyprogesterone acetate
derivative that competes with dihydrotestosterone for the
androgen receptor and to a lesser extent inhibits 5α-reductase
(Blume-Peytavi 2008; Escobar-Morreale 2012; Lumachi 2010).
Well known side effects are liver toxicity, irregular menstrual
bleeding, nausea, and decreased libido.
3. Flutamide and bicalutamide are non-steroidal, competitive
inhibitors of androgen receptor binding (Blume-Peytavi 2008;
Lumachi 2010; Paparodis 2011). The most important side effect,
although rare, is hepatotoxicity including fulminant liver failure.
5α-reductase inhibitor
Finasteride is a type II inhibitor of the 5α-reductase enzyme and
reduces the conversion of testosterone into dihydrotestosterone
(Blume-Peytavi 2008; Paparodis 2011; Shah 2009). Finasteride
can, like antiandrogens, lead to feminisation of the male foetus
and, very rarely, to liver dysfunction.
Insulin-sensitising agents
Women with PCOS frequently have hyperinsulinaemia. Insulin-
sensitising drugs decrease hyperinsulinaemia by increasing in-
sulin sensitivity; the lower insulin levels result in an increase of
SHBG, thereby reducing the levels of circulating free androgens
(Cosma 2008; Lumachi 2010; Paparodis 2011). Practice guide-
lines advise against prescribing insulin-sensitising drugs for the
sole purpose of hirsutism treatment as the advantages are not
proven (Escobar-Morreale 2012; Martin 2008). Possible side ef-
fects include gastrointestinal distress, increased risk of cardiovas-
cular events, liver dysfunction, and lactic acidosis.
Gonadotropin-releasing hormone analogues (GnRH)
Gonadotropin-releasing hormone analogue agonists suppress the
hypothalamic-pituitary-ovarian axis, inhibiting luteinising hor-
mone and follicle-stimulating hormone, thereby decreasing the se-
cretion of androgens by the ovaries (Bode 2012; Lumachi 2010).
When GnRH analogues are not combined with oestrogens, they
lead to menopausal symptoms with hot flushes and osteoporo-
sis. As they do not seem to have advantages over other thera-
pies, are expensive, and need additional oestrogens to prevent
bone loss and menopausal symptoms, practice guidelines advise
against the use of GnRH analogues for most women with hir-
sutism (Escobar-Morreale 2012; Martin 2008).
Glucocorticoids
Glucocorticoids are sometimes used in cases of non-classic con-
genital adrenal hyperplasia, which are not included within the
scope of our review. They suppress adrenocorticotropic hormone-
dependent adrenal androgen synthesis (Escobar-Morreale 2012;
Lumachi 2010; Martin 2008). Well known side effects are weight
gain, osteoporosis, and adrenal suppression.
Miscellaneous treatment options
There are a number of reasons for the apparent effectiveness of
the following treatment options. Spearmint tea has been shown
to have antiandrogenic properties (Grant 2010); statins reduce
theca cell androgen production (Banaszewska 2011); ovary resec-
tion reduces serum testosterone (Ashrafinia 2009); inositol might
have a positive effect on insulin resistance and additional lower-
ing of serum testosterone levels (Ciotta 2012B); and cimetidine is
a weak androgen receptor antagonist (Lissak 1989). Bromocrip-
tine is a dopamine agonist and it is suggested that women with
PCOS have lower LH secretions due to a deficiency in hypothala-
mic dopamine, which may lead to an excess in ovarian androgen
production (Murdoch 1987). Sibutramine is an anti-obesity drug
and, by improving weight loss, SHBG increases and free testos-
terone decreases (Sabuncu 2003). Clomiphene is considered to
improve hormonal abnormalities in women with PCOS and thus
might also have a beneficial effect on hirsutism (Roth 2012). Elec-
tro-acupuncture might reduce testosterone levels (Jedel 2011).
Why it is important to do this review
Hirsutism is a common and distressing disorder, which can have
a major impact on the quality of life of an individual. There are a
wide range of treatment options, but it is not clear which are the
most effective, and many of these interventions may have impor-
tant and undesirable side effects.
Several previous Cochrane reviews covered certain aspects of this
review (Brown 2009; Costello 2007; van der Spuy 2003), but we
will now incorporate these aspects into this review. This review is
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needed to provide reliable decision-making information to clini-
cians and hirsute women about the evidence of effectiveness and
safety of available treatments, and it will be the basis for recom-
mendations for future research. Treatment with laser or photoepi-
lation, which are often used to treat hirsutism, are covered in an-
other Cochrane review (Haedersdal 2006).
We published the plans for this review as a protocol, ’Interventions
for hirsutism excluding laser and photoepilation therapy’, (van
Zuuren 2013).
O B J E C T I V E S
To assess the effects of interventions (except laser and light-based
therapies alone) for hirsutism.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included studies that considered the following participants:
hirsute women of any age or ethnic background, women with
polycystic ovary syndrome, idiopathic hirsutism, and idiopathic
hyperandrogenism.
We excluded participants if their hirsutism was caused by or re-
lated to androgen-producing adrenal or ovary tumours, 21-hy-
droxylase-deficient non-classic adrenal hyperplasia, 21-hydroxy-
lase classic adrenal hyperplasia, hyperprolactinaemia, Cushing’s
syndrome, drug-related hyperandrogenism, or acromegaly.
If studies included women from both of these groups, we only
included those women that matched our inclusion criteria if sep-
arate data were available.
Types of interventions
We included any intervention alone or in combination versus ac-
tive treatment, no treatment, or placebo, i.e. we included any oral
and topical medications, lifestyle measures, or cosmetic treatment
options, but we excluded light-based therapies and lasers alone as
these are covered by another Cochrane review (Haedersdal 2006).
Types of outcome measures
We did not consider these prespecified outcomes as criteria for
including studies in this review, but they are a representative list of
the outcomes of interest within whichever studies were included.
See section 5.1.2 in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Primary outcomes
1. Participant-reported improvement of hirsutism measured at
the end of the study or at other site-dependent and clinically
important time points. Assessment would involve using a
recognised or validated rating scale (e.g. visual analogue scale
(VAS) and Likert scale).
2. Change in health-related quality of life (HRQOL) assessed
using any validated or recognised quality of life instrument at the
end of the study.
3. Proportion of participants who reported an adverse event
throughout the study period. We reported individual serious
adverse events separately.
We evaluated all patient reported outcomes (PROs) against the
’Checklist for describing and assessing PROs inClinical Trials’ (see
Chapter 17.6.a in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Secondary outcomes
1. Clinician’s assessment of improvement of hirsutism with a
standardised and validated scoring system (e.g. Ferriman-
Gallwey score), or assessment of hair diameter, rate of growth,
and length of hair at the end of the study.
2. Change in serum androgen levels (e.g. total testosterone,
free testosterone, dehydroepiandrosterone, androstenedione,
dihydrotestosterone) and SHBG at the end of the study.
3. Change in BMI at the end of the study.
4. Improvement of other clinical signs of hyperandrogenism
(e.g. acne, seborrhoea, female pattern hair loss, ovulatory
dysfunction) at the end of the study.
Depending on the type of intervention and the body area in-
volved, we considered short-term assessments as periods up to six
months and long-term assessments as outcomes after six months.
The length of the hair growth cycles and the rate of hair growth
differ in different body areas (Olsen 1999); therefore, the duration
of the interventions needs to exceed at least the span of the hair
growth cycle of the body areas to be treated. See also ’Physiology of
hair growth’ under Description of the condition and Description
of the intervention.
We produced a ’Summary of findings’ (SoF) table of the following
outcomes listed according to priority:
1. Participant-reported improvement of hirsutism
2. Change in HRQOL
3. Proportion of participants reporting an adverse event
14Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4. Clinician’s assessment of improvement of hirsutism
5. Change in serum androgen levels
6. Change in BMI
7. Improvement of other clinical signs of hyperandrogenism
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
We searched the following databases up to 11 June 2014:
• the Cochrane Skin Group Specialised Register using the
following terms: hirsut* or frazonism or (unwanted and hair and
growth) or (excess* and terminal and hair*);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2014, Issue 6) using the search strategy in
Appendix 1;
• MEDLINE via OVID (from 1946) using the strategy in
Appendix 2; and
• EMBASE via OVID (from 1974) using the strategy in
Appendix 3.
Trials registers
We searched the following trials registers on 14 June 2014 (EvZ
and ZF) using the following search terms: ’hirsutism’, ’hyperan-
drogenism’, and ’unwanted hair growth’.
• the metaRegister of Controlled Trials (www.controlled-
trials.com);
• the US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov);
• the Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au);
• the World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch);
• the EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
References from published studies
We (EvZ and ZF) examined the bibliographies of the included
and excluded studies for further references to potentially eligible
randomised controlled trials.
Correspondence
We (EvZ and ZF) contacted trial investigators and asked them to
provide missing data or clarify study details.
Adverse effects
We did not conduct a separate search for adverse effects of in-
terventions for hirsutism. However, we examined data on adverse
effects from the included studies that were identified.
Data collection and analysis
Some parts of the methods section of this review use text that
was originally published in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), as well as a number of
other Cochrane reviews variously co-authored by EvZ, ZF, and
BC.
Selection of studies
Two authors (EvZ and ZF) independently assessed the abstracts of
studies resulting from the searches. We obtained full copies of all
relevant and potentially relevant studies, those appearing to have
met the inclusion criteria, or for which there was insufficient in-
formation in the title and abstract tomake a clear decision on eligi-
bility. We assessed the full-text papers independently and resolved
any disagreement on the eligibility of included studies through
discussion and consensus. We excluded those records that did not
meet the inclusion criteria, and we noted the reasons for their ex-
clusion in the ’Characteristics of excluded studies’ section of the
review.
Data extraction and management
Two authors (EvZ and ZF) independently collected study details
and outcomes data using a predetermined form designed for this
purpose. We entered study details into the ’Characteristics of
included studies’ table in Review Manager (RevMan 2014). The
authors only included data if there was an independently reached
consensus.
If reported, we extracted the following details.
(a) Trial methods - method of sequence generation and conceal-
ment of allocation sequence; masking of participants, trialists, and
outcome assessors; exclusion of participants after randomisation;
proportion of and reasons for losses to follow-up.
(b) Participants - country and study setting; sample size; age; eth-
nicity; inclusion and exclusion criteria.
(c) Intervention - type; concentration, dose, and frequency; route
of administration; duration of intervention and follow-up.
(d) Control - type; duration of intervention and follow-up.
(e)Outcomes - primary and secondary outcomes as specified in the
’Types of outcomemeasures’ section of this review.We determined
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the outcome as short-term if it was taken between completion of
the intervention and up to one month of follow-up; medium-term
between one month but less than six months’ follow-up; and long-
term for six or more months’ follow-up.
If stated, we recorded the sources of funding of the included stud-
ies.
Assessment of risk of bias in included studies
Two review authors (EvZ and ZF) assessed the risk of bias of the se-
lected studies independently using The Cochrane Collaboration’s
tool for assessing risk of bias as described in Chapter 8, section 8.5,
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We compared the evaluations and discussed and
resolved any inconsistencies between the review authors.
We assessed the following domains as ’low risk of bias’, ’unclear’
(uncertain risk of bias), or ’high risk of bias’:
1. sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcomes assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We reported these assessments for each individual study in the
’Risk of bias’ tables.
We categorised and reported the overall risk of bias of each of the
included studies according to the following:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all criteria were met;
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more criteria were assessed as unclear;
or
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more criteria were not met.
Measures of treatment effect
We presented continuous outcomes on the original scale as re-
ported in each individual study. If similar outcomes were reported
using different scales, we converted these to standardised mean
differences (SMD). We presented either mean differences (MD)
or SMD with their associated standard deviation in parenthesis.
We presented dichotomous outcomes as risk ratios (RR) and, if
found significant, we converted them to either: the number of
patients needed to treat to find one additional beneficial outcome
(NNTB); or the number needed to treat to find one additional
harmful outcome (NNTH) (Newcombe 1998).
We reported all outcomes’ data with their associated 95% confi-
dence intervals (CI) and analysed them in RevMan 5 (RevMan
2014) according to a random-effects model using the Mantel-
Haenszel test for dichotomous outcomes and inverse variance for
continuous outcomes (unless stated otherwise). See section 9.4
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Unit of analysis issues
Cross-over trials
Unit of analysis issues can arise in studies where participants have
been randomised to multiple treatments in multiple periods or
where there has been an inadequate wash-out period. We analysed
these data based on the advice provided in section 16.4.4 in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We assessed the carry-over and period effects descriptively,
and if there was evidence of minimal impact and there were ade-
quate data, we carried out a paired analysis.
Studies with multiple treatment groups
Studies that are reported with multiple treatment groups have the
potential for participant data to contribute to multiple compar-
isons. We assessed the treatments and determined which were rel-
evant to our review then allocated the non-intervention partici-
pants as the ’shared’ group. We split the ’shared’ group equally into
the number of comparisons made, as discussed in section 16.5.4
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Within-patient studies
Unit of analysis issues can arise in studies where participants have
been randomised to multiple treatments on different parts of their
body. We analysed these data based on the advice provided in
sections 9.3.8 in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We assessed the potential risk of
treatment contamination and general change in the control group
descriptively and, if there was little suggestion of these and there
was adequate information, we carried out a paired analysis. For
paired analysis pooled comparisons, we have calculated the natural
logarithm of the marginal odds ratio and variance and used these
as treatment effects in a generic inverse variance model to compare
interventions with a random-effects model (Stedman 2011).
Dealing with missing data
If data were missing from trials that were less than 10 years old,
we tried wherever possible to contact the investigators or sponsors
of these studies. We re-analysed data according to the intention-
to-treat (ITT) principle whenever possible. For dichotomous out-
comes, if authors had conducted a per-protocol analysis, we car-
ried out an ITT analysis with imputation setting the missing data
to their baseline values, checking the degree of imbalance of drop-
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out between the arms to determine the potential impact of bias
(section 16.2.2 in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). If no suitable value could be car-
ried forward (e.g. adverse events), we conducted a complete case
analysis. For continuous outcomes, we carried out a per-protocol
analysis in place of an ITT analysis.
Where change from baseline scores are not presented, but base-
line and follow-up data are summarised, the change from base-
line scores have been estimated assuming a common correlation
of structure of 0.8 (section 16.1.3.2 in the Cochrane Handbook
for Systematic Reviews of Interventions) (Higgins 2011). In studies
where the standard deviation has been summarised at baseline (or
may be estimated at baseline) but not follow-up, the standard devi-
ation has been assumed to remain unchanged at follow-up. Where
only medians were presented with ranges, the mean was estimated
by the median, and the variance estimated using the range and the
number of observations (Hozo 2005).
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the characteristics
of the studies and the similarity between the types of participants
and the interventions. We assessed the degree of heterogeneity be-
tween the studies using the I² statistic. We reported heterogeneity
as important and at least moderate to substantial if the I² statis-
tic > 60% (Higgins 2011). If this could be explained by clinical
reasoning and a coherent argument could be made for combining
the studies, we entered these into a meta-analysis. In cases where
the heterogeneity could not be adequately explained, we did not
pool the data.
Assessment of reporting biases
Our assessments of reporting bias followed the recommendations
on testing for funnel plot asymmetry (Egger 1997), as described in
section 10.4.3.1 in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We performed these for primary
and secondary outcomes for meta-analysis when we included a
minimum number of studies, to allow a reasonable estimate of the
effect of intervention (nominally nine studies). We only presented
funnel plots where there was some evidence of asymmetry in the
plots. We explored possible sources of asymmetry with an addi-
tional sensitivity analysis.
Data synthesis
Two review authors (EvZ and ZF) analysed the data in RevMan
(RevMan 2014) and reported them in accordance with the ad-
vice in Chapter 9 in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We carried out a random-effects
meta-analysis if we were able to identify an adequate number of
studies (n ≥ three) that investigated similar interventions and re-
porting data that exhibited not more than moderate heterogeneity
(Treadwell 2006).
Subgroup analysis and investigation of heterogeneity
We considered the following subgroup analyses:
• ethnic background;
• severity of the hirsutism;
• hyperandrogenism;
• cause of hirsutism;
• premenopausal and postmenopausal status; or
• timing of outcome.
However, we didnot find enough studies to carry out any subgroup
analysis.
Sensitivity analysis
We conducted sensitivity analyses, but did not report these since
the impact of the assumptions that we made did not influence the
interpretation of any of the findings. The two assumptions that
wemade were: using a fixed correlation structure when computing
the change from baseline standard deviation (r = 0.8) and using a
random-effects pooling method.
R E S U L T S
Description of studies
See ’Characteristics of included studies’ and ’Characteristics of
excluded studies’.
Results of the search
Our searches retrieved 1118 references to studies. Searching of the
trial registers identified 14 ongoing studies, and the bibliographies
of the included and excluded studies provided an additional 45
potentially eligible studies. We identified a total of 1177 references
for evaluation.
After the removal of duplicates and examination of the titles and
abstracts, we excluded 880 references from the review. We then
subjected the full-text copies of the remaining 297 studies to fur-
ther evaluation. A number of studies (18) were not published
in the English language; Farsi (one) (Esmaeilzadeh 2010), Span-
ish (two) (Devoto 2000; Devoto 2004), German (six) (Erdmann
1994; Grund 1975; Hahn 2004; Lachnit-Fixson 1977; Lee 2000;
Weiss 2007), Italian (four) (Falsetti 1997B; Farina 2006; LeDonne
2012; Paggi 1981), Danish (two) (Nielsen 1985; Pedersen 1985),
French (one) (Pugeat 1991), Slovakian (one) (Visnovský 2010),
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and Polish (one) (Baranowska 1983), but these were all translated
prior to assessment for eligibility.
Out of the 297 studies, 33 appeared to be duplicate publica-
tions and are listed under the primary references. We excluded
80 with reasons (see ’Characteristics of excluded studies’), 13
studies are awaiting further assessment (see ’Characteristics of
studies awaiting classification’), and 14 are ongoing trials (see
’Characteristics of ongoing studies’ section) leaving a total of 157
included studies (see ’Characteristics of included studies’).
For further details see the ’Study flow diagram’ (Figure 4).
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Figure 4. Study flow diagram.
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Included studies
The review included 157 studies comprising 10,550 women (see
the ’Characteristics of included studies’ section).
Characteristics of the trial setting and methods
All of the studies were randomised controlled trials, 36 included a
placebo arm, 112 had an active control treatment arm, and nine
studies included both arms. Most (100) of the studies were con-
ducted after the year 2000. The majority (138) were single-centre
studies, and the remainder (19) were multi-centre studies. The
studies were conducted in Europe (97), in the USA/Canada (21),
in Mid and South-America (10), in Asia (20), in Africa (three), in
Australia (four), and two on different continents.
Characteristics of the participants
The number of participants included in the individual studies
varied widely, from 8 to 596, with between 30 and 80 representing
themost common sample size. Themean age of the participants in
the individual studies ranged from 15 to 46 years, with an overall
mean age of 25.4 years.
Characteristics of the interventions
A wide range of interventions were evaluated, which we have cat-
egorised into nine groups (see Table 2). The 157 studies covered
165 comparisons, most of which included an active control arm.
A total of 48 studies did not report any usable data (see Table 3),
reducing the total number of comparisons that provided usable
data to 133. Duration of the intervention varied from 10 days to
two years, but in the majority of studies this was between six and
12 (mean 7.9) months. Although a study duration of 10 days or a
month may be too short a period to observe a benefit on hirsutism,
these studies have been included as a short study duration was
not an exclusion criterion (Cedeno 1990; Elnashar 2006; Grant
2010).
Characteristics of the outcome measures
Very few of the included studies addressed our primary outcomes.
Only 26/157 studies reported data on participant-reported im-
provement of hirsutism. In 11 of these this outcome was assessed
using a Likert scale (three- to six-point), in one a visual analogue
scale (VAS) (Harborne 2003), and one study used an alternative
analogue scale (Barth 1991). The trialists in one study utilised an
outcome measure (ESTEEM), which they had modified from the
Bother Assessment in Skin Conditions (BASC) instrument, but
provided very limited information on how the modified assess-
ment tool was subsequently tested and validated (Jackson 2007).
Questionnaires were used in the remaining studies but the reports
provided very limited details about how these were used to assess
outcomes.
Three studies reported change in health-related quality of life
(HRQOL) (Consoli 1994; Grant 2010; Ladson 2011). The
generic Dermatology Quality of Life Index was used in one of
these studies (Grant 2010), and the disease-specific PCOS quality
of life survey was used in Ladson 2011. An 11-item questionnaire
with each question rated on a four-point Likert scale was used in
Consoli 1994.
Less than half of the studies (63/157) reported on adverse events
and as the treatments varied, so did the accompanying adverse
events. None of the instruments used to assess our primary out-
comes, which were all PROs, met all the recommended criteria
based on the ’Checklist for describing and assessing PROs in Clin-
ical Trials’ (see Chapter 17.6.a in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011).
The majority of studies (135/157) reported clinician’s assessment
of improvement of hirsutism, which was predominantly assessed
using the Ferriman-Gallwey score. Change in androgen levels was
measured in most of the studies (140/157), while BMI and im-
provement of other clinical signs of hyperandrogenism were eval-
uated in 49/157 and 56/157 of studies respectively.
Excluded studies
We excluded 80 studies from this review only after evaluation
of their full-text copies. We excluded all of these largely on the
basis that they were non-randomised trials (see ’Characteristics of
excluded studies’). Although the titles of 17 studies appeared to
indicate that these were randomised trials, further examination of
the full-text versions of these reports revealed that they were in fact
quasi-randomised (allocation was done on the basis of a pseudo-
random sequence, e.g. odd/even hospital number or date of birth,
alternation).
Risk of bias in included studies
We assessed each of the included studies for risk of bias and re-
ported the judgements for the individual domains in the ’Risk
of bias’ table associated with each study. We have also presented
these in the ’Risk of bias’ graph in Figure 5 and the ’Risk of bias’
summary in Figure 6.
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Figure 5. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 6. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Only four of the studies met all of the criteria across all of the
domains in The Cochrane Collaboration’s tool for assessing the
risk of bias, and therefore we considered these studies to be at ’low
risk of bias’ (plausible bias unlikely to seriously alter the results)
(Ibáñez 2009; Kjøtrød 2004; Moghetti 2000; Otta 2010). We
considered themajority of the studies (123/157) to be at ’high risk
of bias’ (plausible bias that seriously weakens confidence in the
results) because one ormore domains received a judgement of high
risk.Of all the 157 studies, 96were not blinded, which represented
the most frequent potential source of bias. We categorised the
remaining studies (30/157) as ’unclear risk of bias’ (plausible bias
that raises some doubt about the results) because we assessed one or
more criteria as unclear. For these and further details, see the ’Risk
of bias’ tables in the ’Characteristics of included studies’ section.
Allocation
Themethods used to generate the allocation sequence and how the
sequence was concealed, such that participants and investigators
enrolling participants could not foresee the upcoming assignment,
are the most important and sensitive indicators that bias has been
minimised in a clinical trial (Schulz 1995).
Sequence generation
In 87 out of the 157 trials in this review the method of sequence
generation was not described at all or was at best unclear. In the re-
mainder (70) the method used to generate the allocation sequence
was described in sufficient detail; therefore, we judged this domain
as low risk of bias for these studies.
Allocation concealment
The method used to conceal the allocation sequence was not re-
ported in 111 out of the 157 trials, which received a judgement
of unclear risk of bias for this domain. In 44 studies allocation
concealment was ensured by central allocation, was pharmacy-
controlled, or was achieved through the use of serially numbered,
opaque envelopes. We judged the risk of bias for this domain to
be high in two studies because the investigators had access to the
random-number table and it was likely that allocation could be
foreseen (Fruzzetti 2010; Gambineri 2006).
Blinding
The majority of studies (96) were open-label design and therefore
the outcome or outcome measurement was likely to be influenced
by lack of blinding and, thus, we judged the domain for perfor-
mance bias as at ’high risk’. For two studies, we did not consider
the open-label design to have any significant influence on the out-
come assessment (detection bias) as both outcomes, i.e. ovulation
and serum tests, are unlikely to be influenced by the lack of blind-
ing (Farquhar 2002; Vexiau 1995). The measures used to blind
study participants and personnel from knowledge of which inter-
vention a participant received were described in sufficient detail
in only 27 of the studies. Blinding was achieved largely through
the use of either identical pre-labelled bottles or tubes, or with the
use of similar packaging and the use of identical pills, tablets, or
capsules. In the remaining 34 studies the method used to blind
participants, healthcare providers, or outcome assessors was not
described at all or not in sufficient detail, and therefore we judged
the risk of bias as ’unclear’ for this domain.
Incomplete outcome data
In slightly more than half (88) of the studies, incomplete outcome
data appear to have been adequately addressed and the losses were
reasonably well-balanced across intervention groups, with similar
reasons for missing data across the groups. However, we gave a
judgement of high risk of bias for 36 studies mainly due to sub-
stantial (> 20%) drop-out rates and subsequent per-protocol data
analysis. We judged the risk of bias in the remaining 33 studies to
be unclear for this domain.
Selective reporting
Based on the information in the methods section of the reports,
141 of the 157 studies appear to have reported all prespecified
outcomes and we therefore judged them to be free of selective re-
porting. We judged the 16 remaining studies to be unclear (nine)
and high (seven) risk of bias. Six of these studies were abstracts
or posters to conference proceedings, which provided insufficient
information to make a clear judgement for this domain (Ciotta
2012; Ghosh 2008; Huber 1985; Spuy 1995; Unfer 2000; Wang
2012). There were 29 duplicate publications of included studies,
which we excluded as they would lead to overestimation of inter-
vention effects (multiple publication bias) (see Figure 4).
Other potential sources of bias
We judged this domain as ’low risk of bias’ in most of the studies
(125/157). In 13/157 studies we judged this domain as at high
risk for several reasons, i.e. that the investigators were employed
by the pharmaceutical company of the drug under research and
a potential risk of bias could not be excluded, or if there was
serious baseline imbalance. In situationswhere the report provided
insufficient information on the extent of support provided by the
pharmaceutical company or if the lack of detail in the report did
not allow us to assess adequately the presence of other possible
sources of bias, we judged the domain as ’unclear’ (19/157).
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Effects of interventions
See: Summary of findings for the main comparison Ethinyl
estradiol 35 µg + cyproterone acetate 2 mg compared to ethinyl
estradiol 30 µg + desogestrel 0.15 mg for hirsutism; Summary
of findings 2 Flutamide 250 mg b.i.d. compared to placebo
for hirsutism; Summary of findings 3 Flutamide 250 mg once
to b.i.d. compared to spironolactone 100 mg for hirsutism;
Summary of findings 4 Spironolactone 100 mg compared to
placebo for hirsutism; Summary of findings 5Finasteride 5mg to
7.5 mg compared to placebo for hirsutism; Summary of findings
6 Metformin 500 mg to 2550 mg per day compared to placebo
for hirsutism; Summary of findings 7 Finasteride 5mg compared
to spironolactone 100 mg for hirsutism; Summary of findings
8 Flutamide 250 mg once to twice daily compared to metformin
1275 mg to 1700 mg per day for hirsutism; Summary of findings
9 Finasteride 5 mg compared to flutamide 250 mg once to b.i.d.
for hirsutism
Less than one-third (48/157) of the included studies, which cov-
ered 32 comparisons, provided no usable or retrievable data and
did not contribute further to the results of this review (see Table
3). Themain reasons why data could not be used were: no separate
data reported on hirsute women, the very limited data available
in abstracts to conference proceedings, and losses to follow-up of
participants with drop-out rates in excess of 40%.
Theminimal important difference (MID) represents the between-
groups criterion that needs to be met or exceeded in order for
study results to be considered clinically meaningful. As yet the
MID for the Ferriman-Gallwey score has not been established,
and therefore in order that we provide meaningful data based
on the clinician’s assessments of these scores we indicate, where
appropriate, if the changes from baseline or the mean differences
between groups for these assessments were clinically important.
To this extent a change in Ferriman-Gallwey score in excess of 7
from baseline is generally considered to be a clinically important
change as indeed is a mean difference of at least 7 in Ferriman-
Gallwey score between groups (see Figure 3). Degrees of hirsutism
and thematching assessment scores correlate poorlywith androgen
levels and although we report these changes in androgen levels and
whether they were statistically significant, we only indicate these
as being clinically important if they reflect corresponding changes
in hirsutism score.
None of the studies evaluated cosmeticmeasures such as depilatory
creams, bleaching, waxing, or electrolysis, while laser and pho-
toepilationwere included in another Cochrane review (Haedersdal
2006).
We have addressed our prespecified outcomes under the following
intervention headings
• Lifestyle modification (comparisons 1 to 2)
• Topical treatments (comparisons 3 to 6)
• Oral contraceptive pills (comparisons 7 to 20)
• Antiandrogens (comparisons 21 to 24)
• 5α reductase inhibitors (comparisons 25 to 29)
• Insulin-sensitising agents (comparisons 30 to 37)
• Combined treatments (comparisons 38 to 101)
• Other treatment comparisons (comparisons 102 to 133)
We did not provide detailed data for changes in androgen levels
when these were not statistically significant or not clinically mean-
ingful with respect to improvement or lack of improvement in
hirsutism, but these changes in levels are reported in the ’Changes
in androgen levels’ tables (see Data and analyses). Baseline values
for the individual studies are reported in the ’Characteristics of
included studies’ and will not be repeated to avoid duplication of
text.
Nine ’Summary of findings’ tables for comparisons that were con-
sidered to be important by the review authors, or where data could
be pooled for various outcomes, summarise the quality of the body
of evidence for each of these comparisons (see Summary of findings
for the main comparison; Summary of findings 2; Summary
of findings 3; Summary of findings 4; Summary of findings 5;
Summary of findings 6; Summary of findings 7; Summary of
findings 8; Summary of findings 9).
Lifestyle modification
(1) Exercise three times a week for 30 minutes versus no
exercise over three to four months
This intervention and comparison was examined in two stud-
ies assessed at ’high risk of bias’ (Jedel 2011; Vigorito 2007): a
three-armed study of 51 women with polycystic ovary syndrome
(PCOS) (Jedel 2011) (see comparison 128 and 129) and a further
study,which included90overweightwomenwith PCOS (Vigorito
2007). The entire PCOS study population received general di-
etary and behavioural advice but this did not include a structured
caloric restriction programme.
Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
This outcome was not assessed in Jedel 2011 and although this was
not a prespecified outcome in Vigorito 2007, the trialists indicated
that no adverse events occurred during the training sessions.
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Secondary outcomes
Clinician’s assessment of improvement of hirsutism
In Jedel 2011 both groups showed minimal increases in the mean
Ferriman-Gallwey score of 0.72 (3.54) in the exercise group and
1.40 (3.66) in the no intervention group (mean difference (MD) -
0.68, 95% confidence interval (CI) -3.16 to 1.80; P value = 0.59).
In Vigorito 2007 there was a slight reduction in the mean Ferri-
man-Gallwey score in the exercise group of 0.40 (2.12) as com-
pared to a non-significant increase of 0.20 (2.10) in the control
group (MD -0.60, 95% CI -1.47 to 0.27; P value = 0.18).
Change in serum androgen levels
There were minimal changes from baseline in the serum androgen
levels in both groups and with minimal differences between the
groups (see Analysis 1.1).
Change in body mass index (BMI)
Minimal increases in mean BMI were reported in both groups in
Jedel 2011. In the exercise group there was an increase of 0.01
kg/m² (0.70) and in the control group an increase of 0.11 kg/m²
(0.63) (MD -0.10 kg/m², 95% CI -0.55 to 0.35; P value = 0.66).
In Vigorito 2007 there was a slight improvement, illustrated by a
decreased BMI in the exercise group with a mean change of 1.30
kg/m² (1.83) versus a smaller change of 0.10 kg/m² (2.14) in the
control group (MD -1.20 kg/m², 95% CI -2.02 to -0.38; P value
= 0.004). Although this difference is statistically significant it did
not appear to have any impact on the severity of the hirsutism.
Improvement of other clinical signs of hyperandrogenism
The investigators in Jedel 2011 stated that “menstrual frequency
improvedmore in the physical exercise group than in the no active
intervention group” (authors state P value = 0.014), but data were
only reported in a graph plot. Between-group differences for the
change from baseline to week 16 were determined by Kruskal-
Wallis test followed by Mann-Whitney U-test. This outcome was
not assessed in Vigorito 2007.
(2) Lifestyle modification (+ placebo tablets) versus placebo
tablets for 24 weeks to 12 months
One study, which included four treatment arms, addressed the
effect of a lifestyle modification programme (+ placebo tablets)
that included nutrition, behaviour, and physical activity versus
placebo alone (Hoeger 2004). The study had a high drop-out rate
of almost 40%. The other possible comparisons in this study are
addressed under comparisons 32, 38 to 41. Participants received
a personally tailored diet aiming for a 500 to 1000 calorie deficit
per day and every participant was recommended to undertake 150
minutes of exercise per week. These investigators also conducted a
four-armed study several years later (Hoeger 2008 study 1), which
had a shorter duration of 24 weeks (see also comparison 17, 32,
103, 105, and 112).
Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
This outcome was inadequately addressed in Hoeger 2004, with
no side effects listed per treatment arm, and only reported as gen-
eralised comments covering the four treatment arms. This out-
come was not addressed in Hoeger 2008 (study 1).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The data we report in Hoeger 2004 had to be estimated from a
box-and-whisker plot. The estimated mean change in the modi-
fied Ferriman-Gallwey score in the six participants in the lifestyle
modification programme group showed a reduction of 3.0 (4.64)
compared to an increase of 0.6 (2.58) in the seven participants
in the control group (MD -3.60, 95% CI -7.78 to 0.58; P value
= 0.09), which was not a statistically significant difference. The
effects reported in Hoeger 2008 (study 1) were smaller and most
probably due to the shorter study duration. In this study the mean
Ferriman-Gallwey score reduced by 1.00 (1.24) in the lifestyle
modification group and by 0.90 (3.25) in the placebo group (MD
-0.10, 95% CI -2.29 to 2.09; P value = 0.93).
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Change in serum androgen levels
There were no clinically important differences in testosterone or
sex hormone-binding globulin (SHBG) levels between the two
groups associated with improvements in hirsutism (see Analysis
2.1).
Change in BMI
This outcomewas not assessed inHoeger 2004, whereas inHoeger
2008 (study 1) the mean BMI reduced by 2.90 kg/m² (4.94) in
the lifestyle modification group and in the placebo group by 0.60
kg/m² (4.57) (MD -2.30 kg/m², 95% CI -6.74 to 2.14; P value =
0.31).
Improvement of other clinical signs of hyperandrogenism
Noprecise datawere reported but the authors stated in both studies
that, “overall, no significant differences were demonstrated in ovu-
latory events between treatment groups and the placebo group”.
Topical treatments
(3) Eflornithine HCl 13.9% cream versus vehicle, each
applied twice daily for 24 weeks
Two studies, Jackson 2007 and Wolf 2007, compared and re-
ported data for these interventions but assessed different outcomes.
The numbers of participants completing the study are not consis-
tently reported in the two studies (see Notes in ’Characteristics of
included studies’ and in ’Contact with investigators’ under Addi-
tional tables).
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was not assessed.
Change in health-related quality of life (HRQOL)
In Jackson 2007 the investigators used the ESTEEM instrument
for assessing the level of ’bother’ caused by hirsutism and the
changes brought on by the treatment. Eflornithine was shown to
be more effective than vehicle when assessed for this single out-
come (’overall bother’), which was one of the six patient-reported
outcomes (PROs) integral to the ESTEEM instrument (see Notes
in ’Characteristics of included studies’ and Caro 1996). With re-
gard to being “bothered by facial hair” or “overall bother”, the
mean decrease on the visual analogue scale (VAS) was 30.7 (32.03)
after 24 weeks in the 355 participants using eflornithine cream
compared to a decrease of 14.4 (21.04) in the 173 participants in
the vehicle group (MD 16.30, 95% CI 11.72 to 20.88; P value <
0.001).
Proportion of participants who reported an adverse event
There was inconsistency in reporting of the number of partici-
pants in both studies, however in Wolf 2007 182/395 (46%) of
the participants reported adverse events versus 80/201 (40%) of
those in the vehicle group, indicating a difference that was not
statistically significant (risk ratio (RR) 1.16, 95% CI 0.95 to 1.41;
P value = 0.15). The most important adverse effects were acne
and pseudofolliculitis barbae, which accounted for around 37%
of the participants in both treatment groups. The only side effects
that occurred were burning, stinging, and tingling, which were
reported more frequently in the eflornithine group (14.2%) com-
pared to the vehicle group (5%). Additional adverse effects that
were reported in both groups were pruritus, dry skin, alopecia,
erythema, irritation, dermatitis, and rash.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Physician’s global assessments were dichotomised by the investiga-
tors inWolf 2007 into ’success’ (clear or almost clear ormarked im-
provement) and ’failure’ (improved or no improvement or worse).
In the eflornithine group 126/395 (32%) of the participants were
considered a clinical success compared to 18/201 (9%) of the par-
ticipants in the vehicle group (RR 3.56, 95% CI 2.24 to 5.66; P
value < 0.001, number needed to treat for an additional benefi-
cial outcome (NNTB) = 5, 95% CI 4 to 7), which is a clinically
important difference.
Video analysis confirmed a reduction in hair mass of 26% in the
eflornithine group versus 5% in the vehicle group, as well as a
reduction in hair length of 23% versus 4% respectively (authors
stated P value = 0.016).
Change in serum androgen levels
Change in BMI
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Improvement of other clinical signs of hyperandrogenism
None of the above three outcomes were assessed.
(4) Long-pulsed alexandrite laser + eflornithine 13.9% cream
twice daily versus long-pulsed alexandrite laser + vehicle
cream twice daily for six to eight months
Two studies, both of which were within-participant comparisons,
evaluated the effects of eflornithine cream as add-on therapy to
laser therapy for facial hirsutism (Hamzavi 2007; Smith 2006).
As both treatment arms in the two studies included laser therapy
and the treatment under investigation was eflornithine cream, we
included these studies in our review. Study durationwas sixmonths
in Hamzavi 2007 and 34 weeks in Smith 2006. Insufficient data
were reported in both studies to permit calculation of marginal
odds ratios (OR) for any of the outcomes.
Primary outcomes
Participant-reported improvement of hirsutism
In Hamzavi 2007, 13/33 (39.3%) participants considered that the
side treated with eflornithine cream looked ’better’, while 18/33
(54.5%) noticed no difference but these included two participants
who dropped out. The participants in Smith 2006 were generally
more positive about the effects of eflornithine and 60% (32/54)
of the 54 participants that finished the treatment preferred the
eflornithine treated side compared to 20% (11/54). Ten out of the
64 (15.6%) participants did not complete the study.
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
The number of adverse events reported by participants varied
markedly between the two studies. In Hamzavi 2007 4/33 partic-
ipants reported an adverse event on the eflornithine treated side
(mild discomfort (two), mild tingling (one), and transient hyper-
pigmentation (one)) and none were experienced on the sides of
the face which received placebo (no meaningful OR could be cal-
culated). In Smith 2006 a total of 40 adverse events were reported
in 27/54 participants. On the eflornithine treated side 15 (23%)
participants reported 23 adverse events, and on the vehicle treated
side 12 (19%) participants reported 17 adverse events. Most of
the adverse events (74%) in this study were considered to be mild.
Acne developed on the eflornithine cream side in eight (13%)
women and on the vehicle side in seven (11%) women, a differ-
ence which might reflect the composition of the vehicle. Herpes
simplex reactivation developed on the eflornithine cream side in
four (6%) women and on the vehicle side in two (3%) women.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
InHamzavi 2007 the clinicians considered the eflornithine treated
side to be ’clear or almost clear’ in 29/33 of the participants versus
21/33 on the vehicle-treated side. In Smith 2006 the clinicians
rated both treatments as being more or less equally effective, i.e.
65% to 70% of participants in both groups received a rating of
’marked improvement’ or ’clear’ for chin and upper lip. The data
from both studies appear to indicate that the effect is mainly due
to the laser treatment.
Change in serum androgen levels
Change in BMI
Improvement of other clinical signs of hyperandrogenism
None of the above three outcomes were assessed.
(5) Finasteride (0.25% or 0.5%) cream versus placebo, each
applied twice daily for six months
Two studies reported usable data for these interventions (Iraji
2005; Lucas 2001). Both studies had a within-participant design,
which included only eight participants in the 0.25% finasteride
cream study (Lucas 2001), compared to 35 participants in the
0.5% finasteride cream study (Iraji 2005). The results as reported
in the two studies were contradictory, there was no demonstrable
reduction in the number of terminal hairs or hair thickness in the
0.5% finasteride cream study; whereas the study with the lower
concentration (0.25%) reported a ’significant decrease’. Insuffi-
cient data were reported in both studies to permit calculation of
marginal odds ratios (OR) for any of the outcomes. The investiga-
tors in Iraji 2005 indicated that 5/35 (14.3%) of the participants
failed to complete the study because they did not ”note any dif-
ference“.
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Primary outcomes
Participant-reported improvement of hirsutism
Six out of the eight participants inLucas 2001 noted a considerably
diminished hair growth rate as well as a decreased thickness of the
hair on the side of the face treated with finasteride cream, whilst
the remaining two reported no difference between the sides of the
face. The investigators in Iraji 2005 reported that 25/35 of the
participants ”noted a considerable diminished rate of hair growth
on both sides of the face, especially on the one side that they had
guessed that side is medication“. Five had amildly diminished rate
of hair growth and five indicated that they had not noticed any
change.
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
Neither of the two studies reported any adverse events for either
of the interventions.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The number of terminal hairs/cm² was assessed in both studies.
In Iraji 2005 the mean change from baseline was -2.90 hairs/
cm² (3.70) in the finasteride 0.5% cream group compared to -
1.70 hairs/cm² (3.69) in the placebo group and the investigators
stated that there was no statistically significant difference between
the groups. In contrast, in the eight participants in Lucas 2001
the mean change from baseline was -12 hairs/cm² (23.74) for the
finasteride 0.25% cream group and -3 hairs/cm² (23.74) for the
vehicle group (the investigators stated that there was significantly
’decreased hair growth’). The mean change from baseline of hair
thickness in Iraji 2005 was -0.80µm(0.54) in the finasteride 0.5%
group and -0.20 µm (0.52) in the placebo group, a difference
which the investigators stated was not statistically significant. In
Lucas 2001 no pretreatment data were reported other than that
there was no statistically significant difference between the groups.
The investigators concluded that after the treatments there was a
significant difference between the groups as the thickness of the
hairs was 3.11 µm (0.14) in the finasteride 0.25% group versus
4.33 µm (0.20) (authors state P value < 0.001 (paired t-test)).
Change in serum androgen levels
These outcomes were not assessed in Iraji 2005, and although no
data were reported in Lucas 2001, the investigators stated that the
androgen levels did not change significantly during the study.
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(6) Fennel 1% cream versus fennel 2% cream versus vehicle
each applied twice daily for 24 weeks
A single study assessed at high risk of bias reported data for these
interventions (Javidnia 2003).
Primary outcomes
Participant-reported improvement of hirsutism
Although ’patient satisfaction’ was an outcome that was prespec-
ified in the methods section of this study, no data were reported
(see ’Risk of bias’ assessment under ’Characteristics of included
studies’ for this study (Javidnia 2003)).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
This outcomewas not assessed, however the investigators indicated
that there were no adverse events.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The mean value of the reduction in hair diameter was 7.8% (3.7)
for the fennel 1% cream group (N=11), 18.3% (8.3) for the fennel
2% cream group (N = 15), and 0.5% (2.1) in the vehicle group
(N = 12). Although hair growth rate was one of the prespecified
outcomes for the trial it was not reported by the investigators.
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Change in serum androgen levels
Change in BMI
Improvement of other clinical signs of hyperandrogenism
None of the above three outcomes were assessed.
Oral contraceptive pills
(7) Ethinyl estradiol 35 µg + cyproterone acetate 2 mg
versus ethinyl estradiol 30 µg + drospirenone 3 mg for 12
months
Two studies provided usable data for this comparison (Batukan
2007; Bhattacharya 2012). Bhattacharya 2012 had three treatment
arms and the other comparisons are listed below (comparison 8
and 9).
Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
This outcome was not assessed in Batukan 2007, but in
Bhattacharya 2012 two participants in each group (50) experi-
enced a side effect (RR 1.02, 95%CI 0.15 to 6.98; P value = 0.99).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Themean Ferriman-Gallwey score decreased by 12 in both groups
in Batukan 2007. The mean reduction in the ethinyl estradiol
(EE) + cyproterone acetate (CPA) group was 12 (1.07) and in the
EE + drospirenone group 12 (1.14), which is a clinically meaning-
ful change, however the mean difference between the two groups
was 0.0 (95% CI -0.45 to 0.45; P value = 1.00). Both therapies
appeared to be highly effective in the reduction of terminal hairs.
In Bhattacharya 2012 the reduction in the modified Ferriman-
Gallwey score was lower; 5.29 (5.88) in the EE + CPA group,
which was less pronounced than in Batukan 2007, while in the
EE + drospirenone group the reduction was just 2.12 (6.58) (MD
-3.17, 95% CI -5.61 to -0.73; P value = 0.01). Although this dif-
ference was statistically significant, it is not clinically important.
Change in serum androgen levels
There were minimal changes from baseline in the serum androgen
levels in both groups and minimal differences between the groups,
which were unlikely to be clinically important with respect to any
difference in the improvement of hirsutism and, except for the
difference in SHBG and androstenedione in Batukan 2007, were
also not statistically significant (see Analysis 3.1).
Change in BMI
This outcome was only assessed in Bhattacharya 2012, which re-
ported a reduction in BMI of 0.59 kg/m² (4.76) in the EE +
CPA group and an increase of 0.11 kg/m² (5.54) in the EE +
drospirenone group (MD -0.70 kg/m², 95% CI -2.72 to 1.32; P
value = 0.50).
Improvement of other clinical signs of hyperandrogenism
Only Bhattacharya 2012 addressed this outcome but it was unclear
in the report which type of instrument was used to measure the
change in acne severity, and therefore accurate interpretation of
the outcome data was not feasible. The investigators reported a
reduction in acne score of 1.52 (1.25) in the EE + CPA group and
1.42 (1.27) in the EE + drospirenone group with no statistically
significant difference between the groups (MD -0.10, 95% CI -
0.59 to 0.39; P value = 0.69).
(8) Ethinyl estradiol 35 µg + cyproterone acetate 2 mg
versus ethinyl estradiol 30 µg + desogestrel 0.15 mg for 12
months to two years
This comparison was addressed by four studies (Bhattacharya
2012; Mastorakos 2002; Mastorakos 2006; Porcile 1991), but the
duration of Porcile 1991 was one year longer than the others. One
of these was a three-armed study (Bhattacharya 2012), and the
data are also reported under comparisons 7 and 9. Similarly for
Porcile 1991 we have reported the data under comparison 12 and
13.
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Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
Only Bhattacharya 2012 reported data for this outcome. In the
group treated with EE+CPA2/50 participants reported an adverse
event and in the EE + desogestrel group 5/50 experienced adverse
events (RR 0.41, 95% CI 0.08 to 2.05; P value = 0.28).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Wewere able to pool the data formean change frombaseline in the
Ferriman-Gallwey score from three of the studies (Bhattacharya
2012; Mastorakos 2002; Mastorakos 2006). Both treatment arms
showed clinically meaningful reductions in the Ferriman-Gallwey
score but the mean difference between the EE + CPA group and
EE + desogestrel group was -1.84, which was not statistically sig-
nificant (95% CI -3.86 to 0.18; P value = 0.07 and I² = 45%) (see
Analysis 4.1).
The Lorenzo score was used in Porcile 1991 and reached similar
conclusions (MD 0.20, 95% CI -6.30 to 6.70; P value = 0.95; see
Analysis 4.2).
Change in serum androgen levels
The details for the changes in serum androgen levels are listed in
Analysis 4.3. In Bhattacharya 2012 there were statistically signif-
icant differences between the two study arms for SHBG and the
Free Androgen Index. The more substantial increase in SHBG
reported in this study in the EE + CPA group closely correlates
with the increased reduction in free androgen excess in this group.
For this individual study this was also reflected in a statistically
significant reduction of mean change in Ferriman-Gallwey score,
an effect that was lost when we pooled the data (see Analysis 4.1).
Change in BMI
Two studies addressed this outcome (Bhattacharya 2012;
Mastorakos 2006). There were small changes compared to baseline
in the BMI, and no statistically significant changes between the
two groups in both studies. In Bhattacharya 2012 the reductions
in BMI were 0.59 kg/m² (4.76) for the EE + CPA group and 0.45
kg/m² (6.75) for the EE + desogestrel group (MD -0.14 kg/m²,
95% CI -2.44 to 2.16; P value = 0.90). In Mastorakos 2006 the
reductions in BMI were 0.6 kg/m² (4.41) and 0.7 kg/m² (4.61)
respectively, with a MD of 0.10 kg/m² (95% CI -2.85 to 3.05; P
value = 0.95).
Improvement of other clinical signs of hyperandrogenism
Only Bhattacharya 2012 reported data for this outcome. The
mean changes in acne score showed a reduction of 1.52 (1.25)
in the EE + CPA group and 1.41 (1.32) in the EE + desogestrel
group. There was no statistically significant difference between the
two treatment groups (MD -0.11, 95% CI -0.61 to 0.39; P value
= 0.67).
(9) Ethinyl estradiol + drospirenone versus ethinyl estradiol
30 µg + desogestrel 0.15 mg for 12 months
Both Bhattacharya 2012 and Kriplani 2010 provided usable data
for this comparison. One of these studies, Bhattacharya 2012,
had three treatment arms (the other two comparisons are listed
in comparison 7 and 8). In Kriplani 2010 only nine of the 60
participants were hirsute, but separate data were provided for the
Ferriman-Gallwey-score assessments but not for the other analyses.
Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
There was no statistically significant difference in the number of
adverse events reported between the two oral contraceptive pills
(OCPs) in both of the studies. In Bhattacharya 2012 2/57 of the
participants in the EE + drospirenone group reported an adverse
event versus 5/58 in the EE + desogestrel group (RR 0.41, 95%
CI 0.08 to 2.01; P value = 0.27). In Kriplani 2010 adverse events
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were reported by 12/30 in the EE + drospirenone group compared
to 19/30 in the EE + desogestrel group (RR 0.63, 95% CI 0.38
to 1.06; P value = 0.08). Both treatment groups reported similar
side effects, i.e. nausea, abdominal pain, breakthrough bleeding,
and bloating.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
There were slight reductions in the mean Ferriman-Gallwey score
for the two interventions in Bhattacharya 2012 of 2.12 (6.58)
for the EE + drospirenone group, and 1.69 (5.69) in the EE +
desogestrel group (MD -0.43, 95% CI -2.85 to 1.99; P value =
0.73). In Kriplani 2010 the respective changes in mean Ferriman-
Gallwey score were 4.6 (2.79) based on 5/30 of the participants
who were hirsute in the EE + drospirenone group versus 0 (0.28)
in 4/30 of those in the EE + desogestrel group, with a MD of -
4.60 (95% CI -7.06 to -2.14; P value = 0.0002), a difference that
is unlikely to be clinically important.
Change in serum androgen levels
There were minimal changes from baseline in the serum andro-
gen levels in both groups and with minimal differences between
the groups (see Analysis 5.1). The difference in mean changes in
SHBG level in Bhattacharya 2012 and the testosterone level in
Kriplani 2010 were statistically significant, but not clinically im-
portant with respect to any difference in the improvement of hir-
sutism.
Change in BMI
The changes from baseline in both treatment arms in both studies
were small and there were no statistically significant differences
between the groups (Bhattacharya 2012;Kriplani 2010). TheBMI
changes in Bhattacharya 2012 showed an increase of 0.11 kg/m²
(5.54) for the EE + drospirenone group and a decrease of 0.45
kg/m² (6.75) for the EE + desogestrel group (MD 0.56 kg/m²,
95% CI -1.88 to 3.00; P value = 0.65). In Kriplani 2010 the
BMI changes were a decrease of 0.6 kg/m² (3.38) for the EE +
drospirenone group and increase of 1.4 kg/m² (2.28) for the EE
+ desogestrel group (MD -2.00 kg/m², 95% CI -3.48 to -0.52;
P value = 0.008), which is a statistically significant difference and
correlates with the greater reduction in Ferriman-Gallwey score
for the EE + drospirenone group.
Improvement of other clinical signs of hyperandrogenism
The instrument used to assess this outcome differed between the
two studies and therefore it was not possible to pool the data. In
Bhattacharya 2012 the mean change from baseline in acne score
was a reduction of 1.42 (1.27) in the EE + drospirenone group and
for the EE + desogestrel group 1.41 (1.32). The mean difference
between the two OCPs was -0.01 (95% CI -0.52 to 0.50; P value
= 0.97). Comparable data were reported in Kriplani 2010: 5/10
participants with acne in the EE + drospirenone group responded
versus 3/10 in the EE + desogestrel group (RR 1.67, 95% CI 0.54
to 5.17; P value = 0.38).
(10) Ethinyl estradiol 35 µg + cyproterone acetate 2 mg
versus placebo for 12 months
One study with a small sample size, assessed at high risk of bias,
provided some usable data for this comparison (Saeed 1993).
Primary outcomes
Participant-reported improvement of hirsutism
Seven out of the 10 participants in the EE +CPA group considered
themselves cured compared to 0/10 in the placebo group, which
was a statistically significant and clinically important difference
(RR 15.00, 95% CI 0.97 to 231.84; P value = 0.05, NNTB =
2, 95% CI 2 to 3). A further two participants in each treatment
group considered themselves slightly improved (RR 1.00, 95%CI
0.17 to 5.77; P value = 1.00).
Change in health-related quality of life (HRQOL)
Proportion of participants who reported an adverse event
Neither of the above outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
This outcome was not reported (see ’Risk of bias’ assessment under
’Characteristics of included studies’ for this study (Saeed 1993)).
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Change in serum androgen levels
This outcome was poorly reported for the active treatment group
and not reported for the placebo group (see ’Risk of bias’ assess-
ment under ’Characteristics of included studies’).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(11) Ethinyl estradiol 35 µg + cyproterone acetate 2 mg
versus other OCP (unknown) for three months
One study of short duration and assessed at high risk of bias re-
ported very limited usable data for this comparison (Taheripanah
2010). We were unable to contact the investigators and it was un-
clear from the report which OCP had been evaluated.
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
At the end of threemonths there was no statistically significant dif-
ference in mean reduction of the Ferriman-Gallwey score between
the two groups. The mean reduction in the EE + CPA group was
2.27 (7.97) compared to 2.13 (8.44) for the other OCP group
(MD -0.14, 95% CI -4.29 to 4.01; P value = 0.95).
Change in serum androgen levels
Two serum androgens (free testosterone and dehydroepiandros-
terone sulphate (DHEAS)) were measured and there were no sta-
tistically significant reductions in means of these values compared
to baseline either within or between the two groups (see Analysis
6.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(12) Ethinyl estradiol 35 µg + cyproterone acetate 2 mg
versus ethinyl estradiol 50 µg + desogestrel 0.15 mg for two
years
A single study with three treatment arms reported data for this
comparison (Porcile 1991, see also comparison 8 and 13).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Themean reductions in the Lorenzo score for the EE +CPA group
were 7 (9.79) and for the EE50 + desogestrel group 5.7 (1.69),
with a MD of -1.30 (95% CI -7.87 to 5.27; P value = 0.70).
Change in serum androgen levels
Minimal data were provided (see Analysis 7.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(13) Ethinyl estradiol 30 µg+ desogestrel 0.15 mg versus
ethinyl estradiol 50 µg + desogestrel 0.15 mg for two years
One study with three treatment arms addressed this comparison
(Porcile 1991, see also comparison 8 and 12).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The reductions in Lorenzo score seen within both groups were
7.20 (1.84) in the EE30 + desogestrel group and 5.7 (1.69) for the
EE50 + desogestrel group, but there was no statistically significant
difference in the mean values between the two treatment arms
(MD -1.50, 95% CI -3.37 to 0.37; P value = 0.12).
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Change in serum androgen levels
Minimal data were provided (see Analysis 8.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(14) Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus
ethinyl estradiol 30 µg and levonorgestrel 0.15 mg for nine
months
This comparison was evaluated in one trial (Breitkopf 2003).
Primary outcomes
Participant-reported improvement of hirsutism
Based on a non-specific questionnaire, 6/11 participants in the EE
+ desogestrel group reported a decrease in hair growth compared
to 5/10 in the EE + levonorgestrel group (RR 1.09, 95% CI 0.48
to 2.48; P value = 0.84).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
Three adverse events were reported in the EE + desogestrel group
and two in the EE + levonorgestrel group (RR 1.57, 95% CI 0.29
to 8.53; P value = 0.60).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The mean reduction in Ferriman-Gallwey score was 6.40 (4.79)
in the EE + desogestrel group and 3.1 (3.81) in the EE + lev-
onorgestrel group. The mean difference between the two treat-
ment arms was -3.30 (95% CI -6.99 to 0.39; P value = 0.08). This
difference is not statistically significant.
Change in serum androgen levels
The data for the changes in serum androgen levels are reported
in Analysis 9.1, and in most instances the mean differences were
statistically significant in favour of EE + desogestrel.
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(15) Ethinyl estradiol 30 µg + drospirenone 3 mg versus
ethinyl estradiol 30 µg + chlormadinone acetate 2 mg for six
months
One study at unclear risk of bias with 55 participants provided
usable data for this comparison (Lello 2008).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The mean reduction in the Ferriman-Gallwey score in the OCP
including drospirenone group was 6.78 (1.25), as compared to a
smaller reduction of 4.85 (1.13) in theOCP including chlormadi-
none group and, although the mean difference was statistically
significant (-1.93, 95% CI -2.56 to -1.30; P value < 0.001), it was
not clinically important.
Change in serum androgen levels
Reductions in androstenedione and testosterone levels favoured
EE + drospirenone, however, as with the mean difference in Ferri-
man-Gallwey score, the differences were not clinically important
or associated with any important change in the improvement of
hirsutism (see Analysis 10.1).
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Change in BMI
There was a slight increase in BMI in both groups; 0.58 kg/m²
(1.64) in the EE + drospirenone group and 0.26 kg/m² (1.67)
in the EE + chlormadinone group, with a MD of 0.32 kg/m²
(95% CI -0.56 to 1.20; P value = 0.48), but the difference was
not statistically significant.
Improvement of other clinical signs of hyperandrogenism
Acne was scored on a four-point Likert scale (0 = no acne and 3
= severe acne). The reduction in score in the EE + drospirenone
group was 1.97 (0.27) and was slightly less at 1.75 (0.28) for the
comparator group (MD -0.22, 95% CI -0.37 to 0.07; P value =
0.003).
(16) Ethinyl estradiol 30 µg + desogestrel 0.15 mg every
month versus ethinyl estradiol 30 µg + desogestrel 0.15 mg
every other month for two years
Only one three-armed study with a small sample size compared
these interventions and provided relevant outcomes data (Porcile
1991B) (see also comparison 17 and 18).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The participants in the EE + desogestrel every month group
showed a small and clinically unimportant mean reduction in the
Lorenzo score of 1.40 (1.90) versus no reduction 0 (1.79) in the
bi-monthly comparator group (MD -1.40, 95% CI -3.30 to 0.50;
P value = 0.15).
Change in serum androgen levels
There were minimal changes in serum androgen levels for both
treatment arms, which were not clinically important with respect
to a difference in the improvement of hirsutism (see Analysis 11.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(17) Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus
placebo for 24 weeks to two years
This comparison was evaluated in Hoeger 2008 (study 1) for a
period of 24 weeks (see also comparison 2, 32, and 103, 105, and
112) and for two years in Porcile 1991B (see also comparison 16
and 18).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
In Hoeger 2008 (study 1) the mean Ferriman-Gallwey score
showed a reduction of 1.20 (2.21) in the OCP group compared
to a reduction of 0.90 (3.25) in the placebo group (MD -0.30,
95% CI -2.74 to 2.14; P value = 0.81). The mean reduction in
Lorenzo score in Porcile 1991B was 1.40 (1.90) in the EE + des-
ogestrel group, whereas the placebo group showed an increase of
3.20 (1.61). The MD was -4.60, 95% CI -6.48 to -2.72; P value
< 0.001), which is a statistically significant difference but unlikely
to be clinically important.
Change in serum androgen levels
There were no clinically important changes with respect to a dif-
ference in the improvement of hirsutism in serum androgen levels
in either group (see Analysis 12.1).
Change in BMI
This was only assessed in Hoeger 2008 (study 1). There was a
reduction of 1.40 (3.33) in theOCP group and a smaller reduction
of 0.60 (4.57) in the placebo group (MD -0.80, 95% CI -4.30 to
2.70; P value = 0.65).
Improvement of other clinical signs of hyperandrogenism
This outcome was not assessed in Porcile 1991B and in Hoeger
2008 (study 1) data were inadequately reported and of limited
value.
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(18) Ethinyl estradiol 30 µg + desogestrel 0.15 mg every
other month versus placebo for two years
A single study reported fewusable data for this comparison (Porcile
1991B) (see also comparison 16 and 17).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
There was no change in the mean Lorenzo score in the active
treatment group but there was a small increase of 3.20 (1.61) in
the placebo group, with a MD of -3.20 (95% CI -5.21 to -1.19;
P value = 0.002).
Change in serum androgen levels
The changes in serum androgen levels within each group as well as
between the two treatment groups were not statistically significant
(see Analysis 13.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(19) Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus
ethinyl estradiol 30 µg + gestodene 75 µg for six months
A single study with 34 participants reported data for this compar-
ison (Sobbrio 1990).
Primary outcomes
None of our primary outcomes were assessed.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
There were minor differences in reduction of the mean Ferriman-
Gallwey score between the two OCPs of 5.20 (4.59) for the EE +
desogestrel group and 4.30 (5.51) for the EE + gestodene group,
MD -0.90 (95% CI -4.31 to 2.51; P value = 0.60).
Change in serum androgen levels
No important nor statistically significant differences were found
in serum androgen levels between the two groups (see Analysis
14.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(20) Ethinyl estradiol 30 µg + drospirenone 3 mg versus
ethinyl estradiol 20 µg + drospirenone 3 mg for six months
Only one study provided limited data for this comparison (Oner
2011).
Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
The authors provided no data but reported that there were no
serious side effects in either group.
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Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Both OCPs showed clinically important reductions in Ferriman-
Gallwey scores of 8.60 (3.53) in the 30 µg EE OCP group and
9.60 (3.06) for the 20µg EEOCP group. However, there were no
statistically significant differences in these assessments of efficacy
between the two OCPs (MD 1.00, 95% CI -0.89 to 2.89; P value
= 0.30).
Change in serum androgen levels
There were no statistically significant differences in serum andro-
gen levels for both treatment groups (see Analysis 15.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
Antiandrogens
(21) Flutamide 250 mg twice daily versus placebo for six to
12 months
This comparison was evaluated in two studies, both of which had
four arms (Gambineri 2006; Moghetti 2000). Study duration in
Gambineri 2006 was one year and the other possible compar-
isons of this study are addressed under comparisons 32, 46 to 48,
and 110. The duration of intervention in Moghetti 2000 was six
months (see also comparisons 22, 23, 25, 109, and 111).
In Gambineri 2006 in the first month the women were placed
on a standardised hypocaloric diet (1200 to 1420 kcal/daily) and
randomised subsequently, whilst continuing dietary treatment.
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was not assessed in Gambineri 2006. In Moghetti
2000 8/10 participants in the flutamide group considered them-
selves to have a good to excellent improvement compared to 0/10
in the placebo group (RR 17.00, 95% CI 1.11 to 259.87; P value
= 0.04, NNTB = 2, 95% CI 1 to 2), which suggests a large and
clinically important difference, albeit based on a study with a very
small sample size.
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
InGambineri 2006 four out of the 20 participants in the flutamide
group reported adverse events (gastrointestinal discomfort) versus
none out of the 20 in the placebo group (RR 9.00, 95%CI 0.52 to
156.91; P value = 0.13). InMoghetti 2000 1/10 of the participants
in the flutamide group reported sleepiness and hyporexia and 1/
10 in the placebo group reported mild headache and nausea (RR
1.00, 95% CI 0.07 to 13.87; P value = 1.00).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
In Gambineri 2006 there was a clinically important reduction
in the Ferriman-Gallwey score in the flutamide group of 8.90
(5.53) and a small reduction in the placebo group of 1.30 (2.89)
demonstrating a statistically significant and clinically important
difference (MD -7.60, 95% CI -10.53 to -4.67; P value < 0.001).
In Moghetti 2000 there was a smaller mean reduction of 6.40
(3.42) in the flutamide group compared with an increase of 0.80
(3.32) in the placebo group, with a MD of -7.20 (95% CI -10.15
to -4.25; P value < 0.001).
InMoghetti 2000 themeanhair shaft diameter showed a reduction
of 33 (24.70) µm in the flutamide group and an increase of 3
(21.64) µm in the placebo group (MD -36.00 µm, 95%CI -56.35
to -15.65; P value = 0.0005).
Change in serum androgen levels
In Gambineri 2006 the mean differences in androstenedione and
DHEAS between the two treatment groups were statistically sig-
nificant, but not for testosterone and SHBG, and in Moghetti
2000 only for androstenedione (see Analysis 16.1).
Change in BMI
This was only assessed in Gambineri 2006. There was a substan-
tial reduction of 4.00 kg/m² (2.41) in the flutamide group and a
smaller reduction in the placebo group of 2.00 kg/m² (3.16) (MD
-2.00 kg/m², 95% CI -3.83 to -0.17; P value = 0.03). Reduction
in weight loss was most probably due to the calorie restriction diet.
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Improvement of other clinical signs of hyperandrogenism
The mean number of menses in the previous six months at the
end of the study (Gambineri 2006) increased by 1.30 (1.08) in
the flutamide group compared to 0.50 (0.76) in the placebo group
(MD 0.80, 95% CI 0.18 to 1.42; P value = 0.01). This outcome
was not assessed in Moghetti 2000.
(22) Flutamide 250 mg once to twice a day versus
spironolactone 100 mg once a day for six to nine months
Two small sample size studies, which examined 20 participants,
reported data for this comparison (Erenus 1994; Moghetti 2000).
One of these, Moghetti 2000, was a four-armed study (see com-
parison 21, 23, 25, 109, and 111). The dosage of flutamide used
in Erenus 1994 was 250 mg twice a day for nine months, and in
Moghetti 2000 250 mg once a day for six months.
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was only assessed in Moghetti 2000. In the flu-
tamide group 8/10 participants considered the improvement in
hirsutism as good to excellent compared to 4/10 participants in
the spironolactone group, with a RR of 2.00 (95% CI 0.88 to
4.54; P value = 0.10).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
In Erenus 1994 in the flutamide group 2/10 participants reported
a side effect (both dry skin) compared to 5/10 participants in the
spirolactone group (all five had irregular bleeding) (RR 0.40, 95%
CI 0.10 to 1.60; P value = 0.20). In Moghetti 2000 1/10 in the
flutamide group reported sleepiness and hyporexia compared to
5/10 in the spironolactone group who reported metrorrhagia (RR
0.20, 95% CI 0.03 to 1.42; P value = 0.11).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
In Erenus 1994 both treatment options demonstrated a clinically
important reduction in Ferriman-Gallwey score of 9.80 (3.71) in
the flutamide group and 7.90 (3.37) in the spironolactone group.
However, there was no statistically significant difference between
the two treatment arms (MD -1.90, 95%CI -5.01 to 1.21; P value
= 0.23). These reductions were somewhat smaller in Moghetti
2000, which may be explained by the fact that the study duration
was three months shorter and the dosage of flutamide was half
of the dosage used in Erenus 1994. In Moghetti 2000 the mean
Ferriman-Gallwey score reduced by 6.40 (3.42) in the flutamide
group and in the spironolactone group by 6.89 (2.09), with a
MD of 0.49 (95% CI -1.99 to 2.97; P value = 0.70). In addition,
the mean hair shaft diameter decreased by 33 (24.70) µm in the
flutamide group andby 20 (23.33) µm in the spironolactone group
(MD -13.00 µm, 95% CI -34.06 to 8.06; P value = 0.23).
Change in serum androgen levels
There were no clinically important differences in changes of the
androgen levels with respect to a difference in the improvement
of hirsutism as there were no statistically significant differences in
the mean Ferriman-Gallwey score between the groups for both
studies (see Analysis 17.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(23) Spironolactone 100 mg per day versus placebo for six
months
One four-armed study with small sample size examined these in-
terventions (Moghetti 2000) (see also comparison 21, 22, 25, 109,
and 111).
Primary outcomes
Participant-reported improvement of hirsutism
In the spironolactone group 4/10 considered themselves to have a
good to excellent improvement compared to 0/10 in the placebo
group (RR 9.00, 95% CI 0.55 to 147.95; P value = 0.12).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
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Proportion of participants who reported an adverse event
In the spironolactone group 5/10 participant reported metrorrha-
gia and 1/10 in the placebo group experienced mild headache and
nausea (RR 5.00, 95% CI 0.70 to 35.50; P value = 0.11).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The mean Ferriman-Gallwey score reduced by 6.89 (2.09) in the
spironolactone group and showed a slight increase in the placebo
group of 0.80 (3.32), with a MD of -7.69 (95% CI -10.12 to -
5.26; P value < 0.001). This difference is statistically significant
and clinically important.
Change in serum androgen levels
There were no statistically significant differences in changes in
androgen levels between the spironolactone group and the placebo
group, except for DHEAS in favour of placebo (see Analysis 18.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(24) Ketoconazole 400 mg per day versus ketoconazole 800
mg per day for 10 days
One study with a small sample size reported limited data on the
effects of ketoconazole (Cedeno 1990), which is seldom used in
view of its hepatic toxicity. Our only outcome addressed in this
study was the change in serum androgen levels, which showed
no statistically significant differences between the two groups (see
Analysis 19.1).
5α reductase inhibitors
(25) Finasteride 5 mg to 7.5 mg once a day versus placebo
for six to nine months
Three studies with a small sample size compared these interven-
tions (Ciotta 1995; Lakryc 2003; Moghetti 2000). One of these,
Moghetti 2000, was a four-armed study (see also comparison 21
to 23, 109, and 111).
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was assessed in Lakryc 2003 on a three-point Likert
scale (amelioration, indifference, worse). In the finasteride group
11/16 participants considered themselves improved, compared to
6/18 in the placebo group (RR 2.06, 95%CI 0.99 to 4.29; P value
= 0.05). In Moghetti 2000 it was assessed on a four-point Likert
scale and 5/10 participants in the finasteride group considered
themselves to have a good to excellent improvement compared to
0/10 in the placebo group (RR 11.00, 95% CI 0.69 to 175.86; P
value = 0.09).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
There were no statistically significant differences between the
groups in the number of adverse events. In Ciotta 1995 6/9 par-
ticipants in the finasteride group reported an adverse event com-
pared to 7/9 in the placebo group. These consisted of headache,
depression, and dizziness, which were reported in both groups.
In Lakryc 2003 3/16 participants in the finasteride group experi-
enced side effects versus 1/18 in the placebo group. In Moghetti
2000 1/10 participants in the finasteride group reported ’being
swollen’ compared to 1/10 participants in the placebo group that
complained of mild headache and nausea. Pooled data from the
three trials showed RR 1.13 (95% CI 0.48 to 2.67; P value = 0.78
and I² = 18%) (see Analysis 20.1). The denominator of Moghetti
2000 is partitioned in the finasteride group as these data were also
pooled in comparison 121.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Pooled data from the three studies showed that the MD in mean
Ferriman-Gallwey score between the finasteride group and the
placebo group was -5.73 (95% CI -6.87 to -4.58; P value < 0.001
and I² = 0%), which is a statistically significant difference, however
the difference is unlikely to be clinically important (see Analysis
20.2).
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Change in serum androgen levels
The results of the changes in serum androgen levels are reported
in Analysis 20.3. As would be expected finasteride reduces the
conversionof testosterone into dihydrotestosterone, and thus there
was a statistically significant mean difference in reduction of the
dihydrotestosterone levels in the finasteride groups. Pooling of
the data for the androgens was only possible for androstenedione
and DHEAS (for free testosterone I² > 60%), but there were no
statistically significant changes between the two treatment arms
for these two androgens (data not reported).
Change in BMI
This outcome, which was only assessed in one of the studies
(Lakryc 2003), illustrated minimal changes in both treatment
groups (-0.50 kg/m² (1.53) in the finasteride group and an in-
crease of 0.80 kg/m² (2.50) in the placebo group), with a MD of
-1.30 kg/m² (95% CI -2.96 to 0.36; P value = 0.12).
Improvement of other clinical signs of hyperandrogenism
This outcome was not assessed.
(26) Finasteride 2.5 mg once a day versus finasteride 5 mg
once a day for six to 12 months
The effects of these interventions were evaluated in two studies at
high risk of bias (Al-Khawajah 1998; Bayram 2002). One of these,
Al-Khawajah 1998, was a three-armed study (see also comparison
27 and 28).
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was assessed in only one of the studies, Al-Khawajah
1998, in which the investigators used a five-point Likert scale (-1 =
worse, 3 = much improved). After six months the group using the
2.5 mg formulation of finasteride had a mean score of 1.6 (0.5)
and in the 5 mg group 1.7 (0.4), with both groups showing slight
to moderate improvement (MD -0.10, 95% CI -0.42 to -0.22; P
value = 0.55).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
The reporting of adverse events in Al-Khawajah 1998 was inad-
equate: only that there were two adverse events, and it remains
unclear in which group these occurred. In Bayram 2002 there was
a statistically significant increase in the number of adverse events
with the higher dosage (5 mg) of finasteride. In the 2.5 mg dose
group 5/29 participants reported an adverse event compared to
12/27 in the 5 mg group (RR 0.39, 95% CI 0.16 to 0.96; P value
= 0.04; number needed to find one additional harmful outcome
(NNTH) = 4, 95% CI 2 to 26). Adverse events included well-
known side effects such as dry skin, headache, reduction in libido,
and gastrointestinal complaints.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
There was a clinically important reduction in mean Ferriman-
Gallwey score for both dosages. The reductions in Bayram 2002
were slightlymore than in Al-Khawajah 1998, which was probably
attributable to the six-month longer treatment time in the former
study. In Al-Khawajah 1998 the reductions were 7.4 (0.5) in the
2.5 mg finasteride group and 7.2 (0.4) in the 5 mg group (MD -
0.20, 95% CI -0.52 to 0.12; P value = 0.23). The reductions in
Bayram 2002 were 9.8 (2.81) and 8.4 (3.23), which are clinically
important changes, but the MD was not statistically significant (-
1.40, 95% CI -2.99 to 0.19; P value = 0.08).
Reduction in hair shaft diameter was also assessed in Al-Khawajah
1998. The reduction in the 2.5 mg group was 24.8% (standard
deviation (SD) 3.9) and in the 5 mg group 24.2% (4.2), with a
MD of -0.60% between the groups (95% CI -3.50 to 2.30; P
value = 0.69).
Change in serum androgen levels
The changes in serum androgens were not statistically significant
(except for androstenedione in Bayram 2002) and are summarised
in Analysis 21.1.
Change in BMI
This was only assessed in Bayram 2002 in which there was a re-
duction of 0.90 kg/m² (3.26) in the 2.5 mg group and 3.1 kg/m²
(2.70) in the 5 mg group (MD 2.20 kg/m², 95% CI 0.64 to 3.76;
P value = 0.006). The reduction in the 5 mg group was substantial
and the difference between the groups is statistically significant,
but this did not correlate with a statistically significant difference
in the Ferriman-Gallwey score.
39Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Improvement of other clinical signs of hyperandrogenism
This was not assessed in Al-Khawajah 1998, and the investigators
in Bayram 2002 only reported that the menstrual cycles were not
affected by the treatments.
(27) Finasteride 2.5 mg once a day versus finasteride 7.5 mg
once a day for six months
A single three-armed study in 45 participants reported data for
this comparison (Al-Khawajah 1998, see also comparison 26 and
28).
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was assessed with a five-point Likert scale (see com-
parison 26). The scores after six months were 1.6 (0.5) for the 2.5
mg group, and 2.3 (0.2) for the 7.5 mg group, with aMD of -0.70
(95% CI -0.97 to -0.43; P value < 0.001), which is a statistically
significant difference in favour of the higher dosage. However, the
clinical importance of this difference is difficult to interpret.
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
It was unclear from the report if there were one, two, or no ad-
verse events in the 2.5 mg group, as compared to four which were
reported in the 7.5 mg group and consisted of menstrual abnor-
malities and breast tenderness.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Both treatment arms showed clinically important reductions in
the mean Ferriman-Gallwey score of 7.4 (0.5) for the 2.5 mg
group and 9.9 (0.2) for the 7.5 mg group. Although the mean
difference of 2.50 (95% CI 2.23 to 2.77; P value < 0.001) is
statistically significant, it is not clinically important. There was
also a statistically significant difference in reduction in hair shaft
diameter in favour of the higher dosage. There was a reduction of
24.8% (3.9) in the 2.5 mg group and 35.8% (2.9) in the 7.5 mg
group (MD 11.00%, 95% CI 8.54 to 13.46; P value < 0.001).
Although the 5 mg dose is the most frequently prescribed, the
results in comparisons 25 to 27 suggest that a dosage of 2.5 mg
would be sufficient enough to achieve a beneficial effect.
Change in serum androgen levels
There were no statistically significant differences between the two
treatment arms for the serum androgens (see Analysis 22.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(28) Finasteride 5 mg once a day versus finasteride 7.5 mg
once a day for six months
This comparison was also addressed by Al-Khawajah 1998 (see
comparison 26 and 27).
Primary outcomes
Participant-reported improvement of hirsutism
This outcome was assessed on a five-point Likert scale (see also
comparison 26). The end of study scores at six months were 1.7
(0.4) for the 5 mg group and 2.3 (0.2) for the 7.5 group (MD -
0.60, 95% CI -0.83 to -0.37; P value < 0.001), which is a statis-
tically significant difference between the groups in favour of the
higher dosage. However, the clinical importance of this difference
is difficult to interpret.
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
There were four adverse events in the 7.5 mg group and it was
unclear how many there were in the 5 mg group (0 to 2).
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Secondary outcomes
Clinician’s assessment of improvement of hirsutism
The mean reduction in the Ferriman-Gallwey score was 7.2 (0.4)
in the 5 mg group compared to 9.9 (0.2) in the 7.5 mg group,
which were both clinically important. There was a statistically
significant MD between the two groups of 2.7 (95% CI 2.47
to 2.93; P value < 0.001), but this was not considered clinically
important.
Change in serum androgen levels
There were no statistically significant differences between the two
treatment arms for serum androgens (see Analysis 23.1).
Change in BMI
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(29) Finasteride 2.5 mg once a day versus finasteride 2.5 mg
every three days for 10 months
Only one study with a small sample size evaluated this comparison
(Tartagni 2004).
Primary outcomes
Participant-reported improvement of hirsutism
The participants rated their assessments on a four-point Likert
scale (worsening to good-excellent). Both intervention groups re-
ported similar beneficial results; in the 2.5 mg daily group 16/
19 considered the result good-excellent compared to 15/19 in the
2.5 mg every three days group (RR 1.07, 95% CI 0.79 to 1.44; P
value = 0.68).
Change in health-related quality of life (HRQOL)
This outcome was not assessed.
Proportion of participants who reported an adverse event
Oneparticipant in the 2.5mgdaily group reported gastrointestinal
discomfort (RR 3.00, 95% CI 0.13 to 69.31; P value = 0.49).
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Both groups showed clinically important reductions in the mod-
ified Ferriman-Gallwey score; 9.85 (1.66) for the 2.5 mg daily
group and 8.26 (2.28) for the 2.5 mg every three days group. The
MD was -1.59 (95% CI -2.86 to -0.32; P value = 0.01), which
was not considered a clinically important difference.
Change in serum androgen levels
There were no statistically significant differences in serum an-
drogen levels between the two treatment arms, except for dihy-
drotestosterone, which was in favour of the 2.5 mg daily group
(see Analysis 24.1).
Change in BMI
The reduction in mean BMI was small and comparable for both
groups: 0.9 kg/m² (2.57) in the 2.5 mg daily group and 1.0 kg/
m² (2.57) in the comparator group (MD 0.10 kg/m², 95% CI -
1.53 to 1.73; P value = 0.90).
Improvement of other clinical signs of hyperandrogenism
There were no variations in the menstrual cycle in either group.
Insulin sensitisers
(30) Metformin 850 mg twice daily versus rosiglitazone 2 mg
twice daily for 12 months
Although rosiglitazone is no longer used in Europe, it is still regis-
tered in the US and several other countries. This comparison was
evaluated in Ahmad 2008.
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Primary outcomes
Participant-reported improvement of hirsutism
Change in health-related quality of life (HRQOL)
Neither of the above outcomes were assessed.
Proportion of participants who reported an adverse event
Although it was not a prespecified outcome in the study, the inves-
tigators reported that both drugs were well tolerated, and that gas-
trointestinal disturbances such as nausea, diarrhoea, and abdom-
inal bloating occurred more frequently in the metformin group.
These are well-known side effects of metformin.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
There was a reduction in mean Ferriman-Gallwey score of 4.31
(1.70) in themetformin group and 0.62 (1.39) in the rosiglitazone
group (MD -3.69, 95% CI -4.47 to -2.91; P value < 0.001).
The MD between the groups is statistically significant, albeit not
clinically important.
Change in serum androgen levels
There were no statistically significant differences between the two
treatment arms for serum androgens, except for androstenedione
in favour of metformin (see Analysis 25.1).
Change in BMI
There were minimal changes in the mean BMI in both of the
intervention groups. In themetformin group there was a reduction
of 0.16kg/m² (3.39) and in the rosiglitazone group a slight increase
of 0.61 kg/m² (3.63), with a MD of -0.77 kg/m² (95% CI -2.53
to 0.99; P value = 0.39).
Improvement of other clinical signs of hyperandrogenism
At the end of the study 96% of the women in the metformin
group had a regular cycle versus 90% in the rosiglitazone group,
and 61% of the women in the metformin group were ovulating
compared to 73% in the rosiglitazone group. There was a clear
and increased improvement in these outcome data at each three-
month time point.
(31) Troglitazone 150 mg versus troglitazone 300 mg versus
troglitazone 600 mg versus placebo for 44 weeks
Troglitazone has been withdrawn from the market in the UK and
the US due to concerns about possible hepatic toxicity. As this
drug is not very likely to be prescribed for hirsutism, we have not
subdivided the four arms into two-armed comparisons. Only one
multi-centre study addressed these interventions (Azziz 2001), but
the report was unclear how many participants were randomised to
each arm; the investigators only reported how many participants
completed the study in each arm (see Characteristics of included
studies).
Primary outcomes
None of our primary outcomes were assessed. However, the inves-
tigators reported that 4% to 7% of the participants in each treat-
ment arm withdrew due to side effects.
Secondary outcomes
Clinician’s assessment of improvement of hirsutism
Themean change from baseline in the Ferriman-Gallwey score for
each group was minimal and not clinically important: -0.51 (3.97)
in the troglitazone 150 mg group, -0.80 (3.93) in the troglitazone
300 mg group, and -2.21 (3.86) in the troglitazone 600 mg group
compared to -0.22 (4.00) in the placebo group.
Change in serum androgen levels
The changes in serum androgen levels are reported in Analysis
26.1. The reductions in free testosterone showed a dose-related
effect.
Change in BMI
This outcome was not assessed.
Improvement of other clinical signs of hyperandrogenism
Improvement of other clinical signs of hyperandrogenism
Neither of the above outcomes were assessed.
(133) Bromocriptine 2.5 mg three times a day versus
placebo for 12 months
A small sample size study evaluated this comparison (Murdoch
1987).
Primary outcomes
Participant-reported improvement of hirsutism
This was assessed on a three-point Likert scale (worse, unchanged,
improved). Four participants dropped out in the bromocriptine
group and of the remaining seven, two considered they had
achieved an improvement although daily shaving was still neces-
sary. None of the control group improved and there were 2/11
drop-outs.
Ch nge in health-related quality of life (HRQOL)
Proportion of participants who reported an adverse event
Neither of the above outcomes were assessed.
Secondary outcomes
Clinician’s assessment of i prov ment of hirsutism
No exact data are provided but the investigators stated that ”there
was no statistically significant difference between the two groups
in number of hairs, nor growth rate.“
Change in serum androgen levels
T ere were no statistically significant differences in changes in
androgen levels between the two groups (see Analysis 108.1).
Change in BMI
This outcome was not assessed.
Improvement of other clinical signs of hyperandrogenism
The mean number of me strual periods ove the last six months
the study increased, with 0 (1.85) in the bromocriptine group
versus an increase of 1.4 (2.40) in the control group, with a MD
of -1.40 (95% CI -3.48 to 0.68; P value = 0.19).
42Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Flutamide 250 mg b.i.d. compared to placebo for hirsutism
Patient or population: women with hirsutism
Intervention: flutamide 250 mg b.i.d.
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Flutamide 250 mg b.i.d.
Participant-reported im-
provement of hirsutism
4-point Likert scale
Study population RR 17
(1.11 to 259.87)
20
(1 study)
⊕⊕©©
low1
Improvement as as-
sessed on a Likert scale
was good to excellent but
based on a small sample
size
Low
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
See comment See comment Not estimable 60
(2 studies)
⊕©©©
very low1,2
RR 9.00, 95% CI 0.52
to 156.91; P value = 0.
13 (Gambineri 2006) and
RR 1.00, 95% CI 0.07 to
13.87; P value = 1.00
(Moghetti 2000)
Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
See comment See comment Not estimable 60
(2 studies)
⊕©©©
very low1,2
MD -7.60, 95% CI -10.
53 to -4.67; P value <
0.001 (Gambineri 2006)
and MD -7.20, 95% CI -
10.15 to -4.25; P value
<0.001 (Moghetti 2000)4
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. Both studies demon-
strated a statistically sig-
nificant and clinically
important difference in
favour of the flutamide
group
Change in serum andro-
gen levels
See comment See comment Not estimable 60
(2 studies)
⊕⊕©©
low1
There were in both stud-
ies statistically signifi-
cant differences in an-
drostenedione levels in
favour of the flutamide
group
Change in BMI
kg/m²
The mean change in BMI
in the control groups was
-2 kg/m²
The mean change in BMI
in the intervention groups
was
2.00 kg/m² lower
(3.83 kg/m² to 0.17 kg/
m² lower)
40
(1 study)
⊕©©©
very low1,2
All participants were on a
calorie restriction diet
Improvement of other
clinical signs of hyper-
androgenism
Mean number of menses
in previous 6 months
Scale from: 0 to 6
The mean improvement
of other clinical signs of
hyperandrogenism in the
control groups was
0.50
The mean improvement
of other clinical signs of
hyperandrogenism in the
intervention groups was
0.8 higher
(0.18 to 1.42 higher)
40
(1 study)
⊕©©©
very low1,2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
b.i.d.: twice a day; BMI: body mass index; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1Downgraded two levels due to very serious imprecision (very wide CI due to small sample size).
2Downgraded one level due to serious risk of selection bias (allocation concealment was assessed as ’high risk of bias’ for Gambineri
2006).
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Flutamide 250 mg once to b.i.d. compared to spironolactone 100 mg for hirsutism
Patient or population: women with hirsutism
Intervention: flutamide 250 mg once to b.i.d.
Comparison: spironolactone 100 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Spironolactone 100 mg Flutamide 250 mg once
to b.i.d.
Participant-reported im-
provement of hirsutism
4-point Likert scale
Study population RR 2.00
(0.88 to 4.54)
20
(1 study1)
⊕⊕©©
low2
400 per 1000 800 per 1000
(352 to 1000)
Low
100 per 1000 200 per 1000
(88 to 454)
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study assessed this
outcome
Proportion of partici-
pants who reported an
adverse event
See comment See comment Not estimable 40
(2 studies3)
⊕⊕©©
low4,5
RR 0.40, 95% CI 0.10 to
1.60; P value = 0.20 (
Erenus 1994), RR 0.20,
95% CI 0.03 to 1.42; P
value = 0.11 (Moghetti
2000)
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Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
See comment See comment Not estimable 40
(2 studies3)
⊕©©©
very low2,4
MD -1.90, 95% CI -5.01
to 1.21; P value = 0.23 (
Erenus 1994), 0.49, 95%
CI -1.99 to 2.97; P value
= 0.70 (Moghetti 2000)
Change in serum andro-
gen levels
See comment See comment Not estimable 40
(2 studies3)
⊕⊕⊕©
moderate2
There were no clinically
important differences in
changes of the androgen
levels with respect to a
difference in the improve-
ment of hirsutism
Change in BMI - not mea-
sured
See comment See comment Not estimable - See comment No study assessed this
outcome
Improvement of other
clinical signs of hyper-
androgenism - not mea-
sured
See comment See comment Not estimable - See comment No study assessed this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
b.i.d.: twice a day; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Moghetti 2000.
2Downgraded two levels due to very serious imprecision (wide CI due to low sample size, optimal information size not met by far).
3Erenus 1994, Moghetti 2000.
4Downgraded one level due to performance and detection bias (Erenus 1994 was an open-label study).
5Downgraded one level due to imprecision (wide CI, due to low sample size).
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Spironolactone 100 mg compared to placebo for hirsutism
Patient or population: women with hirsutism
Intervention: spironolactone
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Spironolactone
Participant-reported im-
provement of hirsutism
4-point Likert scale
Study population RR 9.00
(0.55 to 147.95)
20
(1 study)
⊕⊕©©
low1
No statistically significant
difference between the 2
treatments, but based on
a small sample sizeLow
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment Outcome was not as-
sessed
Proportion of partici-
pants who reported an
adverse event
Study population RR 5.00
(0.7 to 35.5)
20
(1 study)
⊕⊕©©
low1
This difference is sta-
tistically significant, but
based on a small sample
size
100 per 1000 500 per 1000
(70 to 1000)
Low
Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
control groups was
0.8
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
intervention groups was
7.69 lower
(10.12 to 5.26 lower)
20
(1 study)
⊕⊕©©
low1
This difference is statisti-
cally significant and clini-
cally important, but based
on a small sample size
4
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Change in serum andro-
gen levels
See comment See comment Not estimable 20
(1 study)
⊕⊕©©
low1
There were no clin-
ically important differ-
ences in changes in an-
drogen levels between the
spironolactone group and
placebo group
Change in BMI - not mea-
sured
See comment See comment Not estimable - See comment Outcome was not as-
sessed
Improvement of other
clinical signs of hyper-
androgenism - not mea-
sured
See comment See comment Not estimable - See comment Outcome was not as-
sessed
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded two levels due to very serious imprecision (very wide CI due to small sample size).
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Finasteride 5 mg to 7.5 mg compared to placebo for hirsutism
Patient or population: women with hirsutism
Intervention: finasteride 5 mg to 7.5 mg
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Finasteride 5 mg to 7.5
mg
Participant-reported im-
provement of hirsutism
3-point (Lakryc 2003)
and 4-point (Moghetti
2000) Likert scale
See comment See comment Not estimable 54
(2 studies)
⊕©©©
very low1,2
RR 2.06, 95% CI 0.99
to 4.29; P value = 0.
05 (Lakryc 2003) and RR
11.00, 95% CI 0.69 to
175.86; P value = 0.09
(Moghetti 2000)
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
Study population RR 1.13
(0.48 to 2.67)
67
(3 studies)
⊕©©©
very low1,2
243 per 1000 275 per 1000
(117 to 649)
Moderate
200 per 1000 226 per 1000
(96 to 534)
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Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
control groups was
0.8
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
intervention groups was
5.73 lower
(6.87 to 4.58 lower)
62
(3 studies)
⊕©©©
very low1,2
MD is statistically signif-
icant, however the differ-
ence is unlikely to be clin-
ically important
Change in serum andro-
gen levels
See comment See comment Not estimable 52
(3 studies)
⊕⊕©©
low2
Finasteride reduces the
conversion of testos-
terone into dihydrotestos-
terone; there was a sta-
tistically significant mean
difference in reduction of
DHT levels
Change in BMI
kg/m2
The mean change in BMI
in the control groups was
0.8 kg/m²
The mean change in BMI
in the intervention groups
was
1.30 kg/m² lower
(2.96 kg/m² lower to 0.
36 kg/m² higher)
24
(1 study)
⊕©©©
very low2,3
Improvement of other
clinical signs of hyper-
androgenism - not mea-
sured
See comment See comment Not estimable - See comment No study addressed this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; DHT: dihydrotestosterone; MD: mean difference; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level due to serious risk of bias (several domains have been judged as at unclear risk of bias (Ciotta 1995)).
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2Downgraded one level due to very serious imprecision (very wide CI due to low sample size).
3Downgraded one level due to serious attrition bias (high drop-out rate of 29% and per-protocol analysis).
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Metformin 500 mg to 2550 mg per day compared to placebo for hirsutism
Patient or population: women with hirsutism
Intervention: metformin 500 mg to 2550 mg per day
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Metformin 500-2550 mg
per day
Participant-reported im-
provement of hirsutism -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
See comment See comment Not estimable 63
(2 studies)
⊕©©©
very low1,2
RR 5.00, 95% CI 0.26 to
98.00; P value = 0.29
(Gambineri 2006), RR 1.
60, 95% CI 0.64 to 4.01;
P value = 0.31 (Moghetti
2000B)
Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
The mean clinician’s as-
sessment of improve-
ment of hirsutism ranged
across control groups
from
-1.3 to 9.6
The mean clinician’s as-
sessment of improve-
ment of hirsutism in the
intervention groups was
0.05 higher
(1.02 lower to 1.12
higher)
264
(7 studies)
⊕⊕©©
low3,4
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Change in serum andro-
gen levels
See comment See comment Not estimable 309
(8 studies)
⊕⊕⊕©
moderate3
Most of the mean differ-
ences were not statisti-
cally significant nor clini-
cally important
Change in BMI
kg/m2
The mean change in
BMI ranged across con-
trol groups from
-2 to 0.4 kg/m²
The mean change in BMI
in the intervention groups
was
0.56 kg/m²higher
(0.37 kg/m² lower to 1.5
kg/m² higher)
252
(5 studies)
⊕⊕⊕©
moderate4
Improvement of other
clinical signs of hyper-
androgenism - not mea-
sured
See comment See comment Not estimable - See comment No study addressed this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level due to serious selection bias (allocation concealment was assessed as ’high risk of bias’ for Gambineri 2006).
2Downgraded two levels due to very serious imprecision (very wide CI, due to low sample size).
3Downgraded one level due to serious risk of selection bias and attrition bias (allocation concealment was assessed as ’high risk of bias’
for Gambineri 2006, high drop-out rate (39%), and per-protocol analysis for Hoeger 2004).
4Downgraded one level due to serious imprecision (wide CI, due to low sample size).
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Finasteride 5 mg compared to spironolactone 100 mg for hirsutism
Patient or population: women with hirsutism
Intervention: finasteride 5 mg
Comparison: spironolactone 100 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Spironolactone 100 mg Finasteride 5 mg
Participant-reported im-
provement of hirsutism
4-point (Moghetti 2000)
and 6-point (Wong 1995)
Likert scale
See comment See comment Not estimable 34
(2 studies)
⊕⊕©©
low1,2
RR of 1.25, 95% CI 0.47
to 3.33; P value = 0.66
(Moghetti 2000) and RR
1.94, 95% CI 0.63 to 6.
01; P value=0.25 (Wong
1995)
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
Study population RR 0.20
(0.03 to 1.41)
20
(1 study)
⊕⊕⊕©
moderate2
500 per 1000 100 per 1000
(15 to 705)
Low
100 per 1000 20 per 1000
(3 to 141)
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Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
See comment See comment Not estimable 34
(2 studies)
⊕⊕©©
low1,2
MD 1.49, 95% CI -0.58
to 3.56; P value = 0.16
(Moghetti 2000) and MD
0.40, 95% CI -1.18 to 1.
98; P value=0.62 (Wong
1995)
Change in serum andro-
gen levels
See comment See comment Not estimable 34
(2 studies)
⊕⊕©©
low3
No clinically important
differences
Change in BMI - not mea-
sured
See comment See comment Not estimable - See comment No study addressed this
outcome
Improvement of other
clinical signs of hyper-
androgenism - not mea-
sured
See comment See comment Not estimable - See comment No study addressed this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level due to serious risk of performance and detection bias (Wong 1995 no blinding reported).
2Downgraded one level due to serious imprecision (wide CI, due to low sample size).
3Downgraded two levels due to very serious imprecision (very wide CI, due to low sample size).
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Flutamide 250 mg once to twice daily compared to metformin 1275 mg to 1700 mg per day for hirsutism
Patient or population: women with hirsutism
Intervention: flutamide 250 mg once to twice daily
Comparison: metformin 1275 mg to 1700 mg per day
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Metformin 1275 to 1700
mg per day
Flutamide 250 mg once
to twice daily
Participant-reported im-
provement of hirsutism -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No prespecified outcome,
but in Esmaeilzadeh 2010
the investigators stated
that the quality of life
improved dramatically in
both groups; however no
additional data were pro-
vided
Proportion of partici-
pants who reported an
adverse event
Study population RR 2
(0.41 to 9.71)
40
(1 study)
⊕©©©
very low1,2
100 per 1000 200 per 1000
(41 to 971)
Low
50 per 1000 100 per 1000
(20 to 486)
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Clinician’s assessment
of improvement of hir-
sutism3
Ferriman-Gallwey score
Scale from: 0 to 36
See comment See comment Not estimable3 95
(3 studies)
⊕©©©
very low4,5,6
MD -1.50, 95% CI -3.20
to 0.20; P value = 0.
08 (Esmaeilzadeh 2010)
, MD -0.70, 95% CI -3.
16 to 1.76; P value = 0.
58 (Ibáñez 2002), MD -
6.30, 95% CI -9.83 to -
2.77; P value = 0.0005
(Gambineri 2006)
Change in serum andro-
gen levels
See comment See comment Not estimable 95
(3 studies)
⊕⊕⊕©
moderate6
No clinically important
differences in changes
in androgen levels be-
tween the 2 groups, ex-
cept for androstenedione
and DHEAS in Gambineri
2006 in favour of flu-
tamide
Change in BMI3
kg/m²
See comment See comment Not estimable3 95
(3 studies)
⊕©©©
very low4,6,7
MD 1.70 kg/m2, 95% CI
0.49 to 2.91; P value= 0.
006 (Esmaeilzadeh 2010)
, MD 2.00 kg/m2, 95% CI
-3.75 to -0.26; P value
= 0.02 (Gambineri 2006)
, MD 0.50 kg/m2, 95% CI
-0.72 to 1.72; P value =
0.42 (Ibáñez 2002)
Improvement of other
clinical signs of hyper-
androgenism
See comment See comment Not estimable 55
(2 studies)
⊕⊕⊕©
moderate6
MD in frequency of men-
struations in the previous
6 months -0.70, 95% CI -
1.40 to 0.00; P value =
0.05 (Gambineri 2006).
More ovulatory cycles in
metformin group (Ibáñez
2002)5
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CI: confidence interval; DHEAS : dehydroepiandrosterone sulphate; MD: mean difference; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level due to serious risk of selection bias (allocation concealment was assessed as ’high risk of bias’ for Gambineri
2006).
2Downgraded two levels due to very serious imprecision (very wide CI, due to low sample size).
3Downgraded one level due to substantial heterogeneity (I2 >60%), pooling of data not feasible.
4Downgraded one level due to serious risk of selection bias, performance and detection bias (allocation concealment was assessed as
’high risk of bias’ for Gambineri 2006, Ibáñez 2002 was not blinded).
5Downgraded one level due to heterogeneity (Gambineri 2006 demonstrated a larger effect in the flutamide group, probably due to longer
treatment duration).
6Downgraded one level due to serious imprecision (wide CI, due to low sample size).
7Downgraded one level due to inconsistency (both arms had more weight loss in Esmaeilzadeh 2010 and Gambineri 2006 in which all
participants were placed on a hypocaloric diet).
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Finasteride 5 mg compared to flutamide 250 mg once to b.i.d. for hirsutism
Patient or population: women with hirsutism
Intervention: finasteride 5 mg
Comparison: flutamide 250 mg once to b.i.d.
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Flutamide 250 mg once
to b.i.d.
Finasteride 5 mg
Participant-reported im-
provement of hirsutism
4-point Likert scale
Study population RR 0.63
(0.31 to 1.25)
20
(1 study)
⊕⊕©©
low1
Improvement as as-
sessed on a Likert scale
was good to excellent but
based on a small sample
size
800 per 1000 504 per 1000
(248 to 1000)
Low
100 per 1000 63 per 1000
(31 to 125)
Change in health-related
quality of life (HRQOL) -
not measured
See comment See comment Not estimable - See comment No study addressed this
outcome
Proportion of partici-
pants who reported an
adverse event
Study population RR 3.87
(0.57 to 26.24)
115
(3 studies)
⊕©©©
very low2,3
17 per 1000 64 per 1000
(9 to 437)
Low
10 per 1000 39 per 1000
(6 to 262)
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Clinician’s assessment
of improvement of hir-
sutism
Ferriman-Gallwey score
Scale from: 0 to 36
See comment See comment Not estimable 226
(4 studies)
⊕©©©
very low1,4,5
MD 3.62, 95% CI 3.04 to
4.20 (Falsetti 1999), MD
1.00, 95% CI -2.50 to 4.
50 (Fruzzetti 1999), MD
1.00, 95% CI -1.66 to 3.
66 (Moghetti 2000), and
MD 5.20, 95% CI 3.46 to
6.94 (Müderris 2000)
Change in serum andro-
gen levels
See comment See comment Not estimable 226
(4 studies)
⊕⊕⊕©
moderate1
There were no clinically
important differences in
changes in androgen lev-
els between the 2 treat-
ment groups
Change in BMI - not mea-
sured
See comment See comment Not estimable - See comment No study assessed this
outcome
Improvement of other
clinical signs of hyper-
androgenism
The mean improvement
of other clinical signs of
hyperandrogenism in the
intervention groups was
0 higher
110
(1 study)
⊕⊕⊕⊕
high
No changes in menstrual
cycles in either interven-
tion group
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
b.i.d.: twice a day; BMI: body mass index; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded two levels due to very serious imprecision (wide CI, due to low sample size, optimal sample size is not met by far).
2Downgraded one level due to serious risk of performance and detection bias (Fruzzetti 1999 and Müderris 2000 were open studies).
3Downgraded two levels due to very serious imprecision (very wide CI, due to low sample size).
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4Downgraded one level due to serious risk of performance and detection bias (Falsetti 1999, Fruzzetti 1999, and Müderris 2000 were
open studies).
5Downgraded one level due to substantial and inexplicable heterogeneity (I2 = 67%), caused by Müderris 2000.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
We included 157 studies with a total of 10,550 participants in
this review. There was wide diversity in the types of interventions
that were evaluated and some of them were either not specifically
intended, or are not currently used, for treating hirsutism, e.g. in-
sulin-sensitising agents, gonadotropin-releasing analogues, statins,
clomiphene, or laparoscopic ovary diathermy or drilling. As some
of these interventions had been evaluated in hirsute women and
addressed several of our review outcomes, i.e. the Ferriman-Gall-
wey scores, we have included the relevant data from these studies
in this systematic review. However, our ’Summary of findings’ ta-
bles mainly cover those interventions that focus specifically on the
treatment of hirsutism. We did not identify any randomised con-
trolled trials addressing cosmetic measures such as waxing, shav-
ing, or bleaching, nor any trials investigating the different meth-
ods of electrolysis, although these are frequently offered as treat-
ment options. Laser and photoepilation therapy have already been
assessed in another Cochrane review (Haedersdal 2006).
Two of our primary outcomes, ’participant-reported improvement
of hirsutism’ and ’change in health-related quality of life’ were ad-
dressed but in only a few of the studies. Hirsutism in women oc-
curs far more frequently than meets the eye and many women will
do everything possible to rid themselves of the superfluous hairs.
The psychosocial impact of hirsutism in women is well recognised
and can affect an individual’s self esteem and self image, leading to
feelings of shame, psychological distress, depression, and to a re-
duction in overall quality of life. It was unfortunate that the impor-
tance of patient-reported outcomes (PROs) such as ’participant-
reported improvement of hirsutism’ and ’health-related quality of
life’ appears to have been underestimated and that these outcomes
were overlooked by the investigators in themajority of the studies.
Moreover, the studies that did address some of these outcomes did
not, in most instances, use a validated measure or internationally
recognised instrument.
Adverse events were evaluated and reported in less than half of the
studies and as most of the interventions would require a lengthy
treatment period the possibility of side effects occurring after pro-
tracted use should have been a consideration. Conversely it could
be argued that, as most of the treatment options have been widely
available for a considerable period of time, many if not all of these
side effects are already well known. However, in most of the com-
parisons there were no statistically significant differences in the
number of adverse events between either of the treatment arms.
The side effects that were reported included mainly known ad-
verse events such as gastrointestinal discomfort, breast tenderness,
reduced libido, and dry skin with flutamide and finasteride; ir-
regular bleeding with spironolactone; nausea, diarrhoea, and ab-
dominal bloating with metformin; and hot flushes, decreased li-
bido, vaginal dryness, breast tenderness, and headaches with the
gonadotropin-releasing analogues.
The Ferriman-Gallwey score, which was one of our secondary
outcomes, was used for the clinician’s evaluation of hirsutism in
most of the studies. Changes in serum androgen levels were also
addressed in the majority of the studies. It was readily apparent
that many of the laboratories used by study investigators applied
their own units of measurement for the different androgens rather
than following the International System of Units (Système In-
ternationale or SI). In most of the comparisons these changes in
androgen levels were not clinically important or not statistically
significant, and therefore there would be limited benefit in con-
verting all of these units to SI units. Change in body mass index
(BMI) and improvement of other clinical signs of hyperandro-
genism were evaluated in around one-third of the studies.
Pooling of data based on Ferriman-Gallwey score was possible in
just three of the comparisons (OCP including cyproterone acetate
versus OCP including desogestrel; finasteride versus placebo; met-
formin versus placebo), adverse events in two (finasteride versus
placebo; finasteride versus flutamide), and BMI in only one of the
comparisons (metformin versus placebo).
Although predominantly examined in single study comparisons,
oral contraceptives (OCPs) reduced the Ferriman-Gallwey score,
but the reduction was not shown to be consistently clinically im-
portant across the studies. It is acknowledged that OCPs gradually
increase sex hormone-binding globulin (SHBG) levels and thereby
decrease free testosterone levels and thus in studies with a dura-
tion of less than six months the SHBG increase might not have
reached the plateau phase nor attained maximum effect. There
was evidence, albeit rated as low quality, that OCP with ethinyl
estradiol 35 µg + cyproterone acetate 2 mg and OCP with ethinyl
estradiol 30 µg + desogestrel 0.15 mg are equally effective in reduc-
ing the Ferriman-Gallwey score in a clinically important manner
(Summary of findings for the main comparison).
Evidence was available showing that one of the antiandrogens, flu-
tamide 250 mg twice daily given for six to 12 months, was more
effective in reducing the Ferriman-Gallwey score than placebo, a
result that was both statistically significant and clinically impor-
tant although we rated the evidence very low quality (see Summary
of findings 2). In the combined treatment comparisons there were
similar reductions in Ferriman-Gallwey score in the ’flutamide
only’ treatment arms. Spironolactone was also shown to be effec-
tive based on three comparisons (flutamide versus spironolactone,
spironolactone versus placebo, and finasteride versus spironolac-
tone in a dosage of 100 mg per day for six months) (see Summary
of findings 3 and Summary of findings 4 for data on compari-
son ’flutamide versus spironolactone’ and ’spironolactone versus
placebo’).
We rated the pooled data for the Ferriman-Gallwey score from
three studies evaluating finasteride 5 mg to 7.5 mg per day, a 5α
reductase inhibitor, as very low quality evidence and demonstrated
that although there was a statistically significant difference in the
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Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
effectiveness of finasteride versus placebo, it was unlikely that this
difference was clinically meaningful. These results were reinforced
by the participant-reported assessments of improvement of hir-
sutism in two of the studies (see Summary of findings 5). Other
comparisons including a ’finasteride monotherapy arm’ showed
limited to more substantial and clinically important decreases in
Ferriman-Gallwey scores (see comparisons 26 to 28, 53, 107, 109,
111, and 117).
Metformin was the most frequently evaluated insulin sensitiser.
Pooled data for the Ferriman-Gallwey score from seven studies
demonstrated no statistically significant benefit of metformin over
placebo but we rated the quality of evidence as low (see Summary
of findings 6).
We were unable to pool data for the combined interventions of
OCPs with cyproterone acetate 20 mg to 100 mg due to clini-
cal and methodological heterogeneity between the studies. How-
ever, it was evident that the addition of cyproterone acetate to
OCP did result in greater reductions in Ferriman-Gallwey scores
than OCP alone. The results reported on the effectiveness of the
gonadotropin-releasing analogues for hirsutism were inconsistent
and varied from minimal improvements to clinically important
improvements.
We had expected to findmore evidence in support of the increased
effectiveness of combination therapies of OCPs, i.e. combined
with flutamide, finasteride, or spironolactone, but the results of
this review failed to confirm this assumption. Two small studies,
which compared finasteride 5 mg and spironolactone 100 mg for
six months, did not show statistically significant differences in par-
ticipant assessments and reduction of the Ferriman-Gallwey score
(both rated as low quality evidence) (see Summary of findings 7).
Data on Ferriman-Gallwey scores, rated as very low quality evi-
dence, from three studies comparing flutamide versus metformin
could not be pooled due to substantial heterogeneity (I² = 62%).
However, one study that compared flutamide 250 mg twice a day
with metformin 850 mg twice a day for 12 months, and which
reached a higher cumulative dosage than in the other two studies
evaluating this comparison, showed a statistically significant dif-
ference in favour of flutamide (see Summary of findings 8). The
data showing a reduction in Ferriman-Gallwey scores could not be
pooled for the four studies comparing finasteride with flutamide
due to substantial heterogeneity (I² = 67%) and the results were
not consistent (see Summary of findings 9).
Several studies that examined the effects of hypocaloric diets re-
ported reductions in BMI, but which did not appear to result in a
greater reduction of the Ferriman-Gallwey score, although it was
not possible to separate out the effect of reduction of BMI from the
effect of the oral pharmacological treatments in terms of improve-
ment of the hirsutism. It remains unclear if this could be attributed
to a synergistic effect, i.e. an enhanced effect of the oral treatments
with the additional increase of SHBG and the corresponding de-
crease of free testosterone induced by the weight loss. Only limited
data were available for some of the other clinical signs of hyper-
androgenism. Comparisons including OCPs showed a beneficial
effect of the use of OCPs on acne, whilst insulin sensitisers seem
to improve the menstrual pattern.
Overall completeness and applicability of
evidence
A broad range of treatment options were covered by the studies in-
cluded in this review, but we assessed the majority of these studies
as at high risk of bias mainly due to inadequate blinding of partic-
ipants, investigators, and outcome assessors. Pooling of study data
was only possible for very few of the interventions as most of the
134 comparisons were examined in single studies. Consequently,
no fair and reliable judgement could be made regarding which
treatment option, or which combination of different therapies, is
most effective. Considering the impact of hirsutism on a woman’s
mental, social, and physical well being there is a pressing need for
studies that include patient-reported outcomes (PROs), whichwill
help fill in some of the gaps about which treatments, according to
the participants, are considered to be the most effective, tolerable,
and acceptable.
Based on the available evidence the following interventions would
appear to be at best both effective and safe: OCP with ethinyl
estradiol 35 µg + cyproterone acetate 2 mg and OCP with ethinyl
estradiol 30 µg + desogestrel 0.15 mg, as well as flutamide 250 mg
twice daily, and spironolactone 100 mg per day for at least six to
12 months.
Quality of the evidence
The overall quality of the evidence across the different outcomes
as summarised in the ’Summary of findings’ tables was moderate
to very low. The key reasons for downgrading the quality of the
evidence for each outcome were: limitations in study design or
execution (risk of bias) and imprecision mainly due to low sample
size.
Limitations in study design and implementation
The ’Risk of bias’ assessments as summarised in the ’Risk of bias
in included studies’ section of this review identified some of the
limitations in study design in the included studies. In more than
half of the studies the method used to generate the sequence was
not adequately described and in almost three-quarters of them
the method used to conceal the allocation was not reported. Fur-
thermore, more than half of the studies had an open-label design,
which represents a potential risk of performance and detection
bias, and in almost half of the studies we judged the risk of attri-
tion bias to be unclear to high as outcome data were incomplete.
Achievement of the optimum effect will to a large extent depend
on the duration of the treatment period as well as on the variable
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rates of hair growth in different parts of the body. Although there
is a widely supported recommendation that the duration of treat-
ment should be not less than six months, some of the studies cov-
ered in this review evaluated interventions lasting just three to four
months with a possibility that they may have shown somewhat
limited beneficial treatment effect over this shorter time period
(see Effects of interventions).
Indirectness of the evidence
The women included in the studies were fairly representative of
the participants as prespecified in ’Types of participants’. Both
placebo-controlled studies as well as active-controlled studies were
included, and therefore for most treatment options it was possible
to make a fair judgement on the comparative effectiveness of some
of the individual treatments.
PROs (patient-reported outcomes) are a prerequisite for evidence-
based shared decision-making, yet the investigators in themajority
of the studies omitted to include these important patient-preferred
outcomes. In the few trials where PROs were considered, these as-
sessments were made based on non-validated and therefore ques-
tionably reliable instruments. Furthermore, none of the PRO as-
sessment tools that were used met most or all of the recommended
criteria based on the ’Checklist for describing and assessing PROs
in Clinical Trials’ (see Chapter 17.6.a in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011)).
Imprecision of the results
In only a few instances was the effect estimate tightly bound by the
confidence interval and consequently imprecision was the most
frequent reason for downgrading the quality of the evidence for dif-
ferent outcomes per comparison. Imprecision was predominantly
due to the small sample size in the studies.
Inconsistency of the results
Most of the comparisons were evaluated in single studies, which
did not permit assessments of consistency of the results across stud-
ies for the majority of treatments. In those studies where outcome
data could be pooled, this was often accompanied by substantial
heterogeneity for one or more outcomes, such as in the follow-
ing comparisons: ’flutamide versus metformin’ (comparison 110)
and ’finasteride versus flutamide’ (comparison 111). In the com-
parison of flutamide versus metformin, which showed flutamide
to be more effective, this could have been associated with the
longer treatment duration of flutamide in one of the studies. In
the other comparison of ’finasteride versus flutamide’ we could not
find a plausible explanation for the heterogeneity. Although not
pooled, the results on the effectiveness of gonadotropin-releasing
analogues for reducing hirsutism were also not consistent. In some
comparisons they seemed more effective than in others, however
this treatment option is no longer widely used for the treatment
of hirsutism.
Publication bias
Since none of the comparisons involved 10 ormore studies, formal
assessment of publication bias was not feasible. However, we did
identify 33 duplicate reports of the same study data in our searches
(see under Results of the search).
Potential biases in the review process
We made concerted efforts to limit bias in the review process
by making certain that an exhaustive and comprehensive search
had been undertaken for potentially eligible studies. The authors
assessed the eligibility of studies for inclusion in this review and
carried out the data extraction independently, thereby minimising
the potential for additional bias beyond that detailed in the ’Risk
of bias’ tables (’Characteristics of included studies’). We took care
to identify duplicate publication of data or co-publication of same-
study data. The incompleteness of some of the trial data and our
inability to retrieve certain study details or to resolve ambiguities in
the reports may have contributed to some bias in their assessment,
but where these conditions occurred, this was explicitly stated
in the text of our review. To minimise the risk of language bias
on the identification and selection of studies for inclusion in our
systematic review, we ensured that any studies that were not in the
English language were translated so that they could be assessed for
eligibility.
Agreements and disagreements with other
studies or reviews
Our comprehensive searches for other relevant studies, re-
views, and clinical guidelines included a number of clini-
cal references and sources for guidelines and systematic re-
views: Agency for Healthcare Research and Quality (http://
www.ahrq.gov/), DynaMed (https://dynamed.ebscohost.com/),
National Guidelines Clearinghouse (http://www.guideline.gov/),
National Institute for Health and Clinical Excellence (http://
www.nice.org.uk/), Scottish Intercollegiate Guidelines Network
(http://www.sign.ac.uk/index.html), Endocrine Society (http://
www.endocrine.org/), UKDatabase ofUncertainties about the Ef-
fects of Treatments (http://www.library.nhs.uk/duets/), and Up-
ToDate (http://www.uptodate.com/home).
We identified a number of relevant intervention-specific system-
atic reviews of randomised controlled trials in addition to several
more broader, overarching clinical guidelines, many of which were
underpinned by systematic and fully inclusive searches for evi-
dence. This clinical topic also attracted a large number of narrative
reviews, which had been published over the last 10 years but were
of variable and less robust methodological quality, more especially
in their approach to searching for, and critical appraisal of, relevant
studies (see Table 5 for an overview on reviews). Several Cochrane
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reviews partially overlapped our inclusion criteria of types of par-
ticipants and interventions or addressed our outcomes or all of
these (see below).
Although we had some concerns about themethodological quality
of some of these studies and reviews, in general the direction of
their conclusions was in agreement with our findings. The over-
riding recommendations were that, to obtain the most beneficial
or desired effect, combination therapies should be used in the
management of hirsutism. In general OCPs were considered to be
the first line of treatment for mild hirsutism, and in the absence
of a satisfactory end result or in case of moderate to severe hir-
sutism, antiandrogens or 5α-reductase inhibitors were to be added
(Blume-Peytavi 2013; Castelo-Branco 2010; Escobar-Morreale
2012; Legro 2013; Martin 2008). In the systematic review of
Swiglo 2008 the investigators concluded: ”weak evidence suggests
antiandrogens are mildly effective agents for the treatment of hir-
sutism“, which was broadly in agreement with our conclusions.
Most of the reviews emphasised that it may take at least six to
12 months for oral treatment to demonstrate a noticeable effect
(Blume-Peytavi 2013; Escobar-Morreale 2010; Paparodis 2011;
Rosenfield 2005), and up to two years to achieve the optimum
effect (Azziz 2003). There was a general consensus that in view
of the possible time lag between treatment and effect, pharma-
cological therapy should be combined with cosmetic procedures
such as bleaching, shaving, waxing, and plucking or more perma-
nent hair removal with electrolysis or light-based therapies (in-
tense pulsed light therapy or laser) or both (Blume-Peytavi 2013;
Castelo-Branco 2010; Escobar-Morreale 2010; Lumachi 2010;
Martin 2008).
Insulin sensitisers are often recommended for women with poly-
cystic ovary syndrome (PCOS) and insulin resistance to improve
insulin sensitivity, decrease androgen production, and raise the
levels of SHBG, which ultimately might lead to an improvement
of hirsutism. The conclusions in the Cosma 2008 review were
in agreement with our review that insulin sensitisers have lim-
ited or no important benefit on hirsutism in women. We found
no evidence to indicate that lifestyle modification was an effec-
tive treatment approach for hirsutism, which was confirmed in
a further review (Domecq 2013). However, there was general
agreement among several of these reviews that for other potential
risk factors associated with PCOS (e.g. cardiovascular disease and
metabolic dysfunction) lifestylemeasures, which included exercise
and hypocaloric diets, should be advised for overweight women
(Escobar-Morreale 2012; Koulouri 2009; Legro 2013; Pasquali
2013).
Gonadotropin-releasing hormone analogue therapy is no longer
widely recommended because it causes symptoms of menopause
including hot flushes, leads to bone loss, and is expensive (Blume-
Peytavi 2008; Brodell 2010; Koulouri 2008).
Cochrane reviews
Several other Cochrane reviews have evaluated the effects of inter-
ventions in hirsute women (Brown 2009; Costello 2007; Farquhar
2012; Moran 2011; Tang 2012; van der Spuy 2003), however our
attempts to draw comparisons between this review and these other
reviews presented a number of challenges. There was a level of dis-
agreement over specific methodological issues and some aspects of
review conduct. These disagreements included how judgements
were made by the review authors in the selection of studies, and in
their ’Risk of bias’ assessments for specific domains. In a number
of instances these ’Risk of bias’ assessments were not presented
with explicit support for the individual judgements. We were also
at variance with some of the approaches used in data collection or
the subsequent analyses and reporting of those data. There was a
degree of variability in how outcome data were reported in these
reviews, i.e. change scores in some as opposed to comparisons of
final values for key outcomes in others, and whilst the recommen-
dations in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (see Chapter 9.4.5.2) (Higgins 2011) are not prescriptive,
they indicate that analyses based on change scores are likely to be
more efficient and more powerful than final value scores.
Our conclusions on the effect of spironolactone for hirsutism were
similar to those reported in Brown 2009, although we note some
disagreement with the studies that had been included as well as
excluded and with several of the judgements of risk of bias for
some of the domains in the selected studies.
In the Costello 2007 systematic review, insulin-sensitising drugs
were compared with the combined oral contraceptive pill for hir-
sutism, as well as acne and risk of diabetes, cardiovascular disease,
and endometrial cancer in participants with polycystic ovary syn-
drome. We judged that three out of six of the studies included in
the review had unusable or potentially unreliable data, because the
primary report was either unclear about how many women were
hirsute, or there were no separate data available for hirsute women,
or the drop-out rate exceeded 40% (Cibula 2005;Morin-Papunen
2000;Morin-Papunen 2003) (see Table 3). In the remaining three
studies, Elter 2002, Harborne 2003, and Rautio 2005, it was not
possible to compare results for the studies between the reviews as
we had calculated changes from baseline for outcomes such as Fer-
riman-Gallwey scores in our comparisons, whilst Costello 2007
reported end values.
We only shared two studies with the Cochrane review of Farquhar
2012,which focused onovulation induction rather thanhirsutism.
Although we had several studies in common, hirsutism was not
an outcome in Moran 2011. The effectiveness of insulin-sensi-
tising drugs on improving reproductive outcomes and metabolic
parameters for women with PCOS was covered in Tang 2012. We
had discordant views on the judgements made for ’Risk of bias’
assessments in several of the domains in the 11 studies common
to both reviews. This disagreement could be explained in part by
the fact that we had ameasure of success in contacting the research
investigators in these 11 studies, which allowed us to fill in many
of the missing trial details that were not adequately addressed in
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Tang 2012. We had the most overlap in terms of type of partici-
pants and intervention and number of shared studies with van der
Spuy 2003 (which is being updated), in which the review authors
examined the effects of cyproterone acetate in hirsutism, but we
identified numerous disagreements with the studies selected for
inclusion and in the review authors judgements for the ’Risk of
bias’ assessments in several of those studies.
Guidelines
The limited number of topic-specific clinical guidelines covering
hirsutism was most likely because it is a clinical condition that is
often covered by broader themes in endocrinology, e.g. polycys-
tic ovary syndrome, hyperandrogenism, the effects of insulin sen-
sitisers, or lifestyle modification programmes. The development
process as reported in all of these guidelines involved a systematic
search of the literature, assessment of the selected studies by an
expert panel, and in a few instances included recommendations
based on the GRADE approach. Although the developers of sev-
eral of these guidelines provided the strength of recommendations,
i.e. ’strong - we recommend’, there was often insufficient clarity in
reporting of how judgements were made as to which factors de-
creased or increased the quality level of a body of evidence. Possible
factors that should be considered for downgrading or upgrading
of the quality of evidence have been specified by GRADE (see
Chapter 12.2 Table 12.2 in the Cochrane Handbook for Systematic
Reviews of Interventions; Higgins 2011). A more detailed reporting
of how and on what basis these decisions were made by the guide-
line developers would most likely provide increased transparency
and add to the robustness of the process of guideline development.
The ’Summary of findings’ tables we present in this review provide
a more complete report of these ratings and supporting reasons
for all important outcomes, both desirable and undesirable, and
the corresponding illustrative risk. We note that two clinical prac-
tice guidelines developed by the Endocrine Society Task Force on
Hirsutism (http://www.endocrine.org/) were well conducted in a
robust systematic way and used the GRADE approach to assess
the quality of evidence and to make subsequent recommendations
(Legro 2013; Martin 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Treatment should aim to remove the unwanted hairs, reduce or
completely inhibit growth of new hairs, correct hormonal imbal-
ances, and improve the self image, self esteem, and quality of life
of the affected woman. To achieve these goals the treatment ap-
proach will need to encompass not only pharmacological thera-
pies but also cosmetic procedures and lifestyle modification, as
well as methods addressing the psychological support required
to enhance individual coping mechanisms (Blume-Peytavi 2011;
Blume-Peytavi 2013; Brodell 2010; Martin 2008). Our conclu-
sions are supported by studies with a duration of between six and
12 months.
The effectiveness of oral contraceptives (OCPs), in particular those
containing ethinyl estradiol 35 µg combined with cyproterone ac-
etate 2 mg and ethinyl estradiol 30 µg combined with desogestrel
0.15 mg, was supported by low quality evidence. OCPs, prefer-
entially those with antiandrogenic activity, can be considered as a
possible first line treatment approach for mild hirsutism.
Among the antiandrogens both flutamide 250 mg twice a day as
well as spironolactone 100 mg per day appeared to be effective and
safe, although we rated the quality of the evidence as low to very
low. Finasteride 5 mg per day showed inconsistent results for its
effectiveness in the different comparisons, and therefore no firm
conclusion can be made regarding this treatment. In addition, as
the side effects of these antiandrogen treatments and finasteride
are well known, these should be taken into account in any clinical
decision-making.
Although we were unable to pool data for the effects of OCP
combined with cyproterone acetate, this combination appeared
to be more effective in reducing hirsutism. We were unable to
draw conclusions on the effects of other combinations of OCPs,
i.e. with flutamide, spironolactone, or finasteride versus OCPs
only to see if these additions would result in a more beneficial
effect on hirsutism. The inability to pool data was largely due to
the wide diversity between treatment arms for these comparisons
and because most of the comparisons examined one combination
therapy against another different combination therapy. It should
be emphasised that all antiandrogens as well as finasteride carry
the risk of feminisation of the male foetus and should therefore
always be combined with effective contraception. Hirsute women
who wish to conceive can only be treated safely with cosmetic
procedures.
Out of the insulin sensitisers, there was evidence rated as low qual-
ity that metformin was not effective in the treatment of hirsutism,
but this does not mean that it has no therapeutic value in the
treatment of overweight women with polycystic ovary syndrome
(PCOS) and hyperinsulinaemia.
Although the gonadotropin-releasing hormone (GnRH) ana-
logues did not show consistent results in reducing hirsutism they
do have significant side effects such as hot flushes, premature
menopausal symptoms, and bone loss. Consequently there would
appear to be no therapeutic advantage with this category of drugs
over OCPs and antiandrogens or finasteride.
Evidence was lacking to support the effect of lifestylemodification
on the improvement of hirsutism and we did not identify any
randomised controlled trials addressing cosmetic procedures for
the treatment of hirsutism.
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Clinical decision-making on the choice of treatment for hirsutism
should be based on high-level evidence if it is available, but in the
absence of such evidence for any other specific intervention, these
decisions should continue to be guided by clinical experience and
peoples’ individual characteristics and preferences until further ev-
idence for these other interventions becomes available. The ap-
propriate monitoring of patients both clinically and biochemically
while on therapy is important. Hirsute women are typically other-
wise healthy and the risks and benefits of each therapeutic option
must be carefully considered and discussed with them. In view of
the fact that it may take six to 12 months before any treatment
effect can be noticed, alternative and interim measures, including
coping strategies and provision of psychological support as well
as cosmetic measures, should also be integrated into the decision-
making process.
Implications for research
This review covers a wide range of treatments used for the treat-
ment of hirsutism and although we were able to include 157 stud-
ies, only very few studies were well designed and rigorously con-
ducted and reported. A minority of the studies addressed patient-
reported outcomes such as the participants’ assessment of improve-
ment of hirsutism, change in health-related quality of life, and
adverse events, but these were frequently inadequately reported.
There is an urgent need for high-quality, well-designed, and rig-
orously reported studies of head-to-head trials examining OCPs
combined with an antiandrogen or a 5α-reductase inhibitor
against OCP monotherapy, as well as the different antiandrogens
and 5α-reductase inhibitors against each other.
A major area for improvement would be in the standardisation
of outcome reporting in any future research. Outcomes collected
in future trials should be primarily based on a standardised scale
of the participant’s assessment of the treatment efficacy, and they
should also have a greater emphasis on changes in quality of life
as a result of the interventions. The minimal clinically important
difference should be established to interpret the outcome data,
and to ascertain if a treatment leads to a clinically meaningful and
relevant reduction of hirsutism and improvement of quality of life.
Follow-up studies addressing the sustainability of hair reduction
after discontinuation of treatment should be taken into account
as this constitutes an important outcome for participants.
Since measurable hyperandrogaenemia and body mass index
(BMI) do not always correlate with the degree of hirsutism, it
may also be that certain forms of treatment have better efficacy in
some women compared to others depending upon their baseline
characteristics. Therefore, subgroup analyses addressing baseline
characteristics might also be appropriate.
Future randomised controlled trials must be well-designed, well-
conducted, and adequately delivered, with subsequent reporting
including high-quality descriptions of all aspects of methodology.
Rigorous reporting needs to conform to the Consolidated Stan-
dards of Reporting Trials (CONSORT) statement, and this will
enable appraisal and interpretation of results, and accurate judge-
ments to be made about the risk of bias and the overall quality
of the evidence. Although it is uncertain whether reported quality
mirrors actual study conduct, it is noteworthy that studies with
unclear methodology have been shown to produce biased esti-
mates of treatment effects (Schulz 1995). Adherence to guidelines,
such as the CONSORT statement, would help ensure complete
reporting.
For further research recommendations based on the EPICOT
(evidence, population, intervention, comparison, outcomes, and
time) format (Brown 2006), see Table 6.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmad 2008
Methods Randomised, open-label, active-controlled trial
Setting
Centre of Diabetes and Endocrinology, Faculty ofMedicine, Jawahar Lal NehruMedical
College Hospital, Aligarh Muslim University, Aligarh, India
Date of study
Not reported. Duration of intervention 12 months
Participants N = 70
Mean age = 23 years
Inclusion criteria of the trial
• Non-diabetic, euthyroid, normoprolactinemic women aged 18-35 years,
attending the outpatient endocrinology clinic with complaints of menstrual
irregularities, hirsutism, and/or sterility
• PCOS diagnosed by the presence of (i) chronic ovulatory dysfunction-
oligomenorrhoea (cycle length > 45 days) or amenorrhoea (cycle length > 6 months),
(ii) evidence of hyperandrogenaemia, whether clinical (hirsutism with Ferriman-
Gallwey (F-G) score ≥ 8) or biochemical (serum concentration of testosterone) and
(iii) exclusion of other causes such as congenital adrenal hyperplasia (CAH), androgen
secreting tumours, hyperprolactinaemia and Cushing’s syndrome
Exclusion criteria of the trial
• History of diabetes mellitus, renal, hepatic or cardiovascular dysfunction
• Medications known or suspected to affect reproductive or metabolic functions (e.
g. clomiphene citrate, antiandrogens, oral contraceptive pills (OCPs) and anti-obesity
compounds) within 6 months of study entry
• Women who had undergone hysterectomy or oophorectomy
Randomised
N = 70
Withdrawals/losses to follow-up
• 9/70 (13%); 4/35 in metformin group, 5/35 in rosiglitazone group
• 2 conceived, 2 poor compliance, 2 incomplete data, 3 lost to follow-up
Baseline data (mean (SD))
Hirsutism score (F-G): metformin group 10.52 (2.63); rosiglitazone group 9.55 (2.31)
BMI (body mass index (kg/cm2))
>30: metformin group (10), rosiglitazone group (9)
25-30: metformin group (14), rosiglitazone group (16)
<25: metformin group (7), rosiglitazone group (7)
Waist/hip ratio: metformin group 0.87 (0.06), rosiglitazone group 0.81 (0.02)
Menstrual pattern
Oligomenorrhoea: metformin group (18), rosiglitazone group (23)
Amenorrhoea: metformin group (13), rosiglitazone group (7)
Interventions Intervention
• Metformin 850 mg b.i.d. for 12 months (35)
Comparator
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Ahmad 2008 (Continued)
• Rosiglitazone 2 mg b.i.d. for 12 months (35)
Women were instructed not to change their dietary intake or exercise pattern during the
study
Outcomes Assessments (4): baseline, month 3, 6 and 12
Outcomes of the trial (as reported)
1. Homeostasis model insulin assessment resistance index (HOMA-IR)
2. Quantitative insulin sensitivity check index (QUICKI)
3. Area under the curve (AUC) for insulin and glucose
4. Evaluation of hyperandrogenaemia by clinical and biochemical parameters
(hirsutism, ovulation, resumption of menstrual cycle, androgen levels)
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 39): ”Subjects were randomly
allocated into two group using random
number tables“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 38): ”open-label“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 38): ”open-label“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 9/70 (13%), drop-outs or lost to follow-
up, 4 in metformin group, 5 in rosiglita-
zone group, reasons reported. Per-protocol
analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Aigner 2009
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Internal Medicine, General Hospital Oberndorf, Oberndorf, Austria
Date of study
Not reported. Duration of the intervention 3 months
Participants N = 40
Mean age = 30 years
Inclusion criteria of the trial
• Women with PCOS diagnosed by the presence of: 1) long-standing ovulatory
dysfunction (oligo- or amenorrhoea); 2) hirsutism (Ferriman-Gallwey score 7), and/or
circulating serum total testosterone greater than 2.5 nmol/L and SHBG concentrations
less than 50 nmol/L; and 3) exclusion of other endocrine disorders, e.g. thyroidal
dysfunction, adrenal diseases, and hyperprolactinaemia
Exclusion criteria of the trial
• Desire for pregnancy or existing pregnancy
• Basal FSH concentration greater than 20 IU/litre
• Diabetes mellitus
• Past hysterectomy
• Intake of medication known or suspected to affect reproductive or metabolic
function
• History of liver disease and/or alcohol abuse, elevated liver enzymes
• Severe uncontrolled illness
Randomised
N = 40
Withdrawals/losses to follow-up
• 5/40 (13%); 3/20 pioglitazone group, 2/20 of placebo group; due to loss to
follow-up and protocol violation
Baseline data (mean (SEM))
BMI: pioglitazone group 29.4 (1.7), placebo group 27.5 (1.2)
Waist/hip ratio: pioglitazone group 0.9 (0.1), placebo group 0.9 (0.0)
Hirsutism score (F-G): pioglitazone group 15.5 (1.2), placebo group 15.6 (2.0)
DHEAS (µmol/L): pioglitazone group 5.4 (0.6), placebo group 6.3 (0.6)
Testosterone (nmol/L): pioglitazone group 2.4 (0.3), placebo group 2.8 (0.2)
SHBG (nmol/L): pioglitazone group 36.8 (4.3), placebo group 40.9 (3.5)
Free androgen index (FAI): pioglitazone group 9.3 (2.2), placebo group 8.5 (1.6)
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Interventions Intervention
• Pioglitazone 30 mg once daily for 3 months (20)
Comparator
• Placebo once daily for 3 months (20)
Outcomes Assessments (7): baseline, week 2, 4, 6, 8, 10, 12
Outcomes of the trial (as reported)
1. Serum concentration retinol-binding protein 4
2. Serum concentration adiponectin
3. Serum concentration visfatin
4. Serum concentration of total testosterone, SHBG, DHEAS, FSH, LH,
progesterone, low-density lipoprotein (LDL) cholesterol, high density lipoprotein
(HDL) cholesterol, cholesterol, triglycerides, and liver enzymes
5. BMI, waist/hip ratio and hirsutism score
6. LHRH test with measurement of concentrations of LH and FSH after iv injection
of 100 g LHRH
7. Oral glucose tolerance test
8. Homeostasis model assessment insulin resistance index (HOMA-IR)
9. Area under the curve (AUC) for insulin
10. The occurrence of ovulation was assessed for each patient by serial measurement
of serum progesterone in combination with self reported menstruation.
Denotes outcomes prespecified for this review
Notes Run-in phase before randomisation adhere to a written list of recommendations con-
cerning a healthy diet and physical activity for weight maintenance during a period of 4
weeks while knowingly receiving placebo (run-in phase). This study used sera and data
fromBrettenthaler 2004. Data will be reported from only one of the 2 studies, whichever
one provides the complete set
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1230): ”...randomization was
performed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication: ”according
to the records the randomization was per-
formed by the hospital pharmacy using a
random number generator (such as used in
EXCEL)“
Comment: probably done
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Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Neither pa-
tients nor physicians knew about the allo-
cation until the end of the trial.“ and ”The
pharmacy delivered “neutral” boxes or con-
tainers identical for verum and placebo
with numbers, the numbers were generated
in random order by the pharmacy and nei-
ther doctors nor patients knew the content
nor the key.“
Comment: sequentially numbered drug
containers of identical appearance; proba-
bly done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1230): ”...(identical tablets,
taken once daily) was begun. Patients and
physicians were blinded to the applied
treatment“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed as
well as participant-assessed (menstruation)
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/40 (13%), 3 of pioglitazone group and 2
of placebo group, reasons unreported. Per-
protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
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Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1234): ”Support for this study
fromLand Salzburg (toW.P.) and Spar Aus-
tria (to C.D.) is gratefully acknowledged.“
Comment: we judged this as at a low risk
of bias
Akalin 1991
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Setting
Section of Endocrinology, Department of Medicine, Hacettepe University, School of
Medicine, Ankara, Turkey
Date of study
Not reported. Duration of intervention 6 months and then cross-over for 6 further
months
Participants N = 11
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• Not reported
Randomised
N = 11
Withdrawals/losses to follow-up
• 2/11 (18%); lost to follow-up (1), pregnancy (1)
Baseline data
Cross-over; no separate data at start of each 6-month treatment period
Interventions Intervention
• Ketoconazole 600 mg once a day for 6 months
Comparator
• Placebo once a day for 6 months
During the study all used non-hormonal contraception. Cross-over after 6 months, no
wash-out period
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum testosterone, DHEAS, progesterone, estradiol, basal and stimulated
cortisol and 17-alpha hydroxyprogesterone
3. FSH and LH levels at 0, 30, 60, and 90 min of a GnRH stimulation test
4. Adverse effects
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Denotes outcomes prespecified for this review
Notes No wash-out period. No separate data for first 6 months treatment period. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 20): ”...dispensed randomly
by the hospital pharmacy“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Low risk Quote (page 20): ”...dispensed randomly
by the hospital pharmacy“
Comment: form of central allocation.
Probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 19): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 19): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 2/11 (18%), lost to follow-up (1), preg-
nancy (1) unclear in which treatment arm.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
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of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Al-Khawajah 1998
Methods Randomised, active-controlled, dose-finding trial
Setting
Department of Medicine, King Saud University, Riyadh, Saudi Arabia
Date of study
Not reported. Duration of intervention 6 months
Participants N = 45
Mean age = 25 years
Inclusion criteria of the trial
• Moderate to severe hirsutism
Exclusion criteria of the trial
• Drug treatment for hirsutism < 6 months prior to study entry
• Signs of virilisation
• Adrenal or ovarian neoplasm
• Hyperprolactinaemia, congenital adrenal hyperplasia, Cushing’s syndrome, or
drug-induced hyperprolactinaemia
Randomised
N = 45
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
F-G score: 22.4 (1.5) in 2.5 mg finasteride group; 20.3 (1.8) in 5 mg finasteride group,
21.0 (1.3) in 7.5 mg finasteride group
Interventions Intervention
• Finasteride 2.5 mg once a day for 6 months (15)
Comparator 1
• Finasteride 5 mg once a day for 6 months (15)
Comparator 2
• Finasteride 7.5 mg once a day for 6 months (15)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Serum testosterone, free testosterone, DHEAS, androstenedione,
dihydrotestosterone (DHT), progesterone, prolactin, LH, FSH, cortisol
2. Ferriman-Gallwey score
3. Self assessment score; 5-point Likert scale
4. Shaft diameter of anagen hairs from facial location
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Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 19): ”The patients were ran-
domly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, active-controlled trial
Setting
Baystate Medical Center Children’s Hospital, Tufts University School of Medicine,
Springfield, MA, US
Date of study
Not reported. Duration of intervention 6 months
Participants N = 35
Mean age = 15 years
Inclusion criteria of the trial
• Female adolescents aged 12 to 21 years with PCOS
• Hyperandrogenaemia (total testosterone > 60 ng/dl and free testosterone > 1.1
pg/ml) with no evidence of androgen secreting tumour (no cliteromegaly, male body
habitus, or total testosterone level > 200 ng/dl))
• Oligomenorrhoea (< 6 menses in the previous 6 months)
• Obesity (> 95th percentile body mass index (BMI) for age)
• Stimulated 17-hydroxyprogesterone < 300 ng/dl
• Hyperinsulinaemic with a fasting insulin level > 20 µU/ml but not diabetic
(fasting glucose level < 126 mg/dl)
Exclusion criteria of the trial
• Current or past sexual activity
• OCP use within the previous 6 months, a positive urine pregnancy test
(performed on all participants at baseline)
• Abnormal blood urea nitrogen, creatinine, aspartate transaminase
• Positive personal or family history of thrombosis
Randomised
N = 36
Withdrawals/losses to follow-up
• 4/35 (11%); 2 in each group, unreachable (2), refused to attend to follow-up (2)
Baseline data (mean (SEM))
BMI: OCP group 40.1 (2.1), metformin group 37.3 (1.3)
Amenorrhoea/oligomenorrhoea: OCP group 4/11, metformin group 3/13
Acne score: OCP group 2.1 (0.53), metformin group 1.1 (0.40)
F-G score: OCP group 12.4 (3.1), metformin group 8.4 (1.6)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + norgestimate 0.25 mg) for 6 months (17)
Comparator
• Metformin 500 mg b.i.d. for 2 weeks and then increased to 1 g b.i.d. up to 6
months (18)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Free testosterone level
2. Ferriman-Gallwey score
3. Menstrual rate
4. Facial acne; Cook’s numeric grading scale (0 to 8, higher is worse)
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5. Fasting insulin level and fasting glucose level
6. Lipid profile
7. Insulin sensitivity; fasting glucose/insulin ratio and QUICKI
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 763): ”...the patient was ran-
domly assigned, using concealed assign-
ments generated from a random numbers
table, to one of two groups“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 763): ”using concealed assign-
ments generated from a random numbers
table...“
After e-mail communication: ”Allocation
assignment for each subject number was
marked on a paper, individually sealed in a
concealing bank envelope by staff not in-
volved in patient care or the clinical por-
tion of the study prior to randomization of
the first patient.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4/35 (11%); 2 in each group, unreachable
(2), refused to attend to follow-up (2). Per-
protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ashrafinia 2009
Methods Randomised, active-controlled trial
Setting
Department of Gynecology andObstetrics, Roointan-Arash Hospital, TehranUniversity
of Medical Sciences, Tehran, Iran
Date of study
March 2006 until February 2008.Duration of intervention 6months (metformin group)
Participants N = 156 enrolled, 126 randomised
Mean age = 26 years
Inclusion criteria of the trial
• Women between 15 to 45 years, with a history of infertility for at least 1 year and
3 treatment cycles with no response to clomiphene citrate
• Eligibility of the women to participate in the trial was based on the following
criteria according to the Rotterdam consensus (Rotterdam Criteria PCOS 2004): (1)
irregular menstruation; (2) clinical and/or biochemical signs of hyperandrogenism; (3)
polycystic ovaries (presence of 12 or more follicles in each ovary measuring 2 mm to 9
mm in diameter, and/or increased ovarian volume greater than 10 ml)
Exclusion criteria of the trial
• Diseases that would disturb clinical and hormonal responses (congenital adrenal
hyperplasia, ovarian tumours, hyperprolactinaemia, or thyroid disease, Cushing
syndrome and androgen-producing tumours)
• Pregnancy during follow-up
• BMI above 30 or below 17
Randomised
N = 126
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
BMI: metformin group 25.43 (2.79), laparoscopic ovarian diathermy group 25.54 (2.
31)
Testosterone (pg/cc): metformin group 1.42 (0.46), laparoscopic ovarian diathermy
group 1.34 (0.48)
Interventions Assessments (2): baseline, month 6
Intervention
• Metformin 1500 mg/day for 6 months (63)
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Comparator
• Laparoscopic ovarian diathermy (63)
Outcomes Outcomes of the trial (as reported)
1. FSH, LH and testosterone
2. Record of menstrual cycles
3. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 237): ”...were randomly di-
vided into 2 equal groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Low risk Quote (page 237): ”...using serially num-
bered opaque envelopes, for treatmentwith
metformin or LOD“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Azziz 1995
Methods Randomised, active-controlled trial
Setting
Departments of Obstetrics and Gynecology, University of Alabama, Birmingham, Al-
abama, US
Date of study
Not reported. Duration of the intervention 6 months
Participants N = 22
Mean age = 30 years
Inclusion criteria of the trial
• Women of reproductive age complaining of hirsutism (Ferriman-Gallwey (F-G)
score > 8)
Exclusion criteria of the trial
• Significant illness or contraindication to the use of OCP, oestrogen replacement,
or leuprolide
• 21-hydroxylase-deficient nonclassic adrenal hyperplasia, with adrenal or ovarian
tumours
• Hormonal medications within the previous 3 months
Randomised
N = 22
Withdrawals/losses to follow-up
• 5/22 (23%); 2/11 in leuprolide ’plus’ group, 3/11 in OCP group
• 2 moved out of state (leuprolide ’plus’ group), 3 side effects (OCP group)
Baseline data
BMI: leuprolide ’plus’ group 32.0, OCP group 28.6
Waist/hip ratio: leuprolide ’plus’ group 0.88, OCP group 0.82
F-G score: leuprolide ’plus’ group 15, OCP group 12
Interventions Intervention
• Leuprolide 3.75 mg/month intramuscularly, 0.625 mg conjugated oestrogen and
medroxyprogesterone acetate (10 mg) from days 1 to 12 of each month for 6 months
(11)
Comparator
• OCP (ethinyl estradiol 35 µg + ethynodiol diacetate 1 mg) for 6 months (11)
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Outcomes Assessments (6): baseline, week 2, 4, 8, 12, and 28
Outcomes of the trial (as reported)
1. LH, FSH, estradiol, DHEAS, androstenedione, SHBG, and total and free
testosterone
2. Self assessment of hirsutism; questionnaire
3. Ferriman-Gallwey score
4. Facial hair density; photography
5. Outer hair shaft diameter; microscopy
6. Growth rate: photography and plucking
7. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 3407): ”Patients were ran-
domly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
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ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/22 (23%); 2/11 in leuprolide ’plus’
group, 3/11 in OCP group. Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 3408): ”Leuprolide-ERT-
treated patients were heavier than their
OCP-treated counterparts and had a
greater initial rate of hair growth“
Comment: although this baseline differ-
ence is small, we judged this as at unclear
risk of bias
Azziz 2001
Methods Randomised, double-blind, placebo-controlled trial
Setting
Multi-centre, US
Date of study
Not reported. Duration of the intervention 44 weeks
Participants N = 782 screened, 410 randomised
Mean age = 29 years
Inclusion criteria of the trial
• Premenopausal women with suspected PCOS
• PCOS was diagnosed by 1) the presence of chronic ovulatory dysfunction,
defined as intermenstrual intervals of 45 days or more or a total of eight or fewer
menses per year; 2) hyperandrogenaemia, defined as a serum level of free testosterone
greater than the upper normal limit used in the central laboratory for this study (i.e. ≥
21.8 pmol/L); and 3) the exclusion of other disorders, such as nonclassic adrenal
hyperplasia, thyroid dysfunction, and hyperprolactinaemia
Exclusion criteria of the trial
• Unresolved medical conditions
• Hysterectomy and/or oophorectomy
• Type 1 or type 2 diabetes mellitus
• Significant cardiovascular disease
• Active cancer within the past 5 years
• Participation in another investigational study within the past 30 days
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• The use of medications known or suspected to affect reproductive or metabolic
functions within 60 days of study entry
Randomised
N = 410 (unclear how many to each arm)
Withdrawals/losses to follow-up
• 104/410 (25%) not completely clear how many from each group, with
inconsistent totals of numbers and percentages
• Early termination of the study by the sponsor (range 11.5% to 19.8%) and lack
of compliance (range 5.0% to 13.6%). The percentage of patients withdrawing from
the study due to adverse events ranged from 4% to 7%; this was not different between
treatment arms
Baseline data (mean (SEM))
N of hirsute women: troglitazone 150 mg group 56, troglitazone 300 mg group 55,
troglitazone 600 mg group 62, placebo group 57
BMI: troglitazone 150 mg group 37.3 (8.3), troglitazone 300 mg group 35.3 (9.3),
troglitazone 600 mg group 35.6 (8.3), placebo group 37.9 (8.3)
Waist/hip ratio: troglitazone 150 mg group 0.89 (0.08), troglitazone 300 mg group 0.
86 (0.08), troglitazone 600 mg group 0.88 (0.09), placebo group 0.89 (0.08)
Number of cycles in the past 12months: troglitazone 150mggroup4.3 (3.1), troglitazone
300 mg group 4.4 (2.7), troglitazone 600 mg group 4.6 (3.0), placebo group 4.5 (2.7)
Total testosterone (ng/ml): troglitazone 150 mg group 0.63 (0.04), troglitazone 300 mg
group 0.64 (0.03), troglitazone 600 mg group 0.63 (0.03), placebo group 0.57 (0.03)
Free testosterone (pg/ml): troglitazone 150 mg group 11.72 (0.73), troglitazone 300 mg
group 11.55 (0.69), troglitazone 600 mg group 10.92 (0.56), placebo group 10.62 (0.
61)
Androstenedione (ng/ml): troglitazone 150 mg group 1.92 (0.08), troglitazone 300 mg
group 2.09 (0.10), troglitazone 600 mg group 1.98 (0.07), placebo group 1.89 (0.08)
SHBG (nmol/L): troglitazone 150 mg group 39.51 (2.56), troglitazone 300 mg group
41.39 (2.44), troglitazone 600 mg group 40.69 (2.18), placebo group 36.14 (2.03)
Interventions Intervention
• Troglitazone 150 mg/day for 44 weeks (78 = number that completed)
Comparator 1
• Troglitazone 300 mg/day for 44 weeks (77 = number that completed)
Comparator 2
• Troglitazone 600 mg/day for 44 weeks (78 = number that completed)
Comparator 3
• Placebo for 44 weeks (73 = number that completed)
Participants were asked to follow a weight maintenance diet throughout the study to
minimise the effect of weight changes on the disease state
Participants in the study were requested not to use electrolysis, waxing, or plucking for
removal of unwanted hair, except for treatment of lower legs and forearms
Outcomes Assessments (7): baseline, week 4, 12, 20, 28, 36, 44
Outcomes of the trial (as reported)
1. Ovulatory function (by monitoring the urinary level of pregnanediol-3-
glucuronide daily)
2. Modified Ferriman-Gallwey score
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3. Hormonal levels (total and free testosterone, androstenedione, SHBG, LH, FSH,
and the LH/FSH ratio)
4. Measures of glycaemic parameters (fasting levels of glucose, insulin, haemoglobin
A1c, and the glucose and insulin areas under the curve during an oral glucose challenge
Denotes outcomes prespecified for this review
Notes Except for Ferriman-Gallwey scores, the N of participants for other outcomes were a
combination of hirsute and non-hirsute women
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1627): ”...eligible patients
were randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1627): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1627): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
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Incomplete outcome data (attrition bias)
All outcomes
High risk 104/410 (25%), not completely clear how
many from each group, with inconsistent
totals of numbers and percentages. Per-pro-
tocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 1826): ”This work was sup-
ported by a grant from Parke-Davis Phar-
maceutical Research.“ Five of the investiga-
tors were employed by Parke-Davis Phar-
maceutical Research
Comment: a potential risk of bias cannot
be excluded
Badawy 2009b
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, Mansoura University, and a private practice
setting, Mansoura, Egypt
Date of study
January 2005 until January 2007. Follow-up 6 months
Participants N = 163
Mean age = 26 years
Inclusion criteria of the trial
• Women with clomiphene citrate resistant PCOS
• Diagnosis of PCOS was based on the Rotterdam Criteria PCOS (Rotterdam
Criteria PCOS 2004)
Exclusion criteria of the trial
• Not reported
Randomised
N = 163
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
BMI: UTND group 29.3 (3.11), laparoscopic electrosurgery ovarian drilling group 28.
2 (3.24)
Duration in infertility in years: UTND group 3.2 (1.12), laparoscopic electrosurgery
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ovarian drilling group 28.2 (3.24)
Menstrual cycle irregularities (%): UTND group 91.5, laparoscopic electrosurgery ovar-
ian drilling group 88.9
Hyperandrogenism (%):UTNDgroup 45.1, laparoscopic electrosurgery ovarian drilling
group 40.7
Interventions Intervention
• Ultrasound-guided transvaginal needle ovarian drilling (UTND) (81)
Comparator
• Laparoscopic electrosurgery ovarian drilling (82)
Outcomes Assessments (unclear): baseline, several times during each cycle up to 6 months
Outcomes of the trial (as reported)
1. Hormonal changes (FSH, LH, T)
2. Ovulation
3. Pregnancy
4. Hirsutism and acne
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1165): ”...randomly allocated
to either treatment...using a computer-gen-
erated random table“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Themethod
of concealment was sealed envelopes after
computer-generated random table alloca-
tion.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Banaszewska 2007
Methods Randomised, open-label, active-controlled, cross-over trial
Setting
Department of Gynecology/Obstetrics, Poznan University of Medical Sciences, Poznan,
Poland
Date of study
April until September 2004. Duration of intervention 12 weeks and then cross-over
another 12 weeks
Participants N = 54 screened, 48 randomised
Mean age = 24 years
Inclusion criteria of the trial
• PCOS
• PCOS was defined according to a recent Rotterdam European Society for Human
Reproduction and Embryology (ESHRE)/American Society for Reproductive
Medicine (ASRM)-sponsored PCOS Consensus Workshop, i.e. in the presence of at
least 2 of the 3 criteria: 1) oligo- or anovulation, 2) clinical and/or chemical signs of
hyperandrogenism, and/or 3) polycystic ovaries; and exclusion of other aetiologies such
as congenital adrenal hyperplasia, Cushing’s syndrome, or androgen-secreting tumours
Exclusion criteria of the trial
• Conditions such as thyroid disease, hyperprolactinaemia, and diabetes mellitus
• < 3 months before the study, use of any form of oral contraceptives, other steroid
hormones, or any other treatments likely to affect ovarian function, insulin sensitivity,
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or lipid profile
Randomised
N = 48
Withdrawals/losses to follow-up
• After cross-over 3/24 (13%) in simvastatin + OCP group
Baseline data
45/48 had evidence of hyperandrogenism (Ferriman-Gallwey score ≥ 8 and/or hyper-
androgenaemia (total testosterone ≥ 0.6 ng/ml); remaining 3 had acne)
Interventions Intervention
• Simvastatin 20 mg/day + OCP (ethinyl estradiol 20 µg + desogestrel 0.15 mg) for
12 weeks (24)
Comparator
• OCP for 12 weeks (24)
Outcomes Assessments (3): baseline, week 12 and 24
Outcomes of the trial (as reported)
1. Total testosterone
2. Free testosterone, DHEAS, SHBG, LH/FSH, LH/FSH ratio, prolactin
3. Ferriman-Gallwey score
4. Waist-hip ratio
5. BMI
6. Total cholesterol, LDL, HDL, triglycerides
7. Fasting insulin, fasting glucose, insulin AUC, glucose AUC
8. QUICKI
9. Adverse effects
Denotes outcomes prespecified for this review
Notes As there was no wash-out period, we only included the first 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 457): ”Randomization (open
label) was performed in blocks of 10, using
sealed envelopes“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 457): ”using sealed envelopes“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
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was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 457): ”open label“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 457): ”open label“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk After cross-over 3/24 in simvastatin +OCP
group were lost to follow-up. Per-protocol
analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 457): ”Simvastatin was pro-
vided by Polfa Grodzisk Mazowiecki
(Grodzisk Mazowiecki, Poland), whereas
OCP was provided by Organon Polska
(Warsaw, Poland).“ and ”Medications used
in this study were obtained by donation
from pharmaceutical companies: simvas-
tatin was obtained from Polfa Grodzisk
Mazowiecki and OCP was obtained from
Organon Polska. Sponsors had no input
into the study design, its execution, or in-
terpretation of the findings.“
Comment: we judged this as at a low risk
of bias
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Methods Randomised, active-controlled trial
Setting
Division of Infertility and Reproductive Endocrinology, Department of Gynecology,
Obstetrics, and Gynecological Oncology, Poznan University of Medical Sciences, Poz-
nan, Poland
Date of study
December 2006 until March 2009. Duration of intervention 6 months
Participants N = 150 screened, 139 randomised
Mean age = 46 years
Inclusion criteria of the trial
• PCOS
• PCOS criteria as defined by the Rotterdam consensus and had at least 2 of the
following: 1) clinical or chemical hyperandrogenism; 2) oligo- or amenorrhoea; and/or
3) polycystic ovaries as viewed by transvaginal ultrasound
Exclusion criteria of the trial
• Congenital adrenal hyperplasia
• Elevated prolactin, thyroid disease, Cushing disease, or diabetes mellitus
• < 3 months before the study oral contraceptives, other steroid hormones, or any
other treatments likely to affect ovarian function, insulin sensitivity, or lipid profile
Randomised
N = 139
Withdrawals/losses to follow-up
• 43/139 (31%); 20/48 in simvastatin group, 14/47 in metformin group, 8/44 in
simvastatin + metformin group
• Loss of telephone and mail contact; 11/48 in simvastatin group, 6/47 in
metformin group, 5/44 in simvastatin + metformin group
• Change of residence address; 6/48 in simvastatin group, 5/47 in metformin
group, 2/44 in simvastatin + metformin group
• Emigration; 4/48 in simvastatin group, 3/47 in metformin group, 1/44 in
simvastatin + metformin group
Baseline data (mean (SEM))
BMI: simvastatin group23.5 (0.6),metformin group24.7 (0.7), simvastatin +metformin
group 24.8 (0.8)
F-G score: simvastatin group 9.1 (0.3), metformin group 9.7 (0.3), simvastatin + met-
formin group 8.7 (0.3)
Acne score: simvastatin group 1.19 (0.12), metformin group 1.21 (0.12), simvastatin +
metformin group 1.55 (0.15)
Total testosterone (ng/ml): simvastatin group 0.84 (0.03), metformin group 0.84 (0.04)
, simvastatin + metformin group 0.85 (0.04)
Free testosterone (ng/dl): simvastatin group 1.32 (0.09), metformin group 1.47 (0.10),
simvastatin + metformin group 1.52 (0.10)
DHEAS (µmol/L): simvastatin group 9.26 (0.42), metformin group 9.26 (0.41), sim-
vastatin + metformin group 9.00 (0.49)
SHBG (nmol/L): simvastatin group 49.3 (3.6), metformin group 41.4 (2.9), simvastatin
+ metformin group 40.3 (3.4)
Interventions Intervention
• Simvastatin 20 mg/day for 6 months (48)
Comparator 1
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• Metformin 850 mg b.i.d. for 6 months (47)
Comparator 2
• Simvastatin 20 mg/day + metformin 850 mg b.i.d. for 6 months (44)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. BMI
2. Ferriman-Gallwey score
3. Acne score; 4-point Likert scale
4. Transvaginal ultrasonographic examination
5. A 2-hour oral glucose tolerance test was performed with determinations of
glucose and insulin in the fasting state as well as after a 75 g glucose load at 30, 60, 90,
and 120 minutes
6. Insulin, total testosterone, free testosterone, 17-hydroxyprogesterone, LH, FSH,
prolactin, SHBG, and DHEAS
7. Total cholesterol and triglycerides, HDL and LDL cholesterol
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3495): ”Randomization was
performed using 1:1:1 allocation ratio with
blocks of random size (6, 9, or 12 subjects
per block). Patient allocation and block size
were obtained using random number ta-
bles.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 3495): ”At the time of ran-
domization, sequentially numbered, sealed
envelopes were opened. Allocation to study
group was concealed until a consent was
obtained and inclusion/exclusion criteria
verified. The randomization list was kept
locked, and the allocation numbers were
generated and sealed in the envelopes by
one of the authors (R.Z.S.). Allocation of
the patients was performed only by the au-
thor whowas blinded to the randomization
schedule.“
Comment: the report provides sufficient
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detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 3495): ”Because commer-
cially available pills were used, there was
no blinding after randomization; conse-
quently, investigators and patients could
identify the actual treatment.“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 3495): ”Because commer-
cially available pills were used, there was
no blinding after randomization; conse-
quently, investigators and patients could
identify the actual treatment.“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 43/139 (31%); 21/48 in simvastatin group,
14/47 in metformin group, 8/44 in sim-
vastatin + metformin group. Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 3495): ”Simvastatin (Simva-
chol) was obtained from Polfa Grodzisk
(Grodzisk Mazowiecki, Poland) and met-
formin (Metformax) was provided by Polfa
Kutno SA (Kutno, Poland).“ and page
3500: ”This work was supported by the
Polish State Committee for Scientific Re-
search (GrantKBNNr 2PO5E 09630) and
by the Eunice Kennedy Shriver National
Institute of Child Health and Human De-
velopment (Grant RO1 HD050656)“
Comment: we judged this as at a low risk
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Barth 1991
Methods Randomised, double-blind, active-controlled, dose finding trial
Setting
Department of Dermatology, Slade Hospital, Oxford, UK
Date of study
Not specified. Duration of intervention 12 months
Participants N = 60
Mean age = 26 years
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• No other medical problems
• Not on OCP
• Therapy that can cause acne of affect hair growth
Randomised
N = 60
Withdrawals/losses to follow-up
• 22/60 (36.7%); 6/21 in Dianette + placebo group, 9/20 in Dianette + 20 mg
cyproterone acetate group (CPA), 7/19 in Dianette + 100 mg CPA group
• Depression; Dianette + placebo group (1), Dianette + 20 mg CPA group (2),
Dianette + 100 CPA group (1)
• Nausea; Dianette + placebo group (1)
• Hypertension; Dianette + 20 mg CPA group (1)
• Lack of effect; Dianette + placebo group (1), Dianette + 20 mg CPA group (1)
• Rest lost to follow-up due to unknown reasons; Dianette + placebo group (3),
Dianette + 20 mg CPA group (5), Dianette + 100 mg CPA group (6)
Baseline data
Ferriman-Gallwey Index: Dianette + placebo group 26, Dianette + 20 mg CPA group
26, Dianette + 100 CPA group 28
BMI: Dianette + placebo group 23.7, Dianette + 20 mg CPA group 24.1, Dianette +
100 CPA group 23.9
Testosterone (nmol/L): Dianette + placebo group 2.5, Dianette + 20 mg CPA group 2.
8, Dianette + 100 CPA group 2.9
Interventions Intervention
• Dianette + placebo for 12 months (21)
Comparator 1
• Dianette + 20 mg CPA for 12 months (20)
Comparator 2
• Dianette + 100 mg CPA for 12 months (19)
Outcomes Assessments: (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey Index
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2. Linear hair growth and diameter with graduated capillary tube and optical
micrometer 7 days after shaving
3. Subjective assessments of hair growth on a linear analogue scale (7.5 cm positive,
7.5 cm negative)
4. Side effects
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 6): ”The hirsute women were
allocated at random into three treatment
groups“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 5-6): ”...double-blind...“ and
”Individual dose regimens were blinded to
both subjects and investigator“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 5-6): ”...double-blind...“ and
”Individual dose regimens were blinded to
both subjects and investigator“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
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study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 22/60 (36.7%); 6/21 inDianette + placebo
group, 9/20 in Dianette + 20 mg cypro-
terone acetate group (CPA), 7/19 in Di-
anette + 100 mg CPA group, reasons re-
ported. Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 9): ”We are grateful to Mrs
M. A. Gales for the hormone assays, Mrs
P. L. Yudkin for statistical advice and to
Dr P. Longthome of Schering Health Care,
Burgess Hill, West Sussex, UK for the sup-
ply and packaging of the medication.“
Comment: we judged this as at a low risk
of bias
Battaglia 2010
Methods Randomised, investigator-blinded, active-controlled pilot study
Setting
Department of Gynecology and Pathophysiology of Human Reproduction, University
of Bologna, Italy
Date of study
January 2007 until June 2008. Duration of study 6 months
Participants N = 40
Mean age = 24 years
Inclusion criteria of the trial
• > 18 years with PCOS referred to the clinic for treatment of hirsutism and
contraceptive necessities
• PCOS diagnosed as the presence of hirsutism (Ferriman-Gallwey score > 8),
oligomenorrhoea or amenorrhoea, increased plasma circulating androgens, typical
bilateral ultrasound (> 10 small-sized 2 mm to 10 mm subcapsular follicles, ovarian
volume > 8 ml, and increased ovarian echogenicity), and colour Doppler findings
(decreased resistances at level of stromal ovarian arteries)
Exclusion criteria of the trial
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• The secondary causes of hyperandrogenism (hyperprolactinaemia and thyroid and
adrenal disorders)
• Ultrasound evidence of multi follicular ovaries
• Smokers, regular intense exercise, hormone therapy < 6 months before the study.
• Women with diabetes, renal or hepatic illness, and folic acid and vitamin B12
deficiencies
• BMI > 30 kg/m2, uterine malformations, endometriosis, ovarian functional cyst,
unilateral ovarian resection, or ovariectomy
Randomised
N = 40
Withdrawals/losses to follow-up
• 3/40 (8%); 1/20 drospirenone (DRSP) + EE group, 2/20 contraceptive vaginal
ring group
• Slight persistent headache; drospirenone + EE group (1)
• Nausea and breast tenderness; contraceptive vaginal ring group (2)
Baseline data (mean (SD))
BMI: DRSP + EE group 25.1 (4.3), contraceptive vaginal ring group 24.0 (4.2)
Waist/hip ratio: DRSP + EE group 0.80 (0.08), contraceptive vaginal ring group 0.78
(0.08)
F-G score: DRSP + EE group 12.2 (4.6), contraceptive vaginal ring group 13.3 (3.6)
Androstenedione (nmol/L): DRSP + EE group 12.0 (3.2), contraceptive vaginal ring
group 13.4 (3.3)
Testosterone (nmol/L): DRSP + EE group 1.7 (0.7), contraceptive vaginal ring group 1.
8 (0.3)
SHBG (nmol/L): DRSP + EE group 38 (16), contraceptive vaginal ring group 49 (11)
FAI %: DRSP + EE group 5.1 (3.7), contraceptive vaginal ring group 4.5 (2.3)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 6 months (20)
Comparator
• Combined contraceptive vaginal ring (ethinyl estradiol 15 µg + etonogestrel 120
µg) (20)
Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Utero-ovarian ultrasound analysis and colour doppler evaluation of uterine and
stromal ovarian arteries
2. Brachial Artery Flow-mediated vasodilatation
3. 24-hour ambulatory blood pressure monitoring
4. Fasting blood samples for testing biochemical and hormonal parameters (LH,
FSH, testosterone, androstenedione, SHBG, LH/FSH ratio, FAI), nitrites/nitrates
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 1418): ”The patients were
randomly submitted“ and ”Randomiza-
tion was performed by opening sequen-
tially numbered sealed envelopes contain-
ing treatment allocation determined by a
random number table“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 1418): ”...sequentially num-
bered sealed envelopes containing treat-
ment allocation...“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1418): ”The clinical examin-
ers were blinded to the type of treatment“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind personnel from knowledge of
which intervention a participant received,
to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1418): ”The clinical examin-
ers were blinded to the type of treatment“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/40, reasons reported. Per-protocol anal-
ysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk The study appears to be free of other forms
of bias
Batukan 2007
Methods Randomised, investigator-blinded, active-controlled trial
Setting
Department of Obstetrics and Gynecology, Erciyes University School of Medicine, Kay-
seri, Turkey
Date of study
Not specified. Duration of intervention 12 months
Participants N = 100
Mean age = 24 years
Inclusion criteria of the trial
• Moderate to severe hirsutism
Exclusion criteria of the trial
• Pregnancy
• Androgen-secreting adrenal or ovarian neoplasm
• Cushing’s syndrome, or congenital adrenal hyperplasia
• Combined oral contraceptives < 6 months prior to study entry
Randomised
N = 100
Withdrawals/losses to follow-up
• 9/100 (9%); 2/50 in OCP including drospirenone (DRSP) group, 7/50 in OCP
including CPA group
• Lost to follow-up or pregnancy
Baseline data
PCOS: OCP including DRSP group (35), OCP including CPA group (30)
Idiopathic hirsutism: OCP including DRSP group (13), OCP including CPA group
(13)
BMI: OCP including DRSP group 23, OCP including CPA group 21
Oligo/amenorrhoea: OCP including DRSP group (25), OCP including CPA group (26)
Obese: OCP including DRSP group (12), OCP including CPA group (5)
SHBG (nmol/L): OCP including DRSP group 35.8 (2.3), OCP including CPA group
40.7 (1.9)
DHEAS (µg/ml): OCP including DRSP group 2.6 (0.2), OCP including CPA group 2.
2 (0.1)
Androstenedione (ng/ml): OCP including DRSP group 2.6 (0.1), OCP including CPA
group 2.7 (0.1)
Total testosterone (ng/dl): OCP including DRSP group 88.7 (4.4), OCP including CPA
group 81.5 (5.1)
Free testosterone (pg/ml): OCP including DRSP group 2.2 (0.2), OCP including CPA
group 2.2 (0.2)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 12 months (50)
Comparator
120Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Batukan 2007 (Continued)
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (50)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Serum total testosterone, free testosterone, androstenedione, DHEAS and SHBG
levels
2. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 39): ”Patients were randomly
assigned...according to a computer-based
randomization sequence“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 39): ”The same physician (I.
I.M.), blinded to the treatment regimen..“
and ”Patients were not blinded to therapy.
..“
Comment: the report did not provide suf-
ficient detail about the measures used to
blind the investigator from knowledge of
which intervention a participant received,
to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 39): ”The same physician (I.
I.M.), blinded to the treatment regimen...
“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/100 (9%); 2/50 in OCP including
drospirenone group, 7/50 in OCP includ-
ing CPA group. Per-protocol analysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Bayhan 2000
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, Endocrinology, Public Health Faculty, Dicle
University, Diyarbakir, Turkey
Date of study
Not specified. Duration of intervention 6 months
Participants N = 60
Mean age = 22 years
Inclusion criteria of the trial
• Idiopathic hirsutism
• Hirsutism defined as Ferriman-Gallwey score > 12
• Normal serum androgens (total testosterone, free testosterone, androstenedione,
DHEAS)
• No clinical or biochemical evidence of PCOS
• Normal serum 17-OH progesterone levels
• Normal ovulatory cycles
Exclusion criteria of the trial
• Adrenal or ovarian neoplasms
• Hyperprolactinaemia
• Cushing’s syndrome
• Congenital adrenal hyperplasia
• PCOS
• Drug-induced hyperandrogenism
Randomised
N = 60
Withdrawals/losses to follow-up
• No losses to follow-up reported
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Baseline data (mean (SD))
F-G score: GnRH-a group 19 (3.5), finasteride group 17.7 (1.8)
Total testosterone: GnRH-a group 0.8 (0.3), finasteride group 1.1 (1.0)
Free testosterone: GnRH-a group 2.2 (0.9), finasteride group 2.3 (1.3)
Androstenedione: GnRH-a group 2.2 (2.2), finasteride group 1.8 (1.2)
DHEAS: GnRH-a group 237 (114), finasteride group 228 (99)
SHBG: GnRH-a group 1.8 (0.7), finasteride group 1.6 (0.4)
Interventions Intervention
• GnRH agonist (depot leuprolide acetate) intramuscularly monthly over 6 months
(30)
Comparator
• Finasteride 5 mg per os for 6 months (30)
The GnRH agonist group received after 2 weeks oestrogen replacement
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum total testosterone, androstenedione, DHEAS, free testosterone, 17-
hydroxyprogesterone, gonadotropins, estradiol, progesterone, SHBG
Denotes outcomes prespecified for this review
Notes Units are not provided for the hormones
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 203): ”...were randomly as-
signed to receive...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Bayram 2002
Methods Randomised, active-controlled trial
Setting
Departments of Endocrinology and Metabolism and 1Obstetrics and Gynecology, Fac-
ulty of Medicine, Erciyes University, Kayseri, Turkey
Date of study
Not specified. Duration of intervention 1 year
Participants N = 56
Mean age = 23 years
Inclusion criteria of the trial
• Moderate to severe hirsutism (Ferriman-Gallwey score > 12)
• Age range 18 to 41 years
Exclusion criteria of the trial
• Adrenal or ovarian neoplasm
• Cushing’s syndrome
• Congenital adrenal hyperplasia
• Prolactinoma
• A history of drug-induced hyperandrogenism
• Thyroid disorder
• Hormonal medication known to influence hair growth or hormone levels < 6
months prior to study entry
Randomised
N = 56
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
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F-G score: 2.5 mg group 18.4 (4.6), 5 mg group 18.7 (5.2)
BMI: 2.5 mg group 24.8 (4.7), 5 mg group 24.4 (4.4)
Testosterone (ng/dl): 2.5 mg group 92.8 (42.1), 5 mg group 86.5 (49.0)
Free testosterone (pg/ml): 2.5 mg group 3.0 (1.3), 5 mg group 3.4 (1.8)
Androstenedione (ng/ml): 2.5 mg group 3.4 (1.7), 5 mg group 3.3 (1.4)
SHBG (nmol/L): 2.5 mg group 49.1 (20.8), 5 mg group 43.4 (18.2)
DHEAS (mg/dl): 2.5 mg group 271.5 (152.2), 5 mg group 285.2 (149.2)
Interventions Intervention
• Finasteride 2.5 mg a day for 1 year (29)
Comparator
• Finasteride 5 mg a day for 1 year (27)
Patients were advised to avoid pregnancy during treatment because of possible femini-
sation of a male fetus. Sexually active women were advised to use barrier methods of
contraception and oestrogens were not administered during the study
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. BMI
3. Hormonal parameters (FSH, LH, estradiol, androstenedione, testosterone, free
testosterone, 17α-hydroxy-progesterone, DHEAS, SHBG)
4. Adverse events
5. Menstrual cycle
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 468): ”Patients were consecu-
tively divided into two groups at random“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
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was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Beigi 2004
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics andGynecology, ArashMaternity Hospital, TehranUniversity
of Medical Sciences, Tehran, Iran
Date of study
Not specified. Duration of intervention 9 months
Participants N = 40
Mean age = 23 years
Inclusion criteria of the trial
• Hirsutism (Ferriman-Gallwey score ≥ 8 ) based on PCOS or idiopathic hirsutism
• PCOS diagnosis was made on presence of 3 or more of the following criteria:
hyperandrogenaemia, hirsutism, anovulatory or oligo-ovulatory cycles, polycystic
ovaries on ultrasound, and LH/FSH ratio > 2; however, with the exclusion of other
known disorders such as Cushing’s syndrome, hyperprolactinaemia, or late-onset
congenital adrenal hyperplasia
Exclusion criteria of the trial
• Hypertension
• Signs of virilisation
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• Drug-induced hyperandrogenism
• Evidence of thyroid dysfunction (abnormal free T4 or TSH)
• Galactorrhoea and/or hyperprolactinaemia (abnormal prolactin levels)
• Cushing’s syndrome
• Late-onset (non-classic) congenital adrenal hyperplasia
Randomised
N = 40
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: finasteride group 23.1 (2.5), CPA + EE2 group 23.4 (3.4)
F-G score: finasteride group 23.7 (4.4), CPA + EE2 group 22.3 (4.2)
Total testosterone (ng/dl): finasteride group 103 (45), CPA + EE2 group 99 (40)
Free testosterone (pg/ml): finasteride group 4 (1), CPA + EE2 group 3.9 (1)
Androstenedione (ng/ml): finasteride group 4 (0.9), CPA + EE2 group 4 (0.9)
DHEAS (µg/dl): finasteride group 344.9 (120.6), CPA + EE2 group 348.8 (73.6)
DHT (ng/dl): finasteride group 40.5 (14), CPA + EE2 group 39.4 (10.5)
SHBG (nmol/L): finasteride group 85.5 (39.1), CPA + EE2 group 83.4 (35.4)
PCOS: finasteride group 14/20, CPA + EE2 group 15/20
Regular menses: finasteride group 7/20, CPA + EE2 group 6/20
Interventions Intervention
• Finasteride 5 mg once a day for 9 months (20)
Comparator
• Cyproterone acetate 25 mg once a day on days 5 to 14 + ethinyl estradiol (EE2)
20 µg daily days 5 to 25 of the menstrual cycle for 9 months (20)
Patients were advised to avoid pregnancy during treatment because of possible femini-
sation of a male fetus
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Serum total and free testosterone, androstenedione, DHEAS, DHT, SHBG
3. Adverse events
4. Blood pressure, body weight, haematological evaluation, liver and renal function
tests, lipid analyses
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 30): ”Patients were randomly
assigned...“
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Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Belisle 1986
Methods Randomised, double-blind, active-controlled trial
Setting
Multi-centre (8) in Canada
Date of study
Not specified. Duration of intervention 12 months
Participants N = 171 recruited, 158 randomised
Age range = 18 to 40 years
Inclusion criteria of the trial
• Severe hirsutism (i.e. chief complaint of excessive hair growth and who, after
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appropriate clinical and para clinical investigation, required systemic therapy for such a
condition)
• Ferriman-Gallwey score > 14
• Age between 18 and 40 years
• Ability to give consent to therapy and to remain in the study for 12 months.
Exclusion criteria of the trial
• Ovarian and adrenal tumours
• Hormonal medications < 60 days prior to study entry
• Other types of prescribed medication
• Absolute contraindications to steroids.
Randomised
N = 158
Withdrawals/losses to follow-up
51/158 (32%); 29/79 in 2 mg CPA group, 22/79 in 100 mg group
• Adverse events; 10/79 in 2 mg CPA group, 12/79 in 100 mg group
• Patient-related; 2/79 in 2 mg CPA group, 4/79 in 100 mg group
• Physician-related; 9/79 in 2 mg CPA group, 4/79 in 100 mg group
• Preterm (> 4 weeks from end of study); 0/79 in 2 mg CPA group, 2/79 in 100 mg
group
• Loss to follow-up; 2/79 in 2 mg CPA group, 0/79 in 100 mg group
Baseline data (mean)
F-G score: 2 mg CPA group 19.5, 100 mg CPA group 20.1
Interventions Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 12 months +
placebo (79)
Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 12 months + CPA
100 mg (79)
Outcomes Assessments (6): baseline, month 1, 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. General complaints, endocrine and menstrual problems
2. Weight, blood pressure
3. Ferriman-Gallwey score
4. Serum total and free testosterone, FSH, LH, prolactin, androstenedione, DHEA
and DHEAS
Denotes outcomes prespecified for this review
Notes There are inconsistencies regarding the number that dropped out. The investigators
report that 51/158 dropped out, but data at 12 months suggest that there were still 56
participants in each group (which would mean 46/158 drop-outs)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 1016): ”They were then ran-
domized and double-blindly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1016): ”...double-blindly...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1016): ”...double-blindly...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 51/158 (32%); 29/79 in 2 mg CPA group,
22/79 in 100 mg group, reasons reported.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, double-blind, active-controlled trial
Setting
Department of Obstetrics and Gynaecology, S. C. Das Memorial Medical and Research
Center, Jodhpur Park, Kolkata, India
Date of study
January 2010 until April 2011. Duration of intervention 12 months
Participants N = 233 screened, 171 randomised
Mean age = 22 years
Inclusion criteria of the trial
• PCOS according to criteria of Androgen Excess Society (Azziz 2006)
• 18 to 35 years
• History of oligomenorrhoea (< 6 menstrual cycles in 12 months)
• Women with abnormal hair growth on their body
Exclusion criteria of the trial
• Cushing syndrome
• Late-onset congenital adrenal hyperplasia
• Gross hypothyroidism
• Hyperprolactinaemia
• Known contraindications for oestrogen therapy
• Oral contraceptive pills in the preceding 3 months
Randomised
N = 171
Withdrawals/losses to follow-up
21/171 (12%); 9/58 in desogestrel group, 5/56 in CPA group, 7/57 in drospirenone
(DRSP) group
• Protocol violations; 2/58 in desogestrel group, 0/56 in CPA group, 3/57 in
drospirenone group
• Adverse events; 5/58 in desogestrel group, 2/56 in CPA group, 0/57 in
drospirenone group
• Unwillingness to continue; 2/58 in desogestrel group, 3/56 in CPA group, 2/57
in drospirenone group
Baseline data (mean (SD))
BMI: desogestrel group 25.41 (4.49), CPA group 26.41 (3.81), DRSP group 26.47 (4.
65)
Waist-hip ratio: desogestrel group 0.80 (0.07), CPA group 0.83 (0.06), DRSP group 0.
81 (0.07)
Modified F-G score: desogestrel group 5.55 (4.51), CPA group 6.84 (5.17), DRSP group
6.14 (5.15)
Testosterone (ng/ml): desogestrel group 0.44 (0.28), CPA group 0.53 (0.36), DRSP
group 0.44 (0.27)
SHBG (nmol/L): desogestrel group 32.05 (19.49), CPA group 23.85 (18.06), DRSP
group 29.88 (19.88)
FAI: desogestrel group 7.24 (8.78), CPA group 10.14 (7.91), DRSP group 7.48 (8.86)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) once a day for 12 months
(58)
Comparator 1
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• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) once a day for 12
months (56)
Comparator 2
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) once a day for 12 months (57)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Free Androgen Index
2. HOMA-IR
3. Changes in the metabolic parameters
4. Changes in the SHBG and T levels
5. BMI, modified Ferriman-Gallwey score, acne, acanthosis nigricans, and blood
pressure
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1054): ”...were then random-
ized into three intervention groups using
computer-generated randomization tables
in a 1:1:1 ratio...“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 1054): ”The intervention
drugs were sealed in sequentially numbered
identical opaque containers according to
the allocation sequence.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1054): ”The authors procured
the medicines from the hospital pharmacy
and the blinding was ensured by removing
the commercial packing and putting the
tablets in the opaque containers (i.e., af-
ter undoing the commercial packing) un-
der the supervision of resident doctors (in-
dependently double checked) and nursing
staff. The patients did not buy medicines
directly and hence were blinded about the
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treatment groups. The entire process of
random number generation, concealment,
and sequential allocation were not dis-
closed to the investigators until the end of
data collection.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 21/171 (12%); 9/58 in desogestrel group,
5/56 in CPA group, 7/57 in drospirenone
group, reasons reported. Intention-to-treat
analysis
Comment: we judged this as at an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Breitkopf 2003
Methods Randomised, double-blind, active-controlled trial
Setting
Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galve-
ston, USA
Date of study
Not specified. Duration of intervention 9 months
Participants N = 47
Mean age = 34 years
Inclusion criteria of the trial
• Hirsutism (a cumulative Ferriman-Gallwey score of ≥ 10)
Exclusion criteria of the trial
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• Androgen-secreting ovarian tumour (testosterone 200 ng/dl)
• Congenital adrenal hyperplasia (17-hydroxyprogesterone 2 ng/ml)
• Cushing’s syndrome
• OCPs within 2 months of enrolment
• Long-acting progestins within 6 months of enrolment
Randomised
N = 47
Withdrawals/losses to follow-up
26/47 (55%); 12/23 EE + desogestrel group, 14/24 EE + levonorgestrel group
• Lost to follow-up; 7/23 EE + desogestrel group, 9/24 in EE + levonorgestrel group
• Adverse events; 2/23 EE + desogestrel group, 3/24in EE + levonorgestrel group
• Ineffectiveness; 2/23 EE + desogestrel group, 1/24 in EE + levonorgestrel group
• Discontinuation for reasons unrelated to medication; 1/24 EE + desogestrel
group, 1/23 in EE + levonorgestrel group
Baseline data (mean (SD))
Ferriman-Gallwey score: EE + desogestrel group 16.9 (3.9), EE + levonorgestrel group
14.7 (4.7)
BMI: EE + desogestrel group 31.6 (7.9), EE + levonorgestrel group 31.7 (11.8)
Total testosterone (ng/ml): EE + desogestrel group 56.7 (28.7), EE + levonorgestrel
group 77.1 (60.0)
Free testosterone (pg/ml): EE + desogestrel group 2.6 (1.5), EE + levonorgestrel group
2.6 (2.0)
SHBG (nmol/L): EE + desogestrel group 21.5 (11.7), EE + levonorgestrel group 24.7
(15.5)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + levonorgestrel 0.15 mg) for 9 months (24)
Comparator
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 9 months (23)
Outcomes Assessments (4): baseline, months 3, 6, and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Adverse events (questionnaire)
3. Participants’ assessment (questionnaire)
4. Serum total and free testosterone, DHEAS, androstenedione, 3-androstanediol
glucuronide, SHBG, 17-hydroxyprogesterone and LH
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 350): ”Subjects were random-
ized into two groups using block random-
ization by the pharmacy service at the Uni-
versity of Texas Medical Branch.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 350): ”block randomization
by the pharmacy service“
Comment: central allocation (pharmacy-
controlled randomisation). Probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 350): ”The pills were identical
in appearance in both groups.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator and partici-
pant-assessed
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 26/47 (55%); 12/23 EE + desogestrel
group, 14/24 in EE + levonorgestrel group.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 352): ”Funded by the Ameri-
can College of Obstetricians and Gynecol-
ogists/OrganonResearchAward inContra-
ception.“
Comment: a potential risk of bias cannot
be excluded
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Methods Randomised, double-blind, placebo-controlled trial
Setting
Division of Gynecological Endocrinology and Reproductive Medicine, University
Women’s Hospital Basel, Basel, Switzerland
Date of study
Not reported. Duration of the intervention 3 months
Participants N = 40
Mean age = 30 years
Inclusion criteria of the trial
• Women with PCOS diagnosed by the presence of: 1) long-standing ovulatory
dysfunction (oligo- or amenorrhoea); 2) hirsutism (Ferriman-Gallwey score 7) and/or
circulating serum total testosterone greater than 2.5 nmol/L and SHBG concentrations
less than 50 nmol/L; and 3) exclusion of other endocrine disorders, e.g. thyroidal
dysfunction, adrenal diseases, and hyperprolactinaemia
Exclusion criteria of the trial
• Desire for pregnancy or existing pregnancy
• Basal FSH concentration greater than 20 IU/L
• Diabetes mellitus
• Past hysterectomy
• Intake of medication known or suspected to affect reproductive or metabolic
function
• History of liver disease and/or alcohol abuse, elevated liver enzymes
• Severe uncontrolled illness
Withdrawals/losses to follow-up
• 5/40 (13%); 3/20 pioglitazone group, 2/20 of placebo group; due to loss to
follow-up and protocol violation
Baseline data (mean (SEM))
BMI: pioglitazone group 29.4 (1.7), placebo group 27.5 (1.2)
Waist/hip ratio: pioglitazone group 0.9 (0.1), placebo group 0.9 (0.0)
Hirsutism score (F-G): pioglitazone group 15.5 (1.2), placebo group 15.6 (2.0)
DHEAS (µmol/L): pioglitazone group 5.4 (0.6), placebo group 6.3 (0.6)
Testosterone (nmol/L): pioglitazone group 2.4 (0.3), placebo group 2.8 (0.2)
SHBG (nmol/L): pioglitazone group 36.8 (4.3), placebo group 40.9 (3.5)
Free androgen index (FAI): pioglitazone group 9.3 (2.2), placebo group 8.5 (1.6)
Interventions Intervention
• Pioglitazone 30 mg once daily for 3 months (20)
Comparator
• Placebo once daily for 3 months (20)
Outcomes Assessments (7): baseline, week 2, 4, 6, 8, 10, 12
Outcomes of the trial (as reported)
1. Serum concentration of total testosterone, SHBG, DHEAS, FSH, LH,
progesterone, LDL cholesterol, HDL cholesterol, cholesterol, triglycerides, and liver
enzymes
2. BMI, waist/hip ratio and hirsutism score
3. LHRH test with measurement of concentrations of LH and FSH after iv injection
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of 100 g LHRH
4. Oral glucose tolerance test
5. Homeostasis model assessment insulin resistance index (HOMA-IR)
6. Area under the curve (AUC) for insulin
7. The occurrence of ovulation was assessed for each patient by serial measurement
of serum progesterone in combination with self reported menstruation
Denotes outcomes prespecified for this review
Notes Run-in phase before randomisation adhere to a written list of recommendations con-
cerning a healthy diet and physical activity for weight maintenance during a period of 4
weeks while knowingly receiving placebo (run-in phase). Aigner 2009 used sera and data
reported in this study. Data will be reported from only one of the 2 studies, whichever
one provides the complete set
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3836): ”...randomization was
performed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication: ”according
to the records the randomization was per-
formed by the hospital pharmacy using a
random number generator (such as used in
EXCEL).“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Neither pa-
tients nor physicians knew about the allo-
cation until the end of the trial.“ and ”The
pharmacy delivered “neutral” boxes or con-
tainers identical for verum and placebo
with numbers, the numbers were generated
in random order by the pharmacy and nei-
ther doctors nor patients knew the content
nor the key.“
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Comment: sequentially numbered drug
containers of identical appearance, proba-
bly done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 3836): ”...(identical tablets,
taken once daily) was begun. Patients and
physicians were blinded to the applied
treatment.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed as
well as participant-assessed (menstruation)
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/40 (13%), 3 of pioglitazone group and 2
of placebo group, reasons unreported. Per-
protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 3839): ”This work was sup-
ported in part by a grant from the Med-
ical Faculty of University of Basel and
in part by an unrestricted educational
grant from Takeda Pharma, Switzerland.
N.B. was supported by a scholarship from
the Schweizerische Eidgenössische Stipen-
dienkommission.“
Comment: Takeda Pharma is themanufac-
turer of pioglitazone and a potential risk of
bias cannot be excluded
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Methods Randomised controlled trial
Setting
Department of Medicine, Duke University Medical Center, Durham, North Carolina,
USA
Date of study
April 2003 until April 2005. Duration of intervention 12 weeks
Participants N = 622 were screened, 37 randomised
Mean age = 32 years
Inclusion criteria of the trial
• Pre-menopausal women with PCOS
• ≤ 8 menses per year and clinical or biochemical evidence of hyperandrogenism
(hirsutism with Ferriman-Gallwey score ≥ 8 or bio-available testosterone > 8.4 ng/dl
(291.2 pmol/L, a value 2 standard deviations above the mean for the performing lab)
• Sedentary lifestyle (defined as no regular exercise during a usual week)
• Ability to come to the study exercise facility for monitored exercise
• Agreement to maintain their current weight and dietary patterns for the study
period.
Exclusion criteria of the trial
• Menopause
• Hormonal contraceptive use
• Antiandrogen therapy
• Pregnancy (current or planned during the study period), recent breastfeeding
• Congenital adrenal hyperplasia
• Uncontrolled thyroid disease
• Hyperprolactinaemia
• Fasting hyperglycaemia (>125 mg/dl (6.9 mmol/l))
• Medication known to affect carbohydrate metabolism (metformin,
thiazolidinediones) within the past 90 days
• Unresolved medical conditions
• History of malignancy other than non melanoma skin cancer in the past 5 years
• Participation in another study within the past 30 days
Randomised
N = 37
Withdrawals/losses to follow-up
• 17/37 (46%); 13/21 in exercise group, 4/16 in control group
• Reasons for dropping out in exercise group; time constraints, injuries unrelated to
exercise, pregnancy, major change in diet
• Reasons for dropping out in control group; not reported
Baseline data of study completers (median (interquartile range))
BMI: exercise group 37.9 (9.4), control group 31.3 (14.9)
F-G score: exercise group 9.0 (16.0), control group 15.0 (8.0)
Bioavailable testosterone (pmol/L): exercise group 319.0 (589.4), control group 450.7
(329.4)
Interventions Intervention
• Moderate-intensity exercise programme for 12 weeks, preceded by a ramp-up of 8
to 12 weeks (21)
Comparator
• No change in lifestyle for 12 weeks (16)
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Outcomes Assessments (2): baseline and week 12
Outcomes of the trial (as reported)
1. Lipoprotein profiles
2. Nuclear magnetic resonance spectroscopy to quantify particle size, total and
subclass concentration of HDL, LDL, and VLDL
Denotes outcomes prespecified for this review
Notes None of our outcomes were assessed, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 498): ”Randomization was
accomplished by generating a random se-
quence of two variables (for instance,
As and Bs, representing the two treat-
ment groups) using the online pro-
gram at http://graphpad.com/quickcalcs/
randomize2.cfm“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 498): ”Each group assignment
was placed in its own sequentially num-
bered envelope by an individual not in-
volved in the study. Participants were as-
signed to a group based on these envelopes,
and each participant had an equal chance
of being randomized to either group.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 17/37 (46%); 13/21 in exercise group, 4/
16 in control group. Reasons for drop-out
only reported for exercise group. Per-pro-
tocol analysis
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Comment: the high drop-out ratewith per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 503): ”J.D.O. is employed by
and is a stockholder of LipoScience Inc.“
The participants within the exercise group
were older; 36.5 years versus 28 years
Comment: a potential risk of bias cannot
be excluded
Calaf 2007
Methods Randomised, double-blind, active- and placebo-controlled trial
Setting
Multi-centre (14) in Spain
Date of study
Not reported. Duration of intervention 12 months
Participants N = 131
Mean age = 24 years
Inclusion criteria of the trial
• Moderate to severe hirsutism (a score of > 15 in the modified Ferriman-Gallwey
scale) hirsutism of either idiopathic or PCOS aetiology
Exclusion criteria of the trial
• Contraindication for oral hormonal contraception
• Iatrogenic hirsutism
• Ovarian or adrenal neoplasia
• Prolactinoma
• Cushing’s syndrome
• Congenital adrenal hyperplasia
• Diabetes mellitus
• Thromboembolic disease
• Oral hormonal contraceptives or systemic treatment of their hirsutism over the
last 3 months or those who had started a cosmetic treatment for fewer than 30 days
before inclusion
Randomised
N = 131
Withdrawals/losses to follow-up
• From the 131 women included, 12 patients did not satisfy the inclusion criteria,
and so, even though they were considered in the safety evaluation, they were excluded
from the efficacy evaluation. Of these 119 women, 77 women completed the study.
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Reasons unclear
Baseline data (mean (SD))
BMI: flutamide 125 mg group 25.2 (3.28), flutamide 250 mg group 26.9 (7.88), flu-
tamide 375 mg 27.3 (6.03), placebo group 25.4 (5.11)
Waist/hip index: flutamide 125 mg group 0.81 (0.07), flutamide 250 mg group 0.80 (0.
08), flutamide 375 mg 0.79 (0.09), placebo group 0.78 (0.09)
Modified F-G score: flutamide 125 mg group 19.3 (3.36), flutamide 250 mg group 18.
7 (2.64), flutamide 375 mg 18.0 (2.90), placebo group 18.4 (2.44)
Acne score: flutamide 125 mg group 0.88 (0.88), flutamide 250 mg group 0.76 (1.15),
flutamide 375 mg 0.76 (1.02), placebo group 0.84 (1.10)
Seborrhoea score: flutamide 125 mg group 1.00 (1.00), flutamide 250 mg group 1.00
(1.04), flutamide 375 mg 0.91 (1.03), placebo group 0.97 (0.84)
Interventions Intervention
• Flutamide 125 mg + triphasic OCP for 12 months (25)
Comparator 1
• Flutamide 250 mg + triphasic OCP for 12 months (29)
Comparator 2
• Flutamide 375 mg + triphasic OCP for 12 months (34)
Comparator 3
• Placebo + triphasic OCP for 12 months (31)
Outcomes Assessments (4): baseline, month 3, 6, and 12
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Acne and seborrhoea by the Cremoncini scale (for acne, a score of 1 indicates
isolated pustules up to 10 in number, 2 indicates more than 10 isolated pustules, 3
indicates clusters of pustules, and 4 indicates confluent pustules; for seborrhoea, 1
indicates mild, 2 moderate, and 3 severe (Cremoncini 1976)
3. Serum levels of prolactin, estradiol, testosterone, DHEAS, androstenedione, 17-
hydroxyprogesterone, SHBG, free androgen index, LH, and FSH
4. Adverse events
5. Haematology and hepatic function evaluation, physical examination and
biochemistry evaluation
Denotes outcomes prespecified for this review
Notes 12/131 randomised participants did not satisfy the inclusion criteria. Thesewere included
for safety evaluation, but not efficacy evaluation
Triphasic OCP was 30 g, 40 g, and 30 g ethinyl estradiol and 50 g, 75 g, and 125g
levonorgestrel
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (3447): ”Patients were randomly as-
signed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 3447): ”This studywas carried
out in double-blind conditions, and so nei-
ther the patient nor the doctor was aware of
the composition of the treatment adminis-
tered. For this purpose, preparation of the
medication was performed in a centralized
manner, and labeling, with the exception of
the relevant randomization code, was iden-
tical in all four presentations.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator and partici-
pant assessed
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 42/119 (35%) dropped out. Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
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Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 3452): ”The study has
been sponsored by Ipsen Pharma, S.A.,
Barcelona, Spain.“
Comment: Ipsen Pharma S.A. is the man-
ufacturer of flutamide. A potential risk of
bias cannot be excluded
Carmina 1994
Methods Randomised, active-controlled trial
Setting
Cattedra di Endocrinologia, Universita di Palermo, Palermo, Italy
Date of study
Not reported. Duration of the intervention 6 months
Participants N = 22
Mean age = 23 years
Inclusion criteria of the trial
• Hirsute women with hyperandrogenic chronic anovulation (HCA), aged 18 to 36
years with previous unsatisfactory treatment results for hirsutism
• Diagnosis of HCA: chronic anovulation of premenarchal onset,
hyperandrogenism (elevations in both serum testosterone and DHEAS), normal basal
and ACTH-stimulated levels of serum 17-hydroxyprogesterone, and the absence of
virilism and pelvic masses
• Modified Ferriman-Gallwey (FG) score ≥ 8
Exclusion criteria of the trial
• Not reported
Randomised
N = 22
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
F-G score: GnRH-A alone group 13.4 (1.5), GnRH-A + oestrogen/progesterone group
13.3 (1.0)
Testosterone (nmol/L): GnRH-A alone group 4.13 (0.5), GnRH-A + oestrogen/proges-
terone group 3.64 (0.3)
Free testosterone (pmol/L): GnRH-A alone group 25.7 (4.0), GnRH-A + oestrogen/
progesterone group 23.2 (3.0)
Androstenedione (nmol/L): GnRH-A alone group 16.4 (1.4), GnRH-A + oestrogen/
progesterone group 14.7 (1.0)
DHEAS (µmol/L): GnRH-A alone group 8.7 (1.6), GnRH-A + oestrogen/progesterone
group 8.9 (1.1)
Interventions Intervention
• GnRH-A alone for 6 months (10)
Comparator
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• GnRH-A + oestrogen + medroxyprogesterone for 6 months (12)
Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Serum, FSH, LH, testosterone, free testosterone, androstenedione, DHEAS,
estradiol, osteocalcin, total cholesterol, HDL, triglycerides
3. Pelvic sonography
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 126): ”...patients were ran-
domized to two different protocols...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Carmina 1998
Methods Randomised, active-controlled trial
Setting
Practice in Italy
Date of study
Not reported. Duration of the intervention 1 year
Participants N = 54
Mean age = 21 years
Inclusion criteria of the trial
• Women with hirsutism and hyperandrogenism
• Ferriman-Gallwey-Lorenzo index ≥ 8 (Hatch 1981)
Exclusion criteria of the trial
• Tumours and adrenal enzymatic defects
Randomised
N = 54
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
Ferriman-Gallwey-Lorenzo index: dex (1 y) 16.5 (1.2), dex + spiro (1 y) 17.0 (1.2), dex
+ spiro (2 y) 17.7 (1.5), spiro (1 y) 16.8 (1.2)
BMI: dex (1 y) 23.8 (1.0), dex + spiro (1 y) 24.5 (1.5), dex + spiro (2 y) 23.2 (1.2), spiro
(1 y) 23.4 (1.2)
Testosterone (ng/dl): dex (1 y) 88 (5), dex + spiro (1 y) 86 (7), dex + spiro (2 y) 92 (5),
spiro (1 y) 80 (8)
Unbound testosterone (pg/ml): dex (1 y) 4.6 (0.5), dex + spiro (1 y) 4.8 (0.6), dex +
spiro (2 y) 5.0 (0.6), spiro (1 y) 4.6 (0.6)
DHEAS (µg/ml): dex (1 y) 2.9 (0.4), dex + spiro (1 y) 3.0 (0.4), dex + spiro (2 y) 2.8
(0.5), spiro (1 y) 2.8 (0.5)
Interventions Intervention
• Dexamethasone 0.37 mg/day for one year (12)
Comparator
• Dexamethasone 0.37 mg/day plus spironolactone 100 mg/day for one year (18)
Comparator 2
• Dexamethasone 0.37 mg/day plus spironolactone 100 mg/day for two years (12)
Comparator 3
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• Spironolactone 100 mg/day for one year (12)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey-Lorenzo scores
2. Serum LH, FSH, testosterone, unbound testosterone, DHEAS, and 17-
hydroxyprogesterone levels; and serum electrolytes
Denotes outcomes prespecified for this review
Notes The investigators of the study combined treatment arms with dexamethasone + spirono-
lactone (1 and 2 years) in their analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1076): ”...the women were as-
signed randomly to...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Carr 1995
Methods Randomised, active-controlled trial
Setting
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology
and Center for Mineral Metabolism and Clinical Research, Department of Internal
Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
Date of study
Not reported. Duration of the intervention 6 months
Participants N = 52 recruited, 38 randomised
Mean age = 27 years
Inclusion criteria of the trial
• Moderate to severe hirsutism (modified Ferriman-Gallwey score > 10)
• 20 to 39 years
Exclusion criteria of the trial
• Ovarian or adrenal neoplasm
• Prolactinoma
• Cushing’s syndrome
• Congenital or adult onset adrenal hyperplasia (21-hydroxylase deficiency)
• Drug-induced hirsutism
• Steroids or other hormones < 2 months before screening
Randomised
N = 38
Withdrawals/losses to follow-up
• 5/38 (13%); unclear from which groups, reasons unreported
Baseline data (mean (SD))
F-G score: OCP group 21.7 (1.7), GnRH-a group 24.3 (1.4), OCP+GnRH-a 21.8 (1.
7)
Testosterone (nmol/L):OCPgroup3.2 (1.33),GnRH-a group 2.3 (1.33),OCP+GnRH-
a 3.0 (1.66)
Free testosterone (pmol/L): OCP group 21.4 (10.61), GnRH-a group 15.5 (9.62),
OCP+GnRH-a 18.6 (13.93)
Androstenedione (nmol/L): OCP group 8.0 (2.32), GnRH-a group 7.2 (2.32),
OCP+GnRH-a 13.0 (8.95)
DHEAS (µmol/L): OCP group 4.8 (2.65), GnRH-a group 6.3 (6.63), OCP+GnRH-a
5.4 (1.99)
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Interventions Intervention
• OCP (ethinyl estradiol 35 µg + norethindrone 1 mg) for 6 months (11 = N that
completed the study)
Comparator 1
• GnRH-a 3.75 mg im every week for 6 months (11 = N that completed the study)
Comparator 2
• Combination of OCP and GnRH-a as stated above for 6 months (11 = N that
completed the study)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Serum FSH, LH, estradiol, total testosterone, free testosterone, DHEAS, 17-
hydroxyprogesterone, androstenedione
2. Total cholesterol, total triglycerides, LDL, HDL, VLDL
3. Ferriman-Gallwey score
4. Participants’ assessment of hair growth and acne
5. Hair diameter and vellus index
6. Adverse events; participants’ diary (hot flushes, headaches, vaginal dryness, breast
tenderness, libido, irritability)
7. Calciotropic hormones, estimated calcium balance, bone density studies
Denotes outcomes prespecified for this review
Notes Data reported only for the 33 participants that completed the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1070): ”the women were
randomized into one of three treatment
groups“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
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tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/38 (13%); unclear from which groups,
reasons unreported. Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1169): ”This work was sup-
ported by NIH Grants ROl-HD-25860
and MOl-RR-00633“
Comment: we judged this as at a low risk
of bias
Cedeno 1990
Methods Randomised, active-controlled trial
Setting
Endocrinology Unit, Hospital Universitario of Los Andes, Merida, Venezuela
Date of study
Not reported. Duration of the intervention 10 days
Participants N = 18
Mean age = 23 years
Inclusion criteria of the trial
• History of severe acne and/or hirsutism, with or without disturbances in menses
or obesity, and were thought to have PCO with hyperandrogenism
• Diagnosis of PCO based on the presence of 3 or more of the following criteria: (1)
persistent menstrual irregularities; (2) hirsutism or acne; (3) multicystic ovaries on
ultrasonographic exploration; (4) luteinising hormone/follicle-stimulating hormone
(LH/FSH) ratio ≥ 25
Exclusion criteria of the trial
• Other endocrine disorders
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• Exogenous sex steroids, or other drugs which might affect lipoprotein metabolism
< 10 days prior to study entry
Randomised
N = 18
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
Free testosterone (pg/ml): ketoconazole 400 mg group 12.15 (4.80), ketoconazole 800
mg group 14.91 (4.66)
DHEAS (µg/ml): ketoconazole 400 mg group 444.95 (80.01), ketoconazole 800 mg
group 443.00 (96.34)
Androstenedione (ng/ml): ketoconazole 400 mg group 2.17 (0.45), ketoconazole 800
mg group 2.98 (0.56)
Interventions Intervention
• Ketoconazole 400 mg/day for 10 days (9)
Comparator
• Ketoconazole 800 mg/ day for 10 days (9)
During the 10-day outpatient treatment programme, the patients followed their usual
diets, exercise, smoking, and alcohol intake patterns
Outcomes Assessments (2): baseline, day 10
Outcomes of the trial (as reported)
1. Serum lipids and lipoproteins and apoproteins
2. Serum free testosterone, DHEAS, androstenedione
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 511): ”The PCOwomenwere
randomly divided into two groups of nine.
..“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
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tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 511):
”Supported by CONICIT SI-1555, Cara-
cas, Venezuela and by the Jewish Hospi-
tal Medical Research Council. Cincinnati
Ohio.“
Comment: we judged this as at a low risk
of bias
Cibula 2005
Methods Randomised, active-controlled trial
Setting
Unit of Reproductive Endocrinology, Charles University, Prague, Czech Republic
Date of study
Not reported. Duration of intervention 6 months
Participants N = 30
Mean age = 23 years
Inclusion criteria of the trial
• Women with PCOS
• PCOS was defined as follows: (i) oligomenorrhoea from menarche (menstrual
cycle 35 days); (ii) an increased concentration of at least one androgen above the upper
reference limit (testosterone 0.5 to 2.63 nmol/L, androstenedione 1.57 to 5.4 nmol/L,
dehydroepiandrosterone 0.8 to 10.5 nmol/L); and (iii) clinical manifestation of
hyperandrogenism (acne, hirsutism, or both)
Exclusion criteria of the trial
• Secondary endocrine disorder, such as hyperprolactinaemia, thyroid dysfunction,
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or a non-classical form of congenital adrenal hyperplasia
• Wishing to conceive within the next 6 months
• Contraindications to oral contraceptive use
Randomised
N = 30
Withdrawals/losses to follow-up
• 2/30 (7%); 0/15 OCP group, 2/15 OCP + metformin group
• Reasons; adverse events (gastrointestinal problem) (1), non-compliance (1)
Baseline data (mean (SD))
Waist/hip ratio: OCP group 0.75 (0.08), OCP + metformin group 0.79 (0.09)
BMI: OCP group 22.1 (3.1), OCP + metformin group 24.7 (4.9)
Testosterone (nmol/L): OCP group 3.94 (1.49), OCP + metformin group 4.84 (1.16)
Androstenedione (nmol/L): OCP group 11.1 (5.8), OCP + metformin group 12.6 (3.
5)
DHEAS (µmol/L): OCP group 10.5 (2.2), OCP + metformin group 12.2 (3.8)
SHBG (nmol/L): OCP group 32 (13), OCP + metformin group 27 (9)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + norgestimate 250 µg) for 6 months (15)
Comparator
• OCP (ethinyl estradiol + norgestimate 250 µg) + metformin 1500 mg/day for 6
months (15)
Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Serum LH, FSH, testosterone, DHEA, DHEAS) and androstenedione
2. FAI
3. Plasma glucose concentration, plasma insulin concentration
4. Serum cholesterol and triglycerides
5. LDL and HDL
6. BMI
Denotes outcomes prespecified for this review
Notes Although one of the criteria for PCOS was clinical manifestation of hyperandrogenism
(acne, hirsutism, or both), it was unclear how many women were hirsute. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 181): ”...randomly assigned
to two groups using a generator of ran-
dom values with a uniform distribution
within the interval 0 to 1 (statistical soft-
ware NCSS 2002). The values obtained
were transformed into rank values.“
Comment: probably done
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/30 (7%); 0/15 in OCP group, 2/15
in OCP + metformin group. Per-protocol
analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 184): ”This study was sup-
ported by grant No. NH/6558-3 of the
Internal Grant Agency of the Ministry of
Health of the Czech Republic.“
Comment: we judged this as at a low risk
of bias
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Cicek 2003
Methods Randomised, active-controlled trial
Setting
Selçuk University Faculty of Medicine Department of Obstetrics and Gynecology,
Konya, Turkey
Date of study
Not reported. Duration of intervention 3 months
Participants N = 50
Mean age = 25 years
Inclusion criteria of the trial
• Women with PCOS, according to clinical, hormonal, and ultrasonographic
parameters, and had hyperandrogenism and complaints of hirsutism in spite of
performed classical treatment with antiandrogens, oral contraceptives, and cyclic
gestagens
• PCOS diagnosis was based on: oligomenorrhoea beginning prepubertally (over
the 35 days of the menstrual cycle length or < 6 menstrual cycles in 1 year), at least one
high level of serum androgens, hirsutism and dens ovarian stroma and more than 10
follicles with 2 mm to 8 mm diameters shown by ultrasound scanning during the
proliferate period
Exclusion criteria of the trial
• Adrenal, thyroid, pituitary, and hypothalamic endocrinological disorders
• Diabetic patients
• Women who did not receive classical PCOS treatment
Randomised
N = 50
Withdrawals/losses to follow-up
• 8/50 (16%); 4/26 metformin group, 4/24 GnRH-a group
• Adverse events; 3/26 metformin group
• Pregnancy; 1/26 metformin group
• Personal reasons; 4/24 GnRH-a group
Baseline data (mean (SEM))
BMI: metformin group 26.6 (5.8), GnRH-a group 26.1(4.7)
F-G score: metformin group 15.3 (1.3), GnRH-a group 15.5 (1.9)
Total testosterone (ng/dl): metformin group 96.2 (46.5), GnRH-a group 115.5 (47.4)
Free testosterone (pg/ml): metformin group 3.8 (2.5), GnRH-a group 3.7 (2.1)
DHEAS (µg/dl): metformin group 251.9 (156.8), GnRH-a group 267.8 (106.2)
SHBG (nmol/l): metformin group 40.4 (24.9), GnRH-a group 49.3 (12.4)
Interventions Intervention
• Metformin 850 mg b.i.d. for 3 months (26)
Comparator
• GnRH-a (goserelin) 3.6 mg/28 day for 3 months (24)
Outcomes Assessments (2): baseline, month 3
Outcomes of the trial (as reported)
1. BMI, waist (cm), hip (cm)
2. Ferriman-Gallwey score
3. Serum FSH, LH, estradiol, total testosterone, free testosterone, DHEAS, 17OH-
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progesterone, progesterone, SHBG
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 108): ”...were randomly as-
signed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 8/50 (16%); 4/26 metformin group, 4/24
GnRH-a group.Reasons reported, per-pro-
tocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk The study appears to be free of other forms
of bias
Ciotta 1995
Methods Randomised, single-blinded, placebo-controlled trial
Setting
Department of Obstetrics and Gynecology, University of Catania, Italy
Date of study
Not reported. Duration of intervention 9 months
Participants N = 18
Mean age = 20 years
Inclusion criteria of the trial
• Moderate to severe idiopathic hirsutism
• Healthy, normal menses, normal BMI
Exclusion criteria of the trial
• Acne/seborrhoea or other sign of hyperandrogenism
• Hormonal treatment < 6 months prior to study entry
Randomised
N = 18
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: finasteride group 20.8 (0.36), placebo group 20.7 (0.47)
F-G score: finasteride group 19.0 (1.57), placebo group 21.8 (0.81)
Total testosterone ng/ml: finasteride group 0.53 (0.05), placebo group 0.53 (0.01)
Free testosterone (pg/ml): finasteride group 2.86 (0.11), placebo group 2.70 (0.08)
Androstenedione (ng/ml): finasteride group 1.84 (0.12), placebo group 1.73 (0.16)
Dihydrotestosterone (pg/ml): finasteride group 380.0 (29.4), placebo group 374.4 (37.
2)
DHEAS (µg/ml): finasteride group 2.02 (0.10), placebo group 2.08 (0.14)
SHBG (µg/ml): finasteride group 2.17 (0.13), placebo group 2.22 (0.15)
Interventions Intervention
• Finasteride 7.5 mg/day for 9 months (9)
Comparator
• Placebo for 9 months (9)
All participants were urged to use contraception barriermethods or an intrauterine device
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Adverse event/evaluation of libido by both participants (interval scale), and
investigators (semi structured talk on frequency of coitus)
3. Serum FSH, LH, androstenedione, total and free testosterone, DHT, DHEAS,
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estradiol, 17OH-progesterone and SHBG
4. Haematological evaluations, renal and liver functions
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 301): ”... they were treated
randomly and blindly“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 301): ”... they were treated ...
blindly“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants or per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 301): ”... they were treated ...
blindly“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ciotta 2001
Methods Randomised, double-blind, placebo-controlled trial
Setting
Reproductive Endocrinology Unit, University Hospital of Catania, Catania, Italy
Date of study
Not reported. Duration of intervention 3 months
Participants N = 30
Mean age = 21 years
Inclusion criteria of the trial
• PCOS
• PCOS diagnosed based on: menstrual abnormalities (< 6 periods in the last year),
clinical manifestations of hyperandrogenism e.g. hirsutism, raised acne/seborrhoea
scores, elevated serum total testosterone (> 80 ng/dl), and/or androstenedione (> 190
ng/dl), normal serum prolactin and normal thyroid function test, regular basal
concentrations and/or normal response of 17 α-hydroxyprogesterone to the
adrenocorticotrophic hormone stimulation test, BMI within normal range, normal
glucose tolerance, elevated insulin response to OGTT
Exclusion criteria of the trial
• Not reported
Randomised
N = 30
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: acarbose group 22.84 (0.52), placebo group 22.70 (0.46)
F-G score: acarbose group 20.93 (0.99), placebo group 19.07 (0.73)
Acne/seborrhoea score: acarbose group 2.10 (0.15), placebo group 1.80 (0.14)
Testosterone (nmol/L): acarbose group 3.33 (0.10), placebo group 3.19 (0.10)
Androstenedione (nmol/L): acarbose group 8.69 (0.42), placebo group 8.73 (0.45)
DHEAS (µmol/L): acarbose group 7.17 (0.42), placebo group 7.08 (0.40)
SHBG (nmol/L): acarbose group 41.1 (2.5), placebo group 35.6 (2.1)
Interventions Intervention
• Acarbose 300 mg/day for 3 months (15)
Comparator
• Placebo for 3 months (15)
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Outcomes Assessments (2): baseline and month 3
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Acne/seborrhoea score
3. Serum FSH, LH testosterone, androstenedione, DHEAS, prolactin, 17OH-
progesterone, SHBG
4. BMI
5. Adverse events
Denotes outcomes prespecified for this review
Notes Study also included 15 healthy controls
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2067): ”...randomly divided.
..“ and ”Randomization was achieved by a
computer generated list.“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 2067): ”...the study was con-
ducted in a double-blind fashion...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 2067): ”...the study was con-
ducted in a double-blind fashion...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
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study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ciotta 2012
Methods Randomised, double-blind, active- and placebo-controlled trial
Setting
Institute of Obstetric and Gynaecological Pathology, Santo Bambino Hospital, Univer-
sity of Catania, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 111
Mean age = 25 years
Inclusion criteria of the trial
• PCOS, characterised by oligomenorrhoea and/or acne, and/or mild hirsutism (<
15 on Ferriman-Gallwey score), insuline resistance
Exclusion criteria of the trial
• Not reported
Randomised
N = 111
Withdrawals/losses to follow-up
• Not reported
Baseline data
Nothing reported
Interventions Intervention
• Myo-inositol 2 g (+ folic acid) b.i.d. for 6 months (40)
Comparator 1
• D-chiro-inositol 500 mg (+ folic acid, B12 vitamin and manganese) b.i.d. for 6
months (42)
Comparator 2
• Multivitamin placebo without folic acid, B12 vitamin, and manganese b.i.d. for 6
months (29)
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Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Menstrual cycle
2. Acne score
3. Hirsutism score (Ferriman-Gallwey)
4. Metabolic parameters (total cholesterol, HDL-cholesterol, LDL-cholesterol,
triglycerides, glycaemia, insulinaemia and HOMA-IR)
5. Endocrine Parameters (LH, FSH, prolactin, total testosterone, free testosterone,
androstenedione, 17-OH-P, DHEA, DHEAS, SHBG)
Denotes outcomes prespecified for this review
Notes Poster, limited data provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page S545): ”...randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page S545): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page S545): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
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study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Ciotta 2012B
Methods Randomised, double-blind, placebo-controlled trial
Setting
Institute of Obstetric and Gynaecological Pathology, Santo Bambino Hospital, Univer-
sity of Catania, Italy
Date of study
Not reported. Duration of intervention 3 months
Participants N = 58
Mean age = 27 years
Inclusion criteria of the trial
• PCOS based on oligo- or amenorrhoea (< 6 menstrual cycles per year),
hyperandrogenism (hirsutism or alopecia), hyperoestrogenaemia (elevated levels of
total or free testosterone), typical feature of ovaries on ultrasound scan
Exclusion criteria of the trial
• Not reported
Randomised
N = 58
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean)
No separate data per group
BMI: 28
Waist/hip ratio: 0.87
Acne score: 3.5
F-G score: 15
Interventions Intervention
• D-chiro-inositol 250 mg in combination with manganese, folic acid, and vitamin
B12 b.i.d. for 3 months (38)
Comparator
• Multivitamin b.i.d. for 3 months (20)
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Outcomes Assessments (2): baseline, month 3
Outcomes of the trial (as reported)
1. BMI
2. Waist/hip ratio
3. Acne score (Cremoncini 1976)
4. Hirsutism score (Ferriman-Gallwey)
5. Blood pressure
6. Menstrual cycles
7. Serum LH, FSH, estradiol, total and free testosterone, androstenedione, DHEAS,
17OH progesterone, SHBG, prolactin, thyroid function
8. Glycaemia, cholesterol, triglycerides, blood urea nitrogen, basal insulin
9. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 146): ”...according to a ran-
domization table...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 146): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
Unclear risk Quote (page 146): ”...double-blind...“
Comment: uncertainty about the effective-
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All outcomes ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) High risk Although the authors conducted clinical
and endocrine evaluations the following
outcomes were either not reported or in-
adequately reported: hirsutism score, BMI,
waist/hip ratio, and blood pressure values
Comment: we judged this as at a high risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Consoli 1994
Methods Randomised, active-controlled trial
Setting
Endocrinology Department, Hospital Saint-Louis, Paris, France
Date of study
Not reported. Duration of intervention 12 months
Participants N = 67
Mean age = 26 years
Inclusion criteria of the trial
• Hirsutism and/or other signs of hyperandrogenism
Exclusion criteria of the trial
• Not reported
Randomised
N = 67
Withdrawals/losses to follow-up
• 13/67 (19%); reasons not reported
Baseline data
Not reported per group. Only 33/67 had hirsutism
Interventions Intervention
• Cyproterone acetate 50 mg + estradiol valerate 2 mg per os for 12 months (28)
Comparator
• Cyproterone acetate 50 mg + transdermal estradiol 50 mg for 12 months (26)
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Outcomes Assessments (2): baseline and month 12
Outcomes of the trial (as reported)
1. Quality of life (11 questions); 4-point Likert scale
2. Acceptance; visual analogue scale (VAS)
3. Tolerance; questionnaire
4. Hirsutism score
Denotes outcomes prespecified for this review
Notes Distribution of participants to either intervention group unclear; no separate data re-
ported for participants with hirsutism, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 784): ”Après randomisation..
.“.
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 13/67 (19%); reasons not reported. Per-
protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk There was baseline imbalance in BMI:
higher in transdermal estradiol group (23.
4) compared to oral estradiol group (21.0)
. One of the investigators was employed by
Schering, the manufacturer of cyproterone
acetate, the transdermal estradiol, and the
oral estradiol
Comment: we judged this as at a high risk
of bias
Couzinet 1986
Methods Randomised, active-controlled, cross-over trial
Setting
Service d’Endocrinologie et des Maladies de la Reproduction Hopital de Bicetre, Bicetre,
France
Date of study
Not reported. Duration of intervention 3 months, wash-out period of 6 months and
then again 3 months intervention
Participants N = 10
Age range 20 to 35 years
Inclusion criteria of the trial
• Clinical and biochemical criteria for PCOS
• > 120% of ideal body weight
• Hirsutism
• Oligo- or amenorrhoea with progesterone (P)-induced withdrawal bleeding
• Evidence of PCOS by ultrasound
• Serum androstenedione > 2.3 ng/ml and a LH/FSH ratio > 3
• Plasma prolactin levels were normal
Exclusion criteria of the trial
• Not reported
Randomised
N = 10
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
Testosterone (ng/ml): CPA group 1.0 (0.11), dTrp6-LHRH group 1.10 (0.10)
Androstenedione (ng/ml): CPA group 2.81 (0.23), DTrp6-LHRH group 2.44 (0.14)
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Interventions Intervention
• Cyproterone acetate 50 mg for 3 months and then 6 months later cross-over
Comparator
• 6-D tryptophane LHRH for 3 months and then 6 months later cross-over
All patients were asked to eat a 1200 kcal/day diet
Outcomes Assessments (4): baseline, month 1, 2, and 3
Outcomes of the trial (as reported)
1. Acne and seborrhoea (Cremoncini 1976)
2. Ferriman-Gallwey score
3. Pelvic ultrasound
4. Serum estradiol, testosterone, androstenedione, DHEAS
5. 3αandrostanediol in 24-hour urine sample
6. LHRH test
Denotes outcomes prespecified for this review
Notes Although the wash-out period of 6 months was considered adequate, there were no end
data for first treatment period, nor baseline data for second treatment period. See Table
3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1031): ”The sequence of drug
administration was randomly allocated in
a cross-over fashion for the 10 patients“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1034): ”We are also most
grateful to Dr. R. Y. Mauvernay (Debio-
pharm, Lausanne, Switzerland) and Dr.
Deschamps de Paillette (Laboratoire Beau-
four, Paris, France) for their kind arrange-
ments for the supply of microcapsules.“
Comment: we judged this as at a low risk
of bias
Crave 1995
Methods Randomised, double-blind, placebo-controlled trial
Setting
Hospices Civils de Lyon, Lyon, France
Date of study
Not reported. Duration of intervention 4 months
Participants N = 24
Mean age = not reported
Inclusion criteria of the trial
• Hirsutism
• BMI > 25 kg/m2
Exclusion criteria of the trial
• Concomitant diseases
• Medication prior to study entry
• Contraindication to metformin
Randomised
N = 24
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: metformin group 35.2 (1.2), placebo group 32.7 (1.5)
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F-G score: metformin group 17 (2), placebo group 9 (3)
Interventions Intervention
• Metformin once daily 850 mg for the first week to 850 mg twice daily for
subsequent 15 weeks
Comparator
• Placebo for 4 months
Each patient was required to follow a detailed and specific low fat and low calorie diet
(1500 cal/day with 30% fat) for 4 months
Outcomes Assessments (3): baseline, month 2 and 4
Outcomes of the trial (as reported)
1. Height, weight, BMI, waist/hip ratio
2. Plasma lipids, SHBG, corticosteroid-binding globulin, androgen levels
3. Glucose, insulin, oral glucose tolerance test, AUC glucose, AUC insulin
4. Evaluation of total energy intake
Denotes outcomes prespecified for this review
Notes Unclear how many participants started in each treatment arm. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 2058): ”Metformin (Lipha
Sante, Aron-Medicia Division, Lyon,
France) and placebo were given in a ran-
domized, double blind design.“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 2058): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of participants/healthcare
providers during the study.
Insufficient information to permit a clear
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judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 2058): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 2057): ”This work was sup-
ported by a grant from Lipha Santé (Di-
vision Aron Medicia).“ Lipha Santé is the
manufacturer of metformin
Baseline imbalance in F-G score, quote
(page 2058): ”...in the metformin group,
the hirsutism score was higher (P < 0.03)
than that in the placebo group (17 (2) vs
9 (3)), and in the placebo group, the mean
plasma A (androstenedione) concentration
was higher (P < 0.04) than that in the met-
formin group.“
Comment: we judged this as at a high risk
of bias
Creatsas 1993
Methods Randomised, active-controlled trial
Setting
1st Department of Obstetrics and Gynecology, ”Alexandra“ Hospital, Division of Pedi-
atric-Adolescent Gynecology, University of Athens, Greece
Date of study
Not reported. Duration of intervention 6 months
Participants N = 45
Mean age = 17 years
Inclusion criteria of the trial
• Oligomenorrhoeic adolescents with PCOS with menstrual intervals of 40 to 65
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days
Exclusion criteria of the trial
• Not reported
Randomised
N = 45
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean SEM):
BMI: EE + CPA group 22.8 (1.1), DTr6 LHRH group 23.6 (1.1)
F-G score: EE + CPA group 10.9 (0.5), DTr6 LHRH group 11.6 (0.9)
Testosterone (nmol/L): EE+ CPA group 3.3 (0.2), DTr6 LHRH group 3.1 (0.2)
Androstenedione (ng/ml): EE+ CPA group 2.9 (0.6), DTr6 LHRH group 3.1 (0.7)
SHBG (nmol/L): EE+ CPA group 42.2 (2.8), DTr6 LHRH group 45.4 (3.7)
DHEAS (µmol/ml): EE+ CPA group 2.8 (0.5), DTr6 LHRH group 3.2 (0.2)
Interventions Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 6 months (31)
Comparator
• D-Tr-6-LHRH 3.75 mg given intramuscularly every 28 days for 6 months (14)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. BMI
2. Waist-hip circumference
3. Ultrasound of ovarian volume, uterine area
4. Clinical characteristics of menstrual period
5. Ferriman-Gallwey score
6. Serum FSH, LH, 17β-estradiol, prolactin, testosterone, SHBG, androstenedione,
DHEAS
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 148): ”...were randomly allo-
cated...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Creatsas 2000
Methods Randomised, active-controlled trial
Setting
Athens University, 2nd Department of Obstetrics and Gynecology, Athens, Greece
Date of study
Not reported. Duration of intervention 12 months
Participants N = 24
Mean age = 17 years
Inclusion criteria of the trial
• Clinical signs of PCOS (oligomenorrhoea, secondary amenorrhoea and/or
hirsutism)
• Normal thyroid function
• Normal prolactin levels
Exclusion criteria of the trial
• Congenital adrenal hyperplasia
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• Hormonal medication (including OCP) < prior to study
Randomised
N = 24
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: desogestrel + EE group 24.9 (4.7), CPA + EE group 23.4 (3.8)
F-G score: desogestrel + EE group 16.2 (6.2), CPA + EE group 16.8 (4.7)
Testosterone (ng/ml): desogestrel + EE group 1.06 (0.3), CPA + EE group 0.9 (0.3)
Free testosterone (pg/ml): desogestrel + EE group 3.2 (0.9), CPA + EE group 2.9 (0.6)
Androstenedione (ng/ml): desogestrel + EE group 3.9 (0.9), CPA + EE group 3.6 (1)
SHBG (nmol/L): desogestrel + EE group 70 (51), CPA + EE group 67 (40)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 12 months (12)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (12)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Lipid profile (triglycerides, total cholesterol, LDL, HDL, apolipoproteins A-I, A-
II, B and lipoprotein (a))
Denotes outcomes prespecified for this review
Notes No final values reported for F-G score, PI did not reply. No usable data, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 250): ”...were randomly as-
signed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Cusan 1994
Methods Randomised, active-controlled trial
Setting
Medical ResearchGroup inMolecular Endocrinology, CentreHospitalier de l’Université
Laval Research Center, Quebec, Canada
Date of study
Not reported. Duration of intervention 9 months
Participants N = 53
Mean age = 26 years
Inclusion criteria of the trial
• Premenopausal women with moderate to severe hirsutism
Exclusion criteria of the trial
• Adrenal or ovarian tumours
• Concomitant disease
• Medication < 6 months prior to study entry
Randomised
N = 53
Withdrawals/losses to follow-up
• 5/53 (9%); 1/28 flutamide group, 4/27 spironolactone group, reasons unreported
Baseline data (mean (SEM))
All participants had a F-G score ≥ 14
BMI: flutamide group 26.2 (1.3), spironolactone group 27.3 (1.4)
Normal/abnormal menses: flutamide group 15/13, spironolactone group 14/13
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F-G score: flutamide group 25 (1.8), spironolactone group 21 (1.6)
Interventions Intervention
• Flutamide 250 mg b.i.d. + triphasic OCP for 9 months (28)
Comparator
• Spironolactone 50 mg b.i.d. + triphasic OCP for 9 months (27)
No epilatory technique was allowed during the study
Outcomes Assessments (10): baseline and then monthly
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Acne score, seborrhoea and hair loss (Cremoncini 1976)
3. Serum gonadotropins, prolactin, SHBG, and steroid levels
4. Biochemical, haematologic, hepatic and renal function
5. Side effects
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 282): ”...were randomized
into two groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/53 (9%); 1/28 flutamide group, 4/27
spironolactone group, reasons unreported
Comment: low number of drop-outs and
although not entirely balanced, we judged
this as at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 281): ”Supported in part by
Schering-Plough“. Schering-Plough is the
manufacturer of flutamide
Moderate baseline imbalance in hirsutism
score (25 (1.8) for flutamide group and 21
(1.6) for spironolactone group)
Comment: unclear to what extent both of
these factors represent a potential risk of
bias
De Leo 2000
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, University of Siena, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 35
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women with PCOS
Exclusion criteria of the trial
• Adrenal or ovarian neoplasm
• Congenital or adult adrenal hyperplasia
• Cushing’s syndrome
• Drug-induced hirsutism
Randomised
N = 35
Withdrawals/losses to follow-up
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• No losses to follow-up reported
Baseline data (mean (SD))
BMI: GnRH-a group 22 (2), GnRH-a+OCP group 20 (1.5), GnRH-a+flutamide group
21 (1)
Menses, oligomenorrhoea/amenorrhoea: GnRH-a group 7/8, GnRH-a+OCP group 8/
4, GnRH-a+flutamide group 6/5
F-G score: GnRH-a group 18 (3), GnRH-a+OCP group 19 (2), GnRH-a+flutamide
group 20 (4)
Interventions Intervention
• GnRH analogue (triptorelin) 3.75 mg every 28 days for 6 months (12)
Comparator 1
• GnRH analogue (triptorelin) 3.75 mg every 28 days + OCP (cyproterone acetate
2 mg/EE 0.035 mg) for 6 months (12)
Comparator 2
• GnRH analogue (triptorelin) 3.75 mg every 28 days + flutamide 250 mg once a
day for 6 months (11)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum LH, FSH, SHBG, estradiol, estrone, total testosterone, free testosterone,
androstenedione and DHEAS
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 412-3): ”...randomly divided
on the basis of a random number table...
“ and ”The obese patients were randomly
assigned to group A (n=4), group B (n=4)
and group C (n=4)“
Comment: it is unclear if a stratified ran-
domisation has been applied for the obese
participants and thus if sequence genera-
tion has been generated at random
E-mail correspondence: did not provide ad-
ditional information to permit altering the
assessment
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
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seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Dereli 2005
Methods Randomised, open-label, active-controlled trial
Setting
Department of Endocrinology and Metabolism, Ege University, Izmir, Turkey
Date of study
Not reported. Duration of intervention 8 months
Participants N = 264 screened, 40 randomised
Mean age = 30 years
Inclusion criteria of the trial
• PCOS based on: hyperandrogenism and/or hyperandrogenaemia, oligo-
anovulation, exclusion of other known disorders, such as Cushing’s syndrome,
hyperprolactinaemia, nonclassic adrenal hyperplasia
• BMI < 27 kg/cm2
• Impaired glucose tolerance test
• HOMA > 2.7
Exclusion criteria of the trial
• BMI > 27 kg/cm2
• Unresolved medical conditions
• Type I or II diabetes mellitus
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• Significant cardiovascular disease, active cancer within the past 5 years
• Medications known to affect reproductive or metabolic functions < 60 days prior
to study entry
Randomised
N = 40
Withdrawals/losses to follow-up
• 4/40 (10%); 2/20 in rosiglitazone 2 mg group, 2/20 in rosiglitazone 4 mg group
• Moved away; 0/20 in rosiglitazone 2 mg group, 1/20 in rosiglitazone 4 mg group
• Desire for pregnancy; 1/20 in rosiglitazone 2 mg group, 1/20 in rosiglitazone 4
mg group
• Unknown reason; 1/20 in rosiglitazone 2 mg group, 0/20 in rosiglitazone 4 mg
group
Baseline data (mean (SD))
BMI: rosiglitazone 2 mg group 23.9 (1.9), rosiglitazone 4 mg group 31.4 (0.9)
F-G score: rosiglitazone 2 mg group 14.1 (3.8), rosiglitazone 4 mg group 14.2 (4.1)
Free testosterone (pg/ml): rosiglitazone 2 mg group 5.69 (1.1), rosiglitazone 4 mg group
5.73 (1.2)
Ovulation: rosiglitazone 2 mg group 0, rosiglitazone 4 mg group 0
Interventions Intervention
• Rosiglitazone 2 mg once a day for 8 months (20)
Comparator
• Rosiglitazone 4 mg once a day for 8 months (20)
Outcomes Assessments (3): baseline, month 3 and 8
Outcomes of the trial (as reported)
1. Ovulatory function
2. Ferriman-Gallwey score
3. Serum total testosterone, free testosterone, estradiol, estrone, androstenedione,
LH, FH, 17OH progesterone, DHEAS, prolactin
4. Glycaemic parameters (fasting and post challenge levels of glucose and insulin,
HOMA-IR, haemoglobin A1c)
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 300): ”Patients entering the
trial received a code provided by a com-
puter program generating random num-
bers at trial centre...“
Comment: probably done
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 301): ”open labeled trial...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 301): ”open labeled trial...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/40, reasons reported. Per-protocol anal-
ysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
Selective reporting (reporting bias) High risk Although the authors conducted clinical,
hormonal, and glycaemic evaluations the
following outcomes were either not re-
ported or inadequately reported: evaluation
of levels of testosterone, androstenedione,
DHEAS, and 17OH progesterone
Comment: we judged this as at a high risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Dixon 1991
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynaecology and of Endocrinology, Guy’s Hospital, Lon-
don, UK
Date of study
Not reported. Duration of intervention 6 months
Participants N = 41
Mean age = 26 years
Inclusion criteria of the trial
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• Hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 41
Withdrawals/losses to follow-up
• 8/41 (20%); 3/21 in spironolactone group, 5/20 in CPA group reasons not
reported
Baseline data (mean (SEM))
Testosterone (nmol/L): spironolactone group 2.9 (0.2), CPA group 2.7 (0.2)
SHBG (nmol/L): spironolactone group 29.8 (2.8), CPA group 33.6 (3.2)
Hair growth (mm/day): spironolactone group 0.38 (0.03), CPA group 0.37 (0.02)
F-G score: spironolactone group 23.0 (1.3), CPA group 20.5 (1.3)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + norethisterone 500 µg) + spironolactone 50 mg b.
i.d. for 6 months (21)
Comparator
• Ethinyl estradiol 30 µg on days 5 to 25 + cyproterone acetate 50 mg a day on days
5 to 15 (20)
Outcomes Assessments (3): baseline, month 2 and 6
Outcomes of the trial (as reported)
1. Photographic assessment (2 methods) of hirsutism
2. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes 1 participant included did not have PCOS or idiopathic hirsutism but delayed onset
congenital adrenal hyperplasia (in the spironolactone group). Although this single par-
ticipant did not match the inclusion criteria we consider this to be of limited impact on
the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 64): ”...allocated at random..
.“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Low risk Quote (page 64): ”... allocated at random
by envelope to treatment...“
Comment: the report provides sufficient
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detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 64): ”The photographs were
coded and all calculations for linear hair
growth rate made at the completion of the
6months. Thus the results were not known
by patients or observer during the trial“
Comment: although the blinding of the
outcome assessment with respect to the
photographical assessment might have
been adequate, as there was no blinding for
treatment arm, the assessment of Ferriman-
Gallwey score is likely to be influenced by
lack of blinding. With respect to all out-
come assessments, we have judged this do-
main as unclear risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/41 (20%); 3/21 in spironolactone group,
5/20 in CPA group reasons not reported.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Gynecological Endocrinology and Reproductive Medicine of the
Women’s University Hospital Heidelberg, Heidelberg, Germany
Date of study
2002 until 2004. Duration of intervention 12 weeks
Participants N = 45
Mean age = 28 years
Inclusion criteria of the trial
• PCOS, based on at least 2 of the 3 following abnormalities: all patients were
expected to have disturbed ovulatory function with chronic oligomenorrhoea (cycle
length 35 days; less than 9 cycles per year) or amenorrhoea (cycle length 12 weeks) and
typical appearance of polycystic ovaries by ultrasound according to the criteria of the
Rotterdam consensus meeting 2003 (Rotterdam Criteria PCOS 2004)
• Facultatively clinical and/or biochemical signs of hyperandrogenism (serum total
testosterone concentration 60 ng/dl or greater (≥ 2.1 nmol/L) or serum
androstenedione (A) concentration greater than 2.9 ng/ml (> 10.1 nmol/L)).
Exclusion criteria of the trial
• Impaired glucose tolerance test (fasting glucose 5.6 mmol/L and/or 2-hour
glucose 7.8 mmol/L) or any form of diabetes mellitus
• Hyperprolactinaemia
• Thyroid disorders
• Late onset congenital adrenal hyperplasia (exclusion of 21-hydroxylase deficiency
by molecular genetic analysis)
• Cushing’s syndrome (normal basal free serum cortisone and 2 mg dexamethasone
suppression test)
• Medications likely to influence hormonal profiles or anti obesity compounds
during 6 months before inclusion in the study
• Heart, liver, or kidney diseases (predisposing lactic acidosis) and unsuspected
pregnancy before inclusion in the study
Randomised
N = 45
Withdrawals/losses to follow-up
• 7/45 (16%); 3/22 in metformin group, 4/23 in placebo group
• Socio-economic reasons; 1/22 in metformin group, 3/23 in placebo group
• Pregnancy; 2/22 in metformin group, 1/23 in placebo group
Baseline data (median (1 to 3 quartiles))
BMI: metformin group 28.9 (23.3 to 34.1), placebo group 32.4 (27.9 to 37.5)
F-G score: metformin group 10.1 (8.5 to 12.3), placebo group 9.3 (7.8 to 11.2)
Interventions Intervention
• Metformin, first week 500 mg b.i.d. thereafter 500 mg 3 times a day for 12 weeks
(22)
Comparator
• Placebo for 12 weeks (23)
Participants were advised to use barrier contraception if fertility was not desired and were
carefully instructed to stop taking the drug immediately on confirmation of pregnancy
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Outcomes Assessments (4): baseline, month 1, 2, and 3
Outcomes of the trial (as reported)
1. Menstrual cycle frequency, basal body temperature curve
2. Height, weight, BMI
3. Ferriman-Gallwey score
4. Serum prolactin, LH, FSH, estradiol, total testosterone, SHBG, progesterone,
TSH, total T3, free T4, DHEAS, androstenedione, 17OH- progesterone, cortisol,
fasting glucose and insulin, total cholesterol, triglycerides, HDL cholesterol, and LDL
cholesterol
5. Complete blood count, hepatic function tests and renal chemistry
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 947): ”Randomization was
done in a prospective, placebo-controlled,
double-blind fashion stratified for insulin
resistance. Patients received either met-
formin or placebo according to computer-
generated code with a randomization in
blocks of six.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 947): ”A copy of the code was
stored in a sealed envelope by a third party
who did not participate in the study for
emergency situations. The randomization
code was not broken until the last patient
completed all observations.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 947): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind personnel from knowledge of
which intervention a participant received,
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to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 947): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7/45 (16%); 4/22 in metformin group, 3/
23 in placebo group. Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 951): ”We are indebted to
Merck (Darmstadt, Germany) and Lipha
S.A. (Pharmacie Centrale (Clinical Trial
Supply Group), Meyzieu, France) for the
unconditional supply of metformin and
placebo.“
Comment: we judged this as at a low risk
of bias
Elkind-Hirsch 1995
Methods Randomised, active-controlled trial
Setting
Baylor College of Medicine, and Obstetrical and Gynecological Associates, Houston,
Texas, US
Date of study
Not reported. Duration of intervention 6 months
Participants N = 36 recruited
Mean age = 28 years
Inclusion criteria of the trial
• Hirsutism (Lorenzo score) (Lorenzo 1970)
• Clinical and biochemical criteria for ovarian hyperandrogenism
• Testosterone ≥ 60 but ≤ 200 ng/dl, prolactin ≥ 20ng/ml, DHEAS ≤ 320 µg/dl,
estradiol ≥ 60 pg/ml, and LH:FSH ratio ≥ 2
Exclusion criteria of the trial
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• Smoking < 5 years prior to study entry
• Hyperandrogenism due to adrenal or ovary tumours
• Cushing’s disease
• 21-hydroxylase deficiency
• Thyroid dysfunction
• Elevated DHEAS
• Hyperprolactinaemia
• OCP, spironolactone, GnRH analogues < 6 months prior to study entry
• Medication known to affect gonadotropins, steroid metabolism, or hair growth
Randomised
N = 36
Withdrawals/losses to follow-up
• 3/36 (8%); 0/12 in GnRH-a group, 2/12 in OCP group, 1/12 in GnRH-a +OCP
group
• Intolerance to OCP; 2/12 in OCP group
Baseline data (mean (SEM))
BMI: GnRH-a group 40 (2.0), GnRH-a + OCP group 35.0 (3.0), OCP group 32.0 (2.
3)
Testosterone (ng/dl): GnRH-a group 79.3 (5.6), GnRH-a + OCP group 91.0 (5.7),
OCP group 71.0 (3.8)
Free testosterone (ng/dl): GnRH-a group 3.5 (0.4), GnRH-a + OCP group 4.8 (0.6),
OCP group 3.1 (0.2)
SHBG (nmol/L): GnRH-a group 48 (7), GnRH-a + OCP group 47 (6), OCP group 68
(15)
Hirsutism score (Lorenzo 1970): GnRH-a group 15.0 (1.1), GnRH-a + OCP group 16.
0 (1.0), OCP group 12.7 (0.8)
Interventions Intervention
• GnRH analogue (leuprolide) 3.75 mg im every 28 days for 6 months (12)
Comparator 1
• OCP (ethinyl estradiol 35 µg + norethindrone 0.4 mg) for 6 months (12)
Comparator 2
• GnRH analogue (leuprolide) 3.75 mg im every 28 days + OCP (ethinyl estradiol
35 µg + norethindrone 0.4 mg) for 6 months (12)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Serum testosterone, free testosterone, estradiol, DHEAS, progesterone, LH, FSH,
SHBG, insulin
2. Hirsutism (modified Lorenzo score) (Lorenzo 1970)
3. Hair shaft diameter
4. Hair density
5. Transvaginal ultrasound examination
6. Adverse events
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7. Frequency of performing cosmetic measures (by participants)
8. Participant self report
Denotes outcomes prespecified for this review
Notes 30/36 were obese having BMI > 29 kg/m2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 971): ”... were assigned ran-
domly...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding reported. However, hair shaft
diameter and density was assessed by a
dermatologist who was blinded as well as
the ultrasound scans were performed by a
blinded investigator
Comment: although the objective mea-
surement of the hirsutism and ultrasound
scansmight have been assessed by a blinded
investigator, the assessment of the other
outcomes were not blinded. The outcome
measurement of most outcomes was likely
to be influenced by the lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/36 (8%); 0/12 in GnRH-a group, 2/12
in OCP group, 1/12 in GnRH-a +OCP
group. Per-protocol-analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
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sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 970 and 977): ”Supported
by an educational grant from TAP Phar-
maceuticals, Deerfield, Illinois and by the
division of Research resources of the Na-
tional Institutes of Health under grant
MO1RR00350, Bethesda, Maryland“ and
”We express our thanks...to TAP Pharma-
ceuticals in Deerfield, Illinois and Mead
Johnson Laboratories in Evansville Indiana
for their generous gifts of Lupron and Ov-
con-35.“
There was serious baseline imbalance in
BMI between the groups
Comment: a potential risk of bias cannot
be excluded
Elnashar 2006
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, Benha University Hospital, Benha, Egypt
Date of study
March until December 2004. Duration of intervention 1 treatment cycle
Participants N = 80
Mean age = 24 years
Inclusion criteria of the trial
• Infertile women with PCOS according to the Rotterdam criteria (Rotterdam
Criteria PCOS 2004)
• 18 and 39 years
• Period of infertility > 2 years
• DHEAS within normal levels (80 to 400 µg/dl)
• Previously received clomiphene citrate (CC) and diagnosed as having CC
resistance (failure of ovulation after 3 cycles of CC reaching the dose of 150 mg daily)
Exclusion criteria of the trial
• Hyperprolactinaemia, clinical evidence of hypercorticism or thyroid dysfunction
• Treatment last 2 months prior to the dexamethasone treatment
Randomised
N = 80
Withdrawals/losses to follow-up
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• No losses to follow-up reported
Baseline data (mean (SD))
BMI: CC + dexamethasone group 29.381 (5.1195), CC group + placebo 29.595 (5.
7958)
Waist/hip ratio: CC + dexamethasone group 0.8948 (0.0940), CC group + placebo 0.
9627 (0.0851)
Oligomenorrhoea/amenorrhoea: CC + dexamethasone group 31/40, CC group +
placebo 32/40
Eumenorrhoea: CC + dexamethasone group 9/40, CC group + placebo 8/40
Hirsutism: CC + dexamethasone group 11/40, CC group + placebo 13/40
Interventions Intervention
• Clomiphene citrate 100 mg/day on day 3 to 7 + dexamethasone 2 mg/day on day
3 to 12 (40)
Comparator
• Clomiphene citrate 100 mg/day on day 3 to 7 + placebo on day 3 to 12 (40)
Outcomes Assessments (2); baseline and end of cycle
Outcomes of the trial (as reported)
1. Ovulation rate
2. Number of follicles of > 18 mm endometrial thickness and pregnancy rate
Denotes outcomes prespecified for this review
Notes No separate data reported for participants with hirsutism, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1806): ”Patients were assigned
randomly to receive CC and either DEX or
placebo using closed dark envelopes“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Low risk Quote (page 1806): ”Patients were assigned
randomly to receive CC and either DEX or
placebo using closed dark envelopes“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1806): ”The patient and
the physician monitoring the cycles were
blinded to the identity of each medication“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind personnel from knowledge of
which intervention a participant received,
to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1806): ”The patient and
the physician monitoring the cycles were
blinded to the identity of each medication“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Elter 2002
Methods Randomised, active-controlled trial
Setting
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and
Gynecology, Marmara University School of Medicine, Istanbul, Turkey
Date of study
Not reported. Duration of intervention 4 months
Participants N = 40
Mean age = 24 years
Inclusion criteria of the trial
• PCOS based on (i) bilateral polycystic ovaries on ultrasound examination, (ii)
chronic oligo-menorrhoea (< 6 menstrual periods in previous year), (iii) manifestations
of hyperandrogenism and/or hyperandrogenaemia, i.e. hirsutism score > 8 (Ferriman-
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Gallwey score), acne, elevated serum testosterone and/or androstenedione and/or free
testosterone levels
• BMI ≤ 26 kg/m2
Exclusion criteria of the trial
• Late-onset congenital adrenal hyperplasia
• Serum 17OH progesterone > 10 nmol/L after ACTH stimulation
• Serum cortisol > 140 nmol/L after dexamethasone suppression test
• Adrenal mass on pelvic sonography
• Diabetes
• Endocrinological disease
• Drugs that affect carbohydrate or lipid metabolism and OGTT results < 6
months prior to study entry
Randomised
N = 40
Withdrawals/losses to follow-up
• No drop-outs
Baseline data (mean (SD))
BMI: OCP + metformin group 22.74 (2.66), OCP group 21.83 (1.40)
Waist/hip ratio: OCP + metformin group 0.827 (0.06), OCP group 0.804 (0.04)
F-G score: OCP + metformin group 9.47 (5.48), OCP group 12.06 (5.25) (14 in each
group were hirsute)
Testosterone (nmol/L): OCP + metformin group 2.72 (1.21), OCP group 2.76 (1.61)
Free testosterone (pg/ml): OCP + metformin group 13.10 (3.11), OCP group 13.00 (4.
62)
Androstenedione (nmol/L): OCP + metformin group 10.65 (3.53), OCP group 10.87
(2.53)
DHEAS (µmol/L): OCP + metformin group 6.31 (2.30), OCP group 7.69 (3.21)
SHBG (nmol/L): OCP + metformin group 54.99 (22.27), OCP group 52.97 (19.08)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + metformin 500 mg 3
times a day for first 15 days then b.i.d. for 4 months (20)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) (20)
Outcomes Assessments (2): baseline and month 4
Outcomes of the trial (as reported)
1. BMI, waist/hip ratio
2. Ferriman-Gallwey score
3. Ovary volume
4. Serum FSH, LH, testosterone, free testosterone, androstenedione, DHEAS,
SHBG, 17OH progesterone
5. Glucose, insulin, total cholesterol, LDL cholesterol, HDL cholesterol
Denotes outcomes prespecified for this review
Notes 14 in each group were hirsute
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1730): ”Randomization was
produced from a computer-generated ran-
dom list...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1730): ”Clinical parameters
(BMI, WHR, Ferriman-Gallwey score and
ovarian volume) of the subjects were eval-
uated by the same person, who was blind
to the type of treatment. No attempt was
made to mask the treatments from the sub-
jects, and placebo was not used“
Comment: we judged this as at unclear risk
of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1730): ”Clinical parameters
(BMI, WHR, Ferriman-Gallwey score and
ovarian volume) of the subjects were eval-
uated by the same person, who was blind
to the type of treatment. No attempt was
made to mask the treatments from the sub-
jects, and placebo was not used“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
193Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Elter 2002 (Continued)
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Erenus 1994
Methods Randomised, active-controlled trial
Setting
Marmara University Hospital Hirsutism Clinic, Istanbul, Turkey
Date of study
Not reported. Duration of intervention 9 months
Participants N = 20
Mean age = 20 years
Inclusion criteria of the trial
• Idiopathic hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 20
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: flutamide group 23.1 (3.75), spironolactone group 22.5 (3.5)
F-G score: flutamide group 21.2 (6), spironolactone group 19.8 (5.6)
Testosterone (ng/dl): flutamide group 41.39 (17.5), spironolactone group 49.4 (10.3)
DHEAS (mg/dl): flutamide group 178.8 (84.64), spironolactone group 218.4 (142.5)
Interventions Intervention
• Flutamide 250 mg b.i.d. for 9 months (10)
Comparator
• Spironolactone 100 mg/day for 9 months (10)
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum testosterone, DHEAS, FSH, LH
3. Adverse effects
Denotes outcomes prespecified for this review
Notes -
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 614): ”... were randomized to
receive...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, single-blind, active-controlled trial
Setting
Marmara University School of Medicine, Istanbul, Turkey
Date of study
Not reported. Duration of intervention 9 months
Participants N = 42
Mean age = 21 years
Inclusion criteria of the trial
• Hirsutism (Ferriman-Gallwey score > 10)
Exclusion criteria of the trial
• Medication < 6 months before study entry
Randomised
N = 42
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
F-G score: CPA group 18.28 (4.60), spironolactone group 18.04 (5.90)
Testosterone (ng/dl): CPA group 48.5 (22.20), spironolactone group 46.31 (24.92)
DHEAS (mg/dl): CPA group 275.4 (103.0), spironolactone group 276.26 (103.28)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + 50 mg cyproterone
acetate on days 1 to 10 for 9 months (21)
Comparator
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) + 100 mg spironolactone/
day for 9 months (21)
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum testosterone, DHEAS, FHSH, LH, and 17OH progesterone
3. Adverse events
Denotes outcomes prespecified for this review
Notes 3 participants had PCOS, 37 idiopathic hirsutism, and 2 had late onset adrenal hyper-
plasia. Although these last 2 participants did not match the inclusion criteria we consider
this to be of limited impact on the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 217): ”... were randomly as-
signed in a 1:2 ratio...“
Comment: insufficient detail was reported
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about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 216): ”...single-blinded...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 217): ”Measurements were
performed by a single examiner (D.Y.) who
was blinded with regard to treatment.“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Erenus 1997
Methods Randomised, single-blind, active-controlled trial
Setting
Marmara University School of Medicine, Istanbul, Turkey
Date of study
Not reported. Duration of intervention 9 months
Participants N = 40
Mean age = 20 years
Inclusion criteria of the trial
• Idiopathic hirsutism (Ferriman-Gallwey score > 10)
Exclusion criteria of the trial
• Medication < 6 months before study entry
Randomised
N = 40
Withdrawals/losses to follow-up
• 24/40 (60%); 13/20 in finasteride group, 11/20 in spironolactone group
• Inefficacy of treatment; 13/20 in finasteride group, 6/20 in spironolactone group
• Additional OCP because of irregular bleeding; 5/20 in spironolactone group
Baseline data (mean (SD))
F-G score: finasteride group 20.05 (5.01), spironolactone group 21.60 (5.56)
Testosterone (ng/dl): finasteride group 41.67 (14.82), spironolactone group 48.49 (17.
40)
DHEAS (mg/dl): finasteride group 224.71 (82.19), spironolactone group 244.30 (121.
78)
Interventions Intervention
• Finasteride 5 mg/day for 9 months (20)
Comparator
• Spironolactone 100 mg/day for 9 months (20)
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum testosterone, DHEAS, FHSH, LH and 17OH progesterone
3. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1001): ”... were randomly as-
signed in a 1:1 ratio...“
Comment: insufficient detail was reported
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Erenus 1997 (Continued)
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1000): ”...single-blinded...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1001): ”Measurements were
performed by a single examiner (D.Y.) who
was blinded with regard to treatment“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/40 (60%); 13/20 finasteride group, 11/
20 in spironolactone group at the end of
the study. Per-protocol-analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Erkkola 1990
Methods Randomised, open, active-controlled trial
Setting
Multi-centre (5) in Finland
Date of study
Not reported. Duration of intervention 9 months
Participants N = 162
Age range = 20 to 40 years
Inclusion criteria of the trial
• Desire for oral contraception
• Androgenisation symptoms (acne, seborrhoea, and hirsutism)
Exclusion criteria of the trial
• Not reported
Randomised
N = 162
Withdrawals/losses to follow-up
• 29/162 (18%); 14/83 cyproterone acetate + ethinyl estradiol group, 15/79
desogestrel + ethinyl estradiol group
• Irregular bleeding; 1/83 cyproterone acetate + ethinyl estradiol group, 5/79
desogestrel + ethinyl estradiol group
• Other side effects such as headache, reduced libido, breast tenderness,
nervousness, depression, oedema; 13/83 cyproterone acetate + ethinyl estradiol group,
10/79 desogestrel + ethinyl estradiol group
Baseline data
Hirsutism: CPA + EE group 3/83, desogestrel + EE group 6/79
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 9 months (83)
Comparator
• OCP (ethinyl estradiol 30 µg+ desogestrel 0.15 mg) for 9 months (79)
Outcomes Assessments (4): baseline, month 3, 6, and 9
Outcomes of the trial (as reported)
1. Gynaecological examination, including palpation of the mammae
2. Body weight and blood pressure
3. Bleeding patterns
4. Side effects
5. Assessments of acne, greasy skin, and hirsutism; 3-point Likert scale
Denotes outcomes prespecified for this review
Notes No separate data reported for participants with hirsutism, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
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Erkkola 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote (page 62):”... randomly enrolled
into the study...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 61): ”...open, randomized...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 61): ”...open, randomized...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/162 (18%); 14/83 cyproterone acetate +
ethinyl estradiol group, 15/79 desogestrel +
ethinyl estradiol group. Per-protocol-anal-
ysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) High risk Outcomes for hirsutism were prespecified
in the ’methods’ and evaluated, but were
not reported
Comment: we judged this as at a high risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Esmaeilzadeh 2010
Methods Randomised, double-blind, active-controlled trial
Setting
Department of Infertility and Reproductive Health Research Center, Babol University
of Medical Sciences, Babol, Iran
Date of study
Not reported. Duration of intervention 6 months
Participants N = 40
Age range = 18 to 45 years
Inclusion criteria of the trial
• Obese women with PCOS according to the Rotterdam criteria (Rotterdam
Criteria PCOS 2004)
Exclusion criteria of the trial
• Ovarian or adrenal tumours
• Congenital adrenal hyperplasia
• Ovarian hypertrophy
• Cushing’s syndrome
• Hyperprolactinaemia
• Use of progesterone/danazol medications
• Thyroid abnormalities
• Pregnant women
• On medication with a diet < 3 months prior to study entry
Randomised
N = 40
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: metformin group 33.7 (4.72), flutamide group 31.8 (3.99)
Waist/hip ratio: metformin group 0.82 (0.05 ), flutamide group 84 (0.05 )
F-G score: metformin group 10.5 (3.6), flutamide group 9.4 (2.52)
Total testosterone (nmol/L): metformin group 1.02 (0.63), flutamide group 0.81 (0.47)
Free testosterone (pmol/L): metformin group 2.76 (1.72), flutamide group 1.46 (1.42)
DHEAS (µmol/L): metformin group 223.12 (103.79), flutamide group 189.49 (186.
98)
SHBG (nmol/L): metformin group 26.93 (12.7), flutamide group 26.93 (12.7)
Interventions Intervention
• Metformin 500 mg 3 times a day for 6 months (20)
Comparator
• Flutamide 250 mg b.i.d. for 6 months (20)
Participants started 1 month prior to study entry with a calorie restricted diet (1200 to
1400 kcal/day), which was continued for the duration of the intervention
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Weight, height, BMI, waist circumference, waist/hip ratio
2. Ferriman-Gallwey score
3. Serum testosterone, free testosterone, DHEAS, SHBG
202Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Esmaeilzadeh 2010 (Continued)
4. Glucose, insulin, OGTT, triglycerides, total cholesterol, LDL cholesterol, HDL
cholesterol
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk From the translation: were randomly cho-
sen (method unspecified)
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (English abstract): ”...double-blind.
..“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (English abstract): ”...double-blind.
..“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
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Esmaeilzadeh 2010 (Continued)
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Falsetti 1992
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynaecology and Department of Pathology, University
of Brescia, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 20
Mean age = not reported
Inclusion criteria of the trial
• Idiopathic hirsutism (10), hirsutism in women with PCOS (10)
Exclusion criteria of the trial
• Not reported
Randomised
N = 20
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
F-G score: idiopathic hirsutism 17 (5), hirsutism in PCOS 16 (4)
Interventions Intervention
• Leuprorelin 3.75 mg im every 28 days for 6 months (10)
Comparator
• Leuprorelin 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) for 6 months (10)
Outcomes Assessments: (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum testosterone, free testosterone, androstenedione, DHEAS, SHBG, 17OH
progesterone, insulin, LH, FSH
Denotes outcomes prespecified for this review
Notes Letter to the Editor, limited information
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Falsetti 1992 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 894): ”... we randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome assessment was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Falsetti 1994
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynaecology and Department of Pathology, University
of Brescia, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 32
Mean age = 25 years
Inclusion criteria of the trial
• Moderate to severe hirsutism (Ferriman-Gallwey score 11 to 25)
• Idiopathic hirsutism (16), hirsutism in PCOS (16)
Exclusion criteria of the trial
• Not reported
Randomised
N = 32
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
F-G score: idiopathic hirsutism 15.3 (4.0), hirsutism in PCOS 17.5 (4.4)
Regular cycles: idiopathic hirsutism 12/16, hirsutism in PCOS 0/16
Oligomenorrhoea: idiopathic hirsutism 4/16, hirsutism in PCOS 16/16
Testosterone (ng/ml): idiopathic hirsutism 0.6 (0.1), hirsutism in PCOS 1.4 (0.4)
Free testosterone (pg/ml): idiopathic hirsutism 2.0 (0.6), hirsutism in PCOS 5.1 (2.1)
Androstenedione (ng/ml): idiopathic hirsutism 3.3 (0.4), hirsutism in PCOS 2.1 (0.3)
DHEAS (µg/ml): idiopathic hirsutism 1.6 (0.8), hirsutism in PCOS 2.1 (0.7)
SHBG (nmol/L): idiopathic hirsutism 44.7 (6.3), hirsutism in PCOS 16.3 (0.2)
Interventions Intervention
• Leuprolide 3.75 mg im every 28 days for 6 months (16)
Comparator
• Leuprolide 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) for 6 months (16)
Outcomes Assessments: (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Hair diameter
3. Serum testosterone, free testosterone, androstenedione, DHEAS, SHBG, 17OH
progesterone, estradiol, insulin, LH, FSH
4. Ovarian morphology (ultrasound)
5. Bone density measurement
Denotes outcomes prespecified for this review
Notes -
206Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Falsetti 1994 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 817/8): ”randomly allocated..
. two randomized treatment arms were cre-
ated...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome assessment was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
207Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Falsetti 1994B
Methods Randomised, active-controlled trial
Setting
Department of Gynaecological Endocrinology, University of Brescia, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 25
Mean age = 24
Inclusion criteria of the trial
• Moderate severe hirsutism in women with PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 25
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: GnRH-a 22 (3), GnRH-a + OCP 24 (1)
Oligomenorrhoea: GnRH-a 12 (100%), GnRH-a + OCP 13 (100%)
F-G score: GnRH-a 18 (4), GnRH-a + OCP 17 (3)
Androstenedione (ng/ml): GnRH-a 3.4 (0.2), GnRH-a + OCP 3.5 (0.3)
Testosterone (ng/ml): GnRH-a 1.2 (0.3), GnRH-a + OCP 1.5 (0.4)
Free testosterone (pg/ml): GnRH-a 5.0 (0.4), GnRH-a + OCP 5.2 (0.9)
DHEAS (µg/ml): GnRH-a 2.1 (0.5), GnRH-a + OCP 2.0 (0.3)
SHBG (nmol/L): GnRH-a 15.0 (7.0), GnRH-a + OCP 17.0 (6.0)
Interventions Intervention
• Leuprolide 3.75 mg im every 28 days for 6 months (12)
Comparator
• Leuprolide 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) for 6 months (13)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Hair diameter
3. Serum testosterone, free testosterone, androstenedione, DHEAS, SHBG, 17OH
progesterone, insulin, insulin growth factor 1, LH, FSH
4. Ovarian morphology (ultrasound)
5. Bone density measurement
6. Side effects
Denotes outcomes prespecified for this review
Notes -
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Falsetti 1994B (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 304): ”The randomization
created two different groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome assessment was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Falsetti 1999
Methods Randomised, active-controlled trial
Setting
Department of Gynaecological Endocrinology, University of Brescia, Italy
Date of study
Not reported. Duration of intervention 12 months
Participants N = 110
Mean age = 23 years
Inclusion criteria of the trial
• Hirsute women with PCOS (64) or idiopathic hirsutism (46)
• Diagnosis of PCOS was based on clinical and endocrine findings
Exclusion criteria of the trial
• Cushing’s syndrome
• Evidence of enzymatic adrenal deficiency
• History of drug-induced hyperandrogenism
• Endocrine profile compatible with androgen-producing neoplasm or prolactin
and thyroid disorder
Randomised
N = 110
Withdrawals/losses to follow-up
• 3/110 (3%); 0/55 in finasteride group, 3/55 in flutamide group
• High transaminase; 2/55 in flutamide group
• Nausea and vomiting; 1/55 in flutamide group
Baseline data (mean (SD))
BMI: PCOS group 23.7 (4.1), idiopathic hirsutism 22.4 (3.2)
Androstenedione (ng/ml): PCOS group 3.6 (0.6), idiopathic hirsutism 2.0 (0.4)
Testosterone (ng/ml): PCOS group 1.0 (0.2), idiopathic hirsutism 0.5 (0.1)
Free testosterone (pg/ml): PCOS group 3.4 (0.6), idiopathic hirsutism 1.9 (0.6)
DHEAS (µg/ml): PCOS group 2.8 (0.9), idiopathic hirsutism 2.1 (0.8)
SHBG (nmol/L): PCOS group 22.0 (6.2), idiopathic hirsutism 46.0 (6.5)
Interventions Intervention
• Finasteride 5 mg daily for 12 months (55)
Comparator
• Flutamide 250 mg b.i.d. for 12 months (55)
Outcomes Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Hair diameter (4 different body areas)
3. Serum testosterone, free testosterone, androstenedione, DHEAS, SHBG, 17OH
progesterone, insulin, 3α-diol G, LH, FSH
4. Haematochemical examinations (haemochrome, glycaemia, azotaemia,
creatinaemia, electrophoretic protidogram, total and fractioned bilirubinaemia,
alkaline phosphatase, transaminases)
5. Menstrual cycle
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Falsetti 1999 (Continued)
6. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 362): ”...were randomly as-
signed in 1:1 ratio...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome assessment was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/110 (3%); 0/55 in finasteride group, 3/
55 in flutamide group, reasons reported.
Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk The study appears to be free of other forms
of bias
Farina 2006
Methods Two randomised, active-controlled studies
Setting
Microbiological and Gynecological Science Department, Gynecology Section Santo
Bambino“ Hospital, University of Catania, Italy
Date of study
Not reported. Duration of intervention 12 months
Participants N = 60 in study A, N = 60 in study B
Mean age = 24 years in study A, 25 years in study B
Inclusion criteria of the trial
• Normal cervical smear, not pregnant
• Euthyroid, spontaneous onset of puberty and sexual development
• Normal renal and hepatic functions, lipids and hormonal evaluation (serum tests)
• Normal gynaecological and dermatological (acne seborrhoea and hirsutism)
screening
Exclusion criteria of the trial
• Contraindication for OCP
• Hormonal treatment, or drugs known to affect plasma sex steroid concentration <
3 months prior to study entry
• Isotretinoin, systemic antibiotics, or other systemic or topical acne treatments (<
6, 4, and 2 weeks prior to study entry respectively)
Randomised
N = 60 in study A, N = 60 in study B
Withdrawals/losses to follow-up
• 19/60 (32%) study A; 8/30 DRSP + EE group, 11/30 DSG + EE group
i) Adverse events: 4/30 DRSP + EE group (2 headache, 1 breast tenderness, 1
amenorrhoea), 8/30 DSG + EE group (5 headache, 2 cellulitis, 1 nausea and vomiting)
ii) Non-compliance: 4/30 DRSP + EE group, 3/30 DSG + EE group
• 21/30 (35%) study B; 10/30 DRSP + EE group, 11/30 DSG + EE group
i) Adverse events: 3/30 DRSP + EE group (2 headache, 1 nausea), 6/30 DSG +
EE group (3 headache, 2 amenorrhoea, 1 cellulitis)
ii) Non-compliance: 7/30 DRSP + EE group, 5/30 DSG + EE group
Baseline data
Not reported. Only figures are provided
Interventions Study A
Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 12 months (30)
Comparator
• OCP (ethinyl estradiol 40 to 30 µg + desogestrel 25 to 125 µg) for 12 months
(30)
Study B
Intervention
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Farina 2006 (Continued)
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 12 months (30)
Comparator
• OCP (ethinyl estradiol 20 µg + desogestrel 0.15 mg) for 12 months (30)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey scores
2. Acne and seborrhoea (Cremoncini 1976)
3. Haematological and hormonal evaluations
4. Gynaecological evaluation
5. Menstrual cycles
6. Adverse events
Denotes outcomes prespecified for this review
Notes Inconsistent and incomplete reporting of outcomes data across intervention groups. No
reliable or usable data. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 20): ”... randomizzati...“.
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
213Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Farina 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk High drop-out rate (32% in study A, 35%
in study B). Intention-to treat analysis (last
observation carried forward)
Comment: although an intention-to treat
analysis was used, the high drop-out rate
represents a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Farquhar 2002
Methods Randomised, active-controlled trial
Setting
Tertiary level fertility clinics in Auckland, New Zealand
Date of study
Between mid 1996 and late 1999. Duration of study 6 months
Participants N = 50
Mean age = 30 years
Inclusion criteria of the trial
• 20 to 38 years with PCOS
• Clomiphene citrate resistance (no ovulation after one or more cycles of 150 mg of
clomiphene citrate from day 2 to day 6 each month), infertility of 12 months duration,
polycystic ovaries on ultrasound scan, a body mass index of 33 kg/m2 for women of
European descent and of 35 kg/m2 for women of Pacific Island or NZ Maori descent,
and normal semen analysis (20 million per millilitre, 96% abnormal forms, and 50%
motility)
Exclusion criteria of the trial
• Other known causes of infertility, including male factor infertility or known tubal
disease
Randomised
N = 50
Withdrawals/losses to follow-up
• 3/50 (6%); 1/29 in laparoscopic ovarian diathermy group, 2/21 in gonadotropins
group
Baseline data (mean (SD))
BMI: laparoscopic ovarian diathermy group 28.3 (3.9), gonadotropins group 27.8 (4.8)
F-G score > 8: laparoscopic ovarian diathermy group 15/29, gonadotropins group 10/
21
Acne present: laparoscopic ovarian diathermy group 13/29, gonadotropins group 8/21
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Testosterone (nmol/L): laparoscopic ovarian diathermy group 2.1 (0.9), gonadotropins
group 2.5 (0.7)
Interventions Intervention
• Laparoscopic ovarian diathermy (29)
Comparator
• 3 cycles of urinary gonadotropins (Metrodin HP, Serono, Rome, Italy) or
recombinant follicle-stimulating hormone (Puregon, Organon, Oss, The Netherlands
or Gonal F, Serono, Rome, Italy) (21)
Outcomes Assessments (2): baseline and end of study
Outcomes of the trial (as reported)
1. Ovulation
2. Pregnancy rates/miscarriage rates
Denotes outcomes prespecified for this review
Notes No separate data on hirsute women, only one secondary outcome was addressed. See
Table 3
Study of Mohiuddin 2007 (second reference under primary reference) is a follow-up
study 6 to 10 years later
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 405): ”Randomization was
performed using computer-generated se-
quences that were sealed in numbered
opaque envelopes“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 405): ”...sealed in numbered
opaque envelopes“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding reported
Comment: although not blinded, the out-
come measurement was not likely to be in-
fluenced by the lack of blinding
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/50 (6%); 1/29 in laparoscopic ovarian
diathermy group, 2/21 in gonadotropins
group
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other
sources of bias
Fruzzetti 1999
Methods Randomised, open, active-controlled trial
Setting
Department of Gynecology and Obstetrics, University of Pisa, Pisa, Italy
Date of study
Not reported. Duration of intervention 1 year
Participants N = 45
Mean age = 22 years
Inclusion criteria of the trial
• Hirsutism
• Normal prolactin levels
Exclusion criteria of the trial
• Clinical signs of virilisation
• Cushing’s syndrome
• Evidence of enzymatic adrenal deficiency
• Drug-induced hyperandrogenism
• Markedly elevated plasma androgen levels
• History compatible with an androgen-producing neoplasm
• Any hormonal treatment in the 6 months prior to study entry
Randomised
N = 45
Withdrawals/losses to follow-up
• 3/45 (7%); 1/15 in finasteride group, 2/15 CPA group, all for personal reasons
Baseline data (mean (SE))
BMI: finasteride group 22.80 (1.08), CPA group 26.20 (1.60), flutamide group 21.70
(0.82)
F-G score: finasteride group 21.60 (2.47), CPA group 28.40 (1.53), flutamide group
18.00 (1.65)
Testosterone (ng/ml): finasteride group 0.59 (0.10), CPA group 0.86 (0.15), flutamide
group 0.54 (0.04)
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Androstenedione (ng/ml): finasteride group 3.48 (0.34), CPA group 4.07 (0.45), flu-
tamide group 2.94 (0.28)
Interventions Intervention
• Finasteride 5 mg/day for 1 year (15)
Comparator 1
• Cyproterone acetate 25 mg/day, day 1 to 10 of menstrual cycle + ethinyl estradiol
20 µg every day for 21 days for 1 year (15)
Comparator 2
• Flutamide 250 mg b.i.d. (15)
Women treated with finasteride and flutamide were advised to use barrier methods
of contraception or an intrauterine device during the study to avoid conception of a
feminised male fetus
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum LH, FSH, prolactin, P, 17β-E2, total testosterone, free testosterone,
androstenedione, DHEAS, dihydrotestosterone, SHBG, and 3α-diol G
3. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 446): ”Women were ran-
domly divided into three treatment groups,
with the Ferriman-Gallwey hirsutism score
used to stratify women before random-
ization to prevent differences in hirsutism
score among groups.“
Comment: stratified form of randomisa-
tion but insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 445): ”...open...study...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 445 and 447): ”...open...
study...“ and ”...the physician performing
the Ferriman-Gallwey score measures was
blinded to the treatment each woman re-
ceived“
Comment: although the assessment of the
Ferriman-Gallwey score was blinded, the
outcome assessment of the other outcomes
was not blinded. We judged this as at un-
clear risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/45 (7%); 1/15 in finasteride group, 2/15
CPA group. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk There was significant baseline imbalance in
F-G score between the groups which was
not acknowledged in the data analysis
Comment: a potential risk of bias cannot
be excluded
Fruzzetti 2010
Methods Randomised, open-label, active-controlled trial
Setting
Outpatient Clinic of Reproductive Endocrinology of the University of Pisa, Pisa, Italy
Date of study
March-November 2008 enrolment. Duration of intervention 6 months
Participants N = 48
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women with PCOS (Ferriman-Gallwey score > 8)
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• PCOS based on Rotterdam Criteria PCOS 2004 and National Institute of Health
criteria (Zawadski 1992)
Exclusion criteria of the trial
• Hypertension
• Glucose intolerance or diabetes mellitus
• History of cardiovascular events
• OCP, antiandrogens, insulin sensitisers, or drugs that might interfere with blood
pressure regulation, lipid profile, or carbohydrate metabolism for the previous 6 months
• Hyperprolactinaemia
• Hypo- or hyperthyroidism
• Congenital adrenal hyperplasia
• Cushing’s syndrome
• Androgen-secreting tumours
Randomised
N = 48
Withdrawals/losses to follow-up
• 1/48 (2%); 1/16 DRSP + EE + metformin group due to gastrointestinal side
effects
Baseline data (mean (SD))
BMI: DRSP + EE group 24.7 (3.0), DRSP + EE + metformin group 24.7 (3.9), DRSP
+ EE + CPA group 23.8 (2.5)
Waist/hip ratio: DRSP + EE group 0.8 (0.2), DRSP + EE + metformin group 0.8 (0.1)
, DRSP + EE + CPA group 0.8 (0.1)
Testosterone (ng/ml): DRSP + EE group 0.7 (0.3), DRSP + EE + metformin group 0.7
(0.2), DRSP + EE + CPA group 0.8 (0.3)
SHBG (ng/ml): DRSP + EE group 29.5 (12.3), DRSP + EE + metformin group 23.7
(10.9), DRSP + EE + CPA group 31.0 (10.3)
Androstenedione (ng/ml): DRSP + EE group 3.1 (1.2), DRSP + EE + metformin group
2.5 (0.9), DRSP + EE + CPA group 3.5 (1.0)
Interventions Intervention
• OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) for 6 months (16)
Comparator 1
• OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + 500 mg metformin 3 times
a day for 6 months (16)
Comparator 2
• OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + cyproterone acetate 12.5
mg (first 10 days of pill strip) for 6 months (16)
All patients were instructed to not modify their diet and physical activity throughout
the trial
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. BMI
2. Waist/hip ratio
3. Blood pressure
4. Total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride
concentrations
219Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fruzzetti 2010 (Continued)
5. Oral glucose tolerance test
6. Plasma samples for glucose and insulin concentrations
7. Total testosterone, androstenedione, and SHBG
8. AUC-insulin, HOMA-IR, and glucose/insulin ratio
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1794): ”The allocation se-
quence of the treatments was decided by a
third party (D.P.) before the recruitment of
patients by random-number tables“
Comment: probably done
Allocation concealment (selection bias) High risk As one of the investigators had access to
the random-number table it is likely that
allocation could be foreseen
Comment: we assessed this as at high risk
of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 1793): ”...randomised, open-
label clinical trial...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 1793): ”...randomised, open-
label clinical trial...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/48 (2%); 1/16 DRSP + EE + metformin
group. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk The study appears to be free of other forms
of bias
Gambineri 2005
Methods Randomised, single-blind, placebo-controlled trial
Setting
Division of Endocrinology, Department of Internal Medicine, S. Orsola-Malpighi Hos-
pital of Bologna, Bologna, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 20
Mean age = 24 years
Inclusion criteria of the trial
• Overweight or obese women with PCOS
• Diagnosis of PCOS made according to the presence of chronic anovulation
(supported by luteal progesterone measurement), oligomenorrhoea/amenorrhoea,
hirsutism (Ferriman-Gallwey score ≥ 8), or elevations in blood levels of total and free
testosterone, and polycystic ovarian morphology at ultrasound
Exclusion criteria of the trial
• Cushing’s syndrome
• Late-onset congenital adrenal hyperplasia
• Hyperprolactinaemia
• Thyroid dysfunction
• Diabetes
• Cardiovascular, renal, or liver disease or gallstones
• Significant change in body weight < 3 months prior to study entry
• Dieting
Randomised
N = 20
Withdrawals/losses to follow-up
• 2/20 (10%); 2/10 in placebo group because of noncompliance
Baseline data (mean (SD))
BMI: octreotide group 35.8 (7.0), placebo group 35.7 (7.5)
F-G score: octreotide group 15.0 (6.8), placebo group 7.1 (3.6)
Testosterone (ng/ml): octreotide group 0.70 (0.26), placebo group 0.60 (0.18)
Androstenedione (ng/dl): octreotide group 335 (66), placebo group 323 (38)
DHEAS (µg/ml): octreotide group 2.25 (0.91), placebo group 2.91 (0.47)
SHBG (nmol/L): octreotide group 21.5 (13.1), placebo group 20.8 (9.2)
Interventions Intervention
• Octreotide-LAR, 10 mg im every month for 6 months (10)
Comparator
• Placebo, saline solution im every months for 6 months (10)
Women were placed, for the first month, on a standardised hypocaloric diet (1200 to
1420 kcal/daily). After this period and while continuing dietary treatment, they were
randomly placed in the treatment arms
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Outcomes Assessments (3): baseline, month 1 and 7
Outcomes of the trial (as reported)
1. Anthropometric parameters (height, weight, waist, and hip circumferences)
2. Hirsutism (Ferriman-Gallwey score)
3. Acanthosis nigricans
4. Computerised tomography of body fat distribution
5. Questionnaire of physical activity
6. Frequency of menses
7. Occurrence of ovulation
8. Serum glucose, insulin, LH, FSH, testosterone, free testosterone,
androstenedione, DHEAS, SHBG, estradiol, progesterone, 17OH progesterone,
cortisol and IGF binding proteins
9. QUICKI, HOMA
10. Adverse events
Denotes outcomes prespecified for this review
Notes 11/20 participants with PCOS were hirsute (8/10 in octreotide group, 3/10 in placebo
group). No separate data on women with hirsutism. See Table 3.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 3855): ”...in a random order.
..“ ”the random allocation sequence to the
two treatments was decided before the re-
cruitment...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk Quote (page 3855: ”One investigator (L.P.)
generated the random allocation sequence
and
administered the drugs (active or placebo)
at the out-patient clinic for the entire pe-
riod of the study, whereas another investi-
gator (A.G.),blinded to group assignment,
enrolled and regularly checked all patients.
“
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The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 3854-5): ”...according to a
single-blind design....“ ”whereas another
investigator (A.G.), blinded to group as-
signment, enrolled and regularly checked
all patients at monthly intervals“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 3855): ”...another investigator
enrolled and regularly checked all patients
at monthly intervals...“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/20 (10%); both in the placebo group be-
cause of non-compliance
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 3861): ”We are indebted
to Novartis Farma S.p.A. (Origgio-Varese,
Italy), who provided both octreotide-LAR
and octreotide.“
Baseline imbalance: Ferriman-Gallwey
score significantly higher (P value = 0.01)
in octreotide than in placebo group
Comment: we judged this as at high risk of
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bias
Gambineri 2006
Methods Randomised, single-blind, placebo and active-controlled trial
Setting
Divisions of Endocrinology and Internal Medicine, Departments of Internal Medicine
and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Italy
Date of study
Not reported. Duration of intervention 12 months
Participants N = 80 (40 from previous study (Gambineri 2004) and ”extending their treatment“)
Mean age = 26 years
Inclusion criteria of the trial
• PCOS according to Rotterdam Criteria PCOS 2004
• Reproductive age 18 to 45 years
• BMI at least 28 kg/m2, and waist circumference at least 88 cm, consistent with an
abdominal fat distribution phenotype
Exclusion criteria of the trial
• Cushing’s syndrome
• Late-onset congenital adrenal hyperplasia
• Hyperprolactinaemia
• Thyroid dysfunction
• Diabetes
• Cardiovascular, renal, or liver disease or gallstones
• Significant change in body weight < 3 months prior to study entry
• Dieting
Randomised
N = 80
Withdrawals/losses to follow-up
• 4/80 (5%); 1/20 in placebo group (non attendance), 3/20 in flutamide group
(increase in transaminases)
Baseline data (mean (SD))
BMI: placebo group 37 (5), metformin group 35 (4), flutamide group 33 (4), metformin
+ flutamide group 35 (5)
Hirsutism score: placebo group 9.3 (4.8), metformin group 13.0 (8.9), flutamide group
14.6 (6.8), metformin + flutamide group 14.5 (6.5)
Total testosterone (nmol/L): placebo group 0.60 (0.27), metformin group 0.65 (0.37),
flutamide group 0.72 (0.23), metformin + flutamide group 0.67 (0.17)
Androstenedione (nmol/L): placebo group 304 (122), metformin group 314 (148),
flutamide group 385 (151), metformin + flutamide group 389 (137)
DHEAS (µmol/ml): placebo group 2.0 (0.1), metformin group 2.2 (0.5), flutamide
group 2.9 (1.4), metformin + flutamide group 2.8 (1.5)
SHBG (nmol/L): placebo group 21.1 (16.8), metformin group 19.9 (11.7), flutamide
group 25.4 (8.7), metformin + flutamide group 22.6 (11.6)
Interventions Intervention
• Placebo for 12 months (20)
Comparator 1
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• Metformin 850 mg b.i.d. for 12 months (20)
Comparator 2
• Flutamide 250 mg b.i.d. for 12 months (20)
Comparator 3
• Metformin 850 mg b.i.d. + flutamide 250 mg b.i.d. for 12 months (20)
Women were placed, for the first month, on a standardised hypocaloric diet (1200 to
1420 kcal/daily). After this period and while continuing dietary treatment, they were
randomly placed in the treatment arms
All women were advised in writing to use non hormonal contraception throughout the
study
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Plasma glucose
2. Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides
3. Computerised tomography of body fat distribution
4. OGTT
5. Serum testosterone, SHBG, androstenedione, DHEAS
6. Hirsutism and menses
7. Anthropometric parameters (height, weight, waist and hip circumferences)
8. Compliance with diet and pharmacological treatment
9. Questionnaire of physical activity
Denotes outcomes prespecified for this review
Notes 40 women were included earlier in a previous study, Gambineri 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3971): ”PCOS women were
randomized to receive...“. ”The allocation
sequence of the treatments was decided by
a third party (A.V.) before the recruitment
of the patients by random number tables.“
Comment: probably done
Allocation concealment (selection bias) High risk As a third party had access to the ran-
dom number tables, allocation conceal-
ment might not have been adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 3971): ”Therefore, the met-
formin plus flutamide group took four
tablets per day, whereas the other groups
took two tablets per day. Metformin, flu-
tamide, and placebo were packaged in sim-
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ilar preparations, and patients were blinded
to the treatments.“
Comment: although the packages looked
similar, the dosing was not similar, therefor
it is unclear if the blinding was effective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 3971): ”All these assessments
were performed by the same researcher (A.
G.), blinded to the treatment, throughout
the study.“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/80 (5%); 1/20 in placebo group (non
attendance), 3/20 in flutamide group (in-
crease in transaminases). Per-protocol anal-
ysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 3979): ”We are indebted to
Laboratori Guidotti SpA, Pisa, Italy, and
Ipsen SpA, Milano, Italy, who provided
metformin, flutamide, and placebo tablets.
“
Baseline imbalance in F-G score, lower in
placebo group
Comment: we judged this as at unclear risk
of bias
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Methods Randomised, open-label, active-controlled trial
Setting
Departments of Endocrinology andMetabolism, All India Institute ofMedical Sciences,
New Delhi, India
Date of study
2000-2001. Duration of intervention 6 months
Participants N = 82
Mean age = 23 years
Inclusion criteria of the trial
• Women with PCOS according to National Institutes of Health National Institute
of Child Health and Human Development 1990 consensus conference criteria
(Zawadski 1992)
• Presence of menstrual disturbances (oligo-/amenorrhoea) and hirsutism
(Ferriman-Gallwey score ≥ 8)
Exclusion criteria of the trial
• Cushing’s syndrome
• Nonclassical adrenal hyperplasia
• Thyroid dysfunction
• Hyperprolactinaemia
• Androgen-secreting tumours
• Any hormonal preparations or drug(s) known or suspected to affect reproductive
or metabolic functions within 60 days of study entry
• Diabetes mellitus or renal, hepatic, or cardiac dysfunction
Randomised
N = 82
Withdrawals/losses to follow-up
• 13/82 (16%); 6/41 in metformin group, 7/41 in spironolactone group
• Dropped out; 4/41 in metformin group, 2/41 in spironolactone group
• Incomplete data, lost to follow-up; 2/41 in metformin group, 5/41 in
spironolactone group
Baseline data (mean (SD))
BMI: metformin group 26.5 (5.6), spironolactone group 25.9 (5.0)
F-G score: metformin group 12.5 (4.9), spironolactone group 12.9 (3.2)
Testosterone (nmol/L): metformin group 3.25 (1.59), spironolactone group 3.57 (0.34)
DHEAS (µmol/L): metformin group 7.0 (3.32), spironolactone group 6.93 (2.75)
Interventions Intervention
• Metformin 500 mg b.i.d. for 6 months (41)
Comparator
• Spironolactone 25 mg b.i.d.for 6 months (41)
All married/sexually active women were advised to use barrier contraception throughout
the study
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Anthropometric assessment (body weight, height, BMI, waist/hip ratio)
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3. Oral glucose tolerance test
4. Serum T4, TSH, LH, FSH, prolactin, testosterone, DHEAS, cortisol, blood
counts, electrolytes, lipids, liver and kidney functions
5. Adverse events
6. Ultrasonography for ovary cysts
Denotes outcomes prespecified for this review
Notes Inconsistency with ’incomplete data/ lost to follow-up’ between Fig 1 and text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2757): ”After baseline evalu-
ation, eligible patients were randomized in
an open-labeled manner by a simple ran-
domization process using computer-gener-
ated random number allocation according
to CONSORT guidelines.“
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (page 2757): ”The allocation con-
cealment was maintained until OGTTwas
done.“
Comment: the method used to conceal
the allocation sequence, that is to de-
termine whether intervention allocations
could have been foreseen in advance of, or
during, enrolment, was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 2757): ”open-labeled man-
ner“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 2758): ”The same observer,
while being blind to the previous score, did
follow-up scoring“ and ”open-labeledman-
ner“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 13/82 (16%); 7/41 in spironolactone
group, 6/41 in metformin group, reasons
reported. Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ghosh 2008
Methods Randomised, active-controlled trial
Setting
Royal Berkshire NHS Foundation Trust, Reading, Berkshire, UK
Date of study
Not reported. Duration of the intervention 6 months
Participants N = 24
Mean age = 33 years
Inclusion criteria of the trial
• Overweight women with PCOS
Exclusion criteria of the trial
• On OCP or antiandrogens
Randomised
N = 24
Withdrawals/losses to follow-up
• Not reported
Baseline data (mean)
BMI: low carbohydrate diet group 33.4, low glycaemic index diet group 31.5
Basal menstrual cycle lengths: low carbohydrate diet group 12 weeks, low glycaemic
index diet group 14 weeks
Interventions Intervention
• Low carbohydrate diet for 6 months
Comparator
• Low glycaemic index diet for 6 months
Outcomes Assessments (7): baseline, month 1, 2, 3, 4, 5, and 6
Outcomes of the trial (as reported)
1. Weight, BMI
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2. Biochemical and endocrine parameters (insulin, testosterone, lipids)
3. Food diaries
4. Menstrual cycle
Denotes outcomes prespecified for this review
Notes Abstract to conference proceedings, limited data reported, unclear how many women
were hirsute. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 279): ”A randomised trial
comparing...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
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Grant 2010
Methods Randomised, active-controlled trial
Setting
Department of Diabetes and Endocrinology, Eastbourne District General Hospital,
Kings Drive, Eastbourne, East Sussex, UK
Date of study
Not reported. Duration of intervention 30 days
Participants N = 42
Mean age = 26 years
Inclusion criteria of the trial
• Women with PCOS, diagnosed based on Rotterdam Criteria PCOS 2004
Exclusion criteria of the trial
• Not reported
Randomised
N = 42
Withdrawals/losses to follow-up
• 1/42 (2%); 0/21 in spearmint tea group, 1/21 in camomile tea group because of
dislike of the flavour
Baseline data (mean (SD))
F-G score: spearmint tea group 17, camomile tea group 17
DLQI index: spearmint tea group 17, camomile tea group 18
Free testosterone (pg/ml): spearmint tea group 5.12 (2.14), camomile tea group 4.98 (2.
84)
Testosterone (ng/ml): spearmint tea group 0.81 (0.39), camomile tea group 0.87 (0.40)
DHEAS (µmol/L): spearmint tea group 184.5 (82.1), camomile tea group 179.5 (85.3)
Interventions Assessments (3): baseline, day 15 and 30
Intervention
• Spearmint tea b.i.d. for 30 days (21)
Comparator
• Camomile tea b.i.d. for 30 days (21)
Outcomes Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Dermatology Quality of Life Index
3. Androgen hormone levels
4. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 187): ”... were randomized by
computer equally into to two groups...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 187): ”...with a standardized
content of dried tea leaves“... ”The re-
searchers were blinded as to the type of tea“
Comment: the report did not provide de-
tail on blinding of participants nor the spe-
cific measures used to blind study person-
nel from knowledge of which intervention
a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 187): ”The researchers were
blinded as to the type of tea“. Participants
were not blinded. Outcomes were assessed
by investigators and participants
Comment: uncertainty about the effective-
ness of blinding of investigators during the
study and the lack of blinding of partici-
pants
We judged this as at a high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/42 lost to follow-up, reason reported.
Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Hamzavi 2007
Methods Randomised, double-blind, within-participant, active-controlled trial
Setting
Department of Dermatology and Skin Science, University of British Columbia and the
Vancouver Coastal Health Research Institute, Canada
Date of study
Not reported. Duration of intervention 6 months
Participants N = 33
Mean age = 41 years
Inclusion criteria of the trial
• Women > 18 years with unwanted facial hair who carried out hair removal of any
kind to their upper lip at least twice a week
• Predominantly dark facial hair
Exclusion criteria of the trial
• Presence of tattoos over or near the upper lip
• Photosensitivity
• Severe acne vulgaris
• Immunosuppression
• Pregnancy
• Lactation
Randomised
N = 33
Withdrawals/losses to follow-up
• 2/33 (6%); 1 because of hyperpigmentation and 1 lost to follow-up
Baseline data
Nothing reported other than skin type and age
Interventions Intervention
• Long-pulsed alexandrite laser every 4 weeks + eflornithine 13.9% cream b.i.d. for
6 months
Comparator
• Long-pulsed alexandrite laser every 4 weeks + vehicle cream b.i.d. for 6 months
Participants were required to discontinue all other modalities of hair removal for 2 weeks
before the first laser treatment session and then throughout the 26-week study period
Outcomes Assessments (7): baseline, week 4, 8, 12, 16, 20, and 24
Outcomes of the trial (as reported)
1. Investigator global assessment; 4-point Likert scale
2. Subjective assessments; 4-point Likert scale
3. Hair counts
4. Adverse events
Denotes outcomes prespecified for this review
Notes Although this study does include laser, it includes laser in both treatment arms and
investigates eflornithine cream as add-on therapy
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 55): ”... assignment of the
color-coded tubes to either the right or left
side of the upper lip was done randomly by
coin toss“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Coin toss.
One toss for each patient to be recruited.
2. Record the successive results of each
coin toss. 3. Put the result of the coin toss
in successive numbered sealed envelopes.
The coin toss result determined which side
of the face was randomized to receive the
treatment cream in a blindedmanner. 4. As
each patient was enrolled, each successive
envelope was opened.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 55): ”All tubes of the same
color code contained the same product,
namely either eflornithine HCl 13.9%
cream or vehicle cream; the only label on
the tubes was the official study title. Pa-
tients and investigators were blinded as
to the overall color code scheme, and the
sealed code was broken only after all statis-
tical analyses.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 55): ”Patients and investiga-
tors were blinded as to the overall color
code scheme, and the sealed code was bro-
ken only after all statistical analyses.“
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/33 (6%), reasons reported. Per-protocol
analysis (within participant comparison)
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 54): ”Dr Lui has been a
speaker for Barrier Therapeutics Canada.
Dr Hamzavi has been a speaker for
Shire Pharmaceuticals and SkinMedica. Dr
Shapiro is a speaker for Shire Pharmaceuti-
cals and Barrier Therapeutics Canada and
has served as a consultant for SkinMedica.
“
Comment: Shire Pharmaceuticals is the
manufacturer of eflornithine 13.9% cream
and a potential risk of bias cannot be ex-
cluded
Harborne 2003
Methods Randomised, active-controlled trial
Setting
University Department of Obstetrics and Gynecology, Royal Infirmary, Glasgow, Scot-
land, UK
Date of study
Not reported. Duration of intervention 12 months
Participants N = 52
Mean age = 31 years
Inclusion criteria of the trial
• Women with PCOS, whose primary complaint was hirsutism
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• The diagnosis of PCOS included at least 2 of the 3 following features:
oligomenorrhoea/amenorrhoea, polycystic ovaries on ultrasound (2), or an elevated
free androgen index
Exclusion criteria of the trial
• Contraindications to either metformin or Dianette (including BMI > 38)
• Use of oral contraception or metformin within the previous 3 months
• Thyroid dysfunction
• Hyperprolactinaemia
• Diabetes mellitus, or late onset congenital adrenal hyperplasia
• Medication known to affect gonadal or adrenal function, or carbohydrate or lipid
metabolism
Randomised
N = 52
Withdrawals/losses to follow-up
• 18/52 (35%); 10/26 in CPA + EE group, 8/26 in metformin group
• Weight gain; 5/26 in CPA + EE group, 0/26 in metformin group
• Blood pressure increase; 1/26 in CPA + EE group, 0/26 in metformin group
• Depression; 1/26 in CPA + EE group, 0/26 in metformin group
• Chest pain; 1/26 in CPA + EE group, 0/26 in metformin group
• Pregnancy; 0/26 in CPA + EE group, 3/26 in metformin group
• Gastrointestinal side effects; 0/26 in CPA + EE group, 8/26 in metformin group
• Lost to follow-up; 2/26 in CPA + EE group, 3/26 in metformin group
Baseline data (mean)
F-G score: CPA + EE group 22.8, metformin group 20.3
BMI: CPA + EE group 31.8, metformin group 31.7
Testosterone (ng/ml): CPA + EE group 3.52, metformin group 3.19
SHBG (nmol/L): CPA + EE group 31.4, metformin group 30.4
Androstenedione (ng/ml): CPA + EE group 11.6, metformin group 11.6
DHEAS (µmol/L): CPA + EE group 7.2, metformin group 6.8
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (26)
Comparator
• Metformin 500 mg 3 times a day for 12 months (26)
Women were also advised to use barrier contraception if randomised to metformin
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Anthropometric measurements of height, weight (BMI), waist/hip ratio, blood
pressure
2. Ferriman-Gallwey score and hair diameter
3. Sebum excretion rate
4. Adverse effects
5. Participants’ perception/status (hirsutism; acne; effects of treatment); VAS
6. Serum concentrations of insulin, glucose, testosterone, SHBG, androstenedione,
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DHEAS, 17-hydroxyprogesterone, cholesterol, triglycerides, LDL cholesterol, HDL
cholesterol, insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-
binding protein 3 (IGFBP-3)
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 4117): ”Patients were block-
randomized (n=10/block) in a 1:1 ratio...
Randomization was by random number ta-
bles“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 4117): ”...patient number
treatment codes were held by a third party
and were allocated individually after ob-
taining written consent. A list of codes was
kept by a third party, and patient names
were checked after completion of the trial“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 18/52 (35%); 10/26 inCPA+EE group, 8/
26 in metformin group. Per-protocol anal-
ysis
Comment: although balanced, high drop-
out rate with per-protocol analysis repre-
sents a potential high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
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appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Heiner 1995
Methods Randomised, double-blind, active-controlled trial
Setting
Departments ofObstetrics andGynecology, InternalMedicine, andAnatomy,University
of California School of Medicine, Los Angeles, California, US
Date of study
Not reported. Duration of intervention 24 weeks
Participants N = 141 screened, 74 randomised
Mean age = 30 years
Inclusion criteria of the trial
• 18 to 45 years
• Any racial background
• Hirsutism in excess of immediate female blood relatives
• Moderate or greater hirsutism (defined by hormonal FG score ≥ 10)
• Negative serum pregnancy test
• Willingness to use a barrier method of contraception if appropriate
• Willingness to refrain from hair removal procedures for at least 3 days before each
study visit
Exclusion criteria of the trial
• Use of sex steroids, adrenal steroids, or spironolactone < 3 months before the study
• Past or current malignancy, cerebral vascular accident, or coronary artery disease
• Uncontrolled hypertension (blood pressure, > 140/95 mmHg)
• Treated or untreated thyroid disease, diabetes mellitus, or drug/alcohol abuse
• Active liver disease (aspartate aminotransferase or alanine aminotransferase, > 50
U/L) or gallbladder disease (prior cholecystectomy permitted)
• Cigarette use, if subject older than 35 years during the study
• Ovarian failure (FSH, > 50 IU/L)
• Acquired adrenal hyperplasia (17-hydroxyprogesterone > 25 nmol/L 1 h after 250
µg iv bolus of Cortrosyn
• Hypercortisolism (fasting cortisol >140 nmol/L 1 mg dexamethasone
administered at 2300 h the evening before testing)
• Cervical dysplasia (moderate or worse)
• Current participation in another clinical trial
Randomised
N = 74
Withdrawals/losses to follow-up
• 10/74 (14%); unclear from which groups
• After 8 weeks further 8/64 (13%), unclear from which group
Baseline data (mean (SE))
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F-G score: nafarelin spray + OCP group 21.9 (1.6), placebo spray + OCP 23.3 (1.7),
nafarelin spray + placebo pill group 24.3 (2.0), placebo spray + placebo pill group 24.9
(1.5)
Interventions Intervention
• Nafarelin nasal spray 400 µg b.i.d. + OCP (norethindrone 1 mg + ethinyl
estradiol) for 24 weeks (16)
Comparator 1
• Placebo nasal spray b.i.d. + OCP (norethindrone 1 mg + ethinyl estradiol) for 24
weeks (16)
Comparator 2
• Nafarelin nasal spray 400 µg b.i.d. + placebo OCP for 24 weeks (14)
Comparator 3
• Placebo nasal spray b.i.d. + placebo OCP for 24 weeks (18)
Outcomes Assessments (4): baseline, week 8, 16, and 24
Outcomes of the trial (as reported)
1. Serum testosterone, free testosterone, androstenedione, DHEAS, LH, FSH,
estradiol, SHBG
2. Ferriman-Gallwey score
3. Hair diameter; measured by light microscopy
4. Hot flush monitoring
5. Bone mineral density of the lumbar spine
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3413): “...assigned by com-
puter-generated randomization code...”
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 3412-13): “...double-masked.
..” “... the placebo spray contained only
the vehicle materials...placebo tablets were
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identical in appearance”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 3412-13): “...double-masked.
..” “... the placebo spray contained only
the vehicle materials...placebo tablets were
identical in appearance”
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote (page 3413): “Intention-to-treat
analysis was employed. The results from
women who were randomized but dropped
out of the study before 8 weeks were not
analyzed”
10/74 (14%)droppedout <8weeks. Losses
8/64 after this period but included in anal-
ysis
Comment: early losses not included in
analysis; high drop-out rate with per-proto-
col analysis represents a potential high risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 3412): “This work was sup-
ported by Syntex Laboratories and USPHS
Grant RR-865. Two investigators were em-
ployed by Syntex Laboratories, Inc
Comment: a potential risk of bias cannot
be excluded
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Methods Randomised, placebo-controlled trial
Setting
University of Rochester School of Medicine and Dentistry and School of Nursing,
Rochester, New York, US
Date of study
Not reported. Duration of intervention 48 weeks
Participants N = 273 screened, 38 randomised
Mean age = 28 years
Inclusion criteria of the trial
• Overweight or obese women with PCOS
• Polycystic ovary syndrome was diagnosed by fewer than 6 menses per year and
evidence of hyperandrogenism
• Minimum body mass index (BMI) of 25 kg/m2
Exclusion criteria of the trial
• Any hormonal medication within the last 2 months before entry into the study
• Subjects actively dieting at time of entry
Randomised
N = 38
Withdrawals/losses to follow-up
• 15/38 (39%); 4/9 in metformin group, 5/11 in lifestyle + placebo group, 4/9 in
lifestyle + metformin group, 2/9 placebo group
• Reasons; adverse events, time commitment, pregnancy, or were unable to be
contacted
Baseline data (mean (SD))
BMI: metformin group 37.1 (4.9), lifestyle + placebo group 40 (7.4), lifestyle + met-
formin group 41.7 (6.2), placebo group 37.1 (4.6)
Waist/hip ratio: metformin group 0.96 (0.07), lifestyle + placebo group 0.9 (0.06),
lifestyle + metformin group 0.89 (0.07), placebo group 0.94 (0.09)
Testosterone (ng/dl): metformin group 61.2 (23.8), lifestyle + placebo group 56.9 (18.
9), lifestyle + metformin group 70.0 (17.1), placebo group 58.1 (17.3)
SHBG (nmol/L): metformin group 22.42 (7.15), lifestyle + placebo group 32.84 (14.
96), lifestyle + metformin group 29.91 (11.74), placebo group 31.19 (10.13)
Interventions Intervention
• Metformin 850 mg b.i.d. for 48 weeks (9)
Comparator 1
• Lifestyle modification + placebo b.i.d. for 48 weeks (11)
Comparator 2
• Lifestyle modification + metformin 850 mg b.i.d. for 48 weeks (9)
Comparator 3
• Placebo b.i.d. for 48 weeks (9)
Outcomes Assessments (8): baseline and every 4 weeks until 48 weeks
Outcomes of the trial (as reported)
1. Evaluate compliance with medication
2. Body weight
3. Side effects
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4. Menstrual diaries
5. Glucose, insulin, testosterone, SHBG, FAI, pregnanediol glucuronide
6. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes All groups had a mean modified Ferriman-Gallwey score > 10, data to be estimated from
Fig 2 in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 423): ” The randomization
schedule was computer generated in blocks
by an independent pharmacy representa-
tive, and block schedule was blinded to the
investigators“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 423): ”... independent phar-
macy representative... packaged and la-
beled according to subject number by the
pharmacy“
Comment: form of central allocation,
probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 423): ”Metformin hydrochlo-
ride ... formulated with the appropriate
dose into capsules by Investigation Phar-
macy Service at theUniversity ofRochester.
Identically appearing placebo capsules were
also formulated“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention (i.e. met-
formin or placebo) a participant received,
however, lifestyle modification was not
blinded for participants and investigators
We judged this as at unclear risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 423): ”Metformin hydrochlo-
ride ... formulated with the appropriate
dose into capsules by Investigation Phar-
macy Service at theUniversity ofRochester.
Identically appearing placebo capsules were
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also formulated“ ... ”Drug and placebo
were packaged and labeled according to
subject number by the pharmacy in a dou-
ble-blind fashion.“
Although participants and investigators
were blinded for metformin or placebo,
they were not blinded for lifestyle modifi-
cation and OCP
Comment: we judged this as at unclear risk
of bias.
Incomplete outcome data (attrition bias)
All outcomes
High risk 15/38 (39%); 4/9 in metformin group,
5/11 in lifestyle + placebo group, 4/9 in
lifestyle + metformin group, 2/9 placebo
group. Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Unclear risk Although participants returnedmonthly to
evaluate compliance and side effects, the
side effects were inadequately reported
Comment: we judged this as at unclear risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Hoeger 2008
Methods 2 randomised, placebo-controlled trials
Setting
Departments of Obstetrics and Gynecology University of Rochester Medical Center,
Rochester, New York, US
Date of study
Enrolment study 1: August 2002 until September 2003, for study 2: May 2006 until
July 2007. Duration of intervention in both studies 24 weeks
Participants N = 79 (study 1: 43, study 2: 36)
Mean age = 16 years in study 1 and 15 years in study 2
Inclusion criteria of the trial
• Obese adolescent women with PCOS (12 to 18 years)
• BMI above the 95th percentile
• Evidence of menstrual irregularity (fewer than 8 menses in the preceding year)
• Clinical or biochemical evidence of hyperandrogenism
Exclusion criteria of the trial
• Other causes of hyperandrogenism and menstrual irregularity
• Hormonal therapy or insulin sensitisers < 2 months prior to study entry
Randomised
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N = 79
Withdrawals/losses to follow-up
Study 1
• 9/43 (21%); 4/10 in metformin group, 1/11 in placebo group, 1/11 in OCP
group, 3/11 in lifestyle group
• Lost to follow-up; 2/10 in metformin group, 1/11 in placebo group, 1/11 in OCP
group, 0/11 in lifestyle group
• Time commitment; 0/10 in metformin group, 0/11 in placebo group, 0/11 in
OCP group, 3/11 in lifestyle group
• Personal reasons; 2/10 in metformin group, 0/11 in placebo group, 0/11 in OCP
group, 0/11 in lifestyle group
Study 2
• 4/36 (11%); 2/18 in metformin group, 2/18 in placebo group
• Gastrointestinal complaints; 1/18 in metformin group, 1/18 in placebo group
• Dose reduction; 1/18 in metformin group, 1/18 in placebo group
Baseline data study 1 (mean (SD))
BMI: metformin group 34.3 (6.5), placebo group 36.1 (7.5), OCP group 37.8 (5.1),
lifestyle group 37.8 (8.2)
F-G score: metformin group 7.8 (2.6), placebo group 12.5 (5.3), OCP group 9.8 (3.5),
lifestyle group 9.2 (1.9)
Testosterone (ng/dl): metformin group 51.3 (13.0), placebo group 61.2 (30.5), OCP
group 63.0 (23.0), lifestyle group 63.9 (29.6)
SHBG (nmol/L): metformin group 23.5 (19.1), placebo group 17.7 (7.4), OCP group
18.0 (11.7), lifestyle group 14.6 (12.6)
Baseline data study 2 (mean (SD))
BMI: metformin group 35.7 (4.9), placebo group 34.1 (4.3)
F-G score: metformin group 10.3 (4.3), placebo group 7.9 (3.1)
Testosterone (ng/dl): metformin group 83.2 (27.8), placebo group 102.6 (22.1)
SHBG (nmol/ml): metformin group 9.6 (11.9), placebo group 10.1 (10.9)
Interventions Study 1
Intervention
• Metformin 850 mg b.i.d. for 24 weeks (10)
Comparator 1
• Placebo b.i.d. for 24 weeks (11)
Comparator 2
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 24 weeks (11)
Comparator 3
• Lifestyle modification for 24 weeks (11)
Study 2
Intervention
• Metformin 1000 mg b.i.d. for 24 weeks (18)
Comparator 1
• Placebo b.i.d. for 24 weeks (18)
All subjects in study 2 were assigned to lifestyle intervention and placed on an OCP
containing 30 µg of ethinyl estradiol and 3.0 mg drospirenone
Outcomes Study 1
Assessments (2): baseline and week 24
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Outcomes of the trial (as reported)
1. Total testosterone, SHBG, lipids, cholesterol, LDL cholesterol, HDL cholesterol,
triglycerides
2. Plasminogen activator inhibitor 1 and highly sensitive C-reactive protein
3. Glucose and oral glucose intolerance test
4. Percentage body fat (dual-energy x-ray absorptiometry)
5. Computed tomogram (CT) for intra-abdominal fat
6. Menstrual data
Study 2
Assessments (2): baseline and week 24
Outcomes of the trial (as reported)
1. Total testosterone, SHBG, lipids, cholesterol, LDL cholesterol, HDL cholesterol,
triglycerides
2. Plasminogen activator inhibitor 1 and highly sensitive C-reactive protein
3. Glucose and oral glucose intolerance test
4. Percentage body fat (dual-energy x-ray absorptiometry)
5. Transabdominal ultrasound to assess ovarian volume
6. Menstrual data
Denotes outcomes prespecified for this review
Notes No subject in the single treatment trial was also included in the combination treatment
trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study 1 quote (page 4300): ”...were ran-
domized to one of four arms by random
number assignment...“
Comment: probably done
Study 2 quote (page 4301): ”Subjects were
assigned by a random number table tomet-
formin or placebo“
Comment: probably done
Allocation concealment (selection bias) Unclear risk Study 1 quote (page 4300): ”Assignment to
metformin or placebo was blinded to sub-
ject and investigator“. No information on
assignment to OCP or lifestyle programme
Study 2. No extra information
The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment
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for both studies, was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study 1 quote (page 4300): ”Metformin
and placebo capsules were prepared by the
Investigational Drug Pharmacy service at
the University of Rochester using a com-
mercially available powdered form of met-
formin or a lactose powder for the placebo,
dispensed into identical capsules“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention regard-
ing metformin or placebo a participant re-
ceived, however, lifestyle modification and
OCPwere not blinded for participants and
investigators. We judged this as at unclear
risk of bias
Study 2 quote (page 4301): ”Assignment.
.. blinded to subject and investigator. ...
capsules prepared by Investigational Drug
Pharmacy service at the University of
Rochester ... powdered ... lactose powder
for placebo, dispensed into identical cap-
sules“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement.
We judged this as at a low risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study 1 quote (page 4300): ”Metformin
and placebo capsules were prepared by the
Investigational Drug Pharmacy service at
the University of Rochester using a com-
mercially available powdered form of met-
formin or a lactose powder for the placebo,
dispensed into identical capsules“
Although participants and investigators
were blinded for metformin or placebo,
they were not blinded for lifestyle modifi-
cation and OCP
Comment: we judged this as at an unclear
risk of bias
Study 2 quote (page 4301): ”Assignment.
.. blinded to subject and investigator. ...
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capsules prepared by Investigational Drug
Pharmacy service at the University of
Rochester ... powdered ... lactose powder
for placebo, dispensed into identical cap-
sules“
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses/withdrawals 13/79 (16%)
Study 1: 9/43 (21%); 4/10 in metformin
group, 1/11 in placebo group, 1/11 inOCP
group, 3/11 in lifestyle group. Per-protocol
analysis
Study 2: 4/36 (11%); 2/18 in metformin
group, 2/18 in placebo group. Per-protocol
analysis
Comment: significant drop-out rate com-
bined with per protocol analysis poses an
unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 4305): ”K.H. reports receiv-
ing lecture fees from EMD Serono and
Organon Pharmaceuticals“. Organon is a
manufacturer of the OCP used in study 1
Comment: a potential risk of bias cannot
be excluded
Holdaway 1985
Methods Randomised, double-blind, active-controlled, cross-over trial
Setting
Department of Endocrinology, Auckland Hospital, Auckland, New Zealand
Date of study
Not reported. Duration of randomised part (second part) 12 months (cross-over at 6
months)
Participants N = 35
Mean age = not reported
Inclusion criteria of the trial
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• Moderate to severe hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 35
Withdrawals/losses to follow-up
• 6/35 (17%); 1/35 during the first 9 months (the non-randomised part), 5/35 in
the randomised part (next 12 months)
• Migraine; 1/35
• Poor response to treatment; 3/35
• Depression; 1/35
• No reason; 1/35
Baseline data
Nothing reported
Interventions All participants received for first 9 months an OCP (50 µg ethinyl estradiol and 2 mg
cyproterone acetate) + 100 mg cyproterone acetate on days 5 to 14 of the menstrual
cycle. After the 9months participants were randomised in a cross-over study (2 treatment
periods of 6 months)
Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) + 25 mg CPA
Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) + placebo
Outcomes Assessments (8): baseline, month 3, 6, 9, 12, 15, and 18
Outcomes of the trial (as reported)
1. Serum testosterone, SHBG, androstenedione, DHEAS
2. Haematology profile, serum electrolytes, liver function tests
3. Ferriman-Gallwey score
4. Subjective self rating; 4-point Likert scale
5. Hair growth assessed by photographic method
6. Weight, blood pressure
7. Adverse events
8. Relapse
Denotes outcomes prespecified for this review
Notes No wash-out period after first 9 months, thereafter cross-over design, but with no wash-
out period. No separate data reported for baseline and end of treatment period for each
of the 3 time periods. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 523): ”... were randomised...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 523): ”...double-blind cross-
over study...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1016): ”...double-blind cross-
over study...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6/35 (17%); 1/35 during the first 9months
(non-randomised period), 5/35 in the ran-
domised period (subsequent 12 months),
reasons reported. Per-protocol analysis
Comment: significant drop-out rate com-
bined with per protocol analysis poses an
unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk Quote (page 528): ”Cyproterone acetate
and Diane® were provided by Schering
(New Zealand) Ltd., who also provided
reagents for cyproterone acetate assay“
Comment: we judged this as at a low risk
of bias
Huber 1985
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology and Department of Dermatology, University
of Vienna, Vienna, Austria
Date of study
Not reported. Duration of intervention 6 months
Participants N = 10
Mean age = not reported
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• Not reported
Randomised
N = 10
Withdrawals/losses to follow-up
• Not reported
Baseline data
Nothing reported
Interventions Intervention
• Cyproterone acetate 300 mg im + OCP (ethinyl estradiol 50 µg + cyproterone
acetate 2 mg) for 6 cycles
Comparator
• Cyproterone acetate 100 mg orally for 10 days + OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg) for 6 cycles
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Serum testosterone, DHEAS, prolactin
2. Hirsutism assessment by determination of hair diameter
Denotes outcomes prespecified for this review
Notes Abstract. Limited data are provided. Unclear if there were 2 groups of 5, see Table 3
Risk of bias
250Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Huber 1985 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 200): ” treated at random...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Ibáñez 2002
Methods Randomised, open-label, active-controlled trial
Setting
Endocrinology Unit and Hormonal Laboratory, Hospital Sant Joan de Déu, University
of Barcelona, Barcelona, Spain
Date of study
Not reported. Duration of intervention 9 months
Participants N = 31
Mean age = 19 years
Inclusion criteria of the trial
251Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ibáñez 2002 (Continued)
• Hyperinsulinaemia on standard 2-hour oral glucose tolerance testing, defined as
peak serum insulin concentration greater than 150 U/ml and/or mean serum insulin
greater than 84 mU/L
• Normal oral glucose tolerance
• Ovarian hyperandrogenism as defined by hirsutism (score ≥ 8 on Ferriman-
Gallwey scale) + elevated serum androstenedione, total testosterone, and/or free
androgen index, 17-hydroxyprogesterone (17-OHP) hyper-response (>160 ng/dl) to
leuprolide acetate, a GnRH agonist
Exclusion criteria of the trial
• BMI > 25 kg/m2
• Thyroid dysfunction
• Hyperprolactinaemia
• A family or personal history of diabetes mellitus
• Late-onset congenital adrenal hyperplasia
• Medication known to affect gonadal or adrenal function, or carbohydrate or lipid
metabolism.
Randomised
N = 31
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: flutamide group 22.3 (0.6), metformin group 22.5 (0.8), flutamide + metformin
group 21.2 (0.6)
F-G score: flutamide group 14.1 (1.0), metformin group 18.0 (1.6), flutamide + met-
formin group 16.2 (0.9)
Testosterone (ng/dl): flutamide group 108 (12), metformin group 132 (17), flutamide
+ metformin group 104 (6)
SHBG (µg/dl): flutamide group 0.8 (0.1), metformin group 0.7 (0.1), flutamide + met-
formin group 0.9 (0.1)
Androstenedione (ng/dl): flutamide group 272 (19), metformin group 274 (26), flu-
tamide + metformin group 336 (27)
DHEAS (µg/dl): flutamide group 231 (15), metformin group 264 (31), flutamide +
metformin group 301 (20)
Interventions Intervention
• Flutamide 250 mg once daily for 9 months (10)
Comparator 1
• Metformin 1275 mg once a day for 9 months (8)
Comparator 2
• Flutamide 250 mg + metformin 1275 mg once a day for 9 months (13)
Outcomes Assessments (5): baseline, month 1, 3, 6, and 9
Outcomes of the trial (as reported)
1. Serum LH, FSH, estradiol, testosterone, androstenedione, DHEAS, SHBG, and
lipid profile
2. Insulin sensitivity (calculated from fasting glucose and insulin data using the
homeostasis model assessment (HOMA)
3. Blood count and liver and kidney function
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4. Ovulation assessment
5. Ferriman-Gallwey score
6. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 2981): ”...were randomized to
receive...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 2871): ”...open-labeled...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 2871): ”...open-labeled...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
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of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ibáñez 2003
Methods Randomised, open-label, active-controlled trial
Setting
Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona,
Spain
Date of study
Not reported. Duration of intervention 9 months
Participants N = 30
Mean age = 16 years
Inclusion criteria of the trial
• Hyperinsulinaemia on a standard 2-hour oral glucose tolerance testing, defined as
peak serum insulin levels > 150 U/ml (29) and/or mean serum insulin > 84 mU/L
• Ovarian hyperandrogenism as defined by a- or oligo-menorrhoea (duration of
menstrual cycles 45 d) and/or hirsutism (Ferriman and Gallwey score > 8, elevated
serum androstenedione, total testosterone, and/or free androgen index and 17-
hydroxyprogesterone hyper response (> 160 ng/dl) to GnRH agonist (leuprolide
acetate)
Exclusion criteria of the trial
• BMI > 25 kg/m2
• Thyroid dysfunction
• Cushing’s syndrome
• Hyperprolactinaemia
• Glucose intolerance
• Family or personal history of diabetes mellitus
• Late onset congenital adrenal hyperplasia
• Intake of medication known to affect gonadal or adrenal function, or
carbohydrate or lipid metabolism; abnormal blood count or serum electrolytes
• Abnormal results in screening tests for liver and kidney function
Randomised
N = 30
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: group 1 21.7 (0.4), group 2 21.7 (0.5)
F-G score: group 1 15.5 (1.0), group 2 14.4 (1.0)
SHBG (µg/dl): group 1 1.0 (0.1), group 2 0.9 (0.1)
Testosterone (ng/dl): group 1 126 (12), group 2 136 (9)
Androstenedione (ng/dl): group 1 271 (24), group 2 296 (33)
DHEAS (µg/dl): group 1 247 (18), group 2 255 (23)
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Interventions Intervention group 1
• 3 months no treatment and then 9 months flutamide 125 mg a day + metformin
1275 mg per day (14)
Comparator
• 9 months flutamide 125 mg a day + metformin 1275 mg per day + 3 months no
treatment (16)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Fasting glucose, insulin, LH, FSH, SHBG, DHEAS, estradiol, testosterone,
androstenedione, and lipid profile
2. Insulin sensitivity (calculated from fasting glucose and insulin data using the
homeostasis model assessment (HOMA)
3. Blood count and liver and kidney function
4. Ovulation assessment
5. Waist/hip ratio
6. Body composition (dual-energy x-ray absorptiometry)
7. Ferriman-Gallwey score
8. Adverse events
Denotes outcomes prespecified for this review
Notes Intervention and comparator are identical, participants ”randomised to“ timing of start
of treatment. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 2601): ”...randomized to...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 2601): ”...open-labeled...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 2601): ”...open-labeled...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ibáñez 2009
Methods Randomised, double-blind, placebo-controlled trial
Setting
Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona,
Spain
Date of study
Not reported. Duration of intervention 24 months
Participants N = 38
Mean age = 20 years
Inclusion criteria of the trial
• Hyperinsulinaemia on a standard 2-hour oral glucose tolerance test, defined as
peak serum insulin levels > 150 U/ml and/or mean serum insulin > 84 U/ml
• Ovarian androgen excess, as defined by: 1) hirsutism (Ferriman-Gallwey score > 8,
amenorrhoea (menses absent for more than 3 months), or oligomenorrhoea (menstrual
cycles > 45 d), 2) high serum androstenedione, total testosterone, or free androgen
index and 3) a 17-hydroxyprogesterone hyper response (> 160 ng/dl) to a GnRH
agonist (leuprolide acetate 500 g sc)
Exclusion criteria of the trial
• Contraceptive or another medication known to affect gonadal or adrenal
function, or carbohydrate or lipid metabolism, < 9 months prior to study entry
• Evidence of thyroid dysfunction, Cushing’s syndrome, or hyperprolactinaemia
• Glucose intolerance, personal history of diabetes mellitus
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• Late-onset adrenal hyperplasia
• Anaemia
• Abnormal serum electrolytes
• Abnormal screening results for liver or kidney function
• Abnormal echocardiogram
Randomised
N = 38
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: pioglitazone group 17.7 (1), placebo group 16.4 (0.9)
F-G score: pioglitazone group 24.3 (0.6), placebo group 23.1 (0.6)
Testosterone (nmol/L): pioglitazone group 2.9 (0.2), placebo group 2.8 (0.2)
SHBG (nmol/L): pioglitazone group 35 (3), placebo group 37 (3)
Androstenedione (nmol/L): pioglitazone group 16.4 (1.3), placebo group 15.9 (1.1)
DHEAS (µmol/L): pioglitazone group 7.1 (0.8), placebo group 7.2 (0.6)
Interventions Intervention
• Pioglitazone 7.5 mg once a day + transdermal contraceptive (ethinyl estradiol 600
µg + norelgestromin 6 mg) + metformin 850 mg per day + flutamide 62.5 mg per day
for 24 months (19)
Comparator
• Placebo once a day + transdermal contraceptive (ethinyl estradiol 600 µg +
norelgestromin 6 mg) + metformin 850 mg per day + flutamide 62.5 mg per day for 24
months (19)
After 12 months the transdermal contraceptive was replaced by an oral contraceptive
(ethinyl estradiol 30 µg + drospirenone 3 mg)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Height, weight, BMI, waist/hip ratio
2. Fasting blood glucose, neutrophil and lymphocyte count, serum insulin, LDL-
and HDL-cholesterol
3. SHBG, testosterone, androstenedione, 17 hydroxyprogesterone, DHEAS, C-
reactive protein, and insulin-like growth factor 1 (IGF-1) were measured together with
alanine- and aspartate aminotransferase, γ -glutamyl transpeptidase, and a screening of
renal function
4. Carotid intima-media thickness
5. RBP4 and vaspin
6. Body composition (dual-energy x-ray absorptiometry) and abdominal fat
distribution (MRI)
7. Adverse effects
Denotes outcomes prespecified for this review
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Notes Quote (page 352): ”After 18 months, the placebo and pioglitazone subgroups were in-
versed (pioglitazone cross-over), and the women in those two subgroups were subran-
domized (1 : 1 ratio) for replacement of flutamide by a second placebo until month 24.
“
We only included the first 18 months as there was no wash-out period between the first
18 months and the last 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 352): ”...randomized (1 : 1
ratio, as described)...“
This refers to reference Ibáñez 2007, which
published the 6-month data
Quote (page 1711): ”...randomly assigned
...After stratification for BMI... randomly
assigned [1:1 ratio, Gran Mos program,
Barcelona Medical Research Institute“
Comment: probably done
Allocation concealment (selection bias) Low risk No additional information is provided in
this paper, but in the earlier published pa-
per Ibáñez 2007: Quote (page 1711): ”The
randomization sequence was known only
to a pharmacist independent to the study
and was thus unknown to the clinically in-
volved investigators“
Comment: pharmacy-controlled alloca-
tion, probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 352): ”All patients and in-
vestigators, except for the study statistician
(ALB), remained blinded to pioglitazone
and flutamide allocation, at least until com-
pletion of the present report. Pioglitazone
and its placebo were packaged in similar
tablets and renewed 3-monthly between 0
and 24 months“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 352): ”Pioglitazone and its
placebo were packaged in similar tablets“
Blinding of participants and key study per-
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sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ibáñez 2011B
Methods Randomised, open-label, active-controlled trial
Setting
Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona,
Spain
Date of study
Not reported. Duration of intervention 4 years, study duration 7 years
Participants N = 38
Mean age = 8 years
Inclusion criteria of the trial
• Girls with low birth weight and precocious pubarche (PP)
• PP due to exaggerated adrenarche, as judged by high serum DHEAS and/or
androstenedione levels
• Weight below 2.9 kg at term birth (38 to 41 weeks) or below 1 SD for gestational
age at preterm birth (33 to 37 weeks)
• BMI less than 22 kg/m2, which corresponds to the 2 SD cutoff in girls aged
approximately 8 years
• Prepuberty (Tanner stage B1)
Exclusion criteria of the trial
• Family or personal history of diabetes
• Evidence for thyroid dysfunction, glucose intolerance, or adrenal hyperplasia
• Medication known to affect gonadal function or carbohydrate metabolism
Randomised
N = 38
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data for whole study group (mean (SEM))
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BMI: 18.4 (0.3)
DHEAS (µg/dl): 102 (6)
Interventions Intervention
• Metformin for 4 years (425 mg/d at dinner time for 2 years and then 850 mg/d
for 2 years), then untreated in years 5 to 7 (19)
Comparator
• Untreated for 5 years, then 1-year treatment with metformin 850 mg/d and no
treatment in 7th year (19)
Outcomes Assessments (15): baseline, every 6 months until end of study
Outcomes of the trial (as reported)
1. Clinical examination, including height measurement with a Harpenden
stadiometer
2. Fasting insulin, insulin-like growth factor 1 (IGF-1), SHBG, DHEAS,
androstenedione, testosterone, lipid profile, and white blood cell count
3. Body composition; dual-energy x-ray absorptiometry
4. Subcutaneous and abdominal fat distribution (MRI)
5. Presence of polycystic ovarian morphology; abdominal ultrasound
6. Presence of PCOS; presence of clinical/biochemical androgen excess and either
oligomenorrhoea (cycles 45 d) or amenorrhoea (no menses for 3 months), besides
exclusion of disorders known to potentially cause the same phenotype, such as
hyperprolactinaemia and 21-hydroxylase deficiency
Denotes outcomes prespecified for this review
Notes Intervention and comparator are identical, participants “randomised to” timing of start
of treatment. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page E1263): “... randomly as-
signed...”. Authors refer to an earlier pa-
per of 2004 “were assembled by randomiza-
tion (1:1 ratio). An assignment list was pro-
duced before the start of each study by the
GranMos program from Barcelona’s Medi-
cal Research Institute; the investigators fol-
lowed the sequence in this list, and patients
were consecutively included as either un-
treated or treated according to their posi-
tions on this list. At the time of deciding
about a patient’s inclusion, the investiga-
tors had no access to the next treatment as-
signment in the sequence
Comment: probably done
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Allocation concealment (selection bias) Low risk See above. Formof central allocation, prob-
ably done.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page E1262): ”...open-label...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page E1262-3): ”...open-label...“.
MRI scans were performed by the same op-
erator (blinded to the treatment allocation)
, and all images were analyzed by the same
radiologist (also blinded to the allocation.”
Comment: although for certain outcomes,
the measurement was blinded for the re-
maining outcomes the measurement is
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ibáñez 2012
Methods Randomised, open-label, active-controlled trial
Setting
Adolescent Endocrinology Unit of Sant Joan University Hospital, Barcelona, Spain
Date of study
Not reported. Duration of intervention 6 months
Participants N = 34
Mean age = 16 years
Inclusion criteria of the trial
• Girls with hyperinsulinaemic androgen excess
• Hyperinsulinaemia, defined as fasting insulinaemia above 15 µU/ml and/or a
peak insulinaemia above 150 µU/ml, and/or mean insulinaemia above 84 µU/ml on a
2-horal glucose tolerance test
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• Presence of both clinical and biochemical androgen excess, as defined by the
following: hirsutism score > 8 (Ferriman-Gallwey), amenorrhoea (no menses for 3
months), or oligomenorrhoea (menstrual cycles > 45 day); and high circulating levels
of androstenedione or testosterone in the follicular phase (day 3 to 7) or after 2 months
of amenorrhoea
Exclusion criteria of the trial
• Evidence of anaemia
• Thyroid dysfunction
• Bleeding disorder
• Cushing syndrome
• Hyperprolactinaemia
• Glucose intolerance; diabetes mellitus
• Late-onset adrenal hyperplasia
• Abnormal electrolytes
• Abnormal screening of liver or kidney function
• Use of medication affecting gonadal or adrenal function, or carbohydrate or lipid
metabolism
• Pregnancy
Randomised
N = 34
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: EE-CPA group 23.0 (0.8), PioFluMet group 22.6 (0.6)
F-G score: EE-CPA group 13.5 (0.9), PioFluMet group 14.0 (0.9)
Acne score: EE-CPA group 2.2 (0.2), PioFluMet group 2.3 (0.2)
SHBG (nmol/L): EE-CPA group 23.0 (3), PioFluMet group 28 (3)
Testosterone (ng/dl): EE-CPA group 58 (7), PioFluMet group 63 (7)
Androstenedione (ng/dl): EE-CPA group 455 (32), PioFluMet group 474 (44)
DHEAS (µg/dl): EE-CPA group 283 (32), PioFluMet group 287 (29)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (17)
Comparator
• Pioglitazone 7.5 mg + flutamide 62.5 mg + metformin 850 mg for 6 months (17)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Weight, height, BMI
2. Ferriman-Gallwey score
3. Acne score; Leeds grading scale (O’Brien 1998)
4. Glucose, insulin, lipid profile
5. SHBG, testosterone, androstenedione, DHEAS
6. C-reactive protein, IGF-1, leptin, high molecular weight adiponectin, and
follistatin, blood count and liver and kidney function
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7. Carotid intima-media thickness
8. Body composition (dual-energy x-ray absorptiometry) and abdominal fat
distribution (MRI)
9. Gene expression in longitudinal biopsies of subcutaneous adipose tissue at the
abdominal level (RT-PCR)
Denotes outcomes prespecified for this review
Notes All of the participants in this study are included in 4 further studies (see under primary
reference)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3631): ”Randomization was
performed with the SealedEnvelope pro-
gram (Sealed Envelope Ltd., London, UK)
(http://www.SealedEnvelope.com), using
randompermuted blockswith strata for age
and BMI.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 3631): ”Randomization was
performed with the SealedEnvelope pro-
gram (Sealed Envelope Ltd., London, UK)
(http://www. SealedEnvelope.com), using
randompermuted blockswith strata for age
and BMI.“
Comment: form of central allocation,
probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 3630): ”...open-label ...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 3630-2): ”...open-label...“
and ”Longitudinal ultrasound scans of the
carotid arteries were obtained by the same
investigator (blinded to treatment alloca-
tion“ and ”All scans were performed by the
same operator, and all images were analyzed
by the same radiologist (both blinded to
treatment allocation).“
Comment: although the measurement was
blinded for certain outcomes, for the re-
maining outcomes the measurement is
likely to be influenced by the lack of blind-
ing
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up. Intention-to-treat
analysis
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Iraji 2005
Methods Randomised, placebo-controlled, within-participant trial
Setting
Dermatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Date of study
Not reported. Duration of the intervention 6 months
Participants N = 35
Age range = 19 to 40 years
Inclusion criteria of the trial
• Idiopathic hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 35
Withdrawals/losses to follow-up
• 5/35 (14%); due to no effect
Baseline data
Nothing reported
Interventions Intervention
• Finasteride cream 0.5% b.i.d. for 6 months
Comparator
• Placebo cream b.i.d. for 6 months
Outcomes Assessments (4): baseline, month 2, 4, and 6
Outcomes of the trial (as reported)
1. Hair density; number of terminal hairs in a 1 cm2 area
2. The subjective view of the effect of the medication; by questioning about the
number of times the patient had shaved or clipped hairs per week
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3. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 337): ”were chosen randomly
and blindly“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 337-8): ”...blindly...“ ”The fi-
nal cream contained 0.5% finasteride. 30g
ofmixture was put into a tube. The placebo
cream consisted of the Dermabase alone
in the same size and type of tube. No dif-
ference in color or texture was evident be-
tween the placebo andmedication contain-
ing creams“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/35 (14%) dropped out due to lack of ef-
fect. Per-protocol analysis
Comment: moderate drop-out rate with
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per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Jackson 2007
Methods 2 randomised, double-blind, vehicle-controlled trials
Setting
Multi-centre (18) in the US (17) and Spain (1)
Date of study
Not reported. Duration of intervention 24 weeks with 8 weeks follow-up
Participants N = 594
Age range = 18 to 83 years
Inclusion criteria of the trial
• Women of at least 16 years of age with a clinical diagnosis of facial hirsutism
• An average hair density of at least 5 hairs per cm2 on both the chin and upper lip
as assessed by video image analysis
• Customary frequency of hair removal of at least twice per week
• Good general health
• A negative serum or urine pregnancy test for women of child-bearing age
• A score of at least 20 on a VAS ranging from 0 (not bothered) to 100 (extremely
bothered) for the question: ”How much are you bothered by your facial hair?“
Exclusion criteria of the trial
• Not reported
Randomised
N = 594
Withdrawals/losses to follow-up
• 86/594 (14%); 10% in eflornithine group and 13% in vehicle group (no exact
numbers)
Baseline data
No data regarding hirsutism score or hormone levels
Interventions Intervention
• Eflornithine HCl 13.9% cream b.i.d. for 24 weeks with 8 weeks follow-up (335 =
N that completed the study)
Comparator
• Vehicle b.i.d. for 24 weeks with 8 weeks follow-up (173 = N that completed the
study)
During the study, subjects were permitted to continue their normal hair removalmethod;
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however, shaving and cuttingwere not permittedwithin 24hours of 1st day of a scheduled
study visit, plucking within 48 hours, or bleaching within 1 week of the first day of a
scheduled visit
Outcomes Assessments (7): baseline, weeks 2, 4, 8, 16, 24, and 32
Outcomes of the trial (as reported)
1. Physician’s Global Assessment (photographic assessment); 4-point Likert scale
2. Patient reported outcome (PRO); ESTEEM (Exchanges of affection, Social
interactions, Time spent removing facial hair, Encountering new people, Engaging in
work or school, Minimizing overall bother with facial hair)
Denotes outcomes prespecified for this review
Notes Unclear how many started in each group, data represent only those that finished. This
is the same study as Wolf 2007, but partly covering other outcomes. The number of
participants completing the study are not consistent in the 2 papers
ESTEEM is a modification of the Bother Assessment in Skin Conditions (BASC) scale
(developed and used in a study on the impact of hyperpigmentation) and consists of 6
questions to cover the discomfort felt in four social situations and bother due to removing
facial hair. Each question elicits responses on a visual analogue scale (VAS), in which 0
is ’not bothered’ and 100 is ’extremely bothered’ (Caro 1996)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 977): ”Subjects were random-
ized to receive...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication (quote):
”Subjects were assigned treatment by a
computer-generated randomization sched-
ule restricted to ensure distribution of eflor-
nithine 15% cream and its vehicle in a 2:
1 ratio, respectively, within each investiga-
tional site.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
After e-mail communication (quote):
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”Subject numbers and numbers identifying
study medication containers corresponded
directly.“ and ” The second panel of the
tear-off part of the label was a sealed enve-
lope concealing the identity and lot num-
ber of the treatments. These tear-off por-
tionswere to be affixed to the subjectsCRFs
and opened only in the case of a medical
emergency in which the investigator had
determined that the information was abso-
lutely necessary, i.e., that it would alter the
subjects immediate management.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 976): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After e-mail communication (quote):
”Blinding of the eflornithine 15% cream
and its vehicle was assured by the fact
that both study medications were packaged
in identically appearing 15g plastic tubes
bearing three-panel, two-part double-blind
labels. Labels affixed to the tubes (the only
label to which subjects had access) con-
tained no evidence of the identity of the
contents... Eflornithine 15% cream and its
vehicle were matching cream formulations
and it was not considered possible to differ-
entiate one treatment from the other solely
by tactile or visual evaluation. The proto-
col for this study specified that dispens-
ing of study medications at the investiga-
tional site was to be done by a staff mem-
ber whowas not responsible for conducting
any of the clinical evaluations. Therefore,
the chances of the investigator equating a
particular level of response with what he/
she considered to be a particular treatment
was minimal.“
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Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 976): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
After e-mail contact (quote): see above
Outcomes were investigator-assessed as
well as participant-assessed (menstruation).
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 86/594 (14%); 10% in eflornithine group
and 13% in vehicle group (no exact num-
bers). Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 976 and 981): ”From the
Bristol Myers-Squibb Pharmaceutical Re-
search Institute...“ and ”This workwas sup-
ported in part by a grant from Bristol-My-
ers Squibb“
Comment: a potential risk of bias cannot
be excluded
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Methods Randomised, double-blind, active and placebo-controlled trial
Setting
Department of Dermatology, Shaheed Faghihi hospital, Shiraz, Iran
Date of study
Not reported. Duration of intervention 12 weeks
Participants N = 45
Mean age = 29 years
Inclusion criteria of the trial
• Mild to moderate forms of idiopathic hirsutism localised to the face
• Normal androgen levels
Exclusion criteria of the trial
• PCOS
Randomised
N = 45
Withdrawals/losses to follow-up
• 7/45 (16%); 4/15 in fennel 1% group, 0/15 in fennel 2% group, 3/15 in vehicle
group
• Reasons unreported
Baseline data
Area involved
Chin: fennel 1% group 7/11, fennel 2% group 10/15, vehicle 6/15
Cheek: fennel 1% group 2/11, fennel 2% group 7/15, vehicle 3/15
Upper lip: fennel 1% group 2/11, fennel 2% group 4/15, vehicle 3/15
Interventions Intervention
• Fennel 1% cream b.i.d. for 12 weeks (15)
Comparator 1
• Fennel 2% cream b.i.d. for 12 weeks (15)
Comparator 2
• Vehicle cream b.i.d. for 12 weeks (15)
Outcomes Assessments (4): baseline, week 4, 8, and 12
Outcomes of the trial (as reported)
1. Patient’s subjective satisfaction
2. Density (hair diameter) and hair growth
Denotes outcomes prespecified for this review
Notes Individual participant data are reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 456): ”...randomly assigned..
.“
Comment: insufficient detail was reported
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about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 456): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 456): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7/45 (16%); 4/15 in fennel 1%group, 0/15
in fennel 2% group, 3/15 in vehicle group.
Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) High risk Patient’s subjective satisfaction and hair
growth rate were prespecified outcomes but
not reported
Comment: we judged this as at a high risk
of bias
Other bias Low risk Quote (page 458): ”This project was un-
dertaken by the financial support of Shiraz
University of Medical Sciences“
Comment: we judged this as at a low risk
of bias
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Methods Randomised controlled trial
Setting
Sahlgrenska University Hospital and Sahlgrenska Academy at University of Göteborg,
Sweden
Date of study
Recruitment between November 2005 and January 2008. Duration of intervention 16
weeks with 16 weeks follow-up
Participants N = 84
Mean age = 30 years
Inclusion criteria of the trial
• PCOS, ultrasound-verified polycystic ovaries with 12 follicles 2 mm to 9 mm
and/or an ovarian volume of 10 ml in one or both ovaries, together with either oligo/
amenorrhoea and/or clinical signs of hyperandrogenism (hirsutism or acne)
• Hirsutism was defined as a Ferriman-Gallwey score of 8, presence of acne was
defined by positive response to the question ”Do you have acne?“
Exclusion criteria of the trial
• Age > 38 years
• Any pharmacological treatment within 12 weeks
• Breast feeding within 24 weeks of entering the study
• Cardiovascular disease
• Diabetes mellitus
• Endocrine or neoplastic causes of hyperandrogenaemia, including androgen-
secreting tumours, Cushing’s syndrome, congenital adrenal hyperplasia, and
hyperprolactinaemia
Randomised
N = 84
Withdrawals/losses to follow-up
• 25/84 (30%); 9/33 in acupuncture group, 12/34 in exercise group, 4/17 in no
intervention group
• Moved from area; 3/33 in acupuncture group, 0/34 in exercise group, 1/17 in no
intervention group
• Personal reasons; 3/33 in acupuncture group, 8/34 in exercise group, 3/17 in no
intervention group
• Pregnancy; 0/33 in acupuncture group, 1/34 in exercise group, 0/17 in no
intervention group
• Diet; 1/33 in acupuncture group, 0/34 in exercise group, 0/17 in no intervention
group
• Pharmacological treatment; 2/33 in acupuncture group, 2/34 in exercise group, 0/
17 in no intervention group
• Other disease; 0/33 in acupuncture group, 1/34 in exercise group, 1/17 in no
intervention group
Baseline data (mean (SD))
BMI: acupuncture group 29.1 (8.83), exercise group 27.7 (6.44), no intervention group
26.8 (5.56)
F-G score: acupuncture group 12.1 (8.06), exercise group 13.1 (7.99), no intervention
group 10.1 (5.20)
Acne yes/no: acupuncture group 19/28, exercise group 15/29, no intervention group
11/15
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Testosterone (ng/ml): acupuncture group 0.40 (0.16), exercise group 0.45 (0.19), no
intervention group 0.47 (0.21)
Free testosterone (pg/ml): acupuncture group 7.27 (4.05), exercise group 7.81 (3.74),
no intervention group 7.58 (4.04)
DHEAS (µg/ml): acupuncture group 1.72 (0.67), exercise group 1.93 (0.99), no inter-
vention group 1.70 (0.67)
SHBG (nmol/L): acupuncture group 42.4 (25.3), exercise group 40.5 (18.8), no inter-
vention group 45.3 (18.96)
Interventions Intervention
• Low-frequency electro-acupuncture, 14 treatments over 16 weeks (33)
Comparator 1
• Regular exercise at least 3 times a week for 30 minutes for 16 weeks (34)
Comparator 2
• No active intervention (17)
All participants received general information concerning the benefits of regular physical
exercise and were instructed to complete a physical exercise diary during weeks 1 to 32
of the study
Outcomes Assessments (3): baseline, week 16 and 32
Outcomes of the trial (as reported)
1. BMI
2. Ferriman-Gallwey score
3. Presence of acne
4. Serum DHEAS, androstenedione, testosterone, free testosterone,
dihydrotestosterone, estrone, estradiol, LH, FSH, SHBG
5. Menstrual bleeding
6. Maximum oxygen uptake
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page E38): ”...were randomly al-
located in a 2:2:1 ratio...“ and ”To en-
sure equal proportions of age and body
mass index (BMI) in each study arm, ran-
domization was stratified by those vari-
ables. Computer-generated randomization
within each stratum was conducted using
permuted blocks of five and was concealed
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until interventions were assigned“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not feasible
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 25/84 (30%); 9/33 in acupuncture group,
12/34 in exercise group, 4/17 in no inter-
vention group. Reasons reported, per-pro-
tocol analysis
Comment: high drop-out rate with per-
protocol analysis represents a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 44): ”This study was financed
by grants from the Osher Center for In-
tegrative Medicine, the Swedish Medical
Research Council ..., the Novo Nordisk
Foundation, Wilhelm and Martina Lund-
grens’ Science Fund, the Hjalmar Svensson
Foundation, the Tore Nilson Foundation,
the Åke Wiberg Foundation, the Adlerbert
Research Foundation, the Ekhaga Founda-
tion, and the Swedish Federal Government
Under Letters of Understanding Agree-
ment of Medical Education ... and the Re-
gional Research and Development Agree-
ment ...).“
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Comment: we judged this as at a low risk
of bias
Kaiser 1984
Methods Randomised, active-controlled trial
Setting
Department ofGynecology andEndocrinology, StiftungDeutscheKlinik fürDiagnostik
GmbH, Wiesbaden, Germany
Date of study
Not reported. Duration of intervention 12 months
Participants N = 80
Mean age = 30 years
Inclusion criteria of the trial
• Women 19 to 47 years with acne, seborrhoea, diffuse hair loss, and/or hirsutism
Exclusion criteria of the trial
• Androgen-producing tumour
Randomised
N = 80
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data
Duration of the virilisation symptoms 8 to 9 years
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + chlormadinone acetate 2 mg) for 12 months (41)
Comparator
• OCP (norethisterone 1 mg and mestranol 50 µg) for 12 months (39)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Effect on acne, seborrhoea, alopecia, and/or hirsutism; 3-point Likert scale
2. Adverse events
Denotes outcomes prespecified for this review
Notes Report of 2 studies. First study, all participants received the intervention, in the 2nd
study participants were randomised. No wash-out period between the 2 studies. Unclear
how many women were hirsute. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 652): ”...erfolgte nach eine
Randomisierungsplan...“
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Kaiser 1984 (Continued)
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Kaya 2010
Methods Randomised, active-controlled trial
Setting
Ufuk University, Faculty of Medicine, Department of Obstetrics and Gynecology, Ufuk,
Turkey
Date of study
Not reported. Duration of intervention 3 months
Participants N = 80 assessed for eligibility, 64 randomised
Mean age = 27 years
Inclusion criteria of the trial
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Kaya 2010 (Continued)
• PCOS
• PCOS diagnosis based on Rotterdam Criteria PCOS 2004
• Hirsutism was determined by a modified Ferriman-Gallwey score > 7
Exclusion criteria of the trial
• Nonclassic adrenal 21-hydroxylase deficiency
• Hyperprolactinaemia
• Androgen-secreting tumours
• Diabetes
• Congenital adrenal hyperplasia
• Thyroid disorders
• Cushing’s syndrome
• Infectious diseases
• Hypertension
• Smoking
• Family history of cardiovascular disease
• Hepatic or renal dysfunction
Randomised
N = 64
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: atorvastatin group 24.0 (5.4), simvastatin group 24.2 (4.2)
F-G score: atorvastatin group 10 (2), simvastatin group 9 (4)
Waist/hip ratio: atorvastatin group 0.79 (0.09), simvastatin group 0.78 (0.07)
DHEAS (µg/dl): atorvastatin group 365.6 (84.6), simvastatin group 326.4 (71.5)
Testosterone (ng/ml): atorvastatin group 0.87 (0.35), simvastatin group 0.89 (0.46)
Interventions Intervention
• Atorvastatin 20 mg once a day for 3 months (32)
Comparator
• Simvastatin 20 mg once a day for 3 months (32)
Outcomes Assessments (2): baseline and month 3
Outcomes of the trial (as reported)
1. BMI, waist/hip ratio
2. FSH, LH, prolactin, total testosterone, DHEAS, 17-OH-progesterone, TSH,
SHBG, lipid profile and basal insulin levels
3. Oral glucose tolerance test
4. HOMA-IR
5. FAI
6. Serum malondialdehyde, total cholesterol, LDL cholesterol, HDL cholesterol,
triglycerides
Denotes outcomes prespecified for this review
Notes -
Risk of bias
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Kaya 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 162): ”... were randomized to
two groups by an allocation sequence gen-
erated from a random number table“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 162): ”...assigned through
consecutively numbered opaque, sealed en-
velopes.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Kelekci 2012
Methods Randomised, active-controlled trial
Setting
DermatologyClinic andDepartment ofObstetrics andGynecology,Numune Education
and Research Hospital, Seyhan Practice Center, Adana, Turkey
Date of study
August 2006 until May 2009. Duration of intervention 6 months
Participants N = 296 assessed for eligibility, 166 randomised
Mean age = 23 years
Inclusion criteria of the trial
• Nulligravid women 17 to 35 years with moderate-to-severe hirsutism
• Not pregnant and not will to conceive
Exclusion criteria of the trial
• Smoking
• Thyroid disease
• Breast or endometrium cancer
• Previous treatment for hirsutism
• Active liver disease
• History of thromboembolic disease
• Diabetes, adrenal disorders, hyperprolactinaemia, late-onset congenital adrenal
hyperplasia
Randomised
N = 166
Withdrawals/losses to follow-up
• 22/166 (13%); 10/55 EE/DRSP + CPA group, 11/55 EE/DRSP + spironolactone
group, 11/56 EE/CPA + CPA
• Cost and fear of weight gain; 4/55 EE/DRSP + CPA group, 3/55 EE/DRSP +
spironolactone group, 4/56 EE/CPA + CPA
• Lost to follow-up; 6/55 EE/DRSP + CPA group, 8/55 EE/DRSP +
spironolactone group, 7/56 EE/CPA + CPA
Baseline data (mean (SD))
Modified F-G score: EE/DRSP + CPA group 16.58 (6.45), EE/DRSP + spironolactone
group 13.75 (5.25), EE/CPA + CPA 14.04 (5.47)
Testosterone (ng/ml): EE/DRSP + CPA group 0.87 (0.20), EE/DRSP + spironolactone
group 0.85 (0.17), EE/CPA + CPA 0.79 (0.23)
DHEAS (µg/ml): EE/DRSP + CPA group 214.56 (64.60), EE/DRSP + spironolactone
group 199.94 (40.83), EE/CPA + CPA 189.72 (42.21)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + 100 mg cyproterone acetate
for 6 months (55)
Comparator 1
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + 100 mg spironolactone for
6 months (55)
Comparator 1
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + 100 mg cyproterone
acetate for 6 months (56)
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Kelekci 2012 (Continued)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Serum total testosterone, DHEAS, and 17-OH progesterone
3. Change in ovarian morphology
4. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 178): ”According to a
computer-generated randomization table,
women were randomly assigned to three
treatment groups...“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 178): ”Group allocation was
predetermined and placed in consecutively
numbered opaque, sealed envelopes. The
next consecutive envelope was drawn after
the patient consented to randomization.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 178): ”Randomization was
carried out blindly with respect to the pa-
tient’s clinical features while patients were
not blind to treatment regimens.“ and
”Hirsutism was always evaluated by the
same blinded physician using the mFGS“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
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Kelekci 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 178): ”Randomization was
carried out blindly with respect to the pa-
tient’s clinical features while patients were
not blind to treatment regimens.“ and
”Hirsutism was always evaluated by the
same blinded physician using the mFGS“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 22/166 (13%); 10/55 EE/DRSP + CPA
group, 11/55 EE/DRSP + spironolactone
group, 11/56 EE/CPA + CPA. Reasons re-
ported. Per-protocol analysis
Comment: moderate drop-out rate with
per-protocol analysis represents an unclear
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Kelly 2002
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Setting
Stobhill Hospital, North Glasgow University NHS Trust, Glasgow, UK
Date of study
Not reported. Duration of intervention 2 phases of 6 months with 2 months wash-out
in between
Participants N = 16
Mean age = not reported
Inclusion criteria of the trial
• PCOS with hirsutism
• PCOS defined as androgen excess (total testosterone > 3.6 nmol/L or a free
androgen index (FAI) ≥ 9%) with ovulatory dysfunction (less than 6 menstrual cycles
per year) once specific disorders, such as adult onset congenital adrenal hyperplasia,
hyperprolactinaemia and androgen-secreting neoplasia had been excluded
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Kelly 2002 (Continued)
• Hirsutism defined as Ferriman-Gallwey score > 8
• Previously noted no improvement in hirsutism following 6 months of OCP
(ethinyl estradiol 35 mg, cyproterone acetate 2 mg)
Exclusion criteria of the trial
• Treatment for hirsutism
Randomised
N = 16
Withdrawals/losses to follow-up
• 6/16 (38%); 3 for non-compliance, 3 for no effect (in first phase on placebo)
Baseline data (mean (SEM))
F-G score: 17.7 (1.4)
Interventions Intervention
• Metformin 500 mg at start up to 3 times a day for 6 months
Comparator
• Placebo for 6 months
After 6 months, 2 months wash-out, and then cross-over for another 6 months
Outcomes Assessments (8): baseline, month 2, 4, 6, 8, 10, 12, and 14
Outcomes of the trial (as reported)
1. Menstrual history
2. Weight, waist-hip ratio, and blood pressure
3. Compliance
4. Hair growth; averaging the length of up to 5 hairs removed from the chin
5. Ferriman-Gallwey score
6. Participant’s self assessment; 5-point Likert scale
7. Glucose, gonadotrophins, total testosterone, DHEAS, androstenedione, SHBG,
total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides
Denotes outcomes prespecified for this review
Notes No end of first-phase data, nor baseline data for 2nd phase. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 147): ”The pharmacist ran-
domised the subjects by coin tossing in
batches of four in a four square design to
metformin or an identical placebo (BMS,
Hounslow, UK)“
Comment: probably done
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Kelly 2002 (Continued)
Allocation concealment (selection bias) Low risk Pharmacy-controlled randomisation
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 147): ”double-blind“ and ”to
metformin or an identical placebo...“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/16 (38%); 3 for non-compliance, 3 for
no effect (in first phase on placebo)
Comment: high drop-out rate with per-
protocol analysis represents a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 221): ”We would also like to
thank BMS (Hounslow, UK) for supplying
metformin and placebo preparations.“
Comment: we judged this as at a low risk
of bias
Kjøtrød 2004
Methods Randomised, double-blind, placebo-controlled study
Setting
IVF Unit, Department of Obstetrics and Gynaecology, Trondheim University Hospital,
Trondheim, Norway
Date of study
Recruitment between January 2001 and June 2002. Duration of intervention 16 weeks
Participants N = 73
Mean age = 30 years
Inclusion criteria of the trial
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Kjøtrød 2004 (Continued)
• Infertile women with PCOS
• PCOS; polycystic with at least 10 follicles 2 ± 10 mm in diameter, and increased
density and area of ovarian stroma determined by the use of ultrasound; oligo/
amenorrhoea; one of the following 5 criteria had to be fulfilled: testosterone > 2.0
nmol/L, SHBG) < 30 nmol/L, LH/FSH ratio > 2, fasting insulin C-peptide > 1.0
nmol/L or hirsutism
• Hirsutism was defined as the need to remove unwanted facial hair at least once a
week
Exclusion criteria of the trial
• Diabetes mellitus
• Renal insufficiency (creatinine > 130 mmol/L)
• Liver disease (alanine aminotransferase > 80 U/L)
• Treatment with oral glucocorticoids
• Hyperprolactinaemia
• Abnormal thyroid function tests
• Congenital adrenal hyperplasia
• Androgen-secreting tumours
Randomised
N = 73
Withdrawals/losses to follow-up
• 10/74 (14%); 2/15 in normal weight placebo group, 4/18 in normal weight
metformin group, 2/21 in obese placebo group, 2/19 in obese metformin group
• Economic reasons; 0/15 in normal weight placebo group, 0/18 in normal weight
metformin group, 2/21 in obese placebo group, 2/19 in obese metformin group
• Pregnancy; 2/15 in normal weight placebo group, 4/18 in normal weight
metformin group, 0/21 in obese placebo group, 0/19 in obese metformin group
Baseline data
N with hirsutism: 10/31 in metformin group, 13/32 in placebo group
N with testosterone > 2 nmol/L: 22/31 in metformin group, 19/32 in placebo group
N with SHBG < 30 nmol/L: 20/31 in metformin group, 18/32 in placebo group
Interventions Intervention
• Metformin 500 mg b.i.d. for 16 weeks (37)
Comparator
• Placebo b.i.d. for 16 weeks (36)
Treatments ended on the day of HCG injection for IVF stimulation
Outcomes Assessments (2): baseline and week 16
Outcomes of the trial (as reported)
1. Total number of days of FSH stimulation and serum estradiol on the day of HCG
injection
2. Number of oocytes
3. Total gonadotrophin dose used
4. Fertilisation rates, embryo quality, pregnancy rates, clinical pregnancy rate, and
live birth rates
Denotes outcomes prespecified for this review
Notes Only 37% of women were hirsute and none of our outcomes were assessed. No separate
data for hirsute women. See Table 3
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Kjøtrød 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1316): ”Randomization was
performed by our hospital pharmacy; it was
performed in blocks of four and stratified
according to BMI <28 kg/m2 or BMI >28
kg/m2.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 1316): ”Randomization codes
were kept in the pharmacy until the last
patient had finished the IVF procedure.“
Pharmacy controlled randomisation
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1316): ”Patients were treated
with identical capsules of metformin or
placebo“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/74 (14%); 2/15 in normal weight
placebo group, 4/18 in normal weightmet-
formin group, 2/21 in obese placebo group,
2/19 in obese metformin group
Comment: as 6 got pregnant, which was a
desired outcome, the number of real drop-
outs (N = 4), balanced between the groups,
is low. We judged this as at low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Kjøtrød 2004 (Continued)
Other bias Low risk Quote (page 1321): ”We gratefully thank
Weifa AS, Norway, for supplying the met-
formin used free of charge, and Organon
AS,Norway, for supporting gonadotrophin
for the last 15 cycles (after public financing
of IVF changed in Norway on January 1,
2002).“
Comment: we judged this as at a low risk
of bias
Kriplani 2009
Methods Randomised, active-controlled trial
Setting
Outpatient Gynecology endocrine clinic, All India Institute of Medical Sciences, New
Delhi, India
Date of study
Not reported. Duration of intervention 12 months
Participants N = 120
Mean age = 23 years
Inclusion criteria
• Hirsutism based on PCOS (Rotterdam Criteria PCOS 2004) and idiopathic
hirsutism
• Hirsutism score ≥ 8 (modified Ferriman-Gallwey score)
• Age between 16 to 40 years
Exclusion criteria
• Androgen-secreting tumours of ovarian or adrenal origin
• Cushing syndrome
• Thyroid dysfunction
• 21-hydroxylase deficiency
• Hyperprolactinaemia
• Cliteromegaly or other evidence of virilism
• Intersex patients
• < 6 months on medication that are known to affect pituitary-gonadal function
Randomised
N = 60
Withdrawals/losses to follow-up
• 8/120 (6.7%); 5/60 in OCP + spironolactone group for side effects, 3/60 in OCP
+ finasteride group also for side effects
Baseline data (mean (SD))
BMI: OCP + spironolactone group 24.2 (6.1), OCP + finasteride group 22.5 (4.2)
Modified F-G score: OCP + spironolactone group 11.4 (2.8), OCP + finasteride group
11.1 (2.4)
Acne present: OCP + spironolactone group 20, OCP + finasteride group 25
Total testosterone (ng/ml): OCP + spironolactone group 1.3 (1.3), OCP + finasteride
group 1.1 (1)
DHEAS (µg/dl): OCP + spironolactone group 212.4 (117.6), OCP + finasteride group
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Kriplani 2009 (Continued)
219.5 (126.3)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + spironolactone 100
mg for 12 months (60)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + finasteride 5 mg for
12 months (60)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Adverse events
3. Acne score (per Indian system)
4. LH, FSH, TSH, prolactin, total testosterone, DHEAS, 17-hydroxyprogesterone
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 237): ”The choice of treat-
ment for each patient was made using a
computerized randomization number ta-
ble.“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
287Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kriplani 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/120 (6.7%); 5/60 in OCP + spironolac-
tone group for side effects, 3/60 in OCP +
finasteride group also for side effects
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 240): ”We are thankful to the
Indian Council of Medical Research, New
Delhi, India for funding and supporting
this project (ID NO: 2007-00940).“
Comment: we judged this as at a low risk
of bias
Kriplani 2010
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New
Delhi, India
Date of study
Not reported. Duration of intervention 6 months with follow-up at 12 months
Participants N = 73 assessed for eligibility, 60 randomised
Mean age = 23 years
Inclusion criteria of the trial
• PCOS according to Rotterdam Criteria PCOS 2004
Exclusion criteria of the trial
• Hypothyroidism
• Hyperprolactinaemia
• History of exogenous hormonal agent within past 6 months
• Smoking
• Alcohol
• Recent history of surgical treatment for PCOS
• Contraindications to combined oral contraceptives
• Associated renal or adrenal insufficiency on drugs that increase serum potassium
(ACE inhibitors, AT II blockers)
Randomised
N = 60
Withdrawals/losses to follow-up
• 2/60 (3%); 1/30 in EE/DRSP group, 1/30 in EE/desogestrel group
• Jaundice; 1/30 in EE/DRSP group, 0/30 in EE/desogestrel group
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• Lower limb pain; 0/30 in EE/DRSP group, 1/30 in EE/desogestrel group
Baseline data
Hirsutism: 5/30 in EE/DRSP group and 4/30 in EE/desogestrel
Acne: 10/30 in EE/DRSP group and 10/30 in EE/desogestrel
Obese (BMI > 25 kg/m2): 19/30 in EE/DRSP group and 20/30 in EE/desogestrel
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 6 months (30)
Comparator
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 6 months (30)
Outcomes Assessments (6): baseline, month 1, 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Acne scoring
3. BMI
4. Haemoglobin, lipid profile, glucose, insulin, FSH, LH, TSH, prolactin,
testosterone, SHBG, DHEAS, 17-OH progesterone
5. Ultrasound of the pelvis for features of PCOS
6. Adverse effects
Denotes outcomes prespecified for this review
Notes Minority had hirsutism
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 140): ”...using a computer-
generated randomization table into two
groups...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
289Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kriplani 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/60 (3%); 1/30 in EE/DRSP group, 1/30
in EE/desogestrel group, reasons reported.
Per-protocol analysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Lachnit-Fixson 1977
Methods Randomised, double-blind, active-controlled trial
Setting
Multi-centre in Germany and Austria
Date of study
Not reported. Duration of intervention 6 to 12 months
Participants N = 88
Mean age = 29 years
Inclusion criteria of the trial
• Participants with acne, seborrhoea, and/or hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 88
Withdrawals/losses to follow-up
• Not clear and duration of therapy variable
Baseline data
Nothing reported
Interventions Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 6 to 12 months (37)
Comparator
• OCP (ethinyl estradiol 50 µg + D-norgestrel 0.25 mg) for 6 to 12 months (51)
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Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Effect on acne, seborrhoea, and/or hirsutism; 5-point Likert scale
Denotes outcomes prespecified for this review
Notes Unclear how many women were hirsute and no precise data on the effect on hirsutism
(only reported as no difference between the treatment groups). See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page1923): ”...durch
Randomisierung...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1923): ”...doppelblind...“ and
”äußerlich identisch...“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many dropped out as study
duration was variable. Appears to be 4 in
the active treatment group and 11 in the
control group that failed to complete 6
months treatment
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Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Principal investigator was employed by
Schering AG, the manufacturer of the
OCPs
Comment: a potential risk of bias cannot
be excluded
Ladson 2011
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Obstetrics and Gynecology, Meharry Medical College, Nashville, Ten-
nessee and Department of Obstetrics and Gynecology, Penn State College of Medicine,
Hershey, Pennsylvania, US
Date of study
2004 until 2007. Duration of intervention 6 months
Participants N = 114
Mean age = 29 years
Inclusion criteria of the trial
• PCOS according to the 1990 National Institutes of Health/National Institute of
Child Health and Human Development PCOS diagnostic criteria (Zawadski 1992);
chronic anovulation, defined as spontaneous intermenstrual periods of ≥ 45 days or a
total of ≤ 8 menses per year, and hyperandrogenism defined as an elevated total
testosterone (> 50 ng/dl) or a free androgen index (ratio of testosterone/SHBG (100))
> 1.5
Exclusion criteria of the trial
• Other causes of anovulation and hyperandrogenism
• Confounding medications (e.g. hormonal contraceptives, diabetic medications,
etc.)
Randomised
N = 114
Withdrawals/losses to follow-up
• 76/114 (67%); 33/55 in metformin group, 43/59 in placebo group
• Side effects; 6/55 in metformin group, 0/59 in placebo group
• Lost interest/unable to comply; 4/55 in metformin group, 7/59 in placebo group
• Personal constraints/health issues; 8/55 in metformin group, 13/59 in placebo
group
• Pregnancy; 0/55 in metformin group, 4/59 in placebo group
• Lost to follow-up; 15/55 in metformin group, 19/59 in placebo group
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Baseline data (mean (SD))
BMI: metformin group 38.0 (7.8), placebo group 38.3 (8.0)
F-G score: metformin group 17.7 (8.3), placebo group 19.1 (8.9)
Acne count: metformin group 4.4 (7.4), placebo group 2.6 (4.1)
Testosterone (ng/dl): metformin group 73.6 (36.9), placebo group 77.3 (36.9)
SHBG (nmol/L); metformin group 28.1 (25.4), placebo group 26.5 (12.9)
Interventions Intervention
• Metformin 500 mg, 4 capsules a day (55)
Comparator
• Placebo capsules, 4 capsules a day (59)
All participants received a combined intervention of diet and exercise with the goal of
achieving an average weight loss of ≥ 7% of initial body weight over 6 months with a
prescription of 150 minutes/week exercise combined with a low-calorie diet
Outcomes Assessments (7): baseline, and then every month until end of study
Outcomes of the trial (as reported)
1. Ovulation rate; pregnanediol-3 alpha-glucuronide in urine
2. Testosterone levels
3. Ferriman-Gallwey score, acne lesion counting
4. Fitness level
5. Dual-energy x-ray absorptiometry
6. LH, FSH, DHEAS, SHBG
7. OGTT, glucose, insulin
8. Ultrasound of pelvis
9. PCOS quality of life survey (Guyatt 2004)
10. Adverse events
Denotes outcomes prespecified for this review
Notes Drop-out rate 67%. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1059): ”... Subjects were ran-
domized in a 1:1 allocation ratio to the two
treatment arms...using a computer gen-
erated random number table using...per-
muted blocks and stratified by center and
prior metformin exposure status after a
baseline visit“
Comment: probably done
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Allocation concealment (selection bias) Unclear risk Quote (page 1059): ”...The block sched-
ule was blinded to the investigators and re-
search subjects“
Comment: the method used to conceal
the allocation sequence, that is to de-
termine whether intervention allocations
could have been foreseen in advance of, or
during, enrolment, was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1060): ”...Metformin hy-
drochloride was... formulated with the ap-
propriate dose of drug into capsules with
identical-appearing placebo capsules. Drug
and placebo were packaged and labeled ac-
cording to subject number by the Investi-
gational Pharmacy laboratory in a double
blind fashion“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were both participant and in-
vestigator assessed. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 76/114 (67%); 33/55 in metformin group,
43/59 in placebo group, reasons reported.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Lakryc 2003
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Gynecology of the Federal University of Sao Paulo, Escola Paulista de
Medicina, Sao Paulo, Brazil
Date of study
October 1997 until December 1999. Duration of intervention 6 months
Participants N = 34
Mean age = not reported
Inclusion criteria of the trial
• Hirsute women (19 to 40 years)
• PCOS as diagnosed by amenorrhoea or oligo menorrhoea (< 6 menstrual periods
per year) or idiopathic hirsutism scored ≥ 8
Exclusion criteria of the trial
• Lipid-lowering drugs
• Antidiabetic medication
• Hormonal drugs or contraception < 6 months prior to study entry
• Cushing’s syndrome
• Late-onset 21-hydroxylase deficiency
• Thyroid dysfunction
• Hyperprolactinaemia
• Androgen-secreting tumours
• Diabetes mellitus
• Renal or hepatic disease
• Adrenal hirsutism
• No previous treatment for hirsutism
Randomised
N = 34
Withdrawals/losses to follow-up
• 10/34 (29%); 4/16 in finasteride group, 6/18 in placebo group
• Pregnancy; 3/34
• Diarrhoea and nausea; 3/34
• Private reasons; 3/34
• Allergic symptoms; 1/34
Baseline data (mean (SEM))
BMI: PCOS group 24.3 (0.7), idiopathic hirsutism group 23.6 (0.6)
F-G score: PCOS group 11.5 (0.8), idiopathic hirsutism group 12.6 (0.6)
Free testosterone (nmol/L): PCOS group 14.6 (1.1), idiopathic hirsutism group 6.8 (0.
5)
Interventions Intervention
• Finasteride 5 mg once a day for 6 months (12)
Comparator
• Placebo for 6 months (12)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Blood pressure
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Lakryc 2003 (Continued)
3. Cardiac frequency
4. BMI
5. Serum prolactin, 17OH progesterone, FSH, LH, total and free testosterone,
DHEAS, androstenedione, dihydrotestosterone
6. Subjective efficacy according to participants; 3-point Likert scale
7. Transvaginal ultrasound (ovarian volume)
8. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 59): ”... by a computerized
random-number generator“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 59): ”All patients received
a numerical randomized envelope, which
had a letter inside labeled no. 1 or no.
2 corresponding... During the study, the
subjects and study personnel were not in-
formed about the order of the treatments.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 59): ”To avoid compromising
the double-blind design the occurrence of
side effects...was recorded by an indepen-
dent gynecologist. The study drugs were
packaged in 30-day flasks...The follow-up
was conducted by a gynecologist who did
not participate in the screening part of the
study or the distribution of the drugs...“
After e-mail communication: ”The capsule
of placebo was similar to the one of finas-
teride and the flask had only identification
of XY (placebo) or YX (finasteride). The
physicians and patients were blind to this
information“
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Comment: the response from the investi-
gators provided sufficient detail about the
measures used to blind study participants
and personnel from knowledge of which
intervention a participant received, to per-
mit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomeswere both participant and inves-
tigator assessed
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/34 (29%); 4/16 in finasteride group, 6/
18 in placebo group, reasons reported. Per-
protocol analysis
Comment: the high drop-out rate (al-
though balanced) with per-protocol analy-
sis represents a potential high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Lam 2011
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong, Peo-
ple’s Republic of China
Date of study
Inclusion from June 2004 until November 2006. Duration of intervention 12 months
Participants N = 80 screened, 70 randomised
Mean age = 26 years
Inclusion criteria of the trial
• Chinese women who were diagnosed with PCOS based on Rotterdam Criteria
PCOS 2004
Exclusion criteria of the trial
• Other causes of hyperandrogenaemia, i.e. adult onset congenital adrenal
hyperplasia and Cushing’s syndrome
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• Endometrial hyperplasia
• Diabetes mellitus managed with oral hypoglycaemic agents or insulin treatment
• Significant cardiovascular disease, hepatic or renal impairment
• Corticosteroid therapy
Randomised
N = 70
Withdrawals/losses to follow-up
• 16/70 (23%); 11/35 in rosiglitazone group, 5/35 in placebo group
• Lost to follow-up; 8/35 in rosiglitazone group, 5/35 in placebo group
• Withdrawn; 1/35 in rosiglitazone group, 0/35 in placebo group
• Refused to continue; 2/35 in rosiglitazone group, 0/35 in placebo group
Baseline data (mean (SD) or number (%))
BMI: rosiglitazone group 23.5 (5.2), placebo group 25.9 (5.6)
F-G score: rosiglitazone group 6, placebo group 6; 8/35 in rosiglitazone group had score
≥ 11, 13/35 in placebo group had score ≥ 11
Waist/hip ratio: rosiglitazone group 0.80 (0.05), placebo group 0.81 (0.07)
Amenorrhoea: rosiglitazone group 12/35, placebo group 20/35
Oligomenorrhoea: rosiglitazone group 21/35, placebo group 15/35
Acne score mild: rosiglitazone group 13 (37.1), placebo group 7 (20.0)
Acne score moderate: rosiglitazone group 4 (11.4), placebo group 1 (2.9)
Acne score severe: rosiglitazone group 2 (5.7), placebo group 2 (5.7)
Interventions Intervention
• Rosiglitazone 4 mg b.i.d. for 12 months (35)
Comparator
• Placebo b.i.d. for 12 months (35)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Menstrual status
2. Hyperandrogenism (hirsutism and free testosterone)
3. Insulin, glucose, lipid levels
4. BMI, waist/hip ratio
5. Blood pressure
6. LH, FSH, total testosterone, SHBG
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 447): ”...randomization gen-
erated in blocks of 10 by a computer pro-
gram...“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 447): ”...The “coding” of the
placebo and the rosiglitazone in each bot-
tle was kept only by the local pharmaceu-
tical company and was concealed from the
research team.“ and ”Both the participants
and the research team were blinded to the
randomization codes, which were not bro-
ken until the completion of the study.“
Pharmacy-controlled randomisation
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 446-7): ”Both the placebo and
the rosiglitazone were encapsulated to ap-
pear the same and were packed into bottles
with serially labeled study numbers“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 16/70 (23%); 11/35 in rosiglitazone group,
5/35 in placebo group, reasons reported.
Per-protocol analysis
Comment: the high and unbalanced drop-
out rate with per-protocol analysis repre-
sents a potential high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk The study appears to be free of other forms
of bias
Lello 2008
Methods Randomised, active-controlled trial
Setting
Endocrinological Gynecology and Pathophysiology of Menopause Unit, IRCCS-IDI,
Rome, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 55
Mean age = 24 years
Inclusion criteria of the trial
• Women with hyperandrogenic manifestations (seborrhoea, acne, increased hair)
and plasma hormonal hyperandrogenic features
Exclusion criteria of the trial
• Not reported
Randomised
N = 55
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
BMI: EE/DRSP group 22.30 (2.60), EE/CMA group 22.24 (2.6)
F-G score: EE/DRSP group 15.53 (2.03), EE/CMA group 15.41 (1.86)
Acne score: EE/DRSP group 2.63 (0.39), EE/CMA group 2.56 (0.41)
Androstenedione (ng/ml): EE/DRSP group 4.24 (0.54), EE/CMA group 4.17 (0.39)
DHEAS (µg/ml): EE/DRSP group 3.134 (0.77), EE/CMA group 3.193 (0.75)
Testosterone (nmol/L): EE/DRSP group 2.00 (0.23), EE/CMA group 2.05 (0.24)
SHBG (nmol/L): EE/DRSP group 34.82 (6.10), EE/CMA group 35.27 (6.43)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 6 months (30)
Comparator
• OCP (ethinyl estradiol 30 µg + chlormadinone 2 mg) for 6 months (25)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Serum FSH, LH 17OH-progesterone, androstenedione, testosterone, DHEAS,
SHBG
2. Seborrhoea; MPA Cutometer 580®
3. Acne score; 4-point Likert scale (higher is worse)
4. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
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Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 719): ”Randomly, 30 patients.
..“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 719): ”...investigator was only
one throughout the study and was always
blinded to treatment...“ The participants
were not blinded
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 719): ”...investigator was only
one throughout the study and was always
blinded to treatment...“ The participants
were not blinded
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Lemay 2006
Methods Randomised, active-controlled trial
Setting
Départements d’Obstétrique-Gynécologie et deBiologieMédicale,Centre deRecherche,
Hôpital St-François d’Assise, CHUQ, Université Laval, Québec, Canada
Date of study
Not reported. Duration of intervention 6 months
Participants N = 50 assessed for eligibility, 28 randomised
Mean age = 23 years
Inclusion criteria of the trial
• 18 to 45 years old with at least 2 previous menses and without menopausal
symptoms
• PCOS according to the presence of 2 out of 3 criteria: (i) oligomenorrhoea (< 8
uterine bleedings/year) or amenorrhoea (≤ 2 uterine bleedings/year); (ii) elevated levels
of androgens (testosterone > 1.5 nmol/l and/or androstenedione > 10 nmol/l); and (iii)
presence of micro-cysts (≥ 12 follicles measuring 2 mm to 9 mm in diameter)
surrounding otherwise enlarged ovaries (> 10 cm3)
• A high fasting insulin (> 90 pmol/l) with normal glucose (< 6 mmol/l) indicative
of insulin resistance
Exclusion criteria of the trial
• Actual desire for pregnancy
• Hysterectomy, abnormal endometrial biopsy if abnormal bleeding in the last 6
months
• Cushing’s syndrome, congenital adrenal hyperplasia (17-OH progesterone > 10
nmol/L), excessive androgens suspicious of a tumour, prolactin levels > 50 µg/L
• Severe renal or hepatic disease
• Gastrointestinal condition interfering with drug absorption
• Previous breast, uterus, ovary, or liver neoplasia
• Previous use of a drug to lower glucose, lipid, or insulin or an oral contraceptive
in the last 2 months
• Previous use of diuretic, β-blocker, corticoid, hormonal replacement therapy in
the last 3 months, depo-medroxyprogesterone acetate injection in the last year and a
research drug in the last 2 months
• Alcohol intake > 40 g/day and smoking > 10 cigarettes/day
Randomised
N = 28
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Withdrawals/losses to follow-up
• 11/28 (39%); 5/15 in rosiglitazone group, 6/13 in EE/CPA group
• Refused to continue; 3/15 in rosiglitazone group, 3/13 in EE/CPA group
• Intolerance; 1/15 in rosiglitazone group, 2/13 in EE/CPA group
• Unrelated to medication; 1/15 in rosiglitazone group, 1/13 in EE/CPA group
Baseline data (mean (SD))
BMI: rosiglitazone group 34.6 (4.7), EE/CPA group 33.9 (4.6)
F-G score: rosiglitazone group 16.7 (5.7), EE/CPA group 17.1 (2.0)
Waist/hip ratio: rosiglitazone group 1.00 (0.03), EE/CPA group 0.98 (0.04)
Baseline data (mean (SEM))
Testosterone (mmol/L): rosiglitazone group 2.29 (0.24), EE/CPA group 1.93 (0.25)
Androstenedione (mmol/L): rosiglitazone group 12.2 (0.8), EE/CPA group 11.2 (1.0)
DHEAS (pmol/L): rosiglitazone group 6.72 (1.00), EE/CPA group 7.37 (1.37)
SHBG (mmol/L): rosiglitazone group 13.2 (1.5), EE/CPA group 13 (2)
Interventions Intervention
• Rosiglitazone 4 mg/day for 6 months (15)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (13)
Admissible candidates were started on diet low in refined sugar for 4 months before ran-
domisation to drug treatment. Subjects were also encouraged to exercise daily whenever
possible
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Glucose, insulin, lipid profile, oral glucose tolerance test, HOMA, QUICKI
2. Compliance to diet and exercise
3. Adverse effects
4. Ferriman-Gallwey score
5. TSH, prolactin, FSH, LH, estradiol, progesterone, total testosterone, DHEAS,
SHBG, androstenedione
6. BMI, waist/hip ratio, blood pressure, and smoking and alcohol drinking habits
Denotes outcomes prespecified for this review
Notes The study continued after 6 months with a combination of the 2 treatments. Losses to
follow-up in the EE + CPA group > 40 % (46.2 %). See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 122): ”Computer generated
allocation blocks of four to six subjects were
used for randomization“
Comment: probably done
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 11/28 (39%); 5/15 in rosiglitazone group,
6/13 in EE/CPA group, reasons reported.
Per-protocol analysis
Comment: the high drop-out rate (al-
though balanced) with per-protocol analy-
sis represents a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 127): ”Drugs were graciously
supplied by Berlex Canada Inc. and Glax-
oSmithKline Montreal, Québec, Canada.“
Comment: we judged this as at a low risk
of bias
Levrier 1988
Methods Randomised, active-controlled trial
Setting
Multi-centre in France
Date of study
Not reported. Duration of intervention 6 months
Participants N = 69
Mean age = 24 years
Inclusion criteria of the trial
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• 18 to 35 years with acne
Exclusion criteria of the trial
• Oral antibiotics < 1 month prior to study entry
• OCP other than minipill
Randomised
N = 69
Withdrawals/losses to follow-up
• 3/69 (4%); 1/30 in EE/desogestrel group, 2/39 in EE/CPA group
• Adverse event; 1/30 in EE/desogestrel group, 1/39 in EE/CPA group
• Lost to follow-up; 0/30 in EE/desogestrel group, 1/39 in EE/CPA group
Baseline data
Nothing reported
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 6 months (30)
Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 6 months (39)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Acne lesions; number
2. Hirsutism on upper lip, preauricular and chin
3. Serum total testosterone, SHBG
4. Adverse events
Denotes outcomes prespecified for this review
Notes Only few of the women had additional hirsutism, unclear how many in each group as
only some of the sites but not the number of participants are reported. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 574): ”...randomisée...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3/69 (4%); 1/30 in EE/desogestrel group,
2/39 in EE/CPA group were lost to follow-
up. Incomplete data 27 in EE/desogestrel
group and 35 in EE/CPA group
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Lissak 1989
Methods Randomised controlled trial
Setting
Department of Obstetrics and Gynecology, Carmel Hospital, Haifa, Israel
Date of study
Not reported. Duration of intervention 3 months
Participants N = 20
Age range = 15 to 35 years
Inclusion criteria of the trial
• Moderate to severe hirsutism for at least 3 years
Exclusion criteria of the trial
• Hirsutism treatment < 6 months prior to study entry
Randomised
N = 20
Withdrawals/losses to follow-up
• 3/20 (15%); 2/12 in cimetidine group, 1/8 in control group, did not show up for
follow-up
Baseline data
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10 women had hirsutism with ovarian source predominating, 4 of adrenal origin, 6 had
idiopathic hirsutism
Interventions Intervention
• Cimetidine 300 mg 5 times a day for 3 months (12)
Comparator
• No treatment (8)
Outcomes Assessments (4): baseline, month 1, 2, and 3
Outcomes of the trial (as reported)
1. Quantitative assessment of body hair
2. Ferriman-Gallwey score
3. Free thyroxine, adrenal corticotropic hormone, FSH, LH, prolactin, total
testosterone, free testosterone, DHEA, DHEAS
4. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 248): ”... were randomised to
treatment...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3/20 (15%); 2/12 in cimetidine group, 1/
8 in control group, did not show up for
follow-up. Per-protocol analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 250): ”The research was sup-
ported in part by a grant from Mr Beni
Peled, President of Elscint Ltd., Haifa, Is-
rael“
Comment: we judged this as at a low risk
of bias
Lucas 2001
Methods Randomised, double-blind, placebo-controlled, within-participant trial
Setting
Down East Medical Associates, Morehead City, North Carolina, US
Date of study
Not reported. Duration of intervention 6 months
Participants N = 8
Mean age = 39 years
Inclusion criteria of the trial
• Excessive facial hair with different severities and causes of hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 8
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: 36.5 (5.72)
4 had PCOS, 2 idiopathic hirsutism, 1 hypertrichosis, and 1 mild congenital adrenal
hyperplasia
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Interventions Intervention
• Finasteride (0.25%) cream b.i.d. for 6 months
Comparator
• Placebo cream b.i.d. for 6 months
Outcomes Assessments (4): baseline, month, 2, 4, and 6
Outcomes of the trial (as reported)
1. Subjective view of effect; questioning about the numbers of times per week
shaving/clipping
2. Perception of differences between the 2 sides by participants
3. Inquiries about hair removal techniques
4. Testosterone, DHEAS, prolactin, TSH
5. Adverse events/tolerability
Denotes outcomes prespecified for this review
Notes 2/8 had diagnosis that did not match our inclusion criteria. Individual patient data are
provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 5): ”... randomized and
blinded...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 7): ”... same size, and type of
tube...cream labeled “R” on right side...“L”
on left side...women and researcher were
blinded to the identity of the cream in each
of the tubes.“
Comment: the report provided sufficient
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detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by participants
and investigators. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 9): ”I thank...the local Merck
& Co representative for the idea of the
study...“
Comment: we judged this as at a low risk
of bias
Lumachi 2003
Methods Randomised, active-controlled trial
Setting
Endocrine Surgery Unit, Department of Surgical and Gastroenterological Sciences, Uni-
versity of Padua, School of Medicine, Padova, Italy
Date of study
Not reported. Duration of intervention 12 months
Participants N = 41
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women Ferriman-Gallwey score ≥ 6
• Regular menstrual cycles of 21 to 35 days
• Progesterone levels greater than 13 nmol/L in the luteal phase
• Normal circulating serum levels of free testosterone, DHEAS, androstenedione,
and 17-hydroxyprogesterone serum levels
• No discontinuation of the therapy
Exclusion criteria of the trial
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• Patients with abnormal results on routine laboratory tests (haematologic
examination, fasting plasma glucose, serum creatinine, liver function, serum
electrolytes, and lipid analysis)
• Abnormal hormonal screening variables (serum cortisol, free T4, thyroid-
stimulating hormone, FSH, LH, and prolactin)
Randomised
N = 41
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: CPA group 20.9 (1.3), finasteride group 21.8 (1.7), spironolactone group 21.1 (1.
3)
F-G score: CPA group 11.17 (1.27), finasteride group 12.08 (1.08), spironolactone
group 11.21 (1.22)
FreeT (pmol/L):CPAgroup20.61 (3.42), finasteride group18.80 (2.34), spironolactone
group 20.30 (3.11)
Androstenedione (nmol/L): CPA group 4.21 (1.87), finasteride group 4.54 (2.43),
spironolactone group 5.98 (2.37)
DHEAS (µmol/L): CPA group 5.12 (2.09), finasteride group 4.32 (1.26), spironolactone
group 4.68 (1.76)
Interventions Intervention
• Cyproterone acetate, 12.5 mg/day for the first 10 days of the cycle for 12 months
(13)
Comparator 1
• Finasteride, 5 mg/day for 12 months (13)
Comparator 2
• Spironolactone, 100 mg/day for 12 months (15)
Patients were requested not to use cosmetic treatments, such as shaving, depilatory, hot
wax, or hair removal by electrolysis. All patients received oral contraceptives for at least
2 years
Outcomes Assessments (4): baseline, month 6, 12, and 24
Outcomes of the trial (as reported)
1. Serum DHEAS, free testosterone, androstenedione, and 17-hydroxyprogesterone
2. Ferriman-Gallwey score
3. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Lumachi 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (page 943): ”The choice of treat-
ment for each patient was made by using a
random number table.“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Luque-Ramírez 2007
Methods Randomised, open-label, active-controlled study
Setting
Departments of Endocrinology and Biochemistry-Research, Hospital Universitario
Ramón y Cajal and Universidad de Alcala, Madrid, Spain
Date of study
April 2004 to December 2006. Duration of intervention 24 weeks
Participants N = 34
Mean age = 24 years
Inclusion criteria of the trial
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• PCOS, diagnosis based on the presence of clinical and/or biochemical
hyperandrogenism, oligo-ovulation, and exclusion of secondary aetiologies
• Hirsutism was defined by a modified Ferriman-Gallwey score > 7
• Oligomenorrhoea (more than 6 cycles longer than 36 days in the previous year) or
amenorrhoea (absence of menstruation for 3 consecutive months), or luteal phase
progesterone measurements less than 4 ng/ml (12.72 nmol/L) in women with regular
menstrual cycles were considered indicative of oligo-ovulation
Exclusion criteria of the trial
• Secondary aetiologies, including hyperprolactinaemia, thyroid dysfunction,
Cushing’s syndrome, congenital adrenal hyperplasia, and virilising tumours
• Hypertension
• Diabetes mellitus
• Cardiovascular events
• Treatment with oral contraceptives, antiandrogens, insulin sensitisers, or drugs
that might interfere with blood pressure regulation, lipid profile, or carbohydrate
metabolism, < 6 months prior to study entry
Randomised
N = 34
Withdrawals/losses to follow-up
• 7/34 (21%); 0/15 in EE/CPA group and 7/19 in metformin group
• Protocol violation; 0/15 in EE/CPA group and 3/19 in metformin group
• Gastrointestinal side effects; 0/15 in EE/CPA group and 2/19 in metformin group
• Pregnancy; 0/15 in EE/CPA group and 1/19 in metformin group
• Lost to follow-up; 0/15 in EE/CPA group and 1/19 in metformin group
Baseline data (mean (SD))
BMI: EE/CPA group 29.2 (5.7), metformin group 30.5 (6.9)
Waist/hip ratio: EE/CPA group 0.79 (0.06), metformin group 0.82 (0.11)
F-G score: EE/CPA group 11 (5), metformin group 10 (6)
Free testosterone (ng/dl): EE/CPA group 1.1 (0.4), metformin group 1.3 (0.6)
Androstenedione (ng/ml): EE/CPA group 3.5 (0.8), metformin group 3.9 (1.1)
DHEAS (ng/dl): EE/CPA group 2738 (1022), metformin group 2250 (933)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 24 weeks (15)
Comparator
• Metformin 850 mg b.i.d. for 24 weeks (19)
Outcomes Assessments (3): baseline, week 12, and 24
Outcomes of the trial (as reported)
1. Clinical and anthropometrical variables (Ferriman-Gallwey score, BMI, waist
circumference, and waist to-hip ratio)
2. Percentage of body fat with respect to total body weight was estimated using a
body fat monitor
3. Serum free testosterone, androstenedione, and DHEAS
4. Glucose, insulin, oral glucose tolerance test
5. Circulating HDL cholesterol, phospholipid levels, total cholesterol, triglycerides,
LDL cholesterol, apolipoprotein, lipoprotein
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Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2453): ”...were randomized.
..“ and ”Simple randomization was con-
ducted using blocks of 10 sealed opaque
envelopes assigning five patients to receive
Diane 35 Diario and five patients to receive
metformin.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 2453): ”...10 sealed opaque
envelopes assigning five patients to receive.
..“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 2453): ”No masking method
was used after randomization.“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 2453): ”No masking method
was used after randomization.“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 7/34 (21%); 0/15 in EE/CPA group and 7/
19 in metformin group, reasons reported.
Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk Quote (page 2460): ”This study was
supported by the Spanish Ministry of
Health and Consumer Affairs, Instituto
de Investigación Carlos III Grants Fondo
de Investigacio´ n Sanitaria PI050341
and PI050551 and Red de Diabetes
y Enfermedades Metabólicas Asociadas
(REDIMET) RD06/0015/0007; Ministry
of Education and Science Grant SAF2005-
07038; and by economic aid fromHospital
Ramón y Cajal.“
Comment: we judged this as at a low risk
of bias
Maciel 2004
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Gynecology of Federal University of São Paulo, São Paulo, Brazil
Date of study
October 1997 until December 1999. Duration of intervention 6 months
Participants N = 34
Mean age = 21 years
Inclusion criteria of the trial
• PCOS
• Women must have history of (1) chronic anovulation since the menarche, as
evidenced by either amenorrhoea or oligomenorrhoea (less than 6 menstrual periods in
the last year); (2) clinical or laboratory evidence of hyperandrogenism (determined by
serum hormonal concentration, and Ferriman and Gallwey score); (3) no secondary
causes of anovulation; (4) and no present use of lipid-lowering drugs, antidiabetic
medications, or hormonal contraception (in the last 3 months)
Exclusion criteria of the trial
• Cushing’s syndrome
• Late-onset 21-hydroxylase deficiency
• Thyroid dysfunction
• Hyperprolactinaemia
• Androgen-secreting tumours
• Diabetes mellitus
• Evidence of chronic renal or hepatic disease
Randomised
N = 34
Withdrawals/losses to follow-up
• 5/34 (15%); 2/17 in metformin group, 3/17 in placebo group
• Pregnancy; 1/17 in metformin group, 1/17 in placebo group
• Unknown reason; 0/17 in metformin group, 2/17 in placebo group
• Diarrhoea; 1/17 in metformin group, 0/17 in placebo group
Baseline data (mean (SEM))
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BMI: non obese placebo group 25.1 (1.6), obese placebo group 35.8 (1.5) non obese
metformin group 25.3 (2.1), obese metformin group 37.2 (1.7)
F-G score: non obese placebo group 8.5 (2.1), obese placebo group 8.9 (2.4), non obese
metformin group 8.2 (1.2), obese metformin group 8.5 (2.9)
Interventions Intervention
• Metformin 500 mg 3 times a day (17)
Comparator
• Placebo 3 times a day (17)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Prolactin, growth hormone, cortisol, TSH, triiodothyronine, and serum and free
thyroxine, 17-hydroxyprogesterone, leptin
2. FSH, LH, total testosterone, DHEA, DHEAS, SHBG and androstenedione
3. Glucose, total cholesterol and lipoproteins levels
4. BMI
5. Ferriman-Gallwey score
6. Post-treatment changes in frequency of cycles
7. Transvaginal sonography of uterus and ovaries
8. Oral glucose tolerance test
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 356): ”...two different treat-
ment arms in a sequence determined by a
computerized random-number generator“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 356): ”All patients received a
sealed envelope that contained either the
number 1 or 2, corresponding to placebo
or metformin 1.5 g/day, respectively“
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 356): ”During the study, pa-
tients and investigators were not aware of
the treatment assignments. To avoid com-
promising the double-blinded design, an
independent gynecologist recorded the oc-
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currence of side effects or physical changes
such as menstrual bleeding“ and ”Study
drugs were packaged in 30-day flasks (90
capsules). The patients were instructed to
take one capsule every 8 hours during the
study. A gynecologist who did not partici-
pate in the screening process or the distri-
bution of the drugs performed the follow-
up evaluations.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by participants
and investigators. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/34 (15%); 2/15 in metformin group, 3/
14 in placebo group
Comment:moderate andbalancednumber
of drop-outs at follow-up, combined with
the per-protocol analysis considered to be
at unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, active-controlled trial
Setting
Out-patient gynaecology clinic, University of Athens, Aretaieion Hospital, Athens,
Greece
Date of study
Not reported. Duration of the intervention 12 months
Participants N = 28
Mean age = 18 years
Inclusion criteria of the trial
• Adolescent girls (age range: 14 to 19 years) with clinically evoked and biologically
confirmed hyperandrogenism and ≤ 6 menses during the past 12 months indicating
chronic anovulation
• The diagnosis of PCOS in these patients was based on the criteria established at
the 1990 PCOS conference organised at the National Institutes of Health (Bethesda,
Maryland) by National Institute of Child Health and Development (Dunaif 1992)
Exclusion criteria of the trial
• Nonclassic adrenal 21-hydroxylase deficiency
• Hyperprolactinaemia
• Androgen-secreting neoplasms
• Hormonal medication, including combined oral contraceptives, for at least 6
months before the study
Randomised
N = 28
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: desogestrel/EE group 25.5 (1.79), CPA/EE group 24.84 (1.09)
F-G score: desogestrel/EE group 15.71 (1.63), CPA/EE group 16.78 (1.15)
Waist/hip ratio: desogestrel/EE group 0.77 (0.02), CPA/EE group 0.75 (0.01)
Testosterone (ng/ml): desogestrel/EE group 1.04 (0.08), CPA/EE group 0.99 (0.10)
Free testosterone (pg/ml): desogestrel/EE group 3.24 (0.24), CPA/EE group 3.20 (0.27)
Androstenedione (ng/ml): desogestrel/EE group 3.77 (0.26), CPA/EE group 3.67 (0.
27)
DHEAS (ng/ml): desogestrel/EE group 2633.71 (352.38), CPA/EE group 2434.33
(229.13)
SHBG (nmol/L): desogestrel/EE group 55.86 (9.63), CPA/EE group 59.07 (8.05)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 12 months (14)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (14)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Total cholesterol and triglycerides, HDL cholesterol and LDL cholesterol,
apolipoproteins A-I, A-II, and B
3. Testosterone, free testosterone, SHBG, androstenedione, DHEAS
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Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 921): ”...patients were ran-
domly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication: ”... computer
generated“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”The ran-
domization is performed by our computer
technicianwhogenerates the randomnum-
bers and he is the only one to know in each
study the allocation sequence until the mo-
ment of assignment.“
Comment: response provides insufficient
information to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Mastorakos 2006
Methods Randomised, active-controlled trial
Setting
Out-patient gynaecology clinic, University of Athens, Aretaieion Hospital, Athens,
Greece
Date of study
Not reported. Duration of the intervention 12 months
Participants N = 36
Mean age = 17 years
Inclusion criteria of the trial
• Adolescent girls (age range: 14 to 19 years) with clinically evoked and biologically
confirmed hyperandrogenism and ≤ 6 menses during the past 12 months indicating
chronic anovulation
• The diagnosis of PCOS in these patients was based on the criteria established at
the 1990 PCOS conference organised at the National Institutes of Health (Bethesda,
Maryland) by the National Institute of Child Health and Development (Dunaif 1992)
Exclusion criteria of the trial
• Adenoma-associated hyperprolactinaemia
• Functional thyroidopathy
• 21-hydroxylase deficiency associated with non-classic congenital adrenal
hyperplasia
• Androgen-secreting neoplasms
• Diabetes mellitus
Randomised
N = 36
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: desogestrel/EE 25.8 (1.81), CPA/EE 25.4 (1.49)
F-G score: desogestrel/EE 16.52 (1.74), CPA/EE 16.88 (1.27)
Waist/hip ratio: desogestrel/EE 0.74 (0.07), CPA/EE 0.73 (0.06)
Testosterone (ng/ml): desogestrel/EE 1.13 (0.09), CPA/EE 1.06 (0.10)
Free testosterone (pg/ml): desogestrel/EE 3.27 (1.8), CPA/EE 3.24 (0.75)
Androstenedione (ng/ml): desogestrel/EE 3.97 (0.35), CPA/EE 3.81 (0.29)
DHEAS (ng/ml): desogestrel/EE 2694.13 (341.45), CPA/EE 2563.42 (357.65)
SHBG (nmol/L): desogestrel/EE 35.31 (8.14), CPA/EE 29.18 (9.24)
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Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 12 months (18)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (18)
Outcomes Assessments (2): baseline and month 12
Outcomes of the trial (as reported)
1. Testosterone, free testosterone, 4-androstenedione, DHEAS), 17OH
progesterone, SHBG, total cholesterol, LDL and HDL cholesterol subfractions,
triglycerides, apolipoproteins (A-I, A-II, B), and lipoprotein
2. Fasting glucose and insulin serum levels were measured and an oral glucose
tolerance test
3. Abdominal ultrasound with a 5 mHz transducer was performed to assess the
morphology and the volume of the uterus and ovaries
4. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes Androgens, Ferriman-Gallwey score and abdominal ultrasound were assessed at baseline,
but not after 12 months as stated in the protocol. None of our outcomes are addressed.
After e-mail communication investigator provided Ferriman-Gallwey scores and andro-
gen levels after 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 421): ”Randomization was
based on computer-generated random
numbers“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”The ran-
domization is performed by our computer
technicianwhogenerates the randomnum-
bers and he is the only one to know in each
study the allocation sequence until the mo-
ment of assignment“
Comment: response provides insufficient
information to permit a clear judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
McLellan 1989
Methods Randomised, placebo-controlled trial
Setting
University Departments of Medicine and Dermatology, Western Infirmary, Glasgow,
UK
Date of study
Not reported. Duration of the intervention 9 months
Participants N = 38
Mean age = not reported
Inclusion criteria of the trial
• Women with presumptive diagnosis of idiopathic hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 38
Withdrawals/losses to follow-up
• 16/38 (42%); 8 pairs
• Non-compliance; 2 pairs (n = 4)
• Menorrhagia in active treatment group; 3 pairs (n = 6)
• Personal reasons unrelated to drug therapy; 3 pairs (n = 6)
Baseline data (mean (SEM))
Testosterone (nmol/L): spironolactone group 3.3 (0.3), placebo group 3.1 (0.2)
Androstenedione (nmol/L): spironolactone group 8.2 (1.0), placebo group 9.1 (1.0)
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DHEAS (µmol/L): spironolactone group 7.0 (0.8), placebo group 6.6 (1.0)
SHBG (nmol/L): spironolactone group 30.2 (4.9), placebo group 30.4 (3.7)
Interventions Intervention
• Spironolactone 100 mg/day for 9 months
Comparator
• Placebo for 9 months
Outcomes Assessments (5): baseline, week 6, 12, 24, and 36
Outcomes of the trial (as reported)
1. Change in hair diameter
2. Subjective effect of treatment; 5-point Likert scale
3. Subjective effect on acne, greasiness of the skin and hair
4. Serum androgens, gonadotrophins, prolactin, canrenone
Denotes outcomes prespecified for this review
Notes The patients were paired, one member of each pair being randomised to active treatment
and the other to placebo. > 40% losses to follow-up. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 459): ”The patients were
paired, one member of each pair being ran-
domized to active treatment and the other
to placebo. Pairs were matched primarily
for menstrual regularity (or irregularity)
but also, as closely as possible, for duration
and degree or hirsutism (Ferriman & Gall-
wey Index), family history of hirsutism, age
of menarche and presence of acne to ensure
equal allocation to the treatment groups of
any patients with unrecognized polycystic
ovary syndrome.“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
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was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 459): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 19): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 16/38 (42%); 8 pairs, per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 462): ”The study was sup-
ported by a grant from G.D. Searle & Co.
Ltd.“
Comment: G.D. Searle & Co. Ltd is the
manufacturer of spironolactone. A poten-
tial risk of bias cannot be excluded
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Methods Randomised, open-label, active-controlled trial
Setting
Monash University VascularMedicine Department at Dandenong Hospital, Melbourne,
Victoria, Australia
Date of study
2003 until 2005. Duration of the intervention 6 months
Participants N = 110
Mean age = 31 years
Inclusion criteria of the trial
• Overweight women (BMI > 27 kg/m2) with PCOS
• PCOS diagnosis was based on perimenarchal onset of irregular cycles (21 days or
35 days) and clinical manifestations of hyperandrogenism (hirsutism or acne) or
biochemical hyperandrogenism with elevation of at least one circulating ovarian
androgen (according to 1990 National Institutes of Health criteria (Teede 2006))
Exclusion criteria of the trial
• Secondary causes of amenorrhoea and hyperandrogenism (clinical screening and
early follicular 17-hydroxyprogesterone levels)
• Diabetes
• Pregnant women
• Medications affecting insulin resistance, including all OCPs < 3 months prior to
treatment
Randomised
N = 110
Withdrawals/losses to follow-up
• 10/110 (9%); 1/37 in metformin group, 4/35 in high dose OCP, 5/38 in low dose
OCP
• 8/10 for personal reasons, 1 from each OCP group for mood swings
Baseline data (mean)
BMI: metformin group 36.3, high-dose OCP 36.5, low-dose OCP 35.5
Waist/hip ratio: metformin group 0.87, high-dose OCP 0.84, low-dose OCP 0.86
F-G score: metformin group 8.80, high-dose OCP 6.7, low-dose OCP 6.4
Testosterone (nmol/L): metformin group 2.50, high-dose OCP 2.10, low-dose OCP 2.
76
DHEAS (µmol/L): metformin group 5.49, high-dose OCP 4.89, low-dose OCP 4.29
SHBG (nmol/L): metformin group 30.1, high-dose OCP 33.9, low-dose OCP 33.5
Interventions Intervention
• Metformin 1 g b.i.d. for 6 months (37)
Comparator 1
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (35)
Comparator 2
• OCP (ethinyl estradiol 30 µg + levonorgestrel 0.1 mg) + spironolactone 50 mg/
day for 6 months (38)
At screening, standard diet and lifestyle advice was delivered according toNational Heart
Foundation of Australia recommendations (www.heartfoundation.com.au)
Outcomes Assessments (2): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Waist/hip ratio, BMI, Ferriman-Gallwey score, menstrual diaries
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2. Insulin resistance
3. Surrogate markers of cardiovascular disease (non-invasive arterial parameters,
arterial stiffness, endothelial function)
4. DHEAS, SHBG, testosterone
5. Cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Denotes outcomes prespecified for this review
Notes Unclear how many women with PCOS were hirsute, the mean hirsutism score was only
> 8 in the metformin group. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 472): ”At randomization, 110
subjects were allocated to one of three
groups based on computer-generated ran-
dom numbers“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 472): ”...open-label...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 472): ”...open-label...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/110 (9%); 1/37 in metformin group,
4/35 in high-dose OCP, 5/38 in low-dose
OCP. Per-protocol analysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 477): ”This work was an in-
vestigator- initiated trial funded by a com-
petitive CVL grant sponsored by Pfizer
Australia and through internal department
funds. Pfizer Australia provided the aldac-
tone, and Douglas Pharmaceuticals Aus-
tralia provided the metformin.“
Comment: a potential risk of bias cannot
be excluded
Moghetti 2000
Methods Randomised, double-blind, placebo-controlled trial
Setting
Division of Endocrinology and Metabolic Diseases, University of Verona, and Division
of Dermatology, University of Bologna, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 40
Mean age = 20 years
Inclusion criteria of the trial
• Moderate to severe hirsutism
Exclusion criteria of the trial
• Cushing’s syndrome
• Adrenal enzyme defects
• Adrenal and ovarian tumours
• Hyperprolactinaemia
• Thyroid dysfunction
• Other disease
• OCP or antiandrogen drugs < 12 months prior to study entry
Randomised
N = 40
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: spironolactone group 25.3 (1.4), flutamide group 23.6 (1.0), finasteride group 23.
3 (0.7), placebo group 25.8 (2.0)
Modified F-G score: spironolactone group 16.9 (0.9), flutamide group 17.5 (1.5), finas-
teride group 18.4 (1.3), placebo group 17.2 (1.6)
Menses (irregular/regular): spironolactone group 2/8, flutamide group 8/2, finasteride
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group 4/6, placebo group 4/6
PCOS/other: spironolactone group 4/6, flutamide group 8/2, finasteride group 4/6,
placebo group 5/5
Interventions Intervention
• Spironolactone 100 mg/day for 6 months (10)
Comparator 1
• Flutamide 250 mg/day for 6 months (10)
Comparator 2
• Finasteride 5 mg/day for 6 months (10)
Comparator 3
• Placebo for 6 months (10)
Sexually active women were advised to use barrier contraceptive methods or intrauterine
devices
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Diameter of hair (5 plucked hairs from linea alba)
3. Participant’s subjective opinion; 4-point Likert scale
4. Questionnaire specifying cosmetic measure for hair removal
5. Serum gonadotropins, total testosterone, free testosterone, DHEAS,
androstenedione, 3α-androstanediol glucuronide
6. C19 and C21 steroid metabolites in 24-hour urine
7. Adverse events
Denotes outcomes prespecified for this review
Notes The Negri 2000 study (additional reference to this study) reports different outcomes,
not relevant to our systematic review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 90): ”...randomly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication: ”...were com-
puter-generated.“
Comment: probably done
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Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: central allo-
cation via the pharmacy
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 90): ”...double-blind treat-
ments, once daily orally as a wafer capsule.
..“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
and participants. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk Although serum total testosterone and an-
drostenedione were prespecified endocrine
assessments, no corresponding data were
reported
Comment: we judged this as at a high risk
of bias
After e-mail communication: these data
were provided by the PI and the judgement
has been amended to low risk of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, double-blind, placebo-controlled trial
Setting
Division of Endocrinology and Metabolic Diseases, University of Verona, Verona, Italy
Date of study
Not reported. Duration of intervention 26 weeks
Participants N = 23
Mean age = 23 years
Inclusion criteria of the trial
• PCOS
• 18 to 35 years
• Diagnosis of PCOS was based on the presence of hyperandrogenic chronic
anovulation, after exclusion of Cushing’s syndrome, late-onset 21-hydroxylase
deficiency, thyroid dysfunction, hyperprolactinaemia, or androgen-secreting tumours,
according to recommendations of the NIH consensus development conference on
PCOS (Dunaif 1992)
Exclusion criteria of the trial
• Other diseases or taking medications
Randomised
N = 23
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: metformin group 27.1 (1.5), placebo group 32.6 (1.1)
Waist/hip ratio: metformin group 0.84 (0.02), placebo group 0.86 (0.02)
Free testosterone (pmol/L): metformin group 11.6 (1.8), placebo group 10.7 (1.4)
Androstenedione (nmol/L): metformin group 12.5 (1.5), placebo group 10.3 (0.7)
DHEAS (µmol/L): metformin group 6.6 (0.7), placebo group 5.2 (0.5)
SHBG (nmol/L): metformin group 35.6 (8.2), placebo group 33.5 (5.7)
Interventions Intervention
• Metformin 500 mg once daily to 3 times a day for 26 weeks (12)
Comparator
• Placebo for 26 weeks (11)
Outcomes Assessments (2): baseline and week 26
Outcomes of the trial (as reported)
1. Assessment of menstrual history, with recording of menses in the 6-month
periods before the study and during treatment
2. Physical examination for body weight, waist/hip ratio, hirsutism score, and blood
pressure
3. Serum gonadotropins, androgens (total and free testosterone, DHEAS,
androstenedione), 17-hydroxyprogesterone, estradiol, SHBG and lipoproteins (total
and HDL cholesterol, triglycerides)
4. GnRH-agonist challenge with measurement of serum 17-hydroxyprogesterone,
gonadotropins and estradiol, 24 hours after 0.1 mg buserelin subcutaneously
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5. Oral glucose tolerance test, with plasma glucose and insulin measurements on
samples obtained every 30 minutes for 2 hours
6. Insulin sensitivity assessment by the glucose clamp technique
7. Adverse events
Denotes outcomes prespecified for this review
Notes Quote (page 140): ”Eighteen out of the 23 women included in protocol A received
metformin in an open design providing treatment for an unscheduled duration after the
completion of the double-blind study“
Quote (page 141): ”Subjects with hirsutism were equally distributed in the two groups,
and no significant change in hirsutism score was found after treatment in either group
(data not shown).“ After e-mail communication, we received additional information, see
Table 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 140): ”Women were ran-
domly assigned...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication: ”...were com-
puter-generated.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: central allo-
cation via the pharmacy
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 140): ”...assigned to double-
blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 140): ”...assigned to double-
blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 139): ”This work was sup-
ported by grants from the Italian Ministry
of Higher Education and Scientific Re-
search, and the Regione del Veneto (DGRV
964, n.652 and n.693).“ There is baseline
imbalance regarding BMI, but the number
of subjects with hirsutism were equally dis-
tributed
Comment: we judged this as at a low risk
of bias
Moltz 1984
Methods Randomised, double-blind, placebo-controlled trial
Setting
Multi-centre (9) in Germany
Date of study
Not reported. Duration of intervention 9 to 12 months
Participants N = 164
Mean age = not reported
Inclusion criteria of the trial
• Women with moderate to severe seborrhoea, acne, and hirsutism
Exclusion criteria of the trial
• Androgen-producing tumours
Randomised
N = 164
Withdrawals/losses to follow-up
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• Unclear; 29/82 (35%) dropped out in OCP + CPA group after 9 months and 41/
82 (50%) after 12 months. Unclear how many dropped out in the control group
Baseline data
Only reported for the first 15 participants in each group
Interventions Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) + 10 mg cyproterone
acetate first 15 days of pill cycle for 9 to 12 months (82)
Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 9 to 12 months (82)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Improvement of seborrhoea
2. Improvement of hirsutism on face, legs, and belly
3. Improvement of acne
Denotes outcomes prespecified for this review
Notes Unclear how many dropped out in control group, unclear how many were hirsute in
control group. Mainly data are reported on the OCP + CPA group, and hardly any data
on control group. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 48): ”...erhielten nach
zufälliger Verteilung...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 48): ”...einer Doppelblind-
Studie...“ The control group received
placebo tablets instead of the 10 mg CPA
during the first 15 days of pill cycle
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Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study personnel from knowl-
edge of which intervention a participant re-
ceived, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/82 (35%) dropped out in OCP + CPA
group after 9 months and 41/82 (50%) af-
ter 12months. Unclear howmany dropped
out in the control group
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Insufficient information to permit a clear
judgement
Morin-Papunen 2000
Methods Randomised, active-controlled trial
Setting
Reproductive Endocrine Unit at Oulu, University Hospital, Oulu, Finland
Date of study
Not reported. Duration of intervention 6 months
Participants N = 32
Mean age = 30 years
Inclusion criteria of the trial
• Obese (BMI > 27 kg/m2) women with PCOS
• Criteria for PCOS were as defined by Homburg 1996
Exclusion criteria of the trial
• Diabetic subjects
• Smokers and alcohol users
• Sex hormones or drugs known to affect lipid metabolism < 2 months prior to
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study entry
Randomised
N = 32
Withdrawals/losses to follow-up
• 14/32 (44%); 6/14 in metformin group, 8/16 in EE + CPA group
• Moved 1/32; 1/14 in metformin group
• Personal reasons 2/32; 1/14 in metformin group, 1/16 in EE + CPA group
• Manifest diabetes mellitus 3/32; 2/14 in metformin group, 1/16 in EE+ CPA
group
• Adverse events 3/32; 2/14 in metformin group, 1/16 in EE+ CPA group
• No reason reported 5/32; 5/16 in EE + CPA group
Baseline data (mean (SEM))
BMI: metformin group 32.5 (1.1), EE + CPA group 37.2 (1.8)
Waist/hip ratio: metformin group 0.89 (0.04), EE + CPA group 0.86 (0.01)
F-G score: metformin group 10.3 (1.9), EE + CPA group 9.0 (2.1)
Interventions Intervention
• Metformin 500 to 1000 mg b.i.d. for 6 months (14)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (16)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Transvaginal ultrasonography
2. Waist and hip circumferences, BMI
3. OGTT
4. Ferriman-Gallwey score
5. Assessment of insulin sensitivity; the euglycaemic hyperinsulinaemic clamp
technique
6. Calorimetry
7. SHBG, LH, FSH, androstenedione, DHEA, DHEAS, 17-hydroxyprogesterone,
testosterone, free testosterone
Denotes outcomes prespecified for this review
Notes Unclear how many were randomised to each group; unclear to which group the 6/14
women that dropped out for unreported reasons were allocated. High number of total
losses (44%), see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 3162): ”...were randomized to
either...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
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cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail contact, quote: ”...it was per-
formed by the hospital pharmacy with 1:
1 allocation in random blocks of ten using
two computer-generated lists.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail contact, quote: ”the allocation
was concealed in a closed envelope where
the number of the patient was written. The
participant knew the allocation after she
had accepted to participate.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/32 (44%); unclear how many in each
group. Per-protocol analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Other bias Low risk Quote (page 3161): ”Supported by grants
from the Sigrid Jusenius Foundation, the
Academy of Finland, and the Finnish As-
sociation of Obstetrics and Gynecology.“
Comment: we judged this as at a low risk
of bias
Morin-Papunen 2003
Methods Randomised, active-controlled trial
Setting
Reproductive Endocrine Unit at Oulu, University Hospital, Oulu, Finland
Date of study
Not reported. Duration of intervention 6 months
Participants N = 17
Mean age = 28 years
Inclusion criteria of the trial
• Non-obese (BMI < 25 kg/m2) women with PCOS
• Criteria for PCOS were as defined by Homburg 1996
Exclusion criteria of the trial
• Diabetic subjects
• Smokers and alcohol users
• Sex hormones or drugs known to affect lipid metabolism < 2 months prior to
study entry
Randomised
N = 17
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: metformin group 22.5 (0.8), EE + CPA group 21.8 (0.8)
Waist/hip ratio: metformin group 0.78 (0.01), EE + CPA group 0.79 (0.02)
F-G score: metformin group 7.88 (1.9), EE + CPA group 5.2 (0.6)
Interventions Intervention
• Metformin 500 to 1000 mg b.i.d. for 6 months (8)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (9)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Transvaginal ultrasonography, blood pressure
2. Waist and hip circumferences, BMI
3. OGTT
4. Ferriman-Gallwey score
5. Assessment of insulin sensitivity; the euglycaemic hyperinsulinaemic clamp
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technique
6. Calorimetry
7. SHBG, LH, FSH, androstenedione, DHEA, DHEAS, 17-hydroxyprogesterone,
testosterone, free testosterone
Denotes outcomes prespecified for this review
Notes No separate data on women that were hirsute, means of Ferriman-Gallwey score in both
groups were below threshold for hirsutism (Ferriman-Gallwey score > 8), see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 149): ”...were randomized to
either...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail contact, quote: ”...it was per-
formed by the hospital pharmacy with 1:
1 allocation in random blocks of ten using
two computer-generated lists.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail contact, quote: ”...the alloca-
tion was concealed in a closed envelope
where the number of the patient was writ-
ten. The participant knew the allocation af-
ter she had accepted to participate.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 154): ”Supported by grants
provided by the University of Oulu, the
Finnish Association of Obstetrics and Gy-
necology, the Sigrid Jusenius Foundation,
and the Academy of Finland.“
Comment: we judged this as at a low risk
of bias
Murdoch 1987
Methods Randomised, double-blind, placebo-controlled trial
Setting
The University of Newcastle upon Tyne, Princess Mary Maternity Hospital, Newcastle
upon Tyne, UK
Date of study
Not reported. Duration of study 1 year
Participants N = 22
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women with PCOS
• PCOS based on the clinical symptoms oligomenorrhoea or amenorrhoea and
hirsutism dating from the menarche. In all the subjects the hirsutism score was > 8
using the scoring system described by Ferriman and Gallwey. In addition the patients
had elevated serum LH concentrations ( > 6 u/L); the LH:FSH ratio was > 2:1 and
plasma testosterone and androstenedione concentration were at or above the upper
limits of the normal female range
Exclusion criteria of the trial
• Other endocrine abnormalities
Randomised
N = 22
Withdrawals/losses to follow-up
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• 6/22 (27%); 4/11 in bromocriptine group, 2/11 in placebo group
• Social reasons; 1/11 in bromocriptine group, 1/11 in placebo group
• Side effects; 3/11 in bromocriptine group, 1/11 in placebo group
Baseline data (range)
Testosterone (nmol/L): bromocriptine group from 3.0 to 6.8, placebo group 3.0 to 5.1
Androstenedione (nmol/L): bromocriptine group 9.5 to 39.2, placebo group 9.0 to 42.
2
Interventions Intervention
• Bromocriptine 2.5 mg 3 times a day for 1 year (11)
Comparator
• Placebo for 1 year (11)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Subjective assessment of hirsutism; 3-point Likert scale
2. Objective assessment; photographic evaluation of number of hairs and growth rate
3. Menstruation frequency
4. Androstenedione, testosterone, estradiol, estrone, SHBG
5. LH and FSH
Denotes outcomes prespecified for this review
Notes Individual participant data are provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 358): ”...were allocated ran-
domly...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 358): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 358): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/22 (27%); 4/11 in bromocriptine group,
2/11 in placebo group. Per-protocol analy-
sis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Unclear risk Quote (page 364): ”We are grateful for the
financial support for this study provided by
Sandoz UK Ltd.“
Comment: a potential risk of bias cannot
be excluded
Müderris 2000
Methods Randomised, active-controlled trial
Setting
Departments of Gynecology and Obstetrics and Endocrinology at Erciyes University
Medical Faculty, Kayseri, Turkey
Date of study
Not reported. Duration of intervention 12 months
Participants N = 70
Mean age = 23 years
Inclusion criteria of the trial
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• Hirsute women
Exclusion criteria of the trial
• Medication < 6 months prior to study entry
Randomised
N = 70
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
PCOS: flutamide group 16/35, finasteride group 21/35
F-G score: flutamide group 17.8 (5.8), finasteride group 19.1 (6.1)
Testosterone (ng/dl): flutamide group 74.3 (24.9), finasteride group 65.7 (39.4)
Free testosterone (pg/ml): flutamide group 3.6 (1.4), finasteride group 3.9 (2.0)
Androstenedione (ng/ml): flutamide group 3.3 (0.9), finasteride group 3.1 (1.3)
DHEAS (ng/ml): flutamide group 192.0 (59.5), finasteride group 299.8 (148.9)
SHBG (nmol/L): flutamide group 28.9 (7.1), finasteride group 33.7 (14.9)
Interventions Intervention
• Flutamide 250 mg/day for 12 months (35)
Comparator
• Finasteride 5 mg/day for 12 months (35)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Total testosterone, free testosterone, FSH, LH, E2, DHEAS, androstenedione,
17a-hydroxyprogesterone and SHBG
3. Haematologic, hepatic, renal function analysis
4. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 985): ”Subjects were assigned
randomly in a 1:1 ratio“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Navali 2012
Methods Randomised, active-controlled trial
Setting
Al-Zahra Educational and Health Hospital Center and Sheikh Alra’ is Clinic of Tabriz
University of Medical Sciences, Tabriz, Iran
Date of study
Not reported. Duration of intervention 6 months
Participants N = 100
Mean age = 28 years
Inclusion criteria of the trial
• Women with PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 100
343Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Navali 2012 (Continued)
Withdrawals/losses to follow-up
• 6/100 (6%); 6/50 in pioglitazone group due to weight gain, these were replaced
by new participants
Baseline data (mean (SEM)/percentage)
BMI: metformin group 27.9 (0.9), pioglitazone group 27.8 (0.7)
Primary infertility: metformin group 44%, pioglitazone group 34%
Secondary infertility: metformin group 30%, pioglitazone group 38%
Hirsutism: metformin group 31/50, pioglitazone group 32/50
Interventions Intervention
• Metformin 500 mg 3 times a day for 6 months (50)
Comparator
• Pioglitazone 15 mg b.i.d. for 6 months (50)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Clinical and laboratory parameters including pattern of menstrual cycles,
hirsutism, fasting blood sugar, hyperinsulinaemia, oral glucose tolerance test, glucose,
insulin, free testosterone and prolactin
2. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 358): ”...were randomly di-
vided...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/100 (6%); 6/50 in pioglitazone group
due to weight gain, these were replaced by
new participants
Comment: low number of losses to follow-
up and although replaced, we judged this
as at a low risk of bias
Selective reporting (reporting bias) Unclear risk Although prespecified as outcomes, serum
free testosterone and prolactin at end of
study, were unreported
Comment: we judged this as at unclear risk
of bias
Other bias Low risk The study appears to be free of other
sources of bias
O’Brien 1991
Methods Randomised, active-controlled trial
Setting
Department of Endocrinology, Austin Hospital, Heidelberg, Victoria, Australia
Date of study
Not reported. Duration of intervention 6 months
Participants N = 50
Mean age = 32 years
Inclusion criteria of the trial
• Hirsute women based on PCOS (8) or idiopathic hirsutism (42)
Exclusion criteria of the trial
• Cliteromegaly and severe virilisation
Randomised
N = 50
Withdrawals/losses to follow-up
• 4/50 (8%); 1/27 in CPA group, 3/23 in spironolactone group
• Personal reasons; 0/27 in CPA group, 2/23 in spironolactone group
• Adverse events; 1/27 in CPA group, 1/23 in spironolactone group
Baseline data (mean (SEM))
Total hair diameters (µm): spironolactone group 182 (9.2), CPA group 184 (12.6)
Testosterone (nmol/L): spironolactone group 2.3 (0.2), CPA group 2.5 (0.2)
DHEAS (µmol/L): spironolactone group 8.1 (0.8), CPA group 8.1 (0.7)
Androstenedione (nmol/L): spironolactone group 6.0 (0.4), CPA group 6.1 (0.6)
SHBG (nmol/L): spironolactone group 35.8 (5.0), CPA group 34.3 (3.9)
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Interventions Intervention
• Spironolactone 100 mg/day + triphasic OCP for 6 months (23)
Comparator
• Cyproterone acetate 100 mg/day + 30 µg ethinyl estradiol on days 5 to 14 of
menstrual cycle for 6 months (27)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Testosterone, androstenedione, DHEAS, SHBG
2. Electrolytes, urea, creatinine, liver function tests
3. Total hair shaft diameter, medullary diameter; 10 hairs plucked from facial area
4. Record of frequency with which participants performed cosmetic measures
5. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1008): ”Randomization was
performed with subjects stratified for the
presence of PCO.“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
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ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/50 (8%); 1/27 in CPA group, 3/23 in
spironolactone group. Per-protocol analy-
sis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Onalan 2005
Methods Randomised, double-blind, placebo-controlled trial
Setting
Reproductive Endocrinology Unit of Centrum Clinic, Ankara, Turkey
Date of study
Not reported. Duration of intervention 6 months
Participants N = 139
Mean age = 27 years
Inclusion criteria of the trial
• Oligomenorrhoea or amenorrhoea as a surrogate for oligo-anovulation since
menarche and who also had at least one of the criteria of hyperandrogenism including a
hirsutism score of more than 7 (according to Ferriman and Gallwey) and/or an elevated
serum concentrations of free testosterone (> 4 ng/dl) were diagnosed as PCOS, after
excluding all other causes of hyperandrogenism
Exclusion criteria of the trial
• Medications known to alter insulin secretion or action
• Endocrinopathies (including Cushing’s syndrome, non-classic congenital adrenal
hyperplasia due to 21-hydroxylase deficiency, hyperprolactinaemia or thyroid
dysfunction, type 2 diabetes)
Randomised
N = 139
Withdrawals/losses to follow-up
• 23/139 (17%); 17/72 in metformin group, 6/67 in placebo group
• Gastrointestinal side effects; 15/72 in metformin group
• Headache; 4/139 unclear which group
• Unreported reason; 4/139
Baseline data
See ’Notes’
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Interventions Intervention
• Metformin 850 mg b.i.d. or 3 times a day according to BMI for 6 months (72)
Comparator
• Placebo for 6 months (67)
Patients were instructed not to modify their usual eating habits throughout the study
Outcomes Outcomes of the trial (as reported)
1. Serum FSH, LH, estradiol, progesterone, prolactin, testosterone, free
testosterone, androstenedione, insulin, cortisol, TSH, DHEAS, SHBG
2. Cholesterol, triglyceride, LDL, HDL
3. Ovulation
4. Weight, height, waist-hip circumferences, BMI
5. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes Participants were randomised into 6 groups according to BMI and normo- or hyper-
insulinaemic, of which half received metformin and remainder placebo, so total of 12
groups, listing baseline criteria for 12 groups is not feasible
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 205): ”Patients were ran-
domized on either metformin or placebo
therapies according to the code provided
by computer generated randomization in
blocks of four“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 204): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
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judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 204): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 23/139 (17%); 17/72 in metformin group,
6/67 in placebo group. Per-protocol analy-
sis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Oner 2011
Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynecology, Faculty of Medicine, Erciyes University,
Kayseri, Turkey
Date of study
Not reported. Duration of intervention 6 months
Participants N = 50
Mean age = 23 years
Inclusion criteria of the trial
• Nonpregnant, premenopausal women with moderate and severe hirsutism
Exclusion criteria of the trial
• Androgen-secreting adrenal or ovarian neoplasm (total plasma T < 200 ng/dl;
plasma DHEAS) < 7000 ng/ml)
• Cushing’s syndrome
• Congenital adrenal hyperplasia (early follicular phase plasma 17-
hydroxyprogesterone < 3 ng/ml) or signs of virilisation
• OCP or long acting progestogens < 12 months prior to study entry
Randomised
N = 50
Withdrawals/losses to follow-up
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• 3/50 (6%); 1/25 in EE 0.03 mg + DRSP group, 2/25 in EE 0.02 mg + DRSP
group
Baseline data (mean (SD))
BMI: EE 0.03 mg + DRSP group 23.4 (4.6), EE 0.02 mg + DRSP group 23.9 (6.6)
Modified F-G score: EE 0.03 mg + DRSP group 17.3 (5.2), EE 0.02 mg + DRSP group
17.5 (4.8)
Total testosterone (ng/dl): EE 0.03 mg +DRSP group 87.5 (43.7), EE 0.02 mg + DRSP
group 80.5 (40.5)
Free testosterone (pg/ml): EE 0.03 mg + DRSP group 2.9 (0.9), EE 0.02 mg + DRSP
group 2.8 (0.7)
Androstenedione (ng/ml): EE 0.03 mg + DRSP group 2.9 (0.3), EE 0.02 mg + DRSP
group 3.0 (0.1)
DHEAS (µg/ml): EE 0.03 mg + DRSP group 2.6 (1.3), EE 0.02 mg + DRSP group 2.
6 (1.3)
SHBG (nmol/L): EE 0.03 mg + DRSP group 45.3 (22.1), EE 0.02 mg + DRSP group
48.1 (30.2)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg 21 days of cycle) for 6 months
(25)
Comparator
• OCP (ethinyl estradiol 20 µg + drospirenone 3 mg 24 days of cycle) for 6 months
(25)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Total testosterone, free testosterone, androstenedione, DHEAS, SHBG, FSH,
LH, estradiol
3. Menstrual cycle, side effects
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 509): ”...were randomized us-
ing a computer-generated randomization
table“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
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seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 509): ”To avoid interobserver
errors, the same physician (I.I.M.) who was
blinded to the treatments graded the degree
of hirsutism according to a modified Ferri-
man-Gallwey (F-G) scoring system“
Comment: although the assessment of
this outcome was blinded, the other out-
come assessments (by participants/health-
care providers) were not blinded
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/50 (6%); 1/25 in EE 0.03 mg + DRSP
group, 2/25 in EE 0.02 mg +DRSP group.
Per-protocol analysis
Comment: low and balanced number of
drop-outs at follow-up and, although per-
protocol analysis, considered to be at a low
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Oner 2011B
Methods Randomised, active-controlled trial
Setting
Gynaecologic Endocrinology Clinic at Erciyes University, Kayseri, Turkey
Date of study
March 2008 until April 2009. Duration of intervention 24 weeks
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Participants N = 100
Mean age = 23 years
Inclusion criteria of the trial
• Women with PCOS with hirsutism and menstrual irregularity
• PCOS according to Rotterdam Criteria PCOS 2004, i.e. the presence of at least 2
of the following 3 criteria: (1) oligo- or anovulation, (2) clinical and/or chemical signs
of hyperandrogenism, and/or (3) polycystic ovaries; and exclusion of other aetiologies
such as congenital adrenal hyperplasia, Cushing’s syndrome or androgen-secreting
tumours
Exclusion criteria of the trial
• Thyroid disease, hyperprolactinaemia, and diabetes mellitus
• Drugs that could interfere with the normal function of the hypothalamic-
pituitary-gonadal axis
Randomised
N = 100
Withdrawals/losses to follow-up
• 25/100 (25%); 20/50 (40%) in metformin group, 5/50 (10%) in N-acetyl-
cysteine group
• Incomplete data or voluntary drop-out; 15/50 in metformin group, 5/50 in N-
acetyl-cysteine group
• Gastrointestinal side effects; 2/50 in metformin group, 0/50 in N-acetyl-cysteine
group
• Protocol violation; 2/50 in metformin group, 0/50 in N-acetyl-cysteine group
• Lost to follow-up; 1/50 in metformin group, 0/50 in N-acetyl-cysteine group
Baseline data (mean (SD))
BMI: metformin group 24.3 (6.2), N-acetyl-cysteine group 23.0 (4.6)
F-G score: metformin group 11.4 (4.6), N-acetyl-cysteine group 12.2 (4.2)
Total testosterone (ng/dl): metformin group 86.1 (48.4), N-acetyl-cysteine group 80.8
(41.1)
Free testosterone (pg/ml): metformin group 2.06 (0.8), N-acetyl-cysteine group 2.7 (1.
1)
Androstenedione (ng/ml): metformin group 3.8 (1.6), N-acetyl-cysteine group 4.3 (1.
3)
DHEAS (ng/ml): metformin group 3090.7 (1711.4), N-acetyl-cysteine group 2608.8
(1121.4)
SHBG (nmol/L): metformin group 43.7 (28.2), N-acetyl-cysteine group 47.5 (21.7)
Interventions Intervention
• Metformin 1500 mg/day for 6 months (50)
Comparator
• N-acetyl-cysteine 1800 mg/day for 6 months (50)
Outcomes Assessments (3): baseline, week 12 and 24
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. BMI
3. FSH, LH, DHEAS, 17-OH progesterone, total and free testosterone,
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androstenedione, TSH, prolactin
4. Oral glucose tolerance test, glucose, insulin, HOMA
Denotes outcomes prespecified for this review
Notes Imbalance in losses to follow-up with 40% losses to follow-up in metformin arm and
10% in the N-acetyl-cysteine arm, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 128): ”...were randomly di-
vided into two groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 25/100 (25%); 20/50 (40%) in metformin
group, 5/50 (10%) in N-acetyl-cysteine
group. Per-protocol analysis
Comment: the high and imbalanced drop-
out rate with per-protocol analysis repre-
sents a potential high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
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appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Ortega-González 2005
Methods Randomised, active-controlled trial
Setting
Department of Endocrinology, InstitutoNacional de Perinatología,MéxicoCity,México
Date of study
Not reported. Duration of intervention 24 weeks
Participants N = 57
Mean age = 29 years
Inclusion criteria of the trial
• Women with PCOS, aged 21 to 35 years, naive to any specific treatment, whose
chief complaints were hirsutism (Ferriman-Gallwey score > 8) and/or sterility
• The diagnosis of PCOS was based on at least 2 of the 3 following abnormalities:
oligomenorrhoea or amenorrhoea, high serum androstenedione (> 2.9 ng/ml) and/or
free testosterone (> 3.075 pg/ml) concentrations, and/or polycystic ovaries detected by
ultrasound (Rotterdam Criteria PCOS 2004)
• BMI > 25 kg/m2, acanthosis nigricans, fasting hyperinsulinaemia (> 16 mIU/ml)
and a fasting glucose/insulin (G/I) ratio < 4.5
Exclusion criteria of the trial
• Type 2 diabetes mellitus
• Hyperprolactinaemia
• Thyroid disorders
• Late-onset congenital adrenal hyperplasia
• Cushing’s syndrome
Randomised
N = 57
Withdrawals/losses to follow-up
• 23/57 (40%); 10/27 in pioglitazone group, 13/30 in metformin group
• Lost to follow-up; 5/27 in pioglitazone group, 5/30 in metformin group
• Pregnancy; 5/27 in pioglitazone group, 3/30 in metformin group
• Adverse events; 0/27 in pioglitazone group, 5/30 in metformin group
Baseline data (mean (SEM))
BMI: pioglitazone group 32.3 (1.1), metformin group 34.4 (1.7)
F-G score: pioglitazone group 15.4 (0.87), metformin group 16.4 (0.95)
Interventions Intervention
• Pioglitazone 30 mg/day for 24 weeks (27)
Comparator
• Metformin 850 mg 3 times a day for 24 weeks (30)
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Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Height, weight, BMI, waist/hip ratio
2. Ferriman-Gallwey score
3. Oral glucose tolerance test, HOMA-IR, QUICKI, serum glucose, and insulin
4. Prolactin curve
Denotes outcomes prespecified for this review
Notes Drop-outs in the metformin arm 43%, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 234): ”...randomly allocated.
..Randomization was by random number
tables“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 234): ”The patients’ number
treatment codes were held and kept until
the end of the trial by a third party (not
participating in the study) and patients’
names were disclosed after completion of
the study.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 23/57 (40%); 10/27 in pioglitazone group,
13/30 in metformin group. Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 238): ”Pharmaceutical com-
panies had no role in the study design, data
collection, data analysis, data interpreta-
tion or writing of the report. No funding
of any kind was ever received to perform
the study nor received by any of the par-
ticipants in the study“ and ”We thank Eli
Lilly Mexico, for the kind supply of piogli-
tazone tablets and to Laboratorios Pisa for
the kind gift of metformin tablets.“
Comment: we judged this as at a low risk
of bias
Otta 2010
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Endocrinology of Hospital Privado Centro Médico, de Córdoba,
Córdoba, Argentina
Date of study
Not reported. Duration of intervention 4 months
Participants N = 30
Mean age = 25 years
Inclusion criteria of the trial
• Women with PCOS, defined by hyperandrogenaemia (elevated serum
testosterone concentrations) and oligomenorrhoea (cycles of 35 days or longer) or
amenorrhoea (no menses in the last 6 months) after negative screening pregnancy test.
Estimation of insulin resistance was derived from the HOMA index and other causes
of hyperandrogenism (Cushing’s syndrome, late-onset congenital adrenal hyperplasia,
and androgen-secreting tumours) were excluded with appropriate diagnostic tests
Exclusion criteria of the trial
• Thyroid dysfunction
• Hyperprolactinaemia
• Diabetes
• Severe infections
• Cardiovascular, renal, or hepatic abnormalities
• Any medications < 3 months prior to study entry
Randomised
N = 30
Withdrawals/losses to follow-up
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• 1/30 (3%); 1/15 in metformin group for lack of adherence to treatment, 0/15 in
placebo group
Baseline data (mean (SD))
F-G score: metformin group 11.73 (5.31), placebo group 13.5 (5.97)
Acne: metformin group 8/15, placebo group 10/15
Androgenetic alopecia: metformin group 4/15, placebo group 5/15
BMI: metformin group 32.4 (6.7), placebo group 35.6 (4.98)
Testosterone (ng/dl): metformin group 93.2 (22.01), placebo group 94.47 (18.22)
Androstenedione (ng/ml): metformin group 2.87 (1.01), placebo group 2.98 (1.27)
Interventions Intervention
• Metformin from 500 mg once a day to 750 mg b.i.d. for 4 months (15)
Comparator
• Placebo for 4 months (15)
Patients were also given a nutritional plan of 1500 calories daily. Thewomenwere advised
to exercise (a minimum of 40 min of brisk walking per day, 4 times a week) and to use
barrier contraceptives during the whole study
Outcomes Assessments (5): baseline, month 1, 2, 3, and 4
Outcomes of the trial (as reported)
1. Menstrual cycles
2. BMI, waist circumference, waist/hip ratio, blood pressure, acanthosis nigricans,
and clinical signs of androgen excess (hirsutism measured by a modification of the
Ferriman-Gallwey method, acne, seborrhoeic skin, and androgenetic alopecia)
3. Total testosterone, androstenedione, DHEAS, progesterone, gonadotropins,
insulin, glucose, total cholesterol, HDL and LDL cholesterol, and triglycerides
4. Oral glucose tolerance test
5. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 174): ”The women were ran-
domly assigned through a computerized al-
location software...“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
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was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Each pack
of treatment was opaque and coded from
the laboratory“
Comment: form of central allocation,
probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 174): ”...in a double-blind
way...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After e-mail communication: ”Pills were
exactly the same in shape and colour, and
both (metformin and placebo) were ta-
pered to one and a half pill BID“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 174): ”...in a double-blind
way...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
After e-mail communication: ”Pills were
exactly the same in shape and colour, and
both (metformin and placebo) were ta-
pered to one and a half pill BID.“
Comment: blinding of participants andkey
study personnel was ensured, and it is un-
likely that the blinding could have been
broken. We judged this as at a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/30 (3%); 1/15 in metformin group for
lack of adherence to treatment, 0/15 in
placebo group. Per-protocol analysis
Comment: low number of drop-outs at fol-
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low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote page 177: ”This trial was done with
a grant from National Institutes of Health
(NCT00679679).“
Comment: we judged this as at a low risk
of bias
Paoletti 1999
Methods Randomised, double-blind, placebo-controlled trial
Setting
Università degli Studi di Cagliari, Cagliari, and Università degli Studi di Modena, Mod-
ena, Italy
Date of study
Not reported. Duration of intervention for at least 5 months
Participants N = 22
Mean age 23 years
Inclusion criteria of the trial
• Women with idiopathic hirsutism (IH) and non obese women with PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 22
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean(SD))
Free testosterone (pg/ml): IH group 1.52 (0.63), PCOS group 2.51 (1.15), control group
1.32 (0.79)
Total testosterone (ng/ml): IH group 0.62 (0.22), PCOS group 1.14 (0.32), control
group 0.59 (0.52)
DHEAS (ng/ml): IH group 1.80 (1.04), PCOS group 2.20 (0.37), control group 2.00
(1.92)
Androstenedione (ng/ml): IH group 2.88 (0.66), PCOS group 5.03 (2.62), control
group 2.22 (1.26)
Interventions Intervention
• Flutamide 250 mg b.i.d. for at least 5 months (12)
Comparator
• Placebo (10)
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Outcomes Assessments (2): baseline and month 4
Outcomes of the trial (as reported)
1. Fasting and oral glucose tolerance test stimulated levels of glucose, insulin and C-
peptide
2. Liver function tests
3. Menstruation calendar
4. Adverse events
5. Hirsutism score (Ferriman-Gallwey score)
Denotes outcomes prespecified for this review
Notes The study also included 10 controls. There were no baseline values for hirsutism per
treatment arm, only baseline values for women with idiopathic hirsutism and for women
with PCOS, and as adverse events appear not to be reported, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 449): ”...on the basis of a ran-
domized, computer-generated list...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 449): ”...in a double-blind
fashion, oral treatmentwith flutamide (250
mg twice a day) or placebo (2 tablets of
inert compound, visually indistinguishable
from tablets of the active compound).“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed as
well as participant-assessed (menstruation)
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
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the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Unclear risk Adverse events, although a prespecified
outcome, were not addressed
Comment: we judged this as at unclear risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Pasquali 1986
Methods Randomised, active-controlled trial
Setting
First Institute of InternalMedicine and the Institute of Physiopathology ofReproduction,
University of Bologna, Bologna, Italy
Date of study
Not reported. Duration of intervention 3 months
Participants N = 14
Mean age = 22 years
Inclusion criteria of the trial
• Women with PCOS and obesity (BMI > 28 kg/m2)
• PCOS was based on oligomenorrhoea or amenorrhoea, hirsutism,
hyperandrogenism, elevated LH/FSH ratio, ultrasound of the ovaries
Exclusion criteria of the trial
• Not reported
Randomised
N = 14
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SEM))
BMI: hypocaloric diet + CPA/EE group 33.5 (1.5), hypocaloric diet alone group 32.0
(1.1)
Interventions Intervention
• Hypocaloric diet (1000 to 1200 kcal/day) + cyproterone acetate 50 mg/day (10
days) + ethinyl estradiol 50 µg (21 days) for 3 months (7)
Comparator
• Hypocaloric diet (1000 to 1200 kcal/day) for 3 months (7)
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Outcomes Assessments (4): baseline, month 1, 2, and 3
Outcomes of the trial (as reported)
1. Clinical condition, weight loss, adherence to diet
2. Hormonal and biochemical evaluations, oral glucose tolerance test
3. Glucose and insulin levels
Denotes outcomes prespecified for this review
Notes Unclear how many women were hirsute, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 141): ”The choice of treat-
ment for each patient was randomized“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
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Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 139): ”This work was sup-
ported in part by a grant from theMinistry
of Education, funds 40%, 1984.“
Comment: we judged this as at a low risk
of bias
Pasquali 2000
Methods Randomised, double-blind, active-controlled trial
Setting
Endocrine Unit of the Department of Internal Medicine and Gastroenterology of the S.
Orsola-Malpighi Hospital of Bologna, Bologna, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 40
Mean age = 31 years
Inclusion criteria of the trial
• Women with PCOS and 20 obese controls, comparable for age and weight (BMI
> 28 kg/m2)
• The diagnosis of PCOS was made according to the presence of oligomenorrhoea
(less than 4 cycles in the last 6 months) or amenorrhoea (no menses in the last 6
months) and hyperandrogenism, defined by supranormal total and free T
concentrations
Exclusion criteria of the trial
• Thyroid dysfunction
• Type II diabetes
• Concomitant cardiovascular, renal, and liver dysfunction
• Cushing syndrome and disease and congenital adrenal hyperplasia
• Medication < 3 months prior to study entry
• Dieting
Randomised
N = 40
Withdrawals/losses to follow-up
• 5/40 (13%); 2/20 in metformin group, 3/20 in placebo group
• Non-compliance; 0/20 in metformin group, 3/20 in placebo group
• Pregnancy; 2/20 in metformin group, 0/20 in placebo group
Baseline data
Hirsutism: 13/20 PCOS were hirsute none of the controls
Interventions Intervention
• Hypocaloric diet (1200 to 1400 kcal/day) + metformin 850 mg b.i.d. for 6
months (20)
Comparator
• Hypocaloric diet (1200 to 1400 kcal/day) + placebo b.i.d. for 6 months (20)
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Outcomes Assessments: (3): baseline, month 1 and 7
Outcomes of the trial (as reported)
1. Body height, weight, waist circumference, BMI, body fat (CT scan)
2. Oral glucose tolerance test
3. Glucose, insulin, C peptide levels
4. LH/FSH, testosterone, DHEAS, estradiol, progesterone, SHBG, leptin
5. Adverse events
Denotes outcomes prespecified for this review
Notes 13/40 women were hirsute, no separate data reported for hirsute women, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2768): ”The randomization
schedule was generated in blocks of 4...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 2768): ”...according to a
double-blind design...“ and ”...drug and
placebo were packaged and labeled accord-
ing to subject number“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by participants
and investigators. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/40 (13%); 2/20 in metformin group, 3/
20 in placebo group. Per-protocol analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Pazos 1999
Methods Randomised, active-controlled trial
Setting
Department of Endocrinology, Hospital Ramón y Cajal, Madrid, Spain
Date of study
Not reported. Duration of study 9 months
Participants N = 54 screened, 39 randomised
Mean age = 22 years
Inclusion criteria of the trial
• Hirsute women with idiopathic or functional ovarian hyperandrogenism
Exclusion criteria of the trial
• Adrenal hyperandrogenism
Randomised
N = 39
Withdrawals/losses to follow-up
• 6/39 (15%); 2/13 in triptorelin + triphasic OCP group, 3/13 in CPA + triphasic
OCP group, 1/13 in flutamide + triphasic OCP group
• Lost to follow-up, did not comply with treatment, or had adverse effects
Baseline data (mean (SEM))
BMI: triptorelin + triphasic OCP group 24.5 (1.5), CPA + triphasic OCP group 25.1
(0.9), flutamide + triphasic OCP group 23.2 (1.2)
F-G score: triptorelin + triphasic OCP group 15.6 (1.8), CPA + triphasic OCP group
12.9 (1.4), flutamide + triphasic OCP group 15.8 (1.0)
Interventions Intervention
• Triptorelin 3.75 mg im every 28 days + triphasic OCP for 9 months (13)
Comparator 1
• Cyproterone acetate 100 mg/day on days 1 to 10 of the menstrual cycle +
triphasic OCP for 9 months (13)
Comparator 2
• Flutamide 250 mg/day + triphasic OCP for 9 months (13)
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Outcomes Assessments (3): baseline, month 3 and 9
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. LH, FSH, estradiol, testosterone, SHBG, 11-deoxycortisol, 17OH progesterone,
DHEA, DHEAS, androstenedione
3. Liver function tests
4. Lipid profile
5. Adverse events
Denotes outcomes prespecified for this review
Notes The triphasic OCP contained ethinyl estradiol and levonorgestrel (30 µg + 0.05 mg/d
on days 1 to 6, 40 µg + 0.075 mg/d on days 7 to 11, and 30 µg + 0.125 mg/d on days
11 to 21)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 123): ”...were randomly as-
signed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6/39 (15%); 2/13 in triptorelin + triphasic
OCP group, 3/13 in CPA + triphasic OCP
group, 1/13 in flutamide + triphasic OCP
group. Per-protocol analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Penna 2005
Methods Randomised, double-blind, placebo-controlled trial
Setting
Gynecology Institute of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Date of study
June 2002 until May 2003. Duration of intervention 6 months
Participants N = 30
Mean age = 26 years
Inclusion criteria of the trial
• Menstrual disorders (< 6 menstruations/12 months)
• Clinical (Ferriman-Gallwey index ≥ 8) or laboratory (testosterone > 80 ng/dl
and/or androstenedione > 190 ng/dl) hyperandrogenism
• BMI of 30 to 40 kg/m2
• Insulin resistance
Exclusion criteria of the trial
• Alterations with threshold values of hepatic function aspartate aminotransferase,
31 IU/l and alanine aminotransferase (GTP), 36 IU/l), alterations of renal function
(creatinine, 1.3 mg/dl and urea, 40 mg/dl), alterations of thyroid function (thyroid-
stimulating hormone (TSH), 5.50 mIU/ml and free thyroxin, 1.76 ng/dl)
• Hyperprolactinaemia
• Congenital adrenal hyperplasia
• Diabetes
• Use of hormonal medications or medications that might interfere with
carbohydrate metabolism < 6 months prior to study entry
Randomised
N = 30
Withdrawals/losses to follow-up
• 3/30 (10%); 2/15 in acarbose group, 1/15 in placebo group
• Pregnancy; 1/15 in acarbose group, 0/15 in placebo group
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• Lost to follow-up; 1/15 in acarbose group, 1/15 in placebo group
Baseline data (mean (SD))
BMI: acarbose group 35.04 (2.84), placebo group 35.87 (2.60)
F-G index: acarbose group 10.29 (4.70), placebo group 8.85 (2.31)
Testosterone (ng/dl): acarbose group 70.64 (29.70), placebo group 76.76 (21.16)
Androstenedione (ng/dl): acarbose group 133.95 (96.13), placebo group 139.72 (63.
03)
SHBG (nmol/L): acarbose group 21.79 (9.31), placebo group 21.01 (7.9)
Interventions Intervention
• Acarbose 50 mg 3 times a day for 6 months (15)
Comparator
• Placebo 3 times a day for 6 months (15)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey index
2. Menstrual cycles
3. Weight, height, BMI
4. LH, FSH, prolactin, testosterone, androstenedione, DHEAS, 17-OH
progesterone, SHBG, urinary cortisol, free thyroxin, TSH, urea, creatinine, GOT and
GTP
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 2397): ”assignedby computed
randomization (GraphPad StatMate, San
Diego, CA, USA)“
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (page 2397): ”Themedicationswere
prepared and coded by the Industrial Phar-
macy of theUniversityHospital of Ribeirão
Preto...“
Comment: form of central allocation,
probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 2397): ”The medications
were prepared and coded by the Indus-
trial Pharmacy of theUniversityHospital of
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Ribeirão Preto using Glucobay (Bayer, Rio
de Janeiro, RJ, Brazil) or flour and identi-
fied by codes (double-blind).“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by participants
and investigators. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/30 (10%); 2/15 in acarbose group, 1/15
in placebo group
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Porcile 1991
Methods Randomised, active-controlled trial
Setting
School of Medicine of the University of Chile, Hospital del Salvador, Santiago, Chile
Date of study
Not reported. Duration of intervention 2 years
Participants N = 26
Mean age = 23 years
Inclusion criteria of the trial
• Idiopathic hirsutism or hirsutism in PCOS
Exclusion criteria of the trial
• Tumours of ovaries or adrenal glands
• Cushing’s disease
• 21-hydroxylase deficiency
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• Drug induced hirsutism
• Hyperprolactinaemia
Randomised
N = 26
Withdrawals/losses to follow-up
• 2/26; (8%); 0/10 in desogestrel + EE 30 µg group, 1/6 in desogestrel + EE 50 µg
group, 1/10 in CPA + EE group
• Reasons unreported
Baseline data (mean (SD))
Hirsutism score (Lorenzo 1970): desogestrel + EE 30 µg group 11.9 (3.0), desogestrel +
EE 50 µg group 10.4 (2.4), CPA + EE group 12.0 (3.2)
BMI: desogestrel + EE 30 µg group 22.5 (2.7), desogestrel + EE 50 µg group 23.5 (2.5)
, CPA + EE group 23.2 (3.6)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 2 years (10)
Comparator 1
• OCP (ethinyl estradiol 50 µg + desogestrel 0.15 mg) for 2 years (6)
Comparator 2
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 2 years (10)
Outcomes Assessments (5): baseline, month 6, 12, 18, and 24
Outcomes of the trial (as reported)
1. Hirsutism score (Lorenzo 1970)
2. Serum 17-hydroxyprogesterone, DHEAS, total and free testosterone, prolactin,
FSH, LH
3. Cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 878): ”... were randomly as-
signed...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
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was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/26; (8%); 0/10 in desogestrel + EE 30
µg group, 1/6 in desogestrel + EE 50 µg
group, 1/10 in CPA + EE group. Per-pro-
tocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Porcile 1991B
Methods Randomised, active- and no treatment-controlled trial
Setting
Department of Obstetrics and Gynecology, School of Medicine of the University of
Chile, Hospital del Salvador, Santiago, Chile
Date of study
Not reported. Duration of intervention 2 years
Participants N = 22
Mean age = not reported
Inclusion criteria of the trial
• Hirsute women (Lorenzo 1970), previously successfully treated with OCPs
Exclusion criteria of the trial
• Androgen-producing tumours
• Congenital defects of steroidogenic enzymes
• Hyperprolactinaemia
• Iatrogenic hirsutism
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Randomised
N = 22
Withdrawals/losses to follow-up
• 2/22 (9%); 0/9 in OCP every month group, 2/8 in OCP every other month
group, 0/5 in the no treatment group
Baseline data (mean (SEM))
Hirsutism score (Lorenzo 1970): 5.2 (0.32)
Testosterone (nmol/L): 1.62 (0.19)
Free testosterone (pmol/L): 5.05 (0.35)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) each month for 2 years (9)
Comparator
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) every other month for 2
years (8)
Comparator 2
• No treatment for 2 years (5)
Outcomes Assessments (5): baseline, month 6, 12, 18, and 24
Outcomes of the trial (as reported)
1. Hirsutism score (Lorenzo 1970)
2. Total and free testosterone
3. Cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Denotes outcomes prespecified for this review
Notes Objective was the maintenance of remission of hirsutism, any prior treatment was dis-
continued during 1 to 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote page 534: ”...randomly assigned to
one of the following three groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/22 (9%); 0/9 in OCP every month
group, 2/8 in OCP every other month
group, 0/5 in the no treatment group. Per-
protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Prezelj 1989
Methods Randomised, active-controlled trial
Setting
University Medical Centre Ljubljana, Ljubljana, Yugoslavia
Date of study
Not reported. Duration of intervention 6 months
Participants N = 25
Mean age = 26 years
Inclusion criteria of the trial
• Ferriman-Gallwey score > 7
• Menstrual disorders (oligomenorrhoea, amenorrhoea)
• Elevated levels of at least one of the androgens determined (serum and salivary
testosterone, serum androstenedione and serum DHEAS)
Exclusion criteria of the trial
• Androgen-secreting tumours
• Thyroid dysfunction
• Hypercorticism
• Congenital adrenal hyperplasia
Randomised
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N = 25
Withdrawals/losses to follow-up
• 2/25 (8%); 2/15 in dexamethasone + spironolactone group, 0/10 in
spironolactone group
• Cushing syndrome; 1/15 in dexamethasone + spironolactone group, 0/10 in
spironolactone group
• Polymenorrhoea; 1/15 in dexamethasone + spironolactone group, 0/10 in
spironolactone group
Baseline data (median)
F-G score: dexamethasone group + spironolactone 12, spironolactone group 11
Testosterone (nmol/L): dexamethasone + spironolactone group 2.3, spironolactone
group 2.2
Androstenedione (nmol/L): dexamethasone + spironolactone group 10.8, spironolactone
group 10.6
DHEAS (µmol/L): dexamethasone + spironolactone 8.3 group, spironolactone group 9.
5
Interventions Intervention
• Dexamethasone 0.5 mg daily + 100 mg of spironolactone b.i.d. in 3-week cycles
after 1-week intervals for 6 months (15)
Comparator
• Spironolactone 100 mg b.i.d. for 6 months (10)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. LH, FSH, prolactin, total testosterone, salivary testosterone, androstenedione,
DHEAS, SHBG, estradiol, estrone
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 282): ”...were randomized
into two treatment groups by means of
computer generated pseudo random num-
bers“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/25 (8%); 2/15 in dexamethasone +
spironolactone group, 0/10 in spironolac-
tone group. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Rautio 2005
Methods Randomised, placebo-controlled trial
Setting
Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland
Date of study
February 2002 until April 2004. Duration of intervention 4 months
Participants N = 30
Mean age = 28 years
Inclusion criteria of the trial
• PCOS, defined as polycystic ovaries (in vaginal ultrasonography) and at least one
of the following symptoms: oligomenorrhoea or amenorrhoea, clinical manifestations
of hyperandrogenism, such as a hirsutism score of more than 7, according to Ferriman
and Gallwey, and/or an elevated serum testosterone level (> 2.7 nmol/L)
Exclusion criteria of the trial
• Diabetes
• Signs of liver or renal failure or active liver disease (alanine aminotransferase
(ALT) > 2.5x the upper limit of normal values)
• Smokers, alcohol users and those taking sex hormones or drugs known to affect
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lipid metabolism < 2 months prior to study entry
Randomised
N = 30
Withdrawals/losses to follow-up
• 4/30 (13%); 3/15 in rosiglitazone group, 1/15 in placebo group
• Personal reasons; 1/15 in rosiglitazone group, 1/15 in placebo group
• Pregnancy; 2/15 in rosiglitazone group, 0/15 in placebo group
Baseline data (mean (SEM))
BMI: rosiglitazone group 33.1 (1.7), placebo group 33.6 (1.0)
Waist/hip ratio: rosiglitazone group 0.87 (0.12), placebo group 0.88 (0.01)
F-G score: rosiglitazone group 8.92 (0.9), placebo group 9.86 (1.5)
Testosterone (nmol/L): rosiglitazone group 2.7 (0.1), placebo group 3.5 (0.3)
SHBG (nmol/L): rosiglitazone group 30.3 (3.4), placebo group 38.6 (5.3)
Androstenedione (nmol/L): rosiglitazone group 16.6 (1.8), placebo group 16.3 (1.7)
DHEAS (µmol/L): rosiglitazone group 8.18 (0.9), placebo group 5.2 (0.7)
Interventions Intervention
• Rosiglitazone 4 mg once daily for 2 weeks and then b.i.d. up to 4 months (15)
Comparator
• Placebo for 4 months (15)
Outcomes Assessments (2): baseline, month 4
Outcomes of the trial (as reported)
1. Waist-hip circumference, BMI, hirsutism score
2. Oral glucose tolerance test, intravenous glucose tolerance test
3. Euglycaemic hyperinsulinaemic clamp
4. Calorimetry
5. LH, FSH, DHEA, DHEAS, SHBG, testosterone, androstenedione, 17OH
progesterone
6. Glucose, insulin, insulin-like growth factor-binding protein-1
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1401): ”Using computer-gen-
erated assignment...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
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Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 1401): ”...blindly allocated to
either a placebo group (PLA group) or a
rosiglitazone group (ROSI group)...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 1401): ”...blindly allocated to
either a placebo group (PLA group) or a
rosiglitazone group (ROSI group)...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4/30 (13%); 3/15 in rosiglitazone group, 1/
15 in placebo group. Per-protocol analysis
Comment: moderate number of drop-outs
at follow-up andper-protocol analysis; con-
sidered to be at an unclear risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, active-controlled, cross-over trial
Setting
Division of Endocrinology andDepartments ofMedicine,DalhousieUniversity,Halifax,
Nova Scotia, Canada
Date of study
Not reported. Duration of intervention 4 months
Participants N = 8
Mean age = 25 years
Inclusion criteria of the trial
• Idiopathic hirsutism
Exclusion criteria of the trial
• Ovarian or adrenal neoplasm
• Cushing’s syndrome
• Attenuated or classical congenital adrenal hyperplasia
• Drug-induced hirsutism
Randomised
N = 8
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data
Individual participant data are provided, no means
Interventions Intervention
• Prednisone 100 µg/kg each night orally for 4 months (4) and then was switched
to the other schedule for 4 months
Comparator
• Prednisone 200 µg/kg every other night orally for 4 months (4) and then was
switched to the other schedule for 4 months
Outcomes Assessments (4): baseline, month 4 and 8 at 2 successive days
Outcomes of the trial (as reported)
1. Serum cortisol, DHEA, androstenediol glucuronide
Denotes outcomes prespecified for this review
Notes No wash-out period between treatment schedules, no separate end data/baseline data at
4 months, no data on hirsutism score, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 400): ”...randomly assigned to
...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
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groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 400): ”This work was sup-
ported by Grant MA-9619 from the Med-
ical Research Council of Canada and a
grant from the Dalhousie University Inter-
nal Medicine Research Foundation“
Comment: we judged this as at a low risk
of bias
Rittmaster 1990
Methods Randomised, placebo-controlled trial
Setting
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Date of study
Not reported. Duration of intervention 4 months
Participants N = 20
Mean age = 31 years
Inclusion criteria of the trial
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• Moderate to severe hirsutism (modified Ferriman-Gallwey score > 10)
• 18 to 40 years
Exclusion criteria of the trial
• Ovarian or adrenal neoplasm
• Prolactinoma
• Cushing’s syndrome
• Homozygous congenital adrenal hyperplasia
• Drug-induced hirsutism
• Medical therapy for hirsutism or other medications known to influence hormone
levels < 3 months prior to study entry
Randomised
N = 20
Withdrawals/losses to follow-up
• 2/20 (10%); 1/10 in dexamethasone group, 1/10 in placebo group
• Adverse effects; 1/10 in dexamethasone group, 1/10 in placebo group
Baseline data (mean (SD))
Modified F-G score: idiopathic hirsutism 26 (7), PCOS 27 (6)
BMI: idiopathic hirsutism 34 (8), PCOS 33 (7)
Interventions Intervention
• Leuprolide + dexamethasone 0.5 mg/day for 4 months (10)
Comparator
• Leuprolide + placebo for 4 months (10)
Outcomes Assessments (2): baseline and month 4
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Testosterone, DHEAS, androstenediol glucuronide, LH, FSH, cortisol
3. Mean vertebral density
Denotes outcomes prespecified for this review
Notes 2-phase study: first phase all participants received leuprolide for 5 to 6 months before
they were randomised for second phase and received dexamethasone or placebo in ad-
dition to leuprolide. However, in the first phase the first 10 women were part of a dose
response study, while the second 10 received a fixed-dose leuprolide. No wash-out phase.
No baseline data for second phase per treatment arm. Data are provided for idiopathic
hirsutism and PCOS, but not clear per treatment arm. Protocol deviation biasing thera-
peutic comparisons in addition to inconsistency and incompleteness in outcome report-
ing did not permit a clear analysis and interpretation of results. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1097): ”...were randomized to
...“
Comment: insufficient detail was reported
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about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 1097): ”...initially double
blind, but because of side-effects in all but
1 woman receiving dexamethasone, blind-
ing became impossible...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 1097): ”...initially double
blind, but because of side-effects in all but
1 woman receiving dexamethasone, blind-
ing became impossible...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/20 (10%); 1/10 indexamethasone group,
1/10 in placebo group
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1096 and 1102): ”This work
was supported by Grant MA-9319 from
the Medical Research Council of Canada
and a grant from the Dalhousie University
Internal Medicine Research Foundation.“
and ”We are indebted to Dr. Claude Au-
clair and Abbott Laboratories, Canada, for
supplying leuprolide.“
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Comment: we judged this as at a low risk
of bias
Roth 2012
Methods Randomised, double-blind, active-controlled trial
Setting
Multi-centre (12) worldwide
Date of study
November 2002 until December 2004. Duration of intervention 6 months
Participants N = 626
Mean age = 28 years
Inclusion criteria of the trial
• Hirsute women with PCOS, with a Ferriman-Gallwey score > 8
Exclusion criteria of the trial
• Not reported
Randomised
N = 626
Withdrawals/losses to follow-up
• 121/626 (19%) were not hirsute; 44/209 in clomiphene group, 36/208 in
metformin group, 41/209 in combination group
Baseline data (mean (SD))
BMI: clomiphene group 36.9 (9.0), metformin group 36.1 (8.3), combination group
35.0 (8.0)
F-G score: clomiphene group 17.3 (7.1), metformin group 16.4 (7.1), combination
group 16.8 (6.1)
SHBG (nmol/L): clomiphene group 29.5 (19.3), metformin group 26.0 (13.9), combi-
nation group 29.4 (18.5)
Total testosterone (ng/dl): clomiphene group 64.2 (34.2), metformin group 63.4 (26.0)
, combination group 66.1 (29.3)
Interventions Intervention
• Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle for 6 cycles
(209)
Comparator 1
• Metformin 1000 mg b.i.d. (starting at lower dosage) for 6 cycles (208)
Comparator 2
• Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle +
metformin 1000 mg b.i.d. (starting at lower dosage) for 6 cycles (209)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Progesterone levels
2. Ferriman-Gallwey score
3. Total testosterone, SHBG, free androgen index
Denotes outcomes prespecified for this review
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Notes No further drop-outs were reported in this study whereas Legro 2007 (secondary refer-
ence under this study) which focused on treating infertility did report losses to follow-
up. Roth 2012 only included some of the participants included in Legro 2007, so it is
unclear what the number of drop-outs were in this subset. In analysing the data from this
study we have only included hirsute participants (clomiphene groupN = 165, metformin
group N = 172 and the combo group N = 168)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1152): ”...randomized by
means of an interactive voice system to
blindly receive standard clomiphene citrate
treatment...“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 1152): ”...randomized by
means of an interactive voice system to
blindly receive standard clomiphene citrate
treatment...“, form of central allocation
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (see Legro, under primary refer-
ence page 552): ”...Extended-release met-
formin (Glucophage XR) plus identical
placebo were provided by Bristol-Myers
Squibb. Overencapsulated clomiphene cit-
rate tablets (purchased from Teva Pharma-
ceuticals) and matching placebo capsules
were packaged and tested by a commercial
pharmacy supply company (CTS) specif-
ically for the study. Neither manufacturer
had any other role in the study.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were investigator-assessed
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
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Incomplete outcome data (attrition bias)
All outcomes
High risk 121/626 (19%); 55/209 in clomiphene
group, 72/208 in metformin group, 49/
209 in combination group. Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1151): ”Supported by Na-
tional Institutes of Health/National Insti-
tute of Child
Health and Human Development... etc“
and ”The other authors did not report any
potential conflicts of interest.“
Comment: we judged this as at a low risk
of bias
Sabuncu 2003
Methods Randomised, active-controlled trial
Setting
Endocrinology and Gynaecology outpatient clinics of the University of Harran, Faculty
of Medicine, Research Hospital, Sanliurfa, Turkey
Date of study
Not reported. Duration of intervention 6 months
Participants N = 40
Mean age = 28 years
Inclusion criteria of the trial
• Obese patients with PCOS
• PCOS defined as a combination of oligomenorrhoea (6 or fewer menses per year)
and hyperandrogenism - elevated serum total testosterone or free testosterone
concentrations. In the vaginal ultrasonographic examination, all the patients had
ovaries consistent with a diagnosis of PCOS: presence of multiple subcapsular follicles
during the first 3 days of menstrual bleeding. The modified Ferriman-Gallwey
hirsutism score was > 8 in all patients
Exclusion criteria of the trial
• Pregnancy
• Diabetes mellitus
• Hypertension
• Liver, renal failure, or thyroid dysfunction
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Sabuncu 2003 (Continued)
• Drug or vitamin treatment
• Smoking or alcohol < 3 months prior to study entry
• Other causes of hirsutism and hyperandrogenism derived from the pituitary,
adrenals, or ovaries, such as prolactinoma, Cushing’s syndrome, congenital adrenal
hyperplasia, and androgen-secreting tumours
Randomised
N = 40
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
BMI: EE/CPA group 37.8 (6.1), sibutramine group 37.5 (5.0), combination group 37.
7 (5.8)
F-G score: EE/CPA group 14.3 (3.9), sibutramine group 13.3 (3.7), combination group
13.4 (3.8)
Waist/hip ratio: EE/CPAgroup0.83 (0.07), sibutramine group0.83 (0.08), combination
group 0.83 (0.06)
Total testosterone (ng/dl): EE/CPA group 133.3 (27.2), sibutramine group 135.9 (23.
6), combination group 134.4 (30.5)
Free testosterone (ng/dl): EE/CPA group 4.2 (1.0), sibutramine group 4.3 (0.9), com-
bination group 4.3 (1.1)
SHBG (nmol/L): EE/CPA group 19.6 (14.4), sibutramine group 17.5 (11.5), combi-
nation group 17.7 (11.6)
DHEAS (µg/dl): EE/CPA group 257.4 (86.9), sibutramine group 252.9 (85.6), combi-
nation group 254.6 (107.2)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (14)
Comparator 1
• Sibutramine 10 mg/day for 6 months (12)
Comparator 2
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + sibutramine 10 mg/
day for 6 months (14)
Additionally, all patients were given a diet of 1200 kcal, and group 2 patients were advised
to use barrier contraception to avoid pregnancy during the study period
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Oral glucose tolerance test, AUC glucose, AUC insulin
2. Weight, height, BMI, waist/hip ratio
3. Serum glucose, serum insulin, total cholesterol, HDL and LDL cholesterol, and
triglyceride
4. Total testosterone, free testosterone, DHEAS, SHBG
Denotes outcomes prespecified for this review
Notes -
Risk of bias
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Sabuncu 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1199): ”...randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Saeed 1993
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Obstetrics and Gynaecology, Allama Iqbal Medical College, Lahore,
Pakistan
Date of study
Not reported. Duration of intervention 1 year
Participants N = 20
Mean age = 21 years
Inclusion criteria of the trial
• PCOS, defined as oligo or amenorrhoea and hirsutism (Ferriman-Gallwey score >
8)
Exclusion criteria of the trial
• Other endocrine or metabolic disorders
• Contraindication for OCP
Randomised
N = 20
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data
Individual participant data are provided, no means
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 1 year (10)
Comparator
• Placebo for 1 year (10)
Participants were advised barrier contraception techniques, and participants in both
groupswere prescribed local cosmetic therapy like electrolysis, bleaching agents or shaving
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Subjective assessment of hirsutism; 3-point Likert scale
2. Objective assessment of hirsutism (increase of terminals hairs, reduced speed in
hair growth, less pigmentation, disappearance of unwanted hair)
3. Testosterone, DHEAS, FSH, LH
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 110): ”...randomly allocated.
..“
Comment: insufficient detail was reported
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Saeed 1993 (Continued)
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 110): ”... in a double-blind
manner...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 110): ”... in a double-blind
manner...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) High risk Objective assessment of hirsutism was a
prespecified outcome but not reported.
Norwere data provided on hormone assess-
ments in the placebo group
Comment: we judged this as at a high risk
of bias
Other bias High risk Quote (page 110): ”patients in both groups
were prescribed local cosmetic therapy like
electrolysis, bleaching agents or shaving“
Comment: these interventions hamper the
assessment of hirsutism and although this
occurred in both groups, we judged this as
at high risk of bias
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Sahin 1998
Methods Randomised, active-controlled trial
Setting
Departments of Obstetrics and Gynecology and Endocrinology, Erciyes University, Fac-
ulty of Medicine, Kayseri, Turkey
Date of study
Not reported. Duration of intervention 9 months
Participants N = 42
Mean age = 22 years
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• Androgen-secreting tumours of ovarian or adrenal origin
• Cushing’s syndrome
• Thyroid dysfunction
• 21-hydroxylase deficiency
• Hyperprolactinoma
Randomised
N = 42
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: EE/CPA group 22.74 (1.95), finasteride group 25.54 (1.61)
Modified F-G score: EE/CPA group 15.81 (1.19), finasteride group 17.81 (1.05)
Free testosterone (pg/ml): EE/CPA group 3.68 (0.42), finasteride group 3.34 (0.38)
DHEAS (µg/dl): EE/CPA group 297 (23), finasteride group 306 (33)
SHBG (nmol/L): EE/CPA group 36.95 (3.92), finasteride group 34.95 (3.61)
PCOS: EE/CPA group 9/21, finasteride group 9/21
Idiopathic hirsutism: EE/CPA group 12/21, finasteride group 12/21
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 9 months (21)
Comparator
• Finasteride 5 mg daily for 9 months (21)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Free testosterone, total testosterone, DHEAS, androstenedione, SHBG
2. Modified Ferriman-Gallwey score
3. Haematologic screening and hepatic and renal function
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Sahin 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote (page 349): ”...were randomized
into two groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Hirsutism was assessed by the same investi-
gator blinded to treatment. The other out-
comes are not likely to be influenced by the
lack of blinding (serum tests)
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) during the study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) High risk Measurements of total testosterone and an-
drostenedione were prespecified outcomes
but not reported
Comment: we judged this as at a high risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Sanam 2011
Methods Randomised, active-controlled trial
Setting
Amir Hospital Family Planning Clinic and some health centres in Semnan, Iran
Date of study
October 2007 until October 2008. Duration of intervention 6 months
Participants N = 100
Mean age = 26 years
Inclusion criteria of the trial
• Healthy women of reproductive age
Exclusion criteria of the trial
• Contraindication OCP
• Hormonal treatment such as ”Norplant“, depot medroxyprogesterone acetate, or
OCP < 6 months prior to study entry
• Lack of co-operation
• Irregular consumption of the pills
• Pregnancy during study
• Prolonged and uncontrollable abnormal uterine bleeding
Randomised
N = 100
Withdrawals/losses to follow-up
• 9/100 (9%); 5/50 in EE/desogestrel group, 4/50 in EE/levonorgestrel group
• Post-randomisation exclusions as those did not match the inclusion criteria
Baseline data (mean (SD))
BMI: EE/desogestrel group 25.7 (4.1), EE/levonorgestrel group 25.0 (5.7)
F-G score: EE/desogestrel group 2.5 (4.3), EE/levonorgestrel group 2.7 (4.4)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 6 months (50)
Comparator
• OCP (ethinyl estradiol 30 µg + levonorgestrel 0.15 mg) for 6 months (50)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Number of acne lesions
3. Free testosterone, SHBG
Denotes outcomes prespecified for this review
Notes The mean of the F-G score as reported does not match the recognised minimum criteria
for hirsutism (score > 8; Hatch 1981). No separate data for hirsute women, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
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Sanam 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (page 24): ”... randomly given...“, ”.
..for this purpose a random number table
was used...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/100 (9%); 5/50 in EE/desogestrel group,
4/50 in EE/levonorgestrel group. Post-ran-
domisation exclusions for not meeting the
inclusion criteria. Per-protocol analysis
Comment: low number of drop-outs and,
although per-protocol analysis, considered
to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Although one of the principal aims of the
study was the effect of the interventions
on hirsutism, the mean Ferriman-Gallwey
score of the participants was between 2 and
3. Hirsutism in women: minimum Ferri-
man-Gallwey score of 8 (Hatch 1981)
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Sathyapalan 2012
Methods Randomised, double-blind, placebo-controlled trial
Setting
Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School,
Hull, UK
Date of study
January 2006 until December 2007. Duration of intervention 3 months
Participants N = 40
Mean age = 28 years
Inclusion criteria of the trial
• PCOS based on all 3 diagnostic criteria of Rotterdam Criteria PCOS 2004:
Ferriman-Gallwey score > 8, free androgen index > 8, oligomenorrhoea, amenorrhoea,
and polycystic ovaries on ultrasound
Exclusion criteria of the trial
• Concurrent diseases
• Medication affecting insulin sensitivity, lipids, or ovarian function including
OCPs < 6 months prior to study entry
• Non classical 21-hydroxylase deficiency
• Hyperprolactinaemia
• Cushing’s disease
• Androgen secreting tumours
Randomised
N = 40
Withdrawals/losses to follow-up
• 3/40 (8%); 1/20 in atorvastatin group, 2/20 in placebo group for non-compliance
Baseline data (mean (SD))
BMI: atorvastatin group 33.20 (1.4), placebo group 33.92 (1.4)
DHEAS (µmol/L): atorvastatin group 7.1 (1.0), placebo group 7.2 (1.2)
Androstenedione (nmol/L): atorvastatin group 5.7 (0.8), placebo group 5.6 (1.3)
Interventions Intervention
• Atorvastatin 20 mg for 3 months (20)
Comparator
• Placebo for 3 months (20)
Afterwards al participants received metformin 500 mg 3 times a day for 3 months
Outcomes Assessments (2): baseline and month 3
Outcomes of the trial (as reported)
1. Change in androstenedione and DHEAS
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Sathyapalan 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (page 81): ”...were randomly
assigned...computer-generated randomiza-
tion list.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 81): ”Labelling was done by
personnel not involved in the trial“
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 81): ”double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 81): ”double-blind...“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(participants/healthcare providers) during
the study. However, measurements (serum
tests) are unlikely to be influenced by lack
of blinding. We judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/40 (8%); 1/20 in atorvastatin group, 2/
20 in placebo group. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Schmidt 1987
Methods Randomised, active-controlled trial
Setting
Department of Dermatology and Gynecology, University of Vienna, Austria
Date of study
Not reported. Duration of intervention 9 months
Participants N = 20
Mean age = 29 years
Inclusion criteria of the trial
• Women with moderate to severe hirsutism
Exclusion criteria of the trial
• Not reported
Randomised
N = 20
Withdrawals/losses to follow-up
• 5/20 (25%); 0/10 in CPA im group, 5/10 in CPA oral group
• ”Technical reasons“; 0/10 in CPA im group, 5/10 in CPA oral group
Baseline data (mean)
Initial hair diameter (chin, micrometer): CPA im group 0.0757, CPA oral group 0.0835
Interventions Intervention
• Cyproterone acetate 300 mg parenterally implant first day of each cycle for 9
months (10)
Comparator
• Cyproterone acetate 100 mg/day orally for first 10 days of the cycle for 9 months
(10)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Hair-diameter; micrometer
2. Dermatological criteria for hair overgrowth
3. Androstenedione, DHEAS, prolactin
4. Adverse events
Denotes outcomes prespecified for this review
Notes Inconsistent data reporting, lack of clarity about missing outcome data and withdrawals
and losses. See Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 126): ”Patients were allotted
to the two regimens at random.“
Comment: insufficient detail was reported
about themethod used to generate the allo-
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Schmidt 1987 (Continued)
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/20 (25%); 0/10 in CPA im group, 5/10
in CPA oral group. Per-protocol analysis
Comment: the high and unbalanced drop-
out rate with per-protocol analysis repre-
sents a potential high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Smith 2006
Methods Randomised, double-blind, within-participant, active-controlled trial
Setting
2 centres in the US
Date of study
Not reported. Duration of study 34 weeks
Participants N = 64
Mean age = 47 years
Inclusion criteria of the trial
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Smith 2006 (Continued)
• Fitzpatrick skin types I through IV
• Bilaterally symmetric facial hirsutism of the lip and chin with predominantly
brown/black terminal hairs, and a hair density of 5 hairs/cm2 in selected target areas
Exclusion criteria of the trial
• Pregnant or lactating women
• Previous laser photo epilation within 6 months or electrolysis or other epilation
methods < 2 months before the start of the study
• Systemic medications that could affect hair growth < 6 months prior to study
entry
Randomised
N = 64
Withdrawals/losses to follow-up
• 10/64 (16%)
• Voluntary withdrawal; 2/64
• Lost to follow-up; 4/64
• Protocol violation; 4/64
Baseline data
Fitzpatrick skin type I 6/54, skin type II 11/54, skin type III 27/54 and skin type IV 10/
54
Interventions Intervention
• Laser therapy (Nd: YAG or alexandrite) at week 2 and 10 + eflornithine cream for
34 weeks
Comparator
• Laser therapy (Nd: YAG or alexandrite) at week 2 and 10 + vehicle cream for 34
weeks
Outcomes Assessments (8): baseline, week 2, 6, 10, 16, 22, 28, and 34
Outcomes of the trial (as reported)
1. Physician’s global assessment of change from baseline for right and left side (chin
and upper lip); 4-point Likert scale
2. Physician’s comparison of appearance of left versus right side
3. Subject’s self assessment comparing left versus right sides
4. Adverse events
Denotes outcomes prespecified for this review
Notes Eflornithine creamwas used as add-on therapy to laser therapy and therefore we included
the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 1238): ”Assignment of med-
ications was determined via a computer-
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Smith 2006 (Continued)
generated randomization schedule.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
After e-mail communication: ”Prior to the
start of the study, the medication container
assignments for EACH subject number
were placed into sealed envelopes marked
with subject numbers.“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 1238): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After e-mail communication: ”The study
medication containers did NOT reveal
whether the product inside was active or
placebo and the numbers were different for
each study container. The actual treatment
assignments were maintained by an off-site
study administrator not directly related to
the site thus the site did not have regular ac-
cess to the treatment assignments and could
only obtain that information through a for-
mal unblinding process. Participants (via
the staff ) received medication containers
that contained either the active medication
or a placebo vehicle prepared by the med-
ication manufacturer that matched the ac-
tive product in colour, feel and odour.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Smith 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 1238): ”...double-blind...“
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(participants/healthcare providers) during
the study. However, measurements (serum
tests) are unlikely to be influenced by lack
of blinding. We judged this as at low risk
of bias
After e-mail communication: see ’perfor-
mance bias’ domain
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10/64 (16%), reasons reported. Both per-
protocol and intention-to-treat analyses
were undertaken and stated to be ”similar“
but only per-protocol analyses were pre-
sented
Comment: moderate number of losses
posed an unclear risk of bias for this do-
main
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 1237): ”An unrestricted ed-
ucational grant was received from Bristol-
Myers Squibb Inc. Laser equipment was
provided for the duration of the study only
by Laserscope Corp. and Candela Corp.“
Comment: we judged this as at a low risk
of bias
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Sobbrio 1990
Methods Randomised, open, active-controlled trial
Setting
Institute of Clinica Medica and Institute of Gynecology, University of Messina, School
of Medicine, Messina, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 34
Age range: 18 to 32 years
Inclusion criteria of the trial
• Non-obese hirsute women with micro polycystic ovary syndrome (MPCOS)
Exclusion criteria of the trial
• Oral medication < 6 months prior to study entry
Randomised
N = 34
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
F-G score: EE/desogestrel 21.4 (7.5), EE/gestodene 19.7 (8.7)
Testosterone (ng/ml): EE/desogestrel 0.77 (0.21), EE/gestodene 0.88 (0.29)
Free testosterone (pg/ml): EE/desogestrel 3.52 (1.48), EE/gestodene 2.96 (1.04)
Androstenedione (ng/ml): EE/desogestrel 3.21 (1.50), EE/gestodene 2.69 (1.47)
DHEAS (µg/dl): EE/desogestrel 306 (178), EE/gestodene 282 (119)
SHBG (nmol/L): EE/desogestrel 35 (17), EE/gestodene 38 (12)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) for 6 months (17)
Comparator
• OCP (ethinyl estradiol 30 µg + gestodene 75 µg) for 6 months (17)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Total and free testosterone, androstenedione, DHEA, DHEAS, 17-OH
progesterone, SHBG, ceruloplasmin, FAI
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 140): ”...in two randomized
groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
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cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 139): ”...open...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 139): ”...open...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Spritzer 2000
Methods Randomised, active-controlled trial
Setting
Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de
Porto Alegre, Porto Alegre, Brazil
Date of study
Not reported. Duration of intervention 12 months
Participants N = 46
Age = 24 years
Inclusion criteria of the trial
• Hirsute women with PCOS and idiopathic hirsutism
• The diagnosis of PCOS was based on the physical features of hyperandrogenism,
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disturbed menstrual cycles, elevated serum LH levels or LH/FSH ratio, increased levels
of serum testosterone and/or androstenedione and no evidence of ovarian or adrenal
neoplasm or Cushing’s syndrome. The diagnosis of PCOS followed NIH consensus
criteria (Zawadski 1992)
Exclusion criteria of the trial
• Late-onset (non-classic) congenital adrenal hyperplasia
• Hyperprolactinaemia
• Drugs known to interfere with hormonal levels < 3 months prior to study entry
Randomised
N = 46
Withdrawals/losses to follow-up
• 2/46 (4%); lost to follow-up unclear from which group
Baseline data (mean (SEM))
F-G score PCOS group: spironolactone group 22 (2), CPA group 21 (1)
F-G score idiopathic hirsutism group: spironolactone group 21 (2), CPA group 23 (2)
Testosterone PCOS group (nmol/L): spironolactone group 3.05 (0.45), CPA group 2.
94 (0.38)
Testosterone idiopathic hirsutism group (nmol/L): spironolactone group 2.35 (0.41),
CPA group 2.25 (0.31)
Androstenedione PCOSgroup (nmol/L): spironolactone group11.62 (2.16),CPAgroup
11.41 (1.39)
Androstenedione idiopathic hirsutism group (nmol/L): spironolactone group 8.65 (0.
76), CPA group 10.48 (0.94)
Interventions Intervention
• Spironolactone 200 mg/day for 12 months (21 = N that completed the study)
Comparator
• Cyproterone acetate 50 mg/day 20 days per month + ethinyl estradiol 35 µg over
the last 10 days for 12 months (23 = N that completed the study)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. LH, testosterone, androstenedione
3. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 588): ”...subjects were ran-
domly separated into two treatment groups
and stratified for the presence of PCOS“
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Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/46 (4%); lost to follow-up unclear from
which group. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 592): ”This study was sup-
ported by grants from Financiadora de
Estudos e Projetos (no. 41960949.00),
Conselho Nacional de Desenvolvimento
Científicoco e Tecnológico (no. 520544/
960-0) and Fundação de Amparo à
Pesquisa do Rio Grande do Sul (no. 96/
1765.7).“
Comment: we judged this as at a low risk
of bias
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Methods Randomised, active-controlled trial
Setting
Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town,
South Africa
Date of study
Not reported. Duration of intervention up to 52 weeks
Participants N = 34
Mean age = not reported
Inclusion criteria of the trial
• Hirsute women with PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 34
Withdrawals/losses to follow-up
• 6/34 (18%); unclear from which group
Baseline data
Nothing reported
Interventions Intervention
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) for 52 weeks
Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone acetate 2 mg) + GnRH agonist
analogue (goserelin) for 52 weeks
Outcomes Assessments: baseline and at end of study, other assessments unclear
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Sebum scores
3. Testosterone, androstenedione, DHEAS, SHBG, estradiol, estrone and FAI
Denotes outcomes prespecified for this review
Notes Abstract from conference proceedings, limited data reported, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 242): ”...randomly allocated.
..“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
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Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6/34 (18%); unclear from which group.
Per-protocol analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Stener-Victorin 2009
Methods Randomised, active- and no treatment controlled trial
Setting
Sahlgrenska University Hospital, Göteborg, Sweden
Date of study
November 2005 until January 2008. Duration of study 16 weeks
Participants N = 504 recruited, 84 randomised
Mean age = 30 years
Inclusion criteria of the trial
• Women with PCOS
• PCOS defined as polycystic ovaries (at least 12 follicles, 2 mm to 9 mm); and/or
increased ovarian volume (10 ml) revealed by two-dimensional ultrasound
examinations in one or both ovaries, together with one of the following clinical
symptoms: oligomenorrhoea with intermenstrual interval 35 days, and/or clinical and/
or biochemical signs of hyperandrogenism (hirsutism or acne), according to the
Rotterdam consensus report (Rotterdam Criteria PCOS 2004)
Exclusion criteria of the trial
• Women on medication(s) < 3 months prior to study entry
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• Breast feeding 6 months prior to study entry
• Known endocrine or neoplastic causes of hyperandrogenaemia including
androgen-secreting tumours, Cushing’s syndrome, congenital adrenal hyperplasia and
hyperprolactinaemia
Randomised
N = 84
Withdrawals/losses to follow-up
• 10/84; 4/33 in low-frequency electro-acupuncture group, 4/34 in physical
exercise group, 2/17 in the untreated control group
• Moved from area; 3/33 in low-frequency electro-acupuncture group, 0/34 in
physical exercise group, 1/17 in the untreated control group
• Personal reasons; 1/33 in low-frequency electro-acupuncture group, 3/34 in
physical exercise group, 1/17 in the untreated control group
• Pregnancy; 0/33 in low-frequency electro-acupuncture group, 1/34 in physical
exercise group, 0/17 in the untreated control group
• Of the remaining 74 participants, 23 were randomly recruited for
microneurography and nerve recordings were successfully performed in 20 women
Baseline data on the 20 women in which nerve recordings have been performed (mean
(SD))
BMI: low-frequency electro-acupuncture group 27.5 (8.6), physical exercise group 26.8
(4.8), untreated control group 28.0 (6.2)
F-G score: low-frequency electro-acupuncture group 16.1 (8.5), physical exercise group
12.8 (10.1), untreated control group 9.5 (5.1)
Interventions Intervention
• Low-frequency electro-acupuncture for 16 weeks according to a schedule that
ranged from two per week to once every two weeks (33)
Comparator 1
• Physical exercise 30 to 45 minutes at least 3 times a week for 16 weeks (34)
Comparator 2
• Untreated for 16 weeks (17)
Outcomes Assessments (2): baseline and week 16
Outcomes of the trial (as reported)
1. BMI, sagittal abdominal diameter, waist/hip ratio
2. Ferriman-Gallwey score
3. LH, FSH, total testosterone, free testosterone, DHEAS, SHBG, FAI, free
thyroxin 4, insulin growth factor 1, insulin, TSH, cholesterol, HDL and LDL
cholesterol, HOMA
4. Microneurography
Denotes outcomes prespecified for this review
Notes Only data reported for 20/84 participants (24%), see Table 3
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page R388): ”The randomization
was performed by the study coordinator
according to a computerized list. PCOS
women were stratified by age and body
mass index (BMI) and thereafter block ran-
domized to one of three study groups in a
2:2:1 ratio:...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 388): ”This was a randomized
controlled trial with independent observers
and with blind, independent analysis“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/84; 4/33 in low-frequency electro-
acupuncture group, 4/34 in physical exer-
cise group, 2/17 in the untreated control
group, reasons reported. Of the remain-
ing 74 participants, 23 were randomly re-
cruited for microneurography and nerve
recordings were successfully performed in
20 women. Data reported for only 20/84
(24%)
Comment: we judged this as at a high risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
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appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page R393): ”This study was
supported by the Swedish Medical Re-
search Council..., Novo Nordisk Founda-
tion, Wilhelm and Martina Lundgrens’
Science Fund, Hjalmar Svensson Founda-
tion, Tore Nilson Foundation, ÅkeWiberg
Foundation, Adlerbert Research Founda-
tion, Ekhaga Foundation, the Swedish fed-
eral government under the letters of under-
standing agreement of Medical Education
..., and a Regional Research and Develop-
ment agreement...“
Comment: we judged this as at a low risk
of bias
Taheripanah 2010
Methods Randomised, active-controlled trial
Setting
Infertility and Reproductive Health ResearchCenter (IRHRC), ImamHosseinHospital,
Tehran, Iran
Date of study
February 2007 until December 2007. Duration of intervention 3 months
Participants N = 60
Mean age = 23 years
Inclusion criteria of the trial
• Hirsute women with PCOS (Rotterdam Criteria PCOS 2004)
Exclusion criteria of the trial
• Hormone therapy < 3 months prior to study entry
• Diet or herbal treatment
• Hyperprolactinaemia
• Thyroid disorders
• Ovarian tumours
• Cushing’s disease
Randomised
N = 60
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
BMI: OCP group 21.17 (2.06), CPA/EE group 21.73 (2.76)
F-G score: OCP group 10.78 (2.4), CPA/EE group 11.5 (2.3)
Free testosterone (ng/ml): OCP group 2.48 (1.3), CPA/EE group 2.0 (1.2)
DHEAS (µg/ml): OCP group 2.36 (1.6), CPA/EE group 2.41 (1.2)
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Interventions Intervention
• OCP not specified for 3 months (30)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 3 months (30)
Outcomes Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Serum PSA, free testosterone, DHEAS, 17-OH progesterone
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 160): ”...were divided ran-
domly into two treatment groups accord-
ing to the computer-based table“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
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Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Tartagni 2000
Methods Randomised, single-blinded, active-controlled trial
Setting
Università di Bari, Policlinico di Bari, Bari, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 50
Mean age = 23 years
Inclusion criteria of the trial
• Premenopausal women with severe hirsutism
• Idiopathic hirsutism or hirsutism in PCOS
Exclusion criteria of the trial
• OCP or other long-term drugs < 6 months prior to study entry
• Diet
Randomised
N = 50
Withdrawals/losses to follow-up
• 4/50 (8%); 2/25 in EE/CPA group, 2/25 in EE/CPA + finasteride group for
personal reasons
Baseline data (mean (SD))
BMI: EE/CPA group 22 (5.6), EE/CPA + finasteride group 21.6 (8.3)
Modified F-G score: 22.4 (4.7) for all included women
Baseline hormone levels for women with idiopathic hirsutism (mean (SD))
Free testosterone (pg/ml): EE/CPA group 3.5 (1.1), EE/CPA + finasteride group 3.6 (0.
1)
Dihydrotestosterone (ng/dl): EE/CPA group 45.9 (6.1), EE/CPA + finasteride group 46.
7 (5.2)
DHEAS (µg/ml): EE/CPA group 3.1 (1.5), EE/CPA + finasteride group 2.5 (1.1)
SHBG (µg/ml): EE/CPA group 2.4 (1.5), EE/CPA + finasteride group 3.1 (2.1)
Androstenedione (ng/ml): EE/CPA group 1.8 (1.0), EE/CPA + finasteride group 2.1 (0.
8)
Baseline hormone levels for women with PCOS (mean (SD))
Free testosterone (pg/ml): EE/CPA group 3.8 (1.9), EE/CPA + finasteride group 4.5 (1.
8)
Dihydrotestosterone (ng/dl): EE/CPA group 42.0 (1.8), EE/CPA + finasteride group 40.
0 (2.1)
DHEAS (µg/ml): EE/CPA group 4.1 (1.0), EE/CPA + finasteride group 3.9 (1.2)
SHBG (µg/ml): EE/CPA group 1.9 (1.4), EE/CPA + finasteride group 2.1 (1.4)
Androstenedione (ng/ml): EE/CPA group 3.8 (1.0), EE/CPA + finasteride group 4.2 (1.
6)
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Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (25)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + finasteride 5 mg once
a day on day 1 to 14 for 6 months (25)
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. LH, FSH, free testosterone, DHT, DHEAS, androstenedione, 3αdiol G
3. Self evaluation; 4 point Likert scale
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 719): ”Patientswere randomly
assigned to two treatment groups on the
basis of a computer-generated randomiza-
tion sequence“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 719): ”The score evaluation
was performed by a single physician who
was unaware of the treatment.“ Results of
serum tests are unlikely to be influenced by
the lack of blinding
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) and the lack of blind-
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ing of participants for certain outcomes
(adverse events and self evaluation of hir-
sutism) poses a high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/50 (8%); 2/25 in EE/CPA group, 2/25
in EE/CPA + finasteride group for personal
reasons. Per-protocol analysis
Comment: low number of drop-outs at fol-
low-up and, although per-protocol analy-
sis, considered to be at a low risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Tartagni 2004
Methods Randomised, single-blinded, active-controlled trial
Setting
Ostetrica e Ginecologica III, Universitá di Bari, Policlinico di Bari, Bari, Italy
Date of study
Not reported. Duration of intervention 10 months
Participants N = 38
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute premenopausal women
• Idiopathic hirsutism or hirsutism in PCOS
Exclusion criteria of the trial
• OCP or other long-term drugs < 6 months prior to study entry
• Hypocaloric diet
Randomised
N = 38
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data in participants with idiopathic hirsutism (mean (SD))
BMI: finasteride every day group 22.9 (4), finasteride every 3 days group 22.5 (4)
Modified F-G score: finasteride every day group 18.5 (1.9), finasteride every 3 days group
19.1 (1.6)
Total testosterone (ng/dl): finasteride every day group 71.1 (1.8), finasteride every 3 days
group 70.9 (2.5)
Dihydrotestosterone (ng/dl): finasteride every day group 46.4 (0.3), finasteride every 3
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days group 45.7 (0.4)
DHEAS (µg/ml): finasteride every day group 3.2 (1.4), finasteride every 3 days group 2.
5 (1.5)
SHBG (µg/ml): finasteride every day group 2.3 (1.6), finasteride every 3 days group 2.
9 (2.0)
Androstenedione (ng/ml): finasteride every day group 1.9 (1.1), finasteride every 3 days
group 2.3 (0.7)
Baseline data in participants with PCOS (mean (SD))
BMI: finasteride every day group 25.1 (4.2), finasteride every 3 days group 24.9 (4.4)
Modified F-G score: finasteride every day group 20.6 (2.6), finasteride every 3 days group
21.0 (1.3)
Total testosterone (ng/dl): finasteride every day group 76.8 (2.7), finasteride every 3 days
group 77.5 (2.1)
Dihydrotestosterone (ng/dl): finasteride every day group 40.9 (1.7), finasteride every 3
days group 40.5 (1.4)
DHEAS (µg/ml): finasteride every day group 4.0 (1.1), finasteride every 3 days group 3.
8 (1.1)
SHBG (µg/ml): finasteride every day group 1.8 (1.2), finasteride every 3 days group 2.
1 (1.6)
Androstenedione (ng/ml): finasteride every day group 3.6 (1.1), finasteride every 3 days
group 4.0 (1.2)
Interventions Intervention
• Finasteride 2.5 mg/day for 10 months (19)
Comparator
• Finasteride 2.5 mg/day every 3 days for 10 months (19)
Outcomes Assessments (3): baseline, month 5 and 10
Outcomes of the trial (as reported)
1. BMI
2. Hirsutism score (modified Ferriman-Gallwey score)
3. Adverse effects
4. Liver and renal function tests, triglycerides, total cholesterol, HDL and LDL
cholesterol, glucose
5. FSH, LH, total testosterone, DHT, DHEAS, androstenedione, 3αdiol G,
estradiol
6. Self evaluation; 4-point Likert scale
7. Menstrual cycle characteristics
Denotes outcomes prespecified for this review
Notes -
Risk of bias
413Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tartagni 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 752): ”The patients were
randomized by a computer-generated se-
quence into two groups of 19 patients“
Comment: probably done
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 752): ”Hirsutism was scored
by means of a modified Ferriman-Gallwey
scoring system by a single physician who
was unaware of the treatment“. Serum tests
are not likely to be influenced by the lack
of blinding
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) and the lack of blind-
ing of participants for certain outcomes
(adverse events and self evaluation of hir-
sutism) poses a high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Methods Randomised, active-controlled trial
Setting
Departments of Obstetrics and Gynecology, Helsinki University Central Hospital,
Helsinki, Finland
Date of study
Not reported. Duration of study 9 months
Participants N = 20
Mean age = 29 years
Inclusion criteria of the trial
• Hirsute women between 18 to 40 years (Ferriman-Gallwey score > 10)
Exclusion criteria of the trial
• Drugs for hirsutism < 3 months prior to study
Randomised
N = 20
Withdrawals/losses to follow-up
• 6/20 (30%); 2/10 in GnRH-a group, 4/10 in GnRH-a + hormone replacement
therapy (HRT) group
• Vasomotor symptoms; 1/10 in GnRH-a group, 0/10 in GnRH-a + HRT group
• Depression; 1/10 in GnRH-a group, 0/10 in GnRH-a + HRT group
• Heavy uterine bleeding; 0/10 in GnRH-a group, 1/10 in GnRH-a + HRT group
• Headache; 0/10 in GnRH-a group, 1/10 in GnRH-a + HRT group
• Premenstrual tension; 0/10 in GnRH-a group, 2/10 in GnRH-a + HRT group
Baseline data (mean (SD))
BMI: GnRH-a group 26.1 (8.3), GnRH-a + HRT group 29.4 (9.9)
F-G score: GnRH-a group 17.0 (5.7), GnRH-a + HRT group 20.6 (7.4)
SHBG (nmol/L): GnRH-a group 42.9 (22.0), GnRH-a + HRT group 31.8 (20.4)
Testosterone (nmol/L): GnRH-a group 4.65 (2.99), GnRH-a + HRT group 3.50 (0.99)
Free testosterone (pmol/L): GnRH-a group 65.6 (35.1), GnRH-a + HRT group 56.9
(22.2)
Androstenedione (nmol/L): GnRH-a group 12.4 (5.0), GnRH-a + HRT group 12.4 (3.
9)
DHEAS (µmol/L): GnRH-a group 9.6 (4.3), GnRH-a group + HRT 10.0 (5.3)
Interventions Intervention
• Goserelin implant every 28 days for 9 months (10)
Comparator
• Goserelin implant every 28 days for 9 months + after first 3 months also
oestrogen-progestin replacement for the last 6 months (10)
Outcomes Assessments (10): baseline and each month until end of study
Outcomes of the trial (as reported)
1. Ferriman-Gallwey scores
2. FSH, LH, SHBG, total testosterone, free testosterone, androstenedione, DHEAS,
prolactin
Denotes outcomes prespecified for this review
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Tiitinen 1994 (Continued)
Notes Participants were not randomised for first 3 months of the study and all received GnRH-
a, only randomised for the last 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 448): ”...were randomized (by
use of a sealed envelope)...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Low risk Quote (page 448): ”...were randomized (by
use of a sealed envelope)...“
Comment: the report provides sufficient
detail and reassurance that participants and
investigators enrolling participants could
not foresee the upcoming assignment. This
was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/20 (30%); 2/10 in GnRH-a group, 4/10
in GnRH-a + hormone replacement ther-
apy (HRT), reasons reported Per-protocol
analysis
Comment: the high drop-out rate with per-
protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
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Tiitinen 1994 (Continued)
Other bias Unclear risk Quote (page 447): ”This work was sup-
ported by grants from the Finnish Academy
of Science and Zeneca Pharmaceuticals
(Helsinki, Finland).“
Comment: a potential risk of bias cannot
be excluded
Unfer 2000
Methods Randomised, active-controlled trial
Setting
Policlinico Monteluce, University of Perugia, Perugia, Italy
Date of study
Not reported. Duration of intervention 18 months
Participants N = 40
Mean age = not reported
Inclusion criteria of the trial
• Hirsute women with PCOS
Exclusion criteria of the trial
• Nothing reported
Randomised
N = 40
Withdrawals/losses to follow-up
• Not reported
Baseline data
Nothing reported
Interventions Intervention
• Ethinyl estradiol 0.02 mg/day for 3 weeks + the first 10 days cyproterone acetate
12.5 mg/day and then 7 pause days for 18 months (24)
Comparator
• Flutamide 250 mg/day for 18 months (16)
Outcomes Assessments: baseline and at least end of study
Outcomes of the trial (as reported)
1. Hirsutism score
2. Hormone levels
3. Multi-screen blood chemistry
Denotes outcomes prespecified for this review
Notes Abstract to conference proceedings. Limited data provided, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
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Unfer 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote (page 36): ”randomized“ and ”...as-
signed randomly...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
van Vloten 2002
Methods Randomised, active-controlled trial
Setting
Multi-centre (6) in the Netherlands and Germany
Date of study
Not reported. Duration of intervention 9 months
Participants N = 128
Mean age = 23 years
Inclusion criteria of the trial
• 16 to 35 years
• Mild to moderate acne and who had minor occurrence of seborrhoea and/or hair
growth on the upper lip, chin, and chest
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van Vloten 2002 (Continued)
Exclusion criteria of the trial
• Pregnancy and lactation
• Contraindication to OCP
• Malignancy
• Vascular and metabolic diseases
• Obesity (> 20% normal weight)
• Pap smear > CII
• Genital infection
• Use of parenteral depot of OCP < 6 months prior to study entry
• Presence of large nodes, cysts, fistular comedos, abscessing fistular ducts
• Previous unsuccessful treatment with antiandrogenic hormone preparations for at
least 3 months
• Treatment with isotretinoin < 12 months
Randomised
N = 128
Withdrawals/losses to follow-up
• 22/128 (17%); 14/82 in EE/DRSP group, 5/43 in EE/CPA group, 3/3 unclear
from which group
• Withdrawal of consent; 4/82 in EE/DRSP group
• Protocol violation; 2/82 in EE/DRSP group
• Failure to attend to the clinic; 2/82 in EE/DRSP group
• Medication not taken; 1/82 in EE/DRSP group
• Adverse events; 4/43 in EE/CPA group
• Lost to follow-up; 1/41 in EE/CPA group
Baseline data (number (%))
Facial acne: EE/DRSP group 82 (100), EE/CPA group 43 (100)
Seborrhoea: EE/DRSP group 64 (78), EE/CPA group 32 (74.4)
Hirsutism location upper lip: EE/DRSP group 13 (15.9), EE/CPA group 6 (14.0)
Hirsutism location chin: EE/DRSP group 3 (3.7), EE/CPA group 3 (7.0)
Hirsutism location chest: EE/DRSP group 1 (1.2), EE/CPA group 3 (7.0)
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 9 months (82)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 9 months (43)
Outcomes Assessments (5): baseline, month 1, 3, 6, and 13
Outcomes of the trial (as reported)
1. Acne lesion count (comedones, papules, pustules and nodules)
2. Sebum production; Sebumeter
3. Ferriman-Gallwey score
4. Total testosterone, free testosterone, androstenedione, DHEAS, SHBG, FSH, LH
5. Haematological and chemistry screening
6. Self evaluation
7. Adverse events
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van Vloten 2002 (Continued)
Denotes outcomes prespecified for this review
Notes Only few women were hirsute, no separate data for hirsute women, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 4): ”...were randomized to re-
ceive in a 2:1 ratio...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 4): ”...one tablet of the al-
located study preparation and one tablet
identical to the study preparation were
taken...“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by participants
and investigators. Blinding of participants
and key study personnel was ensured, and
it is unlikely that the blinding could have
been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 22/128 (17%); 14/82 in EE/DSRP group,
5/43 in EE/CPA group, 3/3 unclear from
which group. Both intention-to-treat anal-
ysis and per-protocol analysis. Inconsistent
reporting of data
Comment: considerable drop-out rate
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combined with inconsistent reporting of
data; we judged this as at a high risk of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk 2 of the authors were employed by Scher-
ing, the manufacturer of the OCPs
Comment: a potential risk of bias cannot
be excluded
Vegetti 1996
Methods Randomised, open, active-controlled trial
Setting
Multi-centre (4), in Italy
Date of study
Not reported. Duration of intervention 48 weeks with follow-up at 24 weeks
Participants N = 56
Mean age = 24 years
Inclusion criteria of the trial
• Hirsute women > 17 years with Ferriman-Gallwey score >10
• Normal biochemical and haematological values
Exclusion criteria of the trial
• OCP or hormonal medication < 2 months prior to study entry
Randomised
N = 56
Withdrawals/losses to follow-up
• 15/56 (27%), 7/28 in OCP group, 8/28 in OCP + goserelin, reasons not reported
Baseline data (mean (SD))
Hair diameter face, abdomen, midthigh (µm): OCP group 64.0 (14.6), OCP + goserelin
66.9 (8.6)
Hair diameter forearm (µm): OCP group 49.1 (9.5), OCP + goserelin 48.1 (10.1)
SHBG (nmol/L): OCP group 34.45 (21.45), OCP + goserelin 22.83 (14.82)
DHEAS (µg/ml): OCP group 1.99 (0.73), OCP + goserelin 2.28 (0.63)
Free testosterone (pg/ml): OCP group 2.35 (1.71), OCP + goserelin 2.37 (1.20)
DHT (pg/ml): OCP group 0.31 (0.11), OCP + goserelin 0.23 (0.06)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 48 weeks (28)
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + monthly depot of
goserelin for 48 weeks (28)
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Outcomes Assessments (4): baseline, week 24, 48 and 24 weeks after end of study
Outcomes of the trial (as reported)
1. Subjective response of hair growth and satisfaction by physician and participant;
3-point Likert scale
2. Acne; 4-point Likert scale
3. Estradiol, SHBG, DHEAS, free testosterone, DHT, LH, FSH
4. Objective response (hair diameter)
5. Serum chemistry, urine analysis, complete blood count
6. Adverse events
Denotes outcomes prespecified for this review
Notes Inconsistent N is used for the different analyses as not always all 41 participants were
available for the measurements; these are listed in the tables of the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 261): ”...using a multiple
computer generated scheme...were cen-
trally randomized...“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: central allocation, probably
done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (page 260): ”...open...“
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (page 260): ”...open...“
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 15/56 (27%), 7/28 in OCP group, 8/28
in OCP + goserelin, reasons not reported.
Per-protocol analysis
Comment: the high drop-out rate with per-
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protocol analysis represents a potential high
risk of bias
Selective reporting (reporting bias) High risk Although subjective evaluation and ’pa-
tient satisfaction’ were prespecified assess-
ments, no data are reported on these out-
comes
Comment: we judged this as at a high risk
of bias
Other bias Low risk Quote (page 267): ”...We thank Zeneca
Spa., Italy for providing the drugs...“
Comment: we judged this as at a low risk
of bias
Venturoli 1998
Methods Randomised, active-controlled trial
Setting
Institute of Reproductive Physiology and Pathology of the University of Bologna,
Bologna, Italy
Date of study
No reported. Duration of intervention 6 months
Participants N = 18
Mean age = 23 years
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• Adrenal or ovarian tumour
Randomised
N = 18
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data
Nothing reported
Interventions Intervention
• OCP (ethinyl estradiol 0.01 mg/day for the 1st week, 0.02 mg/day for the 2nd
week, 0.01 mg/day for the 3rd week and 7 ’pause’ days) + cyproterone acetate 12.5 mg/
day for the first 10 days of treatment for 6 months (8)
Comparator
• OCP (ethinyl estradiol 0.01 mg/day for 10 days, 0.02 mg/day for the next 11
days and 7 ’pause’ days) + cyproterone acetate 12.5 mg/day for the first 10 days of
treatment for 6 months (10)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
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2. Hair growth; IBAS image analyser
3. FSH, LH, DHEAS, testosterone, 17OH progesterone, DHT, androstenedione,
17β estradiol, SHBG
4. GnRH test
5. Biochemical parameters
6. Adverse events
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 30): ”...were randomized into
two different regimens...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
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Selective reporting (reporting bias) Low risk Although limited data have been provided,
the prespecified outcomes and those men-
tioned in the methods section appeared to
have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 33): ”This work was sup-
ported in part by a grant from Ministero
dell’ Università e della Ricerca Scientifica
e Tecnologica( funds 60%,1997) Rome,
Italy“
Comment: we judged this as at a low risk
of bias
Venturoli 1999
Methods Randomised, active-controlled study
Setting
Reproductive Medicine Unit, Institute of Obstetrics and Gynecology, University of
Bologna, Bologna, Italy
Date of study
Not reported. Duration of intervention 12 months
Participants N = 66
Mean age = 23 years
Inclusion criteria of the trial
• Hirsute women
Exclusion criteria of the trial
• Hormonally active adrenal gland
• Ovarian tumour
• Cushing’s, prolactin, or thyroid disorder
Randomised
N = 66
Withdrawals/losses to follow-up
• 9/66 (14%); 0/15 in flutamide group, 0/15 in finasteride group, 8/16 in
ketoconazole group, 1/20 in EE/CPA group
Baseline data (mean (SD))
BMI: 27 (2.6)
27 had PCOS, 25 idiopathic hirsutism, 14 non-classic adrenal hyperplasia
Interventions Intervention
• Flutamide 250 mg/day for 12 months (15)
Comparator 1
• Finasteride 5 mg/day for 12 months (15)
Comparator 2
• Ketoconazole 300 mg/day for 12 months (16)
Comparator 3
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• OCP (ethinyl estradiol 0.01 mg/day for the 1st week, 0.02 mg/day for the 2nd
week, 0.01 mg/day for the 3rd week and 7 ’pause’ days) + cyproterone acetate 12.5 mg/
day for the first 10 days of treatment for 12 months (20)
Outcomes Assessments (5): baseline, month 3, 6, 9, and 12
Outcomes of the trial (as reported)
1. Modified Ferriman-Gallwey score
2. Hair growth; IBAS analyser
3. Self reported evaluation; 3-point Likert scale
4. Biochemical parameters
5. FSH, LH, prolactin, 17OH progesterone, DHEAS, DHEA, testosterone, free
testosterone, DHT, androstenedione, 17β estradiol and SHBG
6. Adverse events
Denotes outcomes prespecified for this review
Notes Quote (page 1304): ”Fourteen hirsute patients (21%) suffered from a mild form of
nonclassic adrenal hyperplasia with high 17a-hydroxyprogesterone values, as diagnosed
by ACTH test“. No separate data for women with PCOS and idiopathic hirsutism, see
Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1304): ”Patients were ran-
domized into four groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 9/66 (14%); 0/15 in flutamide group, 0/15
in finasteride group, 8/16 in ketoconazole
group, 1/20 in EE/CPA group. Per-proto-
col analysis
Comment: we judged this as at unclear risk
of bias
Selective reporting (reporting bias) High risk Self reported evaluation was a prespecified
outcome but not reported
Comment: we judged this as at a high risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Vermeulen 1988
Methods Randomised, double-blind, active-controlled trial
Setting
Department of Endocrinology, Medical Clinic, University Hospital Ghent, Belgium
Date of study
Not reported. Duration of intervention 6 months
Participants N = 30
Age range 18 to 35 years
Inclusion criteria of the trial
• Acne or hirsutism
Exclusion criteria of the trial
• Smoking > 10 cigarettes/day
• Alcohol > 40 ml/day
• Hypertension
Randomised
N = 30
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
Testosterone (ng/dl): Diane 35 group 42 (5), Diane 50 group 33 (3)
DHT (ng/dl): Diane 35 group 25 (3), Diane 50 group 20 (2)
Androstenedione (ng/dl): Diane 35 group 213 (21), Diane 50 group 201 (33)
DHEAS (ng/dl): Diane 35 group 162 (21), Diane 50 group 155 (14)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone 2 mg) for 6 months (13)
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Comparator
• OCP (ethinyl estradiol 50 µg + cyproterone 2 mg) for 6 months (17)
Outcomes Assessments (7): baseline and every month until end of study
Outcomes of the trial (as reported)
1. Total cholesterol, HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol, LDL
cholesterol, ApoB containing lipoproteins, triglycerides
2. Testosterone, free testosterone, DHT, 5α-androstane-3α, 17β-diol, and its
glucuronide, androstenedione, DHEA and DHEAS
Denotes outcomes prespecified for this review
Notes Quote (page 420): ”The mildly hirsute women had been treated previously successfully
with high dose CPA (50-100 mg) and ethinyl estradiol (50 µg) for several months and
after a washout period of at least 2 months, they entered the study, the Diane treatment
being considered as a maintenance therapy for these subjects. Data from this laboratory
had previously shown that within 2 months of stopping therapy any effects of the drugs
on either plasma androgen levels or lipids had disappeared.“
Unclear how many women were hirsute, as women with acne were also included, see
Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 420): ”...randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 420): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 420): ”...double-blind...“
Comment: as outcomes are serum tests, un-
likely to be influenced by potential lack of
adequate blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Vexiau 1995
Methods Randomised, active-controlled trial
Setting
Endocrinology and Diabetology Department, Hôpital Saint-Louis, Paris, France
Date of study
July 1989 until July 1990. Duration of intervention 12 months
Participants N = 65
Mean age = 26 years
Inclusion criteria of the trial
• Persistent acne, acne associated with hirsutism, hirsutism without acne
Exclusion criteria of the trial
• Steroid therapy < 3 months prior to study entry
Randomised
N = 65
Withdrawals/losses to follow-up
• 10/65 (15%); 6/34 in transdermal patch group, 4/31 in oral group
• Ineffectiveness; 2/34 in transdermal patch group, 0/31 in oral group
• Patch intolerance; 4/34 in transdermal patch group, 0/31 in oral group
• Drop-out; 0/34 in transdermal patch group, 1/31 in oral group
• Moved away; 0/34 in transdermal patch group, 2/31 in oral group
• Morbus Pfeiffer; 0/34 in transdermal patch group, 1/31 in oral group
Baseline data (mean (SEM))
BMI: transdermal patch group 23.6 (0.9), oral group 20.6 (0.5)
Interventions Intervention
• Cyproterone acetate 50 mg/day with 17β estradiol by transdermal patch (20/28
days) for 12 months (34)
429Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vexiau 1995 (Continued)
Comparator
• Cyproterone acetate 50 mg/day with 17β estradiol valerate orally (20/28) days)
for 12 months (31)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Glucose tolerance
2. Plasma lipid level parameters
3. Coagulation parameters
4. Fibrinolysis parameters
5. Angiotensinogen
Denotes outcomes prespecified for this review
Notes Unclear how many women were hirsute; no separate data for hirsute women, and none
of our outcomes are assessed, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 509): ”...were constituted at
random...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding reported
Comment: as outcomes are serum tests, un-
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10/65 (15%); 6/34 in transdermal patch
group, 4/31 in oral group, reasons reported.
Per-protocol analysis
Comment: we judged this as at an unclear
risk of bias
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Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Vigorito 2007
Methods Randomised controlled trial
Setting
University ”Federico II“ of Naples, School of Medicine, Naples, Italy
Date of study
Not reported. Duration of study 3 months
Participants N = 90
Mean age = 22 years
Inclusion criteria of the trial
• Overweight nonsmoking women with PCOS
• PCOS according to Rotterdam Criteria PCOS 2004, hirsutism according to
Ferriman-Gallwey score > 8
Exclusion criteria of the trial
• Pregnancy
• Glucose intolerance (as screened by a 2-hour oral glucose tolerance test) and
diabetes
• Hypothyroidism
• Hyperprolactinaemia
• Cushing’s syndrome
• Nonclassical congenital adrenal hyperplasia
• Use of oral contraceptives, glucocorticoids, antiandrogens, ovulation induction
agents, antidiabetic or anti-obesity drugs, or other hormonal drugs < 6 months prior to
study entry
• Neoplastic, hepatic, respiratory, and any cardiovascular disorder or other
concurrent medical illness (i.e. heart failure, lung or renal disease)
Randomised
N = 90
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (mean (SD))
BMI: trained group 29.3 (2.9), untrained group 29.4 (3.5)
F-G score: trained group 11.9 (3.5), untrained group 12.1 (3.4)
Testosterone (nmol/L): trained group 2.3 (0.7), untrained group 2.5 (0.5)
Androstenedione (nmol/L): trained group 5.1 (0.7), untrained group 5.3 (0.9)
DHEAS (µmol/L): trained group 4320 (465), untrained group 4290 (441)
SHBG (nmol/L): trained group 27 (6.2), untrained group 29 (6.5)
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Vigorito 2007 (Continued)
Interventions Intervention
• Exercise training 3 times a week for 30 minutes (45)
Comparator
• No exercise (45)
At study entry, general dietary and behavioural advice without a structured caloric re-
striction programme was given to the entire PCOS study population. All of the PCOS
population was counselled to achieve a healthy balanced meal plan with regular food
with a nutritional composition of 50% of calories from carbohydrate, 25% from protein,
and 25% from fat. Intake of low glycaemic index foods was encouraged
Outcomes Assessments (2): baseline and month 3
Outcomes of the trial (as reported)
1. LH, FSH, prolactin, estradiol, progesterone, 17OH progesterone, testosterone,
androstenedione, DHEAS, SHBG
2. Ferriman-Gallwey score, BMI, waist/hip ratio
3. Glucose and insulin (AUCs)
4. Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, C-reactive
protein
5. Diary for menses and serious events
6. Leisure-time physical activity questionnaire
Denotes outcomes prespecified for this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1380): ”PCOS women were
randomly subdivided into two groups...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
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Vigorito 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible.
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk All clinical assessments were performed by
the same physician who was blinded to the
patient allocation into the study protocol
Comment: uncertainty about the effec-
tiveness of blinding of outcomes assessors
(healthcare providers) and the lack of blind-
ing of the outcomes (serious events and
menses) by the participants poses a high
risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Visnovský 2010
Methods Randomised, active-controlled trial
Setting
Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius
University, Martin, Slovak Republic
Date of study
March 2003 until April 2005. Duration of the intervention 1 year
Participants N = 90
Mean age = 25 years
Inclusion criteria of the trial
• Women with hyperandrogenic syndrome
• Infertility
• Nulligravida
• 2 criteria of PCOS (oligo/anovulation respectively oligo/amenorrhoea, menstrual
cycle of 35 to 90 days or absence of menses more than 90 days, clinical or biochemical
signs of hyperandrogenism - hirsutism and virilisation on 3 predilection places,
testosterone level > 0.65 nmol/L polycystic ovaries on ultrasound)
Exclusion criteria of the trial
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Visnovský 2010 (Continued)
• Endocrinological disease
• Contraindication for OCP
• Hormonal treatments
• Dysmenorrhoea
Randomised
N = 90
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data
Oligomenorrhoea: 82/90
Hirsutism: 54/90
Polycystic ovaries on ultrasound: 81/90
Hyperandrogenic hormone profile: 65/90
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 12 months (30)
Comparator 1
• OCP (ethinyl estradiol 30 µg + dienogest 2 mg) for 12 months (30)
Comparator 2
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 12 months (30)
Outcomes Assessments (4): baseline, month 6, 12, and 18
Outcomes of the trial (as reported)
1. Menses
2. Effect on clinical parameters of hyperandrogenism
3. Ultrasound of ovaries
Denotes outcomes prespecified for this review
Notes 54/90 had hirsutism, no separate data on hirsute women, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 481): ”...randomized...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
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Visnovský 2010 (Continued)
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
Wang 2012
Methods Randomised, active-controlled trial
Setting
Obstetrics and Gynecology, West China Second University Hospital of Sichuan Univer-
sity, Chengdu, Sichuan, China
Date of study
Not reported. Duration of intervention 6 months
Participants N = 110
Mean age = not reported
Inclusion criteria of the trial
• PCOS diagnosed according to Rotterdam criteria (Rotterdam Criteria PCOS
2004)
Exclusion criteria of the trial
• Not reported
Randomised
N = 110
Withdrawals/losses to follow-up
• Not reported
Baseline data
Nothing reported
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Wang 2012 (Continued)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (55)
Comparator
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 6 months (55)
Meantime, they received 1500 mg/dmetformin and lifestylemodification such as dietary
and exercise
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. BMI, waist/hip ratio, score of GAGS, Ferriman-Gallwey score
2. Biochemical profile as hormone profile, HOMA-IR, the insulin and glucose AUC
by means of oral glucose tolerance tests and lipid profile (total cholesterol, LDL
cholesterol, HDL cholesterol, triglyceride, and haemoglobin A1c)
Denotes outcomes prespecified for this review
Notes Abstract to conference proceedings. Limited data and no contact details of investigators
provided, see Table 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page S482): ”...randomly separated
into two groups ...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Selective reporting (reporting bias) Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Other bias Unclear risk There was insufficient information to per-
mit a clear judgement of the risk of bias
Wolf 2007
Methods 2 randomised, double-blind, vehicle-controlled trials
Setting
Multi-centre (18) in the US (17) and Spain (1)
Date of study
Not reported. Duration of intervention 24 weeks with 8 weeks follow-up
Participants N = 596
Age range = 18 to 83 years
Inclusion criteria of the trial
• Women of at least 16 years of age with a clinical diagnosis of facial hirsutism
• An average hair density of at least 5 hairs per cm2 on both the chin and upper lip
as assessed by video image analysis
• Customary frequency of hair removal of at least twice per week
• Good general health
• A negative serum or urine pregnancy test for women of child-bearing age
• A score of at least 20 on a VAS ranging from 0 (not bothered) to 100 (extremely
bothered) for the question: ”How much are you bothered by your facial hair?“
Exclusion criteria of the trial
• Score < 20% on a subject’s self assessment questionnaire
• Laser or epilation within 2 months
• Chemical depilatories within 2 weeks
• Bleaching within 1 week
• Plucking within 48 hours or shaving within 24 hours before the study
• Medications considered to have an effect on hair growth within 6 months of the
study
• Facial conditions such as severe inflammatory acne
• Pregnancy or nursing mothers
Randomised
N = 596
Withdrawals/losses to follow-up
• 153/596 (26%); 100/295 in eflornithine group and 53/201 in vehicle group
Baseline data
No data regarding hirsutism score or hormone levels
Interventions Intervention
• Eflornithine HCl 13.9% cream b.i.d. for 24 weeks with 8 weeks follow-up (395)
Comparator
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Wolf 2007 (Continued)
• Vehicle b.i.d. for 24 weeks with 8 weeks follow-up (201)
During the study, subjects were permitted to continue their normal hair removalmethod;
however, shaving and cuttingwere not permittedwithin 24hours of 1st day of a scheduled
study visit, plucking within 48 hours, or bleaching within 1 week of the first day of a
scheduled visit
Outcomes Assessments (7): baseline, weeks 2, 4, 8, 16, 24, and 32
Outcomes of the trial (as reported)
1. Physician’s Global Assessment (photographic assessment); 4-point Likert scale
2. Evaluations of acne and pseudo folliculitis barbae
3. Adverse events
Denotes outcomes prespecified for this review
Notes This is the same study as Jackson 2007, but partly covering other outcomes. The number
of participants completing the study are not consistent in the 2 papers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 95): ”Subjects were random-
ized to receive...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
After e-mail communication (quote):
”Subjects were assigned treatment by a
computer-generated randomization sched-
ule restricted to ensure distribution of eflor-
nithine 15% cream and its vehicle in a 2:
1 ratio, respectively, within each investiga-
tional site.“
Comment: probably done
Allocation concealment (selection bias) Low risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
After e-mail communication (quote):
”Subject numbers and numbers identifying
study medication containers corresponded
directly.“ and ” The second panel of the
tear-off part of the label was a sealed enve-
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lope concealing the identity and lot num-
ber of the treatments. These tear-off por-
tionswere to be affixed to the subjectsCRFs
and opened only in the case of a medical
emergency in which the investigator had
determined that the information was abso-
lutely necessary, i.e., that it would alter the
subjects immediate management.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 94): ”...double-blind...“
Comment: the report did not provide suf-
ficient detail about the specific measures
used to blind study participants and per-
sonnel from knowledge of which interven-
tion a participant received, to permit a clear
judgement
After e-mail communication (quote):
”Blinding of the eflornithine 15% cream
and its vehicle was assured by the fact
that both study medications were packaged
in identically appearing 15g plastic tubes
bearing three-panel, two-part double-blind
labels. Labels affixed to the tubes (the only
label to which subjects had access) con-
tained no evidence of the identity of the
contents... Eflornithine 15% cream and its
vehicle were matching cream formulations
and it was not considered possible to differ-
entiate one treatment from the other solely
by tactile or visual evaluation. The proto-
col for this study specified that dispens-
ing of study medications at the investiga-
tional site was to be done by a staff mem-
ber whowas not responsible for conducting
any of the clinical evaluations. Therefore,
the chances of the investigator equating a
particular level of response with what he/
she considered to be a particular treatment
was minimal.“
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 976): ”...double-blind...“
Comment: uncertainty about the effective-
ness of blinding of outcomes assessors (par-
ticipants/healthcare providers) during the
study
Insufficient information to permit a clear
judgement
After e-mail contact (quote): see above
Outcomes were investigator-assessed as
well as participant-assessed (menstruation).
Blinding of participants and key study per-
sonnel was ensured, and it is unlikely that
the blinding could have been broken
Comment: we judged this as at a low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 153/596 (26%); 100/395 in eflornithine
group and 53/201 in vehicle group. Per-
protocol analysis
Comment: high drop-out rate with per-
protocol analysis represents a high risk of
bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias High risk Quote (page 97): ”These studies were
funded by the partnership of Bristol-My-
ers Squibb, Princeton, NJ and The Gillette
Company, Needham, MA. Eflornithine
HCl 13.9% cream is marketed as Vaniqa®
(SkinMedica Inc., Carlsbad, CA and Shire
Pharmaceuticals Group PLC, UK)“
Comment: a potential risk of bias cannot
be excluded
440Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wong 1995
Methods Randomised, active-controlled trial
Setting
Department ofObstetrics andGynecology,Division of Reproductive Endocrinology and
Infertility,University of SouthernCalifornia School ofMedicine, LosAngeles, California,
US
Date of study
Not reported. Duration of intervention 6 months
Participants N = 14
Mean age = 31 years
Inclusion criteria of the trial
• Women 15 to 40 years with moderate to severe hirsutism
• Ferriman-Gallwey score > 12
Exclusion criteria of the trial
• Evidence of virilisation, pelvic mass, or elevated 17-hydroxyprogesterone levels
Randomised
N = 14
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SEM))
F-G score: spironolactone group 19 (2), finasteride group 19 (2)
Testosterone (pmol/L): spironolactone group 1838 (347), finasteride group 1422 (173)
DHT (pmol/L): spironolactone group 544.1 (79.2), finasteride group 509.6 (58.5)
Androstenedione (pmol/L): spironolactone group 9777 (1,466), finasteride group 7926
(873)
DHEAS (nmol/L): spironolactone group 8163 (2449), finasteride group 8707 (1905)
Interventions Intervention
• Spironolactone 100 mg daily for 6 months (5)
Comparator
• Finasteride 5 mg daily for 6 months (9)
All were fully informed of the potential risk should they have become pregnant with a
male fetus during the trial and were either using or were placed on non hormonal forms
of contraception
Outcomes Assessments (3): baseline, month 3 and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. Total testosterone, DHT, androstenedione, DHEAS
3. Hair analysis; optic micrometer
4. Self reported assessment; 6-point Likert scale
Denotes outcomes prespecified for this review
Notes -
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 233): ”...were randomly as-
signed in a 1:2 ratio...“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk The study appears to be free of other forms
of bias
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Zheng 2005
Methods Randomised, active-controlled trial
Setting
Research laboratory of Reproductive Endocrinology, First Hospital of Xi’an Jiaotong
University, Xi’an, China
Date of study
Not reported. Duration of intervention 6 months
Participants N = 90
Mean age = 29 years
Inclusion criteria of the trial
• PCOS based on the presence of oligomenorrhoea or amenorrhoea,
hyperandrogenism (testosterone levels > 2.8 nmol/L, serum LH/FSH ratio ≥ 2, and
ultrasound evidence of polycystic ovaries (presence ≥ 10 cysts, 2 mm to 8 mm in
diameter)
• Clomiphene citrate resistant
Exclusion criteria of the trial
• Not reported
Randomised
N = 90
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (mean (SD))
BMI: metformin group 25.30 (3.64), rosiglitazone group 26.67 (3.67)
F-G score: metformin group 9.35 (1.41), rosiglitazone group 9.62 (1.58)
Testosterone (nmol/L): metformin group 2.82 (1.51), rosiglitazone group 3.09 (0.73)
Interventions Intervention
• Metformin 500 mg 3 times a day + clomiphene citrate 50 to 100 mg/day during
day 5 to 9 of the menstrual cycle for 6 months (50)
Comparator
• Rosiglitazone 4 mg once a day + clomiphene citrate 50 to 100 mg/day during day
5 to 9 of the menstrual cycle for 6 months (40)
Outcomes Assessments (7): baseline, month 1, 2, 3, 4, 5, and 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. BMI, weight
3. Ultrasonography for ovaries/cysts/follicles
4. LH, FSH, prolactin, estradiol, testosterone
5. Oral glucose tolerance test, insulin release test
6. HOMA-IR
Denotes outcomes prespecified for this review
Notes -
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 63): ”...randomized to receive.
..“
Comment: insufficient detail was reported
about themethod used to generate the allo-
cation sequence to allow a clear assessment
of whether it would produce comparable
groups
Allocation concealment (selection bias) Unclear risk The method used to conceal the allocation
sequence, that is to determine whether in-
tervention allocations could have been fore-
seen in advance of, or during, enrolment,
was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported
Comment: the outcome was likely to be
influenced by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported
Comment: the outcome measurement was
likely to be influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Comment: we judged this as at a low risk
of bias
Selective reporting (reporting bias) Low risk The protocol for the study was not avail-
able, but the prespecified outcomes and
those mentioned in the methods section
appeared to have been reported
Comment: we judged this as at a low risk
of bias
Other bias Low risk Quote (page 62): ”This work was sup-
ported by the Foundation of Science &
Technique Investigation Project of Shaanxi
Province.“
Comment: we judged this as at a low risk
of bias
ACE: angiotensin-converting-enzyme
AUC: area under the curve
b.i.d.: twice a day
BMI: body mass index
CAH: congenital adrenal hyperplasia
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CC: clomiphene citrate
CMA: chlormadinone acetate
CPA: cyproterone acetate
DHEAS: dehydroepiandrosterone sulphate
DHT: dihydrotestosterone
DQLI: Dermatology Quality of Life Index
DRSP: drospirenone
DSG: desogestrel
EE: ethinyl estradiol
FAI: Free Androgen Index
F-G: Ferriman-Gallwey score
FSH: follicle-stimulating hormone
GnRH-a: gonadotropin-releasing hormone analogue
HDL: high-density lipoprotein
HOMA-IR: Homeostasis Model Assessment Insulin Resistance index
IH: idiopathic hirsutism
im: intramuscular
iv: intravenous
IVF: in vitro fertilisation
LDL: low-density lipoprotein
LH: luteinising hormone
LHRH: luteinising hormone-releasing hormone
OCP: oral contraceptive pill
OGTT: oral glucose tolerance test
PCOS: polycystic ovary syndrome
PI: principal investigator
QUICKI: Quantitative Insulin Sensitivity Check Index
sc: subcutaneous
SD: standard deviation
SEM: standard error of the mean
SHBG: sex hormone-binding globulin
TSH: thyroid-stimulating hormone
UTND: ultrasound-guided transvaginal needle ovarian drilling
VAS: visual analogue scale
VLDL: very low-density lipoprotein
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acién 1997 Full text confirms: CCT
Anderson 1977 Full text confirms: CCT
Ansarin 2007 Abstract (English) confirms: CCT
Avnstorp 1982 Translated from Swedish, full text confirms case series
Baranowska 1983 Translated from Polish, full text confirms CCT see Acknowledgements
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Barrett-Connor 1999 Interventions not relevant for this review
Barth 1989 Full text confirms: CCT
Batukan 2006 Partial report (only one treatment arm); full data set in Batukan 2007
Bazex 1982 Translated from French, full text confirms case series
Benjamin 1971 Full text confirms: CCT
Bridger 2006 Full text confirms: participants were not hirsute
Buckshee 1986 Full text confirms: CCT
Carmina 1997 Full text confirms: CCT
Castel-Branco 1998 Full text confirms: CCT
Castello 1991 Full text confirms: CCT
Codner 2009 Full text: hirsutism was not a prerequisite inclusion criterion
Cremoncini 1976 Full text confirms: CCT
Cullberg 1985 Full text confirms: CCT
Cunliffe 1973 Full text confirms: within-patient controlled study (CCT)
Dahlgren 1998 Full text confirms: CCT
Dennerstein 1984 Full text confirms: CCT
Devoto 2000 Full text confirms: CCT
Devoto 2004 Full text confirms: CCT
Dikensoy 2009 Full text confirms: CCT
Erdmann 1994 Translated from German, full text confirms CCT
Erenus 1995 Full text, letter to the editor commenting on Cusan 1994
Escobar-Morreale 1998 Full text confirms: CCT
Falsetti 1997 Full text confirms quasi-randomised (CCT)
Falsetti 1997B Full text confirms quasi-randomised (CCT)
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Fruzzetti 1993 Full text confirms quasi-randomised (CCT)
Givens 1976 Full text confirms: CCT
Gomez 1987 Full text, letter to the editor confirms CCT
Gregoriou 2000 Full text confirms: CCT
Grigoriou 1996 Full text confirms quasi-randomised (CCT)
Grund 1975 Translated from German, full text confirms CCT
Gupta 1978 Full text confirms: CCT
Guzick 1994 Full text: not on interventions for hirsutism
Gökmen 1996 The investigators describe a method used to generate the allocation sequence that does not provide
comparable groups (quasi-randomised)
Hahn 2004 Full text confirms: CCT
Inal 2005 Full text confirms quasi-randomised (CCT)
Jasonni 1991 Full text confirms: case series
Karakurt 2008 Full text confirms quasi-randomised (CCT)
Kazerooni 2010 Full text confirms quasi-randomised (CCT)
Keletimur 1998 Full text confirms quasi-randomised (CCT)
Keletimur 2004 Full text confirms quasi-randomised (CCT)
Knopp 2001 Full text, not in hirsute women
Lachnit-Fixson 1979 Full text confirms: literature review, non-RCT
Landman 2001 Full text, letter to the editor commenting on Azziz 2001
Le Donne 2012 After e-mail contact with trialist, confirmed as quasi-randomised (CCT). See Table 4
Lee 2000 Full text, summary of related Cochrane Review (Brown 2009), non-RCT
Lobo 1985 Full text confirms: CCT
Lunde 1987 Full text confirms: CCT
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Madani 2012 After e-mail contact with trialist, confirmed as quasi-randomised (CCT). See Table 4
Manieri 1997 Full text confirms: CCT
Medical Letter 2000 Full text: a short summary on eflornithine hydrochloride cream 13.9%, following its approval by FDA
Mowbray 1959 Full text confirms: case series
Müderris 1997 Full text confirms quasi-randomised (CCT)
Nielsen 1985 Translated from Danish, full text confirms CCT
Paggi 1981 Translated from Italian, full text confirms case series
Pai 1982 Full text confirms: case series, with only one woman with hirsutism
Pedersen 1985 Translated from Danish, full text confirms case series
Peereboom-Wynia 1985 Full text confirms: CCT
Pugeat 1991 Translated from French, full text confirms CCT
Rubens 1985 Full text confirms: CCT
Sahin 2001 Full text confirms quasi-randomised (CCT)
Sert 2003 Full text and e-mail contact with trialist confirms: quasi-randomised (CCT). See Table 4
Siegberg 1987 Full text confirms: CCT
Taner 2002 Full text confirms quasi-randomised (CCT)
Thomas 1985 Full text confirms: CCT
Tolino 1996 Full text confirms: case series
Unluhizarci 2009 Full text confirms quasi-randomised (CCT)
Unlühizarci 2002 Full text confirms quasi-randomised (CCT)
van Wayjen 1976 Translated from Dutch, full text confirms review
Vicente 2009 Full text confirms that although these women have an excess of terminal hairs in androgen-dependent
areas, they did not meet the Ferriman-Gallwey criteria for hirsutism (mean score of 4)
Wagner 1993 Full text confirms: literature review
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(Continued)
Weiss 2007 Translated from German, full text confirms non-RCT, summary of Batukan 2007
Wild 1991 Full text confirms: CCT, selected on the basis of contraceptive need and allocated according to the need
Yari 2010 Study objectives not relevant for this systematic review
Yilmaz 2005 Full text confirms quasi-randomised (CCT)
Yücelten 1999 Full text confirms: CCT
CCT controlled clinical trial (quasi-randomised)
FDA: (US) Food and Drug Administration
Characteristics of studies awaiting assessment [ordered by study ID]
Akha 2014
Methods Randomised, double-blind, placebo-controlled trial
Setting
Several departments, Mazandaran University of Medical Sciences, Sari, Iran
Date of study
2009-2011. Duration of intervention 24 weeks
Participants N = 44
Mean age = 26 years
Inclusion criteria of the trial
• 15 to 45 years
• Mild to moderate hirsutism limited to the face
Exclusion criteria of the trial
• Increased serum androgen level
• Irregular menstrual cycle
• Severe hirsutism
• History of using spironolactone, cyproterone acetate, cyproterone compound, corticosteroids,
medroxyprogesterone acetate, contraceptive pills
• Also, pregnant and lactating women
• Use of laser therapy for hair depilation during the previous 6 months
Randomised
N = 44
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data
Degree of hirsutism: fennel group mild 2, moderate 20, control group mild 8, moderate 12
Interventions Intervention
• Fennel gel 3% for 24 weeks (22)
Comparator
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Akha 2014 (Continued)
• Placebo gel for 24 weeks (22)
Outcomes Assessments (2): baseline, week 24
Outcomes of the trial (as reported)
1. Change in hair thickness; microscope
2. Adverse events
Denotes outcomes prespecified for this review
Notes -
Atabekoglu 2013
Methods Randomised, active-controlled trial
Setting
Obstetrics and Gynecology, Ankara University, Ankara, Turkey
Date of study
Not reported. Duration of intervention 12 months
Participants N = 52
Mean age not reported
Inclusion criteria of the trial
• PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 52
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data
Nothing reported
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) once a day for 12 months (26)
Comparator
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) once a day for 12 months (26)
Outcomes Assessments (unclear): baseline, month 12 and probably more
Outcomes of the trial (as reported)
1. BMI, WHR
2. Modified Ferriman-Gallwey score
3. Changes in androgens (not specified)
Denotes outcomes prespecified for this review
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Atabekoglu 2013 (Continued)
Notes Poster abstract: Conference: International Federation of Fertility Societies 21st World Congress on Fertility and
Sterility and the 69th Annual Meeting of the American Society for Reproductive Medicine, IFFS-ASRM 2013
Boston, MA United States
Chung 2014
Methods Randomised, active-controlled, cross-over study
Setting
Paediatric and adolescent gynaecology clinic (PAGC) of a university-affiliated tertiary hospital, Hong Kong
Date of study
July 2007- July 2010. Duration of intervention 12 months
Participants N = 76
Mean age = 17 years
Inclusion criteria of the trial
• Adolescents aged 14 to 19 with PCOS according to the Rotterdam consensus (Rotterdam Criteria PCOS
2004)
Exclusion criteria of the trial
• Current desire for fertility
• Confirmed concomitant diabetes mellitus
• Liver disease, or other medical conditions where MPA or Diane-35 may be contraindicated
• Unable to give informed consent
Randomised
N = 76
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data (SD)
F-G score: group 1 7.7 (6.4), group 2 7.7 (6.0)
Interventions Intervention
• Medroxyprogesterone acetate (MPA) 10 mg per day first 10 days of the month for 4 months followed by a
wash-out period of 4 months and then Diane-35 for 4 months (38)
Comparator
• Medroxyprogesterone acetate (MPA) 10 mg per day first 10 days of the month followed by a wash-out period
of 4 months and then medroxyprogesterone acetate (MPA) 10 mg per day first 10 days of the month for 4 months
(38)
Outcomes Assessments (4): baseline, month 4, 8, and 12
Outcomes of the trial (as reported)
1. BMI
2. Waist to hip ratio
3. Serum testosterone, LH, FSH
4. Acne
5. Ferriman-Gallwey score
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Chung 2014 (Continued)
6. Chinese validated standard questionnaire 36-item Short Form Health Survey (SF-36) and a client satisfaction
questionnaire
Denotes outcomes prespecified for this review
Notes -
Ibañez 2013
Methods Randomised, open-label, active-controlled trial
Setting
Adolescent Endocrinology Unit of Sant Joan University Hospital, Barcelona, Spain
Date of study
2010. Duration of intervention 6 months
Participants N = 34
Mean age = 16 years
Inclusion criteria of the trial
• Girls with hyperinsulinaemic androgen excess
• Hyperinsulinaemia, defined as fasting insulinaemia above 15 µU/ml and/or a peak insulinaemia above 150
µU/ml, and/or mean insulinaemia above 84 µU/ml on a 2-horal glucose tolerance test
• Presence of both clinical and biochemical androgen excess, as defined by the following: hirsutism score > 8
(Ferriman-Gallwey), amenorrhoea (no menses for 3 months) or oligomenorrhoea (menstrual cycles > 45 days); and
high circulating levels of androstenedione or testosterone in the follicular phase (days 3 to 7) or after 2 months of
amenorrhoea
Exclusion criteria of the trial
• Evidence of anaemia
• Thyroid dysfunction
• Bleeding disorder
• Cushing syndrome
• Hyperprolactinaemia
• Glucose intolerance; diabetes mellitus
• Late-onset adrenal hyperplasia
• Abnormal electrolytes
• Abnormal screening of liver or kidney function
• Use of medication affecting gonadal or adrenal function, or carbohydrate or lipid metabolism
• Pregnancy
Randomised
N = 34
Withdrawals/losses to follow-up
• No losses to follow-up reported
Baseline data [Mean (SEM)]
BMI: EE-CPA group 23.1 (0.6), PioFluMet group 23.2 (0.5)
F-G score: EE-CPA group 13.5 (0.9), PioFluMet group 14.0 (0.9)
Acne score: EE-CPA group 2.2 (0.2), PioFluMet group 2.3 (0.2)
SHBG (nmol/L): EE-CPA group 23.0 (3), PioFluMet group 28 (3)
Testosterone (ng/dl): EE-CPA group 58 (7), PioFluMet group 63 (7)
Androstenedione (ng/dl): EE-CPA group 455 (32), PioFluMet group 474 (44)
DHEAS (µg/dl): EE-CPA group 283 (32), PioFluMet group 287 (29)
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Ibañez 2013 (Continued)
Interventions Intervention
• OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) for 6 months (17)
Comparator
• Pioglitazone 7.5 mg + flutamide 62.5 mg + metformin 850 mg for 6 months (17)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. Weight, height, BMI
2. Ferriman-Gallwey score
3. Acne score; Leeds grading scale (O’Brien 1998)
4. Glucose, insulin, lipid profile
5. SHBG, testosterone, androstenedione, DHEAS
6. C-reactive protein, IGF-1, leptin, high molecular weight adiponectin, and follistatin, blood count and liver
and kidney function
7. Carotid intima-media thickness
8. Body composition (dual-energy x-ray absorptiometry) and abdominal fat distribution (MRI)
Denotes outcomes prespecified for this review
Notes Is full text report of the included Ibanez 2012 and will be addressed in next update
Lai 2014
Methods Randomised, participant-blinded, active-controlled trial
Setting
Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Hampshire, United King-
dom
Date of study
January 2013-July 2013. Duration of intervention 6 months
Participants N = 40
Mean age not reported
Inclusion criteria of the trial
• PCOS presenting with oligo- or amenorrhoea
• 18 to 44 years
Exclusion criteria of the trial
• Not reported
Randomised
N = 40
Withdrawals/losses to follow-up
• 11/40 (28%); 4 in standardised Chinese herbal medicine (CHM), 7 in individualised CHM
• Adverse events; 2 in standardised CHM, 3 in individualised CHM
• Taste; 1 in standardised CHM, 2 in individualised CHM
• Pregnancy; 0 in standardised CHM, 2 in individualised CHM
Baseline data
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Nothing reported
Interventions Intervention
• Standardised Chinese herbal medicine 8 g b.i.d. for 6 months (20)
Comparator
• Individualised Chinese herbal medicine 8 g b.i.d. for 6 months for 6 months (20)
Outcomes Assessments (8): baseline, week 2, 4, 8, 12, 16, 20, and 24
Outcomes of the trial (as reported)
1. Menstrual regularity
2. BMI
3. Waist hip ratio
4. Modified Ferriman-Gallwey score
5. Dermatology Life Quality Index, Measure Yourself Medical Outcome Profile
6. Liver and kidney function
7. Adverse events
Denotes outcomes prespecified for this review
Notes Conference: International Research Congress on IntegrativeMedicine andHealth, IRCIMH 2014Miami, FLUnited
States
Martin Hernandez 1995
Methods Randomised, active-controlled trial
Setting
Department of Endocrinology and Dermatology and Venereology, University Hospital ”Virgen Macarena“, Sevilla,
Spain
Date of study
Not reported. Duration of intervention 6 months
Participants N = 31
Mean age = 26 years
Inclusion criteria of the trial
• PCOS
• Ferriman-Gallwey score ≥ 8
Exclusion criteria of the trial
• Idiopathic hirsutism
• Adrenal cause of hirsutism
• Pregnancy
• OCP < 6 months before study entry
Randomised
N = 31
Withdrawals/losses to follow-up
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• No losses to follow-up reported
Baseline data
BMI: CPA group 26.3, flutamide group 25.2
Ferriman-Gallwey score: CPA group 14.1, flutamide group 14.9
Testosterone: CPA group 108.4, flutamide group 105.4
Interventions Intervention
• Cyproterone acetate 100 mg/day for 6 months (17)
Comparator
• Flutamide 250 mg b.i.d. for 6 months (14)
Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Serum testosterone, LH, FSH, prolactin, DHEAS, androstenedione
2. Ferriman-Gallwey score
3. Adverse events
Denotes outcomes prespecified for this review
Notes Randomisation according to age, BMI, and hormone levels. Unclear if stratified randomisation took place or that
the study is quasi-randomised
Mazza 2014
Methods Randomised, active-controlled trial
Setting
Endocrine Unit of University ”Magna Græcia“ of Catanzaro, Italy
Date of study
Not reported. Duration of intervention 6 months
Participants N = 56
Mean age = 23 years
Inclusion criteria of the trial
• Overweight/obese women with PCOS
• Ferriman-Gallwey score ≥ 8
Exclusion criteria of the trial
• Pregnancy
• Thyroid disorders
• Abnormal prolactin
• Late-onset non-classic congenital hyperplasia
• Cushing’s disease
• OCP < 6 months before study entry
• Antihypertensive agents, antidiabetic drugs and agents for weight loss
Randomised
N = 56
Withdrawals/losses to follow-up
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Mazza 2014 (Continued)
• 4/56 (7%); 2 in each group lost to follow-up
Baseline data (SD)
BMI: LSM group 31.1 (5), LSM + spironolactone group 32.8 (5.6)
Ferriman-Gallwey score: LSM group 12.2 (5.1), LSM + spironolactone group 15.1 (6.2)
Testosterone (ng/dl): LSM group 77.3 (25.1), LSM + spironolactone group 69.3 (15.6)
Interventions Intervention
• Lifestyle modification plus metformin 1700 mg/day for 6 months (28)
Comparator
• Lifestyle modification plus metformin 1700 mg/day + 25 mg spironolactone for 6 months (58)
Outcomes Assessments (2): baseline, month 6
Outcomes of the trial (as reported)
1. Anthropometric parameters (height, weight, waist circumference, and BMI)
2. Menstrual cycles
3. Ferriman-Gallwey score
4. Laboratory investigations included glycaemia, lipid profile, blood count, coagulation parameters, and hepatic
adrenal function indexes
5. Serum testosterone, SHBG, androstenedione, DHEAS, FAI
Denotes outcomes prespecified for this review
Notes -
Mirfeizi 2013
Methods Randomised, single-blind, active-controlled trial
Setting
Nursing and Midwifery, Islamic Azad University Karaj Branch, Karaj, Iran
Date of study
Not reported. Duration of intervention 12 weeks
Participants N = 50
Mean age unreported
Inclusion criteria of the trial
• PCOS
Exclusion criteria of the trial
• Not reported
Randomised
N = 50
Withdrawals/losses to follow-up
• Not reported
Baseline data (SD)
Nothing reported
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Interventions Intervention
• Diet for 12 weeks (25)
Comparator
• Physical activity for 12 weeks (25)
Outcomes Assessments (2): baseline, week 12
Outcomes of the trial (as reported)
1. Serum FSH, LH, estradiol, free testosterone, testosterone, SHBG, T3, T4, TSH, hydroxy progesterone,
cholesterol
2. BMI
3. Ultrasound
4. Menstrual cycles
5. Acne
6. Ferriman-Gallwey score
7. Alopecia
Denotes outcomes prespecified for this review
Notes Probably CCT
Nidhi 2013
Methods Randomised, active-controlled trial
Setting
Swami Vivekananda Yoga Anusandhana Samsthana, Division of Yoga and Life Sciences, Bangalore, India
Date of study
Not reported. Duration of intervention 12 weeks
Participants N = 90
Mean age = 16 years
Inclusion criteria of the trial
• 15 to 18 years with PCOS according to Rotterdam criteria (Rotterdam Criteria PCOS 2004)
Exclusion criteria of the trial
• OCP < 6 weeks prior to study entry
• Insulin-sensitising agents < 6 weeks prior to study entry
• Thyroid abnormalities
• Non-classic adrenal hyperplasia
• Prior experience with yoga
• No consent
Randomised
N = 90
Withdrawals/losses to follow-up
• 18/90 (20%); 8 in yoga group, 10 in control group
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Baseline data (SD)
Number of girls with mF-G score > 6: yoga group 15, control group 13
Interventions Intervention
• Yoga exercises for 12 weeks (25)
Comparator
• Physical exercises for 12 weeks (25)
Outcomes Assessments (2): baseline, week 12
Outcomes of the trial (as reported)
1. Serum Anti-Müllerian hormone, FSH, LH, estradiol, free testosterone, testosterone, SHBG, T3, T4, TSH,
hydroxy progesterone, cholesterol
2. BMI
3. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes -
Romualdi 2013
Methods Randomised, open-label, active-controlled trial
Setting
Department of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, Roma
Date of study
Not reported. Duration of intervention 12 months
Participants N = 30
Mean age = 22 years
Inclusion criteria of the trial
• 18 to 30 years with PCOS according to Rotterdam criteria (Rotterdam Criteria PCOS 2004)
Exclusion criteria of the trial
• Pregnancy
• Past history of cardiovascular disease
• Diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test)
• Hypertension, significant liver or renal impairment
• Other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs)
• Neoplasms, and unstable mental illness
• The presence of a late-onset adrenal enzyme defect
Randomised
N = 30
Withdrawals/losses to follow-up
• 4/30 (13%); 2 in each group
• Reasons reported for loss to follow-up; distance and time consuming
Baseline data (SD)
F-G score: group 20EE + DRSP 11.62 (5.66), group 30EE + DRSP 16.42 (5.88)
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BMI: group 20EE + DRSP 22.13 (3.34), group 30EE + DRSP 22.65 (2.75)
Interventions Intervention
• OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) for 12 months (15)
Comparator
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 12 months (15)
Outcomes Assessments (3): baseline, month 6 and 12
Outcomes of the trial (as reported)
1. FSH, LH, estradiol, free testosterone, testosterone, SHBG, progesterone, 17 hydroxy progesterone, DHEAS
2. Plasma glucose, total cholesterol, triglycerides, LDL, VLDL
3. Ferriman-Gallwey score
Denotes outcomes prespecified for this review
Notes -
Sangeeta 2012
Methods Randomised, double-blind, active-controlled trial
Setting
Department of Obstetrics & Gynecology, Gandhi Medical College, Hyderabad, Andhra Pradesh, India
Date of study
Not reported. Duration of intervention 6 months
Participants N = 100
Mean age = 22 years
Inclusion criteria of the trial
• 18 to 30 years with PCOS according to Rotterdam criteria (Rotterdam Criteria PCOS 2004)
Exclusion criteria of the trial
• Pregnancy and nursing
• Significant liver impairment
• Significant renal impairment
• Neoplastic disease
• Cardiovascular diseases
• Cushing’s disease
• Hypothyroidism
• Hyperprolactinaemia
• Any drug intake like antidiabetic, oestrogen and progesterone
Randomised
N = 100
Withdrawals/losses to follow-up
• 15/100 (15%); metformin group 7, pioglitazone group 8
• Non-compliance; metformin group 2, pioglitazone group 1
• Pregnancy; metformin group 5, pioglitazone group 7
Baseline data (SD)
F-G score: metformin group 15.9 (5.89), pioglitazone group 14.32 (5.29)
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Interventions Intervention
• Metformin 500 mg b.i.d. for 6 months (50)
Comparator
• Pioglitazone 15 mg once a day for 6 months (50)
Outcomes Assessments (2): baseline and month 6
Outcomes of the trial (as reported)
1. Menstrual cycle irregularity
2. Ferriman-Gallwey score
3. CBP, ESR, liver function, renal function, lipid profile, OGTT
4. Serum testosterone, SHBG, LH/FSH
5. Ultrasound
Denotes outcomes prespecified for this review
Notes -
Tartagni 2014
Methods Randomised, placebo-controlled trial
Setting
Department of Obstetrics and Gynecology, Hospital of Sondrio, Sondrio, Italy
Date of study
January 2010-November 2012. Duration of intervention 6 months
Participants N = 28
Mean age = 17 years
Inclusion criteria of the trial
• 15 to 19 years with hirsutism
Exclusion criteria of the trial
• Glucose intolerance or diabetes
• Kidney, liver thyroid dysfunction
• OCPs or other drugs < 6 months prior to study entry
• On diet
• Pregnancy
• Anaemia
• Bleeding disorder
• Late-onset adrenal hyperplasia
• Abnormal electrolytes
Randomised
N = 28
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (SD)
F-G score: finasteride group 8.5 (1.4), placebo group 7.8 (1.2)
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Interventions Intervention
• Finasteride 2.5 mg every 3 days for 6 months (14)
Comparator
• Placebo for 6 months (14)
Outcomes Assessments (3): baseline, month 3 and month 6
Outcomes of the trial (as reported)
1. Ferriman-Gallwey score
2. BMI
3. Adverse events; semi-structured talk
4. Serum levels of transaminases (AST; ALT), total and direct bilirubin, uric acid, creatine, triglycerides, total and
HDL-cholesterol, blood glucose, and estradiol
5. FSH, LH, total testosterone, DHT, DHEAS, androstenedione, androstenediol glucuronide, SHBG
Denotes outcomes prespecified for this review
Notes -
Tirabassi 2013
Methods Randomised, open-label, placebo-controlled trial
Setting
Division of Endocrinology, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic Uni-
versity of Marche,
Ancona, Italy
Date of study
January 2010-February 2012. Duration of intervention 3 months
Participants N = 24
Mean age = 28 years
Inclusion criteria of the trial
• Mild idiopathic hirsutism (Ferriman-Gallwey score 8 to 15)
Exclusion criteria of the trial
• Intake of exogenous androgens
• PCOS
• Drug intake for hirsutism < 12 months prior to study entry
• Topical treatments for hirsutism
• Known hypersensitivity to components for topical treatment
• Pregnancy or breast feeding
• Chronic systemic disease
Randomised
N = 24
Withdrawals/losses to follow-up
• No losses to follow-up
Baseline data (SD)
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Interventions Intervention
• Oil spray containing lavender and tea tree oil b.i.d. for 3 months (12)
Comparator
• Placebo oil spray b.i.d. for 3 months (12)
Outcomes Assessments (2): baseline and month 3
Outcomes of the trial (as reported)
1. Reduction hair diameter
2. Blood count, glycaemia, lipid profile, kidney and liver function tests, electrophoretic protidogram, total
proteins; hormonal tests included TSH, LH, FSH, estradiol, progesterone, 17-hydroxyprogesterone, total
testosterone, free testosterone, SHBG, DHEAS, androstenedione, prolactin, fasting insulin
3. Ferriman-Gallwey score
4. Adverse events
Denotes outcomes prespecified for this review
Notes -
ALT: alanine aminotransferase
AST: aspartate aminotransferase
b.i.d.: twice a day
BMI: body mass index
CBP: complete blood picture
CCT: controlled clinical trial
CHM: Chinese herbal medicine
CPA: cyproterone acetate
DHEAS: dehydroepiandrosterone sulphate
DHT: dihydrotestosterone
DRSP: drospirenone
EE: ethinyl estradiol
ESR: erythrocyte sedimentation rate
FAI: Free Androgen Index
F-G score: Ferriman-Gallwey score
FSH: follicle-stimulating hormone
HDL: high-density lipoprotein
LDL: low-density lipoprotein
LH: luteinising hormone
LSM: lifestyle modification
MRI: magnetic resonance imaging
MPA: medroxyprogesterone acetate
OCP: oral contraceptive pill
OGTT: oral glucose tolerance test
PCOS: polycystic ovary syndrome
SD: standard deviation
SHBG: sex hormone-binding globulin
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TSH: Thyroid-stimulating hormone
VLDL: very low-density lipoprotein
WHR: waist hip ratio
Characteristics of ongoing studies [ordered by study ID]
IRCT201104251760N13
Trial name or title Comparison of combined oral contraceptive Yasmin and cyproteron compound on hirsutism and androgens
in women with a polycystic ovary syndrome
Methods Randomised, double-blind, active-controlled trial in Iran
Participants Inclusion criteria
• 18 to 28 year-old nonsmoker women with polycystic ovary syndrome and hirsutism taking
contraceptive necessities
Exclusion criteria
• Hyper-prolactinaemia
• Hypothyroidism; diabetes
• Doing regular intense exercise
• Taking diet or herbal treatment
• Non-steroidal anti-inflammatory drugs, diuretics, or hormone therapy during last 3 months
Interventions Intervention
• OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) for 4 months
Comparator
• OCP (ethinyl estradiol 35 µg + cyproterone acetate mg) for 4 months
Outcomes Primary outcomes
1. Back to spontaneous menstrual periods
Secondary outcomes
1. Adverse events
Starting date 20 February 2012
Contact information Dr. Molod Aghajani-delavar moloodaghajani@yahoo.com
Notes Website accessed 14 June 2014
IRCT2013072214106N1
Trial name or title Studying and preparing semi-solid formulations of finasteride and clinical evaluation of optimal form in the
treatment of hirsutism
Methods Randomised, placebo-controlled trial in Iran
Participants Inclusion criteria
• Women after puberty that have hirsutism based on the Ferriman-Gallwey scoring system
Exclusion criteria
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IRCT2013072214106N1 (Continued)
• The patient uses any other drugs
• History of other disease with an appearance like hirsutism
• The patient is less likely to continue participating in this study
Interventions Intervention
• Finasteride 0.25% gel b.i.d. for 6 months
Comparator
• Placebo gel b.i.d. for 6 months
Outcomes Outcomes
1. Severity of hirsutism
2. Acne
Starting date 23 August 2013
Contact information Dr. Ali Ebrahimi, aebrahimi@kums.ac.ir
Notes Website accessed 14 June 2014
ISRCTN01915371
Trial name or title Weight loss in obese women with polycystic ovary syndrome (PCOS)
Methods Randomised controlled trial in the UK
Participants Inclusion criteria
• Women after puberty that have hirsutism based on the Ferriman-Gallwey scoring system
• Obese women body mass index (BMI) > 30 kg/m². Aged between 20 and 40 years old who wish to
conceive and have polycystic ovary syndrome (PCOS) as defined by the Rotterdam criteria (2003)
Exclusion criteria
• Previously diagnosed diabetics (both types 1 and 2)
• History of renal disorder, hepatic disease, thyroid disease or cancer
• Eating disorders
• Weight altering medication
• Weight loss > 2% in the last 3 months
• Major cardiovascular or cerebrovascular event in the last 6 months
• Pregnancy or lactation
• Miscarriage in the last 3 months
• Following contraception methods
• Cardiac dysrhythmia
• Porphyria (disorder of certain enzymes in the haem biosynthetic pathway)
• Thrombosis
• Total lactose intolerance
• Convulsions, seizures, epilepsy
• Major depressive episodes, psychotic episodes, schizophrenia
• Serious illness, injury or trauma/surgery in the last 3 months or due to undergo surgery
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ISRCTN01915371 (Continued)
Interventions Intervention
• 600 calorie deficit diet (CDD) for 6 months
Comparator
• Nutritionally balanced, commercial, very low calorie diet (VLCD) (LighterLife)
Outcomes Primary outcomes
1. Weight loss will be measured with subjects wearing light clothing and no shoes, on a calibrated digital scale
(Tanita Body Composition Analyzer, type BC 410 MA III)
2. Ovulation-A calendar will be provided for the patients to keep track of their menses for the 12 month
duration of the study
Secondary outcomes
1. Changes in hirsutism evaluated using the Ferriman-Gallwey questionnaire
2. Changes in quality of life evaluated using the Obesity-Related Well-Being (ORWELL 97) questionnaire
3. Changes in activity levels: a questionnaire adapted from the Framingham study will be administered to the
patients
4. Changes in body composition: to ensure accuracy it will be determined by both air-displacement method
(Bod Pod, Life Measurement Inc, USA) and whole body impedance analysis (Body Composition Analyzer
BC-418MA, Tanita Corporation of America Inc., USA
5. Changes in androgen levels - blood samples will be drawn and analysed for levels of testosterone, an-
drostenedione, dehydroepiandrosterone sulphate (DHEAS), 17-alpha-hydroxyprogesterone (17-OHP)
6. Changes in lipid profile - blood samples will be drawn and analysed for levels of low-density lipoprotein
(LDL), high-density lipoprotein level (HDL), total cholesterol levels and triglycerides
7. Changes in ACTH, cortisol
8. Changes in glycaemia and insulin sensitivity
9. Changes in levels of prolactin, progesterone, luteinising hormone (LH), follicle-stimulating hormone (FSH)
, sex hormone binding globulin (SHBG) evaluated by blood tests
Starting date 1 November 2011
Contact information Dr Catherine Rolland
c.rolland@rgu.ac.uk, beca rolland@yahoo.ca
Centre for Obesity Research and Epidemiology
Robert Gordon University
St. Andrew Street
Aberdeen, AB25 1HG, UK
Notes Completed, no data published yet, website last accessed 13 June 2014. Sent e-mail requesting further update.
E-mail address incorrect
ISRCTN29234515
Trial name or title Ethinyl-estradiol-levonorgestrel versus low-dose pioglitazone + spironolactone + metformin in adolescents
with hyperinsulinaemic ovarian hyperandrogenism: Effects on ovulatory function, parameters of chronic
inflammation, on cardiovascular risk factors and on risk factors for the development of type 2 diabetes
Methods Open, prospective, randomised study in Spain
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Participants Inclusion criteria
• Age > 14 and < 18 years
• Menarche at least 2 years before
• BMI < 97th percentile and > 10th percentile
• Clinical and biochemical hyperandrogenism
• Hyperinsulinaemia (fasting and/or after an OGTT)
Exclusion criteria
• Pregnancy or pregnancy risk
• Late onset congenital adrenal hyperplasia, Cushing’s syndrome, uncompensated hypothyroidism
• Liver or renal dysfunction, diabetes, glucose intolerance
• Treatment with oral contraceptives, antiandrogens, or insulin sensitisers over the previous 6 months
• Severe bacterial infections
Interventions Intervention
• Pioglitazone (7.5 mg/d) + spironolactone (50 mg/d) + metformin (850 mg/d), once daily, at dinner
time
Comparator
• An oral contraceptive containing ethinyl-estradiol (20 µg) + levonorgestrel (100 mg), once daily
Outcomes Primary outcomes
1. Fasting insulin
2. Visceral fat
3. Hepatic fat
4. Carotid intima-media thickness
Secondary outcomes
1. Ferriman-Gallwey score
2. Androgens
3. Lipids
4. C-reactive protein
5. High molecular weight
6. Adiponectin
7. Insulin resistance index in adipocytes
8. Ovulation
9. Breast density (DXA)
Starting date 05 October 2012
Contact information Prof Lourdes Ibañez
Hospital Sant Joan de Déu
University of Barcelona
Passeig de Sant Joan de Deu, 2
Esplugues de Llobregat 08950 Spain
libanez@hsjdbcn.org
Notes Website accessed 13 June 2014. Study completed; no data available. Sent e-mail requesting further update
Response: the preliminary (6 month) results of this trial will be presented as poster at the Endocrine Society
in Chicago on June 22; they plan to go for a first publication in the autumn
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NCT00145340
Trial name or title Pioglitazone treatment in polycystic ovary syndrome
Methods Randomised controlled trial in Denmark
Participants Inclusion criteria
• Hirsute women with PCOS
• Irregular menses, i.e. cycle length of > 36 days
• Premenopausal increased fasting insulin > 50 pmol/l
• Increased free testosterone > 0.035 nmol/l
Exclusion criteria
• Age: < 18 years
• Contraceptive pill within the past 3 months
• Postmenopausal (increased FSH)
• Known diabetes mellitus, endocrine disease or other disease requiring treatment
• Drug use
• Pregnancy
• Planned pregnancy during the treatment period
• Increased liver parameters
Interventions Intervention
• Pioglitazone 30 mg per day
Comparator
• Placebo
Outcomes Primary outcome
Glucose infusion rate (M value) below euglycaemic hyperinsulinaemic clamp (comparing baseline with 4
months)
Starting date September 2002
Contact information Dorte Glintborg, MD, PhD
Tel: +45 6541 1769
dorte.glintborg@dadlnet.dk
Notes Completed, no data published yet, website accessed 13 June 2014. Sent e-mail requesting further update
NCT00152048
Trial name or title A 24 week randomised double blind placebo controlled study to evaluate the atrophogenic potential of
eflornithine in the treatment of women with excessive facial hair
Methods Randomised, controlled, double-blind trial
Participants Inclusion criteria
• Female subjects with clinical diagnosis of facial hirsutism/excessive facial hair
• Women of childbearing potential must agree to use an effective form of birth control for the duration
of the study
• Skin type I-IV
• Customary frequency of removal of facial hair 2 or more times per week
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Exclusion criteria
• Pregnant or lactating women
• Severe inflammatory acne or presence of significant scarring on the face
• History of skin malignancy
• Connective tissue disorders
Interventions Intervention
• Eflornithine hydrochloride cream for 24 weeks
Comparator
• Placebo cream for 24 weeks
Outcomes Primary outcome
1. Change in facial skin thickness measured by ultrasound at 24 weeks
Secondary outcomes
1. Skin biopsies
2. Histology and histochemistry in the dermis
3. Physician Global Assessment
4. Subject Self-Assessment Questionnaire
Starting date November 2004
Contact information Shire Development LLC. Contact e-mail Professor Jean-Paul Ortonne: ortonne@unice.fr
Notes Completed, no data published yet, website accessed 13 June 2014. Sent e-mail requesting further update
NCT00451568
Trial name or title Metformin and oral contraceptives in PCOS
Methods Randomised controlled open trial in Denmark
Participants Inclusion criteria
• Irregular menses or anovulatory cycles
• High free testosterone > 0.035 nmol/l or hirsutism
• PCO in vaginal US Criteria 1 and 2 OR 2 and 3
Exclusion criteria
• Age > 18 years
• Postmenopausal
• Diagnosis diabetes mellitus
• Use of medicine known to affect hormones measured in the project
• Pregnancy or planned pregnancy during study period
• Non-Caucasian
• Previous thromboembolic disease
• Heavy smoker > 35 years and BMI > 35 kg/m²
Interventions Intervention
• Metformin
Comparator
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• Yasmin (OAC)
Outcomes Primary outcome
1. Changes in fasting insulin and area under the curve for insulin (2 hours)
Secondary outcomes
1. Changes in BMI, WHR, LH, FSH, total and free testosterone, fasting blood glucose, fasting C-
peptide, urine-cortisol secretion, body composition, number of hypoglycaemic cases, AUC for insulin,
glucose and C-peptide during OGTT (2 and 5 hours)
Starting date March 2007, estimated completion date April 2010, no further updates posted since start
Contact information Dorte Glintborg, MD, PhD
Tel: +45 6541 1769
dorte.glintborg@dadlnet.dk
Notes Website accessed 13 June 2014. Sent e-mail requesting further update
NCT00744510
Trial name or title Reflexology’s effect on polycystic ovary syndrome (PCOS) (REPOS)
Methods Randomised, controlled, double-blind trial in the UK
Participants Inclusion criteria
• Women with PCOS
Exclusion criteria
• Use of complimentary therapies within 6/12 prior to recruitment
• BMI > 35
• Taken combined oral contraceptives, metformin, or cyclical progestogens within 3/12 prior to
recruitment
Interventions Intervention
• Reflexology
Comparator
• No treatment
Outcomes Primary outcome
1. To identify the most appropriate primary outcome measure for the ensuing RCT
Secondary outcomes
1. Attainment of normal menstrual cycle length (i.e. 21 to 35 days)
2. Hormonal imbalances and irregular menses (commonly regarded at 6 cycles per annum or less)
3. Weight, body mass index (BMI), hirsutism, thinning hair
4. Fasting insulin and blood sugar levels
5. Quality of life
Starting date December 2012
Contact information Dawn-Marie Walker, dawn-marie.walker@nottingham.ac.uk
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Notes Website accessed 13 June 2014; this study is not yet open for participant recruitment. E-mail sent requesting
update
NCT00746148
Trial name or title Reflexology’s effect on polycystic ovary syndrome: A Pilot Study (REPOS)
Methods Randomised controlled double-blind trial in the UK
Participants Inclusion criteria
• Women with PCOS
Exclusion criteria
• Use of complimentary therapies within 6/12 prior to recruitment
• BMI > 35
• Taken combined oral contraceptives, metformin, or cyclical progestogens within 3/12 prior to
recruitment
Interventions Intervention
• Reflexology, 10 weekly sessions of 45 minutes each
Comparator
• No treatment
Outcomes Primary outcome
1. To identify the most appropriate primary outcome measure for the ensuing RCT
Secondary outcomes
1. Attainment of normal menstrual cycle length (i.e. 21 to 35 days)
2. Hormonal imbalances and irregular menses (commonly regarded at 6 cycles per annum or less)
3. Weight, body mass index (BMI), hirsutism, thinning hair
4. Fasting insulin and blood sugar levels
5. Quality of life
Starting date December 2012
Contact information Dawn-Marie Walker, dawn-marie.walker@nottingham.ac.uk
Notes Website accessed 13 June 2014, this study is not yet open for participant recruitment. E-mail sent requesting
update. ”Thanks for your email. I’m afraid this trial never begun, as I am still trying to get funding for it.“
NCT01051024
Trial name or title Diamel in the treatment of polycystic ovary syndrome
Methods Randomised, controlled, double-blind trial in Cuba
Participants 18 to 40 years
Inclusion criteria
• 2 of the following criteria: oligo or anovulation polycystic ovary diagnosed by ultrasound technique;
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clinical signs of hyperandrogenism
• Signed informed consent
Exclusion criteria
• Personal history of other causes of hyperandrogenism: hyperprolactinaemia, suprarenal tumours, ovary
tumours, suprarenal hyperplasia, hypercortisolism
• Patients under other experimental treatment
• Treatment with ovulation inducers and/or insulin sensitisers within 60 days before treatment
• Treatment with vitamins within 7 days before treatment
• Treatment with dietary supplements within 60 days before treatment
• Non-compensated intercurrent diseases: diabetes mellitus, thyroid disease, hypertension
Interventions Intervention
• Dietary supplement: Diamel
Comparator
• Dietary supplement: placebo
Outcomes Primary outcomes
Normalisation of blood concentrations of
1. androgens at week 24
2. prolactin at week 24
3. oestrogens at week 24
4. FSH at week 24
5. LH at week 24
Secondary outcomes
1. Regularisation of the menstrual cycle at week 24
2. Reappearance of ovulatory cycles at week 24
3. Normalisation of blood concentrations of insulin at week 24
4. Normalisation of blood concentrations of cholesterol at week 24
5. Normalisation of blood concentrations of triglycerides at week 24
6. Normalisation of blood concentrations of glucose at week 24
7. Improvement of clinical signs associated with polycystic ovary syndrome: acne, hirsutism, abdominal
obesity, and blood pressure at week 24
Starting date November 2009
Contact information MercedesHernandez,MD,RamónGonzálezCoroGynecologic andObstetricHospitalHavanaCity,Havana,
Cuba, 10400
Notes Website accessed 13 June 2014, this study has been completed, no results posted. No other information or
contact details
NCT01396369
Trial name or title Impact of flaxseed lignan (Brevail) on polycystic ovarian syndrome
Methods Randomised, controlled, open-label trial in the US
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Participants Inclusion criteria
• 18 to 40 years
• Diagnosis of PCOS by menstrual irregularity (fewer than 9 menses annually/interval over 40 days),
Ferriman-Gallwey score > 8, and/or hyperandrogenaemia defined as total testosterone > 80 ng/dl or
bioavailable testosterone > 8.4 ng/dl
• Mentally competent
Exclusion criteria
• Use of oral contraceptives, spironolactone, or insulin-sensitising agents within the past 2 months
• Long-term or chronic use of oral antibiotics
• Hysterectomy
• FSH > 15
• Pregnancy/lactation
• Consumption of flaxseed within the last month
• Diagnosis of thyroid disease, nonclassical adrenal hyperplasia, and hyperprolactinaemia
• Use of any dietary fibre supplements, which are newly started (within the past 6 months) and
agreement not to use any new fibre supplements during the study period
Interventions Intervention
• OCP
Comparator
• OCP + Brevail
Outcomes Primary outcomes
1. Changes of testosterone levels and hirsutism
Secondary outcomes
1. Lipid profile and oestrogen levels
Starting date January 2011
Contact information Sam Kim skim2@kumc.edu
Notes Website accessed 13 June 2014. This study is currently recruiting participants
NCT01555190
Trial name or title Combination therapy with myo-inositol and folic acid versus myo-inositol alone: Effects of six months
treatment on clinical, endocrine and metabolic features in obese women with polycystic ovary syndrome
Methods Randomised, controlled, open-label trial in Italy
Participants Inclusion criteria
• Women with PCOS diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003
• BMI > 25 kg/m²
• Age 18 to 35 years
Exclusion criteria
• Pregnancy
• Significant liver or renal impairment
• Other hormonal dysfunctions (hypothalamic, pituitary, thyroidal, or adrenal causes for the clinical
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signs)
• Neoplasms
• Unstable mental illness
• Diagnosis of diabetes mellitus or impaired glucose tolerance
• Use of drugs able to interfere with gluco-insulinaemic metabolism for at least 3 months prior entering
the study
Interventions Intervention
• Myo-inositol 1500 g
Comparator
• Myo-inositol 2000 g + folic acid 200 µg
Outcomes Primary outcome
1. Number of cycles in 6 months of therapy
Secondary outcomes
1. Effects on oral glucose tolerance test
2. Effects on hormonal assay
3. Effects on lipid profile
Starting date January 2012
Contact information Antonio Lanzone, Catholic University of Sacred Heart Rome, Italy Maurizio Guido; maurizioguido@libero.
it
Notes Website accessed 13 June 2014. The recruitment status of this study is unknown because the information has
not been verified recently. E-mail sent requesting update
NCT01626443
Trial name or title Role of myo-inositol and D-chiro Inositol on the ovaric and metabolic functions
Methods Randomised controlled trial in Italy
Participants Inclusion criteria
• PCOS
• Women aged between 14 and 40 years
• BMI > 28
• Hyperinsulinaemia
Exclusion criteria
• Pre-existing secondary endocrine and metabolic disorders
• Pre-existing secondary adrenal disorders
• Pharmacologic treatment in the last 3 months before entering the study
• Pregnancy
Interventions Intervention
• Myo-inositol + D-chiro-inositol + folic acid
Comparator
• Folic acid
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Outcomes Primary Outcomes
1. Menstrual cycle restoration
2. Score hirsutism (Ferriman-Gallwey classification)
3. Serum progesterone
4. Testosterone level test
5. Oral glucose tolerance test (OGTT). Evaluation of glycaemia and insulinaemia levels
6. Homeostasis Model Assessment (HOMA-index)
7. Sex hormone binding globulin (SHBG) test
8. Androstenediol level test
9. Androstenedione level test
10. Free Androgen Index (FAI) level test
Secondary Outcomes
1. Body mass index (BMI)
2. Change from baseline in diastolic blood pressure levels
3. Change from baseline in systolic blood pressure levels
4. Number of patients with abnormal ovarian size and morphology. Ovarian ultrasound scan for the
assessment of size and morphology
5. Luteinising hormone (LH) level test. Analysis of LH levels should be performed between the 7th and
the 10th day of the cycle
6. Follicle-stimulating hormone (FSH) level test. Analysis of FSH levels should be performed between the
7th and the 10th day of the cycle
7. Estradiol (E2) level test. Analysis of E2 levels should be performed between the 7th and the 10th day
of the cycle
Starting date June 2012
Contact information Elena Bonelli, University of Pisa Department of Endocrinology, Pisa, Italy; elena684@interfree.it
Notes Website accessed 13 June 2014. The recruitment status of this study is unknown because the information has
not been verified recently. E-mail sent requesting update
NCT01791647
Trial name or title Myo-inositol versus metformin in obese women with polycystic ovary syndrome
Methods Randomised, controlled, open-label trial in Italy
Participants Inclusion criteria
• Women with polycystic ovary syndrome, diagnosed in accordance with Rotterdam Consensus
Conference Criteria 2003;
• BMI > 25 kg/m²
• Age 18 to 35 years
Exclusion criteria
• Pregnancy
• Significant liver or renal impairment
• Other hormonal dysfunction (hypothalamic, pituitary, thyroidal, or adrenal causes for the clinical
signs)
• Neoplasms
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• Unstable mental illness
• Diagnosis of diabetes mellitus or impaired glucose tolerance
• Use of drugs able to interfere with gluco-insulinaemic metabolism for at least 3 months prior to
entering the study
Interventions Intervention
• 1500 mg/day myo-inositol
Comparator
• 1500 mg/day of metformin
Outcomes Primary outcome
1. Number of cycles
Secondary outcomes
1. Effects of two therapies on glyco-insulinaemic metabolism
2. Area under the curve insulin post oral glucose tolerance test (µUI/ml/180 min), M value of
euglycaemic hyperinsulinaemic clamp (mg/kg/min)
Starting date June 2011
Contact information Antonio Lanzone or Maurizio Guido 063057794
Notes Website accessed 13 June 2014. This study is currently recruiting participants
ACTH: adrenocorticotropic hormone
AUC: area under the curve
b.i.d.: twice a day
BMI: body mass index
FSH: follicle-stimulating hormone
LH: luteinising hormone
OCP: oral contraceptive pill
OGTT: oral glucose tolerance test
PCOS: polycystic ovary syndrome
RCT: randomised controlled trial
WHR: waist hip ratio
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D A T A A N D A N A L Y S E S
Comparison 1. Exercise 3 times a week for 30 minutes versus no exercise
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 2. Lifestyle modification + placebo tablets versus placebo tablets
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 3. Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30 µg + drospirenone
3 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 4. Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30 µg + desogestrel
0.15 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change from baseline in
Ferriman-Gallwey score
3 164 Mean Difference (IV, Random, 95% CI) -1.84 [-3.86, 0.18]
2 Mean change from baseline in
Lorenzo score
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Changes in androgen levels Other data No numeric data
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Comparison 5. Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 30 µg + desogestrel 0.15 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 6. Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus other OCP (unknown)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 7. Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 50 µg + desogestrel
0.15 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 8. Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 50 µg + desogestrel 0.15 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 9. Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg and levonorgestrel
0.15 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 10. Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 30 µg + chlormadinone
acetate 2 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 11. Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg + desogestrel 0.15
mg every other month
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 12. Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 13. Ethinyl estradiol 30 µg + desogestrel 0.15 mg every other month versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 14. Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg + gestodene 75 µg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 15. Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 20 µg + drospirenone 3 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 16. Flutamide 250 mg b.i.d. versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 17. Flutamide 250 mg b.i.d. versus spironolactone 100 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 18. Spironolactone 100 mg per day versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 19. Ketoconazole 400 mg per day versus ketoconazole 800 mg per day for 10 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 20. Finasteride 5 mg to 7.5 mg/day versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events 3 67 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.48, 2.67]
2 Mean change from baseline in
Ferriman-Gallwey score
3 62 Mean Difference (IV, Random, 95% CI) -5.73 [-6.87, -4.58]
3 Changes in androgen levels Other data No numeric data
Comparison 21. Finasteride 2.5 mg once a day versus finasteride 5 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 22. Finasteride 2.5 mg once a day versus finasteride 7.5 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 23. Finasteride 5 mg once a day versus finasteride 7.5 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 24. Finasteride 2.5 mg once a day versus finasteride 2.5 mg every 3 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 25. Metformin 850 mg b.i.d. versus rosiglitazone 2 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 26. Troglitazone 150 mg versus troglitazone 300 mg versus troglitazone 600 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 27. Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change from baseline in
Ferriman-Gallwey score
7 264 Mean Difference (IV, Random, 95% CI) -0.27 [-1.46, 0.91]
2 Changes in androgen levels Other data No numeric data
3 Mean change from baseline in
BMI
6 252 Mean Difference (IV, Random, 95% CI) 0.56 [-0.37, 1.50]
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Comparison 28. Rosiglitazone 4 mg b.i.d. versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 29. Metformin 850 mg b.i.d. versus simvastatin 20 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 30. Pioglitazone 30 mg once a day versus placebo once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 31. Lifestyle modification + metformin 850 mg b.i.d. versus metformin 850 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 32. Lifestyle modification + placebo versus metformin 850 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 33. Lifestyle modification + metformin 850 mg b.i.d. versus lifestyle modification + placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 34. Lifestyle modification + metformin 850 mg b.i.d. versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 35. Metformin 2000mg per day + lifestyle modification +OCP versus placebo + lifestyle modification
+ OCP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 36. OCP (ethinyl estradiol 20 µg + desogestrel 0.15 mg) + simvastatin 20 mg versus OCP (ethinyl
estradiol 20 µg + desogestrel 0.15 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 37. Metformin 850 mg b.i.d. versus metformin 850 mg b.i.d. + simvastatin 20 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 38. Simvastatin 20 mg once a day versus metformin 850 mg b.i.d. + simvastatin 20 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 39. Metformin 850 mg b.i.d. + flutamide 250 mg b.i.d. versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 40. Metformin 1275 mg to 1700 mg per day + flutamide 250 mg to 500 mg per day versus flutamide
250 mg to 500 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 41. Metformin 1275 mg to 1700 mg per day + flutamide 250 mg to 500 mg per day versus metformin
1275 mg to 1700 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 42. Finasteride 5 mg once a day versus cyproterone acetate 25 mg once a day + ethinyl estradiol 20
µg 21 days of the month
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 43. Flutamide 250 mg b.i.d. versus cyproterone acetate 25 mg once a day + ethinyl estradiol 20 µg
21 days of the month
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 44. Flutamide 125 mg per day + triphasic OCP versus placebo + tricyclic OCP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 45. Flutamide 250 mg per day + triphasic OCP versus placebo + tricyclic OCP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 46. Flutamide 375 mg per day + triphasic OCP versus placebo + tricyclic OCP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 47. Flutamide 125 mg per day + triphasic OCP versus flutamide 375 mg per day + triphasic OCP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 48. GnRH-A 3.75 mg im every 28 days versus GnRH-A 3.75 mg im every 28 days + oestrogen 0.625
mg and medroxyprogesterone 10 mg both on day 1 to 21
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 49. GnRH-A 3.6 mg sc every 28 days versus GnRH-A 3.6 mg sc every 28 days + estradiol valerate 2
mg days 5 to 25 + medroxyprogesterone days 16 to 25
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 50. GnRH-A 3.6mg + OCP (ethinyl estradiol 35µg + cyproterone acetate 2 mg) versus OCP (ethinyl
estradiol 0.35 µg + cyproterone acetate 2 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 51. GnRH-A 3.75 im every 28 days + OCP (ethinyl estradiol 35 µg + norethindrone 1 mg) versus
GnRH-A 3.75 im every 28 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 52. GnRH-A 3.75 im every 28 days + OCP (ethinyl estradiol 35 µg + norethindrone 1 mg) versus
OCP (ethinyl estradiol 35 µg + norethindrone 1 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 53. GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg)
versus GnRH-A 3.75 mg im every 28 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 54. GnRH-A 3.75 mg im every 28 days + flutamide 250 mg per day versus GnRH-A 3.75 mg im
every 28 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 55. GnRH-A 3.75 mg im every 28 days + flutamide 250 mg per day versus GnRH-A 3.75 mg im
every 28 days + OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 56. GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg + norethindrone 0.4 mg)
versus GnRH-A 3.75 mg im every 28 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 57. GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg + norethindrone 0.4 mg)
versus OCP (ethinyl estradiol 35 µg + norethindrone 0.4 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 58. GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 0.35 µg + cyproterone acetate 2
mg) versus GnRH-A 3.75 mg im every 28 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 59. GnRH-A 3.75 im every 28 days + conjugated oestrogen 0.625 mg +medroxyprogesterone acetate
10 mg day 1 to 12 versus OCP (ethinyl estradiol 35 µg + ethynodiol diacetate 1 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 60. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + metformin 500 b.i.d. versus OCP
(ethinyl estradiol 35 µg + cyproterone acetate 2 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 61. OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + metformin 500 mg three times a day versus
OCP (ethinyl estradiol 20 µg + drospirenone 3 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 62. OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) versus OCP (drospirenone 3 mg + ethinyl
estradiol 20 µg) + cyproterone acetate 12.5 mg (first 10 days of pill strip)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 63. OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + metformin 500 mg three times a day versus
OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + cyproterone acetate 12.5 mg (first 10 days of pill strip)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 64. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus OCP (ethinyl estradiol 35 µg
+ cyproterone acetate 2 mg) + finasteride 5 mg once a day on day 1 to 14
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 65. OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + cyproterone acetate 12.5 mg day 1 to 10
versus OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + spironolactone 100 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 66. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone acetate 50 mg once a
day on day 1 to 10 versus OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) + spironolactone 100 mg once a
day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 67. OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + cyproterone acetate 50 mg b.i.d. versus
OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + spironolactone 100 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 68. OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + cyproterone acetate 50 mg b.i.d. versus
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone acetate 50 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 69. OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + spironolactone 100 mg once a day versus
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone acetate 50 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 70. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + spironolactone 100 mg once daily
versus OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + finasteride 5 mg once daily
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 71. OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + spironolactone 100 mg versus OCP (ethinyl
estradiol 30 µg + gestodene 75 µg) + finasteride 5 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 72. OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + cyproterone acetate 12.5 mg day 1 to 10
versus OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + finasteride 5 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 73. OCP (triphasic including ethinyl estradiol and levonorgestrel) + spironolactone 100 mg once a
day versus ethinyl estradiol 30 µg day on day 5 to 25 + cyproterone acetate 100 mg once a day on day 5 to 14
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 74. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus OCP (ethinyl estradiol 35 µg
+ cyproterone acetate 2 mg) + sibutramine 10 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 75. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + sibutramine 10 mg once a day versus
sibutramine 10 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 76. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus pioglitazone 7.5 mg + flutamide
62.5 mg + metformin 850 mg all once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 77. Pioglitazone + transdermal contraceptive + metformin + flutamide versus placebo + transdermal
contraceptive + metformin + flutamide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 78. Cyproterone acetate 50 mg per day 20 days per month + ethinyl estradiol 35 µg over the last 10
days of CPA treatment versus spironolactone 200 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 79. Dexamethasone 0.37 mg/day versus dexamethasone 0.37 mg/day + spironolactone 100 mg per
day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 80. Spironolactone 100 mg/day versus dexamethasone 0.37 mg/day + spironolactone 100 mg per
day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 81. Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle + metformin 1000 mg
b.i.d. versus metformin 1000 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 82. Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle + metformin 1000 mg
b.i.d. versus clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 83. OCP (ethinyl estradiol 35 µg + norgestimate 0.25 mg) versus metformin 1000 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 84. OCP ethinyl estradiol 30 µg + desogestrel 0.15 mg) versus metformin 850 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 85. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus metformin 850 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 86. OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) versus lifestyle modification
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 87. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus sibutramine 10 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 88. OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus finasteride 5 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 89. OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) versus combined contraceptive vaginal ring
(ethinyl estradiol 15 µg + etonogestrel 1.2 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 90. Finasteride 5 mg versus spironolactone 100 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 91. Flutamide 250 mg once to b.i.d. versus metformin 1275 mg to 1700 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change from baseline in
Ferriman-Gallwey score
3 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Less than 12 month
duration of study drug
2 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 12 month duration of
study drug
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Changes in androgen levels Other data No numeric data
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Comparison 92. Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of adverse events 3 115 Risk Ratio (M-H, Random, 95% CI) 3.87 [0.57, 26.24]
2 Mean change from baseline in
Ferriman-Gallwey score
4 Mean Difference (IV, Random, 95% CI) Subtotals only
3 Change in androgen levels Other data No numeric data
Comparison 93. Metformin 850 mg b.i.d. versus lifestyle modification
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 94. GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 35 µg + norethindrone 1 mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 95. GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 50 µg + cyproterone acetate 2
mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
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Comparison 96. GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 35 µg + norethindrone 0.4
mg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 97. GnRH-A 3.75 mg im every 28 days versus finasteride 5 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 98. GnRH-A 3.6 mg im every 28 days versus metformin 850 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 99. Dexamethasone 0.37 mg per day compared to spironolactone 100 mg per day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 100. Spironolactone 25 mg b.i.d. versus metformin 500 mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
498Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 101. Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle versus metformin 1000
mg b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
Comparison 102. Acarbose 150 mg to 300 mg per day versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 103. Spearmint tea b.i.d. versus camomile tea b.i.d.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
Comparison 104. Low-frequency electro-acupuncture versus exercise 3 times a week for 30 minutes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Changes in androgen levels Other data No numeric data
Comparison 105. Low-frequency electro-acupuncture (14 treatments) versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
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Comparison 106. Atorvastatin 20 mg once a day versus simvastatin 20 mg once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
Comparison 107. Atorvastatin 20 mg once a day versus placebo once a day
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
Comparison 108. Bromocriptine 2.5 mg three times a day versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in androgen levels Other data No numeric data
Analysis 1.1. Comparison 1 Exercise 3 times a week for 30 minutes versus no exercise, Outcome 1 Changes
in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in exercise group
(standard deviation)
N = 22 Jedel 2011;
N = 45 Vigorito 2007
Mean change from base-
line in control group
(standard deviation)
N = 13 Jedel 2011;
N = 45 Vigorito 2007
Meandifference (95%CI;
P value)
Jedel 2011 Testosterone (ng/ml) -0.04 (0.14) 0.01 (0.09) -0.05 (95% CI -0.13 to 0.
03; P value = 0.20)
Jedel 2011 Free testosterone (pg/ml) -1.24 (2.66) 0.03 (1.71) -1.27 (95% CI -2.72 to 0.
18; P value = 0.09)
Jedel 2011 Dihydrotestosterone (pg/
ml)
-9.30 (34.2) 4.48 (31.9) -13.78 (95% CI -36.25 to
8.69; P value = 0.23)
Jedel 2011 DHEAS (µg/ml) -0.24 (0.55) 0.66 (3.40) -0.90 (95% CI -2.96 to 0.
34; P value = 0.34)
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Changes in androgen levels (Continued)
Jedel 2011 SHBG (nmol/L) 7.30 (22.0) 3.33 (12.7) 3.97 (95% CI -7.53 to 15.
47; P value = 0.50)
Vigorito 2007 Testosterone (nmol/L) -0.20 (0.42) -0.10 (0.30) -0.10 (95% CI -0.25 to 0.
05; P value = 0.19)
Vigorito 2007 DHEAS (µmol/L) -152 (312.16) -115 (267.94) -37 (95%CI -157.20 to 83.
20; P value = 0.55)
Vigorito 2007 Androstenedione (nmol/L) -0.20 (0.48) -0.20 (0.54) 0.00 (95% CI -0.21 to 0.
21; P value = 1.00)
Vigorito 2007 SHBG (nmol/L) 2.00 (3.81) -1.00 (4.25) 3.00 (95%CI 1.33 to 4.67;
P value = 0.0004)
Vigorito 2007
Analysis 2.1. Comparison 2 Lifestyle modification + placebo tablets versus placebo tablets, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in lifestyle modification
group + placebo (standard
deviation)
N = 6 Hoeger 2004;
N = 8 Hoeger 2008
Mean change from baseline
in placebo group (standard
deviation)
N = 7 Hoeger 2004;
N = 10 Hoeger 2008
Mean difference (95%CI; P
value)
Hoeger 2004 Testosterone (ng/dl) 1.7 (11.39) 4.8 (20.06) -3.10 (95% CI -20.53 to 14.
33; P value = 0.73)
Hoeger 2004 SHBG (nmol/L) -4.74 (32.40) -8.19 (7.22) 3.45 (95% CI -26.43 to 33.
33; P value = 0.82)
Hoeger 2008 Testosterone (ng/dl) 0.60 (18.92) 10.40 (20.57) -9.80 (95% CI -28.09 to 8.
49; P value = 0.29)
Hoeger 2008 SHBG (nmol/L) 17.40 (13.86) 1.40 (5.64) 16.00 (95%CI 5.78 to 26.22;
P value = 0.002)
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Analysis 3.1. Comparison 3 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30
µg + drospirenone 3 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + CPA group
(standard deviation)
N = 43 Batukan 2007;
N = 51 Bhattacharya
2012
Mean change from base-
line
in EE + drospirenone
group (standard devia-
tion)
N = 48 Batukan 2007;
N = 50 Bhattacharya
2012
Mean Difference (95%
CI; P value)
Batukan 2007 Testosterone (ng/dl) -20.30 (20.15) -19.00 (18.73) -1.30 (95% CI -9.32 to 6.
72; P value = 0.75)
Batukan 2007 Free testosterone (pg/ml) -0.40 (0.88) -0.50 (0.93) 0.10 (95% CI -0.27 to 0.
47; P value = 0.60)
Batukan 2007 DHEAS (µg/ml) -0.20 (0.42) -0.10 (0.88) -0.10 (95% CI -0.38 to 0.
18; P value = 0.48)
Batukan 2007 Androstenedione (ng/ml) -0.50 (0.42) -0.30 (0.44) -0.20 (95% CI -0.38 to -
0.02; P value = 0.03)
Batukan 2007 SHBG (nmol/L) 9 (8.71) 16.80 (20.15) -7.80 (95% CI -14.07 to
-1.53; P value = 0.01)
Bhattacharya 2012 Testosterone (ng/ml) -0.03 (0.42) -0.06 (0.32) 0.03 (95% CI -0.12 to 0.
18; P value = 0.69)
Bhattacharya 2012 SHBG (nmol/L) 142.91 (60.71) 131.52 (72.89) 11.39 (95% CI -14.80 to
37.58; P value = 0.39)
Bhattacharya 2012 Free androgen index -10.57 (7.93) -7.89 (9.13) -2.68 (95% CI -6.02 to 0.
66; P value = 0.12)
Bhattacharya 2012
Bhattacharya 2012
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Analysis 4.1. Comparison 4 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30
µg + desogestrel 0.15 mg, Outcome 1 Mean change from baseline in Ferriman-Gallwey score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 4 Ethinyl estradiol 35 g + cyproterone acetate 2 mg versus ethinyl estradiol 30 g + desogestrel 0.15 mg
Outcome: 1 Mean change from baseline in Ferriman-Gallwey score
Study or subgroup EE + CPA EE + desogestrel
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bhattacharya 2012 51 -5.29 (5.88) 49 -1.69 (5.69) 38.2 % -3.60 [ -5.87, -1.33 ]
Mastorakos 2002 14 -9.78 (4.3) 14 -8.71 (3.86) 27.8 % -1.07 [ -4.10, 1.96 ]
Mastorakos 2006 18 -9.99 (3.24) 18 -9.51 (4.45) 34.0 % -0.48 [ -3.02, 2.06 ]
Total (95% CI) 83 81 100.0 % -1.84 [ -3.86, 0.18 ]
Heterogeneity: Tau2 = 1.44; Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours EE + CPA Favours EE + desogestrel
Analysis 4.2. Comparison 4 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30
µg + desogestrel 0.15 mg, Outcome 2 Mean change from baseline in Lorenzo score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 4 Ethinyl estradiol 35 g + cyproterone acetate 2 mg versus ethinyl estradiol 30 g + desogestrel 0.15 mg
Outcome: 2 Mean change from baseline in Lorenzo score
Study or subgroup EE + CPA EE + desogestrel
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Porcile 1991 9 -7 (9.79) 10 -7.2 (1.84) 0.20 [ -6.30, 6.70 ]
-10 -5 0 5 10
Favours EE + CPA Favours EE + desogestrel
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Analysis 4.3. Comparison 4 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 30
µg + desogestrel 0.15 mg, Outcome 3 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + CPA group
(standard deviation)
N = 51 Bhattacharya
2012;
N = 14Mastorakos 2002;
N = 18Mastorakos 2006;
N = 9 Porcile 1991
Mean change from base-
line in EE + desogestrel
group (standard devia-
tion)
N = 49 Bhattacharya
2012;
N = 14Mastorakos 2002;
N = 18Mastorakos 2006;
N = 10 Porcile 1991
Mean difference (95%
CI; P value)
Bhattacharya 2012 Testosterone (ng/ml) -0.03 (0.42) -0.10 (0.39) -0.07 (95% CI -0.09 to 0.
23; P value = 0.39)
Bhattacharya 2012 SHBG (nmol/L) 142.91 (60.71) 99.53 (67.52) 43.38 (95% CI 18.18 to
68.58; P value = 0.007)
Bhattacharya 2012 Free Androgen Index -10.57 (7.93) -5.58 (9.15) -4.99 (95% CI -8.35 to -
1.63; P value = 0.004)
Bhattacharya 2012
Bhattacharya 2012
Mastorakos 2002 Testosterone (ng/ml) -0.43 (0.23) -0.35 (0.18) -0.08 (95% CI -0.23 to 0.
07; P value = 0.31)
Mastorakos 2002 SHBG (nmol/L) 274.26 (47.39) 264.56 (54.69) 9.70 (95% CI -28.21 to
47.61; P value = 0.62)
Mastorakos 2002 Free testosterone (pg/ml) -1.46 (0.68) -1.57 (0.54) 0.11 (95% CI -0.34 to 0.
56; P value = 0.64)
Mastorakos 2002 Androstenedione (ng/ml) -1.16 (0.64) -1.53 (0.60) 0.41 (95% CI -0.04 to 0.
86; P value = 0.08)
Mastorakos 2002 DHEAS (ng/ml) -472.67 (572.34) -292.05 (808.65) -180.62 (95% CI -6.99.
57 to 338.33; P value =0.
50)
Mastorakos 2006 Testosterone (ng/ml) -0.48 (0.27) -0.51 (0.24) 0.03 (95% CI -25.24 to
25.30; P value = 1.00)
Mastorakos 2006 SHBG (nmol/L) 309.03 (80.46) 287.22 (80.86) 21.81 (95% CI -30.89 to
74.51; P value = 0.42)
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Changes in androgen levels (Continued)
Mastorakos 2006 Free testosterone (pg/ml) -1.55 (2.12) -1.50 (6.57) -0.05 (95% CI -3.24 to 3.
14; P value = 0.98)
Mastorakos 2006 Androstenedione (ng/ml) -1.32 (0.97) -1.66 (0.96) 0.34 (95% CI -0.29 to 0.
97; P value = 0.29)
Mastorakos 2006 DHEAS (ng/ml) -578.28 (915.49) -321.61 (887.67) -256.67 (95%CI -845.76
to 332.42; P value = 0.39)
Porcile 1991 Testosterone (nmol/L) -1.52 (0.93) -1.52 (0.93) 0.00 (95% CI -0.84 to 0.
84; P value = 1.00)
Porcile 1991
Porcile 1991 Free testosterone (pmol /
L)
-10.06 (3.06) -10.06 (3.06) 0.00 (95% CI -2.76 to 2.
76; P value = 1.00)
Porcile 1991
Porcile 1991 DHEAS (µmol/L) -1.5 (2.10) -3 (1) 1.50 (95% CI -0.01 to 3.
01; P value = 0.05)
Analysis 5.1. Comparison 5 Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 30 µg +
desogestrel 0.15 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + drospirenone
group (standard devia-
tion)
N= 50 Bhattacharya 2012;
N = 29 Kriplani 2010
Mean change from base-
line in EE + desogestrel
group (standard devia-
tion)
N= 50 Bhattacharya 2012;
N = 29 Kriplani 2010
Mean difference (95%CI;
P value)
Bhattacharya 2012 Testosterone (ng/ml) -0.06 (0.32) -0.10 (0.39) 0.04 (95% CI -0.10 to 0.
18; P value = 0.58)
Bhattacharya 2012 SHBG (nmol/L) 131.52 (72.89) 99.53 (67.52) 31.99 (95% CI 4.32 to 59.
66; P value = 0.02)
Bhattacharya 2012 Free Androgen Index -7.89 (9.13) -5.58 (9.15) -2.31 (95% CI -5.91 to 1.
29; P value = 0.21)
Kriplani 2010 Testosterone (ng/ml) -0.10 (0.18) 0.0 (0.13) -0.10 (95% CI -0.18 to -0.
02; P value = 0.02)
Kriplani 2010 SHBG (nmol/L) 42.30 (41.33) 37.50 (29.13) 4.80 (95%CI -13.60 to 23.
20; P value = 0.61)
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Changes in androgen levels (Continued)
Kriplani 2010
Analysis 6.1. Comparison 6 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus other OCP
(unknown), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + CPA group
(standard deviation)
N = 30
Mean change from base-
line in OCP group (stan-
dard deviation)
N = 30
Mean difference (95%
CI; P value)
Taheripanah 2010 Free testosterone (ng/ml) -0.36 (4.93) -0.24 (5.48) -0.12 (95% CI -2.76 to 2.
52; P value = 0.93)
Taheripanah 2010 DHEAS (µg/ml) 0.12 (4.62) -0.31 (5.38) 0.43 (95% CI -2.11 to 2.
97; P value = 0.74)
Analysis 7.1. Comparison 7 Ethinyl estradiol 35 µg + cyproterone acetate 2 mg versus ethinyl estradiol 50
µg + desogestrel 0.15 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + CPA group
(standard deviation)
N = 9
Mean change from base-
line in EE50 + desogestrel
group (standard devia-
tion)
N = 5
Mean difference (95% CI;
P value)
Porcile 1991 Testosterone (nmol/L) -1.52 (0.93) -1.52 (0.93) 0.00 (95% CI -1.02 to 1.
02; P value = 1.00)
Porcile 1991 Free testosterone (pmol /L) -10.06 (3.06) -10.06 (3.06) 0.00 (95% CI -3.35 to 3.
35; P value = 1.00)
Porcile 1991 DHEAS (µmol/L) -1.5 (2.10) -3 (0.77) 1.50 (95% CI -0.03 to 3.
03; P value = 0.05)
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Analysis 8.1. Comparison 8 Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 50 µg +
desogestrel 0.15 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE30 + desogestrel
group (standard devia-
tion)
N = 5
Mean change from base-
line in EE50 + desogestrel
group (standard devia-
tion)
N = 10
Mean Difference (95%
CI; P value)
Porcile 1991 Testosterone (nmol/L) -1.52 (0.93) -1.52 (0.93) 0 (95% CI -1.00 to 1.00; P
value = 1.00)
Porcile 1991 Free testosterone (pmol /L) -10.06 (3.06) -10.06 (3.06) 0 (95% CI -3.28 to 3.28; P
value = 1.00)
Porcile 1991 DHEAS (µmol/L) -3 (1) -3 (0.77) 0 (95% CI -0.92 to 0.92; P
value = 1.00)
Analysis 9.1. Comparison 9 Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg and
levonorgestrel 0.15 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + desogestrel
group (standard devia-
tion)
N = 11
Mean change from base-
line in
EE+ levonorgestrel group
(standard deviation)
N = 10
Mean difference (95%
CI; P value)
Breitkopf 2003 Testosterone (ng/ml) -22.27 (12.65) -0.48 (19.32) -21.79 (95% CI -35.91 to
-7.67; P value = 0.002)
Breitkopf 2003 Free testosterone (pg/ml) -1.58 (1.20) 0.25 (2.64) -1.83 (95% CI -3.61 to -0.
05; P value = 0.04)
Breitkopf 2003 DHEAS (ng/ml) -434 (481.69) 155 (747.82) -589.00 (95%CI -1132.93
to -45.07; P value = 0.03)
Breitkopf 2003 SHBG (nmol/L) 59.05 (38.44) 11.06 (15.35) 47.99 (95% CI 23.36 to
72.62; P value = 0.0001)
Breitkopf 2003 Androstenedione (ng/ml) -0.67 (0.58) -0.60 (0.69) -0.07 (95% CI -0.62 to 0.
48; P value = 0.80)
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Analysis 10.1. Comparison 10 Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 30 µg +
chlormadinone acetate 2 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + drospirenone
group (standard deviation)
N = 30
Mean change from base-
line in EE + chlormadi-
none group (standard devi-
ation)
N = 25
Mean Difference (95% CI;
P value)
Lello 2008 Androstenedione (ng/ml) -2.44 (0.34) -1.63 (0.28) -0.81 (95% CI -0.97 to -0.
65; P value < 0.001)
Lello 2008 DHEAS (µg/ml) -0.77 (0.52) -0.75 (0.52) -0.02 (95%CI -0.30 to 0.26;
P value = 0.89)
Lello 2008 Testosterone (nmol/L) -1.09 (0.17) -0.85 (0.17) -0.24 (95% CI -0.33 to -0.
15; P value < 0.001)
Lello 2008 SHBG (nmol/L) 143.93 (12.56) 144.73 (8.81) -0.80 (95%CI -6.47 to 6.87;
P value = 0.78)
Analysis 11.1. Comparison 11 Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg +
desogestrel 0.15 mg every other month, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + desogestrel
each month group (stan-
dard deviation)
N = 9
Mean change from base-
line in EE + desogestrel
every other month group
(standard deviation)
N = 6
Meandifference (95%CI;
P value)
Porcile 1991B Testosterone (nmol/L) -0.65 (1.08) -0.20 (1.23) -0.45 (95% CI -1.66 to 0.
76; P value = 0.47)
Porcile 1991B Free testosterone (pmol/L) -0.65 (3.85) -0.30 (0.36) -0.35 (95% CI -2.88 to -2.
18; P value =0.79)
508Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.1. Comparison 12 Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus placebo, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + desogestrel
each month group (stan-
dard deviation)
N = 10 Hoeger 2008;
N = 9 Porcile 1991B
Mean change from base-
line in placebo group
(standard deviation)
N = 10 Hoeger 2008;
N = 5 Porcile 1991B
Mean Difference (95%
CI; P value)
Hoeger 2008 Testosterone (ng/dl) -28.50 (17.16) 10.40 (20.57) -38.90 (95% CI -55.50 to
-22.30; P value < 0.001)
Hoeger 2008 SHBG (nmol/L) 75.20 (57.57) 1.40 (5.64) 73.80 (95% CI 37.95 to
109.65; P value < 0.001)
Porcile 1991B Testosterone (nmol/L) -0.65 (1.08) 0.05 (0.59) -0.70 (95% CI -1.57 to 0.
17; P value = 0.12)
Porcile 1991B Free testosterone (pmol/L) -0.65 (3.85) -0.15 (0.15) -0.50 (95% CI -3.02 to 2.
02; P value = 0.70)
Analysis 13.1. Comparison 13 Ethinyl estradiol 30 µg + desogestrel 0.15 mg every other month versus
placebo, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + desogestrel
every other month group
(standard deviation)
N = 6
Mean change from base-
line in placebo group
(standard deviation)
N = 5
Meandifference (95%CI;
P value)
Porcile 1991B Testosterone (nmol/L) -0.20 (1.23) 0.05 (0.59) -0.25 (95% CI -1.36 to 0.
86; P value = 0.66)
Porcile 1991B Free testosterone (pmol/L) -0.30 (0.36) -0.15 (0.15) -0.15 (95% CI -0.47 to 0.
17; P value = 0.35)
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Analysis 14.1. Comparison 14 Ethinyl estradiol 30 µg + desogestrel 0.15 mg versus ethinyl estradiol 30 µg +
gestodene 75 µg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in EE + desogestrel
group (standard devia-
tion)
N = 17
Mean change from base-
line in EE + gestodene
group (standard devia-
tion)
N = 17
Mean differences (95%
CI; P value)
Sobbrio 1990 Total testosterone (ng/ml) -0.13 (0.19) -0.18 (0.17) 0.05 (95% CI -0.07 to 0.
17; P value = 0.42)
Sobbrio 1990 Free testosterone (pg/ml) -2.23 (0.91) -1.93 (0.72) -0.30 (95% CI -0.85 to 0.
25; P value = 0.29)
Sobbrio 1990 Androstenedione (ng/ml) -1.37 (0.92) -0.97 (0.99) -0.40 (95% CI -1.04 to 0.
24; P value = 0.22)
Sobbrio 1990 DHEAS (µg/dl) -111 (109.55) -112 (72.27) 1.00 (95%CI -61.39 to 63.
39; P value = 0.97)
Sobbrio 1990 SHBG (nmol/L) 128 (73.11) 110 (60.83) 18 (95% CI -27.21 to 63.
21; P value = 0.44)
Analysis 15.1. Comparison 15 Ethinyl estradiol 30 µg + drospirenone 3 mg versus ethinyl estradiol 20 µg +
drospirenone 3 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change
from baseline in EE 30+
drospirenone group (stan-
dard deviation)
N = 24
Mean change
from baseline in EE 20 +
drospirenone group (stan-
dard deviation)
N = 23
Mean difference (95% CI;
P value)
Oner 2011 Total testosterone (ng/dl) -28.80 (28.90) -19.50 (24.63) -9.30 (95% CI -24.63 to 6.
03; P value = 0.23)
Oner 2011 Free testosterone (pg/ml) -0.80 (0.58) -0.70 (0.48) -0.10 (95% CI -0.40 to 0.
20; P value = 0.52)
Oner 2011 Androstenedione (ng/ml) -0.10 (0.18) -0.10 (0.23) 0 (95% CI -0.12 to 0.12; P
value = 1.00)
Oner 2011 DHEAS (µg/ml) 0.00 (1.24) 0.00 (0.86) 0 (95% CI -0.61 to 0.61; P
value = 1.00)
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Changes in androgen levels (Continued)
Oner 2011 SHBG (nmol/L) 17.50 (18.72) 22.00 (38.92) -4.50 (95%CI -22.08 to 13.
08; P value = 0.62)
Analysis 16.1. Comparison 16 Flutamide 250 mg b.i.d. versus placebo, Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide group
(standard deviation)
N = 17 Gambineri 2006;
N = 10Moghetti 2000
Mean change from base-
line in placebo group
(standard deviation)
N = 19 Gambineri 2006;
N = 10 Moghetti 2000
Mean difference (95%
CI; P value)
Gambineri 2006 Total testosterone (nmol/
L)
-0.22 (0.14) -0.15 (0.18) -0.07 (95% CI -0.17 to 0.
03; P value = 0.19)
Gambineri 2006 Androstenedione (nmol/
L)
-161 (100.24) -62.00 (73.29) -99.00 (95% CI -156.94
to -41.06; P value = 0.
0008)
Gambineri 2006 DHEAS (µmol/ml) -1.40 (0.94) 0.40 (0.72) -1.80 (95% CI -2.35 to -
1.25; P value < 0.001)
Gambineri 2006 SHBG (nmol/L) 3.00 (6.79) 1.50 (11.02) 1.50 (95% CI -4.41 to 7.
41; P value = 0.62)
Moghetti 2000 Free testosterone (pg/ml) -0.58 (0.90) 0.04 (0.62) -0.62 (95% CI -1.30 to 0.
06; P value = 0.07)
Moghetti 2000 DHEAS (µgram/L) -613 (438.41) -451 (451.51) -162.00 (95% CI -552.06
to 228.06; P value = 0.42)
Moghetti 2000 Testosterone (nmol/L) -0.05 (0.44) 0.10 (0.31) -0.05 (95% CI -0.38 to 0.
28; P value = 0.77)
Moghetti 2000 Androstenedione (nmol/
L)
-2.7 (3.36) 1.40 (3.42) -4.10 (95% CI -7.07 to -
1.13; P value = 0.007)
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Analysis 17.1. Comparison 17 Flutamide 250 mg b.i.d. versus spironolactone 100 mg once a day, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide group
(standard deviation)
N = 10 Erenus 1994;
N = 10 Moghetti 2000
Mean change from base-
line in spironolactone
group (standard devia-
tion)
N = 10 Erenus 1994;
N = 10Moghetti 2000
Mean difference (95%
CI; P value)
Erenus 1994 Testosterone (ng/dl) -10.49 (10.99) -6.70 (6.81) -3.97 (95%CI -11.80 to 4.
22; P value = 0.35)
Erenus 1994 DHEAS (mg/dl) -38.00 (50.81) -117.5 (86.56) 79.50 (95% CI 17.29 to
191.71; P value = 0.01)
Erenus 1994
Erenus 1994
Moghetti 2000 Free testosterone (pg/ml) -0.58 (0.90) -0.04 (0.59) -0.54 (95% CI -1.21 to 0.
13; P value = 0.11)
Moghetti 2000 DHEAS (µgram/L) -613 (438.41) 159 (607.07) -772.00 (95% CI -1236.
12 to -307.88; P value = 0.
001)
Moghetti 2000 Testosterone (nmol/L) -0.05 (0.44) -0.02 (0.42) -0.03 (95% CI -0.41 to 0.
35; P value = 0.88)
Moghetti 2000 Androstenedione (nmol/
L)
-2.7 (3.36) 1.20 (4.56) -3.90 (95% CI -7.41 to -0.
39; P value = 0.03)
Analysis 18.1. Comparison 18 Spironolactone 100 mg per day versus placebo, Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in spironolactone
group (standard devia-
tion)
N = 10
Mean change from base-
line in placebo group
(standard deviation)
N = 10
Mean difference (95%
CI; P value)
Moghetti 2000 Free testosterone (pg/ml) -0.04 (0.59) 0.04 (0.62) 0.00 (95% CI -0.53 to 0.
53; P value = 1.00)
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Changes in androgen levels (Continued)
Moghetti 2000 DHEAS (µgram/L) 159 (607.07) -451 (451.51) 610.00 (95% CI 141.08 to
1078.92; P value = 0.01)
Moghetti 2000 Testosterone (nmol/L) -0.02 (0.42) 0.10 (0.31) -0.12 (95% CI -0.44 to 0.
20; P value = 0.47)
Moghetti 2000 Androstenedione (nmol/
L)
1.20 (4.56) 1.40 (3.42) -0.20 (95% CI -3.73 to 3.
33; P value = 0.91)
Analysis 19.1. Comparison 19 Ketoconazole 400 mg per day versus ketoconazole 800 mg per day for 10
days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in ketoconazole 400
mg group (standard devi-
ation)
Mean change from base-
line in ketoconazole 800
mg group (standard devi-
ation)
Mean difference (95% CI;
P value)
Cedeno 1990 Free testosterone (pg/ml) -5.77 (12.13) -10.58 (12.52) 4.81 (95% CI -6.58 to 16.
20; P value = 0.41)
Cedeno 1990 DHEAS (µg/ml) -79.77 (147.97) -162.18 (174.22) 82.41 (95% CI -31.69 to
196.51; P value = 0.16)
Cedeno 1990 Androstenedione (ng/ml) -0.11 (0.84) -1.04 (1.27) 0.93 (95% CI -0.06 to 1.
92; P value = 0.07)
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Analysis 20.1. Comparison 20 Finasteride 5 mg to 7.5 mg/day versus placebo, Outcome 1 Adverse events.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 20 Finasteride 5 mg to 7.5 mg/day versus placebo
Outcome: 1 Adverse events
Study or subgroup Finasteride Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ciotta 1995 6/9 7/9 75.9 % 0.86 [ 0.48, 1.53 ]
Lakryc 2003 3/16 1/18 13.9 % 3.38 [ 0.39, 29.28 ]
Moghetti 2000 1/5 1/10 10.3 % 2.00 [ 0.16, 25.75 ]
Total (95% CI) 30 37 100.0 % 1.13 [ 0.48, 2.67 ]
Total events: 10 (Finasteride), 9 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 2.43, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours finasteride Favours placebo
Analysis 20.2. Comparison 20 Finasteride 5 mg to 7.5 mg/day versus placebo, Outcome 2 Mean change
from baseline in Ferriman-Gallwey score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 20 Finasteride 5 mg to 7.5 mg/day versus placebo
Outcome: 2 Mean change from baseline in Ferriman-Gallwey score
Study or subgroup Finasteride Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ciotta 1995 9 -8 (2.93) 9 -1.8 (1.51) 28.2 % -6.20 [ -8.35, -4.05 ]
Lakryc 2003 12 -6.1 (2.02) 12 -0.8 (1.92) 52.6 % -5.30 [ -6.88, -3.72 ]
Moghetti 2000 10 -5.4 (2.6) 10 0.8 (3.32) 19.2 % -6.20 [ -8.81, -3.59 ]
Total (95% CI) 31 31 100.0 % -5.73 [ -6.87, -4.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 9.81 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours finasteride Favours placebo
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Analysis 20.3. Comparison 20 Finasteride 5 mg to 7.5 mg/day versus placebo, Outcome 3 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride group
(standard deviation)
N = 9 Ciotta 1995;
N =12 Lakryc 2003;
N = 10 Moghetti 2000
Mean change from base-
line in placebo group
(standard deviation)
N = 9 Ciotta 1995;
N =12 Lakryc 2003;
N = 10Moghetti 2000
Mean difference (95%
CI; P value)
Ciotta 1995 Total testosterone (ng/ml) 0.23 (0.09) 0.13 (0.13) 0.10 (95%CI0.00 to 0.20;
P value = 0.06)
Ciotta 1995 Free testosterone (pg/ml) 0.18 (0.20) 0.22 (0.16) -0.04 (95% CI -0.21 to 0.
13; P value = 0.64)
Ciotta 1995 Androstenedione (ng/ml) -0.01 (0.22) 0.11 (0.29) -0.12 (95% CI -0.36 to 0.
12; P value = 0.32)
Ciotta 1995 Dihydrotestosterone (pg/
ml)
-210 (53.96) -54.40 (90.39) -155.60 (95% CI -224.38
to -86.82; P < 0.001)
Ciotta 1995 DHEAS (µg/ml) -0.17 (0.19) 0.17 (0.36) -0.34 (95% CI -0.61 to -0.
07; P value = 0.01)
Ciotta 1995 SHBG (µg/ml) -0.30 (0.24) -0.26 (0.30) -0.04 (95% CI -0.29 to 0.
21; P value = 0.75)
Lakryc 2003 Total testosterone (ng/ml) -3.10 (19.21) 10.10 (28.80) -13.20 (95% CI -32.79 to
6.39; P value = 0.19)
Lakryc 2003 Free testosterone (nmol/L) -1.20 (2.96) -0.10 (2.91) -1.10 (95% CI -3.45 to 1.
25; P value = 0.36)
Lakryc 2003 Androstenedione (ng/ml) 0.10 (0.44) -0.10 (0.66) 0.20 (95% CI -0.25 to 0.
65; P value = 0.38)
Lakryc 2003 Dihydrotestosterone (ng/
ml)
-0.41 (0.11) 0 (0.06) -0.41 (95% CI -0.48 to -0.
34; P < 0.001)
Lakryc 2003 DHEAS (µg/ml) -0.50 (0.64) -0.20 (0.64) -0.30 (95% CI -0.81 to 0.
21; P value = 0.25)
Lakryc 2003
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Changes in androgen levels (Continued)
Moghetti 2000 Free testosterone (pg/ml) 0.74 (0.83) 0.04 (0.62) 0.70 (95%CI0.06 to 1.34;
P value = 0.03)
Moghetti 2000 DHEAS (µgram/L) -301 (358.81) -451 (451.51) 150.00 (95% CI -207.45
to 507.45; P value = 0.41)
Moghetti 2000 Testosterone (nmol/L) 0.56 (0.34) 0.10 (0.31) 0.46 (95%CI0.17 to 0.75;
P value = 0.002)
Moghetti 2000 Androstenedione (nmol/
L)
1.70 (2.58) 1.40 (3.42) 0.30 (95% CI -2.36 to 2.
96; P value = 0.82)
Moghetti 2000
Moghetti 2000
Analysis 21.1. Comparison 21 Finasteride 2.5 mg once a day versus finasteride 5 mg once a day, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride 2.5mg
group (standard devia-
tion)
N = 15 Al-Khawajah
1998;
N = 29 Bayram 2002
Mean change from base-
line in finasteride 5 mg
group (standard devia-
tion)
N = 15 Al-Khawajah
1998;
N = 27 Bayram 2002
Mean difference (95%
CI; P value)
Al-Khawajah 1998 Testosterone (nmol/l) 0.22 (0.36) 0.25 (0.38) -0.03 (-0.29 to 0.23; P
value = 0.82)
Al-Khawajah 1998 DHT (ng/ml) -2.08 (3.88) -2.24 (3.48) 0.16 (95% CI -2.48 to 2.
80; P value = 0.91)
Al-Khawajah 1998 Free testosterone Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
Al-Khawajah 1998 DHEAS Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
Al-Khawajah 1998
Bayram 2002 Testosterone (ng/dl) 0.70 (30.07) 2.90 (30.99) -2.20 (95% CI -18.21 to
13.81; P value = 0.79)
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Changes in androgen levels (Continued)
Bayram 2002 Free testosterone (pg/ml) 0 (0.91) -0.20 (1.26) 0.20 (95% CI -0.38 to 0.
78; P value = 0.50)
Bayram 2002 Androstenedione (ng/ml) 0.10 (1.05) -0.40 (0.84) 0.50 (95% CI 0 to 1.00;
P value = 0.05)
Bayram 2002 SHBG (nmol/L) 1.30 (18.95) 3.80 (10.97) -2.50 (95% CI -10.54 to
5.54; P value = 0.54)
Bayram 2002 DHEAS (mg/dl) 28.90 (95.35) -13.80 (89.55) 42.70 (95% CI -5.73 to
91.13; P value = 0.08)
Analysis 22.1. Comparison 22 Finasteride 2.5 mg once a day versus finasteride 7.5 mg once a day, Outcome
1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride 2.5mg
group (standard devia-
tion)
N = 15
Mean change from base-
line in finasteride 7.5mg
group (standard devia-
tion)
N = 15
Mean difference (95%
CI; P value)
Al-Khawajah 1998 Testosterone (nmol/l) 0.22 (0.36) 0.15 (0.46) 0.07 (95% CI -0.23 to 0.
37; P value = 0.64)
Al-Khawajah 1998 Dihydrotestosterone (ng/
ml)
-2.08 (3.88) -1.29 (3.54) -0.79 (95% CI -3.45 to 1.
87; P value = 0.56)
Al-Khawajah 1998 Free testosterone Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
Al-Khawajah 1998 DHEAS Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
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Analysis 23.1. Comparison 23 Finasteride 5 mg once a day versus finasteride 7.5 mg once a day, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride 5 mg
group (standard devia-
tion)
N = 15
Mean change from base-
line in finasteride 7.5mg
group (standard devia-
tion)
N = 15
Mean difference (95%
CI; P value)
Al-Khawajah 1998 Testosterone (nmol/l) 0.25 (0.38) 0.15 (0.46) 0.10 (95% CI -0.12 to 0.
32; P value = 0.37)
Al-Khawajah 1998 Dihydrotestosterone (ng/
ml)
-2.24 (3.48) -1.29 (3.54) -0.95 (95% CI -3.46 to 1.
56; P value =0.46)
Al-Khawajah 1998 Free testosterone Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
Al-Khawajah 1998 DHEAS Authors stated no statis-
tically significant changes
compared to baseline
Authors stated no statis-
tically significant changes
compared to baseline
Cannot be calculated
Analysis 24.1. Comparison 24 Finasteride 2.5 mg once a day versus finasteride 2.5 mg every 3 days,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride 2.5 mg
group (standard devia-
tion)
N = 19
Mean change from base-
line in finasteride 2.5 mg
every 3 days group (stan-
dard deviation)
N = 19
Meandifference (95%CI;
P value)
Tartagni 2004 Total testosterone (ng/dl) -0.19 (1.38) -0.14 (2.24) -0.05 (95% CI -1.23 to 1.
13; P value = 0.93)
Tartagni 2004 Dihydrotestosterone ng/
dl)
-21.47 (0.53) -20.98 (0.54) -0.49 (95% CI -0.83 to -0.
15; P value = 0.005)
Tartagni 2004 DHEAS (µg/ml) 0.35 (0.78) 0.54 (0.8) -0.19 (95% CI -0.69 to 0.
31; P value = 0.46)
Tartagni 2004 SHBG (µg/ml) -0.02 (0.99) -0.14 (1.11) 0.12 (95% CI -0.55 to 0.
79; P value = 0.73)
Tartagni 2004 Androstenedione (ng/ml) -0.02 (0.83) -0.03 (0.55) -0.01 (95% CI -0.44 to 0.
46; P value = 0.97)
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Analysis 25.1. Comparison 25 Metformin 850 mg b.i.d. versus rosiglitazone 2 mg b.i.d., Outcome 1 Changes
in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin group
(standard deviation)
N = 31
Mean change from base-
line in rosiglitazone group
(standard deviation)
N = 30
Mean difference (95% CI;
P value)
Ahmad 2008 Testosterone (pg/ml) -0.66 (0.44) -0.67 (0.39) 0.01 (95%CI -0.20 to 0.22;
P value = 0.93)
Ahmad 2008 DHEAS (µg/ml) -56.30 (19.56) -57.69 (17.20) 1.39 (95% CI -7.85 to 10.
63; P value =0.77)
Ahmad 2008 Androstenedione (ng/ml) -1.44 (0.53) -0.39 (0.30) -1.05 (95% -1.27 to -0.83;
P value < 0.001)
Analysis 26.1. Comparison 26 Troglitazone 150 mg versus troglitazone 300 mg versus troglitazone 600 mg
versus placebo, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from
baseline in troglita-
zone 150 mg group
(standard deviation)
N = 78
Mean change from
baseline in troglita-
zone 300 mg group
(standard deviation)
N = 77
Mean change from
baseline in troglita-
zone 600 mg group
(standard deviation)
N = 78
Mean change from
baseline in placebo
group (standard de-
viation)
N = 73
Azziz 2001 Total testosterone
(ng/mL)
-0.06 (0.26) -0.01 (0.26) -0.01 (0.26) -0.04 (0.26)
Azziz 2001 Free testosterone (pg/
mL)
-2.72 (4.86) -3.07 (4.83) -4.13 (4.86) -1.11 (4.87)
Azziz 2001 Androstenedione
(ng/mL)
-0.16 (0.53) -0.11 (0.53) -0.14 (0.53) -0.01 (0.51)
Azziz 2001 SHBG (nmol/L) -8.05 (21.90) -18.69 (21.85) -29.12 (21.99) -2.22 (21.96)
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Analysis 27.1. Comparison 27 Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks,
Outcome 1 Mean change from baseline in Ferriman-Gallwey score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 27 Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks
Outcome: 1 Mean change from baseline in Ferriman-Gallwey score
Study or subgroup Metformin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gambineri 2006 20 -2.6 (5.37) 19 -1.3 (2.89) 19.4 % -1.30 [ -3.99, 1.39 ]
Hoeger 2004 5 -1.9 (9.49) 7 0.6 (2.58) 1.9 % -2.50 [ -11.03, 6.03 ]
Hoeger 2008 6 0.4 (2.04) 10 -0.9 (3.25) 20.9 % 1.30 [ -1.29, 3.89 ]
Maciel 2004 15 -0.1 (3.6) 14 0.5 (3.6) 20.4 % -0.60 [ -3.22, 2.02 ]
Moghetti 2000B 12 0.7 (3.37) 11 1.8 (3.9) 15.7 % -1.10 [ -4.09, 1.89 ]
Onalan 2005 55 6.2 (50.06) 61 9.6 (20.2) 0.7 % -3.40 [ -17.57, 10.77 ]
Otta 2010 14 -0.13 (3.35) 15 -0.5 (3.77) 20.9 % 0.37 [ -2.22, 2.96 ]
Total (95% CI) 127 137 100.0 % -0.27 [ -1.46, 0.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.01, df = 6 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours metformin Favours placebo
Analysis 27.2. Comparison 27 Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks,
Outcome 2 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin group
(standard deviation)
N = 19 Eisenhardt 2006;
N = 20 Gambineri 2006;
N = 5 Hoeger 2004; N
= 6 Hoeger 2008; N =
15 Maciel 2004; N =12
Moghetti 2000B; N = 55
Onalan 2005; N = 14
Otta 2010
Mean change from base-
line in placebo group
(standard deviation)
N = 19 Eisenhardt 2006;
N = 19 Gambineri 2006;
N = 7 Hoeger 2004; N
= 10 Hoeger 2008; N =
14 Maciel 2004; N =11
Moghetti 2000B; N = 61
Onalan 2005; N = 15
Otta 2010
Mean difference (95%
CI; P value)
Eisenhardt 2006 DHEAS (µmol/L) Median change from base-
line 0.19 (SD cannot be
calculated)
Median change from base-
line 0.78 (SD cannot be
calculated)
Cannot be calculated
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Changes in androgen levels (Continued)
Eisenhardt 2006 Testosterone (nmol/L) Median change from base-
line 0 (SD cannot be cal-
culated)
Median change from base-
line -0.13 (SD cannot be
calculated)
Cannot be calculated
Eisenhardt 2006 Androstenedione (nmol/
L)
Median change from base-
line 3.37 (SD cannot be
calculated)
Cannot be calculated
Eisenhardt 2006 SHBG (nmol/L) Median change from base-
line 1.4 (SD cannot be cal-
culated)
Median change from base-
line 1.4 (SD cannot be cal-
culated)
Cannot be calculated
Gambineri 2006 Total testosterone (nmol/
L)
-0.15 (0.22) -0.15 (0.18) 0.0 (95%CI -0.13 to 0.13;
P value = 1.00)
Gambineri 2006 Androstenedione (nmol/
L)
-51 (103.72) -62.00 (73.29) 11 (95% CI -45.15 to 67.
15; P value = 0.70)
Gambineri 2006 DHEAS (µmol/ml) 0.10 (0.36) 0.40 (0.72) -0.30 (95% CI -0.66 to 0.
06; P value = 0.10)
Gambineri 2006 SHBG (nmol/L) 2.20 (7.69) 1.50 (11.02) 0.70 (95% CI -5.29 to 6.
69; P value = 0.82)
Hoeger 2004 Testosterone (ng/dl) 4.0 (16.75) 4.8 (20.06) -0.80 (95% CI -21.92 to
20.09; P value = 0.94)
Hoeger 2004 SHBG (nmol/L) 0.48 (34.05) -8.19 (7.22) 8.67 (95% CI -21.65 to
38.99; P value = 0.58)
Hoeger 2004
Hoeger 2004
Hoeger 2008 Testosterone (ng/dl) -1.60 (22.12) 10.40 (20.57) -12.00 (95% CI -33.81 to
9.81; P value = 0.28)
Hoeger 2008 SHBG (nmol/L) -2.40 (13.37) 1.40 (5.64) -3.80 (95% CI -15.05 to
7.45; P value = 0.51)
Hoeger 2008
Hoeger 2008
Maciel 2004 Testosterone (ng/dL) -23.9 (17.3) 3.1 (30) -27.00 (95% CI -44.99 to
-9.01; P value = 0.003)
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Changes in androgen levels (Continued)
Maciel 2004 Free testosterone
(pg/dL)
-1.7 (1.4) 0.1 (0.8) -1.8 (95% CI -2.62 to -0.
98; P value < 0.001)
Maciel 2004 Androstenedione
(ng/dL)
-0.55 (0.49) 0.1 (0.7) -0.65 (95% CI -1.09 to -
0.21; P value = 0.004)
Maciel 2004 SHBG (nmol/L) 13.3 (54.5) 46.1 (63.3) -32.80 (95% CI -75.93 to
10.33; P value = 0.14)
Moghetti 2000B Free testosterone (pmol/L) -2.90 (3.75) -0.30 (3.39) -2.60 (95% CI -5.52 to 0.
32: P value = 0.08)
Moghetti 2000B Androstenedione (nmol/
L)
1.10 (4.41) 0.40 (2.02) 0.70 (95% CI -2.07 to 3.
47; P value = 0.62)
Moghetti 2000B DHEAS (µmol/L) 0.60 (1.46) -0.30 (0.99) 0.90 (95% CI -0.11 to 1.
91; P value = 0.08)
Moghetti 2000B SHBG (nmol/L) 9 (22.05) 0.90 (11.96) 8.10 (95% -6.24 to 22.44;
P value = 0.27)
Onalan 2005 Free testosterone (pg/ml) 20.6 (12.6) 9.0 (15.2) -11.60 (95% CI 6.54 to
16.66; P < 0.001)
Onalan 2005 SHBG (nmol/ml) 23.3 (60.7) -24. 4 (96.4) 47.70 (95% CI 18.67 to
76.32; P value = 0.001)
Onalan 2005 Androstenedione (ng/dl) 21.5 (15.8) 7.3 (11.6) 14.20 (95%CI 9.11 to 19.
29; P value < 0.001)
Onalan 2005 DHEAS (µg/dl) 6.32 (21.55) -4.78 (28.54) 11.10 (95%CI 1.95 to 20.
25; P value = 0.02)
Otta 2010 Testosterone (ng/dl) -16.84 (13.80) -6.27 (14.99) -10.57 (95% CI -21.05 to
-0.09; P value = 0.05)
Otta 2010 DHEAS (µgram/dl) 2 (39.4) -26 (79.14) 28 (95% -17.05 to 73.05;
P value = 0.22)
Otta 2010 Androstenedione (ng/ml) -0.29 (0.73) -0.02 (0.87) -0.27 (95% CI -0.85 to 0.
31; P value = 0.36)
Otta 2010
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Analysis 27.3. Comparison 27 Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks,
Outcome 3 Mean change from baseline in BMI.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 27 Metformin 500 mg to 1500 mg per day versus placebo for 12 to 48 weeks
Outcome: 3 Mean change from baseline in BMI
Study or subgroup Metformin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gambineri 2006 20 -2 (3) 19 -2 (3.16) 18.4 % 0.0 [ -1.94, 1.94 ]
Hoeger 2008 6 1.4 (5.17) 10 -0.6 (4.57) 3.3 % 2.00 [ -3.01, 7.01 ]
Maciel 2004 15 -0.55 (3.62) 14 0.4 (2.66) 13.8 % -0.95 [ -3.25, 1.35 ]
Moghetti 2000B 12 -1.1 (3.19) 11 -0.7 (2.31) 14.2 % -0.40 [ -2.66, 1.86 ]
Onalan 2005 55 1.2 (3.2) 61 -0.39 (2.9) 39.3 % 1.59 [ 0.47, 2.71 ]
Otta 2010 14 -0.87 (4.04) 15 -1.44 (3.14) 10.9 % 0.57 [ -2.08, 3.22 ]
Total (95% CI) 122 130 100.0 % 0.56 [ -0.37, 1.50 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 6.09, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours metformin Favours placebo
Analysis 28.1. Comparison 28 Rosiglitazone 4 mg b.i.d. versus placebo, Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in rosiglitazonegroup
(standard deviation)
N = 24 Lam 2011; N = 12
Rautio 2005
Mean change from base-
line in placebo group
(standard deviation)
N = 30 Lam 2011; N = 14
Rautio 2005
Mean difference (95% CI;
P value)
Lam 2011 Total testosterone (nmol/L) -0.39 (0.82) -0.42 (0.69) 0.03 (95% CI -0.38 to 0.
43; P value = 0.89)
Lam 2011 SHBG (nmol/L) 2.5 (18.07) 4.3 (19.22) -1.80 (95% CI -11.78 to 8.
18; P value = 0.72)
Lam 2011 Free testosterone (nmol/L) -0.007 (0.02) -0.009 (0.02) 0.0 (95% CI -0.01 to 0.01;
P value = 0.72)
Lam 2011
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Changes in androgen levels (Continued)
Rautio 2005 Testosterone (nmol/L) 0 (0.46) -0.30 (0.71) 0.30 (95% CI -0.15 to 0.
75; P value = 0.20)
Rautio 2005 SHBG (nmol/L) 6.60 (11.12) -2.40 (12.02) 9.00 (95% CI 0.10 to 17.
90; P value = 0.05)
Rautio 2005 Androstenedione (nmol/L) -2.70 (3.95) 0.50 (3.85) -3.20 (95% CI -6.21 to 0.
19; P value = 0.04)
Rautio 2005 DHEAS (µmol/L) -0.78 (2.74) 0.20 (1.81) -0.98 (95% CI -2.80 to 0.
84; P value = 0.29)
Analysis 29.1. Comparison 29 Metformin 850 mg b.i.d. versus simvastatin 20 mg once a day, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin group
(standard deviation)
N = 33
Mean change from base-
line in simvastatin group
(standard deviation)
N = 28
Mean difference (95%
CI; P value)
Banaszewska 2011 Total testosterone (ng/ml) -0.15 (0.23) -0.22 (0.16) 0.07 (95% CI -0.03 to 0.
17; P value = 0.16)
Banaszewska 2011 Free testosterone (ng/dl) -0.30 (0.46) -0.28 (0.32) -0.02 (95% CI -0.22 to 0.
18; P value = 0.84)
Banaszewska 2011 DHEAS (µmol/ml) 0.54 (2.13) -1.64 (2.28) 2.18 (95% CI 1.07 to 3.
29; P value = 0.001)
Banaszewska 2011 SHBG (nmol/L) 2.27 (13.04) -5.19 (11.64) 7.46 (95% CI 1.26 to 13.
66; P value = 0.02)
Analysis 30.1. Comparison 30 Pioglitazone 30 mg once a day versus placebo once a day, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in pioglitazone group
(standard deviation)
N = 17
Mean change from base-
line in placebo group
(standard deviation)
N = 18
Mean difference (95% CI;
P value)
Aigner 2009 DHEAS (µmol/L) 0.40 (1.74) 0.50 (1.53) -0.10 (95% CI -1.19 to 0.
99; P value = 0.86)
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Changes in androgen levels (Continued)
Aigner 2009 Testosterone (nmol/L) -0.30 (0.76) -0.30 (0.54) 0.0 (95% CI -0.44 to 0.44;
P value = 1.00)
Aigner 2009 Free androgen index (U) -2.9 (5.91) 1.3 (5.09) -4.20 (95% CI -7.86 to -0.
54; P value = 0.02)
Aigner 2009 SHBG (nmol/L) 4.0 (10.65) -5.1 (22.55) 9.10 (95% CI -2.48 to 20.
68; P value = 0.12)
Analysis 31.1. Comparison 31 Lifestyle modification + metformin 850 mg b.i.d. versus metformin 850 mg
b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in lifestyle modification +
metformin group (standard
deviation)
N = 5
Mean change from baseline
in metformin group (stan-
dard deviation)
N = 5
Mean difference (95%CI; P
value)
Hoeger 2004 Testosterone (ng/dl) -18.5 (10.26) 4.0 (16.75) -22.50 (95% CI -39.72 to -5.
28; P value = 0.01)
Hoeger 2004 SHBG (nmol/L) -1.01 (31.12) 0.48 (34.05) -1.49 (95% CI -41.92 to 38.
94; P value = 0.94)
Analysis 32.1. Comparison 32 Lifestyle modification + placebo versus metformin 850 mg b.i.d., Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in lifestyle modification +
placebo group (standard de-
viation)
N = 6
Mean change from baseline
in metformin group (stan-
dard deviation)
N = 5
Mean difference (95%CI; P
value)
Hoeger 2004 Testosterone (ng/dl) 1.7 (11.39) 4.0 (16.75) -2.30 (95% CI -19.58 to 14.
98; P value = 0.79)
Hoeger 2004 SHBG (nmol/L) -4.74 (32.40) 0.48 (34.05) -5.22 (95% CI -44.75 to 34.
31; P value = 0.80)
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Analysis 33.1. Comparison 33 Lifestyle modification + metformin 850 mg b.i.d. versus lifestyle modification
+ placebo, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in lifestyle modification +
metformin group (standard
deviation)
N = 5
Mean change from baseline
in lifestyle + placebo group
(standard deviation)
N = 6
Mean difference (95%CI; P
value)
Hoeger 2004 Testosterone (ng/dl) -18.5 (10.26) 1.7 (11.39) -20.20 (95% CI -33.00 to -7.
40; P value = 0.002)
Hoeger 2004 SHBG (nmol/L) -1.01 (31.12) -4.74 (32.40) 3.73 (95% CI -33.90 to 41.
36; P value = 0.85)
Analysis 34.1. Comparison 34 Lifestyle modification + metformin 850 mg b.i.d. versus placebo, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in lifestyle modification +
metformin group (standard
deviation)
N = 5
Mean change from baseline
in placebo group (standard
deviation)
N = 7
Mean difference (95%CI; P
value)
Hoeger 2004 Testosterone (ng/dl) -18.5 (10.26) 4.8 (20.06) -23.30 (95% CI -40.67 to -5.
93; P value = 0.009)
Hoeger 2004 SHBG (nmol/L) -1.01 (31.12) -8.19 (7.22) 7.18 (95% CI -20.62 to 34.
98; P value = 0.61)
Analysis 35.1. Comparison 35 Metformin 2000 mg per day + lifestyle modification + OCP versus placebo +
lifestyle modification + OCP, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in metformin group (stan-
dard deviation)
N = 16
Mean changes frombaseline
in placebo group (standard
deviation)
N = 16
Mean difference (95%CI; P
value)
Hoeger 2008 Testosterone (ng/dl) -27.50 (19.58) -57.70 (13.77) 30.20 (95% CI 18.47 to 41.
93; P value < 0.001)
Hoeger 2008 SHBG (nmol/L) 58.50 (46.83) 72.80 (44.17) -14.30 (95%CI -45.84 to 17.
24; P value = 0.37)
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Analysis 36.1. Comparison 36 OCP (ethinyl estradiol 20 µg + desogestrel 0.15 mg) + simvastatin 20 mg
versus OCP (ethinyl estradiol 20 µg + desogestrel 0.15 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + sim-
vastatin group (standard
deviation)
N = 24
Mean change from base-
line inOCP group (stan-
dard deviation)
N = 24
Mean difference (95%
CI; P value)
Banaszewska 2007 Total testosterone (ng/ml) -0.34 (0.14) -0.11 (0.21) -0.23 (95% CI -0.33 to -
0.13; P value < 0.001)
Banaszewska 2007 Free testosterone (pg/ml) -0.54 (0.47) -0.36 (0.62) -0.18 (95% CI -0.49 to 0.
13; P value = 0.26)
Banaszewska 2007 DHEAS (µ/ml) -1.01 (0.98) -0.96 (0.90) -0.05 (95% CI -0.58 to 0.
48; P value = 0.85)
Banaszewska 2007 SHBG (nmol/L) 64.5 (37.99) 78.30 (33.92) -13.80 (95% CI -34.18 to
6.58; P value = 0.18)
Analysis 37.1. Comparison 37 Metformin 850 mg b.i.d. versus metformin 850 mg b.i.d. + simvastatin 20 mg
once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin group
(standard deviation)
N = 33
Mean change from base-
line in metformin + sim-
vastatin group (standard
deviation)
N = 36
Mean difference (95%
CI; P value)
Banaszewska 2011 Total testosterone (ng/ml) -0.15 (0.23) -0.16 (0.18) 0.01 (95% CI -0.09 to 0.
11; P value = 0.84)
Banaszewska 2011 Free testosterone (ng/dl) -0.30 (0.46) -0.27 (0.48) -0.03 (95% CI -0.25 to 0.
19; P value = 0.79)
Banaszewska 2011 DHEAS (µmol/ml) 0.54 (2.13) 0.59 (1.86) -0.05 (95% CI -1.00 to 0.
90; P value = 0.92)
Banaszewska 2011 SHBG (nmol/L) 2.27 (13.04) 0.43 (10.68) 1.84 (95% CI -3.81 to 7.
49; P value = 0.52)
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Analysis 38.1. Comparison 38 Simvastatin 20 mg once a day versus metformin 850 mg b.i.d. + simvastatin
20 mg once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in simvastatin group
(standard deviation)
N = 28
Mean change from base-
line in metformin + sim-
vastatin group (standard
deviation)
N = 36
Mean difference (95%
CI; P value)
Banaszewska 2011 Total testosterone (ng/ml) -0.22 (0.16) -0.16 (0.18) -0.06 (95% CI -0.14 to 0.
02; P value = 0.69)
Banaszewska 2011 Free testosterone (ng/dl) -0.28 (0.32) -0.27 (0.48) -0.01 (95% CI -0.21 to 0.
19; P value = 0.92)
Banaszewska 2011 DHEAS (µmol/ml) -1.64 (2.28) 0.59 (1.86) -2.23 (95% CI -3.29 to -
1.19; P < 0.001)
Banaszewska 2011 SHBG (nmol/L) -5.19 (11.64) 0.43 (10.68) -5.62 (95% CI -11.16 to
-0.07; P value = 0.05)
Analysis 39.1. Comparison 39 Metformin 850 mg b.i.d. + flutamide 250 mg b.i.d. versus placebo, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin + flu-
tamide group (standard
deviation)
N = 20
Mean change from base-
line in placebo group
(standard deviation)
N = 19
Mean difference (95%
CI; P value)
Gambineri 2006 Total testosterone (nmol/
L)
-0.24 (0.12) -0.15 (0.18) -0.09 (95% CI -0.19 to 0.
01; P value = 0.07)
Gambineri 2006 Androstenedione (nmol/
L)
-31.00 (82.63) -62.00 (73.29) 31.00 (95% CI -17.96 to
79.96; P value = 0.21)
Gambineri 2006 DHEAS (µmol/ml) -1.10 (0.90) 0.40 (0.72) -1.50 (95% CI -2.01 to -
0.99; P value < 0.001)
Gambineri 2006 SHBG (nmol/L) 3.80 (7.85) 1.50 (11.02) 2.30 (95% CI -3.73 to 8.
3; P value = 0.45)
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Analysis 40.1. Comparison 40 Metformin 1275 mg to 1700 mg per day + flutamide 250 mg to 500 mg per
day versus flutamide 250 mg to 500 mg per day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin + flu-
tamide group (standard
deviation)
N = 20 Gambineri 2006;
N = 13 Ibáñez 2002
Mean change from base-
line in flutamide group
(standard deviation)
N = 17 Gambineri 2006;
N = 10 Ibáñez 2002
Mean difference (95%
CI; P value)
Gambineri 2006 Total testosterone (nmol/
L)
-0.24 (0.12) -0.22 (0.14) -0.02 (95% CI -0.10 to 0.
06; P value = 0.64)
Gambineri 2006 Androstenedione (nmol/
L)
-31.00 (82.63) -161.00 (100.24) 130.00 (95% CI 70.15 to
189.95; P value < 0.001)
Gambineri 2006 DHEAS (µmol/ml) -1.10 (0.90) -1.40 (0.94) 0.30 (95% CI -0.30 to 0.
90; P value = 0.32)
Gambineri 2006 SHBG (nmol/L) 3.80 (7.85) 3.00 (6.79) 0.80 (95% CI -3.92 to 5.
52; P value = 0.74)
Ibáñez 2002 Testosterone (ng/dl) -51.00 (13.29) -31.00 (27.02) -20.00 (95% CI -38.24 to
-1.76; P value = 0.03)
Ibáñez 2002 SHBG (µg/dl) 0.50 (0.23) 0.30 (0.20) 0.20 (95% CI 0.02 to 0.
38; P value = 0.03)
Ibáñez 2002 Androstenedione (ng/dl) -147.00 (66.13) -40.00 (42.63) -107.00 (95% CI -151.61
to -62.39; P value < 0.001)
Ibáñez 2002 DHEAS (µg/dl) -128.00 (43.86) -4.00 (28.63) -124.00 (95% -153.72 to
-94.28; P value < 0.001)
Analysis 41.1. Comparison 41 Metformin 1275 mg to 1700 mg per day + flutamide 250 mg to 500 mg per
day versus metformin 1275 mg to 1700 mg per day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in metformin + flu-
tamide group (standard
deviation)
N =20 Gambineri 2006;
N = 13 Ibáñez 2002
Mean change from base-
line in metformin group
(standard deviation)
N = 17 Gambineri 2006;
N = 8 Ibáñez 2002
Mean difference (95%
CI; P value)
Gambineri 2006 Total testosterone (nmol/
L)
-0.24 (0.12) -0.15 (0.22) -0.09 (95% CI -0.20 to 0.
02; P value = 0.11)
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Changes in androgen levels (Continued)
Gambineri 2006 Androstenedione (nmol/
L)
-31.00 (82.63) -51 (103.72) 20.00 (95% CI -38.12 to
78.12; P value = 0.50)
Gambineri 2006 DHEAS (µmol/ml) -1.10 (0.90) 0.10 (0.36) -1.20 (95% CI -1.62 to -
0.78; P value < 0.001)
Gambineri 2006 SHBG (nmol/L) 3.80 (7.85) 2.20 (7.69) 1.6 (95%CI -3.22 to 6.42;
P value = 0.51)
Ibáñez 2002 Testosterone (ng/dl) -51.00 (13.29) -67.00 (35.97) 16.00 (95% CI -9.95 to
41.95; P value = 0.23)
Ibáñez 2002 SHBG (µg/dl) 0.50 (0.23) 0.40 (0.18) 0.10 (95% CI -0.08 to 0.
28; P value = 0.27)
Ibáñez 2002 Androstenedione (ng/dl) -147.00 (66.13) -42.00 (48.13) -105 (95% CI -154.04 to
-55.96; P value < 0.001)
Ibáñez 2002 DHEAS (µg/dl) -128.00 (43.86) -44.00 (52.66) -84.00 (95% CI -127.59
to -40.41; P value = 0.
0002)
Analysis 42.1. Comparison 42 Finasteride 5 mg once a day versus cyproterone acetate 25 mg once a day +
ethinyl estradiol 20 µg 21 days of the month, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride group
(standard deviation)
N = 20 Beigi 2004; N = 14
Fruzzetti 1999
Mean change from base-
line in CPA + ethinyl
estradiol group
N = 20 Beigi 2004; N = 13
Fruzzetti 1999
Mean difference (95%
CI; P value)
Beigi 2004 Total testosterone (ng/dl) 38 (27.17) -66 (27.29) 104 (95%CI 87.12 to 120.
88; P value < 0.001)
Beigi 2004 Free testosterone (pg/ml) 0.3 (0.63) -3.15 (0.85) 3.45 (95%CI 2.99 to 3.91;
P value < 0.001)
Beigi 2004 Androstenedione (ng/ml) 0.20 (0.55) -2.90 (0.58) 3.10 (95%CI 2.75 to 3.45;
P value < 0.001)
Beigi 2004 DHEAS (µg/dl) -2.10 (75.99) -108.70 (48.19) 106.60 (95% CI 67.16 to
146.04; P value < 0.001)
Beigi 2004 Dihydrotestosterone (ng/
dl)
-29.80 (10.81) -22.80 (7.86) -7.00 (95% CI -12.86 to -
1.14; P value = 0.02)
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Changes in androgen levels (Continued)
Beigi 2004 SHBG (nmol/L) 1.80 (24.96) 31.60 (27.19) -29.80 (95% CI -45.98 to
-13.62; P value = 0.0003)
Fruzzetti 1999 Testosterone (ng/ml) 0.30 (0.32) -0.57 (0.37) 0.87 (95%CI 0.61 to 1.13;
P value < 0.001)
Fruzzetti 1999 Free testosterone (ng/ml) 0.87 (1.15) -4.21 (1.58) 5.08 (95%CI 4.03 to 6.13;
P value < 0.001)
Fruzzetti 1999 Dihydrotestosterone (ng/
ml)
-0.39 (0.67) -0.25 (0.13) -0.14 (95% CI -0.50 to 0.
22; P value 0.44)
Fruzzetti 1999 Androstenedione (ng/ml) Unchanged (no further
data)
-2.70 (0.98) Cannot be calculated
Fruzzetti 1999 DHEAS (µg/ml) Unchanged (no further
data)
-0.57 (1.09) Cannot be calculated
Fruzzetti 1999 SHBG (ng/ml) Unchanged (no further
data)
32 (29.75) Cannot be calculated
Analysis 43.1. Comparison 43 Flutamide 250 mg b.i.d. versus cyproterone acetate 25 mg once a day +
ethinyl estradiol 20 µg 21 days of the month, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide group
(standard deviation)
N = 15
Mean change from base-
line in CPA + ethinyl
estradiol group (standard
deviation)
N = 13
Mean difference (95%
CI; P value)
Fruzzetti 1999 Testosterone (ng/ml) Unchanged (no further
data)
-0.57 (0.37) Cannot be calculated
Fruzzetti 1999 Free testosterone (ng/ml) -0.25 (1.27) -4.21 (1.58) 3.96 (95%CI 2.89 to 5.03;
P value < 0.001)
Fruzzetti 1999 Dihydrotestosterone (ng/
ml)
Unchanged (no further
data)
-0.25 (0.13) Cannot be calculated
Fruzzetti 1999 Androstenedione (ng/ml) Unchanged (no further
data)
-2.70 (0.98) Cannot be calculated
Fruzzetti 1999 DHEAS (µg/ml) -0.38 (0.39) -0.57 (1.09) 0.19 (95% CI -0.43 to 0.
81; P value = 0.55)
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Changes in androgen levels (Continued)
Fruzzetti 1999 SHBG (ng/ml) -1.81 (3.04) 32 (29.75) -33.81 (95% CI -50.05 to
-17.57; P value < 0.001)
Analysis 44.1. Comparison 44 Flutamide 125 mg per day + triphasic OCP versus placebo + tricyclic OCP,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide + OCP
group (standard devia-
tion)
N = 25
Mean change from base-
line in placebo + OCP
group (standard devia-
tion)
N = 31
Mean difference (95% CI;
P value)
Calaf 2007 Testosterone (nmol/L) -0.16 (0.69) -0.51 (0.55) 0.35 (95% CI 0.02 to 0.68;
P value = 0.04)
Calaf 2007 SHBG (nmol/L) 109.10 (42.43) 37.60 (31.34) 71.50 (95%CI 51.54 to 91.
46; P value < 0.001)
Calaf 2007 Free Androgen Index -4.62 (4.71) -2.20 (2.40) -2.42 (95% CI -4.45 to -0.
39; P value = 0.02)
Calaf 2007 DHEAS (nmol/L) -2.59 (1.80) -1.07 (1.61) -1.52 (95% CI -2.43 to -0.
61; P value = 0.001)
Calaf 2007 Androstenedione (nmol/L) -3.70 (4.20) -1.99 (2.32) -1.71 (95% CI -3.55 to 0.1;
P value = 0.07)
Analysis 45.1. Comparison 45 Flutamide 250 mg per day + triphasic OCP versus placebo + tricyclic OCP,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide + OCP
group (standard devia-
tion)
N = 29
Mean change from base-
line in placebo + OCP
group (standard devia-
tion)
N = 31
Mean difference (95% CI;
P value)
Calaf 2007 Testosterone (nmol/L) -0.59 (0.74) -0.51 (0.55) -0.08 (95% CI -0.41 to 0.
25; P = 0.64)
Calaf 2007 SHBG (nmol/L) 104.30 (85.51) 37.60 (31.34) 66.70 (95%CI 33.68 to 99.
72; P value < 0.001)
Calaf 2007 Free Androgen Index -5.41 (3.34) -2.20 (2.40) -3.21 (95% CI -4.69 to -1.
73; P value < 0.001)
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Changes in androgen levels (Continued)
Calaf 2007 DHEAS (nmol/L) -3.53 (2.13) -1.07 (1.61) -2.46 (95% CI -3.42 to -1.
50; P value < 0.001)
Calaf 2007 Androstenedione (nmol/L) -3.67 (2.33) -1.99 (2.32) -1.68 (95% CI -2.86 to -0.
50; P value = 0.005)
Analysis 46.1. Comparison 46 Flutamide 375 mg per day + triphasic OCP versus placebo + tricyclic OCP,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide + OCP
group (standard devia-
tion)
N = 34
Mean change from base-
line in placebo + OCP
group (standard devia-
tion)
N = 35
Mean difference (95% CI;
P value)
Calaf 2007 Testosterone (nmol/L) -0.18 (0.48) -0.51 (0.55) 0.33 (95% CI 0.08 to 0.58;
P value = 0.01)
Calaf 2007 SHBG (nmol/L) 129.40 (71.23) 37.60 (31.34) 91.80 (95% CI 65.44 to
118.16; P value < 0.001)
Calaf 2007 Free Androgen Index -4.72 (2.57) -2.20 (2.40) -2.52 (95% CI -3.73 to -1.
31; P value < 0.001)
Calaf 2007 DHEAS (nmol/L) -3.10 (1.48 -1.07 (1.61) -2.03 (95% CI -2.78 to -1.
28; P value < 0.001)
Calaf 2007 Androstenedione (nmol/L) -1.90 (2.70) -1.99 (2.32) 0.09 (95%CI -1.13 to 1.31;
P value = 0.89)
Analysis 47.1. Comparison 47 Flutamide 125 mg per day + triphasic OCP versus flutamide 375 mg per day
+ triphasic OCP, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide 125 mg +
OCP group (standard de-
viation)
N = 25
Mean change from base-
line in flutamide 375 mg +
OCP group (standard de-
viation)
N = 34
Mean difference (95% CI;
P value)
Calaf 2007 Testosterone (nmol/L) -0.16 (0.69) -0.18 (0.48) 0.02 (95%CI -0.29 to 0.33;
P value = 0.90)
Calaf 2007 SHBG (nmol/L) 109.10 (42.43) 129.40 (71.23) -20.30 (95% CI -49.45 to
8.85; P value = 0.17)
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Changes in androgen levels (Continued)
Calaf 2007 Free Androgen Index -4.62 (4.71) -4.72 (2.57) 0.10 (95%CI -1.94 to 2.14;
P value = 0.92)
Calaf 2007 DHEAS (nmol/L) -2.59 (1.80) -3.10 (1.48 0.51 (95%CI -0.35 to 1.37;
P value = 0.25)
Calaf 2007 Androstenedione (nmol/L) -3.70 (4.20) -1.90 (2.70) -0.60 (95% CI -2.48 to 1.
28; P value = 0.53)
Analysis 48.1. Comparison 48 GnRH-A 3.75 mg im every 28 days versus GnRH-A 3.75 mg im every 28 days
+ oestrogen 0.625 mg and medroxyprogesterone 10 mg both on day 1 to 21, Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 10
Mean change from base-
line in GnRH-A + oestro-
gen + progesterone group
(standard deviation)
N = 12
Mean difference (95%
CI; P value)
Carmina 1994 Total testosterone (nmol/
L)
-1.53 (1.00) -2.04 (0.66) 0.51 (95% CI -0.21 to 1.
23; P value = 0.17)
Carmina 1994 Free testosterone (pmol/L) -11.20 (7.65) -14.2 (7.33) 3.00 (95% CI -3.30 to 9.
30; P value = 0.35)
Carmina 1994 Androstenedione (nmol/L) -6.40 (2.80) -8.70 (2.19) 2.30 (95%CI 0.17 to 4.43;
P value = 0.03)
Carmina 1994 DHEAS (µmol/L) 0.3 (3.16) -1.60 (2.41) 1.90 (95% CI -0.49 to 4.
29; P value = 0.12)
Analysis 49.1. Comparison 49 GnRH-A 3.6 mg sc every 28 days versus GnRH-A 3.6 mg sc every 28 days +
estradiol valerate 2 mg days 5 to 25 + medroxyprogesterone days 16 to 25, Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 8
Mean change from base-
line in GnRH-A group +
oestrogen-
progestogen replacement
(standard deviation)
N = 6
Meandifference (95%CI;
P value)
Tiitinen 1994 SHBG (nmol/L) -6 (6.96) 7 (12.66) -13.00 (95% CI -24.22 to
-1.78; P value = 0.02)
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Tiitinen 1994 Testosterone (nmol/L) 0.08 (0.55) 0.01 (0.68) 0.07 (95%CI 0.59 to 0.73;
P value = 0.84)
Tiitinen 1994 Free testosterone (pmol/L) 2.90 (8.08) -4.60 (15.81) 7.50 (95% CI -6.33 to 21.
33; P value = 0.29)
Tiitinen 1994 Androstenedione (nmol/L) -0.30 (2.21) 0.30 (2.10) -0.60 (95% CI -2.87 to 1.
67; P value = 0.60)
Tiitinen 1994 DHEAS (µmol/L) -1.20 (2.17) -1.90 (4.08) 0.70 (95% CI -2.89 to 4.
29; P value = 0.70)
Analysis 50.1. Comparison 50 GnRH-A 3.6 mg + OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg)
versus OCP (ethinyl estradiol 0.35 µg + cyproterone acetate 2 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 15
Mean change from base-
line in OCP group (stan-
dard deviation)
N = 14
Mean difference (95%CI;
P value)
Vegetti 1996 SHBG (nmol/L) 147.95 (73.02) 137.61 (64.79) 10.34 (95% CI -39.83 to
60.51; P value = 0.69)
Vegetti 1996 DHEAS (µg/ml) -0.27 (0.52) -0.23 (0.45) -0.04 (95% CI -0.39 to 0.
31; P value = 0.82)
Vegetti 1996 Free testosterone (pg/ml) -1.23 (0.82) -1.09 (1.05) -0.14 (95% CI -0.83 to 0.
55; P value = 0.69)
Vegetti 1996 Dihydrotestosterone (pg/
ml)
0.10 (0.06) 0 (0.10) 0.10 (95% CI 0.04 to 0.16;
P value = 0.001)
Analysis 51.1. Comparison 51 GnRH-A 3.75 im every 28 days + OCP (ethinyl estradiol 35 µg +
norethindrone 1 mg) versus GnRH-A 3.75 im every 28 days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-
A + OCP group (standard
deviation)
N = 11
Mean change from base-
line line in GnRH-A group
(standard deviation)
N = 11
Mean difference (95% CI;
P value)
Carr 1995 Testosterone (nmol/L) -1.80 (1.05) -1.20 (0.89) -0.60 (95% CI -1.41 to 0.
21; P value = 0.15)
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Carr 1995 Free testosterone (pmol/L) -12.60 (10.80) -7.3 (5.82) -5.30 (95% CI -12.55 to 1.
95; P value = 0.15)
Carr 1995 Androstenedione (nmol/L) -8.00 (7.45) -2.00 (1.40) -6.00 (95% CI -10.48 to -1.
52; P value = 0.009)
Carr 1995 DHEAS (µmol/L) -0.10 (1.26) -2.60 (4.97) 2.50 (95%CI -0.53 to 5.53;
P value = 0.11)
Analysis 52.1. Comparison 52 GnRH-A 3.75 im every 28 days + OCP (ethinyl estradiol 35 µg +
norethindrone 1 mg) versus OCP (ethinyl estradiol 35 µg + norethindrone 1 mg), Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-
A + OCP group (standard
deviation)
N = 11
Mean change from base-
line line in OCP group
(standard deviation)
N = 11
Mean difference (95% CI;
P value)
Carr 1995 Testosterone (nmol/L) -1.80 (1.05) -1.70 (1.08) -0.10 (95% CI -0.99 to 0.
79; P value = 0.83)
Carr 1995 Free testosterone (pmol/L) -12.60 (10.80) -12.80 (6.85) 0.20 (95%CI -7.36 to 7.76;
P value = 0.96)
Carr 1995 Androstenedione (nmol/L) -8.00 (7.45) -2.30 (1.41) -5.70 (95% CI -10.18 to -1.
22; P value = 0.01)
Carr 1995 DHEAS (µmol/L) -0.10 (1.26) -0.40 (1.60) 0.30 (95%CI -0.90 to 1.50;
P value = 0.63).
Analysis 53.1. Comparison 53 GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) versus GnRH-A 3.75 mg im every 28 days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 12
Mean change from base-
line in GnRH-A group
(standard deviation)
N = 12
Mean difference (95%CI;
P value)
De Leo 2000 SHBG (nmol/L) 42 (13.42) -14 (7.21) 56.00 (95%CI47.38 to 64.
62; P value < 0.001)
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Changes in androgen levels (Continued)
De Leo 2000 Androstenedione (nmol/L) -6.00 (1.34) -5.40 (1.34) -0.60 (95% CI -1.67 to 0.
47; P value = 0.27)
De Leo 2000 DHEAS (µmol/L) -4.70 (1.20) -3.20 (1.22) -1.50 (95% CI -2.47 to -0.
53; P value = 0.002)
De Leo 2000 Testosterone (nmol/L) -2.10 (0.59) -1.60 (0.75) -0.50 (95% CI -1.04 to 0.
04; P value = 0.07)
De Leo 2000 Free testosterone (pmol/L) -24 (3.16) -19 (3.16) -5.00 (95% CI -7.53 to -2.
47; P value = 0.0001)
Analysis 54.1. Comparison 54 GnRH-A 3.75 mg im every 28 days + flutamide 250 mg per day versus GnRH-
A 3.75 mg im every 28 days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + flu-
tamide group (standard
deviation)
N = 11
Mean change from base-
line in GnRH-A group
(standard deviation)
N = 12
Mean difference (95%CI;
P value)
De Leo 2000 SHBG (nmol/L) -13 (6.00) -14 (7.21) 1.00 (95% CI -4.40 to 6.
40; P value = 0.72)
De Leo 2000 Androstenedione (nmol/L) -6.60 (1.34) -5.40 (1.34) -1.20 (95% CI -2.30 to -0.
10; P value = 0.03)
De Leo 2000 DHEAS (µmol/L) -6.60 (1.22) -3.20 (1.22) -3.40 (95% CI -4.40 to -2.
40; P < 0.001)
De Leo 2000 Testosterone (nmol/L) -2.30 (0.85) -1.60 (0.75) -0.70 (95% CI -1.36 to -0.
04; P value = 0.04)
De Leo 2000 Free testosterone (pmol/L) -24 (3.16) -19 (3.16) -5.00 (95% CI -7.59 to -2.
41; P value = 0.0002)
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Analysis 55.1. Comparison 55 GnRH-A 3.75 mg im every 28 days + flutamide 250 mg per day versus GnRH-
A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg), Outcome 1 Changes
in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + flu-
tamide group (standard
deviation)
N = 11
Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 12
Mean difference (95%CI;
P value)
De Leo 2000 SHBG (nmol/L) -13 (6.00) 42 (13.42) -55 (95% CI -63.38 to -46.
62; P value < 0.001)
De Leo 2000 Androstenedione (nmol/L) -6.60 (1.34) -6.00 (1.34) -0.60 (95% CI -1.70 to 0.
50; P value = 0.28)
De Leo 2000 DHEAS (µmol/L) -6.60 (1.22) -4.70 (1.20) -1.90 (95% CI -2.89 to -0.
91; P value = 0.0002)
De Leo 2000 Testosterone (nmol/L) -2.30 (0.85) -2.10 (0.59) -0.20 (95% CI -0.80 to 0.
40; P value = 0.52)
De Leo 2000 Free testosterone (pmol/L) -24 (3.16) -24 (3.16) 0 (95% CI -2.59 to 2.59; P
value = 1.00)
Analysis 56.1. Comparison 56 GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
norethindrone 0.4 mg) versus GnRH-A 3.75 mg im every 28 days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 11
Mean change from base-
line in GnRH-A group
(standard deviation)
N = 12
Mean difference (95%
CI; P value)
Elkind-Hirsch 1995 Testosterone (ng/dl) -65.80 (14.98) -53.50 (14.47) -12.30 (95%CI -24.36 to
-0.24; P value = 0.05)
Elkind-Hirsch 1995 Free testosterone (ng/dl) -2.70 (1.60) -2.10 (0.83) -0.60 (95%CI -1.66 to 0.
46; P value = 0.27)
Elkind-Hirsch 1995 SHBG (nmol/L) 110 (67.46) 0 (23.70) 110 (95% CI 67.94 to
152.06; P value < 0.001)
Elkind-Hirsch 1995 DHEAS (µg/dl) Authors state ”no signifi-
cant difference“
Authors state ”no signifi-
cant difference“
cannot be calculated
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Analysis 57.1. Comparison 57 GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 35 µg +
norethindrone 0.4 mg) versus OCP (ethinyl estradiol 35 µg + norethindrone 0.4 mg), Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 11
Mean change from base-
line in OCP group
(standard deviation)
N = 10
Mean difference (95%
CI; P value)
Elkind-Hirsch 1995 Testosterone (ng/dl) -65.80 (14.98) -29.40 (8.59) -36.40 (95%CI -46.73 to
-26.07; P value < 0.001)
Elkind-Hirsch 1995 Free testosterone (ng/dl) -2.70 (1.60) -1.30 (0.87) -1.40 (95% CI -2.49 to -
0.31; P value = 0.01)
Elkind-Hirsch 1995 SHBG (nmol/L) 110 (67.46) 116 (87.50) -6.00 (95% CI -73.31 to
61.31; P value = 0.86)
Elkind-Hirsch 1995 DHEAS (µg/dl) Authors state ”no signifi-
cant difference“
Authors state ”no signifi-
cant difference“
Cannot be calculated
Analysis 58.1. Comparison 58 GnRH-A 3.75 mg im every 28 days + OCP (ethinyl estradiol 0.35 µg +
cyproterone acetate 2 mg) versus GnRH-A 3.75 mg im every 28 days, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A + OCP
group (standard devia-
tion)
N = 16 Falsetti 1994; N =
13 Falsetti 1994B
Mean change from base-
line in GnRH-A group
(standard deviation)
N = 16 Falsetti 1994; N =
12 Falsetti 1994B
Mean difference (95%
CI; P value)
Falsetti 1992 Androstenedione (units
not provided)
-54.5% (no standard devi-
ation provided)
-47.5% (no standard devi-
ation provided)
Cannot be calculated
Falsetti 1992 Testosterone (units not
provided)
-59.5% (no standard devi-
ation provided)
-48.5% (no standard devi-
ation provided)
Cannot be calculated
Falsetti 1992 Free testosterone (units not
provided)
-69.5% (no standard devi-
ation provided)
-61% (no standard devia-
tion provided)
Cannot be calculated
Falsetti 1992 DHEAS (units not pro-
vided)
23.5% (no standard devia-
tion provided)
-12.5% (no standard devi-
ation provided)
Cannot be calculated
Falsetti 1992 SHBG (units not pro-
vided)
-26% (no standard devia-
tion provided)
150% (no standard devia-
tion provided)
Cannot be calculated
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Changes in androgen levels (Continued)
Falsetti 1994 Testosterone (ng/ml) -0.50 (0.26) -0.45 (0.24) -0.05 (95% CI -0.22 to 0.
12; P value = 0.57)
Falsetti 1994 Androstenedione (ng/ml) -1.55 (0.46) -1.45 (0.29) -0.10 (95% CI -0.37 to 0.
17; P value = 0.46)
Falsetti 1994 Free testosterone (pg/ml) -2.55 (1.51) -2.25 (1.46) -0.30 (95% CI -1.33 to 0.
73; P value = 0.57)
Falsetti 1994 DHEAS (µg/ml) -0.65 (0.72) -0.25 (0.71) -0.40 (95% CI -0.90 to 0.
10; P value = 0.11)
Falsetti 1994 SHBG (nmol/L) 115 (31.21) 3.5 (4.71) 111.50 (95% CI 96.03 to
126.97; P value < 0.001)
Falsetti 1994B Androstenedione (ng/ml) -2.30 (0.19) -2.0 (0.27) -0.303 (95% CI -0.48 to -
0.12; P value = 0.001)
Falsetti 1994B Testosterone (ng/ml) -0.90 (0.27) -0.70 (0.19) -0.20 (95% CI -0.38 to -0.
02; P value = 0.03)
Falsetti 1994B Free testosterone (pg/ml) -3.70 (0.63) -3.10 (0.37) -0.60 (95% CI -1.00 to -0.
20; P value = 0.003)
Falsetti 1994B DHEAS (µg/ml) -0.60 (0.19) -0.50 (0.30) -0.10 (95% CI -0.30 to 0.
10; P value = 0.32)
Falsetti 1994B SHBG (nmol/L) 102 (22.49) 3.00 (4.94) 99.00 (95% CI 86.46 to
111.54; P value < 0.001)
Analysis 59.1. Comparison 59 GnRH-A 3.75 im every 28 days + conjugated oestrogen 0.625 mg +
medroxyprogesterone acetate 10 mg day 1 to 12 versus OCP (ethinyl estradiol 35 µg + ethynodiol diacetate 1
mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 9
Mean change from base-
line in OCP group (stan-
dard deviation)
N = 8
Mean difference (95% CI;
P value)
Azziz 1995 Testosterone (nmol/L) -0.5 (0.25) 0 (0.34) -0.50 (95% CI -0.79 to -0.
21; P value = 0.0006)
Azziz 1995 Androstenedione (nmol/L) -2.60 (1.5) 0.1 (3.9) -2.70 (95% CI -5.57 to 0.
17; P value = 0.07)
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Changes in androgen levels (Continued)
Azziz 1995 SHBG (nmol/L) 20 (25.30) 100 (96.04) -80.00 (95% CI -148.57 to
-11.43; P value = 0.02)
Analysis 60.1. Comparison 60 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + metformin 500
b.i.d. versus OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change in OCP +
metformin group (stan-
dard deviation)
N = 20
Mean change in OCP
group (standard devia-
tion)
N = 20
Mean difference (95% CI;
P value)
Elter 2002 Testosterone (nmol/L) -1.13 (0.98) -1.13 (0.97) 0.00 (95%CI -0.60 to 0.60;
P value = 1.00)
Elter 2002 Free testosterone (pg/ml) -4.99 (1.95) -4.11 (2.80) -0.88 (95% CI -2.38 to 0.
62; P value = 0.25)
Elter 2002 Androstenedione (nmol/L) -7.31 (2.66) -4.81 (1.73) -2.50 (95% CI -3.89 to -1.
11; P value = 0.0004)
Elter 2002 DHEAS (µmol/L) 0.84 (1.65) 0.11 (1.95) 0.73 (95%CI -0.39 to 1.85;
P value = 0.20)
Elter 2002 SHBG (nmol/L) 59.71 (20) 31.83 (14.20) 27.88 (95% CI 17.13 to 38.
63; P value < 0.001)
Analysis 61.1. Comparison 61 OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + metformin 500 mg three
times a day versus OCP (ethinyl estradiol 20 µg + drospirenone 3 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + metformin
group (standard devia-
tion)
N = 15
Mean change from base-
line in OCP group (stan-
dard deviation)
N = 16
Mean difference (95%
CI; P value)
Fruzzetti 2010 Total testosterone (ng/ml) -0.06 (0.13) -0.17 (0.19) 0.11 (95% CI -0.00 to 0.
22; P value = 0.06)
Fruzzetti 2010 SHBG (ng/ml) 6.28 (6.89) 7.07 (7.78) -0.79 (95% CI -5.96 to 4.
38; P value = 0.76)
Fruzzetti 2010 Androstenedione (ng/ml) -0.29 (0.57) -0.39 (0.76) 0.10 (95% CI -0.37 to 0.
57; P value = 0.68)
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Analysis 62.1. Comparison 62 OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) versus OCP
(drospirenone 3 mg + ethinyl estradiol 20 µg) + cyproterone acetate 12.5 mg (first 10 days of pill strip),
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 16
Mean change from base-
line in OCP + CPA group
(standard deviation)
N = 16
Mean difference (95%
CI; P value)
Fruzzetti 2010 Total testosterone (ng/ml) -0.17 (0.19) -0.17 (0.19) 0.0 (95% CI -0.13 to 0.13;
P value = 1.00)
Fruzzetti 2010 SHBG (ng/ml) 7.07 (7.78) 5.94 (6.51) 1.13 (95% CI -3.84 to 6.
10; P value = 0.66)
Fruzzetti 2010 Androstenedione (ng/ml) -0.39 (0.76) -0.43 (0.63) 0.04 (95% CI -0.44 to 0.
52; P value = 0.87)
Analysis 63.1. Comparison 63 OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + metformin 500 mg
three times a day versus OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + cyproterone acetate 12.5 mg
(first 10 days of pill strip), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + metformin
group (standard devia-
tion)
N = 15
Mean change from base-
line in OCP + CPA group
(standard deviation)
N = 16
Mean difference (95%
CI; P value)
Fruzzetti 2010 Total testosterone (ng/ml) -0.06 (0.13) -0.17 (0.19) 0.11 (95% CI -0.00 to 0.
22; P value = 0.06)
Fruzzetti 2010 SHBG (ng/ml) 6.28 (6.89) 5.94 (6.51) 0.34 (95% CI -4.39 to 5.
07; P value = 0.89)
Fruzzetti 2010 Androstenedione (ng/ml) -0.29 (0.57) -0.43 (0.63) 0.14 (95% CI -0.28 to 0.
56; P value = 0.52)
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Analysis 64.1. Comparison 64 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus OCP
(ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + finasteride 5 mg once a day on day 1 to 14, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 23
Mean change from base
line in OCP + finas-
teride group (standard de-
viation)
N = 23
Mean difference (95%CI:
P value)
Tartagni 2000 Free testosterone (pg/ml) -2.26 (0.90) -2.76 (0.31) 0.50 (95% CI 0.11 to 0.89;
P value = 0.01)
Tartagni 2000 DHEAS (µg/ml) -1.36 (0.8) 1.52 (0.82) -2.88 (95% CI -3.35 to -2.
41; P value < 0.001)
Tartagni 2000 SHBG (µg/ml) -0.1 (0.75) -0.68 (1.07) 0.58 (95% CI 0.05 to 1.11:
P value = 0.03)
Tartagni 2000 Androstenedione (ng/ml) -3.66 (1.39) -4.34 (1.31) 0.68 (95% CI -0.10 to 1.
46; P value = 0.09)
Analysis 65.1. Comparison 65 OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + cyproterone acetate 12.5
mg day 1 to 10 versus OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + spironolactone 100 mg, Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + CPA group
(standard deviation)
N = 13
Mean change from base-
line in OCP + spironolac-
tone group (standard de-
viation)
N = 15
Mean difference (95%
CI; P value)
Lumachi 2003 Testosterone (pmol/L) -3.5 (2.52) -1.7 (2.75) -1.80 (95% CI -3.75 to 0.
15; P value = 0.07)
Lumachi 2003 DHEAS (µmol/L) 0.09 (1.62) -0.27 (1.17) 0.36 (95% CI -0.70 to 1.
42; P value = 0.51)
Lumachi 2003 Androstenedione (nmol/L) -0.72 (1.20) -0.56 (1.55) -0.16 (95% CI -1.18 to 0.
86; P value = 0.76)
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Analysis 66.1. Comparison 66 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone
acetate 50 mg once a day on day 1 to 10 versus OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) +
spironolactone 100 mg once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in OCP + CPA group (stan-
dard deviation)
N = 21
Mean change from baseline
in OCP + spironolactone
group (standard deviation)
N = 21
Mean difference (95% CI; P
value)4
Erenus 1996 Testosterone (ng/dl) -12.20 (13.34) -14.13 (15.32) 1.93 (95% CI -6.76 to 10.62;
P value = 0.66)
Erenus 1996 DHEAS (mg/dl) -63.7 (64.18) -47.41 (62.06) -16.29 (95%CI -54.47 to 21.
89; P value = 0.40)
Analysis 67.1. Comparison 67 OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + cyproterone acetate 50
mg b.i.d. versus OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + spironolactone 100 mg once a day,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + CPA group
(standard deviation)
N = 45
Mean change from base-
line in OCP + spironolac-
tone group (standard de-
viation)
N = 44
Mean difference (95% CI;
P value)
Kelekci 2012 Total testosterone (ng/ml) -0.20 (0.12) -0.23 (0.10) 0.03 (95% CI -0.02 to 0.
08; P value = 0.20)
Kelekci 2012 DHEAS (µg/ml) -55.04 (42.77) -43.97 (24.64) -11.07 (95% CI -25.53 to
3.39; P value = 0.13)
Analysis 68.1. Comparison 68 OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + cyproterone acetate 50
mg b.i.d. versus OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone acetate 50 mg b.i.d.,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP (includ-
ing DRSP) + CPA group
(standard deviation)
N = 45
Mean change from base-
line in OCP (including
CPA) + CPA group (stan-
dard deviation)
N = 45
Mean difference (95% CI;
P value)
Kelekci 2012 Total testosterone (ng/ml) -0.20 (0.12) -0.13 (0.15) -0.07 (95% CI -0.13 to -0.
01; P value = 0.01)
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Changes in androgen levels (Continued)
Kelekci 2012 DHEAS (µg/ml) -55.04 (42.77) -40.25 (25.39) -14.79 (95% CI -29.32 to -
0.26; P value = 0.05)
Analysis 69.1. Comparison 69 OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + spironolactone 100 mg
once a day versus OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + cyproterone acetate 50 mg
b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP (including
DRSP) + spironolactone
group (standard devia-
tion)
N = 44
Mean change from base-
line in OCP (including
CPA) + CPA group (stan-
dard deviation)
N =45
Mean difference (95% CI;
P value)
Kelekci 2012 Total testosterone (ng/ml) -0.23 (0.10) -0.13 (0.15) -0.10 (95% CI -0.15 to -0.
05; P value = 0.002)
Kelekci 2012 DHEAS (µg/ml) -43.97 (24.64) -40.25 (25.39) -3.72 (95% CI -14.11 to 6.
67; P value = 0.48)
Analysis 70.1. Comparison 70 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + spironolactone
100 mg once daily versus OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + finasteride 5 mg once
daily, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + spironolac-
tone group (standard de-
viation)
N = 55
Mean change from base-
line in OCP + finasteride
group (standard devia-
tion)
N = 57
Meandifference (95%CI;
P value)
Kriplani 2009 Total testosterone (ng/ml) -0.50 (0.82) -0.30 (0.63) -0.20 (95% CI -0.47 to 0.
07; P value = 0.15)
Kriplani 2009 DHEAS (µg/dl) -44.30 (74.38) -57.50 (79.88) 13.20 (95% CI -15.37 to
41.77; P value = 0.37)
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Analysis 71.1. Comparison 71 OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + spironolactone 100 mg
versus OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + finasteride 5 mg, Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + spironolac-
tone group (standard de-
viation)
N = 15
Mean change from base-
line in OCP + finasteride
group (standard devia-
tion)
N = 13
Mean difference (95%
CI; P value)
Lumachi 2003 Testosterone (pmol/L) -1.7 (2.75) 2.4 (1.49) -4.10 (95% CI -5.71 to -2.
49; P value < 0.001)
Lumachi 2003 DHEAS (µmol/L) -0.27 (1.17) 0.19 (0.86) -0.46 (95% CI -1.21 to 0.
29; P value = 0.23)
Lumachi 2003 Androstenedione (nmol/L) -0.56 (1.55) 0.37 (1.52) -0.93 (95% CI -2.07 to 0.
21; P value = 0.11)
Analysis 72.1. Comparison 72 OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + cyproterone acetate 12.5
mg day 1 to 10 versus OCP (ethinyl estradiol 30 µg + gestodene 75 µg) + finasteride 5 mg, Outcome 1 Changes
in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + CPA group
(standard deviation)
N = 13
Mean change from base-
line in OCP + finasteride
group (standard devia-
tion)
N = 13
Mean difference (95%
CI; P value)
Lumachi 2003 Testosterone (pmol/L) -3.5 (2.52) 2.4 (1.49) -5.90 (95% CI -7.49 to -4.
31; P value < 0.001)
Lumachi 2003 DHEAS (µmol/L) 0.09 (1.62) 0.19 (0.86) -0.10 (95% CI -1.10 to 0.
90; P value = 0.84)
Lumachi 2003 Androstenedione (nmol/L) -0.72 (1.20) 0.37 (1.52) -1.09 (95% CI -2.14 to -0.
04; P value = 0.04)
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Analysis 73.1. Comparison 73 OCP (triphasic including ethinyl estradiol and levonorgestrel) +
spironolactone 100 mg once a day versus ethinyl estradiol 30 µg day on day 5 to 25 + cyproterone acetate 100
mg once a day on day 5 to 14, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP + spironolac-
tone group (standard de-
viation)
N = 20
Mean change from base-
line in EE + CPA group
(standard deviation)
= 26
Meandifference (95%CI;
P value)
O’Brien 1991 Testosterone (nmol/L) -0.60 (0.61) -1.00 (0.70) 0.40 (95%CI 0.02 to 0.78;
P value = 0.04)
O’Brien 1991 DHEAS (µmol/L) -0.10 (2.32) -1.90 (2.19) 1.80 (95%CI 0.48 to 3.12;
P value = 0.008)
O’Brien 1991 Androstenedione (nmol/L) -1.10 (3.46) -2.40 (1.92) 1.30 (95% CI -0.39 to 2.
99; P value = 0.13)
O’Brien 1991 SHBG (nmol/L) 51.70 (55.15) 62.40 (42.22) -10.70 (95% CI -39.81 to
18.41; P value = 0.47)
Analysis 74.1. Comparison 74 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus OCP
(ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + sibutramine 10 mg once a day, Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 14
Mean change from base-
line inOCP+ sibutramine
group (standard devia-
tion)
N = 14
Mean difference (95% CI;
P value)
Sabuncu 2003 Testosterone (ng/dl) -44.0 (17.62) -41.80 (20.58) -2.20 (95% CI -16.39 to
11.99; P value = 0.76)
Sabuncu 2003 Free testosterone (ng/dl) -2.20 (0.61) -2.60 (0.72) 0.40 (95%CI -0.09 to 0.89;
P value = 0.11)
Sabuncu 2003 SHBG (nmol/L) 41.30 (31.30) 60.50 (34.63) -19.20 (95% CI -43.65 to
5.25; P value = 0.12)
Sabuncu 2003 DHEAS (µg/dl) -59.30 (52.38) -63.40 (65.44) 4.10 (95% CI -39.81 to 48.
01; P value = 0.85)
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Analysis 75.1. Comparison 75 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + sibutramine 10
mg once a day versus sibutramine 10 mg once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line inOCP+ sibutramine
group (standard devia-
tion)
N = 14
Mean change from base-
line in sibutramine group
(standard deviation)
N = 12
Mean difference (95% CI;
P value)
Sabuncu 2003 Testosterone (ng/dl) -41.80 (20.58) -51.80 (16.58) 10.00 (95% CI -4.29 to 24.
29; P value = 0.17)
Sabuncu 2003 Free testosterone (ng/dl) -2.60 (0.72) -2.0 (0.61) -0.60 (95% CI -1.11 to -0.
09; P value = 0.02)
Sabuncu 2003 SHBG (nmol/L) 60.50 (34.63) 31.70 (18.63) 28.80 (95% CI -7.82 to 49.
78; P value = 0.007)
Sabuncu 2003 DHEAS (µg/dl) -63.40 (65.44) -52.70 (51.37) -10.70 (95% CI -55.64 to
34.24; P value = 0.64)
Analysis 76.1. Comparison 76 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus pioglitazone
7.5 mg + flutamide 62.5 mg + metformin 850 mg all once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stand
deviation)
N = 17
Mean change from base-
line in combined treat-
ment group (standard de-
viation)
N = 17
Mean difference (95% CI;
P value)
Ibáñez 2012 Testosterone (ng/dl) -27 (24.74) -22 (24.74) -5.00 (95%CI -21.63 to 11.
63; P value = 0.56)
Ibáñez 2012 SHBG (nmol/l) 139 (32.98) 8 (8.25) 131.00 (95% CI 114.84 to
147.16; P value < 0.001)
Ibáñez 2012 Androstenedione (ng/dl) -111 (32) -109 (38) -2.00 (95%CI -25.62 to 21.
62; P value = 0.87)
Ibáñez 2012 DHEAS (µg/dl) -61 (19) 13 (13) -74.00 (95% CI -84.94 to -
63.06; P value < 0.001)
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Analysis 77.1. Comparison 77 Pioglitazone + transdermal contraceptive + metformin + flutamide versus
placebo + transdermal contraceptive + metformin + flutamide, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in pioglitazone + com-
bined treatment group
(standard deviation)
N = 19
Mean changes from base-
line in placebo + combined
treatment group (standard
deviation)
N = 19
Mean difference (95% CI;
P value)
Ibáñez 2009 Testosterone (ng/dl) -29 (13.78) -27 (13.07) -2.00 (95% CI -10.54 to 6.
54; P value = 0.65)
Ibáñez 2009 Androstenedione (ng/dl) -208 (115.82) -168 (90.70) -40.00 (95% CI -106.15 to
26.15; P value = 0.24)
Ibáñez 2009 SHBG (nmol/L) 135 (21.53) 132 (21.53) 3.00 (95% CI -10.69 to 16.
69; P value = 0.67)
Ibáñez 2009 DHEAS µg/dl) -91.00 (85.80) -51.00 (66.68) -40.00 (95%CI -88.86 to 8.
86; P value = 0.11)
Analysis 78.1. Comparison 78 Cyproterone acetate 50 mg per day 20 days per month + ethinyl estradiol 35
µg over the last 10 days of CPA treatment versus spironolactone 200 mg per day, Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in CPA + EE group
(standard deviation)
N = 23
Mean change from base-
line in spironolac-
tone group (standard de-
viation)
N = 21
Mean difference (95%CI;
P value)
Spritzer 2000 Testosterone (nmol/L) -1.18 (0.69) 0.2 (0.88) -1.38 (95% CI -1.85 to -0.
91; P value < 0.001)
Spritzer 2000 Androstenedione (nmol/L) -3.19 (2.27) 2.04 (2.98) -5.23 (95% CI -6.81 to -3.
65; P value < 0.001)
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Analysis 79.1. Comparison 79 Dexamethasone 0.37 mg/day versus dexamethasone 0.37 mg/day +
spironolactone 100 mg per day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in dexamethasone
group (standard devia-
tion)
N = 12
Mean change from base-
line in dexamethasone
+ spironolactone group
(standard deviation)
N = 30
Mean difference (95%CI;
P value)
Carmina 1998 Testosterone (ng/dl) -60 (10.39) -64.40 (15.41) 4.40 (95% CI -3.66 to 12.
46; P value = 0.28)
Carmina 1998 Free testosterone (pg/ml) -3.10 (1.09) -3.48 (1.63) 0.38 (95% CI -0.47 to 1.
23; P value = 0.38)
Carmina 1998 DHEAS (µg/ml) -2.60 (0.84) -2.62 (1.19) 0.02 (95% CI -0.62 to 0.
66; P value = 0.95)
Analysis 80.1. Comparison 80 Spironolactone 100 mg/day versus dexamethasone 0.37 mg/day +
spironolactone 100 mg per day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in spironolactone
group (standard devia-
tion)
N = 12 Carmina 1998; N
= 10 Prezelj 1989
Mean change from base-
line in dexamethasone
+ spironolactone group
(standard deviation)
N = 30 Carmina 1998; N
= 13 Prezelj 1989
Mean difference (95%
CI; P value)
Carmina 1998 Testosterone (ng/dl) -12 (4.56) -64.40 (15.41) 76.40 (95% CI 70.31 to
82.49; P value < 0.001)
Carmina 1998 Free testosterone (pg/ml) -0.40 (1.28) -3.48 (1.63) 3.08 (95%CI 2.15 to 4.01;
P value < 0.001)
Carmina 1998 DHEAS (µg/ml) 0.20 (1.09) -2.62 (1.19) 2.82 (95%CI 2.07 to 3.57;
P value < 0.001)
Prezelj 1989 Testosterone (nmol/L) -0.4 (2.16) -1.1 (2.53) 0.70 (95% CI -1.22 to 2.
62; P value = 0.47)
Prezelj 1989 Androstenedione (nmol/L) 3.4 (7.16) -4.2 (7.9) 7.60 (95% CI 1.42 to 13.
78; P value = 0.02)
Prezelj 1989 DHEAS (µmol/L) -1.8 (6.7) -3.9 (7.45) 2.10 (95% CI -3.70 to 7.
90; P value = 0.48)
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Analysis 81.1. Comparison 81 Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle +
metformin 1000 mg b.i.d. versus metformin 1000 mg b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in clomiphene + metformin
group (standard deviation)
N = 168
Mean change from baseline
in metformin only group
(standard deviation)
N = 172
Mean difference (95% CI; P
value)
Roth 2012 Testosterone (ng/dl) -9.1 (33.1) -7.4 (27.6) -1.70 (95% CI -8.19 to 4.79;
P value = 0.61)
Roth 2012 SHBG (nmol/L) 15.4 (19.5) 2.7 (13.5) 12.70 (95% CI 9.13 to 16.27;
P value < 0.001)
Analysis 82.1. Comparison 82 Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle +
metformin 1000 mg b.i.d. versus clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle,
Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in clomiphene + metformin
group (standard deviation)
N = 168
Mean change from baseline
in clomiphene only group
(standard deviation)
N = 165
Mean difference (95% CI; P
value)
Roth 2012 Testosterone (ng/dl) -9.1 (33.1) -2.6 (31.7) -6.50 (95%CI -13.46 to 0.46;
P value = 0.07)
Roth 2012 SHBG (nmol/L) 15.4 (19.5) 13.4 (16.0) 2.00 (95% CI -1.83 to 5.83; P
value = 0.31)
Analysis 83.1. Comparison 83 OCP (ethinyl estradiol 35 µg + norgestimate 0.25 mg) versus metformin
1000 mg b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change frombaseline
in OCP group (standard
deviation)
N = 15
Mean change in metformin
group (standard deviation)
N = 16
Mean difference (95% CI;
P value)
Allen 2005 Testosterone (ng/dl) -18.0 (5.49) -18.5 (3.96) 0.50 (95% CI -2.89 to 3.89;
P value = 0.77)
Allen 2005 Free testosterone (ng/dl) -0.9 (0.19) -0.5 (0.13) -0.40 (95% CI -0.52 to -0.
28; P value < 0.001)
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Analysis 84.1. Comparison 84 OCP ethinyl estradiol 30 µg + desogestrel 0.15 mg) versus metformin 850 mg
b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
inOCP group (standard de-
viation)
N = 10
Mean change from baseline
in metformin group (stan-
dard deviation)
N = 6
Mean difference (95%CI; P
value)
Hoeger 2008 Testosterone (ng/dl) -28.50 (17.16) -1.60 (22.12) -26.90 (95% CI -47.55 to -6.
25; P value = 0.01)
Hoeger 2008 SHBG (nmol/L) 75.20 (57.57) -2.40 (13.37) 77.60 (95% CI 40.35 to 114.
85; P value < 0.001)
Analysis 85.1. Comparison 85 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus metformin
850 mg b.i.d., Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from
baseline in OCP group
(standard deviation)
N = 15
Mean change in met-
formin group (standard
deviation)
N = 12
Mean difference (95%
CI; P value)
Harborne 2003 Testosterone (ng/ml) -0.84 -0.37
Harborne 2003 SHBG (nmol/L) 86 -1.6
Harborne 2003 DHEAS (µmol/L) -2.8 0.6
Harborne 2003 Androstenedione (ng/
ml)
-3.4 -1.2
Luque-Ramírez 2007 Free testosterone (ng/dl) -0.7 (0.37) -0.2 (0.38) -0.50 (95% CI -0.79 to -
0.21; P value = 0.0006)
Luque-Ramírez 2007 Androstenedione (ng/
ml)
-1.3 (0.51) -0.2 (0.70) -1.10 (95% CI -1.57 to -
0.63; P value < 0.001)
Luque-Ramírez 2007 DHEAS (ng/dl) -738 (618.71) 250 (580.49) -988.00 (95% CI -1441.
77 to -534.23; P value <
0.001)
Luque-Ramírez 2007
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Analysis 86.1. Comparison 86 OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) versus lifestyle
modification, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
inOCP group (standard de-
viation)
N = 10
Mean change from base-
line in lifestyle modification
group (standard deviation)
N = 8
Mean difference (95%CI; P
value)
Hoeger 2008 Testosterone (ng/dl) -28.50 (17.16) 0.60 (18.92) -29.10 995% CI -45.98 to -
12.22; P value = 0.0007)
Hoeger 2008 SHBG (nmol/L) 75.20 (57.57) 17.40 (13.86) 57.80 (95% CI 20.85 to 94.
75; P value = 0.002)
Analysis 87.1. Comparison 87 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus sibutramine
10 mg once a day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 14
Mean change from base-
line in sibutramine group
(standard deviation)
N = 12
Mean difference (95% CI;
P value)
Sabuncu 2003 Testosterone (ng/dl) -44.0 (17.62) -51.80 (16.58) 7.80 (95% CI -5.36 to 20.
96; P value = 0.25)
Sabuncu 2003 Free testosterone (ng/dl) -2.20 (0.61) -2.0 (0.61) -0.20 (95% CI -0.67 to 0.
27; P value = 0.40)
Sabuncu 2003 SHBG (nmol/L) 41.30 (31.30) 31.70 (18.63) 9.60 (95% CI -9.89 to 29.
09; P value = 0.33)
Sabuncu 2003 DHEAS (µg/dl) -59.30 (52.38) -52.70 (51.37) -6.60 (95% CI -46.57, to
33.37; P value = 0.75)
Analysis 88.1. Comparison 88 OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) versus finasteride
5 mg, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 21
Mean change from base-
line in finasteride group
(standard deviation)
N = 21
Mean difference (95% CI;
P value)
Sahin 1998 Free testosterone (pg/ml) -1.96 (1.17) 0.31 (1.38) -2.27 (95% CI -3.04 to -1.
50; P value < 0.001)
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Changes in androgen levels (Continued)
Sahin 1998 DHEAS (µgram/dl) -45 (68.25) -7 (98.92) -38.00 (95% CI -89.40 to
13.40; P value = 0.15)
Sahin 1998 SHBG (nmol/L) 144.25 (85.75) -1.66 (10.96) 145.91 995% CI 108.94 to
182.88; P value < 0.001)
Analysis 89.1. Comparison 89 OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) versus combined
contraceptive vaginal ring (ethinyl estradiol 15 µg + etonogestrel 1.2 mg), Outcome 1 Changes in androgen
levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in OCP group (stan-
dard deviation)
N = 19
Mean change from base-
line in vaginal contracep-
tive ring group (standard
deviation)
N = 18
Mean difference (95%
CI; P value)
Battaglia 2010 Androstenedione (nmol/L) -4.0 (1.97) -3.10 (1.98) -0.90 (95% CI -2.17 to 0.
37; P value = 0.17)
Battaglia 2010 Testosterone (nmol/L) -0.60 (0.42) -0.20 (0.32) -0.40 (95% CI -0.64 to -0.
16; P value = 0.001)
Battaglia 2010 SHBG (nmol/L) 127 (14.75) 108 (24.12) 19.00 (95% CI 6.03 to 31.
97; P value = 0.004)
Analysis 90.1. Comparison 90 Finasteride 5 mg versus spironolactone 100 mg, Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in finasteride group
(standard deviation)
N = 10Moghetti 2000; N
= 9 Wong 1995
Mean change from base-
line in spironolactone
group (standard devia-
tion)
N = 10Moghetti 2000; N
= 5 Wong 1995
Mean difference (95%
CI; P value)
Moghetti 2000 Free testosterone (pg/ml) 0.74 (0.83) -0.04 (0.59) 0.78 995% CI 0.15 to 1.
41; P value = 0.02)
Moghetti 2000 DHEAS (µgram/L) -301 (358.81) 159 (607.07) -460.00 (95% CI -897.07
to -22.93; P value = 0.04)
Moghetti 2000 Testosterone (nmol/L) 0.56 (0.34) -0.02 (0.42) 0.58 (95%CI0.25 to 0.91;
P value = 0.0007)
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Changes in androgen levels (Continued)
Moghetti 2000 Androstenedione (nmol/
L)
1.70 (2.58) 1.20 (4.56) 0.50 (95% CI -2.75, 3.75;
P value = 0.76)
Wong 1995 Testosterone (pmol/L) No change No significant increase at 6
months
Cannot be calculated
Wong 1995 DHT (pmol/L) No change Negligible decrease at 6
months
Cannot be calculated
Wong 1995 Androstenedione (pmol/
L)
No change No significant decrease at 6
months
Cannot be calculated
Wong 1995 DHEAS (nmol/L) No change No significant decrease at 6
months
Cannot be calculated
Analysis 91.1. Comparison 91 Flutamide 250 mg once to b.i.d. versus metformin 1275 mg to 1700 mg per
day, Outcome 1 Mean change from baseline in Ferriman-Gallwey score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 91 Flutamide 250 mg once to b.i.d. versus metformin 1275 mg to 1700 mg per day
Outcome: 1 Mean change from baseline in Ferriman-Gallwey score
Study or subgroup Favours flutamide Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Less than 12 month duration of study drug
Esmaeilzadeh 2010 20 -4.3 (2.43) 20 -2.8 (3.01) -1.50 [ -3.20, 0.20 ]
Ib ez 2002 10 -6.3 (2.47) 8 -5.6 (2.77) -0.70 [ -3.16, 1.76 ]
2 12 month duration of study drug
Gambineri 2006 17 -8.9 (5.53) 20 -2.6 (5.37) -6.30 [ -9.83, -2.77 ]
-10 -5 0 5 10
Favours flutamide Favours metformin
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Analysis 91.2. Comparison 91 Flutamide 250 mg once to b.i.d. versus metformin 1275 mg to 1700 mg per
day, Outcome 2 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in flutamide group
(standard deviation)
N = 20 Esmaeilzadeh
2010; N = 20 Gambineri
2006; N = 10 Ibáñez
2002
Mean change from base-
line in metformin group
(standard deviation)
N = 20 Esmaeilzadeh
2010; N = 20 Gambineri
2006; N = 8 Ibáñez 2002
Mean difference (95%
CI; P value)
Esmaeilzadeh 2010 Total testosterone (nmol/
L)
-0.24 (0.44) -0.32 (0.62) 0.08 (95% CI -0.25 to 0.
41; P value = 0.64)
Esmaeilzadeh 2010 Free testosterone (pmol/
L)
-0.62 (2.49) -0.44 (2.04) -0.18 (95% CI -1.59 to 1.
23; P value = 0.80)
Esmaeilzadeh 2010 DHEAS (µmol/L) -29.08 (143.79) -2.82 (77.21) -26.26 (95%CI -97.79 to
45.27; P value = 0.47)
Esmaeilzadeh 2010 SHBG (nmol/L) 5.67 (37.81) 1.65 (16.61) 4.02 (95% CI -14.08 to
22.12; P value = 0.66)
Gambineri 2006 Total testosterone (nmol/
L)
-0.22 (0.14) -0.15 (0.22) -0.07 (95% CI -0.19 to 0.
05; P value = 0.24)
Gambineri 2006 Androstenedione (nmol/
L)
-161 (100.24) -51 (103.72) -110.00 (95%CI -175.85
to -44.15; P value = 0.
001)
Gambineri 2006 DHEAS (µmol/ml) -1.40 (0.94) 0.10 (0.36) -1.50 (95% CI -1.97 to -
1.03; P value < 0.001)
Gambineri 2006 SHBG (nmol/L) 3.00 (6.79) 2.20 (7.69) 0.80 (95% CI -3.87 to 5.
47; P value = 0.74)
Ibáñez 2002 Testosterone (ng/dl) -31.00 (27.02) -67.00 (35.97) 36.00 (95% CI 5.97, 66.
03; P value = 0.02)
Ibáñez 2002 SHBG (µg/dl) 0.30 (0.20) 0.40 (0.18) -0.10 (95% CI -0.28, 0.
08; P value = 0.27)
Ibáñez 2002 Androstenedione (ng/dl) -40.00 (42.63) -42.00 (48.13) 2.00 (95% CI -40.55 to
44.55; P value = 0.93)
Ibáñez 2002 DHEAS (µg/dl) -4.00 (28.63) -44.00 (52.66) 40.00 (95% CI -0.58 to
80.58; P value = 0.05)
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Analysis 92.1. Comparison 92 Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d., Outcome
1 Number of adverse events.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 92 Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d.
Outcome: 1 Number of adverse events
Study or subgroup Finasteride Flutamide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fruzzetti 1999 0/15 0/15 Not estimable
Moghetti 2000 1/5 1/10 56.0 % 2.00 [ 0.16, 25.75 ]
Mu¨derris 2000 4/35 0/35 44.0 % 9.00 [ 0.50, 161.13 ]
Total (95% CI) 55 60 100.0 % 3.87 [ 0.57, 26.24 ]
Total events: 5 (Finasteride), 1 (Flutamide)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours finasteride Favours flutamide
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Analysis 92.2. Comparison 92 Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d., Outcome
2 Mean change from baseline in Ferriman-Gallwey score.
Review: Interventions for hirsutism (excluding laser and photoepilation therapy alone)
Comparison: 92 Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d.
Outcome: 2 Mean change from baseline in Ferriman-Gallwey score
Study or subgroup Finasteride Flutamide
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Falsetti 1999 55 -5.58 (1.43) 52 -9.2 (1.6) 3.62 [ 3.04, 4.20 ]
Fruzzetti 1999 14 -8.9 (5.55) 15 -9.9 (3.85) 1.00 [ -2.50, 4.50 ]
Moghetti 2000 10 -5.4 (2.6) 10 -6.4 (3.42) 1.00 [ -1.66, 3.66 ]
Mu¨derris 2000 35 -7.8 (3.66) 35 -13 (3.77) 5.20 [ 3.46, 6.94 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours finasteride Favours flutamide
Analysis 92.3. Comparison 92 Finasteride 5 mg once a day versus flutamide 250 mg once to b.i.d., Outcome
3 Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in finasteride group
(standard deviation)
N = 55 Falsetti 1999; N
= 14 Fruzzetti 1999; N =
10Moghetti 2000;N= 35
Müderris 2000
Mean change from base-
line in flutamide group
(standard deviation)
N = 52 Falsetti 1999; N
= 15 Fruzzetti 1999; N =
10Moghetti 2000;N= 35
Müderris 2000
Mean difference (95%
CI; P value)
Falsetti 1999 Testosterone (ng/ml) 0.36 (0.13) -0.04 (0.16) 0.40 (95%CI0.34 to 0.46;
P value < 0.001)
Falsetti 1999 Free testosterone (pg/ml) 0.24 (0.33) 0.02 (0.31) 0.22 (95%CI0.10 to 0.34;
P value = 0.004)
Falsetti 1999 Androstenedione (ng/ml) 0.24 (0.37) -0.20 (0.33) 0.44 (95%CI0.31 to 0.57;
P value < 0.001)
Falsetti 1999 DHEAS (µg/ml) -0.14 (0.53) -0.20 (0.51) 0.06 (95% CI -0.14 to 0.
26; P value = 0.55)
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Change in androgen levels (Continued)
Falsetti 1999 SHBG (nmol/L) -2.20 (3.79) -0.67 (4.17) -1.53 (95% CI -3.04 to -0.
02; P value = 0.05)
Falsetti 1999
Fruzzetti 1999 Testosterone (ng/ml) 0.30 (0.32) Authors state not signifi-
cantly changed
Cannot be calculated
Fruzzetti 1999 Free testosterone (ng/ml) 0.87 (1.15) -0.25 (1.27) 1.12 (95%CI0.24 to 2.00;
P value = 0.01)
Fruzzetti 1999 Androstenedione (ng/ml) Authors state unchanged Authors state not signifi-
cantly changed
Cannot be calculated
Fruzzetti 1999 DHEAS (µgram/ml) Authors state unchanged -0.38 (0.39) Cannot be calculated
Fruzzetti 1999 SHBG (ng/ml) Authors state unchanged -1.81 (3.04) Cannot be calculated
Fruzzetti 1999 Dihydrotestosterone (ng/
ml)
-0.39 (0.67) Authors state not signifi-
cantly changed
Cannot be calculated
Moghetti 2000 Testosterone (nmol/L) 0.56 (0.34) -0.05 (0.44) 0.61 (95%CI0.27 to 0.95;
P value = 0.0005)
Moghetti 2000 Free testosterone (pg/ml) 0.74 (0.83) -0.58 (0.90) 1.32 (95%CI0.56 to 2.08;
P value = 0.0007)
Moghetti 2000 Androstenedione (nmol/
L)
1.70 (2.58) -2.7 (3.36) 4.40 (95%CI1.77 to 7.03;
P value = 0.001)
Moghetti 2000 DHEAS (µgram/L) -301 (358.81) -613 (438.41) 312.00 (95% CI -39.13 to
663.13; P value = 0.08)
Moghetti 2000
Moghetti 2000
Müderris 2000 Testosterone (ng/dl) 6.00 (23.64) 1.20 (15.63) 4.80 (95% CI -4.59 to 14.
19; P value = 0.32)
Müderris 2000 Free testosterone (pg/ml) -0.50 (1.44) -0.40 (1.22) -0.10 (95% CI -0.73 to 0.
53; P value = 0.75)
Müderris 2000 Androstenedione (ng/ml) -0.30 (0.82) -0.40 (0.57) 0.10 (95% CI -0.23 to 0.
43; P value = 0.55)
Müderris 2000 DHEAS (ng/ml) -53.60 (89.37) -0.70 (36.89) -52.90 (95% CI -84.93 to
-20.87; P value = 0.001)
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Change in androgen levels (Continued)
Müderris 2000 SHBG (nmol/L) 8.90 (9.71) 0.70 (6.21) 8.20 (5%CI4.38 to 12.02;
P value < 0.001)
Müderris 2000
Analysis 93.1. Comparison 93 Metformin 850 mg b.i.d. versus lifestyle modification, Outcome 1 Changes in
androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in metformin group (stan-
dard deviation)
N = 6
Mean change from base-
line in lifestyle modification
group (standard deviation)
N = 8
Mean difference (95%CI; P
value)
Hoeger 2008 Testosterone (ng/dl) -1.60 (22.12) 0.60 (18.92) -2.20 (95% CI -24.23 to 19.
83; P value = 0.84)
Hoeger 2008 SHBG (nmol/L) -2.40 (13.37) 17.40 (13.86) -19.80 (95% CI -34.18 to -5.
42; P value = 0.007)
Analysis 94.1. Comparison 94 GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 35 µg +
norethindrone 1 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 11
Mean change from base-
line line in GnRH-A group
(standard deviation)
N = 11
Mean difference (95% CI;
P value)
Carr 1995 Testosterone (nmol/L) -1.20 (0.89) -1.70 (1.08) 0.50 (95%CI -0.33 to 1.33;
P value = 0.24)
Carr 1995 Free testosterone (pmol/L) -7.3 (5.82) -12.80 (6.85) 5.50 (95%CI0.19 to 10.81;
P value = 0.04)
Carr 1995 Androstenedione (nmol/L) -2.00 (1.40) -2.30 (1.41) 0.30 (95%CI -0.87 to 1.47;
P value = 0.62)
Carr 1995 DHEAS (µmol/L) -2.60 (4.97) -0.40 (1.60) -2.20 (95% CI -5.29 to 0.
89; P value = 0.16)
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Analysis 95.1. Comparison 95 GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 14
Mean change from base-
line in OCP group (stan-
dard deviation)
N = 31
Mean difference (95%CI;
P value)
Creatsas 1993 Testosterone (nmol/L) -0.40 (0.50) -0.60 (0.74) 0.20 (95% CI -0.17 to 0.
57; P value = 0.29)
Creatsas 1993 SHBG (nmol/L) 6.30 (8.31) 6.20 (9.36) 0.10 (95% CI -5.36 to 5.
56; P value = 0.97)
Creatsas 1993 Androstenedione (ng/ml) -0.70 (2.07) -0.90 (3.21) 0.20 (95% CI -1.37 to 1.
77; P value = 0.80)
Creatsas 1993 DHEAS (nmol/L) -0.70 (0.47) -0.40 (2.36) -0.30 (95% CI -1.17 to 0.
57; P value = 0.50)
Analysis 96.1. Comparison 96 GnRH-A 3.75 mg im every 28 days versus OCP (ethinyl estradiol 35 µg +
norethindrone 0.4 mg), Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 12
Mean change from base-
line in OCP group
(standard deviation)
N = 10
Mean difference (95%
CI; P value)
Elkind-Hirsch 1995 Testosterone (ng/dl) -53.50 (14.47) -29.40 (8.59) -24.10 (95%CI -33.87 to
-14.33; P value < 0.001)
Elkind-Hirsch 1995 Free testosterone (ng/dl) -2.10 (0.83) -1.30 (0.87) -0.80 (95% CI -1.52 to -
0.08; P value = 0.03)
Elkind-Hirsch 1995 SHBG (nmol/L) 0 (23.70) 116 (87.50) -116 (95% CI -171.85 to
-60.13; P value < 0.001)
Elkind-Hirsch 1995 DHEAS (µg/dl) Authors state ”no signifi-
cant difference“
Authors state ”no signifi-
cant difference“
Cannot be calculated
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Analysis 97.1. Comparison 97 GnRH-A 3.75 mg im every 28 days versus finasteride 5 mg per day, Outcome
1 Changes in androgen levels.
Changes in androgen levels
Study Androgen (units not pro-
vided)
Mean change from base-
line in GnRH-A group
(standard deviation)
N = 30
Mean change from base-
line in finasteride group
(standard deviation)
N = 30
Mean difference (95%CI;
P value)
Bayhan 2000 Total testosterone -0.30 (0.23) -0.60 (0.72) 0.30 (95%CI 0.03 to 0.57;
P value = 0.03)
Bayhan 2000 Free testosterone -0.70 (0.55) -0.90 (0.90) 0.20 (95% CI -0.18 to 0.
58; P value = 0.30)
Bayhan 2000 Androstenedione -0.90 (1.63) -0.40 (0.74) -0.50 (95% CI -1.14 to 0.
14; P value = 0.13)
Bayhan 2000 DHEAS -59 (69.02) 30 (84.29) -89.00 (95% CI -127.98 to
-50.02; P value < 0.001)
Bayhan 2000 SHBG 1.30 (0.42) 0.41 (0.45) 0.89 (95%CI 0.67 to 1.11;
P value < 0.001)
Analysis 98.1. Comparison 98 GnRH-A 3.6 mg im every 28 days versus metformin 850 mg b.i.d., Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in GnRH-A group
(standard deviation)
N = 20
Mean change from base-
line from baseline in met-
formin group (standard
deviation)
N = 22
Mean difference (95% CI;
P value)
Cicek 2003 Total testosterone (ng/dl) -25.9 (140.49) -4.80 (183.71) -21.10 (95% CI -119.51 to
77.31; P value = 0.67)
Cicek 2003 Free testosterone (pg/ml) -0.6 (6.38) -0.9 (7.66) 0.30 (95% CI -3.95 to 4.55;
P value = 0.89)
Cicek 2003 DHEAS (µg/dl) -72.4 (320.43) -54.5 (517.14) -17.90 (95% CI -275.62 to
239.82; P value = 0.89)
Cicek 2003 SHBG (nmol/l) 23.2 (117.31) 18.7 (83.06) 4.50 (95% CI -57.53 to 66.
53; P value = 0.89)
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Analysis 99.1. Comparison 99 Dexamethasone 0.37 mg per day compared to spironolactone 100 mg per
day, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in dexamethasone
group (standard devia-
tion)
N = 12
Mean change from base-
line in spironolac-
tone group (standard de-
viation)
N = 12
Mean difference (95%CI;
P value)
Carmina 1998 Testosterone (ng/dl) -60 (10.39) -12 (4.56) -48.00 (95% CI -54.42 to -
41.58; P value < 0.001)
Carmina 1998 Free testosterone (pg/ml) -3.10 (1.09) -0.40 (1.28) -2.70 (95% CI -3.65 to -1.
75; P value < 0.001)
Carmina 1998 DHEAS (µg/ml) -2.60 (0.84) 0.20 (1.09) -2.80 (95% CI -3.58 to -2.
02; P value < 0.001)
Analysis 100.1. Comparison 100 Spironolactone 25 mg b.i.d. versus metformin 500 mg b.i.d., Outcome 1
Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from baseline
in spironolactone group
(standard deviation)
N = 34
Mean change from baseline
in metformin group (stan-
dard deviation)
N = 35
Meandifference (95%CI; P
value)
Ganie 2004 Testosterone (nmol/L) -1.63 (0.76) -1.55 (1.04) -0.08 (95% CI -0.51 to 0.35;
P value = 0.71)
Ganie 2004 DHEAS (µmol/L) -0.70 (1.66) -0.90 (1.99) 0.20 (95%CI -0.66 to 1.06;
P value = 0.65)
Analysis 101.1. Comparison 101 Clomiphene 50 mg once a day for 5 days starting at day 3 of the cycle
versus metformin 1000 mg b.i.d., Outcome 1 Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from baseline
in clomiphene group (stan-
dard deviation)
N = 165
Mean change from baseline
in metformin only group
(standard deviation)
N = 172
Mean difference (95% CI; P
value)
Roth 2012 Testosterone (ng/dl) -2.6 (31.7) -7.4 (27.6) 4.80 (95% CI -1.56 to 11.16;
P value = 0.14)
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Change in androgen levels (Continued)
Roth 2012 SHBG (nmol/L) 13.4 (16.0) 2.7 (13.5) 10.70 (95% CI 7.53 to 13.87;
P value < 0.001)
Analysis 102.1. Comparison 102 Acarbose 150 mg to 300 mg per day versus placebo, Outcome 1 Changes
in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in acarbose group
(standard deviation)
N = 15 Ciotta 2001; N =
13 Penna 2005
Mean change from base-
line in placebo group
(standard deviation)
N = 15 Ciotta 2001; N =
14 Penna 2005
Mean difference (95% CI;
P value)
Ciotta 2001 Testosterone (nmol/L) -1.46 (0.33) -0.10 (0.24) -1.36 (5% CI -1.57 to -1.
15; P value < 0.001)
Ciotta 2001 Androstenedione (nmol/L) -2.34 (1.00) -1.60 (1.06) -0.74 (95% CI-1.48 to -0.
00; P value < 0.05)
Ciotta 2001 DHEAS (µmol/ L) -0.32 (1.01) 0.36 (0.95) -0.68 (95% CI -1.38 to 0.
02; P value = 0.06)
Ciotta 2001 SHBG (nmol/L) 13.60 (5.92) -0.40 (4.90) 14.00 (5% CI 10.11 to 17.
89; P value < 0.001)
Penna 2005 Testosterone (ng/dl) -7.30 (13.99) 3.21(20.72) -10.51 (95% CI -23.76 to
2.74; P value = 0.12)
Penna 2005 Androstenedione (ng/dl) -1.34 (38.38) 4.30 (65.53) -5.64 (95% CI -45.81 to
34.53; P value = 0.78)
Penna 2005 SHBG (nmol/L) 2.84 (4.96) 0.36 (6.03) 2.48 (95% CI -1.67 to 6.
63; P value = 0.24)
Penna 2005
Analysis 103.1. Comparison 103 Spearmint tea b.i.d. versus camomile tea b.i.d., Outcome 1 Change in
androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in spearmint tea group
(standard deviation)
N = 21
Mean change from base-
line in camomile tea group
(standard deviation)
N = 20
Mean difference (95% CI;
P value)
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Change in androgen levels (Continued)
Grant 2010 Free testosterone (pm/ml) -1.48 (1.60) -0.49 (1.81) -0.99 (95% CI -2.04 to 0.
06; P value = 0.06)
Grant 2010 Testosterone (ng/ml) -0.19 (0.24) -0.07 (0.30) -0.12 (95% CI -0.29 to 0.
05; P value = 0.16)
Grant 2010 DHEAS (µg/ml) -1.20 (54.00) 3.80 (53.21) -5.00 (95%CI -37.82 to 27.
82; P value = 0.77)
Analysis 104.1. Comparison 104 Low-frequency electro-acupuncture versus exercise 3 times a week for 30
minutes, Outcome 1 Changes in androgen levels.
Changes in androgen levels
Study Androgen Mean change from base-
line in acupuncture group
(standard deviation)
N = 24
Mean change from base-
line in exercise group
(standard deviation)
N = 22
Mean difference (95% CI;
P value)
Jedel 2011 Testosterone (ng/ml) -0.10 (0.14) -0.04 (0.14) -0.06 (95% CI -0.14 to 0.
02; P value = 0.15)
Jedel 2011 Free testosterone (pg/ml) -2.21 (2.99) -1.24 (2.66) -0.97 (95% CI -2.60 to 0.
66; P value = 0.24)
Jedel 2011 Dihydrotestosterone (pg/
ml)
-23.2 (41.2) -9.30 (34.2) -13.90 (95%CI -35.72 to 7.
92; P value = 0.21)
Jedel 2011 DHEAS (µg/ml) -0.29 (0.56) -0.24 (0.55) -0.05 (95% CI -0.37 to 0.
27; P value = 0.76)
Jedel 2011 SHBG (nmol/L) 3.52 (11.8) 7.30 (22.0) -3.78 (95% CI -14.11 to 6.
55; P value = 0.47)
Analysis 105.1. Comparison 105 Low-frequency electro-acupuncture (14 treatments) versus no treatment,
Outcome 1 Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in acupuncture group
(standard deviation)
N = 24
Mean change from base-
line in control (no inter-
vention) group (standard
deviation)
N = 13
Mean difference (95% CI;
P value)
Jedel 2011 Testosterone (ng/ml) -0.10 (0.14) 0.01 (0.09) -0.11 (95% CI -0.18 to -0.
04; P value = 0.004)
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Change in androgen levels (Continued)
Jedel 2011 Free testosterone (pg/ml) -2.21 (2.99) 0.03 (1.71) -2.24 (95% CI -3.75 to -0.
73; P value = 0.004)
Jedel 2011 Dihydrotestosterone (pg/
ml)
-23.2 (41.2) 4.48 (31.9) -27.68 (95% CI -51.60 to -
3.76; P value = 0.02)
Jedel 2011 DHEAS (µg/ml) -0.29 (0.56) 0.66 (3.40) -0.95 (95% CI -2.81 to 0.
91; P value = 0.32)
Jedel 2011 SHBG (nmol/L) 3.52 (11.8) 3.33 (12.7) 0.19 (95%CI -8.17 to 8.55;
P value = 0.96)
Analysis 106.1. Comparison 106 Atorvastatin 20 mg once a day versus simvastatin 20 mg once a day,
Outcome 1 Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in atorvastatin group
(standard deviation)
N = 32
Mean change from base-
line in simvastatin group
(standard deviation)
N = 32
Mean difference (95% CI;
P value)
Kaya 2010 Total testosterone (ng/ml) -0.16 (1.24) -0.27 (1.56) 0.11 (95% CI -0.58 to 0.80;
P value = 0.75)
Kaya 2010 DHEAS (µg/dl) -4.40 (291.84) 4.80 (260.57) -9.20 (95% CI -144.75 to
126.35; P value = 0.89)
Analysis 107.1. Comparison 107 Atorvastatin 20 mg once a day versus placebo once a day, Outcome 1
Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in ator-
vastatin group (standard
deviation)
N = 19
Mean change from base-
line in simvastatin group
(standard deviation)
N = 18
Mean difference (95%
CI; P value)
Sathyapalan 2012 DHEAS (µmol/L) -1.10 (0.61) -0.30 (0.77) -0.80 (95% CI -1.25 to -
0.35; P value = 0.0005)
Sathyapalan 2012 Androstenedione (nmol/
L)
-1.00 (0.48) 0.70 (2.30) -1.70 (95% CI -2.78 to -
0.62; P value = 0.002)
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Analysis 108.1. Comparison 108 Bromocriptine 2.5 mg three times a day versus placebo, Outcome 1
Change in androgen levels.
Change in androgen levels
Study Androgen Mean change from base-
line in bromocrip-
tine group (standard de-
viation)
N = 7
Mean change from base-
line in placebo group
(standard deviation)
N = 9
Mean difference (95%
CI; P value)
Murdoch 1987 Testosterone (nmol/L) -0.9 (1.32) -0.3 (0.30) -0.60 (95% CI -1.60 to 0.
40; P value = 0.24)
Murdoch 1987 Androstenedione (nmol/
L)
-10.2 (8.20) -7.7 (12.00) -2.50 (95%CI -12.42 to 7.
42; P value = 0.62)
Murdoch 1987 SHBG (nmol/L) 4 (13.23) 2 (9.00) 2.00 (95% CI -9.43 to 13.
43; P value = 0.73)
A D D I T I O N A L T A B L E S
Table 1. Glossary of unfamiliar terms
Term Definition
Acanthosis nigricans Skin disorder in which there is darker, thick, velvety skin in body
folds and creases. It is often found in people with obesity-related
diabetes
Alopecia Visibly-reduced hair density (can be diffuse, patchy, or patterned)
Anagen hair Active growing hair
Anagen phase Active growth phase of hair follicles (2 to 7 years)
Anovulation An anovulatory cycle is a menstrual cycle during which the ovaries
do not release an oocyte. Therefore, ovulation does not take place
Androgen The generic term for any natural or synthetic compound, usually
a steroid hormone, which stimulates or controls the development
and maintenance of male characteristics by binding to androgen
receptors
BMI (body mass index) Weight in kilograms/height in metres
Box-and-whisker plot Statistics assumes that your data points (the numbers in your list)
are clustered around some central value. The ’box’ in the box-and-
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Table 1. Glossary of unfamiliar terms (Continued)
whisker plot contains, and thereby highlights, the middle half of
these data points. Boxplotsmay also have lines extending vertically
from the boxes (whiskers) indicating variability outside the upper
and lower quartiles, hence the terms box-and-whisker plot
Catagen phase Involution phase of the hair follicle
Effluvium Loss of hair from the scalp or body
Galactorrhoea Spontaneous flowofmilk from the breast, unassociatedwith child-
birth or nursing
Glabrous skin External skin that is naturally hairless. It is found on the palmar
surfaces of hands and fingers, soles of feet, lips, labia minora (inner
vaginal lips), and glans penis
Gonadotropin-releasing hormone analogues (GnRH-ana-
logues)
An analogue that activates the GnRH receptor. Chronic use in-
hibits secretion of follicle stimulating hormone and luteinising
hormone by the pituitary gland resulting in decreased production
of androgens by the ovaries
Hepatotoxic Chemical-driven liver damage
Hyperandrogenism Condition characterised by excessive production or secretion of
androgens, or both
Hyperprolactinaemia The presence of abnormally high levels of prolactin in the blood.
Hyperprolactinaemiamay cause production and spontaneous flow
of breast milk and disruptions in the normal menstrual period in
women
Hypertrichosis Excessive (terminal and vellus) hair in non-androgen-dependent
body sites, which varies in people with different ethnic back-
grounds without any pathological findings
Hirsutism Excessive hairiness on women in those parts of the body where
terminal hair does not normally occur or is minimal - for example,
beard or chest hair
Insulin resistance Condition where the natural hormone insulin becomes less effec-
tive at lowering blood sugars
Metrorrhagia Irregular bleeding between menstrual periods; menometrorrhagia
is prolonged or excessive bleeding from the uterus
Oligo-ovulation Infrequent, irregular ovulation
Postpartum Period after birth
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Table 1. Glossary of unfamiliar terms (Continued)
5α-reductase An enzyme that converts testosterone, themale sex hormone, into
the more potent hormone, dihydrotestosterone
Seborrhoea Greasy skin caused by excess sebum
SHBG Sex hormone-binding globulin
Telogen hair Club hair or resting hair, prior to expulsion of hair canal by new
anagen hair
Terminal hair Thicker, longer, coarse pigmented hair
Vellus hair Short, fine, light-coloured, andbarely noticeable hair that develops
on most of a person’s body from childhood
Virilisation The abnormal development of male sexual characteristics in a
woman
Table 2. Interventions of the included studies
Lifestyle measures
Low carbohydrate diet Ghosh 2008
Low caloric diet Pasquali 1986; Pasquali 2000
Low glycaemic index diet Ghosh 2008
Moderate-intensity exercise programme Brown 2009B; Jedel 2011; Stener-Victorin 2009; Vigorito 2007
Lifestyle modification (advice on diet/exercise/behaviour) Hoeger 2004; Hoeger 2008
Topical therapies
Eflornithine HCl 13.9% cream Jackson 2007; Wolf 2007
Finasteride 0.25% or 0.5% cream Iraji 2005; Lucas 2001
Fennel 1% and 2% cream Javidnia 2003
Long-pulsed alexandrite laser + eflornithine 13.9% cream Hamzavi 2007; Smith 2006
Oral contraceptive pills
Ethinyl estradiol 35 µg + ethynodiol diacetate 1 mg Azziz 1995
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Table 2. Interventions of the included studies (Continued)
Ethinyl estradiol 20 µg + desogestrel 0.15 mg Banaszewska 2007; Farina 2006
Ethinyl estradiol 30 µg + desogestrel 0.15 mg Bhattacharya 2012; Breitkopf 2003;Creatsas 2000; Erkkola1990;
Hoeger 2008; Kriplani 2010; Levrier 1988; Mastorakos 2002;
Mastorakos 2006; Porcile 1991; Porcile 1991B; Sanam 2011;
Sobbrio 1990
Ethinyl estradiol 50 µg + desogestrel 0.15 mg Porcile 1991
Ethinyl estradiol 30 µg + levonorgestrel 0.15 mg Breitkopf 2003; Sanam 2011
Ethinyl estradiol 35 µg + cyproterone acetate 2 mg Barth 1991; Batukan 2007; Belisle 1986 Bhattacharya 2012;
Creatsas 2000; Elter 2002; Erkkola 1990; Harborne 2003; Ibáñez
2012; Lemay 2006; Luque-Ramírez 2007; Mastorakos 2002;
Mastorakos 2006; Meyer 2007; Moltz 1984; Morin-Papunen
2000; Morin-Papunen 2003; Porcile 1991; Sabuncu 2003; Saeed
1993; Sahin 1998; Taheripanah 2010; Tartagni 2000; van Vloten
2002; Vegetti 1996; Vermeulen 1988; Wang 2012
Ethinyl estradiol 50 µg + cyproterone acetate 2 mg Creatsas 1993; Holdaway 1985; Lachnit-Fixson 1977; Levrier
1988; Spuy 1995; Vermeulen 1988
Ethinyl estradiol 30 µg + drospirenone 3 mg Battaglia 2010; Batukan 2007; Bhattacharya 2012; Farina 2006;
Kriplani 2010; Lello 2008; Oner 2011; van Vloten 2002; Wang
2012
Ethinyl estradiol 20 µg + drospirenone 3 mg Oner 2011; Fruzzetti 2010
Triphasic OCP (30, 40, and 30 µg ethinyl estradiol and 50, 75,
and 125 µg levonorgestrel)
Calaf 2007
Ethinyl estradiol 35 µg + norethindrone 1 mg Carr 1995; Heiner 1995
Ethinyl estradiol 35 µg + norgestimate 0.25 mg Allen 2005; Cibula 2005
Ethinyl estradiol 30 µg + chlormadinone acetate 2 mg Kaiser 1984; Lello 2008
Ethinyl estradiol 35 µg + norethindrone 0.4 mg Elkind-Hirsch 1995
Norethisterone 1 mg and mestranol 50 µg Kaiser 1984
Ethinyl estradiol 50 µg + D-norgestrel 0.25 mg Lachnit-Fixson 1977
Ethinyl estradiol 30 µg + gestodene 75 µg Sobbrio 1990
Antiandrogens
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Table 2. Interventions of the included studies (Continued)
Cyproterone acetate Barth 1991; Lumachi 2003; Schmidt 1987
Flutamide Erenus 1994; Esmaeilzadeh 2010; Falsetti 1999; Fruzzetti 1999;
Gambineri 2006; Ibáñez 2002; Moghetti 2000; Müderris 2000;
Paoletti 1999; Venturoli 1999
Ketoconazole Akalin 1991; Cedeno 1990; Venturoli 1999
Spironolactone Carmina 1998; Erenus 1994; Erenus 1997; Ganie 2004; Lumachi
2003;McLellan 1989;Moghetti 2000; Prezelj 1989; Spritzer 2000
5α reductase inhibitors
Finasteride Al-Khawajah 1998; Bayhan 2000; Bayram 2002: Beigi 2004;
Ciotta 1995; Erenus 1997; Falsetti 1999; Fruzzetti 1999; Lakryc
2003; Lumachi 2003; Moghetti 2000; Müderris 2000; Sahin
1998; Tartagni 2004; Venturoli 1999
Insulin sensitising agents
Metformin Ahmad 2008; Allen 2005; Ashrafinia 2009; Banaszewska 2011;
Cicek 2003; Crave 1995; Eisenhardt 2006; Esmaeilzadeh 2010;
Gambineri 2006; Ganie 2004; Harborne 2003; Hoeger 2004;
Hoeger 2008; Ibáñez 2002; Ibáñez 2011B; Kelly 2002; Kjøtrød
2004; Ladson 2011; Luque-Ramírez 2007; Maciel 2004; Meyer
2007; Moghetti 2000B; Morin-Papunen 2000; Morin-Papunen
2003; Navali 2012; Onalan 2005; Oner 2011B; Ortega-González
2005; Otta 2010; Roth 2012
Pioglitazone Aigner 2009; Brettenthaler 2004; Navali 2012; Ortega-González
2005
Rosiglitazone Ahmad 2008; Dereli 2005; Lam 2011; Lemay 2006; Rautio 2005
Troglitazone Azziz 2001
Gonadotropin-releasing analogues
GnRH analogue (leuprolide) Azziz 1995; Bayhan 2000; Carr 1995; Elkind-Hirsch 1995;
Falsetti 1992; Falsetti 1994; Falsetti 1994B; Rittmaster 1990
GnRH analogue (goserelin) Cicek 2003; Tiitinen 1994
GnRH analogue (triptorelin) Carmina 1994; De Leo 2000
GnRH analogue (nafarelin nasal spray) Heiner 1995
Other therapies
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Acarbose Ciotta 2001; Penna 2005
Clomiphene citrate 50 to 100 mg/day on day 3 to 7 Elnashar 2006; Roth 2012
Combined contraceptive vaginal ring (15 µg ethinyl estradiol +
120 µg etonogestrel)
Battaglia 2010
Ovarian diathermy Ashrafinia 2009; Farquhar 2002
Ultrasound-guided transvaginal needle ovarian drilling Badawy 2009b
Laparoscopic electrosurgery ovarian drilling Badawy 2009b
Atorvastatin Kaya 2010; Sathyapalan 2012
Simvastatin Banaszewska 2007; Banaszewska 2011; Kaya 2010
Dexamethasone Carmina 1998
Prednisone 100 to 200 µg/kg Rittmaster 1988
Myo-inositol Ciotta 2012
D-chiro-inositol Ciotta 2012; Ciotta 2012B
D-Tr-6-LHRH Creatsas 1993
Camomile tea Grant 2010
Spearmint tea Grant 2010
Electro acupuncture Jedel 2011; Stener-Victorin 2009
Bromocriptine Murdoch 1987
Cimetidine Lissak 1989
N-acetyl-cysteine Oner 2011B
Octreotide-LAR Gambineri 2005
Sibutramine Sabuncu 2003
Combination therapies
Hypocaloric diet + cyproterone acetate 50 mg/day (10 days) +
ethinyl estradiol 50 µg (21 days)
Pasquali 1986
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Hypocaloric diet (1200 to 1400 kcal/day) + metformin Pasquali 2000
Diet 1200 kcal + 6-D tryptophane luteinizing hormone-releasing
hormone
Couzinet 1986
Life style modification + metformin Hoeger 2004
Clomiphene citrate + dexamethasone 2 mg/day on day 3 to 12 Elnashar 2006
Dexamethasone + spironolactone Carmina 1998; Prezelj 1989
Simvastatin + metformin Banaszewska 2011
Pioglitazone + flutamide + metformin Ibáñez 2012
Flutamide + metformin Gambineri 2006; Ibáñez 2002; Ibáñez 2003
Pioglitazone + transdermal contraceptive (ethinyl estradiol 600 µg
+ norelgestromin 6 mg) + metformin + flutamide
Ibáñez 2009
Transdermal contraceptive (ethinyl estradiol 600 µg + norelge-
stromin 6 mg) + metformin + flutamide
Ibáñez 2009
OCP (ethinyl estradiol 35 µg + norgestimate 250 µg) + met-
formin
Cibula 2005
OCP (ethinyl estradiol 35µg + cyproterone acetate 2mg) + cypro-
terone acetate (variable dose)
Barth 1991; Belisle 1986; Erenus 1996; Kelekci 2012;Moltz 1984
OCP (ethinyl estradiol 0.01 mg/day for 10 days, 0.02 mg/day for
the next 11 days and 7 ’pause’ days) + cyproterone acetate
Venturoli 1998
OCP (ethinyl estradiol 50µg + cyproterone acetate 2mg) + cypro-
terone acetate (variable dose)
Holdaway 1985; Huber 1985
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + sibu-
tramine
Sabuncu 2003
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) +
spironolactone
Kriplani 2009
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + fi-
nasteride
Kriplani 2009; Tartagni 2000
OCP (ethinyl estradiol 35 µg + cyproterone acetate 2 mg) + met-
formin
Elter 2002
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OCP (ethinyl estradiol 30 µg + desogestrel 0.15 mg) + spirono-
lactone
Erenus 1996
OCP (ethinyl estradiol 20 µg + drospirenone 3 mg) + metformin Fruzzetti 2010
OCP (ethinyl estradiol 20/30 µg + drospirenone 3 mg) + cypro-
terone acetate
Fruzzetti 2010; Kelekci 2012
OCP (ethinyl estradiol 30 µg + drospirenone 3 mg) + spironolac-
tone
Kelekci 2012
OCP (ethinyl estradiol 20 µg + levonorgestrel 0.1 mg) + spirono-
lactone
Meyer 2007
OCP (ethinyl estradiol 35 µg + norethisterone 0.5 mg) + spirono-
lactone
Dixon 1991
Triphasic OCP + spironolactone 100 mg/day Cusan 1994; O’Brien 1991
Triphasic OCP + flutamide Calaf 2007; Cusan 1994; Pazos 1999
Triphasic OCP + cyproterone acetate Pazos 1999; Venturoli 1998; Venturoli 1999
Cyproterone acetate 50 mg + estradiol valerate 2 mg Consoli 1994; Vexiau 1995
Cyproterone acetate 25 mg + ethinyl estradiol 20 µg Beigi 2004; Fruzzetti 1999
Cyproterone acetate 50 mg + transdermal estradiol 50 mg Consoli 1994; Vexiau 1995
Cyproterone acetate 50 to 100 mg + ethinyl estradiol 30 to 35 µg Dixon 1991; O’Brien 1991; Spritzer 2000
Cyproterone acetate 50 mg + 1200 kcal diet Couzinet 1986
GnRH-A (triptorelin) + oestrogens Carmina 1994
GnRH-A (leuprolide) +OCP (ethinyl estradiol 35µg + norethin-
drone 1 mg)
Carr 1995
GnRH-A (goserelin) implant + oestrogen-progestin replacement Tiitinen 1994
GnRH-A (goserelin) + OCP (ethinyl estradiol 35 µg + cypro-
terone acetate 2 mg)
Vegetti 1996
GnRH analogue (triptorelin) + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg)
De Leo 2000
GnRH analogue (goserelin) + OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg)
Spuy 1995
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GnRH analogue (triptorelin) + flutamide 250 mg De Leo 2000
GnRH analogue (leuprolide) + OCP (ethinyl estradiol 35 µg +
norethindrone 0.4 mg)
Elkind-Hirsch 1995
GnRH analogue (leuprolide) + OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg)
Falsetti 1992; Falsetti 1994; Falsetti 1994B
GnRH analogue (leuprolide) + dexamethasone Rittmaster 1990
GnRH analogue (triptorelin) + triphasic OCP Pazos 1999
Nafarelin nasal spray 400 µg b.i.d. + OCP (norethindrone 1 mg
+ ethinyl estradiol)
Heiner 1995
Clomiphene citrate + metformin Roth 2012; Zheng 2005
Clomiphene citrate 100 mg/day on day 3 to 7 + dexamethasone
2 mg/day on day 3 to 12
Elnashar 2006
Clomiphene citrate + rosiglitazone Zheng 2005
3 cycles of urinary gonadotropins or recombinant follicle-stimu-
lating hormone
Farquhar 2002
b.i.d.: twice a day
GnRH: gonadotropin-releasing hormone
OCP: oral contraceptive pill
Table 3. Included studies with no usable or irretrievable data
Study ID Interventions and comparisons N Comments
Akalin 1991 Ketoconazole 600 mg versus
placebo
11 No separate data for each of the 2 treatment periods (cross-over
design), no wash-out period
Brown 2009B Moderate-intensity exercise pro-
gramme versus
no change in lifestyle
37 None of our outcomes were assessed
Cibula 2005 OCP (ethinyl estradiol 35 µg/
norgestimate 250µg) versus OCP
(ethinyl estradiol 35 µg/norgesti-
mate 250µg) + metformin 1500
mg/day
30 Unclear how many women with PCOS were hirsute
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Consoli 1994 Cyproterone acetate 50 mg +
estradiol valerate 2 mg per os ver-
sus cyproterone acetate 50 mg +
transdermal estradiol 50 mg
67 No separate data for women with hirsutism
Couzinet 1986 Cyproterone acetate versus 6-D
tryptophane LHRH
10 Cross-over design, no separate data at end of first period, nor
baseline data for second period
Crave 1995 Metformin versus placebo 24 Unclear how many women in each treatment arm
Creatsas 2000 OCP (desogestrel 0.15 mg +
ethinyl estradiol 30 µg) versus
OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg)
24 No end data for F-G score, PI did not reply, no usable data
Elnashar 2006 Clomiphene citrate + dexametha-
sone versus clomiphene citrate +
placebo
80 No separate data for women with hirsutism
Erenus 1997 Finasteride versus spironolactone 40 60% drop-outs
Erkkola 1990 Cyproterone acetate 2 mg +
ethinyl estradiol 35µg versus des-
ogestrel 0.150 mg + ethinyl estra-
diol 0.03 mg
162 No separate data for women with hirsutism
Farina 2006 OCP (ethinyl estradiol 30 µg +
drospirenone 3 mg) versus OCP
(ethinyl estradiol 40 to 30 µg +
desogestrel 25 to 125 µg)
120 Inconsistent and incomplete reporting of outcomes data across
intervention groups. No reliable or usable data
Farquhar 2002 Laparoscopic ovarian diathermy
versus gonadotropins
50 No separate data for womenwith hirsutism, only one secondary
outcome of our review was addressed (ovulation)
Gambineri 2005 Octreotide LAR versus placebo 20 No separate data for women with hirsutism
Ghosh 2008 Low carbohydrate diet for 6
months versus low glycaemic in-
dex diet for 6 months
24 Abstract, limited data, unclear how many women were hirsute
Holdaway 1985 Maintenance therapy with OCP
(including 2 mg cyproterone ac-
etate) + 25 mg cyproterone ac-
etate versus OCP (including 2 mg
cyproterone acetate) + placebo
35 No wash-out period after first 9 months, thereafter cross-over
design, with no wash-out period. No separate data for baseline
and end of treatment period for each of the 3 time periods were
reported
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Huber 1985 Cyproterone acetate 300 mg im +
OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg) versus
cyproterone acetate 100 mg orally
for 10 days + OCP (ethinyl estra-
diol 50 µg + cyproterone acetate
2 mg)
10 Abstract. Limited data reported. Unclear if there were 2 groups
of 5
Ibáñez 2003 Flutamide +metformin versus flu-
tamide +metformin, only starting
at different time points
30 Intervention and comparator were identical, participants ”ran-
domised to“ timing of start of treatment
Ibáñez 2011B Metformin versus metformin 38 Intervention and comparator were identical, participants ”ran-
domised to“ timing of start of treatment
Kaiser 1984 OCP (combination of ethyl estra-
diol and chlormadinone acetate)
versus OCP (1 mg norethisterone
and 50 µg mestranol)
80 Paper describes 2 studies. In the first study, all participants re-
ceive the intervention, in the 2nd study participants are ran-
domised. No wash-out period between the 2 studies. Unclear
how many women were hirsute
Kelly 2002 Metformin versus placebo 16 No end of first phase data no baseline data for second phase
Kjøtrød 2004 Metformin versus placebo 73 Only 37% of women were hirsute and no separate data for
those. Furthermore, none of our outcomes were assessed
Lachnit-Fixon 1977 OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg) versus
OCP (ethinyl estradiol 50 µg + 0.
25 mg D-norgestrel)
88 Unclear howmanywomenwere hirsute andno exact data on the
effect on hirsutism (only no difference between the treatment
groups)
Ladson 2011 Metformin versus placebo 114 Drop-out rate > 40% (67%)
Levrier 1988 OCP (ethinyl estradiol 30 µg
+ 150 µg desogestrel) versus
(ethinyl estradiol 50 µg + 2 mg
cyproterone acetate)
69 Only few of the women had hirsutism, unclear how many in
each group as only several locations are provided and not num-
ber of participants
Lemay 2006 Rosiglitazone versus
OCP (ethinyl estradiol 35 µg + 2
mg CPA)
28 Drop-outs in OCP arm > 40% (46.2%)
Mc Lellan 1989 Spironolactone versus placebo 38 Drop-outs > 40%
Meyer 2007 Metformin versus OCP (ethinyl
estradiol 35 µg + 2 mg CPA) ver-
susOCP (ethinyl estradiol 30µg+
levonorgestrel 100 µg) + spirono-
lactone 50 mg
110 Unclear how many women with PCOS were hirsute, the mean
hirsutism score was only > 8 in the metformin group
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Moltz 1984 OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2mg) +10mg
cyproterone acetate versus OCP
(ethinyl estradiol 50 µg + cypro-
terone acetate 2 mg)
164 Unclear how many dropped out in control group, unclear how
many were hirsute in control group. Mainly data are reported
on the OCP + CPA group, and hardly any data on control
group
Morin-Papunen 2000 OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) versus
metformin
32 Drop-outs 44%
Morin-Papunen 2003 OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) versus
metformin
17 No separate data on women that were hirsute, means of Fer-
riman-Gallwey score in both groups were below threshold for
hirsutism (Ferriman-Gallwey score > 8)
Oner 2011B Metformin versus N-acetyl-cys-
teine
100 Imbalance in losses to follow-up with 40% losses in metformin
arm and 10% in the N-acetyl-cysteine arm
Ortega-González 2005 Pioglitazone versus metformin 57 Drop-outs in one arm 43%
Paoletti 1999 Flutamide versus placebo 22 No separate Ferriman-Gallwey scores per arm, only per group of
women with idiopathic hirsutism and per women with PCOS,
and the only other outcome that matched our inclusion criteria
was adverse events, which was not reported
Pasquali 1986 Hypocaloric diet + cyproterone
acetate/ethinyl estradiol versus
hypocaloric diet
14 Unclear how many women with PCOS were hirsute
Pasquali 2000 Hypocaloric diet + metformin
versus hypocaloric diet + placebo
40 13/40 were hirsute, no separate data on hirsute women
Rittmaster 1988 Prednisone every day versus pred-
nisone every other day
8 No wash-out period between treatment schedules, no separate
end data/baseline data at 4 months, no data on hirsutism score
Rittmaster 1990 Leuprolide + dexamethasone ver-
sus leuprolide + placebo
20 No wash-out phase. No baseline data for second phase per
treatment arm. Data are provided for idiopathic hirsutism and
PCOS, but not clear per treatment arm. Protocol deviation bi-
asing therapeutic comparisons in addition to inconsistency and
incompleteness in outcome reporting did not permit a clear
analysis and interpretation of results
Sanam 2011 OCP (ethinyl estradiol 30 µg +
desogestrel 150 µg) versus OCP
(ethinyl estradiol 30 µg + lev-
onorgestrel 150 µg)
100 The mean of the F-G score as reported (between 2 and 3) does
not match the recognised criteria for hirsutism (should be > 8;
Hatch 1981). No separate data for hirsute women
Schmidt 1987 Cyproterone acetate im versus
cyproterone acetate orally
20 Inconsistent data reporting, lack of clarity about missing out-
come data and about withdrawals and losses
578Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Included studies with no usable or irretrievable data (Continued)
Spuy 1995 OCP (cypro-
terone acetate/ethinyl estradiol)
versus OCP (cyproterone acetate/
ethinyl estradiol) +GnRHagonist
analogue
34 Abstract from conference proceedings, limited data reported
Stener-Victorin 2009 Low-frequency electro acupunc-
ture versus physical exercise versus
untreated control
84 Only data reported on 20/84 participants (24%)
Unfer 2000 Ethinyl estradiol 20 µg/day for 3
weeks + the first 10 days cypro-
terone acetate 12.5 mg/day versus
flutamide
40 Abstract from conference proceedings, limited data reported
van Vloten 2002 OCP (ethinyl estradiol 30 µg +
3 mg drospirenone) versus OCP
(OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg)
128 Few hirsute women included, no separate data for hirsute
women
Venturoli 1999 Flutamide versus finasteride ver-
sus ketoconazole versus OCP
(ethinyl estradiol 0.01 mg/day for
the 1st week, 0.02 mg/day for the
2nd week, 0.01 mg/day for the
3rd week and 7 ’pause’ days) +
cyproterone acetate 12.5 mg/day
for the first 10 days
66 Women with nonclassic adrenal hyperplasia included, no sep-
arate data for women with PCOS and idiopathic hirsutism
Vermeulen 1988 OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) versus
OCP (ethinyl estradiol 50 µg +
cyproterone acetate 2 mg)
30 Unclear how many were hirsute, no separate data for hirsute
women
Vexiau 1995 Cyproterone acetate with 17β
estradiol by transdermal patch
versus cyproterone acetate with
17β estradiol valerate orally
65 Unclear how many were hirsute, no separate data for hirsute
women, and none of our outcomes are assessed
Visnovský 2010 OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) ver-
sus OCP (ethinyl estradiol 30
µg + dienogest 2 mg) versus
OCP (ethinyl estradiol 30 µg +
drospirenone 3 mg)
90 54/90 were hirsute, no separate data for hirsute women
Wang 2012 OCP (ethinyl estradiol 35 µg +
cyproterone acetate 2 mg) versus
OCP (ethinyl estradiol 30 µg +
110 abstract from conference proceedings, limited data reported
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drospirenone 3 mg)
CPA: cyproterone acetate
F-G score: Ferriman-Gallwey score
GnRH: gonadotropin-releasing hormone
im: intramuscular
OCP: oral contraceptive pill
PCOS: polycystic ovary syndrome
per os: orally
PI: principal investigator
Table 4. Contact with investigators
Study ID Response Additional Comment
Ahmad 2008 Email:
jamalahmad11@rediffmail.
com (sequence generation and
concealment)
10-3-13, 27-3-2013, 30-4-
2013,14-5-2013
Reply 17-5-2013/ 27-5-2013.
No trial details provided but
promised to reply
Resent 02-06-2013, 09-06-
2013, 29-6-2013
No
Aigner 2009/Brettenhaler 2004 10-3-
2013 c.datz@kh-obdf.salzburg.
at (sequence generation and al-
location concealment)
and 5/40 were lost to follow
up.Howmany from each group
and were there any reasons for
this?
New mail of me
11-3-2013 cdegeyter@uhbs.ch;
ukeller@uhbs.ch
Reply 21-3-2013: ulrich.
keller@unibas.ch
Dear Dr. Zuuren
thank you for your mail.
I am somewhat surprised that
I heard the first time that an-
other paper had been pulled out
of our pioglitazone study (I was
the senior author and PI of the
Yes
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earlier study after all) -
…remarkable behaviour of
CDG and NB (formerly Bret-
tenthaler now Bachofner)…
I will try to find the details of
the protocol of the JCEMpaper
2004 and let you know.
Kind regards
later mail; Dear Dr. van Zuuren
according to the records the
randomization was performed
by the hospital pharmacy us-
ing a randomnumber generator
(such as used in EXCEL).
The pharmacy prepared tablets
with 30 mg pioglotazone or
matching placebo tablets.
Neither patients nor physicians
knew about the allocation until
the end of the trial.
I hope this helps, kind regards.
”Sorry I am not sure if I un-
derstand your question. Blind-
ing and allocation concealment
to me are the same with other
words. Blind is blind, is it not?
The pharmacy delivered “neu-
tral” boxes or containers identi-
cal for verum and placebo with
numbers, the numbers were
generated in random order by
the pharmacy and neither doc-
tors nor patients knew the con-
tent nor the key.“
17-4-2013 mail
Dear professor Keller,
We have found one inconsis-
tency with the paper of Bret-
tenhaler 2004 and that is the
Ferriman-Gallwey score after 3
months for the placebo group
which was 15.8 (2.8) in the
2009 paper (Aigner et al), but
15.9 (1.9) in the 2004 paper
(Brettenthaler et al). Can you
please confirm what the correct
end value is of the FG score
for the placebo group after 3
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months?
18-4-2013
Dear Dr van Zuuren
I checked the data from the
Brettenthaler Paper 2004, I
found in the EXCEL tables
from 2002 that the 3 month
Placebo value of the FG Score
was correct (15.9 +/- 1.9)
I have not been involved in the
Aigner Paper and I can not tell
you why they came up with
slightly different numbers
All other numbers e.g. age and
BMI are identical in the 2 pa-
pers - so I suspect it was a typing
error?
If you want to be sure you
have to ask Aigner or Nora Ba-
chofner (whose name was Bret-
tenthaler when she was in Basel,
before she was married)
Kind regards
Ulrich Keller, Prof. Dr.med.
Allen 2005 10-3-2013 holley.
allen@bhs.org (allocation con-
cealment) and are there 36 or
35 patients randomized? In ab-
stract it states 35, and under pa-
tients and methods 36?
Reply 11-3-2013
Dear Prof. Zuuren,
Using a computerized random
number generator an allocation
sequence was determined. Allo-
cation assignment for each sub-
ject number was marked on a
paper, individually sealed in a
concealing bank envelope by
staff not involved in patient care
or the clinical portion of the
study prior to randomization of
the first patient.
The correct number is 35, with
4 drop outs and 31 subject an-
alyzable.
Thanks. I look forward to your
Yes
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results. Please let me know if I
can be of further help.
Regards,
Holley Allen
Ashrafinia 2009 Email hosp arash@tums.ac.ir
(sequence generation)
23-7-2013
Resent 8-8-2013, 25-08-2013.
No response
No
Badawy 2009B 10-3-2013 ambadawy@yahoo.
com (allocation concealment)
and the baseline values for
testosterone in each group
Resent 27-3-2013
Resent 30-4-2013
Resent 14-5-2013
Reply 18-05-2013
Dear, The method of conceal-
ment was sealed envelops after
computeri- generated random
table allocation. Basal testos-
terone is not available to me
now. Best regards Ahmed
Badawy, MSC MD FRCOG
PhD
Professor of OB/GYN
Mansoura University, Egypt
Yes
Banaszweska 2007 10-3-2013 an-
toni.duleba@yale.edu: Baseline
data for each group for the first
treatment period
The data at 12 weeks (end of
first treatment period) for each
of the 2 groups
Reply 11-3-2013
2 attachments: Dear Dr. Van
Zuuren,
Please note that the table
presentsmeans andnot geomet-
ric means as we did in the orig-
inal paper. I also enclose auto-
matic printout from our statis-
tical analysis program.
Kind regards,
ajd
Yes
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Bayhan 2000 Email: bayhan@tr-net.net.tr (e-
mail of 1999)
; mbahceci@dicle.edu.tr; gbay-
han@dicle.edu.tr (e-mail in-
vented by me); mertem@dicle.
edu.tr; ahmetyalinkaya@ixir.
com (sequence generation, con-
cealment, losses to follow-up)
6-4-2013
Not applicable None of the e-mail addresses
were correct
Bayram 2002 Email: fbayram@erciyes.edu.tr
(sequence generation, conceal-
ment, losses to follow-up, ITT
or PP)
6-4-2013
Resent 30-4-2013,15-5-2013,
2-6-2013. No response
Not applicable
Beigi 2004 Email: beigi a@yahoo.com (se-
quence generation, conceal-
ment)
8-4-2013
Resent 30-4-2013,14-5-2013,
02-6-2013. No response
Not applicable
Calaf 2007 Email: jcalaf@hsp.santpau.es
(sequence generation, conceal-
ment, losses to follow-up)
19-4-2013
Resent 30-4-2013, 14-5-2013
Reply 15-5-2014 Incomplete
reply no additional detail
Resent 02-06-2013, 09-06-
2013, 29-06-2013
No
Ciotta 1995 Email lilliana.ciotta@tin.it
21-4-2013
Resent 12-05-2013, 2-6-2013
Not applicable
Ciotta 2001 Email lilliana.ciotta@tin.it
(concealment, blinding, losses
to follow-up)
22-4-2013
Resent 12-05-2013, 02-06-
2013. No response
Not applicable
Ciotta 2012B Email lilliana.ciotta@tin.it
(concealment, blinding, losses
to follow-up)
Not applicable
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Resent 12-05-2013, 02-06-
2013. No response
Colonna 2012 Email l.colonna@idi.it
(Sequence generation, conceal-
ment)
24-4-2013
Resent 19-5-2013, 02-06-
2013. No response
Not applicable
Appeared to include same data
as 2008 (Copub)
Cosma 2008 12-05-2014
Dear professor Montori,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and we read your
Systematic review ”Insulin Sen-
sitizers for the Treatment of
Hirsutism: A Systematic Re-
view and Metaanalyses of Ran-
domized Controlled Trials“ J
Clin Endocrinol Metab, April
2008, 93(4):1135-1142
Can you maybe help us how
the quality of evidence was
rated? The article refers to
”The Endocrine Society Task
Force on Hirsutism, assem-
bled to produce clinical prac-
tice guidelines, commissioned
these metaanalyses to support
the formulation of evidence-
based recommendations“ but
what method was used?
Response 12-05-2014
I am a little confused by your
question given that the quality
assessment and its results are de-
scribed in the paper with head-
ings that indicate so. For exam-
ple, we describe themethod un-
der the section ”Quality Assess-
ment“:
Quality assessmentTo ascertain
the reported methodological
quality of eligible trials,pairs
of reviewers (M.C., B.A.S., D.
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M.K., M.L.L., R.J.M., and V.
M.M.),working independently
and with adequate reliability,
determined the adequacy of al-
location concealment ( 0.56)
and blinding of patients(0.69),
healthcare providers (0.63), and
outcome assessors (0.88). The
proportion of participants ran-
domized for whom the trial au-
thors did not report hirsutism
outcomes (i.e. the extent of loss
to follow-up) was also noted.
The paper also reports the re-
sults of this
assessment. The full text of the
paper can be found here: http:/
/press.endocrine.org/doi/pdf/
10.1210/jc.2007-2429
Our reply:Dear professorMon-
tori, I did not refer to limita-
tions in study designs as done
in risk of bias assessment in
Cochrane reviews, but I re-
ferred to how decisions were
made on low or very low qual-
ity of evidence? So I did not
refer to methodological qual-
ity, but quality of the evidence.
How did you decide on that?
There are several systems/meth-
ods how to rate quality of evi-
dence. Best regards Esther
Reply: No, we just noticed
those issues and reported on
them. No scale, risk of bias or
other summative approachwere
used.V
Our reply: Thank you, based
on the wording we thought
GRADE was used to rate the
level of evidence (which in-
cludes limitations in study de-
sign, indirectness, imprecision,
inconsistency, publication bias
etc) and as we saw you also
worked on the GRADE guide-
lines.
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Reply: Grade was used to deter-
mine high, moderate, low, and
very low quality for the guide-
lines
I do not recall if we were us-
ing GRADE explicitly for qual-
ity assessment in the reviews at
that time.
V
2-6-2014: Murad.Moham-
mad@mayo.edu sent different
GRADE tables on Cosma,
Swiglo 2008
Creatsas 1993 and 2000 Email: geocre@aretaieio.uoa.gr
(sequence generation, conceal-
ment, blinding, baseline values,
losses to follow-up)
26-4-2014
Resent 12-5-2013, 2-6-2013.
No response
Not applicable
De Leo 2000 deleo@unisi.it e-mail sent 30-
4-2013
Dear professor de Leo
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclu-
sion (Hormonal and clinical ef-
fects of GnRH agonist alone,
or in combination with a com-
bined oral contraceptive or flu-
tamide in women with severe
hirsutism. Gynecological En-
docrinology 2000;14(6):411-6.
)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. Were the obese patients ran-
domised separately?, as it is a
bit unclear that on page 412
it states that patients were ran-
Yes
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domly divided in 3 groups of
12, and on page 413 it states
that the obese patients were
randomly assigned, 4 to each
group?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!). Who
had access to the random num-
ber table?
Thank you somuch for your ef-
forts.
Resent 12-5-2013
Resent 2-06-2013
Reply 3-6-2013Dear dr, Zuure,
I apologize for delay,but I was
in holiday.
Regarding your questions, I re-
member that the obese women
were 4 in each group and
the randomised was done sepa-
rately to be secure to have same
number of obese patients in all
groups.
All women were randomised
before different protocols.
e-mail of evz: Thank you pro-
fessor De Leo,
And how was the allocation
concealed (my 2nd question)
? Could the upcoming assign-
ment been foreseen by the in-
vestigator or patient?, and if
not, what method was used to
make sure they did not know
in which treatment arm they
would end up?Was the random
number table accessible to in-
vestigators or participants?
588Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Contact with investigators (Continued)
4-6-2013: Dear dr.Ester van
Zuure,
the study is very old and my
priciple collaborator now works
in other place.
I remember that all women
didn’t know what kind of treat-
ments they should be inserted
, the patients asked only to
improve their hyperandrogenic
simptoms
Dereli 2005 Unable to find a recent e-mail
address, or recent working ad-
dress
Not applicable
Eisenhardt 2006 stefan.eisenhardt@med.
uni-heidelberg.de mail is incor-
rect 3-5-2013
eisenhardt-praxis@t-online.de
Dear professor Eisenhardt
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepi-
lation therapy) and one of
your studies have been iden-
tified as potentially eligible
for inclusion (Early Effects of
Metformin in Women with
Polycystic Ovary Syndrome: a
prospective randomized, dou-
ble-blind, placebo controlled
trial J Clin Endocrinol Metab
91:946-952, 2006)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. What were the specific mea-
sures used to blind personnel
and patients from knowledge
of which intervention a partici-
pant received (howwas the dou-
ble blinding done)?
2.Instead of the provided me-
dians (1-3 quartiles), could you
help us with Means SD’s
Yes
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or SEM’s (baseline and at
end of study), for the Fer-
riman-Galwey scores, testos-
terone, DHEAS, androstene-
dione, SHBG and BMI?
Resent 12-5-2013
14-5 reply
Dear Dr. van Zuuren,
thanks for being interested in
our study from former days.
I sent your Email-Request to
Prof. Strowitzki - hopefully he
can answer and help you with
your questions
27-5-
2013 thomas strowitzki@med.
uni-heidelberg.de sent again
Resent 02-6-2013
Reply 3-6-2013
Dear Dr van Zuuren
I apologize for the delay. The
reason is that we have some
difficulties with the raw data.
Data collection was done ap-
proximately 2005. The statisti-
cian has left our medical fac-
ulty. So we have no further ac-
cess to the statistical data. Fur-
thermore we are currently mov-
ing to a completely new build-
ing and a lot of data got lost.
The first author Stefan Eisen-
hardt is also no longer working
in the department.
I have checked all my archives,
but I don’t possess the original
data.
I apologize for this inconve-
nience.
Kind regards
T. Strowitzki
Elnashar 2006 Email: elnashar53@hotmail.
com e-mail (sequence genera-
tion, SDor SE, separate data for
hirsute women)
3-5-2013
Resent 12-5-2013, 02-6-2013.
No response
Not applicable
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Elter 2002 Email: korayel-
ter@marmara.edu.tr (sequence
generation, concealment)
3-5-2013
Resent 12-5-2013, 2-6-2013
Not applicable
Fruzetti 2010 ffruzzi@tin.it sent 6-5-2013
Dear Professor Fruzzetti,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified
as potentially eligible for in-
clusion ( Comparison of ef-
fects of 3 mg drospirenone
plus 20 ug ethinyl estradiol
alone or combined with met-
formin or cyproterone acetate
on classic metabolic cardiovas-
cular risk factors in nonobese
women with polycystic ovary
syndrome. Fertility and Sterility
2010;94(5):1793-8)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial detail:
1. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
Resent 2-6-2013
Reply 03-06-2013
sorry for my delay but I am
out of my Office. I can answer
within a few days
thank you
No
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franca fruzzetti
12-06-2013
Dear Esther sorry for the delay
but as I wrote you I was out
of my office . As for your an-
swer please note that at the time
of the enrollement the inter-
vention allocations, i.e. the type
of combination to be adminis-
tered, have not been known in
advance by the physician
12-06-2013
Thanks for your reply. I sent out
more than 20 e-mails to people,
so sorry if I chased you. I under-
stand that it was not known, but
how was this protected? How
did you make sure that the al-
location could not been fore-
seen by patients or investiga-
tors. What method was used
that until they had the treat-
ment in their hands nobody
knew. It states that one of the in-
vestigators decided on the allo-
cation sequence...so that inves-
tigator (Daria Perini) knew?
Thanks for your time
Gambineri 2004 Email: renato.pasquali@unibo.
it (sequence generation, con-
cealment, blinding, baseline
data)
7-5-2013
Resent 13-5-2013, 2-6-2013,
29-6-2013. No response
Not applicable
Gambineri 2005 Email: renato.pasquali@unibo.
it (sequence generation, con-
cealment, blinding)
7-5-2013
Resent 2-6-2013, 29-6-2013.
No response
Not applicable
Gambineri 2006 ’alessandra.gambiner3@unibo.
it’ and renato.pasquali@unibo.
it
Dear professor Gambineri and
professor Pasquali,
Not applicable
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I have sent already 2 mails
to professor Pasquali on the
papers of 2004 and 2005
you had together in women
with PCOS, but we now have
some additional questions on
the 2006 study (Treatment
with flutamide,metformin, and
their combination added to a
hypocaloric diet in overweight-
obese women with polycystic
ovary syndrome: a randomized,
12-month, placebo-controlled
study. Journal of Clinical En-
docrinology and Metabolism
2006;91(10):3970-80.)
As said in my earlier mails, my
colleagues and I are conducting
a Cochrane review (Interven-
tions for hirsutism excluding
laser and photoepilation ther-
apy) and several of your stud-
ies have been identified as po-
tentially eligible for inclusion.
We now like to discuss the 2006
publication mentioned above
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. 40 of the eighty patients
had already started in 2004 for
six months. Were all 80 ran-
domised prior to start of 2004
study or only 40 ? Fig 1 in 2006
study shows all 80 randomised
at one time?
2. How were data pooled for
40 from 2004 at the 12 month
period when the 40 from 2006
were only 6 months into that
study?
3. the method used to con-
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ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!). Quote
”The allocation sequence of the
treatments was decided by a
third party (A.V.) before the
recruitment of the patients by
random number tables.“ So was
this an open random number
table?
4. Inconsistency in number
of losses drop outs reported
in 2004 (2 in placebo group
due to non compliance and
1 in flutamide group because
she got pregnant) but not re-
ported in 2006 (there only 1
in placebo group dropped out
for non attendance and 3 in
flutamide group because of in-
creased transaminases), can you
please explain?
Resent 13-5-2013
Resent 2-6-2013
Ganie 2004 aca433@yahoo.com, e-mail
sent 10-5-2013
Dear professor Ammini,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified
as potentially eligible for in-
clusion (Comparison of effi-
cacy of spironolactone with
metformin in the management
of polycystic ovary syndrome:
an open-labeled study. Journal
of Clinical Endocrinology and
Metabolism 2004;89(6):2756-
62)
Not applicable
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To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
2. There is inconsistency be-
tween the text and Figure
1 about the numbers that
dropped out. Can you clarify
how many dropped out in each
group and for what reason?
Thank you somuch for your ef-
forts
Best regards Esther van Zuuren
Resent 2-6-2013
Resent 29-6-2013
Reply 28-7-2013
The consecutive subjects were
enrolled and assigned a code.
One clinician would assign the
code and the subsequent allo-
cation would be done by the
another. Theywere randomized
on the basis of random num-
ber allocation which was com-
puter generated. Neither the
subjects nor the investigators
could forsee the assigned group
till OGTT was done. After that
the study was open label
Sorry there is discrepancy, as
data is not clearly indicated.
As indicated in Fig 1. Ad-
verse events of numbers 4 ver-
sus 2 has inadvertently got
transposed between metformin
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and spironolactone arms.The
details are as under:
Spironolactone n=41
Polyurea =4 withdrew 1
Abdominal pain =1 withdrew 1
Menstrual irregularity= 9 with-
drew 2
Lost to follow up =1
Incomplete data= 2
Total analysed =34
Metformin n=41
GI effects -Vomiting /nausea=4
withdrew=1
Diarrhea =8 withdrew =1
Hyeradrenergic symptoms= 2
Incomplete data =2
Lost to follow up=2
Total analysed= 35
29-7-2013:
Dear professor Ganie,
I did not receive your first mail,
unfortunately. I still have some
questions. The method to con-
ceal the allocation is still not
clear to me. It now looks like
the investigator could see the
code. I understand indeed from
the paper that it was computer
generated, but how were the
codes hidden for the investi-
gators and the patients?
And the number in the met-
formin group are also not com-
pletely clear
GI effects -Vomiting /nausea=4
withdrew=1
Diarrhea =8 withdrew =1
Hyeradrenergic symptoms= 2
withdrew????
Incomplete data =2 withdrew??
??
Lost to follow up=2 I suppose
these were withdrawn
Total analysed= 35
It now looks like 8 instead of 6
were withdrawn, please clarify?
Ghosh 2008 Elsheikh Mohgah (Mohgah.
Elsheikh@royalberkshire.nhs.
No
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uk] e-mail sent 10-5-2013
Dear Dr Mohgah
My colleagues and I are con-
ducting a Cochrane Systematic
Review
Interventions for hirsutism ex-
cluding laser and photo epila-
tion therapy and we have iden-
tified the study conducted by
Ghosh D Murphy C and your-
self.
We note that the study was pre-
sented in Harrogate in 2008,
can you please confirm if you
have published the full study or
if further trial conduct and data
are available and you would be
able to share these with us?
Thanks you so much for your
efforts
Best regards
Esther van Zuuren
Reply 14-5-2013
Hello
I’m afraidwe only published the
study in abstract form, present-
ing it at the British Endocrine
Society meeting in 2008.
Regards
Mohgah Elsheikh
Hamzavi 2007 18-5-2013 hlui@interchange.
ubc.ca (sequence generation)
reply 18-5
Thanks for your email and con-
sideration of our article.
Here is how we did the ran-
domization. Prior to recruiting
any of the subjects:
1. Coin toss. One toss for each
patient to be recruited.
2. Record the successive results
of each coin toss.
3. Put the result of the coin toss
in successive numbered sealed
envelopes. The coin toss re-
sult determined which side of
Yes
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the face was randomized to re-
ceive the treatment cream in a
blinded manner.
4. As each patient was enrolled,
each successive envelope was
opened.
Ibáñez 2009 14-5-2013 ’libanez@hsjdbcn.
org’
Could you provide us with
data at 18 months for Ferri-
man-Gallwey scores for the two
groups? (before they were sub-
randomised)
The table below does not pro-
vide data for “met+ oestro pro-
gestagen + flu + pio group”
and “met+ oestro progestagen
+ flu + placebo group”, but al-
ready incorporated the subran-
domisation afterwards. Could
you provide us with data for
testosterone, androstenedione,
DHEAS and SHBG at 18
months for the original ran-
domized groups?
The baseline data are also some-
what different then in the 2008
paper. Not sure which are cor-
rect? Could you clarify?
Response 14-5-2013
Dear Dr. van Zuuren,
This was a double-blinded,
placebo-controlled study. Ac-
cordingly, I did not know the
identity of the patients until af-
ter the compeltion of the study
I have searched through my
files, and I hope that the results
I provide are correct
met+ oestro progestagen + flu
+ pio group
baseline at 18 months
F&G score 17.7 ± 1.0 9.5 ± 0.
5
Testosterone (ng/dL) 55 ± 5
D4-A (ng/dL) 264 ± 15
Yes
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DHEAS (ug/dL) 172 ± 14
SHBG (nmol/L) 170 ± 7
met+ oestro progestagen + flu
+ placebo group
F&G score 16.4 ± 0.9 8.9 ± 0.
5
Testosterone (ng/dL) 55 ± 4
D4-A (ng/dL) 287 ± 20
DHEAS (ug/dL) 213± 25
SHBG (nmol/L) 169 ± 7
The baseline data are also
somewhat different then in
the 2008 paper. Not sure
which are correct? Could you
clarify?
I think that one of the women
dropped out of the study, and
we deleted her data
Ibáñez 2012 14-5-2013 ’libanez@hsjdbcn.
org’
We have another include in our
Cochrane review on hirsutism
“Ethinyl estradiol-cyproterone
acetate versus low-dose pioglita-
zone-flutamide-metformin for
adolescent girls with andro-
gen excess: divergent effects
on CD163, TWEAK recep-
tor, ANGPTL4, and LEP-
TIN expression in subcuta-
neous adipose tissue. Jour-
nal of Clinical Endocrinology
and Metabolism 2012;97(10)
:3630-8.” (We have included
otehr studies as well)
Could you provide us with
the data for 1 0-12 months
androstenedione in ng/dl and
DHEAS in microgram/dl for
both groups. Those miss in ta-
ble 2 (and were available in the
2011 paper for 6 months)
19-5-2013 reply
Here they are:
D4-A:
Diane: -111 +/- 32
PioFluMet: -109 +/- 38
Yes
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DHEAS:
Diane: -61 +/-19
PioFuMet: 13 +/- 13
EvZ had additional question if
the data were with SEM or SD,
seemed SD. Prof Ibáñez con-
firms SD
Jackson 2007 mail sent 16-5
jcaro@caroresearch.com
Dear professor Caro
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclusion
(Jackson J, Caro JJ, Caro G,
Garfield F, Huber F, Zhou W,
et al. The effect of eflornithine
13.9% cream on the bother and
discomfort due tohirsutism. In-
ternational Journal of Derma-
tology 2007;46(9):976-81)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence. It states
that it was a computer gener-
ated random listwhere even and
odd numbers were allocated to
the treatments. Was it on alter-
nation?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
Yes
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pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
3. The numbers that started in
each group? In the study ofWolf
2007, it also states 594, but the
numbers add up to 496?
4. What was the method of
blinding, howwere patients and
investigator blinded to treat-
ment
5. What were the reasons for
loss to follow-up?
reply 17-5-2013
Dear Dr van Zuuren
Thank you for contacting me
about this. My involvement in
these studies was limited to the
design and implementation of
the PRO component. Thus, I
do not have the answers to your
questions. I have passed them
on, however, to Dr. Jackson
who is now at Thomas Jefferson
University.Hopefully, hewill be
able to respond.
Best regards,
Jaime
27-5-2013, asked for Jackson’s
mail address
Hi
I
am copying him on your email.
Joseph.Jackson@jefferson.edu
Later 27-5-2013
Hi Esther,
Sorry for the delay in getting
back to you. I was away at a
meeting in NewOrleans. I have
to follow up on this with for-
mer colleagues at BMS; I re-
tired in 2010. I did discuss the
matter with a colleague and we
believe dynamic balancing was
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used to balance the randomiza-
tion across sites. I hope to have
a more definitive soon. Let me
know if this helps,
Joe
Dear Esther,
I will need to discuss this with
my statistical colleagues. I know
that dynamic balancing was
used across many trials in the
Pharmaceutical Research Insti-
tute of BMS, andof course there
were many filings with FDA,
EMA...
I’ll get on this tomorrow as to-
day is a holiday for us,
Cheers, Joe
29-
5-2013 cc chensheng.lin@bms.
com; kathyschrode@yahoo.
com; jaime.caro@mcgill.ca;
wenjiong.
Zhou@unitedbiosource.com
Dear Dr. van Zuuren,
I have followed up with every-
one on the cc list [2 statisti-
cians (Drs. Zhou and Lin), the
regulatory lead (Dr. Schrode)
and Dr. Caro (The MD for the
QOL work)] and have the fol-
lowing to report:
1. Below please find Dr.
Zhou’s summary concerning
the randomization.
2. Dr. Schrode plans follow
up with the company
concerning other questions
regarding hirsutism in women
that could be answered by
access to the final study report.
3. I believe that Dr. Schrode
will follow up with you directly
Hope this helps,
Joe
Hi Joe -
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I dug out text portion of the fi-
nal study report for the two piv-
otal studies (DE140-001 and
DE140-002)
Here is the language for ran-
domization -
Subjects were assigned treat-
ment by a computer-gener-
ated randomization schedule
restricted to ensure distribution
of eflornithine 15% cream and
its vehicle in a 2:1 ratio, re-
spectively, within each investi-
gational site
Subjects were randomized to
treatments with study medica-
tion on day two if qualified
by the criteria of the proto-
col. Subject numbers and num-
bers identifying study medi-
cation containers corresponded
directly. Subject numbers were
assigned sequentially at each in-
vestigational site in strict nu-
merical order as subjects were
randomized
[Wenjiong’s comment -- So,
this is simple randomization
with 2:1 ratio, stratified by site.
I don’t believe the randomiza-
tion schedule is an even and
odd number alternating. Sub-
ject numbers were sequentially
assigned within the site based
on the timing of randomization
within the site.]
Here is the language for
blinding of study drug-
Blinding of the eflornithine
15% cream and its vehicle was
assured by the fact that both
study medications were pack-
aged in identically appearing
15g plastic tubes bearing three-
panel, two-part double-blind
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labels. Labels affixed to the
tubes (the only label to which
subjects had access) contained
no evidence of the identity of
the contents. The second panel
of the tear-off part of the label
was a sealed envelope conceal-
ing the identity and lot number
of the treatments. These tear-
off portionswere to be affixed to
the subjects CRFs and opened
only in the case of a medical
emergency in which the inves-
tigator had determined that the
informationwas absolutely nec-
essary, i.e., that it would al-
ter the subjects immediateman-
agement.
Eflornithine 15% cream and its
vehicle were matching cream
formulations and it was not
considered possible to differen-
tiate one treatment from the
other solely by tactile or visual
evaluation
The protocol for this study
specified that dispensing of
study medications at the inves-
tigational site was to be done by
a staff member who was not re-
sponsible for conducting any of
the clinical evaluations. There-
fore, the chances of the investi-
gator equating a particular level
of response with what he/she
considered to be a particular
treatment was minimal
So above should suffice ques-
tions #1, #2, and #4.
For question #5. I don’t see a
reason further specified for “lost
to follow-up”. Don’t recall or
have CRF, I have a feeling that
“lost to follow-up” is just a sim-
ple check-box without further
specification
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For question #3. 594 seems to
be referring to total number of
treated patients in both studies
(287 for DE140-001 and 307
for DE140-002). I don’t know
what 496 is referring to. I don’t
have the paper
That is all I can do. Hope that
helps.
Thanks,
Wenjiong
24-12-2013 jaime.
caro@mcgill.ca
Dear professor Caro,
We are conducting a Cochrane
review on interventions for hir-
sutism, and we would like to
have the information on Caro
JJ, Caro G, O’Brien JA, et al.
Assessing quality of life impli-
cation of depigmentation: the
BASC scale. Which was pre-
sented at the 54thAnnualmeet-
ing of theAmericanAcademyof
Dermatology 1996 10-15 Feb
in Washington
Can you provide me with a
scanned copy, or an abstract? I
need the full author string as
well as poster number. Our uni-
versity Library has no access to
it, and the AAD could not help
me anymore with this. I looked
everywhere on the web without
success
I would appreciate it enor-
mously if you could help me
Reply: Thank you for contact-
ing me about this. I will ask
my assistant to see if she can
find a copy but it is quite un-
likely given that it is nearly 18
years ago. All of that has long
ago been sent to off-site storage
or destroyed.The application to
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hirsutism was published later,
however, as ’The effect of eflor-
nithine 13.9% cream on the
bother and discomfort due to
hirsutism. International Jour-
nal of Dermatology 2007;46(9)
:976-81)’
24-12-2013: Yes we have that
study included, but the link of
the reference is not working to
leads to the abstract of the An-
nual meeting. As we need to
refer to the original source of
the instrument, we need to have
the details of that abstract. So I
hope your assistant can find it
and send me it
09-01-2014. Both Prof Caro, as
well as the AAD could not pro-
vide us with the abstract on the
BASC scale
Kriplani 2009 Email: kriplanialka@gmail.
com (concealment)
30-12-2013
Resent 12-5-2014.No response
Not applicable
Kriplani 2010 Email: kriplanialka@gmail.
com (concealment)
20-5-2013
Resent 2-6-2013, 29-6-2013.
No response
Not applicable
Lakryc 2003 edmund@baracat.com.br and
jsoares415@hotmail.com e-
mail sent 20-5-2013
Dear professor Baracat
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies for which you are cor-
responding author, have been
identified as potentially eligi-
ble for inclusion (The ben-
efits of finasteride for hir-
sute women with polycystic
ovary syndrome or idiopathic
Yes
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hirsutism. Gynecological En-
docrinology 2003;17(1):57-63.
)
I have copied professor Soares
in the mail as I was not sure if
the e-mail address was correct
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. There were 10 drop-outs,
how many in each treatment
arm?
2. What were the specific mea-
sures used to blind participants
from knowledge of which inter-
vention a participant received
(how was the blinding done)?
The blinding of the personnel
is clear.
Thank your for your time and
efforts
Best regards Esther van Zuuren
reply 20-5-2013
I and Prof Baracat are pleased
with your e-mail. The answers
for your questions are above:
1) 10 drop-outs: 6 for placebo
group and 4 for finasteride
group
2) The capsule of placebo was
similar to the one of finasteride
and the flask had only identifi-
cationofXY (placebo) or YX (fi-
nasteride). The physicians and
patients were blind to this in-
formation. After the end of this
study, both physicians and pa-
tients were informed on the
groups. Also, we did not per-
mit a direct conduct the pa-
tients during the study.
If you have any questions,
please contact me.
Best regards,
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José Maria Soares Jr
Edmund C Baracat
Le Donne 2012 e-mail sent 21-5-2013 mariale-
donne@tin.it
Dear professor Le Donne
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclusion
(Le Donne M, Alibrandi A, Gi-
arrusso R, Lo Monaco I, Mu-
racaU.Diet,metformin and in-
ositol in overweight and obese
women with polycystic ovary
syndrome: effects on body com-
position [Dieta, Metformina e
Inositolo in Donne Sovrappeso
e Obese Con Sindrome
Dell’Ovaio Policistico: Effetti
SullaComposizione Corporea].
Minerva Ginecologica 2012;64
(1):23-9)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence. It states
that it was a computer gener-
ated random listwhere even and
odd numbers were allocated to
the treatments. Was it on alter-
nation?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
Yes
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Thank you somuch for your ef-
forts.
Reply 30-5-2013
Thank you for your interest
about my publication ”Diet,
metformin and inositol in over-
weight and obese women with
polycystic ovary syndrome: ef-
fects on body composition“
1. The method used to gener-
ate the allocation sequence, was
a computer generated random
list where even and odd num-
bers were allocated to the treat-
ments.It was on alternation.
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment. It is the
same as blinding.
Best regards
Maria Le Donne
Our response: Dear professor
Le Donne,
Thank you for your additional
information.
Allocation concealment is not
the same as blinding, therefore
we added that information that
it is not the same, examples of
adequate methods of allocation
concealment are e.g. include se-
quentially numbered, opaque,
sealed envelopes (SNOSE); se-
quentially numbered contain-
ers; pharmacy controlled ran-
domization; and central ran-
domization
Blinding is about procedures
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that prevent study participants,
caregivers, or outcome asses-
sors from knowing which inter-
vention was received (e.g same
tablets, same package, smeel,
taste)
As your study has been ran-
domised based on alternation
it is not truly randomised but
quasirandomised, and therefore
unfortunately we will not be
able to include this study
Just for my understanding, why
did you use a computer gener-
ated random list when it was on
alternation for odd/even num-
bers? You don’t need a computer
for alternation, do you?
Response Zbys:Dear Dr Le
donne
Alternate allocation by odd and
even number is not a method of
true randomization. True ran-
domization ensures that every
participant has an equal oppor-
tunity to receive one or other
intervention by chance alone.
This cannot be said to apply to
alternation ie odd even alloca-
tion.
Regarding allocation conceal-
ment and blinding... these are
not the same and dont share the
same potential to adversely af-
fect ie bias the outcome. Alloca-
tion concealment is always pos-
sible whereas blinding may not
and refers to the period prior to
the administration of the inter-
ventions whereas blinding oc-
curs or doesnt occur at the ac-
tual time of the administration
of the intervention.
Your perception of these as be-
ing identical is quite commonly
held but regrettably is incorrect.
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There is quite an extensive liter-
ature on this which I would be
happy to provide.
The impact of inadequate allo-
cation concealment on the ef-
fect estimate is far greater than
that of blinding, and conse-
quently of significant impor-
tance.
Thank you for the information
you have provided it has en-
able us to clarify aspects of your
study which have a potential
impact on the conclusions that
can be drawn
I do hope you find this helpful?
2-6-2013: sent additional mail
as I think she gave confusing re-
ply
Dear professor le Donne,I am
wondering before I exclude
your study, if you are sure it
was computer generated AND
on alternation as this does not
make sense. If it has been com-
puter generated I cannot see
how it would be on alternation,
so can you please confirm it it
was on alternation? I think you
might have been confused?
Resent 9-6-2013
Resent 29-6-2013
Reply 30-6-2013
Yes I was confused, I confirm
that it was on alternation
Best regards
Maria Le Donne
Lello 2008 e-mail sent 21-5-2013 lelloste-
fano@libero.it
Dear professor Lello
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
Not applicable
611Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Contact with investigators (Continued)
potentially eligible for inclusion
(Effects of two estroprogestins
containing ethynilestradiol 30
microg and drospirenone 3 mg
and ethynilestradiol 30 microg
and chlormadinone 2 mg on
skin andhormonal hyperandro-
genic manifestations. Gyneco-
logical Endocrinology 2008;24
(12):718-23.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence. It states
that it was a computer gener-
ated random listwhere even and
odd numbers were allocated to
the treatments. Was it on alter-
nation?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
Thank you somuch for your ef-
forts.
Best regards Esther van Zuuren
Resent 2-6-2013
Resent 29-6-2013
Maciel 2004 e-mail sent 27-5-2013 ecbara-
cat@gmail.com,
garmaciel@gmail.com,
jsoares415@hotmail.com
Dear professor Baracat, you
and professor Soarez Jr have
been very helpful with the
other study, so I hope you
can help with this one as well
Yes
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(Nonobese women with poly-
cystic ovary syndrome respond
better than obese women to
treatment with metformin. Fer-
tility and Sterility 2004;81(2):
355-60. The study is very well
designed, but I only have one
extra question
Howmany dropped exactly out
from each group, it says 5/34,
howmany from each group and
for which reason in each group?
Thank you so much again for
your efforts
Best regards Esther van Zuuren
Reply 27-5-2013
Dear Dr van Zuuren,
I talked with Dr Gustavo Ma-
ciel about your question. He
will check the data for answer-
ing your question. If you have
any difficult with Dr Maciel re-
sponse, please, contact me.
Best regards,
José Maria
Dear prof Zuuren
It is a pleasure for us to collab-
orate in your research.
kind regards
Edmund C Baracat, MD, PhD
Professor and Head
Gynecology Division
University of SaoPauloMedical
School
6-6-2013
Dear Dr Esther,
we reviewed our records and
identified the reasons the sub-
jects dropped out the study:
pregnancy (n=2): one of the
PCOS group and one of the
control; both were nonobese;
unknown reason (n=2): two
from the control group, both
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obese.
diarrhea (n=1): PCOS obese
I hope the information will be
useful.
Our best regards
Gustavo
Madani 2012 e-mail 9-6-2013
ashrafim@royaninstitute.org
Dear professor Ashrafi,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclu-
sion (Madani T, Irani S, Ashrafi
M, Nabavi M.A. The effect of
flutamide on ovulation induc-
tion in PCOS patients. Inter-
national Journal of Fertility and
Sterility 2012;6(1):65-70.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence. It states
that it was a computer gener-
ated random listwhere even and
odd numbers were allocated to
the treatments. Was it on alter-
nation?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
Yes Quasi-randomised so an ex-
clude
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the same as blinding!!).
3. How was grade 1 and grade
2 defined? What were the cut-
off points?
4. What were the baseline val-
ues for hirsutism, I only see the
values after first and second cy-
cle?
5. What were the values of
testosterone after the 2 cycles
for both groups?
6. What was the mean BMI
(SE) for both treatment groups
after 2 months?
Resent 29-6-2013
Resent 06-07-2013
Resent 11-7-2013
Reply 20-7-2013
Dear professor Zuuren
Many thanks to your interest.
To answer your questions we
can explain in this manner:
1- The method we used was on
alternation
2- It was a blind study and nei-
ther participants nor investiga-
tors could fore see the treat-
ment.
3- According to ferrimann-Gall
way classification there are four
grade but for simplify we con-
sidered the grade I,II as hypo-
hirsutism( grade I in our study)
and grade III , IV we consid-
ered as hyperhirsutism(grade II
in our study )
4- In the beginning of the study
hirsutism was assessed.
5- Testestron wasn’t measured
at the end of the study because
it wasn’t the main aim of the
study.
6- Regarding to BMI, No
changed was seen.
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Mastorakos 2002 9-6-2013 mastorak@mail.kap-
atel.gr incorrect, then
mastorakg@ath.forthnet.gr
Dear professor Mastorakos,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclu-
sion (Mastorakos G, Koliopou-
los C, Creatsas G. Androgen
and lipid profiles in adolescents
with polycystic ovary syndrome
who were treated with two
forms of combined oral contra-
ceptives. Fertility and Sterility
2002;77(5):919-27)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence.
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
3. Where there no drop-outs?
4. Are these adolescents also
part of the 2006 paper (Fer-
tility and Sterility 2006;85(2):
420-7)?
Resent:11-07-2013
Resent 26-7-2013
Reply 29-7-2013
1. No all numbers generated
(odds and even) were randomly
Yes
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given and not on alternation.
2. If question #2 is not re-
sponded by the random alloca-
tion of numbers then, I am not
sure I understand the meaning
of question #2. I would greatly
appreciate if you could be more
specific.
3. No drop-outs
4.I responded to this in my pre-
vious email (see study below)
Reply by EVZ: explanation of
allocation concealment
Reply 29-7-2013:
Thank you for the analytical ex-
planation of concealment of al-
location. In our everyday clini-
cal research practice we consid-
ered this procedure as part of
the whole randomaization. The
randomization is performed by
our computer technicien who
generates the random numbers
and he is the only one to know
in each study the allocation se-
quence until the moment of as-
signment
Thanks again for your informa-
tive intervention
Reply evz sent paper Altman-
Schulz
Mastorakos 2006 mastorakg@ath.forthnet.gr
Dear professor Mastorakos,
As said in my former mail, my
colleagues and I are conducting
a Cochrane review (Interven-
tions for hirsutism excluding
laser and photoepilation ther-
apy) and one of your stud-
ies have been identified as po-
tentially eligible for inclusion
(Mastorakos G, Koliopoulos
C, Deligeoroglou E, Diamanti-
Kandarakis E, Creatsas G. Ef-
fects of two forms of combined
oral contraceptives on carbo-
hydrate metabolism in adoles-
Yes
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cents with polycystic ovary syn-
drome. Fertility and Sterility
2006;85(2):420-7.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
2. Are these adolescents also
part of the 2002 paper (Fer-
tility and Sterility 2002;77(5):
919-27)?
3. Can you provide us with the
data on the Ferriman- Gallwey
score and the androgen levels af-
ter 12 months
12-6-2013
Dear Professor van Zuuren
Thank you for your interest to
our work. I am out of town till
the 21st. I will be happy to re-
spond then
29-6-2013
Dear Professor Mastorakos,
Have you already time to look
at the two e-mails I sent you on
the two studies?
Resent 11-7-2013
Resent 26-7-2013
Reply 29-7-2013
1. I believe this question regards
the randomness of the assign-
ment cause this is not reported
in our paper. In all our studies
we employ randomly generated
numbers from the appropriate
softwares.
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2. No. In fact we repeated the
same study because all the ma-
terial collected from the first
study had been utilized.
3. I ll try to do so. I have to
check with Dr. Caroline Ko-
liopoulos cause this study was
part of her thesis and Iwill come
back ASAP
Reply by EvZ
Regarding 1, it is about conceal-
ment, not about the sequence
generation. So howwas the ran-
domisation sequence kept se-
cret to investigator and pa-
tients? Which method of con-
cealment was used
Regarding 2. OK other adoles-
cents
3, we wait then
Resent 8-8-2013
9-8-2013
Dear Esther
I am sending you the data re-
quested for the 2006 paper as
prepared by my co-author Dr.
C. Koliopoulos
Thank you for having requested
them. Hope you find it useful
I remain at your disposal for
any further clarification. I will
be out of town till august the
26th. Wish you happy summer
vacation
Moghetti 2000 paolo.moghetti@univr.it 17-6-
2013
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclusion
(Moghetti P, Tosi F, Tosti A,Ne-
gri C, Misciali C, Perrone F, et
al. Comparison of spironolac-
Yes
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tone, flutamide, and finasteride
efficacy in the treatment of hir-
sutism: a randomized, double
blind, placebo-controlled trial.
Journal of Clinical Endocrinol-
ogy and Metabolism 2000;85
(1):89-94.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence
2. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
3. Baseline values and end of
treatment values for total testos-
terone and androstenedione
Thank you somuch for your ef-
forts.
Resent 29-6-2013
Reply 28-7-2013
1: The allocation sequence was
obtained by randomly gener-
ated numbers
2:A person, not involved in the
study and working in the hospi-
tal pharmacy, prepared a series
of identical wafer capsules con-
taining the different drugs or
placebo, in numbered packets.
The packets were assigned pro-
gressively to the recruited par-
ticipants. The capsule content
corresponding to the sequence
of the numbers remained un-
known to the researchers until
the end of the study, and mea-
surements of both hirsutism
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score and hair diameter were
blinded to the treatment group
3. Baseline and end of treat-
ment values (nmol/L, mean,
SD) for total testosterone and
androstenedione in the 4 treat-
ment groups were respectively
the following:
Total testosterone
Spironolactone 2.06+0.69 and
2.04+0.47
Flutamide 1.78+0.65 and 1.
73+0.31
Finasteride 2.15+0.56 and 2.
71+0.51
Placebo: 1.76+0.51 and 1.
86+0.47
Androstenedione
Spironolactone 13.5+7.3 and
14.7+7.1
Flutamide 15.3+5.6 and 12.
6+4.4
Finasteride 16.6+3.5 and 18.
3+4.3
Placebo: 15.0+5.1 and 16.4+5.
6
Reply by EvZ 30-7-2013:
Thank you for your reply. Ev-
erything is clear except the
method of how the numbers
were generated at random, as
there are several methods. Of
course the numbers are gener-
ated at random, otherwise it
would not have been a ran-
domised controlled trial, but
how were the numbers gener-
ated at random?
Reply 30-7-2013 The numbers
were generated by a computer.
Moghetti 2000B paolo.moghetti@univr.it 18-6-
2013
Dear professor Moghetti,
Yesterday I already sent you an
e-mail about one of your studies
in hirsute women, today I have
questions about another study
of yours
Yes
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My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and another of
your studies have been identi-
fied as potentially eligible for
inclusion (Moghetti P, Castello
R, Negri C, Tosi F, Perrone
F, Caputo M, et al. Met-
formin effects on clinical fea-
tures, endocrine and metabolic
profiles, and insulin sensitiv-
ity in polycystic ovary syn-
drome: a randomized, double-
blind, placebo-controlled 6-
month trial, followed by open,
long-term clinical evaluation.
Journal of Clinical Endocrinol-
ogy and Metabolism 2000;85
(1):139-46.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. how many were randomised
to each group in protocol A?
2. the method used to generate
the allocation sequence
3. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
4.Whatweremeanbaseline val-
ues of hirsutism score and what
were the mean end values at 6
months in protocol A
Thank you somuch for your ef-
forts.
Resent 29-6-2013
Reply 29-6-2013
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Dear Dr. van Zuuren,
Thank you for your interest in
my studies.
I am out of work in these days
and it is not easy for me to
answer your questions immedi-
ately. However, I will do all my
best to reply asap.
Best regards
Paolo Moghetti
Resent 11-7-2013, he is away
until 20-7
Reply 28-7-2013
1. The number of subjects ran-
domized in the double-blind,
placebo-controlled trial (proto-
col A) was 12 in the metformin
group and 11 in the placebo
group
2.The allocation sequence was
obtained by randomly gener-
ated numbers
3.A person, not involved in the
study and working in the hospi-
tal pharmacy, prepared a series
of identical wafer capsules con-
taining the different drugs or
placebo, in numbered packets.
The packets were assigned pro-
gressively to the recruited par-
ticipants. The capsule content
corresponding to the sequence
of the numbers remained un-
known to the researchers until
the end of the study, and mea-
surements of both hirsutism
score and hair diameter were
blinded to the treatment group
4. The baseline and end of treat-
ment hirsutism scores (mean,
SD) of subjects included in pro-
tocol Awere respectively the fol-
lowing:
Metformin: 8.9±5.5 and 9.6±5.
1
Placebo: 12.7±3.8 and 14.5±6.
2
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It should be noted that hir-
sutism was not a predefined
outcome in this study and
PCOS women were not re-
cruited according to the pres-
ence of hirsutism
Morin-Papunen 2000 21-6-2013
juha.tapanainen@oulu.fi,
laure.morin-papunen@oulu.fi
Dear professor
Morin-Papunen, and professor
Tapanainen,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and another of
your studies have been iden-
tified as potentially eligible
for inclusion (Morin-Papunen
LC, Vauhkonen I, Koivunen
RM,RuokonenA,Martikainen
HK, Tapanainen JS. Endocrine
and metabolic effects of met-
formin versus ethinyl estradiol-
cyproterone acetate in obese
women with polycystic ovary
syndrome: a randomized study.
Journal of Clinical Endocrinol-
ogy and Metabolism 2000;85
(9):3161-8.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. how many were randomised
were originally randomised to
each group (it is clear howmany
finished 3 and 6 months, but
not how many started in each
group)?
2. the method used to generate
the allocation sequence
3. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
Yes
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foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
Reply 20-6-2013
Dear doctor van Zuuren,
Thank you for your mail. I try
to answer to your questions.
1. how many were randomised
were originally randomised to
each group (it is clear howmany
finished 3 and 6 months, but
not how many started in each
group)?
Five more patients wer ran-
domised,3 in the metformin
group and 2 in the DN group.
Three of themwere droppedbe-
cause of discovered T2DM (2
in the met group and 1 in the
DN group), and 2 (one in each
group) did not want to partici-
pate for personal reasons
2. the method used to gener-
ate the allocation sequence: it
was performed by the hospital
pharmacywith 1:1 allocation in
random blocks of ten using two
computer-generated lists
3. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!): the
allocation was concealed in a
closed envelopewhere the num-
ber of the patient was written.
The participant knew the allo-
cation after she had accepted to
participate
In this study, no blinding was
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possible nor done.
I hope that this helps you!
Best regards
Laure Morin-Papunen
Morin-Papunen 2003 21-6-2013 laure.morin-
papunen@oulu.fi
Dear professor Morin-
Papunen,
We have also 2 questions about
your study “Morin-Papunen
L, Vauhkonen I, Koivunen
R, Ruokonen A, Martikainen
H, Tapanainen JS. Metformin
versus ethinyl estradiol-cypro-
terone acetate in the treatment
of nonobese women with poly-
cystic ovary
syndrome: a randomized study.
Journal of Clinical Endocrinol-
ogy and Metabolism 2003;88
(1):148-56”
1. the method used to generate
the allocation sequence
2. the method used to conceal
the allocation sequence to en-
sure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!)
29-10-2013
Dear professor Morin-
Papunen,
I am not sure if you have
seen these questions on another
study of yours (see below). The
answers to the other study were
really helpful
Best regards Esther van Zuuren
30-6-2013
Dear professor van Zuuren,
I am sorry to be so late with my
answer. I was on holidays last
week and had no access at my
Yes
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mail
The sudy on nonobese women
was done exactly as the previous
one on obese, ie the answers to
your questions are the same as in
the previous study. I hope that
this helps you, do not hesitate
too ask more if needed
Best regards
Laure
Navali 2012 27-6-2013
mashrabi1383@yahoo.com;
parvinbastani@yahoo.com
Dear professor Mashrabi
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and another of
your studies have been identi-
fied as potentially eligible for
inclusion (Navali N, Shok-
oufe LA, Mallah F, Bastani P,
Mashrabi O. Comparing ther-
apeutic effects of metformin
and pioglitazone in polycystic
ovary syndrome (PCOS). Pak-
istan Journal of Medical Sci-
ences 2012;28(3):390-4)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to generate
the allocation sequence
2. the method used to con-
ceal the allocation sequence to
ensure that intervention allo-
cations could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
Thank you somuch for your ef-
forts.
Not applicable
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Resent 06-07-2013
Resent 24-07-2013
Önalan 2005 Email:
gogsenonalan@yahoo.com (se-
quence generation, conceal-
ment, blinding)
27-6-2013
Resent 06-07-2013, 24-07-
2013. No response
Not applicable
Oner 2011B Email: onerg@yahoo.com (se-
quence generation, conceal-
ment)
27-6-2013
Resent 06-07-2013, 23-07-
2013, 8-8-2013. No response
Not applicable
Ortega 2005 and 2005B ortegacarlos@hotmail.com 1-
7-2013
Dear professor Ortega-
González,
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and two of your
studies have been identified as
potentially eligible for inclu-
sion (Ortega-González C, Car-
doza L, Coutiño B, Hidalgo R,
Arteaga-Troncoso G, Parra A.
In-
sulin sensitizing drugs increase
the endogenous dopaminer-
gic tone in obese insulin-re-
sistant women with polycys-
tic ovary syndrome. Journal
of Endocrinology 2005;184(1)
:233-9. and Ortega-González
C, Luna S, Hernández L, Cre-
spo G, Aguayo P, Arteaga-Tron-
coso G, et al. Responses of
serum androgen and insulin re-
sistance to metformin and pi-
oglitazone in obese, insulin-re-
sistant women with polycys-
tic ovary syndrome. Journal
of Clinical Endocrinology and
Yes Copub so 2005B removed from
included studies
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Metabolism 2005;90(3):1360-
5.)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing information:
1. Is the same study population
involved in both studies? As I
don’t see any referring to each of
the papers, but study design is
the same and only difference in
total number of 3 participants
Reply 2-7-2013
Dear Dr. E.J.van Zuuren:
I appreciate your interest in our
research. This is effectively the
same cohort of patients
Originally we recruit 57 pa-
tients, of which, 10 were lost
to follow up (5 in each group),
5 were excluded for presenting
gastrointestinal side effects (all
of them belonged to the group
treated with metformin), and 8
were pregnant (5 from group
treated with pioglitazone, 2 in
the first half of the study and 3
in the second half, while 3 preg-
nant patients were assigned to
group management with met-
formin). At the end were 34
women (17 in each group) to
which they do metoclopramide
protocol to assess dopaminergic
tone
The difference between the two
studies, it is basically for work
published in J Clin Endocrinol
Metab we do not include a 5
women lost to follow up, very
early in the study (two women
in the pioglitazone group and
three women in the metformin
group) and for the analysis of
the study published in J En-
docrinology, a woman who pre-
sented severe gastrointestinal ef-
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fects towards the end of study
in the metformin group did not
authorize the second test with
metoclopramide, so it was ex-
cluded from the final analysis
Hence the difference between
the ”n“ of both studies.
I hope this information will be
useful to you and your group of
researchers
Otta 2010 05-07-2013 endofux@yahoo.
com.ar
Dear professor Otta,
My colleagues and I are con-
ducting a Cochrane review (
(Interventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified
as potentially eligible for in-
clusion (Otta CF, Wior M,
Iraci GS, Kaplan R, Torres D,
Gaido MI, Wyse EP. Clinical,
metabolic, and endocrine pa-
rameters in response to met-
formin and lifestyle interven-
tion in women with polycys-
tic ovary syndrome: a ran-
domized, double-blind, and
placebo control trial. Gyneco-
logical Endocrinology 2010;26
(3):173-8)
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!)
2. The method used to blind
Yes
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participants and investigators
from knowledge of which inter-
vention a participant received
Resent 23-07-2013
Resent 8-8-2013
Reply 8-8-2013
Dear Dr van Zuuren
I give you my apologies for not
answering your first mail.
I have sent your questions to the
person who was responsable of
the randomization of my trial.
As soon as he answer, I will mail
it to you.
I thank your consideration to
choose my trial for your meta
analysis.
Sincerely
Fux Otta, Carolina
Reply 18-8-2013
1- Simple random was used to
allocate patients to treatment or
placebo
2 - Each pack (en vez de sa-
chet) of treatment was opaque
and coded from the laboratory.
We guarantee the double blind-
ing because neither patients nor
us knew which treatment they
were allocated; nor could we
find out because that was done
from the laboratory. Blinding
was opened at the end of the
study of 30 patients. The labo-
ratory sends us a letter with the
codes
19-8-2013
Pills were exactly the same in
shape and colour, and both
(metformin and placebo) were
tapered to one and a half pill
BID
Package codes were generated
by random program from the
laboratory
Sabuncu 2003 Email: sabuncu@ixir.com and
tsabuncu@harrou.edu.tr (both
addresses are no longer in use)
Not applicable
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and no recent one available.
(concealment, blinding)
11-7-2013
Sert 2003 e-mail 13-7-2013
muratser@mail.cu.edu.tr
Dear professor Sert
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclusion
(Sert M, Tetiker T, Kirim S.
Comparison of the efficiency of
anti-androgenic regimens con-
sisting of spironolactone, Di-
ane 35, and cyproterone ac-
etate in hirsutism. Acta Med-
ica Okayama 2003;57(2):73-6.
[PubMed: 12866746]
To enable us to further assess
this trial for inclusion I would
be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1. the method used to gener-
ate the allocation sequence, as
it does not seem to be random-
ized (people that came first pe-
riod came in group 1, people in
second months in group 2 and
people in 3 months in group 3)
?
2. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
Thank you somuch for your ef-
forts.
Reply 14-7-2013
Dear E.J.van Zuuren, MD
Yes It is a CCT
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I have just seen your e-mail.
I thank you for interesting
our study. Regarding with the
study;
1. Inclusion of the patients
were done by randomly and se-
quentialy their appliance to our
outpatient clinic at the deter-
mined period (one month for
each group). So, the inclusion
method for the 3 groups were
similar
2. In this study, study sub-
jects did not know the compare-
ment of the different therapy
groups with each other. They
informed about whether their
treatment were efficious or not
with respect to their basal find-
ings and complaints (the same
for 3 groups). And, investiga-
tor who evaluated the Ferriman
score did not know the study
patients (he had been perform-
ing routin all outpatient sub-
jectswhowere also not included
the study
I hope this explanationwill help
you.
With my best regards,
Prof. Dr. Murat Sert
Smith 2006 e-mail 13-7-2013
ssmith@therapeuticsresearch.
com; ssmith@stacyrsmithmd.
com
Dear professor Smith,
My colleagues and I are con-
ducting a Cochrane review (
(Interventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclu-
sion (Smith SR, Piacquadio DJ,
Beger B, Littler C. Eflornithine
cream combined with laser
therapy in the management of
unwanted facial hair growth
Yes
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in women: a randomized trial.
Dermatologic Surgery 2006;32
(10):1237-43).To enable us to
further assess this trial for in-
clusion I would be obliged if
you could you kindly provide us
with the following missing trial
details:
1. the method used to con-
ceal the allocation sequence to
ensure that intervention alloca-
tions could not have been fore-
seen in advance of, or during,
enrolment ie participants and
investigators enrolling partici-
pants could not foresee the up-
coming assignment (this is not
the same as blinding!!).
2. The method used to blind
participants and investigators
from knowledge of which inter-
vention a participant received
Best regards Esther van Zuuren
Reply 22-7-2013
Dr. van Zuuren,
With respect to your inquiries:
- The treatment allocation se-
quence was predetermined us-
ing a coputer-generated ran-
domization sequence. Prior to
the start of the study, the med-
ication container assignments
for EACH subject number were
placed into sealed envelopes
marked with subject numbers.
As each new subject was en-
rolled, the next highest num-
ber was assigned and at the time
of randomization, the envelope
was opened which instructed
the site staff to dispense certain
containers of study medication.
The study medication contain-
ers did NOT reveal whether
the product inside was active or
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placebo and the numbers were
different for each study con-
tainer. The actual treatmant as-
signements were maintained by
an off-site study administator
not directly related to the site
thus the site did not have reg-
ular access to the treatment as-
signments and could only ob-
tain that information through a
formal unblinding process.
- Participants (via the staff )
received medication containers
that contained either the active
medication or a placebo vehi-
cle prepared by the medication
manufacturer that matched the
active product in color, feel and
odor.
Please let me know if you need
further details or clarification
Taheripanah 2010 Taheri-
panah@sbmu.ac.ir e-mail 14-7-
2013 (e-mail address is not
correct anymore) Can’t find a
more recent one, and I cannot
find recent e-mail address of
any of the other authors
Dear Professor Taheripanah
My colleagues and I are con-
ducting a Cochrane review (In-
terventions for hirsutism ex-
cluding laser and photoepila-
tion therapy) and one of your
studies have been identified as
potentially eligible for inclu-
sion (Taheripanah R, Sepah-
vandi M, Entezari A, Amiri
Z, Neisani Samani E. Eval-
uation of serum PSA after
cyproterone compound treat-
ment compared with oral con-
traceptive pill in hirsute poly-
cystic ovary syndrome patients.
Middle East Fertility Society
Journal 2010;15(3):159-62)
To enable us to further assess
this trial for inclusion I would
Not applicable
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be obliged if you could you
kindly provide us with the fol-
lowing missing trial details:
1.the method used to conceal
the allocation sequence to en-
sure that intervention alloca-
tions could not have been
foreseen in advance of, or dur-
ing, enrolment ie participants
and investigators enrolling par-
ticipants could not foresee the
upcoming assignment (this is
not the same as blinding!!)
2. What was the first OCP (in-
gredients/brandname)?
3. Were there no drop-outs?
4. Are data presented with SD
or SEM?
5. What were the units of
DHEAS? (free testosterone was
ng/ml)
Thank you somuch for your ef-
forts.
Tartagni 2000 and 2004 Email: m.
tartagni@gynecology3.uniba.it
(concealment, blinding)
27-7-2013
Resent 8-8-2013, 25-08-2013.
No response
Not applicable
Vigorito 2007 Email: francescoorio@virgilio.
it (Sequence generation, con-
cealment)
2-8-2013
Resent 8-8-2013. Reply 8-8-
2013. No further response.
No
Visnovský 2010 Email: visnovsky@jfmed.
uniba.sk (sequence generation,
concealment)
8-8-2010
Resent 25-08-2013. No re-
sponse
No
Zheng 2005 Email: dcotorzheng52@yahoo.
com.cn, e-mail incorrect, no
other contact. (sequence gener-
ation, concealment)
Not applicable
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9-8-2013. No response
Table 5. Overview of published reviews and guidelines
Study ID Type of publica-
tion
Systematic search Critical appraisal Quality of
evidence
Comments
Azziz 2003 Narrative review No No Not assessed Conclusions:
”Treat-
ment should be un-
dertakenusing com-
bination therapy, to
possibly include 1)
hormonal suppres-
sion (oral contra-
ceptives, long-act-
ing gonadotropin
releasing hormone
analogues, and in-
sulin sensitizers), 2)
peripheral androgen
blockade (spirono-
lactone, flutamide,
cyproterone acetate,
or finasteride), and
3) mechanical/cos-
metic amelioration
and de-
struction of the un-
wanted hairs (elec-
trology and, poten-
tially, laser
hair removal). Eflor-
nithine hydrochlo-
ride 13.9% topical
cream may also be
useful to ameliorate
unwanted facial hair
growth“
Bailey 2014 NHS Question &
Answer
Only addressed effi-
cacy of metformin
No No Not assessed Conclu-
sions: ”Metformin
has shown limited
efficacy in PCOS
symp-
toms of hirsutism
(dose 1.5-2.0g/day)
and acne (dose 1.
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5g/day), but further
studies would be re-
quired to determine
whether metformin
has any real clinical
benefits with regard
to these symptoms.“
Blume-Peytavi
2008
Narrative review
Broad overview
with recommenda-
tions for treatment
supported by trials
and systematic re-
views if available
No No Not assessed Con-
clusions: ”For the
majority of women,
a monotherapy with
oral contraceptives
that have antian-
drogenic activity is
recommended as a
first-line treatment
for hirsutism. Com-
bining an oral con-
traceptive pill with
an antiandrogen is
recommended
if clinical improve-
ment of hirsutism is
insufficient after 6-9
months’ monother-
apy. In women who
present with hir-
sutism, hyperandro-
genism, and insulin
re-
sistance, insulin sen-
sitizers are effective
for the hirsutism as
well as the hyperin-
sulinaemia, hyper-
andro-
genism, and infertil-
ity but there is no
convincing evidence
that they are ef-
fective for hirsutism
alone. Topical eflor-
nithine is a medi-
cal therapy that can
be a useful adju-
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vant for hirsutism
when used in con-
junction with sys-
temic medications
or with laser/pho-
toepilation“
Blume-Peytavi
2011
Narrative review
Short overview on
unwanted
hair growth and hy-
pertrichosis
No No Not assessed Conclusions:
”holistic treatment
approach including
evaluation of
the implementation
of emotional coping
strategies
and on-going sup-
port, lifestyle mod-
ifications, pharma-
cological inter-
ventions (to address
underlying patholo-
gies) and the use of
cos-
metic hair removal
methods as either a
stand-alone or ad-
junct treatment as
appropriate to the
individual.“
Blume-Peytavi
2013
Narrative review
Broad review on di-
ag-
nosis and treatment
of women with ex-
cessive hair includ-
ing hypertrichosis
No No Not assessed Conclusions: ”Be-
cause excessive hair
growth in women
may cause psy-
chological and psy-
chosocial problems,
a holistic treatment
approach, including
support and emo-
tional coping strate-
gies, should be rec-
ommended.“ and
”treatment options,
...range from phar-
maceuticals, includ-
ing anti-androgens,
enzyme inhibitors,
and insulin-sensitiz-
ing agent to various
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physical and chem-
ical epilation meth-
ods
as well as laser hair
removal.Monother-
apie with OCPs that
have an androgenic
activity is usually
first choice. Espe-
cially if quick im-
provement is de-
sired, pharmaceuti-
cal treatment can
be combined with
epilation method of
preference.“
Brodell 2010 Narrative review
Review of hirsutism
on the aetiologies,
clinical features, ap-
proach to diagnos-
tic evaluation, and
treatment options
No, PubMed from
1981 and reference
lists from review ar-
ticles on hirsutism
No Not assessed Conclusions: ”A
variety of treatments
exist to help mini-
mize the appearance
of unwanted hair.
“ OCPs, spirono-
lactone, finasteride,
metformin,
eflornithine hy-
drochloride, photo-
epilation, and phys-
ical epilation are dis-
cussed
Castelo-Branco
2010
Narrative review
General overview of
hirsutism treatment
options, supported
by trials and meta-
analyses or system-
atic reviews if avail-
able
No No Not assessed Conclusions: ”Hir-
sutism can be ef-
fectively treated in
many
women by combin-
ing a non-pharma-
cologic method of
hair removal and
an OCP in women
who not wish to be-
come pregnant... If
there is no improve-
ment in 6 months,
antiandrogen treat-
ment may be added
to the OC. Some
clinicians prefer to
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initiate therapy with
a combination of
OC plus antiandro-
gens. Women with
PCOS have other
issues that require
attention, including
menstrual dysfunc-
tion, anovulatory
infertility, and an in-
creased risk of type
2 diabetes and other
metabolic disorders.
In this case, insulin
lowering agents may
be considered.
Women who wish
to become pregnant
should not initiate
pharmacologic ther-
apy for hirsutism“
Cosma 2008 Systematic
review and meta-
analysis of RCTs of
metformin or thi-
azolidinediones for
the treatment of hir-
sutism
Yes
MEDLINE,
EMBASE, and
Cochrane
CENTRAL
(up to May 2006)
Yes, well done, not
fully reported
GRADE Conclusions: ”Im-
precise and incon-
sistent evidence of
low to very lowqual-
ity suggests that in-
sulin sensitizers pro-
vide limited or
no important bene-
fit for women with
hirsutism.“
”The ac-
companying clinical
practice guidelines,
based on the evi-
dence from this re-
view along with the
values, preferences,
and expertise of the
Task Force mem-
bers, provide clin-
icians and patients
with current recom-
mendations“
Domecq 2013 Systematic
review and meta-
analysis of RCTs
of lifestyle modifi-
Yes Ovid MED-
LINE, OVID EM-
BASE, OVID The
Yes, well done GRADE Conclusions: ”We
found no significant
effect of LSM on
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Table 5. Overview of published reviews and guidelines (Continued)
cation (LSM) pro-
grammes in PCOS
Cochrane Library,
Web of
Science,
Scopus, PsycINFO,
and CINAHL (up
to January 2011)
pregnancy rate, and
the effect on hir-
sutism was unclear.“
Du 2012 Meta-analysis
Meta-
analysis of RCTs
on effects of thiazo-
lidinediones versus
placebo on PCOS
MEDLINE,
EMBASE,
and The Cochrane
Library up to June
2012
Yes (PRISMA) Not assessed Conclusions: ”The
effects of thiazo-
lidinediones on the
F-G score were not
significantly differ-
ent from placebo“
Du 2012b Systematic review
Systematic review
and meta-analysis of
RCTs comparingpi-
ogli-
tazone versus met-
formin in the treat-
ment of PCOS
MEDLINE,
EMBASE, China
National
Knowledge Infras-
tructure, andWAN-
FANG DATA up to
November 2011
In part based on
PRISMA
Not assessed Conclusions: ”The
meta-analy-
sis revealed that the
effect of pioglita-
zone on Ferriman-
Gallwey scores was
not significantly dif-
ferent from that of
metformin“. No re-
porting on effective-
ness on hirsutism
Escobar-Morreale
2010
Narra-
tive review: diagno-
sis and management
of hirsutism
No No Not assessed Conclusions:
”Treat-
ment must consider
not only ameliora-
tion of hirsutismbut
also treatment of
the underlying eti-
ology and of any
metabolic associa-
tions. When caused
by a functional dis-
order, treatment of
hirsutism should be
chronic and should
include cosmetic as
well as interventions
such as oral contra-
ceptives and antian-
drogens.
For nonfunctional
disorders, treatment
should focus on
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Table 5. Overview of published reviews and guidelines (Continued)
solving the underly-
ing etiology as hir-
sutism is usually re-
sponsive to the elim-
ination of the source
of androgen excess.“
Escobar-Morreale
2012
Systematic review
A systematic review
and critical assess-
ment of the avail-
able evidence per-
taining to the epi-
demiology, patho-
physiology, diagno-
sis, and manage-
ment of hirsutism:
a consensus state-
ment by the An-
drogen Excess and
PCOS Soci-
ety. Broad overview
with recommenda-
tions for treatment
supported by trials
Re-
views of published
peer-reviewed med-
ical literature identi-
fied studies
evaluat-
ing hirsutism. Mul-
tiple databases were
searched, including
MEDLINE, EM-
BASE, Cochrane,
ERIC, EBSCO, dis-
sertation abstracts,
and
Current Contents
The committee cri-
tiqued each re-
view before submit-
ting the manuscript
to
the Androgen Ex-
cess-PCOS Society
Board for approval.
Incomplete report-
ing of assessments
only blinding
Although the paper
refers to
GRADE, there is a
lack of a clear transi-
tion from GRADE-
ing the quality of
evidence to recom-
mendations
Conclusions: ”Fol-
low-
ing evidence-based
diagnostic and treat-
ment strategies that
address not only the
amelioration of hir-
sutism but also the
treatment of the un-
derlying etiology is
essential for the
propermanagement
of affected women,
especially consider-
ing that
hirsutism“. ”we rec-
ommend prescrib-
ing a low-dose neu-
tral or antiandro-
genic OCP as first-
line therapy for hir-
sutism...we recom-
mendprescribing an
antiandrogen com-
bined with OCPs in
women presenting
withmoderate or se-
vere hirsutism, or in
those with a milder
hirsutism who do
not reach a satisfac-
tory control of hair
growth using OCPs
alone after 1 year of
treatment...we rec-
ommend against the
use of metformin or
other insulin sensi-
tizers as therapy for
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Table 5. Overview of published reviews and guidelines (Continued)
hirsutism as its pos-
sible ef-
fects are unconvinc-
ing and possibly not
superior to placebo..
....We therefore rec-
ommend against the
use of glucocorti-
coids, ketoconazole
and GnRH
analogues for first-
line therapy of hir-
sutism because their
effects are generally
limited. In addition,
other drugs are safer
and/ormore cost-ef-
fective.“
Guerra-Tapia 2011 Narrative review
Review on effects
of ethinyl estradiol/
chlormadinone ac-
etate for the treat-
ment of dermato-
logical disorders un-
der the control of
androgens
No No Not assessed Conclu-
sions: ”In addition,
in trials investigat-
ing the contracep-
tive efficacy of EE/
CMA, limited data
suggest that there
were also improve-
ments in hirsutism,
FPHL and sebor-
rhea in small sub-
groups of patients.“
Jing 2008 Systematic review
Systematic review of
RCTS on the effects
of Diane-35 and
metformin in treat-
ment of polycystic
ovary syndrome
MEDLINE,
the Cochrane Cen-
tral Register
of Controlled Trials
and theChineseNa-
tional Knowledge
Infrastructure up to
February 2008
Yes Not assessed The primary out-
come was hirsutism
Conclusions: ”Di-
ane-35 could be ap-
plied to reduce an-
drogen levels and in-
crease
SHBG. Whether its
effect on improving
hirsutism is superior
to that ofmetformin
is unclear“
Koulouri 2008 Systematic review
Systematic review of
com-
monly used med-
ical treatments for
Cochrane Central
Register
of Controlled Trials,
MEDLINE
(1966 to 2006) and
No Not assessed Conclusions:
”A significant re-
duction in hirsutism
was found for flu-
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Table 5. Overview of published reviews and guidelines (Continued)
hirsutism in women
supported by RCTs
EMBASE (1983 to
2006)
tamide, spironolac-
tone, cypro-
terone acetate com-
bined with an oral
contraceptive, thia-
zolidinediones, oral
contracep-
tive pills (OCPs), fi-
nasteride and met-
formin but not for
placebo. Reduction
in F-G score in re-
sponse to treatment
was negatively as-
sociated with body
mass index (BMI)“
Koulouri 2009 Narrative review
Clinical review on
management of hir-
sutism supported by
literature
No No Not assessed Different treatment
options are dis-
cussed with OCPs
as first line treat-
ment option. The
use of anti-andro-
gens, GNRH ana-
logues and cosmetic
procedures are also
discussed
”Topical and sys-
temic treatments or
combinations of the
two can adequately
control hirsutism in
most cases“
Legro 2013 Guideline
Evidence-
based guideline on
diagnosis and treat-
ment of PCOS
Although not fully
reported a system-
atic search appears
to have been done
Although not fully
reported it appears
that a critical ap-
praisal has been per-
formed
GRADE Conclusions:
”Hormonal contra-
ceptives are the first-
line man-
agement for men-
strual abnormalities
and hirsutism/acne
in PCOS.
Clomiphene is cur-
rently the first-line
therapy for infertil-
ity;
metformin is bene-
ficial for metabolic/
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Table 5. Overview of published reviews and guidelines (Continued)
glycemic abnormal-
ities and for improv-
ing menstrual irreg-
ularities, but it has
limited or no ben-
efit in treating hir-
sutism, acne, or in-
fertility. Hormonal
contraceptives and
metformin are the
treatment options in
adolescents with
PCOS. The role of
weight loss in im-
proving PCOS sta-
tus per se is uncer-
tain, but lifestyle in-
tervention is bene-
ficial in overweight/
obese patients for
other health ben-
efits. Thiazolidine-
diones have an un-
favourable risk ben-
efit ratio overall, and
statins require fur-
ther study“
Lumachi 2010 Narrative review
Clinical review on
management of hir-
sutism supported by
literature
No No Not assessed Con-
clusions: ”After an
ineffective local ap-
proach by direct hair
removal, a pharma-
cological treatment
should be suggested,
using estrogen and
progestin combina-
tions,
antiandrogens (i.e.
cyproterone acetate,
spironolactone)
or both as a first
line. Finasteride, go-
nadotropin-re-
leasing hormone ag-
onists,
and glucocorticoids
should be used in
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Table 5. Overview of published reviews and guidelines (Continued)
selected cases. Ade-
quate contraception
is also recom-
mended if antian-
drogens are used.
Unfortunately, since
systemic therapy re-
duces hair growth in
less
than 50% of cases,
hirsute women fre-
quently require cos-
metic
measures. The use
of a logical com-
bination of differ-
ent options has been
shown to achieve a
satisfactory result in
most cases.“
Martin 2008 Guideline
Guideline on evalu-
ation and treatment
of hirsutism in pre-
menopausal women
Although not fully
reported it appears
that a systematic
search has been per-
formed
Although not fully
reported it appears
that a critical ap-
praisal has been per-
formed
GRADE Conclu-
sions: ”For women
with patient-impor-
tant hirsutism de-
spite cosmetic mea-
sures, we suggest ei-
ther pharmacologi-
cal therapy or direct
hair removal meth-
ods. For pharmaco-
logical therapy, we
suggest oral contra-
ceptives for the ma-
jority
of women, adding
an antiandrogen af-
ter 6 months if the
response is subop-
timal. We recom-
mend against an-
tiandrogen
monotherapy unless
adequate contracep-
tion is used. We
suggest against us-
ing insulin-lowering
drugs.“
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Paparodis 2011 Narrative review
Clinical
review on diagnosis
and management of
hirsutism supported
by literature
No No Not assessed Conclu-
sions: ”...therapies
proven to be effec-
tive are OCPs alone
, or in combina-
tion with spirono-
lactone, for women
not desiring preg-
nancy. For women
with PCOS con-
sidering pregnancy,
metformin is the
treatment of choice.
“
Pasquali 2013 Narrative review
Clinical
review on diagnosis
and management of
hirsutism in PCOS
supported by litera-
ture
No No Not assessed Conclusions: ”Cos-
metic procedures
and pharmacologi-
cal intervention are
commonly used in
the treatment of hir-
sutism and are dis-
cussed in this paper.
Importantly, there
are different phe-
notypes of women
with hirsutism and
PCOS that may re-
quire specific atten-
tion in the choice of
treatment. In partic-
ular, when obesity is
present,lifestyle
intervention should
be always consid-
ered, and if neces-
sary combined with
pharmacotherapy.“
Rosenfield 2005 Narrative review
Clinical
review on diagnosis
and management of
hirsutism supported
by literature
No No Not assessed Con-
clusions: ”A trial
of eflornithine chlo-
ride cream might be
tried initially for fa-
cial hirsutism,.... I
would also encour-
age weight control.
.... If hirsutism re-
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mained inad-
equately controlled.
.... I would recom-
mend oral contra-
cep-
tives, which would
be expected to sub-
stantially reduce the
need for cosmetic
treatments over a
9-to-12-month pe-
riod. I would also
discuss the poten-
tial permanent ben-
efit, risks, and costs
of laser hair re-
moval or electroly-
sis. For more severe
hirsutism, spirono-
lactone could
be added to oral-
contraceptive ther-
apy, which would
require closer mon-
itoring for side ef-
fects than would the
other options.“
Swiglo 2008 Systematic review
Systematic re-
view on antiandro-
gens for the treat-
ment of hirsutism
MEDLINE,
EMBASE, and
Cochrane
CENTRAL (up to
May 2006), review
of reference lists,
and contact with
hirsutism experts to
identify
eligible RCTs
Yes, allocation con-
cealment, blinding
of investigators, par-
ticipants and out-
come assessors, at-
trition bias
GRADE Con-
clusions as stated
in text: ”Weak ev-
idence suggests an-
tiandrogens
are mildly effective
agents for the treat-
ment of hirsutism.“
PCOS: polycystic ovary syndrome
RCT: randomised controlled trial
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Table 6. Research recommendations based on a gap in the evidence of the effects of interventions for hirsutism excluding laser
and photoepilation therapy
Core elements Issues to consider Status of research for this review and recommenda-
tions
Evidence (E) What is the current evidence? This systematic review identified 157 RCTs, of which
109 provided usable data. Ferriman-Gallwey score and
serum androgen levels were addressed in most of the
studies, adverse events in nearly half of the studies, par-
ticipant-assessed improvement and change in health-re-
lated quality of life in a minority of studies and change
in BMI and improvement of other clinical signs of hy-
perandrogenism were evaluated in around one-third of
the studies
OCPs, especially with antiandrogenic activity, flutamide
and spironolactone are effective for the treatment of hir-
sutism. There were no consistent results for finasteride.
Metformin and lifestyle modification are not effective
for hirsutism
Population (P) Diagnosis, disease stage, comorbidity, risk factors, gen-
der, age, ethnic group, specific inclusion or exclusion
criteria, clinical setting
Inclusion criteria
• Hirsute women with PCOS or idiopathic
hirsutism
• Ferriman-Gallwey score > 8
Exclusion criteria
• Thyroid disease, hyperprolactinaemia, and
diabetes mellitus
• < 3 months before the study, use of any form of
oral contraceptives, other steroid hormones, or any
other treatments likely to affect ovarian function,
insulin sensitivity, or lipid profile
• Pregnancy
• Androgen-secreting adrenal or ovarian neoplasm
• Cushing’s syndrome, or congenital adrenal
hyperplasia
• Intake of medication known or suspected to
affect reproductive or metabolic function < 3 months
prior to study entry
• History of liver disease and/or alcohol abuse,
elevated liver enzymes
• Contraindication for OCP
• Laser or epilation within 2 months
• Chemical depilatories within 2 weeks
• Bleaching within 1 week
• Plucking within 48 hours or shaving within 24
hours before the study
Intervention (I) Type, frequency, dose, duration, prognostic factor The study duration should be at least 6 to 12 months
Oral contraceptives + androgens (such as cyproterone
acetate, flutamide and spironolactone) or oral contra-
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Table 6. Research recommendations based on a gap in the evidence of the effects of interventions for hirsutism excluding laser
and photoepilation therapy (Continued)
ceptives + 5α inhibitors
Comparison (C) Type, frequency, dose, duration, prognostic factor Oral contraceptives, no treatment or another androgen
or 5α inhibitors
Outcome (O) Which clinical or patient-related outcomes will the re-
searcher need tomeasure, improve, influence, or accom-
plish? Which methods of measurement should be used?
1. Participant-reported improvement of hirsutism
measured at the end of the study or at other site-
dependent and clinically important time points.
Assessment involving a recognised or validated rating
scale (e.g. visual analogue scale (VAS) and Likert scale)
2. Change in health-related quality of life
(HRQOL) assessed using any validated or recognised
quality of life instrument at the end of the study
3. Proportion of participants who reported an
adverse event throughout the study period. Individual
serious adverse events reported separately
4. Clinician’s assessment of improvement of
hirsutism with a standardised and validated scoring
system (e.g. Ferriman-Gallwey score), or assessment of
hair diameter, rate of growth, and length of hair at the
end of the study
5. Change in serum androgen levels (e.g. total
testosterone, free testosterone,
dehydroepiandrosterone, androstenedione,
dihydrotestosterone) and SHBG at the end of the
study.
6. Change in BMI at the end of the study
7. Improvement of other clinical signs of
hyperandrogenism (e.g. acne, seborrhoea, female
pattern hair loss, ovulatory dysfunction) at the end of
the study
Time stamp (T) Date of literature search or recommendation 11 June 2014
Study type What is the most appropriate study design to address
the proposed question?
Randomised controlled trial
BMI: body mass index
OCP: oral contraceptive pill
RCT: randomised controlled trial
SHBG: sex hormone-binding globulin
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A P P E N D I C E S
Appendix 1. CENTRAL (The Cochrane Library) search strategy
#1 MeSH descriptor: [Hirsutism] explode all trees
#2 hirsut*
#3 frazonism
#4 excess*
#5 terminal
#6 hair*
#7 #4 and #5 and #6
#8 unwanted
#9 hair
#10 growth
#11 #8 and #9 and #10
#12 #1 or #2 or #3 or #7 or #11
Appendix 2. MEDLINE (OVID) search strategy
1. unwanted hair growth.mp.
2. (unwanted and hair and growth).ti,ab.
3. exp Hirsutism/
4. hirsut$.mp.
5. frazonism.mp.
6. or/3-5
7. excess$.ti,ab.
8. terminal.ti,ab.
9. hair$.ti,ab.
10. 7 and 8 and 9
11. 1 or 2
12. randomized controlled trial.pt.
13. controlled clinical trial.pt.
14. randomized.ab.
15. placebo.ab.
16. clinical trials as topic.sh.
17. randomly.ab.
18. trial.ti.
19. 12 or 13 or 14 or 15 or 16 or 17 or 18
20. exp animals/ not humans.sh.
21. 19 not 20
22. 6 or 10 or 11
23. 21 and 22
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Appendix 3. EMBASE (OVID) search strategy
1. exp hirsutism/
2. hirsut$.mp.
3. frazonism.mp.
4. hair$.ti,ab.
5. excess$.ti,ab.
6. terminal.ti,ab.
7. 4 and 5 and 6
8. unwanted.ti,ab.
9. hair.ti,ab.
10. growth.ti,ab.
11. 8 and 9 and 10
12. unwanted hair growth.mp.
13. 1 or 2 or 3 or 7 or 11 or 12
14. crossover procedure.sh.
15. double-blind procedure.sh.
16. single-blind procedure.sh.
17. (crossover$ or cross over$).tw.
18. placebo$.tw.
19. (doubl$ adj blind$).tw.
20. allocat$.tw.
21. trial.ti.
22. randomized controlled trial.sh.
23. random$.tw.
24. or/14-23
25. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
26. human/ or normal human/
27. 25 and 26
28. 25 not 27
29. 24 not 28
30. 13 and 29
31. remove duplicates from 30
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We judged several of the studies included in this review to be at a substantial risk of bias, which was largely attributable to the significant
lack of data on the losses at follow-up. Whilst we made every attempt to ensure accurate and complete data extraction, we used the
following algorithm to determine the appropriate judgement for risk of bias due to incomplete data:
• When the overall loss to follow-up (LTFU) was less than 10%, we judged this domain as at ’low’ risk of bias.
• When the overall LTFU was between 10% and 20%, and balanced between the arms, we judged this as at ’unclear’ risk of bias,
and if unbalanced as at ’high’ risk of bias.
• When either the overall or each individual arm LTFU was between 20% and 40%, and balanced between the arms, we judged
this as at ’high’ risk of bias.
• When either the overall or each individual arm LTFU was between 20% and 40%, and not balanced between the arms, or when
the overall LTFU was greater than 40% we did not extract the data.
We had planned to compare and present the pooled data for the androgen levels for each comparison. Although we carried out several
pooled analyses these have not been presented, based on a decision following discussions with the Editorial board of the Skin Group.
The changes in androgen levels have been reported for each individual study in the additional tables.
We had planned to include Web of Science in our searches. However, we considered that the comprehensive search strategy provided
sufficient coverage to identify all potentially eligible studies without the additional necessity to search this database.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
5-alpha Reductase Inhibitors [∗therapeutic use]; Androgen Antagonists [∗therapeutic use]; Body Mass Index; Contraceptive Agents,
Female [∗therapeutic use]; Cyproterone Acetate [therapeutic use]; Desogestrel [therapeutic use]; Drug Combinations; Eflornithine
[therapeutic use]; Ethinyl Estradiol [therapeutic use]; Finasteride [therapeutic use]; Flutamide [therapeutic use]; Hirsutism [∗drug
therapy]; Hypoglycemic Agents [∗therapeutic use]; Metformin [therapeutic use]; Quality of Life; Randomized Controlled Trials as
Topic; Spironolactone [therapeutic use]
MeSH check words
Adult; Female; Humans
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